tid,src_assay_id,relationship_type,tissue_id,assay_strain,assay_id,assay_organism,description,assay_tissue,curated_by,variant_id,chembl_id,assay_test_type,assay_tax_id,cell_id,confidence_score,src_id,assay_cell_type,assay_type,assay_category,assay_subcellular_fraction,bao_format,doc_id
12052,,H,,,1,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,,Autocuration,,CHEMBL615117,,,,8,1,,B,,,BAO_0000019,11087
22226,,U,,,2,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,,Autocuration,,CHEMBL615118,,,,0,1,,F,,,BAO_0000219,684
22226,,U,,,3,,,,Autocuration,,CHEMBL615119,,,,0,1,,B,,,BAO_0000019,15453
104729,,H,,,4,Bos taurus,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,,Autocuration,,CHEMBL615120,,9913.0,,4,1,,B,,,BAO_0000249,17841
80001,,N,,,5,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,Intermediate,,CHEMBL615121,,9606.0,163.0,1,1,143B,F,,,BAO_0000219,17430
80001,,N,,,6,Homo sapiens,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),,Intermediate,,CHEMBL615122,,9606.0,163.0,1,1,143B,F,,,BAO_0000219,17430
80001,,N,,,7,Mus musculus,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,,Intermediate,,CHEMBL615123,,10090.0,163.0,1,1,143B,F,,,BAO_0000219,13799
80001,,N,,,8,Homo sapiens,In vitro cell cytotoxicity was determined against 143B cell line,,Expert,,CHEMBL615124,,9606.0,163.0,1,1,143B,F,,,BAO_0000219,17774
80001,,N,,,9,Homo sapiens,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,,Intermediate,,CHEMBL615125,,9606.0,163.0,1,1,143B,F,,,BAO_0000219,3801
80001,,N,,,10,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,Intermediate,,CHEMBL615126,,9606.0,163.0,1,1,143B,F,,,BAO_0000219,17430
80001,,N,,,11,Homo sapiens,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,,Intermediate,,CHEMBL615127,,9606.0,163.0,1,1,143B,F,,,BAO_0000219,17430
80001,,N,,,12,Homo sapiens,In vitro cell cytotoxicity was determined against 143B-LTK cell line,,Expert,,CHEMBL615128,,9606.0,163.0,1,1,143B,F,,,BAO_0000219,17774
50185,,N,,,13,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Intermediate,,CHEMBL857900,,1280.0,,1,1,,F,,,BAO_0000218,11324
50185,,N,,,14,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Intermediate,,CHEMBL615129,,1280.0,,1,1,,F,,,BAO_0000218,11324
50185,,N,,,15,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Intermediate,,CHEMBL615130,,1280.0,,1,1,,F,,,BAO_0000218,11324
50185,,N,,,16,Staphylococcus aureus,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",,Intermediate,,CHEMBL615131,,1280.0,,1,1,,F,,,BAO_0000218,11324
100122,,D,,,17,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,,Expert,,CHEMBL884521,,10116.0,,9,1,,A,,,BAO_0000357,11347
12054,,H,,,18,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),,Autocuration,,CHEMBL615132,,,,8,1,,B,,,BAO_0000357,16474
12054,,H,,,19,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,,Autocuration,,CHEMBL615133,,,,8,1,,B,,,BAO_0000019,10091
12054,,H,,,20,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,Autocuration,,CHEMBL615134,,,,8,1,,B,,,BAO_0000357,16474
12054,,H,,,21,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),,Autocuration,,CHEMBL615135,,,,8,1,,B,,,BAO_0000357,16474
12054,,H,,,22,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),,Autocuration,,CHEMBL615136,,,,8,1,,B,,,BAO_0000357,16474
12054,,H,,,23,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,Autocuration,,CHEMBL615137,,,,8,1,,B,,,BAO_0000357,16474
12054,,H,,,24,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,,Autocuration,,CHEMBL615138,,,,8,1,,B,,,BAO_0000357,16474
22226,,U,,,25,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",,Autocuration,,CHEMBL836324,,,,0,1,,B,,,BAO_0000219,14352
12054,,H,,,26,Oryctolagus cuniculus,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,,Autocuration,,CHEMBL615139,,9986.0,,8,1,,B,,,BAO_0000357,5646
12054,,H,,,27,Oryctolagus cuniculus,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),,Autocuration,,CHEMBL615140,,9986.0,,8,1,,B,,,BAO_0000357,5646
12426,,H,,,28,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,,Autocuration,,CHEMBL615141,,,,8,1,,B,,,BAO_0000219,10997
12054,,H,,,29,soya bean,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,,Autocuration,,CHEMBL615142,,3847.0,,8,1,,B,,,BAO_0000357,6309
12054,,H,,,30,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated,,Autocuration,,CHEMBL615143,,3847.0,,8,1,,B,,,BAO_0000357,167
12054,,H,,,31,Glycine max,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,,Autocuration,,CHEMBL615144,,3847.0,,8,1,,B,,,BAO_0000357,167
12054,,H,,,32,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,,Autocuration,,CHEMBL872867,,3847.0,,8,1,,B,,,BAO_0000357,11087
12054,,H,,,33,Glycine max,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,,Autocuration,,CHEMBL615145,,3847.0,,8,1,,B,,,BAO_0000357,11087
12054,,H,,,34,Glycine max,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,,Autocuration,,CHEMBL615146,,3847.0,,8,1,,B,,,BAO_0000357,13622
12054,,H,,,35,Glycine max,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,,Autocuration,,CHEMBL615147,,3847.0,,8,1,,B,,,BAO_0000357,13622
22226,,U,,,36,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,,Autocuration,,CHEMBL615148,,10116.0,,0,1,,A,,,BAO_0000019,11347
22226,,U,,,37,Escherichia coli,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,,Autocuration,,CHEMBL615149,,562.0,,0,1,,B,,,BAO_0000019,5926
22226,,U,,,38,,Dissociation constant with dimeric 16S rRNA RNA construct B,,Autocuration,,CHEMBL615150,,,,0,1,,B,,,BAO_0000019,4567
22222,,M,,,39,,Dissociation constant towards 16S rRNA construct A,,Intermediate,,CHEMBL615151,,,,3,1,,B,,,BAO_0000225,3782
22222,,M,,,40,,Dissociation constant towards 16S rRNA construct B,,Intermediate,,CHEMBL615152,,,,3,1,,B,,,BAO_0000225,3782
100263,,M,,,41,Escherichia coli,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,,Expert,,CHEMBL615153,,562.0,,3,1,,B,,,BAO_0000225,4466
100263,,M,,,42,Escherichia coli,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,,Expert,,CHEMBL615154,,562.0,,3,1,,B,,,BAO_0000225,6592
13053,,H,,,43,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,Autocuration,,CHEMBL615155,,,,8,1,,B,,,BAO_0000019,898
13053,,H,,,44,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,Autocuration,,CHEMBL615156,,,,8,1,,B,,,BAO_0000019,898
20001,,H,,,45,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,Autocuration,,CHEMBL615157,,9606.0,,8,1,,B,,,BAO_0000019,13163
20001,,H,,,46,Homo sapiens,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,,Autocuration,,CHEMBL615158,,9606.0,,8,1,,B,,,BAO_0000019,13163
12971,,D,,,47,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,Expert,,CHEMBL615159,,10116.0,,9,1,,B,,,BAO_0000019,10691
12971,,D,,,48,Rattus norvegicus,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",,Expert,,CHEMBL615172,,10116.0,,9,1,,B,,,BAO_0000019,10691
12971,,D,,,49,Rattus norvegicus,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,Expert,,CHEMBL615173,,10116.0,,9,1,,B,,,BAO_0000019,10691
12971,,D,,,50,Rattus norvegicus,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",,Expert,,CHEMBL615174,,10116.0,,9,1,,B,,,BAO_0000019,10691
13053,,H,,,51,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),,Autocuration,,CHEMBL884518,,,,8,1,,B,,,BAO_0000019,898
11512,,H,,,52,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),,Autocuration,,CHEMBL615175,,,,8,1,,B,,,BAO_0000357,912
11512,,H,,,53,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,,Autocuration,,CHEMBL615176,,,,8,1,,B,,,BAO_0000357,912
11512,,H,,,54,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,,Autocuration,,CHEMBL615177,,,,8,1,,B,,,BAO_0000357,912
104740,,D,,,55,Rattus norvegicus,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,,Autocuration,,CHEMBL615178,,10116.0,,5,1,,B,,Membranes,BAO_0000249,15103
80002,,N,,,56,Homo sapiens,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,,Intermediate,,CHEMBL615179,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,5116
104835,,D,,,57,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,,Autocuration,,CHEMBL615180,,10116.0,,7,1,Oocytes,F,,,BAO_0000219,14578
104821,,D,,,58,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,,Autocuration,,CHEMBL615181,,10116.0,,7,1,Oocytes,F,,,BAO_0000219,14578
104848,,D,,,59,Rattus norvegicus,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,,Autocuration,,CHEMBL615182,,10116.0,,7,1,Oocytes,F,,,BAO_0000219,14578
80002,,N,,,60,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,,Expert,,CHEMBL615183,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,4787
80002,,N,,,61,Homo sapiens,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,,Intermediate,,CHEMBL615184,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,4787
80002,,N,,,62,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line,,Intermediate,,CHEMBL615185,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,3547
80002,,N,,,63,Homo sapiens,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,,Intermediate,,CHEMBL615186,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,3547
80002,,N,,,64,Homo sapiens,Effective dose of compound against replication of 1A9 cell line was evaluated,,Intermediate,,CHEMBL615187,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,6726
80002,,N,,,65,Homo sapiens,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,,Expert,,CHEMBL885343,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,3455
80002,,N,,,66,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),,Intermediate,,CHEMBL615188,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,5726
80002,,N,,,67,Homo sapiens,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,,Intermediate,,CHEMBL615189,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,5726
80002,,N,,,68,Homo sapiens,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,,Intermediate,,CHEMBL615190,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,5726
80002,,N,,,69,Homo sapiens,Inhibitory activity against Taxol resistant 1A9 cell lines,,Intermediate,,CHEMBL615191,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,3395
80002,,N,,,70,Homo sapiens,Cytotoxicity against human ovarian cancer (1A9) cell lines.,,Expert,,CHEMBL615192,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,3415
80002,,N,,,71,Homo sapiens,Percentage inhibition of human ovarian cancer (1A9) cell lines.,,Expert,,CHEMBL827083,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,3415
80002,,N,,,72,Homo sapiens,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,,Expert,,CHEMBL615193,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,17099
80002,,N,,,73,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,,Intermediate,,CHEMBL615194,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,17099
80002,,N,,,74,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,,Intermediate,,CHEMBL615195,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,17099
80002,,N,,,75,Homo sapiens,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,,Intermediate,,CHEMBL615196,,9606.0,506.0,1,1,1A9,F,,,BAO_0000219,17099
81072,,N,,,76,Homo sapiens,Inhibitory concentration against Jurkat cells,,Intermediate,,CHEMBL615197,,9606.0,503.0,1,1,Jurkat,F,,,BAO_0000219,17721
22226,,U,,,77,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,,Intermediate,,CHEMBL615198,,,,0,1,,F,,,BAO_0000019,1229
100121,,D,,,78,Rattus norvegicus,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,,Expert,,CHEMBL615199,,10116.0,,9,1,,A,,,BAO_0000357,11347
11231,,H,,,79,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,Expert,,CHEMBL615200,,,,8,1,,B,,,BAO_0000357,17117
11231,,H,,,80,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",,Expert,,CHEMBL615201,,,,8,1,,B,,,BAO_0000357,17117
11231,,H,,,81,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",,Expert,,CHEMBL615202,,,,8,1,,B,,,BAO_0000357,17117
11231,,H,,,82,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",,Autocuration,,CHEMBL615203,,5476.0,,8,1,,B,,Microsomes,BAO_0000251,11375
11231,,H,,,83,Candida albicans,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",,Autocuration,,CHEMBL615204,,5476.0,,8,1,,B,,Microsomes,BAO_0000251,11375
11231,,H,,,84,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",,Autocuration,,CHEMBL615205,,4932.0,,8,1,,B,,Microsomes,BAO_0000251,11375
11231,,H,,,85,Saccharomyces cerevisiae,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",,Autocuration,,CHEMBL615206,,4932.0,,8,1,,B,,Microsomes,BAO_0000251,11375
12083,,H,2107.0,,86,Sus scrofa,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",Liver,Autocuration,,CHEMBL615207,,9823.0,,8,1,,B,,Microsomes,BAO_0000251,11375
11231,,H,,,87,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",,Autocuration,,CHEMBL827084,,10116.0,,8,1,,B,,,BAO_0000019,791
11231,,H,,,88,Rattus norvegicus,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",,Autocuration,,CHEMBL615208,,10116.0,,8,1,,B,,,BAO_0000019,791
11231,,H,,,89,Rattus norvegicus,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",,Autocuration,,CHEMBL615209,,10116.0,,8,1,,B,,,BAO_0000019,791
12083,,D,2107.0,,90,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",Liver,Autocuration,,CHEMBL615210,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,11375
12083,,D,2107.0,,91,Rattus norvegicus,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Liver,Autocuration,,CHEMBL615211,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,11375
12083,,D,2107.0,,92,Rattus norvegicus,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",Liver,Autocuration,,CHEMBL615212,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,153
11377,,H,,,93,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),,Expert,,CHEMBL615213,,,,8,1,,B,,,BAO_0000357,8269
11377,,H,,,94,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,,Expert,,CHEMBL615273,,,,8,1,,B,,,BAO_0000357,8269
81020,,N,,,95,Homo sapiens,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,Expert,,CHEMBL615274,,9606.0,726.0,1,1,HepG2,F,,,BAO_0000219,17653
81020,,N,,,96,Homo sapiens,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,,Intermediate,,CHEMBL615275,,9606.0,726.0,1,1,HepG2,F,,,BAO_0000219,14277
81020,,N,,,97,Homo sapiens,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,,Intermediate,,CHEMBL615276,,9606.0,726.0,1,1,HepG2,F,,,BAO_0000219,1717
81020,,N,,,98,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,,Intermediate,,CHEMBL615277,,9606.0,726.0,1,1,HepG2,F,,,BAO_0000219,14091
81020,,N,,,99,Homo sapiens,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,,Intermediate,,CHEMBL615326,,9606.0,726.0,1,1,HepG2,F,,,BAO_0000219,14091
50606,,N,,,100,Hepatitis B virus,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,,Expert,,CHEMBL883130,,10407.0,,1,1,,F,,,BAO_0000218,17653
81020,,N,,,101,Homo sapiens,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,,Intermediate,,CHEMBL884519,,9606.0,726.0,1,1,HepG2,F,,,BAO_0000219,13105
81020,,N,,,102,Homo sapiens,Concentration required to inhibit 50% of 2.2.15 cell line,,Intermediate,,CHEMBL615327,,9606.0,726.0,1,1,HepG2,F,,,BAO_0000219,1717
81020,,N,,,103,Homo sapiens,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,,Intermediate,,CHEMBL615328,,9606.0,726.0,1,1,HepG2,A,,,BAO_0000219,13105
50587,,N,,,104,Homo sapiens,Cytotoxic activity of compound against uninfected 2.2.15 cells.,,Intermediate,,CHEMBL615329,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,13600
50587,,N,,,105,Homo sapiens,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,,Intermediate,,CHEMBL615330,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,13467
50606,,N,,,106,Hepatitis B virus,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",,Expert,,CHEMBL615331,,10407.0,,1,1,2.2.15,F,,,BAO_0000218,17477
50587,,N,,,107,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells,,Intermediate,,CHEMBL615332,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,1593
50587,,N,,,108,Homo sapiens,In vitro anti-HBV activity in 2.2.15 cells; Not determined,,Intermediate,,CHEMBL615333,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,1593
50587,,N,,,109,Homo sapiens,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,,Intermediate,,CHEMBL615334,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,15089
50587,,N,,,110,Homo sapiens,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,,Intermediate,,CHEMBL615335,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,15089
50587,,N,,,111,Homo sapiens,Cytotoxicity in 2.2.15 cells,,Intermediate,,CHEMBL615336,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,1593
50587,,N,,,112,Homo sapiens,Cytotoxicity in 2.2.15 cells; Not determined,,Intermediate,,CHEMBL615337,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,1593
50587,,N,,,113,Homo sapiens,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,,Intermediate,,CHEMBL615338,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,13600
50587,,N,,,114,Homo sapiens,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,,Intermediate,,CHEMBL615339,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,13467
50587,,N,,,115,Homo sapiens,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,,Intermediate,,CHEMBL615340,,9606.0,,1,1,2.2.15,F,,,BAO_0000218,13467
81020,,N,,,116,Homo sapiens,Antiviral activity against HBV was determined in 2.215 cell line,,Intermediate,,CHEMBL615341,,9606.0,726.0,1,1,HepG2,F,,,BAO_0000219,14764
22226,,U,,,117,Homo sapiens,Inhibition of 20-HETE synthesis in human renal microsomes,,Autocuration,,CHEMBL615342,,9606.0,,0,1,,B,,Microsomes,BAO_0000251,6531
22226,,U,,,118,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,,Autocuration,,CHEMBL615343,,,,0,1,,B,,,BAO_0000019,17322
80612,,N,,,119,Homo sapiens,Inhibitory concentration against 2008 (ovarian) cells,,Intermediate,,CHEMBL615344,,9606.0,388.0,1,1,2008,F,,,BAO_0000219,17072
80612,,N,,,120,Homo sapiens,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,,Intermediate,,CHEMBL615345,,9606.0,388.0,1,1,2008,F,,,BAO_0000219,16936
80612,,N,,,121,Homo sapiens,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),,Intermediate,,CHEMBL615346,,9606.0,388.0,1,1,2008,F,,,BAO_0000219,16936
80612,,N,,,122,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,,Intermediate,,CHEMBL615347,,9606.0,388.0,1,1,2008,F,,,BAO_0000219,17146
80612,,N,,,123,Homo sapiens,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,,Intermediate,,CHEMBL615348,,9606.0,388.0,1,1,2008,F,,,BAO_0000219,17146
80613,,N,,,124,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line,,Intermediate,,CHEMBL827085,,9606.0,561.0,1,1,2008/R,F,,,BAO_0000219,10797
80613,,N,,,125,Homo sapiens,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,,Intermediate,,CHEMBL615349,,9606.0,561.0,1,1,2008/R,F,,,BAO_0000219,10797
80614,,N,,,126,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line,,Intermediate,,CHEMBL615350,,9606.0,389.0,1,1,2008/S,F,,,BAO_0000219,10797
80614,,N,,,127,Homo sapiens,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,,Intermediate,,CHEMBL615351,,9606.0,389.0,1,1,2008/S,F,,,BAO_0000219,10797
100256,,S,,,128,Homo sapiens,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,,Expert,,CHEMBL615352,,9606.0,,2,1,,B,,,BAO_0000220,4823
100256,,S,,,129,Homo sapiens,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,,Intermediate,,CHEMBL615353,,9606.0,,2,1,,B,,,BAO_0000220,12912
100256,,S,,,130,,Inhibition of chymotrypsin-like activity of 20S proteasome,,Expert,,CHEMBL615354,,,,2,1,,B,,,BAO_0000220,2957
100256,,S,,,131,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,,Expert,,CHEMBL615355,,,,2,1,,B,,,BAO_0000220,2957
100256,,S,,,132,,Inhibitory activity against 20S proteosome,,Intermediate,,CHEMBL615356,,,,2,1,,B,,,BAO_0000220,3260
22226,,U,,,133,Homo sapiens,Compound was tested for inhibitory activity against tryptase,,Autocuration,,CHEMBL615357,,9606.0,,0,1,,B,,,BAO_0000019,3451
81020,,N,,,134,Homo sapiens,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,,Intermediate,,CHEMBL615358,,9606.0,726.0,1,1,HepG2,F,,,BAO_0000219,13885
81020,,N,,,135,Homo sapiens,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,,Intermediate,,CHEMBL827086,,9606.0,726.0,1,1,HepG2,F,,,BAO_0000219,13885
22226,,U,,,136,,Compound was tested for the inhibition of Alpha-glucosidase,,Autocuration,,CHEMBL615359,,,,0,1,,B,,,BAO_0000019,3676
235,,H,,,137,,Inhibitory concentration against human neutrophil elastase (HNE),,Autocuration,,CHEMBL615360,,,,8,1,,B,,,BAO_0000357,6043
22226,,U,948.0,,138,Rattus norvegicus,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,Heart,Autocuration,,CHEMBL615361,,10116.0,,0,1,,F,,,BAO_0000218,11140
19640,,H,,,139,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,Autocuration,,CHEMBL615362,,,,8,1,,F,,,BAO_0000019,10543
19640,,H,,,140,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,Expert,,CHEMBL615363,,,,8,1,,F,,,BAO_0000019,10543
19640,,H,,,141,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,,Autocuration,,CHEMBL615364,,,,8,1,,B,,,BAO_0000357,10543
19640,,H,,,142,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,,Expert,,CHEMBL615365,,,,8,1,,F,,,BAO_0000019,10543
80360,,N,,,143,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,,Intermediate,,CHEMBL615366,,10090.0,524.0,1,1,P338,F,,,BAO_0000219,11365
80360,,N,,,144,Mus musculus,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,,Intermediate,,CHEMBL615367,,10090.0,524.0,1,1,P338,F,,,BAO_0000219,11365
80384,,N,,,145,Homo sapiens,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,,Intermediate,,CHEMBL615368,,9606.0,554.0,1,1,PBL,F,,,BAO_0000219,11803
22226,,U,,,146,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,,Autocuration,,CHEMBL615369,,9940.0,,0,1,,F,,,BAO_0000019,11803
22226,,U,,,147,Ovis aries,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,,Autocuration,,CHEMBL615370,,9940.0,,0,1,,F,,,BAO_0000019,11803
191,,H,,,148,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),,Autocuration,,CHEMBL615673,,,,8,1,,B,,,BAO_0000357,12278
22226,,U,,,149,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,,Autocuration,,CHEMBL615674,,9606.0,,0,1,,F,,,BAO_0000019,8249
22226,,U,,,150,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,,Autocuration,,CHEMBL615675,,9606.0,,0,1,,F,,,BAO_0000019,8249
22226,,U,,,151,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,,Autocuration,,CHEMBL615676,,9606.0,635.0,0,1,CCRF-CEM,F,,,BAO_0000219,8249
22226,,U,,,152,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,,Autocuration,,CHEMBL615677,,9606.0,635.0,0,1,CCRF-CEM,F,,,BAO_0000219,8249
22226,,U,,,153,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,,Autocuration,,CHEMBL615678,,9606.0,635.0,0,1,CCRF-CEM,F,,,BAO_0000219,8249
22226,,U,,,154,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,,Autocuration,,CHEMBL615679,,9606.0,635.0,0,1,CCRF-CEM,F,,,BAO_0000219,8249
22226,,U,,,155,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,,Autocuration,,CHEMBL615680,,9606.0,,0,1,,F,,,BAO_0000019,8249
22226,,U,,,156,Homo sapiens,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,,Autocuration,,CHEMBL615681,,9606.0,,0,1,,F,,,BAO_0000019,8249
104290,,H,,,157,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,,Autocuration,,CHEMBL857972,,,,6,1,,B,,,BAO_0000249,16992
50264,,N,,,158,Streptococcus pyogenes,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,,Intermediate,,CHEMBL857899,,1314.0,,1,1,,F,,,BAO_0000218,10543
50527,,N,,,159,Human herpesvirus 3,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),,Intermediate,,CHEMBL615371,,10335.0,,1,1,,F,,,BAO_0000218,17833
50527,,N,,,160,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,,Expert,,CHEMBL615372,,10335.0,468.0,1,1,HEL,F,,,BAO_0000218,17290
50527,,N,,,161,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND: No data,,Intermediate,,CHEMBL615373,,10335.0,,1,1,,F,,,BAO_0000218,17290
50527,,N,,,162,vericilla zoster virus,Antiviral activity against 07/1 strain of VZV; ND=No data,,Intermediate,,CHEMBL615374,,10335.0,,1,1,,F,,,BAO_0000218,17290
50145,,N,,,163,escherichia cloac,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",,Intermediate,,CHEMBL615375,,561.0,,1,1,,F,,,BAO_0000218,10932
22226,,U,,,164,,Ratio of Ki at A2 to Ki at A1 receptors,,Autocuration,,CHEMBL615376,,,,0,1,,B,,,BAO_0000019,9707
11143,,H,,,165,Candida albicans,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",,Expert,,CHEMBL615377,,5476.0,,8,1,,B,,,BAO_0000249,2346
18077,,H,,,166,Candida glabrata CBS 138,"Inhibition of 1,3-beta-glucan synthase",,Expert,,CHEMBL615378,,284593.0,,8,1,,B,,,BAO_0000357,2205
80609,,N,,,167,Homo sapiens,Inhibition of growth of 1-87 human tumor cell line,,Intermediate,,CHEMBL615379,,9606.0,832.0,1,1,1-87 tumor cell line,F,,,BAO_0000219,11900
12166,,D,,,168,Rattus norvegicus,Inhibition of 1-lipoxygenase (LOX)in RBL cells,,Expert,,CHEMBL615380,,10116.0,,9,1,,B,,,BAO_0000219,14864
100171,,D,,,169,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO),,Autocuration,,CHEMBL615381,,3847.0,,9,1,,B,,,BAO_0000357,16474
100171,,D,,,170,Glycine max,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,,Autocuration,,CHEMBL615382,,3847.0,,9,1,,B,,,BAO_0000357,16474
100171,,D,,,171,Glycine max,% inhibition against soybean 1-lipoxygenase (SLO),,Autocuration,,CHEMBL615383,,3847.0,,9,1,,B,,,BAO_0000357,16474
100171,,D,,,172,Glycine max,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,,Autocuration,,CHEMBL615384,,3847.0,,9,1,,B,,,BAO_0000357,16474
100171,,D,,,173,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,,Autocuration,,CHEMBL615385,,3847.0,,9,1,,B,,,BAO_0000357,3094
100171,,D,,,174,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,,Autocuration,,CHEMBL615386,,3847.0,,9,1,,B,,,BAO_0000357,3094
100171,,D,,,175,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,,Autocuration,,CHEMBL615387,,3847.0,,9,1,,B,,,BAO_0000357,3094
100171,,D,,,176,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,,Autocuration,,CHEMBL615388,,3847.0,,9,1,,B,,,BAO_0000357,3094
100171,,D,,,177,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,,Autocuration,,CHEMBL615214,,3847.0,,9,1,,B,,,BAO_0000357,3094
100171,,D,,,178,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,,Autocuration,,CHEMBL827087,,3847.0,,9,1,,B,,,BAO_0000357,3094
100171,,D,,,179,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,,Autocuration,,CHEMBL615215,,3847.0,,9,1,,B,,,BAO_0000357,3094
100171,,D,,,180,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,,Autocuration,,CHEMBL615216,,3847.0,,9,1,,B,,,BAO_0000357,3094
100171,,D,,,181,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,,Autocuration,,CHEMBL615217,,3847.0,,9,1,,B,,,BAO_0000357,3094
100171,,D,,,182,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,,Autocuration,,CHEMBL615218,,3847.0,,9,1,,B,,,BAO_0000357,3094
100171,,D,,,183,Glycine max,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,,Autocuration,,CHEMBL615219,,3847.0,,9,1,,B,,,BAO_0000357,3094
22226,,U,,,184,Mus musculus,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,,Autocuration,,CHEMBL615220,,10090.0,,0,1,,B,,,BAO_0000019,10413
80049,,N,,,185,Mus musculus,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),,Intermediate,,CHEMBL615221,,10090.0,294.0,1,1,C3H 10T1/2,F,,,BAO_0000219,16929
22226,,U,,,186,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,,Intermediate,,CHEMBL615222,,,,0,1,,F,,,BAO_0000019,1229
11489,,H,,,187,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,Autocuration,,CHEMBL615223,,,,8,1,,B,,,BAO_0000357,16587
11862,,H,,,188,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),,Autocuration,,CHEMBL615224,,,,8,1,,B,,,BAO_0000357,16587
11862,,H,,,189,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,,Autocuration,,CHEMBL615225,,,,8,1,,B,,,BAO_0000357,16587
11489,,H,,,190,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,,Autocuration,,CHEMBL615226,,,,8,1,,B,,,BAO_0000357,16587
11862,,H,,,191,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,,Autocuration,,CHEMBL615227,,,,8,1,,B,,,BAO_0000357,16587
12347,,D,,,192,Bos taurus,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,,Expert,,CHEMBL615228,,9913.0,,9,1,,F,,,BAO_0000019,8058
100120,,D,,,193,Rattus norvegicus,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,,Expert,,CHEMBL615229,,10116.0,,9,1,,B,,,BAO_0000357,9065
100120,,D,2369.0,,194,Rattus norvegicus,Inhibition of 11 beta-hydroxylase from rat adrenal gland,Adrenal gland,Expert,,CHEMBL615230,,10116.0,,9,1,,B,,,BAO_0000357,8865
100120,,D,,,195,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,,Expert,,CHEMBL615231,,10116.0,,9,1,,B,,,BAO_0000357,9066
100120,,D,,,196,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase,,Expert,,CHEMBL884520,,10116.0,,9,1,,B,,,BAO_0000357,8394
100120,,D,,,197,Rattus norvegicus,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,,Expert,,CHEMBL615232,,10116.0,,9,1,,B,,,BAO_0000357,8394
10328,,H,,,198,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,,Autocuration,,CHEMBL615233,,,,8,1,,B,,,BAO_0000019,6431
11490,,H,,,199,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,Autocuration,,CHEMBL827088,,,,8,1,,B,,,BAO_0000357,6431
11490,,H,,,200,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,,Autocuration,,CHEMBL615234,,,,8,1,,B,,,BAO_0000357,6431
11134,,H,,,201,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,,Autocuration,,CHEMBL615235,,,,8,1,,F,,,BAO_0000019,9295
12052,,H,,,202,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,Autocuration,,CHEMBL615236,,,,8,1,,B,,,BAO_0000019,10193
11134,,H,,,203,,Compound was tested in vitro for inhibition of 12-LO human platelet,,Autocuration,,CHEMBL615237,,,,8,1,,B,,,BAO_0000019,13622
11134,,H,,,204,,Inhibitory concentration against human platelet 12-lipoxygenase,,Autocuration,,CHEMBL615238,,,,8,1,,F,,,BAO_0000019,12079
11134,,H,,,205,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,,Autocuration,,CHEMBL615239,,,,8,1,,B,,,BAO_0000019,13622
11134,,D,,,206,Homo sapiens,Inhibitory concentration against human platelet 12-lipoxygenase,,Autocuration,,CHEMBL615240,,9606.0,,9,1,,F,,,BAO_0000019,12079
11835,,H,,,207,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,,Expert,,CHEMBL615241,,,,8,1,,B,,,BAO_0000019,13500
11601,,H,,,208,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,,Expert,,CHEMBL615242,,,,8,1,,B,,,BAO_0000357,13723
11134,,H,,,209,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),,Autocuration,,CHEMBL615243,,,,8,1,,B,,,BAO_0000019,16474
11134,,H,,,210,,Inhibitory activity against human platelet 12-lipoxygenase,,Autocuration,,CHEMBL615244,,,,8,1,,B,,,BAO_0000019,1630
11134,,H,,,211,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,,Autocuration,,CHEMBL615245,,,,8,1,,B,,,BAO_0000019,167
11134,,H,,,212,,% inhibition against human platelet 12-lipoxygenase (12-HLO),,Autocuration,,CHEMBL615246,,,,8,1,,B,,,BAO_0000019,16474
11134,,H,,,213,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,,Autocuration,,CHEMBL615247,,,,8,1,,B,,,BAO_0000019,167
11134,,H,,,214,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,,Autocuration,,CHEMBL615248,,,,8,1,,B,,,BAO_0000019,16474
11601,,H,,,215,,Inhibitory activity towards porcine 12-lipoxygenase,,Autocuration,,CHEMBL615249,,,,8,1,,B,,,BAO_0000357,10091
11601,,H,,,216,,Tested for inhibition against porcine 12-LO,,Autocuration,,CHEMBL615250,,,,8,1,,B,,,BAO_0000357,11966
12052,,H,,,217,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,,Autocuration,,CHEMBL615251,,,,8,1,,B,,,BAO_0000019,951
12052,,H,,,218,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,,Autocuration,,CHEMBL615252,,,,8,1,,B,,,BAO_0000019,10997
12052,,H,,,219,,In vitro inhibition of rat platelet 12-lipoxygenase,,Expert,,CHEMBL828340,,,,8,1,,B,,,BAO_0000019,10193
12052,,H,,,220,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,Autocuration,,CHEMBL615253,,,,8,1,,B,,,BAO_0000019,10193
12052,,H,,,221,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,,Autocuration,,CHEMBL615254,,,,8,1,,B,,,BAO_0000019,10193
12052,,H,,,222,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,,Autocuration,,CHEMBL615255,,,,8,1,,B,,,BAO_0000019,10193
12052,,H,,,223,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,,Autocuration,,CHEMBL615256,,,,8,1,,B,,,BAO_0000019,10193
12052,,H,,,224,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,,Autocuration,,CHEMBL615257,,,,8,1,,B,,,BAO_0000019,10193
12052,,H,,,225,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,,Autocuration,,CHEMBL615258,,,,8,1,,B,,,BAO_0000019,11087
80007,,N,,,226,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,,Intermediate,,CHEMBL615259,,9606.0,621.0,1,1,41M,F,,,BAO_0000219,15569
80007,,N,,,227,Homo sapiens,In vitro antitumor activity against 41M cell line.,,Expert,,CHEMBL615260,,9606.0,621.0,1,1,41M,F,,,BAO_0000219,12989
80007,,N,,,228,Homo sapiens,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,,Intermediate,,CHEMBL615261,,9606.0,621.0,1,1,41M,F,,,BAO_0000219,16745
80007,,N,,,229,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,,Intermediate,,CHEMBL615262,,9606.0,621.0,1,1,41M,F,,,BAO_0000219,15569
80007,,N,,,230,Homo sapiens,In vitro antitumor activity against 41McisR cell line.,,Expert,,CHEMBL615263,,9606.0,621.0,1,1,41M,F,,,BAO_0000219,12989
80007,,N,,,231,Homo sapiens,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,,Expert,,CHEMBL838393,,9606.0,621.0,1,1,41M,F,,,BAO_0000219,12989
80007,,N,,,232,Homo sapiens,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,,Intermediate,,CHEMBL615264,,9606.0,621.0,1,1,41M,F,,,BAO_0000219,16745
84,,D,,,233,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),,Expert,,CHEMBL615265,,9606.0,,9,1,,B,,,BAO_0000357,6210
68,,D,,,234,Homo sapiens,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,Expert,,CHEMBL615266,,9606.0,,9,1,,B,,,BAO_0000357,6210
68,,H,,,235,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),,Expert,,CHEMBL615267,,,,8,1,,B,,,BAO_0000357,6226
10201,,H,,,236,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,,Expert,,CHEMBL615268,,,,8,1,,B,,,BAO_0000357,17855
10201,,H,,,237,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,,Expert,,CHEMBL615269,,,,8,1,,B,,,BAO_0000357,17855
10201,,H,,,238,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,,Expert,,CHEMBL615270,,,,8,1,,B,,,BAO_0000357,17855
12220,,H,,,239,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,Autocuration,,CHEMBL615271,,,,8,1,,B,,,BAO_0000357,10413
11303,,H,,,240,Escherichia coli,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,Autocuration,,CHEMBL615272,,562.0,,8,1,,B,,,BAO_0000357,10413
11303,,H,,,241,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",,Autocuration,,CHEMBL615103,,562.0,,8,1,,B,,,BAO_0000357,10413
11303,,H,,,242,Escherichia coli,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",,Autocuration,,CHEMBL615104,,562.0,,8,1,,B,,,BAO_0000357,10413
12220,,H,,,243,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",,Autocuration,,CHEMBL615105,,,,8,1,,B,,,BAO_0000357,10413
12220,,H,,,244,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",,Autocuration,,CHEMBL872866,,,,8,1,,B,,,BAO_0000357,10413
11303,,H,,,245,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Autocuration,,CHEMBL615106,,9823.0,,8,1,,B,,,BAO_0000357,7587
11303,,H,,,246,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",,Autocuration,,CHEMBL615107,,9823.0,,8,1,,B,,,BAO_0000019,7587
11303,,H,,,247,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",,Autocuration,,CHEMBL615108,,9823.0,,8,1,,B,,,BAO_0000357,7587
11303,,H,,,248,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",,Autocuration,,CHEMBL615109,,9823.0,,8,1,,B,,,BAO_0000357,7587
11303,,H,,,249,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Autocuration,,CHEMBL615110,,9823.0,,8,1,,B,,,BAO_0000357,7587
11303,,H,,,250,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,Autocuration,,CHEMBL840105,,9823.0,,8,1,,B,,,BAO_0000019,7587
11303,,H,,,251,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",,Autocuration,,CHEMBL615111,,9823.0,,8,1,,B,,,BAO_0000019,7587
11303,,H,,,252,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",,Autocuration,,CHEMBL615112,,9823.0,,8,1,,B,,,BAO_0000019,7587
11303,,H,,,253,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",,Autocuration,,CHEMBL615113,,9823.0,,8,1,,B,,,BAO_0000019,7587
11303,,H,,,254,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",,Autocuration,,CHEMBL615114,,9823.0,,8,1,,B,,,BAO_0000019,7587
11303,,H,,,255,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",,Autocuration,,CHEMBL615115,,9823.0,,8,1,,B,,,BAO_0000357,7587
11303,,H,,,256,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",,Autocuration,,CHEMBL615116,,9823.0,,8,1,,B,,,BAO_0000019,7587
11303,,H,,,257,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",,Autocuration,,CHEMBL615698,,,,8,1,,B,,,BAO_0000357,7323
22226,,U,,,258,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",,Autocuration,,CHEMBL615699,,9823.0,,0,1,,B,,,BAO_0000019,7587
22226,,U,,,259,Sus scrofa,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",,Autocuration,,CHEMBL615700,,9823.0,,0,1,,B,,,BAO_0000019,7587
100249,,H,,,260,Saccharomyces cerevisiae,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,,Expert,,CHEMBL615701,,4932.0,,8,1,,B,,,BAO_0000357,13750
22226,,U,,,261,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,Autocuration,,CHEMBL615702,,10116.0,,0,1,,B,,,BAO_0000019,7662
22226,,U,,,262,Rattus norvegicus,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,,Autocuration,,CHEMBL615703,,10116.0,,0,1,,B,,,BAO_0000019,7662
22226,,U,,,263,Rattus norvegicus,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",,Autocuration,,CHEMBL615704,,10116.0,,0,1,,B,,,BAO_0000019,7662
104698,,H,,,264,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,Autocuration,,CHEMBL615705,,,,6,1,,F,,,BAO_0000019,12211
104698,,H,,,265,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",,Autocuration,,CHEMBL615706,,,,6,1,,F,,,BAO_0000019,12211
20033,,D,2116.0,,266,Cavia porcellus,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,Ileum,Intermediate,,CHEMBL615707,,10141.0,,9,1,,F,,,BAO_0000221,12211
10623,,H,,,267,,Stimulatory activity of intragastric pressure was tested in the rat,,Expert,,CHEMBL615708,,,,8,1,,F,,,BAO_0000019,12211
121,,H,,,268,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,,Autocuration,,CHEMBL615709,,,,8,1,,B,,,BAO_0000357,15453
22226,,U,,,269,Rattus norvegicus,Dose to reduce neuronal firing against 5-HT cells in rats (iv),,Autocuration,,CHEMBL615710,,10116.0,,0,1,,F,,,BAO_0000218,11884
12688,,H,,,270,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,Autocuration,,CHEMBL615711,,,,8,1,,F,,,BAO_0000019,7185
121,,D,,,271,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,,Expert,,CHEMBL615712,,9606.0,,9,1,,B,,,BAO_0000357,6876
121,,D,,,272,Homo sapiens,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,,Expert,,CHEMBL836325,,9606.0,,9,1,,B,,,BAO_0000357,6876
12198,,H,,,273,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,,Autocuration,,CHEMBL615713,,,,8,1,,F,,,BAO_0000019,11863
12198,,H,,,274,,Inhibition constant of high-affinity 5-HT uptake,,Autocuration,,CHEMBL615714,,,,8,1,,B,,,BAO_0000357,11863
12198,,H,,,275,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,,Autocuration,,CHEMBL615715,,,,8,1,,F,,,BAO_0000019,11863
12198,,H,,,276,,Maximum rate was determined for high affinity transport of 5-HT,,Autocuration,,CHEMBL615716,,,,8,1,,F,,,BAO_0000019,11863
104714,,H,,,277,,Compound was tested for agonistic activity against 5-HT uptake,,Autocuration,,CHEMBL615717,,,,4,1,,F,,,BAO_0000019,4639
10577,,H,,,278,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,,Expert,,CHEMBL881818,,,,8,1,,B,,,BAO_0000019,15796
105,,H,,,279,Bos taurus,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,,Expert,,CHEMBL884540,,9913.0,,8,1,,B,,,BAO_0000357,15796
104744,,D,,,280,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL615718,,10116.0,,5,1,,B,,,BAO_0000224,12801
104744,,H,,,281,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,,Autocuration,,CHEMBL615719,,,,4,1,,B,,,BAO_0000224,12801
104744,,H,,,282,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,,Autocuration,,CHEMBL615720,,,,4,1,,B,,Membranes,BAO_0000249,12120
104744,,H,,,283,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,,Autocuration,,CHEMBL615721,,,,4,1,,B,,Membranes,BAO_0000249,12120
104744,,H,,,284,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,Autocuration,,CHEMBL615722,,,,4,1,,B,,,BAO_0000019,11963
51,,H,,,285,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,,Autocuration,,CHEMBL615723,,,,8,1,,F,,,BAO_0000019,11701
51,,H,10000000.0,,286,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615724,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,287,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615725,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,288,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615726,,,,8,1,,B,,,BAO_0000221,9995
10576,,H,,,289,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),,Autocuration,,CHEMBL615727,In vivo,,,8,1,,F,,,BAO_0000218,16394
105570,,D,,,290,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,,Intermediate,,CHEMBL615728,,10141.0,,9,1,,F,,,BAO_0000019,11574
279,,H,,,291,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL857971,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
107,,H,,,292,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL615729,,,,8,1,,B,,,BAO_0000357,15363
12687,,D,,,293,Rattus norvegicus,Efficacy against 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL615730,,10116.0,,9,1,,F,,,BAO_0000019,15363
12687,,H,,,294,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,,Expert,,CHEMBL615731,,,,8,1,,F,,,BAO_0000019,15329
12687,,H,,,295,,Relative potency towards 5-HT2A receptor of rat tail artery,,Expert,,CHEMBL615732,,,,8,1,,F,,,BAO_0000019,15329
12687,,H,,,296,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,,Expert,,CHEMBL615733,,,,8,1,,F,,,BAO_0000019,15329
12687,,H,,,297,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,,Expert,,CHEMBL615734,,,,8,1,,F,,,BAO_0000019,15329
12687,,H,,,298,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,,Autocuration,,CHEMBL615735,,,,8,1,,F,,,BAO_0000019,15329
12687,,H,,,299,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,,Expert,,CHEMBL615736,,,,8,1,,F,,,BAO_0000019,15329
20033,,D,2116.0,,300,Cavia porcellus,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,Intermediate,,CHEMBL615737,,10141.0,,9,1,,F,,,BAO_0000221,273
20033,,D,2116.0,,301,Cavia porcellus,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),Ileum,Intermediate,,CHEMBL615738,,10141.0,,9,1,,F,,,BAO_0000221,273
20033,,D,2116.0,,302,Cavia porcellus,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,Intermediate,,CHEMBL615739,,10141.0,,9,1,,F,,,BAO_0000221,273
10623,,H,,,303,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,,Autocuration,,CHEMBL615278,,,,8,1,,B,,,BAO_0000357,12092
10623,,D,,,304,Rattus norvegicus,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,Expert,,CHEMBL615279,,10116.0,,9,1,,F,,,BAO_0000019,1317
168,,H,,,305,,Binding affinity against 5-hydroxytryptamine 4 receptor,,Expert,,CHEMBL615280,,,,8,1,,B,,,BAO_0000357,12409
22226,,U,,,306,Gallus gallus,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,,Autocuration,,CHEMBL615281,,9031.0,,0,1,,B,,,BAO_0000019,11126
22226,,U,,,307,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,,Autocuration,,CHEMBL615282,,9606.0,,0,1,,F,,,BAO_0000019,11126
22226,,U,,,308,Homo sapiens,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,,Autocuration,,CHEMBL615283,,9606.0,,0,1,,F,,,BAO_0000019,11126
80156,,N,,,309,Homo sapiens,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,,Autocuration,,CHEMBL615284,,9606.0,649.0,1,1,HL-60,B,,,BAO_0000219,11126
22226,,U,,,310,Homo sapiens,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,,Autocuration,,CHEMBL615285,,9606.0,,0,1,,B,,,BAO_0000019,11126
22226,,U,,,311,Homo sapiens,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,,Autocuration,,CHEMBL615286,,9606.0,,0,1,,B,,,BAO_0000019,11126
104703,,D,,,312,Homo sapiens,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,,Autocuration,,CHEMBL615287,,9606.0,,7,1,Oocytes,B,,,BAO_0000219,17807
100256,,S,,,313,,Chymotryptic inhibitory activity against 26S proteasome,,Intermediate,,CHEMBL615288,,,,2,1,,F,,,BAO_0000220,16575
100256,,S,,,314,,Inhibitory activity against 26S proteasome degradation of IkB,,Intermediate,,CHEMBL615289,,,,2,1,,B,,,BAO_0000220,15407
81034,,N,,,315,Homo sapiens,In vitro inhibition of 2780/DOX ovarian cancer cell line,,Intermediate,,CHEMBL615290,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,10797
81034,,N,,,316,Homo sapiens,In vitro inhibition of 2780/S ovarian cancer cell line,,Intermediate,,CHEMBL884522,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,10797
22226,,U,,,317,Homo sapiens,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,,Autocuration,,CHEMBL615291,,9606.0,,0,1,,F,,,BAO_0000019,3469
22222,,M,,,318,,Association constant for binding to AATT 28-mer AATT hairpin,,Intermediate,,CHEMBL615292,,,,3,1,,B,,,BAO_0000225,16037
22222,,M,,,319,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,,Intermediate,,CHEMBL615293,,,,3,1,,B,,,BAO_0000225,16037
22222,,M,,,320,,Reaction Rate Parameter for 28-mer AATT hairpin,,Intermediate,,CHEMBL615294,,,,3,1,,B,,,BAO_0000225,16037
22222,,M,,,321,,Reaction Rate Parameter for 28-mer AATT hairpin,,Intermediate,,CHEMBL615295,,,,3,1,,B,,,BAO_0000225,16037
22226,,U,,,322,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),,Autocuration,,CHEMBL825021,,9606.0,,0,1,,F,,,BAO_0000019,16524
22226,,U,,,323,Homo sapiens,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),,Autocuration,,CHEMBL615296,,9606.0,,0,1,,F,,,BAO_0000019,16524
22226,,U,,,324,Homo sapiens,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,,Autocuration,,CHEMBL615297,,9606.0,,0,1,,F,,,BAO_0000019,16524
22226,,U,,,325,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 determined by MTT test,,Autocuration,,CHEMBL615298,,10029.0,,0,1,,F,,,BAO_0000019,16758
22226,,U,,,326,Cricetulus griseus,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,,Autocuration,,CHEMBL615299,,10029.0,,0,1,,F,,,BAO_0000019,16758
22226,,U,,,327,Cricetulus griseus,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,,Autocuration,,CHEMBL615300,,10029.0,,0,1,,F,,,BAO_0000019,16758
241,,H,,,328,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,,Autocuration,,CHEMBL615301,,,,8,1,,B,,,BAO_0000357,14360
241,,D,,,329,Homo sapiens,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,,Expert,,CHEMBL615302,,9606.0,,9,1,,B,,,BAO_0000357,14360
22226,,U,,,330,Rattus norvegicus,Selectivity ratio of ID50 in liver and heart,,Autocuration,,CHEMBL615303,,10116.0,,0,1,,B,,,BAO_0000019,9964
12132,,H,,,331,,"Selectivity, ratio of relative ID50 in liver and heart",,Autocuration,,CHEMBL615304,,,,8,1,,B,,,BAO_0000019,9964
12132,,H,,,332,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,,Autocuration,,CHEMBL615305,,,,8,1,,B,,,BAO_0000019,9964
12132,,H,,,333,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,Autocuration,,CHEMBL615306,,,,8,1,,B,,,BAO_0000218,9964
12132,,H,,,334,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,Autocuration,,CHEMBL615307,,,,8,1,,B,,,BAO_0000218,9964
12132,,H,,,335,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,Autocuration,,CHEMBL615308,In vivo,,,8,1,,B,,,BAO_0000218,9964
12132,,H,,,336,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,Autocuration,,CHEMBL615309,In vivo,,,8,1,,F,,,BAO_0000218,9964
22226,,U,,,337,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",,Autocuration,,CHEMBL615310,,,,0,1,,B,,,BAO_0000019,9964
12132,,H,,,338,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,,Autocuration,,CHEMBL615311,,,,8,1,,B,,,BAO_0000019,9964
22226,,U,,,339,Homo sapiens,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",,Autocuration,,CHEMBL615312,,9606.0,,0,1,,B,,,BAO_0000019,9964
12132,,H,,,340,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,Autocuration,,CHEMBL615313,,,,8,1,,B,,,BAO_0000019,9964
12132,,H,,,341,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,,Autocuration,,CHEMBL615314,,,,8,1,,F,,,BAO_0000019,9964
12132,,H,,,342,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",,Autocuration,,CHEMBL615315,,,,8,1,,B,,,BAO_0000019,9964
22226,,U,,,343,Rattus norvegicus,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",,Autocuration,,CHEMBL615316,,10116.0,,0,1,,B,,,BAO_0000218,9964
12132,,H,,,344,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,,Autocuration,,CHEMBL615317,In vivo,,,8,1,,B,,,BAO_0000218,9964
12132,,H,,,345,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",,Autocuration,,CHEMBL615318,,,,8,1,,B,,,BAO_0000218,9964
22226,,U,,,346,Rattus norvegicus,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",,Autocuration,,CHEMBL615319,,10116.0,,0,1,,B,,,BAO_0000218,9964
12132,,H,,,347,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,Autocuration,,CHEMBL615320,,,,8,1,,B,,,BAO_0000019,9964
12132,,H,,,348,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",,Autocuration,,CHEMBL615321,,,,8,1,,F,,,BAO_0000019,9964
22226,,U,,,349,Rattus norvegicus,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",,Autocuration,,CHEMBL615322,,10116.0,,0,1,,B,,,BAO_0000019,3796
19690,,H,,,350,Escherichia coli,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,Autocuration,,CHEMBL615323,,562.0,,8,1,,B,,,BAO_0000357,4251
19690,,H,,,351,Escherichia coli,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,,Autocuration,,CHEMBL615407,,562.0,,8,1,,B,,,BAO_0000357,4251
19690,,H,,,352,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,Autocuration,,CHEMBL857267,,562.0,,8,1,,B,,,BAO_0000357,4251
19690,,H,,,353,Escherichia coli,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,,Autocuration,,CHEMBL615408,,562.0,,8,1,,B,,,BAO_0000357,4251
19690,,H,,,354,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,,Autocuration,,CHEMBL615409,,,,8,1,,B,,,BAO_0000357,166
19690,,H,,,355,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,,Autocuration,,CHEMBL615410,,,,8,1,,B,,,BAO_0000357,17861
19690,,H,,,356,,Inhibition constant against 3-dehydroquinate synthase,,Autocuration,,CHEMBL615411,,,,8,1,,B,,,BAO_0000357,166
19690,,H,,,357,,Association rate constant against 3-dehydroquinate synthase,,Autocuration,,CHEMBL615412,,,,8,1,,B,,,BAO_0000357,166
19690,,H,,,358,,Rate constant against 3-dehydroquinate synthase,,Autocuration,,CHEMBL615413,,,,8,1,,B,,,BAO_0000357,166
22226,,U,,,359,,Inhibitory activity against fuc-TVII,,Autocuration,,CHEMBL615414,,,,0,1,,B,,,BAO_0000019,3548
12236,,D,2107.0,,360,Rattus norvegicus,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,Autocuration,,CHEMBL615415,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
12236,,D,2107.0,,361,Rattus norvegicus,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,Autocuration,,CHEMBL615416,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
12236,,D,2107.0,,362,Rattus norvegicus,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,Autocuration,,CHEMBL615417,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
12236,,D,2107.0,,363,Rattus norvegicus,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,Autocuration,,CHEMBL615418,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
12236,,D,2107.0,,364,Rattus norvegicus,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,Liver,Autocuration,,CHEMBL615419,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
12236,,D,2107.0,,365,Rattus norvegicus,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,Liver,Autocuration,,CHEMBL615420,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
12236,,D,2107.0,,366,Rattus norvegicus,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,Liver,Autocuration,,CHEMBL615421,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
12236,,D,2107.0,,367,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,Liver,Autocuration,,CHEMBL615422,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
12236,,D,2107.0,,368,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,Liver,Autocuration,,CHEMBL615423,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
12236,,D,2107.0,,369,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,Liver,Autocuration,,CHEMBL872868,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
12236,,D,2107.0,,370,Rattus norvegicus,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,Liver,Autocuration,,CHEMBL615424,,10116.0,,9,1,,B,,Microsomes,BAO_0000251,9877
104832,,H,,,371,,Inhibitory activity against 3-phosphoglycerate kinase.,,Autocuration,,CHEMBL825022,,,,4,1,,B,,,BAO_0000224,3003
104832,,H,,,372,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,,Autocuration,,CHEMBL615425,,,,4,1,,B,,,BAO_0000224,3003
104832,,H,,,373,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",,Autocuration,,CHEMBL615426,,,,4,1,,B,,,BAO_0000224,3003
10612,,D,,,374,Homo sapiens,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,,Expert,,CHEMBL615427,,9606.0,,9,1,,B,,,BAO_0000357,17185
80616,,N,,,375,Homo sapiens,Cytotoxicity on 3677 melanoma cells,,Intermediate,,CHEMBL615428,,9606.0,844.0,1,1,3677 melanoma cell line,F,,,BAO_0000219,6072
80616,,N,,,376,Homo sapiens,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,,Intermediate,,CHEMBL615429,,9606.0,844.0,1,1,3677 melanoma cell line,F,,,BAO_0000219,6072
80617,,N,,,377,Mus musculus,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,,Intermediate,,CHEMBL615430,,10090.0,700.0,1,1,MC-38,F,,,BAO_0000219,5018
22226,,U,,,378,Homo sapiens,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,,Intermediate,,CHEMBL615431,,9606.0,,0,1,,F,,,BAO_0000019,2852
22226,,U,,,379,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,,Autocuration,,CHEMBL615432,,,798.0,0,1,B16,F,,,BAO_0000218,8663
22226,,U,,,380,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,,Autocuration,,CHEMBL615433,,,798.0,0,1,B16,F,,,BAO_0000218,8663
12464,,D,,,381,Human rhinovirus 14,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,,Expert,,CHEMBL615434,,12131.0,,9,1,,F,,,BAO_0000019,3245
50085,,N,,,382,Human rhinovirus sp.,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,,Intermediate,,CHEMBL615435,,169066.0,,1,1,,F,,,BAO_0000218,3245
50679,,N,,,383,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,,Intermediate,,CHEMBL615436,,169066.0,,1,1,,F,,,BAO_0000218,3877
50679,,N,,,384,human rhinovirus type 14,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,,Intermediate,,CHEMBL615437,,169066.0,,1,1,,F,,,BAO_0000218,3877
12464,,D,,,385,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Expert,,CHEMBL615438,,12131.0,,9,1,,F,,,BAO_0000019,5861
12464,,D,,,386,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Expert,,CHEMBL615439,,12131.0,,9,1,,F,,,BAO_0000019,5861
12464,,D,,,387,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,,Expert,,CHEMBL615440,,12131.0,,9,1,,F,,,BAO_0000019,5861
12464,,D,,,388,Human rhinovirus 14,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,,Expert,,CHEMBL615441,,12131.0,,9,1,,F,,,BAO_0000019,5861
50665,,N,,,389,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,,Intermediate,,CHEMBL615641,,12059.0,,1,1,,F,,,BAO_0000218,13748
50665,,N,,,390,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,,Intermediate,,CHEMBL872065,,12059.0,,1,1,,F,,,BAO_0000218,13748
50665,,N,,,391,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,,Intermediate,,CHEMBL825023,,12059.0,,1,1,,F,,,BAO_0000218,13748
50665,,N,,,392,Enterovirus,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,,Intermediate,,CHEMBL615642,,12059.0,,1,1,,F,,,BAO_0000218,13748
12464,,H,,,393,Human rhinovirus B,Inhibition of human rhinovirus 3C protease,,Expert,,CHEMBL615643,,147712.0,,8,1,,B,,,BAO_0000357,13748
22226,,U,,,394,Homo sapiens,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,,Autocuration,,CHEMBL615644,,9606.0,,0,1,,B,,,BAO_0000019,17699
80619,,N,,,395,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),,Intermediate,,CHEMBL615645,,10090.0,833.0,1,1,3EM 37,F,,,BAO_0000218,7145
80619,,N,,,396,Mus musculus,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),,Intermediate,,CHEMBL615646,,10090.0,833.0,1,1,3EM 37,F,,,BAO_0000218,7145
80619,,N,,,397,Mus musculus,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),,Intermediate,,CHEMBL615647,,10090.0,833.0,1,1,3EM 37,F,,,BAO_0000218,7145
80619,,N,,,398,Mus musculus,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),,Intermediate,,CHEMBL615648,,10090.0,833.0,1,1,3EM 37,F,,,BAO_0000218,7145
80619,,N,,,399,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,,Intermediate,,CHEMBL615649,,10090.0,833.0,1,1,3EM 37,F,,,BAO_0000218,7145
80619,,N,,,400,Mus musculus,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,,Intermediate,,CHEMBL615650,,10090.0,833.0,1,1,3EM 37,F,,,BAO_0000218,7145
80620,,N,,,401,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,Intermediate,,CHEMBL615651,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000218,5325
80620,,N,,,402,Mus musculus,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,,Intermediate,,CHEMBL615652,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000218,5325
80620,,N,,,403,Mus musculus,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,,Expert,,CHEMBL615653,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000218,5325
80620,,N,,,404,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,,Intermediate,,CHEMBL615654,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,405,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,,Intermediate,,CHEMBL615655,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,406,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,,Intermediate,,CHEMBL825024,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,407,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,,Intermediate,,CHEMBL615656,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,408,Mus musculus,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,,Intermediate,,CHEMBL615657,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,409,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,,Intermediate,,CHEMBL615658,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,410,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,,Intermediate,,CHEMBL615659,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,411,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,,Intermediate,,CHEMBL615660,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,412,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,Intermediate,,CHEMBL615661,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,413,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,,Intermediate,,CHEMBL615662,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,414,Mus musculus,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,,Intermediate,,CHEMBL615663,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,415,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,,Intermediate,,CHEMBL615664,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,416,Mus musculus,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,,Intermediate,,CHEMBL615665,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,417,Mus musculus,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,,Intermediate,,CHEMBL615666,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,418,Mus musculus,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,,Intermediate,,CHEMBL615667,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,419,Mus musculus,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,,Intermediate,,CHEMBL615668,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,420,Mus musculus,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,,Intermediate,,CHEMBL615669,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,421,Mus musculus,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,,Intermediate,,CHEMBL615670,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,422,Mus musculus,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,,Intermediate,,CHEMBL836739,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,423,Mus musculus,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,,Intermediate,,CHEMBL615671,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,424,Mus musculus,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,,Intermediate,,CHEMBL615672,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,425,Mus musculus,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,,Intermediate,,CHEMBL615791,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,426,Mus musculus,spermine levels in 3LL cells after the treatment of 1 uM of Compound,,Intermediate,,CHEMBL615792,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,427,Mus musculus,spermine levels in 3LL cells after the treatment of 10 uM of Compound,,Intermediate,,CHEMBL615793,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,428,Mus musculus,spermine levels in 3LL cells after the treatment of 250 uM of Compound,,Intermediate,,CHEMBL615794,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80620,,N,,,429,Mus musculus,spermine levels in 3LL cells after the treatment of 50 uM of Compound,,Intermediate,,CHEMBL615795,,10090.0,847.0,1,1,3LL cell line,F,,,BAO_0000219,16169
80621,,N,,,430,Homo sapiens,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,,Intermediate,,CHEMBL615590,,9606.0,971.0,1,1,3LLD122,F,,,BAO_0000219,15547
22226,,U,,,431,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,,Autocuration,,CHEMBL615591,,,,0,1,,F,,,BAO_0000218,8663
22226,,U,,,432,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,,Autocuration,,CHEMBL615592,,,,0,1,,F,,,BAO_0000218,8663
22226,,U,,,433,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,,Autocuration,,CHEMBL615593,,,,0,1,,F,,,BAO_0000218,8663
22226,,U,,,434,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,,Autocuration,,CHEMBL615594,,,,0,1,,F,,,BAO_0000218,8663
80951,,N,,,435,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,Intermediate,,CHEMBL615595,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,4504
80951,,N,,,436,Mus musculus,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,,Intermediate,,CHEMBL615596,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,4504
11169,,H,,,437,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,,Expert,,CHEMBL615597,,,723.0,8,1,NIH3T3,F,,,BAO_0000219,12695
80951,,N,,,438,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,,Intermediate,,CHEMBL615598,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12695
80951,,N,,,439,Mus musculus,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,,Intermediate,,CHEMBL615599,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12695
80951,,N,,,440,Mus musculus,Effective dose against murine 3T3 fibroblasts cells,,Expert,,CHEMBL615600,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,17642
80951,,N,,,441,Mus musculus,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,,Expert,,CHEMBL615601,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,17642
80951,,N,,,442,Mus musculus,Cytotoxic effect on 3T3 cells,,Expert,,CHEMBL615602,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12340
80951,,N,,,443,Mus musculus,Cytotoxic effect on 3T3 cells,,Expert,,CHEMBL615603,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12340
80951,,N,,,444,Mus musculus,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,,Intermediate,,CHEMBL615604,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12716
80951,,N,,,445,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,Intermediate,,CHEMBL615605,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,6277
80951,,N,,,446,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,,Intermediate,,CHEMBL615606,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,6277
80951,,N,,,447,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,,Expert,,CHEMBL884526,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,6277
80951,,N,,,448,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,,Expert,,CHEMBL615607,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,6277
80951,,N,,,449,Mus musculus,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,,Intermediate,,CHEMBL615608,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,6277
80951,,N,,,450,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,,Expert,,CHEMBL615609,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,6277
80951,,N,,,451,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,,Expert,,CHEMBL615682,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,6277
80951,,N,,,452,Mus musculus,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,,Intermediate,,CHEMBL615683,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,6277
80951,,N,,,453,Mus musculus,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,,Expert,,CHEMBL615684,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000218,17780
104860,,D,,,454,Mus musculus,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,,Autocuration,,CHEMBL615685,,10090.0,,7,1,,F,,,BAO_0000219,12751
80951,,N,,,455,Mus musculus,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,,Expert,,CHEMBL615686,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12380
80951,,N,,,456,Mus musculus,Inhibitory activity against 3T3 cell line,,Intermediate,,CHEMBL615687,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,14892
80951,,N,,,457,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,,Intermediate,,CHEMBL884523,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12695
11169,,H,,,458,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,,Expert,,CHEMBL615688,,,,8,1,,F,,,BAO_0000019,12695
80951,,N,,,459,Mus musculus,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,,Intermediate,,CHEMBL615689,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12695
80951,,N,,,460,Mus musculus,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,,Intermediate,,CHEMBL615690,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12695
11169,,H,,,461,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,,Expert,,CHEMBL615691,,,,8,1,,F,,,BAO_0000019,12695
11169,,H,,,462,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,,Expert,,CHEMBL615692,,,,8,1,,F,,,BAO_0000019,12695
80951,,N,,,463,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,,Intermediate,,CHEMBL615693,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,6277
80951,,N,,,464,Mus musculus,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,,Expert,,CHEMBL615324,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,6277
9,,D,,,465,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,,Expert,,CHEMBL615325,,9606.0,723.0,9,1,NIH3T3,F,,,BAO_0000219,4959
9,,D,,,466,Homo sapiens,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),,Expert,,CHEMBL615490,,9606.0,723.0,9,1,NIH3T3,F,,,BAO_0000219,4959
188,,D,,,467,Homo sapiens,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,,Expert,,CHEMBL615491,,9606.0,723.0,9,1,NIH3T3,F,,,BAO_0000219,4959
188,,D,,,468,Homo sapiens,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),,Expert,,CHEMBL615492,,9606.0,723.0,9,1,NIH3T3,F,,,BAO_0000219,4959
80951,,N,,,469,Mus musculus,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,,Intermediate,,CHEMBL615493,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12082
80951,,N,,,470,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,,Intermediate,,CHEMBL615494,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12082
80951,,N,,,471,Mus musculus,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,,Intermediate,,CHEMBL615495,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12082
80951,,N,,,472,Mus musculus,Inhibitory concentration was calculated on 3T3 cells by using growth assay,,Intermediate,,CHEMBL615496,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12082
80951,,N,,,473,Mus musculus,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,,Intermediate,,CHEMBL615497,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,2643
80951,,N,,,474,Mus musculus,Inhibition of Swiss 3T3 mouse fibroblast proliferation,,Expert,,CHEMBL615498,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,11926
80951,,N,,,475,Mus musculus,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,,Intermediate,,CHEMBL615499,,10090.0,723.0,1,1,NIH3T3,A,,,BAO_0000219,15204
80951,,N,,,476,Mus musculus,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,,Expert,,CHEMBL835522,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,15992
80951,,N,,,477,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,,Intermediate,,CHEMBL615500,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,16279
80951,,N,,,478,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Intermediate,,CHEMBL615501,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,16279
80951,,N,,,479,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Intermediate,,CHEMBL615502,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,16279
80951,,N,,,480,Mus musculus,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Intermediate,,CHEMBL615503,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,16279
80951,,N,,,481,Mus musculus,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Intermediate,,CHEMBL615504,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,16279
80951,,N,,,482,Mus musculus,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),,Intermediate,,CHEMBL615505,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,16279
80951,,N,,,483,Mus musculus,Inhibition of swiss 3T3 mouse fibroblast proliferation,,Expert,,CHEMBL615506,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,12831
80951,,N,,,484,Mus musculus,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,,Intermediate,,CHEMBL615507,,10090.0,723.0,1,1,NIH3T3,F,,,BAO_0000219,13497
80006,,N,,,485,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,Intermediate,,CHEMBL615508,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,486,Mus musculus,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,,Intermediate,,CHEMBL615509,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,13618
80006,,N,,,487,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,,Intermediate,,CHEMBL615510,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,11902
80006,,N,,,488,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,,Intermediate,,CHEMBL615511,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,11902
80006,,N,,,489,Mus musculus,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,,Intermediate,,CHEMBL615512,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,11902
80006,,N,,,490,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",,Intermediate,,CHEMBL615513,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000218,14840
80006,,N,,,491,Mus musculus,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",,Intermediate,,CHEMBL615514,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000218,14840
80006,,N,,,492,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,,Intermediate,,CHEMBL615515,,,620.0,1,1,3T3-L1,F,,,BAO_0000219,13715
80006,,N,,,493,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,Intermediate,,CHEMBL615516,,,620.0,1,1,3T3-L1,F,,,BAO_0000219,13715
80006,,N,,,494,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,Intermediate,,CHEMBL615517,,,620.0,1,1,3T3-L1,F,,,BAO_0000219,13715
80006,,N,,,495,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,Intermediate,,CHEMBL615518,,,620.0,1,1,3T3-L1,F,,,BAO_0000219,13715
80006,,N,,,496,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,Intermediate,,CHEMBL615519,,,620.0,1,1,3T3-L1,F,,,BAO_0000219,13715
80006,,N,,,497,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,,Intermediate,,CHEMBL615520,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,498,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,,Intermediate,,CHEMBL615521,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,499,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,Intermediate,,CHEMBL615522,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,500,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,Intermediate,,CHEMBL615523,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,501,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,Expert,,CHEMBL615524,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,502,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,Expert,,CHEMBL615525,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,503,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,,Intermediate,,CHEMBL615526,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,504,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,Intermediate,,CHEMBL615527,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,505,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,,Intermediate,,CHEMBL615528,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,506,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,Expert,,CHEMBL615529,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,507,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,Expert,,CHEMBL615530,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,508,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,Expert,,CHEMBL615531,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,509,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,,Intermediate,,CHEMBL615532,,,620.0,1,1,3T3-L1,F,,,BAO_0000219,13715
80006,,N,,,510,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,,Intermediate,,CHEMBL615533,,,620.0,1,1,3T3-L1,F,,,BAO_0000219,13715
80006,,N,,,511,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,,Intermediate,,CHEMBL615534,,,620.0,1,1,3T3-L1,F,,,BAO_0000219,13715
80006,,N,,,512,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,,Intermediate,,CHEMBL615535,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,513,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,,Intermediate,,CHEMBL615536,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,514,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,,Intermediate,,CHEMBL615537,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,515,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,,Intermediate,,CHEMBL615538,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
80006,,N,,,516,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,,Intermediate,,CHEMBL836166,,,620.0,1,1,3T3-L1,F,,,BAO_0000218,13715
11214,,H,,,517,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,,Expert,,CHEMBL615539,,,620.0,8,1,3T3-L1,F,,,BAO_0000219,6411
80006,,N,,,518,Mus musculus,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,,Intermediate,,CHEMBL615540,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,6411
11214,,H,,,519,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,,Expert,,CHEMBL615541,,,620.0,8,1,3T3-L1,F,,,BAO_0000219,6411
80006,,N,,,520,Mus musculus,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,,Expert,,CHEMBL615542,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,3966
80006,,N,,,521,Mus musculus,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,,Intermediate,,CHEMBL615543,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,3966
80006,,N,,,522,Mus musculus,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,,Expert,,CHEMBL615544,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,15556
80006,,N,,,523,Mus musculus,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,Expert,,CHEMBL615545,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,5845
80006,,N,,,524,Mus musculus,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,,Expert,,CHEMBL615546,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,14422
80006,,N,,,525,Mus musculus,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,,Expert,,CHEMBL615547,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,5845
80006,,N,,,526,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,,Expert,,CHEMBL615548,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,14508
80006,,N,,,527,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,,Expert,,CHEMBL615549,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,14508
80006,,N,,,528,Mus musculus,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,,Expert,,CHEMBL615550,,10090.0,620.0,1,1,3T3-L1,F,,,BAO_0000219,14508
80622,,N,,,529,Rattus norvegicus,Inhibitory activity against rat fibroblast (3Y1) cell line,,Intermediate,,CHEMBL615551,,10116.0,1118.0,1,1,3Y1 cell line,F,,,BAO_0000219,6349
80622,,N,,,530,Rattus norvegicus,Mean concentration causing inhibition of cell growth in 3Y1 cells.,,Expert,,CHEMBL615552,,10116.0,1118.0,1,1,3Y1 cell line,F,,,BAO_0000219,15899
80622,,N,,,531,Rattus norvegicus,Cytotoxicity in 3Y1 cells.,,Expert,,CHEMBL615553,,10116.0,1118.0,1,1,3Y1 cell line,F,,,BAO_0000219,15899
80622,,N,,,532,Rattus norvegicus,Cytostatic effect in 3Y1 cells.,,Expert,,CHEMBL615554,,10116.0,1118.0,1,1,3Y1 cell line,F,,,BAO_0000219,15899
80622,,N,,,533,Rattus norvegicus,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",,Intermediate,,CHEMBL615555,,10116.0,1118.0,1,1,3Y1 cell line,F,,,BAO_0000219,15899
80622,,N,,,534,Rattus norvegicus,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,,Expert,,CHEMBL615556,,10116.0,1118.0,1,1,3Y1 cell line,F,,,BAO_0000219,17038
22226,,U,,,535,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,,Autocuration,,CHEMBL615557,,,,0,1,,B,,,BAO_0000019,12421
22226,,U,,,536,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,Autocuration,,CHEMBL615558,,,,0,1,,B,,,BAO_0000019,12947
22226,,U,,,537,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,,Autocuration,,CHEMBL872066,,,,0,1,,B,,,BAO_0000019,12947
11607,,D,,,538,Sus scrofa,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,,Expert,,CHEMBL615559,,9823.0,,9,1,,B,,,BAO_0000019,4896
11607,,H,,,539,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,,Autocuration,,CHEMBL615560,,,,8,1,,B,,,BAO_0000019,6148
11607,,H,,,540,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,,Autocuration,,CHEMBL615561,,,,8,1,,B,,,BAO_0000019,16432
11607,,H,,,541,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,,Expert,,CHEMBL857062,,,,8,1,,B,,,BAO_0000019,4978
11607,,H,,,542,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),,Expert,,CHEMBL615562,,,,8,1,,B,,,BAO_0000019,4978
11607,,H,,,543,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,,Autocuration,,CHEMBL615563,,,,8,1,,B,,,BAO_0000019,3723
11607,,H,,,544,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),,Autocuration,,CHEMBL615564,,,,8,1,,B,,,BAO_0000357,3518
11607,,H,,,545,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,,Autocuration,,CHEMBL615565,,,,8,1,,B,,,BAO_0000019,4164
11607,,H,,,546,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,,Autocuration,,CHEMBL615566,,,,8,1,,B,,,BAO_0000019,3518
11607,,D,,,547,Sus scrofa,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,,Expert,,CHEMBL615567,,9823.0,,9,1,,B,,,BAO_0000019,4164
11607,,H,,,548,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,,Autocuration,,CHEMBL615568,,,,8,1,,B,,,BAO_0000019,3518
11607,,H,,,549,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),,Autocuration,,CHEMBL615569,,,,8,1,,B,,,BAO_0000357,3518
11607,,H,,,550,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,,Autocuration,,CHEMBL615570,,,,8,1,,B,,,BAO_0000019,4978
11607,,H,,,551,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),,Autocuration,,CHEMBL615571,,,,8,1,,B,,,BAO_0000019,4978
104733,,H,,,552,,Binding affinity against melatonin (MT1) receptor (pC1),,Autocuration,,CHEMBL615572,,,,4,1,,B,,,BAO_0000224,6455
22226,,U,,,553,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,,Autocuration,,CHEMBL615573,,,,0,1,,B,,,BAO_0000019,2222
22226,,U,,,554,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,,Autocuration,,CHEMBL615574,,,,0,1,,B,,,BAO_0000019,13020
22226,,U,,,555,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,,Autocuration,,CHEMBL615575,,,,0,1,,B,,,BAO_0000019,13021
10619,,H,,,556,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,,Autocuration,,CHEMBL615576,,,,8,1,,B,,,BAO_0000357,14532
10619,,H,,,557,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL615577,,,,8,1,,B,,,BAO_0000357,14118
51,,H,10000000.0,,558,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,Hippocampus,Autocuration,,CHEMBL615578,,,,8,1,,B,,,BAO_0000221,11884
51,,H,,,559,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,,Expert,,CHEMBL615579,,,,8,1,,B,,,BAO_0000357,13969
51,,H,,,560,,Binding affinity for 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL615580,,,,8,1,,B,,,BAO_0000357,13392
51,,H,,,561,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,,Expert,,CHEMBL615581,,,,8,1,,B,,,BAO_0000019,14430
51,,H,10000000.0,,562,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615582,,,,8,1,,B,,,BAO_0000221,12248
51,,H,10000000.0,,563,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615583,,,,8,1,,B,,,BAO_0000221,12249
51,,H,10000000.0,,564,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615584,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,565,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL833691,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,566,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615585,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,567,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615586,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,568,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL884524,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,569,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615587,,,,8,1,,B,,,BAO_0000221,12249
51,,H,10000000.0,,570,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Hippocampus,Autocuration,,CHEMBL615588,,,,8,1,,B,,,BAO_0000221,11799
10576,,D,,,571,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,,Expert,,CHEMBL615589,,10116.0,,9,1,,B,,Membranes,BAO_0000249,14331
51,,H,10000000.0,,572,Bos taurus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,Hippocampus,Expert,,CHEMBL615442,,9913.0,,8,1,,B,,,BAO_0000221,11884
51,,H,10000000.0,,573,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,Hippocampus,Autocuration,,CHEMBL615443,,,,8,1,,B,,,BAO_0000221,14331
51,,H,10000000.0,,574,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615444,,,,8,1,,B,,,BAO_0000221,11701
51,,H,10000000.0,,575,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,Hippocampus,Expert,,CHEMBL615445,,,,8,1,,B,,,BAO_0000221,11701
51,,H,10000000.0,,576,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615446,,,,8,1,,B,,,BAO_0000221,12248
51,,H,,,577,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,,Autocuration,,CHEMBL615447,,,449.0,8,1,CHO,B,,,BAO_0000219,12248
51,,H,10000000.0,,578,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,Expert,,CHEMBL615448,,,,8,1,,B,,,BAO_0000221,12248
51,,H,10000000.0,,579,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,Hippocampus,Expert,,CHEMBL615449,,,,8,1,,B,,,BAO_0000221,12249
51,,H,,,580,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,Autocuration,,CHEMBL615450,,,449.0,8,1,CHO,B,,,BAO_0000219,12248
51,,H,10000000.0,,581,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",Hippocampus,Expert,,CHEMBL615451,,,,8,1,,B,,,BAO_0000221,11799
51,,H,,,582,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,Autocuration,,CHEMBL615452,,,,8,1,,B,,,BAO_0000357,634
51,,H,10000000.0,,583,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615453,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,584,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615454,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,585,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615455,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,586,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615456,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,587,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL615457,,,,8,1,,B,,,BAO_0000221,9995
51,,H,10000000.0,,588,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,Hippocampus,Expert,,CHEMBL615458,,,,8,1,,B,,,BAO_0000218,12210
51,,H,10000000.0,,589,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,Expert,,CHEMBL615459,,,,8,1,,B,,,BAO_0000221,13311
51,,D,,,590,Homo sapiens,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",,Expert,,CHEMBL615460,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,2331
51,,H,,,591,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,,Autocuration,,CHEMBL615461,,10141.0,,8,1,,F,,,BAO_0000019,1375
51,,H,,,592,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,,Autocuration,,CHEMBL615462,,10141.0,,8,1,,F,,,BAO_0000019,1375
51,,H,10000000.0,,593,Cavia porcellus,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,Hippocampus,Autocuration,,CHEMBL615463,,10141.0,,8,1,,F,,,BAO_0000221,11574
51,,H,2116.0,,594,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Ileum,Autocuration,,CHEMBL615464,,10141.0,,8,1,,B,,,BAO_0000221,12867
51,,H,2116.0,,595,Cavia porcellus,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,Autocuration,,CHEMBL615465,,10141.0,,8,1,,B,,,BAO_0000221,12867
51,,H,2116.0,,596,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,Ileum,Autocuration,,CHEMBL615466,,10141.0,,8,1,,B,,,BAO_0000221,12867
51,,H,2116.0,,597,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,Autocuration,,CHEMBL615467,,10141.0,,8,1,,B,,,BAO_0000221,12867
51,,H,2116.0,,598,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,Ileum,Autocuration,,CHEMBL615468,,10141.0,,8,1,,B,,,BAO_0000221,12867
51,,H,2116.0,,599,Cavia porcellus,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,Ileum,Autocuration,,CHEMBL615469,,10141.0,,8,1,,B,,,BAO_0000221,12867
51,,H,,,600,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615470,,10141.0,,8,1,,B,,,BAO_0000357,11574
51,,H,,,601,Cavia porcellus,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615471,,10141.0,,8,1,,B,,,BAO_0000357,13114
51,,H,,,602,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615472,,10141.0,,8,1,,B,,,BAO_0000357,13181
106,,H,10000000.0,,603,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Hippocampus,Autocuration,,CHEMBL883242,,10141.0,,8,1,,B,,,BAO_0000221,10639
106,,H,10000000.0,,604,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,Hippocampus,Autocuration,,CHEMBL615473,,10141.0,,8,1,,F,,,BAO_0000221,10639
11863,,H,,,605,Cricetulus griseus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,Autocuration,,CHEMBL615474,,10029.0,449.0,8,1,CHO,B,,,BAO_0000218,11883
51,,H,,,606,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615475,,,,8,1,,B,,,BAO_0000357,17785
51,,H,,,607,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,,Autocuration,,CHEMBL615476,,,308.0,8,1,HeLa,F,,,BAO_0000219,1558
51,,H,,,608,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,,Autocuration,,CHEMBL615477,,,308.0,8,1,HeLa,F,,,BAO_0000219,1558
51,,H,,,609,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615478,,,,8,1,,F,,,BAO_0000019,15740
51,,H,,,610,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615160,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,611,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL615161,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,612,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,,Autocuration,,CHEMBL615162,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,613,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,,Autocuration,,CHEMBL615163,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,614,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,Expert,,CHEMBL615164,,,449.0,8,1,CHO,B,,,BAO_0000219,17624
51,,H,,,615,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,Expert,,CHEMBL615165,,,449.0,8,1,CHO,B,,,BAO_0000219,17624
51,,H,,,616,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,,Autocuration,,CHEMBL615166,,,449.0,8,1,CHO,B,,,BAO_0000219,17624
51,,H,,,617,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,,Autocuration,,CHEMBL615167,,,,8,1,,F,,,BAO_0000219,14256
51,,D,,,618,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,Expert,,CHEMBL615168,,9606.0,308.0,9,1,HeLa,B,,,BAO_0000219,3445
51,,D,,,619,Homo sapiens,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,,Expert,,CHEMBL615169,,9606.0,308.0,9,1,HeLa,B,,,BAO_0000219,3445
51,,D,,,620,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL615170,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,17200
51,,D,,,621,Homo sapiens,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,,Expert,,CHEMBL615171,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,17200
51,,H,,,622,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615694,,,,8,1,,F,,,BAO_0000019,15180
51,,H,,,623,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615695,,,,8,1,,F,,,BAO_0000019,15180
51,,H,,,624,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,Autocuration,,CHEMBL615696,,,,8,1,,F,,,BAO_0000019,16026
51,,H,,,625,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,Autocuration,,CHEMBL615697,,,449.0,8,1,CHO,F,,,BAO_0000219,2759
51,,D,,,626,Homo sapiens,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,Expert,,CHEMBL859410,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,2759
51,,H,,,627,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,Autocuration,,CHEMBL615841,,,449.0,8,1,CHO,F,,,BAO_0000219,2759
51,,D,,,628,Homo sapiens,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,Expert,,CHEMBL615842,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,2759
51,,H,,,629,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,Autocuration,,CHEMBL835003,,,449.0,8,1,CHO,F,,,BAO_0000219,2759
51,,H,,,630,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),,Autocuration,,CHEMBL615843,,,449.0,8,1,CHO,F,,,BAO_0000219,2759
51,,D,,,631,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),,Expert,,CHEMBL615979,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,2759
51,,H,,,632,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),,Autocuration,,CHEMBL615980,,,449.0,8,1,CHO,F,,,BAO_0000219,2759
51,,D,,,633,Homo sapiens,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),,Expert,,CHEMBL615981,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,2759
51,,D,,,634,Homo sapiens,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,,Expert,,CHEMBL615982,,9606.0,,9,1,,F,,,BAO_0000019,3445
51,,D,,,635,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Expert,,CHEMBL615983,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,636,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",,Expert,,CHEMBL615984,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,637,Homo sapiens,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",,Expert,,CHEMBL615985,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,H,,,638,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,Autocuration,,CHEMBL615986,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,639,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,Autocuration,,CHEMBL615987,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,640,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,Autocuration,,CHEMBL615988,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,641,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,,Expert,,CHEMBL615989,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,642,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,,Autocuration,,CHEMBL615990,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,643,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,,Autocuration,,CHEMBL615991,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,644,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,Autocuration,,CHEMBL615992,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,645,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,,Autocuration,,CHEMBL615993,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,646,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,Expert,,CHEMBL615994,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,647,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,,Autocuration,,CHEMBL615995,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,648,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,,Autocuration,,CHEMBL615996,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,649,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,,Autocuration,,CHEMBL615997,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,650,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,Autocuration,,CHEMBL615998,,,,8,1,,F,,,BAO_0000019,6563
51,,H,,,651,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,Autocuration,,CHEMBL615999,,,,8,1,,F,,,BAO_0000019,6563
51,,H,,,652,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,Autocuration,,CHEMBL616000,,,,8,1,,F,,,BAO_0000019,6563
51,,H,,,653,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,Autocuration,,CHEMBL616001,,,722.0,8,1,HEK293,F,,,BAO_0000219,17296
51,,D,,,654,Homo sapiens,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",,Expert,,CHEMBL616002,,9606.0,,9,1,,F,,,BAO_0000019,6876
51,,H,,,655,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",,Expert,,CHEMBL616003,,,,8,1,,F,,,BAO_0000019,6876
51,,D,,,656,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616004,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,657,Homo sapiens,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,,Expert,,CHEMBL616005,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,H,,,658,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,Autocuration,,CHEMBL616006,,,,8,1,,F,,,BAO_0000019,5548
51,,H,,,659,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",,Expert,,CHEMBL616007,,,,8,1,,F,,,BAO_0000019,5548
51,,H,,,660,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,Autocuration,,CHEMBL616008,,,,8,1,,F,,,BAO_0000019,5548
51,,H,,,661,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",,Autocuration,,CHEMBL616009,,,,8,1,,F,,,BAO_0000019,5548
51,,H,,,662,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",,Expert,,CHEMBL616010,,,,8,1,,F,,,BAO_0000019,5929
51,,D,,,663,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",,Expert,,CHEMBL616011,,9606.0,,9,1,,F,,,BAO_0000019,5929
51,,D,,,664,Homo sapiens,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",,Expert,,CHEMBL615740,,9606.0,,9,1,,F,,,BAO_0000019,5929
51,,H,,,665,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",,Autocuration,,CHEMBL615741,,,,8,1,,F,,,BAO_0000019,16245
51,,H,,,666,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,Expert,,CHEMBL615742,,,,8,1,,F,,,BAO_0000019,5640
51,,H,,,667,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",,Autocuration,,CHEMBL615743,,,,8,1,,F,,,BAO_0000019,5640
51,,H,,,668,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,,Autocuration,,CHEMBL615744,,,449.0,8,1,CHO,F,,,BAO_0000219,14509
51,,H,,,669,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,,Expert,,CHEMBL615745,,,449.0,8,1,CHO,F,,,BAO_0000219,14509
51,,H,,,670,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,Autocuration,,CHEMBL615746,,,,8,1,,B,,,BAO_0000357,15331
51,,H,,,671,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,Autocuration,,CHEMBL615747,,,,8,1,,B,,,BAO_0000357,15331
51,,H,,,672,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,Autocuration,,CHEMBL615748,,,,8,1,,F,,,BAO_0000019,6563
51,,H,,,673,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",,Autocuration,,CHEMBL615749,,,,8,1,,F,,,BAO_0000019,6563
51,,H,,,674,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,,Autocuration,,CHEMBL615750,,,,8,1,,F,,,BAO_0000019,6563
51,,D,,,675,Homo sapiens,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616259,,9606.0,,9,1,,F,,,BAO_0000019,6563
51,,H,,,676,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,Autocuration,,CHEMBL616260,,,,8,1,,F,,,BAO_0000019,6563
51,,D,,,677,Homo sapiens,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,,Expert,,CHEMBL616261,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,678,Homo sapiens,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Expert,,CHEMBL616262,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,679,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,Expert,,CHEMBL616263,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,680,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,,Expert,,CHEMBL616264,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,681,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,,Expert,,CHEMBL616265,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,682,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",,Expert,,CHEMBL616266,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,683,Homo sapiens,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",,Expert,,CHEMBL616267,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,684,Homo sapiens,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,,Expert,,CHEMBL616268,,9606.0,,9,1,,F,,,BAO_0000019,5272
51,,D,,,685,Homo sapiens,Inhibition of human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616269,,9606.0,,9,1,,B,,,BAO_0000357,16146
51,,H,,,686,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,Autocuration,,CHEMBL884528,,,449.0,8,1,CHO,B,,,BAO_0000219,17624
105,,D,,,687,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,,Expert,,CHEMBL616270,,,722.0,9,1,HEK293,B,,,BAO_0000219,13706
51,,H,,,688,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,,Autocuration,,CHEMBL616271,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
51,,H,,,689,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616272,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,690,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,,Expert,,CHEMBL616273,,,,8,1,,B,,,BAO_0000357,6861
51,,D,,,691,Homo sapiens,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616274,,9606.0,,9,1,,B,,,BAO_0000357,17200
51,,H,,,692,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,,Autocuration,,CHEMBL616275,,,449.0,8,1,CHO,B,,,BAO_0000219,17624
51,,H,,,693,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,Autocuration,,CHEMBL616276,,,449.0,8,1,CHO,B,,,BAO_0000219,17624
22226,,U,,,694,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,Autocuration,,CHEMBL616277,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,695,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,,Autocuration,,CHEMBL616278,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,696,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,,Autocuration,,CHEMBL616279,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,697,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,Autocuration,,CHEMBL616280,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,698,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,,Autocuration,,CHEMBL616281,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,699,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,,Autocuration,,CHEMBL616282,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,700,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,,Autocuration,,CHEMBL616283,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,701,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,,Autocuration,,CHEMBL616284,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,702,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,,Autocuration,,CHEMBL616285,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,703,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,,Autocuration,,CHEMBL616286,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,704,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,,Autocuration,,CHEMBL616287,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,705,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,,Autocuration,,CHEMBL616288,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,706,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,,Autocuration,,CHEMBL616289,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,707,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,,Autocuration,,CHEMBL615610,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,708,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,,Autocuration,,CHEMBL615611,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,709,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,,Autocuration,,CHEMBL615612,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,710,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,,Autocuration,,CHEMBL615613,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,711,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,,Autocuration,,CHEMBL615614,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
22226,,U,,,712,Rattus norvegicus,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,,Autocuration,,CHEMBL615615,In vivo,10116.0,,0,1,,F,,,BAO_0000218,12058
105093,,H,,,713,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,,Autocuration,,CHEMBL615616,,,,4,1,,B,,,BAO_0000019,11440
11923,,H,1898.0,,714,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,Hypothalamus,Autocuration,,CHEMBL615617,,,,8,1,,B,,,BAO_0000249,6238
10577,,H,,,715,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,,Autocuration,,CHEMBL615618,,,,8,1,,B,,,BAO_0000019,10046
10577,,H,,,716,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,,Autocuration,,CHEMBL615619,,,,8,1,,B,,,BAO_0000019,10046
10577,,H,,,717,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,Expert,,CHEMBL615620,,,,8,1,,B,,,BAO_0000019,10046
55,,H,,,718,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",,Autocuration,,CHEMBL615621,,,,8,1,,B,,,BAO_0000357,167
55,,H,,,719,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",,Autocuration,,CHEMBL615622,,,,8,1,,B,,,BAO_0000357,167
12166,,H,,,720,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),,Autocuration,,CHEMBL615623,,,,8,1,,F,,,BAO_0000019,11520
12166,,H,,,721,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,Autocuration,,CHEMBL615624,,,,8,1,,F,,,BAO_0000019,11520
12166,,H,,,722,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,Autocuration,,CHEMBL615625,,,,8,1,,F,,,BAO_0000019,11520
12166,,H,,,723,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,,Autocuration,,CHEMBL767045,,,,8,1,,F,,,BAO_0000019,11520
55,,H,,,724,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,,Autocuration,,CHEMBL615626,,10141.0,,8,1,,F,,,BAO_0000019,135
55,,H,,,725,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,,Autocuration,,CHEMBL615627,,10141.0,,8,1,,F,,,BAO_0000019,135
55,,H,,,726,Cavia porcellus,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,,Autocuration,,CHEMBL615628,,10141.0,,8,1,,B,,,BAO_0000019,11311
55,,H,,,727,Cavia porcellus,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,Autocuration,,CHEMBL615629,,10141.0,,8,1,,B,,,BAO_0000357,10193
55,,D,,,728,Homo sapiens,Inhibitory concentration against 5-lipoxygenase from human whole blood,,Expert,,CHEMBL615630,,9606.0,,9,1,,B,,,BAO_0000357,12281
55,,H,,,729,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],,Autocuration,,CHEMBL615631,,,,8,1,,B,,,BAO_0000219,11311
17087,,H,,,730,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,Autocuration,,CHEMBL615632,,,,8,1,,F,,,BAO_0000218,12576
17087,,H,,,731,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,,Autocuration,,CHEMBL615633,,,,8,1,,B,,,BAO_0000357,12281
17087,,H,,,732,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,,Autocuration,,CHEMBL615634,,,,8,1,,F,,,BAO_0000218,12576
55,,H,,,733,Sus scrofa,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,,Expert,,CHEMBL615635,,9823.0,,8,1,,B,,,BAO_0000019,11089
12166,,H,,,734,,In vitro inhibition of rat 5-Lipoxygenase,,Expert,,CHEMBL615636,,,,8,1,,B,,,BAO_0000357,11006
12166,,D,,,735,Rattus norvegicus,Inhibitory activity against 5-Lipoxygenase,,Expert,,CHEMBL615637,,10116.0,,9,1,,B,,,BAO_0000357,11481
12166,,H,,,736,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,,Expert,,CHEMBL615638,,,702.0,8,1,RBL-1,B,,,BAO_0000219,10864
12166,,H,,,737,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,Autocuration,,CHEMBL615639,,,702.0,8,1,RBL-1,B,,,BAO_0000219,3595
12166,,H,,,738,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,,Autocuration,,CHEMBL615640,,,702.0,8,1,RBL-1,B,,,BAO_0000219,11311
12166,,H,,,739,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,,Autocuration,,CHEMBL615796,,,,8,1,,B,,,BAO_0000019,11311
12166,,H,,,740,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],,Autocuration,,CHEMBL615845,,,,8,1,,B,,,BAO_0000219,11311
12166,,H,,,741,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,Autocuration,,CHEMBL615846,,,,8,1,,B,,,BAO_0000357,11006
12166,,H,,,742,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,Autocuration,,CHEMBL615847,,,702.0,8,1,RBL-1,B,,,BAO_0000219,3595
12166,,H,,,743,,The compound was tested for inhibition of isolated 5-Lipoxygenase,,Autocuration,,CHEMBL615848,,,,8,1,,B,,,BAO_0000357,11311
22226,,U,,,744,Rattus norvegicus,Ratio of IC50 against 5-LO and COX,,Autocuration,,CHEMBL615849,,10116.0,,0,1,,B,,,BAO_0000019,11481
12166,,H,,,745,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,,Autocuration,,CHEMBL615850,,,,8,1,,B,,,BAO_0000357,11006
12166,,H,,,746,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,,Autocuration,,CHEMBL615851,,,,8,1,,B,,,BAO_0000357,11006
12166,,H,,,747,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,,Autocuration,,CHEMBL615852,,,,8,1,,B,,,BAO_0000219,11311
12166,,H,,,748,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,,Autocuration,,CHEMBL615853,,,,8,1,,F,,,BAO_0000019,11006
120,,H,2367.0,,749,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,Prostate gland,Autocuration,,CHEMBL884527,,,,8,1,,B,,,BAO_0000357,4288
22226,,U,,,750,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,,Autocuration,,CHEMBL872871,,8932.0,,0,1,,B,,,BAO_0000019,7587
22226,,U,,,751,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,,Autocuration,,CHEMBL615854,,8932.0,,0,1,,B,,,BAO_0000019,7587
22226,,U,,,752,Columba livia,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,,Autocuration,,CHEMBL767046,,8932.0,,0,1,,B,,,BAO_0000019,7587
10732,,H,,,753,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,,Autocuration,,CHEMBL615855,,,,8,1,,B,,,BAO_0000357,11249
12198,,D,,,754,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,,Expert,,CHEMBL615856,,10116.0,,9,1,,F,,,BAO_0000019,8003
12198,,D,,,755,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,Expert,,CHEMBL615857,,10116.0,,9,1,,F,,,BAO_0000019,8003
12198,,D,,,756,Rattus norvegicus,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),,Expert,,CHEMBL615858,,10116.0,,9,1,,F,,,BAO_0000019,8003
10576,,H,10000000.0,,757,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Hippocampus,Expert,,CHEMBL615859,,,,8,1,,B,,,BAO_0000221,12416
51,,H,,,758,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,,Autocuration,,CHEMBL615860,,,,8,1,,B,,,BAO_0000357,16293
22226,,U,,,759,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Autocuration,,CHEMBL615861,,9986.0,,0,1,,B,,,BAO_0000019,13047
22226,,U,,,760,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Autocuration,,CHEMBL615862,,9986.0,,0,1,,B,,,BAO_0000019,13047
22226,,U,,,761,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,,Autocuration,,CHEMBL615863,,9986.0,,0,1,,B,,,BAO_0000019,13047
22226,,U,,,762,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,Autocuration,,CHEMBL615864,,9986.0,,0,1,,B,,,BAO_0000019,13047
104744,,H,10000000.0,,763,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,Autocuration,,CHEMBL615865,,,,4,1,,B,,,BAO_0000221,10085
104744,,H,10000000.0,,764,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,Autocuration,,CHEMBL615866,,,,4,1,,B,,,BAO_0000221,10085
104744,,H,10000000.0,,765,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,Hippocampus,Autocuration,,CHEMBL615867,,,,4,1,,B,,,BAO_0000221,10085
104744,,H,,,766,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,,Autocuration,,CHEMBL615868,,,,4,1,,B,,Membranes,BAO_0000249,9841
104744,,D,,,767,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,,Autocuration,,CHEMBL615869,,10116.0,,5,1,,B,,,BAO_0000249,8822
104744,,D,,,768,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,,Autocuration,,CHEMBL615870,,10116.0,,5,1,,B,,,BAO_0000019,9806
104744,,D,,,769,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,,Autocuration,,CHEMBL615871,,10116.0,,5,1,,B,,,BAO_0000019,9806
104744,,H,,,770,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,,Autocuration,,CHEMBL615872,,,,4,1,,B,,,BAO_0000224,8868
104744,,H,10000000.0,,771,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,Hippocampus,Autocuration,,CHEMBL833492,,,,4,1,,B,,,BAO_0000221,9036
104744,,H,10000000.0,,772,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,Hippocampus,Autocuration,,CHEMBL615873,,,,4,1,,B,,,BAO_0000221,11374
104744,,H,,,773,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,,Autocuration,,CHEMBL615479,,,,4,1,,B,,,BAO_0000224,10881
104744,,H,,,774,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,,Autocuration,,CHEMBL615480,,,,4,1,,B,,,BAO_0000019,8822
104744,,D,,,775,Rattus norvegicus,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,,Autocuration,,CHEMBL615481,,10116.0,,5,1,,B,,,BAO_0000249,9806
104744,,H,,,776,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,Autocuration,,CHEMBL872869,,,,4,1,,B,,,BAO_0000019,15463
104744,,H,,,777,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,Autocuration,,CHEMBL615482,,,,4,1,,B,,,BAO_0000019,15463
104744,,H,955.0,,778,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,Autocuration,,CHEMBL615483,,,,4,1,,B,,,BAO_0000221,14542
104744,,H,955.0,,779,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,Autocuration,,CHEMBL615484,,,,4,1,,B,,,BAO_0000221,14542
104744,,H,,,780,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,,Autocuration,,CHEMBL615485,,,,4,1,,B,,,BAO_0000019,8569
104744,,D,,,781,Rattus norvegicus,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,,Autocuration,,CHEMBL615486,,10116.0,,5,1,,B,,,BAO_0000224,10062
104744,,H,,,782,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,,Autocuration,,CHEMBL615487,,,,4,1,,B,,,BAO_0000224,4771
104744,,H,,,783,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,Autocuration,,CHEMBL615488,,,,4,1,,B,,,BAO_0000224,10062
104744,,H,,,784,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,Autocuration,,CHEMBL615489,,,,4,1,,B,,,BAO_0000224,10062
104744,,H,,,785,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,,Autocuration,,CHEMBL615389,,,,4,1,,B,,,BAO_0000224,10062
104744,,H,,,786,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,Autocuration,,CHEMBL615390,,,,4,1,,B,,,BAO_0000019,15463
104744,,H,,,787,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,,Autocuration,,CHEMBL615391,,,,4,1,,B,,,BAO_0000019,15463
104744,,H,,,788,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,,Autocuration,,CHEMBL615392,,,,4,1,,B,,,BAO_0000224,9098
22226,,U,,,789,Rattus norvegicus,Affinity for 5-hydroxytryptamine 1 receptor,,Autocuration,,CHEMBL615393,,10116.0,,0,1,,B,,,BAO_0000019,3070
104744,,H,955.0,,790,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,Brain,Autocuration,,CHEMBL615394,,,,4,1,,B,,,BAO_0000221,14542
104744,,H,955.0,,791,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,Brain,Autocuration,,CHEMBL615395,,,,4,1,,B,,,BAO_0000221,14542
104744,,H,,,792,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,,Autocuration,,CHEMBL615396,,,,4,1,,B,,,BAO_0000224,6398
104744,,H,955.0,,793,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,Brain,Autocuration,,CHEMBL615397,,,,4,1,,B,,,BAO_0000221,1344
104744,,H,,,794,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,,Autocuration,,CHEMBL615398,,,,4,1,,B,,,BAO_0000019,11963
22226,,U,,,795,Rattus norvegicus,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,,Autocuration,,CHEMBL615399,,10116.0,,0,1,,B,,,BAO_0000019,8908
104744,,H,,,796,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,,Autocuration,,CHEMBL615400,,,,4,1,,B,,,BAO_0000019,9098
104744,,D,,,797,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,,Autocuration,,CHEMBL615401,,10116.0,,5,1,,B,,,BAO_0000019,8841
22226,,U,,,798,Rattus norvegicus,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,,Autocuration,,CHEMBL615402,,10116.0,,0,1,,B,,,BAO_0000019,8814
104744,,H,,,799,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,,Autocuration,,CHEMBL615403,,,,4,1,,B,,,BAO_0000019,11752
104744,,H,955.0,,800,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,Brain,Autocuration,,CHEMBL615404,,,,4,1,,B,,,BAO_0000221,11642
104744,,H,,,801,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,,Autocuration,,CHEMBL615781,,,,4,1,,B,,,BAO_0000019,11642
104744,,H,955.0,,802,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,Brain,Autocuration,,CHEMBL615782,,,,4,1,,B,,,BAO_0000220,9231
104744,,H,955.0,,803,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,Brain,Autocuration,,CHEMBL615783,,,,4,1,,B,,,BAO_0000221,11351
22226,,U,,,804,,Compound was tested for binding affinity against 5-HT1 receptor,,Autocuration,,CHEMBL873481,,,,0,1,,B,,,BAO_0000019,4639
22226,,U,,,805,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,,Autocuration,,CHEMBL615784,,,,0,1,,B,,,BAO_0000019,1205
10576,,H,,,806,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,Expert,,CHEMBL615785,,,,8,1,,B,,,BAO_0000357,10025
10576,,H,,,807,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,Autocuration,,CHEMBL615786,,,,8,1,,F,,,BAO_0000249,13241
10576,,H,,,808,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,Autocuration,,CHEMBL615787,In vivo,,,8,1,,F,,,BAO_0000218,16245
10576,,H,,,809,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,Autocuration,,CHEMBL615788,In vivo,,,8,1,,F,,,BAO_0000218,16245
10576,,H,,,810,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL767044,,,,8,1,,F,,,BAO_0000019,12438
10576,,H,,,811,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,,Autocuration,,CHEMBL615789,In vivo,,,8,1,,F,,,BAO_0000218,16245
10576,,H,,,812,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,,Autocuration,,CHEMBL615790,In vivo,,,8,1,,F,,,BAO_0000218,16245
10576,,H,,,813,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,,Autocuration,,CHEMBL615813,,,,8,1,,F,,,BAO_0000019,15740
10576,,H,,,814,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,,Autocuration,,CHEMBL615814,,,,8,1,,F,,,BAO_0000219,15535
51,,H,,,815,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,,Expert,,CHEMBL615815,,,,8,1,,F,,,BAO_0000219,15535
10576,,H,,,816,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,,Autocuration,,CHEMBL615816,,,,8,1,,F,,,BAO_0000219,15535
10576,,H,,,817,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,,Expert,,CHEMBL615817,,,,8,1,,B,,,BAO_0000249,9888
10576,,H,10000000.0,,818,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,Hippocampus,Autocuration,,CHEMBL615818,,,,8,1,,B,,,BAO_0000221,10085
10576,,H,10000000.0,,819,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,Hippocampus,Autocuration,,CHEMBL615819,,,,8,1,,B,,,BAO_0000221,10085
10576,,H,,,820,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,,Expert,,CHEMBL615820,,,,8,1,,B,,Membranes,BAO_0000249,17331
10576,,D,10000000.0,,821,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,Hippocampus,Expert,,CHEMBL615821,,10116.0,,9,1,,B,,,BAO_0000221,10845
10576,,D,10000000.0,,822,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Hippocampus,Expert,,CHEMBL615822,,10116.0,,9,1,,B,,,BAO_0000221,10845
10576,,H,10000000.0,,823,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,Hippocampus,Expert,,CHEMBL615823,,,,8,1,,B,,,BAO_0000221,10845
10576,,D,10000000.0,,824,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,Hippocampus,Expert,,CHEMBL615824,,10116.0,,9,1,,B,,,BAO_0000221,10845
10576,,D,10000000.0,,825,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,Hippocampus,Expert,,CHEMBL615825,,10116.0,,9,1,,B,,,BAO_0000221,10845
10576,,H,,,826,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,,Expert,,CHEMBL615826,,,,8,1,,B,,,BAO_0000357,13730
10576,,H,,,827,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,,Expert,,CHEMBL615827,,,,8,1,,B,,,BAO_0000249,13508
10576,,H,10000000.0,,828,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,Hippocampus,Expert,,CHEMBL615828,,,,8,1,,B,,,BAO_0000249,13508
10576,,H,10000000.0,,829,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Expert,,CHEMBL615829,,,,8,1,,B,,,BAO_0000221,12073
10576,,H,10000000.0,,830,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,Hippocampus,Autocuration,,CHEMBL615830,,,,8,1,,B,,,BAO_0000221,4671
10576,,H,10000000.0,,831,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,Hippocampus,Expert,,CHEMBL615831,,,,8,1,,B,,,BAO_0000221,13631
10576,,H,,,832,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615832,,,,8,1,,B,,,BAO_0000357,12438
10576,,H,,,833,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,,Autocuration,,CHEMBL615833,,,,8,1,,B,,,BAO_0000019,10483
10576,,H,10000000.0,,834,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,Hippocampus,Autocuration,,CHEMBL615834,,,,8,1,,B,,,BAO_0000221,10483
10576,,H,,,835,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,,Intermediate,,CHEMBL615835,,,,8,1,,B,,,BAO_0000249,12352
10576,,H,10000000.0,,836,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,Hippocampus,Autocuration,,CHEMBL615836,,,,8,1,,B,,,BAO_0000249,14732
10576,,D,,,837,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,,Expert,,CHEMBL615837,,10116.0,,9,1,,B,,,BAO_0000019,11049
10576,,D,,,838,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,,Expert,,CHEMBL615838,,10116.0,,9,1,,B,,,BAO_0000019,11049
10576,,H,,,839,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",,Expert,,CHEMBL615839,,,,8,1,,B,,,BAO_0000249,13657
10576,,H,,,840,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,,Autocuration,,CHEMBL884525,,,,8,1,,B,,,BAO_0000019,11473
10576,,H,,,841,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,Autocuration,,CHEMBL615840,,,,8,1,,B,,,BAO_0000249,2014
10576,,H,10000000.0,,842,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Expert,,CHEMBL615405,,,,8,1,,B,,,BAO_0000221,3086
10576,,H,,,843,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,Expert,,CHEMBL615406,,,,8,1,,B,,,BAO_0000019,15854
10576,,H,10000000.0,,844,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Hippocampus,Expert,,CHEMBL615900,,,,8,1,,B,,,BAO_0000221,10922
10576,,H,10000000.0,,845,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,Hippocampus,Expert,,CHEMBL615901,,,,8,1,,B,,,BAO_0000221,13346
10576,,H,,,846,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,,Expert,,CHEMBL615902,,,,8,1,,B,,,BAO_0000357,15311
10576,,H,10000000.0,,847,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,Hippocampus,Autocuration,,CHEMBL615903,,,,8,1,,B,,,BAO_0000221,10922
10576,,H,,,848,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,,Autocuration,,CHEMBL615904,,,,8,1,,B,,,BAO_0000357,10025
10576,,H,,,849,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,,Expert,,CHEMBL615905,,,,8,1,,B,,,BAO_0000357,10025
10576,,H,,,850,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,Autocuration,,CHEMBL615906,,,,8,1,,B,,,BAO_0000019,9742
10576,,H,,,851,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,,Autocuration,,CHEMBL615907,,,,8,1,,F,,,BAO_0000019,9742
10576,,H,,,852,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,Expert,,CHEMBL615908,,,,8,1,,B,,,BAO_0000019,12304
10576,,H,10000000.0,,853,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,Hippocampus,Autocuration,,CHEMBL615909,,,,8,1,,B,,,BAO_0000221,15789
10576,,H,,,854,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",,Autocuration,,CHEMBL615910,,,,8,1,,B,,,BAO_0000019,9912
10576,,H,,,855,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",,Autocuration,,CHEMBL615911,,,,8,1,,B,,,BAO_0000019,9912
10576,,H,,,856,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",,Autocuration,,CHEMBL615912,,,,8,1,,B,,,BAO_0000019,9912
10576,,H,,,857,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,Expert,,CHEMBL615913,,,,8,1,,B,,,BAO_0000019,16693
10576,,H,,,858,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,Expert,,CHEMBL615914,,,,8,1,,B,,,BAO_0000357,13276
10576,,H,10000000.0,,859,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Hippocampus,Autocuration,,CHEMBL615915,,,,8,1,,B,,,BAO_0000221,12678
10576,,H,,,860,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,,Autocuration,,CHEMBL615916,,,,8,1,,B,,,BAO_0000357,11825
10576,,H,,,861,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,,Expert,,CHEMBL615917,,,,8,1,,B,,,BAO_0000357,12443
10576,,H,,,862,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL615918,,,,8,1,,B,,,BAO_0000357,13830
10576,,H,10000000.0,,863,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,Hippocampus,Expert,,CHEMBL615919,,,,8,1,,B,,,BAO_0000249,14286
10576,,D,10000000.0,,864,Rattus norvegicus,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,Expert,,CHEMBL615920,,10116.0,,9,1,,B,,,BAO_0000221,14356
10576,,H,,,865,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615921,,,,8,1,,B,,,BAO_0000357,15306
10576,,H,,,866,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),,Expert,,CHEMBL615922,,,,8,1,,B,,,BAO_0000357,15306
10576,,D,,,867,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,Expert,,CHEMBL881290,,10116.0,,9,1,,F,,,BAO_0000249,16616
10576,,H,10000000.0,,868,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",Hippocampus,Autocuration,,CHEMBL615923,,,,8,1,,B,,,BAO_0000221,3651
10576,,H,10000000.0,,869,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Autocuration,,CHEMBL615924,,,,8,1,,F,,,BAO_0000221,14331
10576,,H,10000000.0,,870,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Autocuration,,CHEMBL615925,,,,8,1,,F,,,BAO_0000221,14331
10576,,D,,,871,Rattus norvegicus,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL615926,,10116.0,,9,1,,B,,,BAO_0000357,14178
10576,,D,,,872,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL615927,,10116.0,,9,1,,B,,,BAO_0000019,10639
10576,,H,10000000.0,,873,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,Autocuration,,CHEMBL615928,,,,8,1,,B,,,BAO_0000221,12306
10576,,D,,,874,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,,Expert,,CHEMBL615929,,10116.0,,9,1,,B,,,BAO_0000357,1348
10576,,H,10000000.0,,875,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,Hippocampus,Autocuration,,CHEMBL615930,,,,8,1,,B,,,BAO_0000221,13605
51,,H,,,876,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,,Autocuration,,CHEMBL615931,,,449.0,8,1,CHO,B,,,BAO_0000219,17624
51,,H,,,877,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615932,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,878,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615933,,,449.0,8,1,CHO,F,,,BAO_0000219,17624
51,,H,,,879,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615934,,,,8,1,,B,,,BAO_0000357,15267
51,,H,,,880,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,,Autocuration,,CHEMBL615935,,,,8,1,,B,,,BAO_0000357,16532
51,,H,,,881,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",,Autocuration,,CHEMBL615936,,,,8,1,,F,,,BAO_0000019,6563
51,,H,,,882,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,,Autocuration,,CHEMBL615937,,,449.0,8,1,CHO,B,,,BAO_0000219,4751
51,,H,,,883,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615938,,,,8,1,,B,,,BAO_0000357,15463
51,,H,,,884,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),,Autocuration,,CHEMBL615797,,,,8,1,,B,,,BAO_0000357,3805
51,,H,,,885,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL615798,,,,8,1,,B,,,BAO_0000357,5640
51,,H,,,886,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,,Autocuration,,CHEMBL872870,,,,8,1,,B,,,BAO_0000357,6563
51,,H,,,887,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,,Autocuration,,CHEMBL615799,,,,8,1,,B,,,BAO_0000357,5548
51,,H,,,888,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615800,,,,8,1,,B,,,BAO_0000357,6347
51,,H,,,889,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,Autocuration,,CHEMBL615801,,,722.0,8,1,HEK293,F,,,BAO_0000219,17296
51,,H,,,890,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,,Autocuration,,CHEMBL615802,,,,8,1,,B,,,BAO_0000019,13047
51,,H,,,891,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,,Autocuration,,CHEMBL615803,,,,8,1,,B,,,BAO_0000357,15740
51,,H,,,892,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",,Expert,,CHEMBL835002,,,,8,1,,F,,,BAO_0000019,5640
51,,H,,,893,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",,Autocuration,,CHEMBL615804,,,,8,1,,F,,,BAO_0000019,5640
51,,H,,,894,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL615805,,,308.0,8,1,HeLa,B,,,BAO_0000219,17211
51,,H,,,895,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615806,,,449.0,8,1,CHO,B,,,BAO_0000219,4751
51,,D,,,896,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,,Expert,,CHEMBL615807,,9606.0,,9,1,,B,,,BAO_0000357,6491
51,,H,,,897,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,,Autocuration,,CHEMBL615808,,,,8,1,,B,,,BAO_0000357,4707
51,,D,,,898,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL615809,,9606.0,,9,1,,B,,,BAO_0000357,13910
51,,H,,,899,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,,Autocuration,,CHEMBL615810,,,308.0,8,1,HeLa,B,,,BAO_0000219,16190
51,,H,,,900,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL615811,,,,8,1,,B,,,BAO_0000357,16633
51,,H,,,901,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,,Autocuration,,CHEMBL615812,,,449.0,8,1,CHO,B,,,BAO_0000219,11898
51,,H,,,902,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,Autocuration,,CHEMBL615751,,,449.0,8,1,CHO,B,,,BAO_0000219,11898
51,,H,,,903,,Binding affinity against human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615752,,,,8,1,,B,,,BAO_0000357,14331
51,,H,,,904,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,,Expert,,CHEMBL615753,,,449.0,8,1,CHO,B,,,BAO_0000219,17624
51,,H,,,905,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,,Autocuration,,CHEMBL615754,,,449.0,8,1,CHO,B,,,BAO_0000219,17624
51,,H,,,906,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615755,,,,8,1,,B,,,BAO_0000357,3307
51,,D,,,907,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Expert,,CHEMBL615756,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,6563
51,,H,,,908,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL615757,,,,8,1,,B,,,BAO_0000019,14165
51,,H,,,909,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,Autocuration,,CHEMBL615758,,,,8,1,,B,,,BAO_0000357,5732
51,,H,,,910,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,Expert,,CHEMBL615759,,,,8,1,,B,,,BAO_0000357,13366
51,,H,,,911,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615760,,,,8,1,,B,,,BAO_0000357,17626
51,,H,,,912,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,,Expert,,CHEMBL615761,,,308.0,8,1,HeLa,B,,,BAO_0000219,6588
51,,H,,,913,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,,Autocuration,,CHEMBL872104,,,,8,1,,B,,,BAO_0000357,16209
51,,H,,,914,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL615762,,,,8,1,,B,,,BAO_0000357,15463
51,,H,,,915,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL615763,,,,8,1,,B,,,BAO_0000357,15463
51,,H,,,916,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL615764,,,,8,1,,B,,,BAO_0000357,14770
51,,H,,,917,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),,Autocuration,,CHEMBL615765,,,1167.0,8,1,Cell line,B,,,BAO_0000219,16245
51,,H,,,918,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),,Autocuration,,CHEMBL615766,,,,8,1,,B,,,BAO_0000019,16245
51,,H,,,919,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL615767,,,,8,1,,B,,,BAO_0000357,5548
51,,H,,,920,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Expert,,CHEMBL615768,,,,8,1,,B,,,BAO_0000357,5548
51,,H,,,921,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL615769,,,,8,1,,B,,,BAO_0000357,5548
51,,H,,,922,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,,Expert,,CHEMBL615770,,,,8,1,,B,,,BAO_0000357,6876
51,,H,,,923,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL615771,,,,8,1,,B,,,BAO_0000357,2598
51,,H,,,924,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,,Expert,,CHEMBL615772,,,,8,1,,B,,,BAO_0000357,17785
51,,H,,,925,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL615773,,,,8,1,,B,,,BAO_0000357,6013
51,,H,,,926,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,Expert,,CHEMBL615774,,,,8,1,,B,,,BAO_0000357,5929
51,,H,,,927,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL615775,,,,8,1,,B,,,BAO_0000357,16633
51,,H,,,928,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,,Autocuration,,CHEMBL615776,,,,8,1,,B,,,BAO_0000357,1558
51,,H,,,929,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Expert,,CHEMBL615777,,,,8,1,,B,,,BAO_0000357,16026
51,,H,,,930,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,,Autocuration,,CHEMBL615778,,,,8,1,,B,,,BAO_0000219,12469
51,,D,,,931,Homo sapiens,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,Expert,,CHEMBL615779,,9606.0,,9,1,,B,,,BAO_0000357,15874
51,,H,,,932,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,Autocuration,,CHEMBL615780,,,,8,1,,B,,,BAO_0000357,15874
51,,H,,,933,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616298,,,,8,1,,B,,,BAO_0000357,3935
51,,H,,,934,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616299,,,,8,1,,B,,,BAO_0000357,15818
51,,H,,,935,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,,Autocuration,,CHEMBL616300,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,13706
51,,H,,,936,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,,Expert,,CHEMBL616301,,,485.0,8,1,CHO-K1,F,,,BAO_0000219,13729
51,,H,,,937,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616302,,,,8,1,,B,,,BAO_0000019,15413
51,,H,,,938,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),,Autocuration,,CHEMBL616117,,,,8,1,,B,,,BAO_0000019,15413
51,,H,,,939,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),,Autocuration,,CHEMBL616118,,,,8,1,,B,,,BAO_0000019,15413
51,,H,,,940,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,,Autocuration,,CHEMBL616119,,,,8,1,,B,,,BAO_0000019,15413
51,,D,,,941,Homo sapiens,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,,Expert,,CHEMBL616120,,9606.0,308.0,9,1,HeLa,B,,,BAO_0000219,3445
51,,H,,,942,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616121,,,,8,1,,B,,,BAO_0000357,15740
51,,H,,,943,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,,Autocuration,,CHEMBL616122,,,,8,1,,B,,,BAO_0000357,15740
51,,H,,,944,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616123,,,,8,1,,B,,,BAO_0000357,17626
51,,D,,,945,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616124,,9606.0,,9,1,,B,,,BAO_0000357,4234
51,,H,,,946,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,,Expert,,CHEMBL616125,,,,8,1,,B,,,BAO_0000357,5640
51,,H,,,947,Rattus norvegicus,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,,Expert,,CHEMBL616126,,10116.0,,8,1,,B,,,BAO_0000357,5272
51,,H,,,948,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616127,,,449.0,8,1,CHO,B,,,BAO_0000219,4622
51,,H,,,949,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616128,,,,8,1,,B,,,BAO_0000019,17085
51,,H,,,950,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,,Autocuration,,CHEMBL616129,,,,8,1,,B,,,BAO_0000357,3025
51,,H,,,951,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616130,,,,8,1,,B,,,BAO_0000357,15315
51,,H,,,952,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,,Autocuration,,CHEMBL616131,,,,8,1,,B,,,BAO_0000357,15267
51,,H,,,953,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,,Autocuration,,CHEMBL616132,,,308.0,8,1,HeLa,B,,,BAO_0000219,17158
51,,D,,,954,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,,Expert,,CHEMBL616133,,9606.0,308.0,9,1,HeLa,B,,,BAO_0000219,14214
51,,H,,,955,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616134,,,,8,1,,B,,,BAO_0000357,17133
51,,H,,,956,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,,Autocuration,,CHEMBL616135,,,,8,1,,B,,,BAO_0000357,16532
51,,D,,,957,Homo sapiens,Affinity for 5-hydroxytryptamine 1A receptor subtype,,Expert,,CHEMBL616136,,9606.0,,9,1,,B,,,BAO_0000357,2391
51,,H,,,958,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,,Autocuration,,CHEMBL616137,,,,8,1,,B,,,BAO_0000019,14447
51,,H,,,959,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,,Autocuration,,CHEMBL872105,,,,8,1,,B,,,BAO_0000019,14447
51,,H,,,960,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,,Autocuration,,CHEMBL616138,,,,8,1,,B,,,BAO_0000357,15086
51,,D,,,961,Homo sapiens,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616139,,9606.0,,9,1,,B,,,BAO_0000357,13051
51,,H,,,962,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",,Autocuration,,CHEMBL616140,,,,8,1,,F,,,BAO_0000019,16026
51,,H,,,963,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,,Expert,,CHEMBL616141,,,,8,1,,B,,,BAO_0000019,17085
51,,H,,,964,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616142,,,,8,1,,B,,,BAO_0000357,17133
51,,H,,,965,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,,Autocuration,,CHEMBL616143,,,,8,1,,B,,,BAO_0000357,17133
51,,H,,,966,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,Autocuration,,CHEMBL616144,,,308.0,8,1,HeLa,B,,,BAO_0000219,17211
51,,H,,,967,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,,Autocuration,,CHEMBL616145,,,308.0,8,1,HeLa,B,,,BAO_0000219,17211
51,,H,,,968,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,Autocuration,,CHEMBL616012,,,308.0,8,1,HeLa,B,,,BAO_0000219,17211
51,,H,,,969,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,,Autocuration,,CHEMBL616013,,,308.0,8,1,HeLa,B,,,BAO_0000219,17211
51,,H,,,970,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,Autocuration,,CHEMBL616014,,,,8,1,,F,,,BAO_0000019,16394
51,,H,,,971,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,Autocuration,,CHEMBL616015,,,,8,1,,F,,,BAO_0000019,16394
51,,H,,,972,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",,Autocuration,,CHEMBL616016,,,,8,1,,F,,,BAO_0000019,16394
51,,H,,,973,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,,Autocuration,,CHEMBL616017,In vivo,,,8,1,,F,,,BAO_0000218,16394
51,,H,,,974,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,,Autocuration,,CHEMBL616018,,,,8,1,,B,,,BAO_0000019,16394
51,,H,,,975,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,,Autocuration,,CHEMBL616019,,,,8,1,,F,,,BAO_0000019,15740
51,,H,,,976,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,,Autocuration,,CHEMBL616020,,,,8,1,,F,,,BAO_0000019,15740
51,,H,,,977,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL858018,,,,8,1,,B,,,BAO_0000357,15740
51,,H,,,978,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,Autocuration,,CHEMBL616021,,,722.0,8,1,HEK293,F,,,BAO_0000219,17296
51,,H,,,979,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",,Expert,,CHEMBL616022,,,,8,1,,F,,,BAO_0000019,5640
51,,H,,,980,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",,Autocuration,,CHEMBL616023,,,,8,1,,F,,,BAO_0000019,5640
51,,H,,,981,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",,Autocuration,,CHEMBL616024,,,,8,1,,F,,,BAO_0000019,5640
51,,H,,,982,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",,Autocuration,,CHEMBL616025,,,,8,1,,F,,,BAO_0000019,5640
51,,H,,,983,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,,Autocuration,,CHEMBL616026,,,449.0,8,1,CHO,F,,,BAO_0000219,2759
51,,H,,,984,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",,Autocuration,,CHEMBL616027,,,,8,1,,F,,,BAO_0000019,16394
51,,D,,,985,Homo sapiens,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",,Expert,,CHEMBL616028,,9606.0,,9,1,,F,,,BAO_0000019,16394
51,,D,,,986,Homo sapiens,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,,Expert,,CHEMBL616029,,9606.0,,9,1,,F,,,BAO_0000019,3445
51,,H,,,987,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,,Expert,,CHEMBL616030,,,449.0,8,1,CHO,B,,,BAO_0000219,4316
51,,H,,,988,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,,Expert,,CHEMBL616031,,,,8,1,,B,,,BAO_0000019,4316
51,,D,,,989,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,Expert,,CHEMBL616032,,9606.0,,9,1,,F,,,BAO_0000019,15180
51,,D,,,990,Homo sapiens,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,,Expert,,CHEMBL616033,,9606.0,,9,1,,F,,,BAO_0000019,15180
51,,H,,,991,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,Autocuration,,CHEMBL616034,,,,8,1,,F,,,BAO_0000019,15042
51,,H,,,992,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,Autocuration,,CHEMBL616035,,,,8,1,,F,,,BAO_0000019,15042
51,,H,,,993,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616036,,,,8,1,,F,,,BAO_0000019,15042
51,,H,,,994,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,Autocuration,,CHEMBL616037,,,,8,1,,F,,,BAO_0000019,15042
51,,H,,,995,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,Autocuration,,CHEMBL616038,,,,8,1,,F,,,BAO_0000019,15042
51,,H,,,996,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,,Autocuration,,CHEMBL616039,,,,8,1,,F,,,BAO_0000019,15042
51,,H,,,997,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616040,,,,8,1,,F,,,BAO_0000019,15042
51,,D,,,998,Homo sapiens,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Expert,,CHEMBL616041,,9606.0,308.0,9,1,HeLa,F,,,BAO_0000219,15180
51,,D,,,999,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Expert,,CHEMBL616042,,9606.0,308.0,9,1,HeLa,F,,,BAO_0000219,15180
51,,D,,,1000,Homo sapiens,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,,Expert,,CHEMBL616043,,9606.0,308.0,9,1,HeLa,F,,,BAO_0000219,15180
51,,H,,,1001,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",,Autocuration,,CHEMBL616044,,,,8,1,,F,,,BAO_0000019,16245
51,,H,,,1002,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,Autocuration,,CHEMBL616045,,,,8,1,,F,,,BAO_0000019,16026
51,,H,,,1003,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,,Autocuration,,CHEMBL616046,,,722.0,8,1,HEK293,F,,,BAO_0000219,17296
51,,H,,,1004,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,Autocuration,,CHEMBL616047,,,449.0,8,1,CHO,F,,,BAO_0000219,2759
51,,H,,,1005,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Autocuration,,CHEMBL616048,,,449.0,8,1,CHO,F,,,BAO_0000219,2759
51,,D,,,1006,Homo sapiens,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),,Expert,,CHEMBL616049,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,2759
51,,H,,,1007,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),,Autocuration,,CHEMBL616050,,,449.0,8,1,CHO,F,,,BAO_0000219,2759
51,,H,,,1008,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,,Expert,,CHEMBL616051,,,,8,1,,F,,,BAO_0000219,15419
51,,H,,,1009,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,,Autocuration,,CHEMBL616212,,,,8,1,,F,,,BAO_0000219,15419
51,,H,,,1010,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",,Autocuration,,CHEMBL616213,,,,8,1,,F,,,BAO_0000019,16026
51,,H,,,1011,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,,Expert,,CHEMBL616214,In vitro,,,8,1,,B,,,BAO_0000219,1414
51,,H,,,1012,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,,Expert,,CHEMBL616215,In vitro,,,8,1,,B,,,BAO_0000219,1414
51,,H,,,1013,,Binding activity radioligand.,,Autocuration,,CHEMBL616216,,,,8,1,,B,,,BAO_0000357,12861
51,,H,,,1014,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,Autocuration,,CHEMBL616217,,,,8,1,,B,,,BAO_0000019,12861
51,,H,,,1015,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616218,,,,8,1,,B,,,BAO_0000357,5104
51,,H,,,1016,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616219,,,,8,1,,B,,,BAO_0000357,5105
51,,H,,,1017,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616220,,,,8,1,,B,,,BAO_0000357,16312
51,,D,,,1018,Homo sapiens,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL833493,,9606.0,,9,1,,B,,,BAO_0000357,15180
51,,H,,,1019,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616221,,,,8,1,,B,,,BAO_0000357,5033
51,,D,,,1020,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,Expert,,CHEMBL616222,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,16909
51,,H,,,1021,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616223,,,,8,1,,F,,,BAO_0000019,2590
51,,H,,,1022,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,,Autocuration,,CHEMBL616224,,,,8,1,,F,,,BAO_0000019,2590
51,,H,,,1023,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,,Expert,,CHEMBL616225,,,,8,1,,B,,,BAO_0000019,16394
51,,D,,,1024,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,,Expert,,CHEMBL616226,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,4540
51,,H,,,1025,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,,Autocuration,,CHEMBL616227,,,722.0,8,1,HEK293,B,,,BAO_0000219,17296
51,,H,,,1026,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616228,,,722.0,8,1,HEK293,B,,,BAO_0000219,17296
51,,H,,,1027,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,Autocuration,,CHEMBL616229,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
51,,H,,,1028,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,,Autocuration,,CHEMBL616230,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
51,,H,,,1029,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,,Autocuration,,CHEMBL616231,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
51,,H,,,1030,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616232,,,,8,1,,B,,,BAO_0000357,6166
51,,H,,,1031,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,,Autocuration,,CHEMBL616233,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
51,,H,,,1032,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,,Autocuration,,CHEMBL857973,,,722.0,8,1,HEK293,B,,,BAO_0000219,4199
51,,H,,,1033,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,,Autocuration,,CHEMBL616234,,,,8,1,,B,,,BAO_0000219,15316
51,,H,,,1034,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616235,,,,8,1,,B,,,BAO_0000357,14875
51,,H,,,1035,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,Expert,,CHEMBL616236,,,308.0,8,1,HeLa,B,,,BAO_0000219,14727
51,,H,,,1036,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,,Expert,,CHEMBL616237,,,,8,1,,B,,,BAO_0000019,14727
51,,H,,,1037,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,,Autocuration,,CHEMBL616238,,,722.0,8,1,HEK293,B,,,BAO_0000219,15146
51,,H,,,1038,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,,Autocuration,,CHEMBL616239,,,722.0,8,1,HEK293,B,,,BAO_0000219,5213
51,,H,,,1039,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,,Autocuration,,CHEMBL616240,,,,8,1,,B,,,BAO_0000219,16429
51,,D,,,1040,Homo sapiens,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,,Expert,,CHEMBL616241,,9606.0,308.0,9,1,HeLa,B,,,BAO_0000219,15042
51,,H,,,1041,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,,Autocuration,,CHEMBL616242,,,722.0,8,1,HEK293,B,,,BAO_0000219,14818
51,,H,,,1042,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",,Autocuration,,CHEMBL616243,,,722.0,8,1,HEK293,B,,,BAO_0000219,4829
51,,D,,,1043,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616244,,,,9,1,,B,,,BAO_0000357,17200
51,,D,,,1044,Homo sapiens,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616245,,9606.0,,9,1,,B,,,BAO_0000357,13051
106,,H,,,1045,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,Autocuration,,CHEMBL616246,,,,8,1,,B,,,BAO_0000357,5486
105,,H,,,1046,,Binding affinity against 5-HT1D receptor,,Autocuration,,CHEMBL616247,,,,8,1,,B,,,BAO_0000357,5254
105,,H,,,1047,,Binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616248,,,,8,1,,B,,,BAO_0000357,5254
107,,H,,,1048,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,,Autocuration,,CHEMBL616249,,,,8,1,,B,,,BAO_0000357,15331
10576,,H,,,1049,Homo sapiens,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,Autocuration,,CHEMBL616250,,9606.0,,8,1,,B,,,BAO_0000357,13506
51,,H,,,1050,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616251,,,,8,1,,B,,,BAO_0000357,15267
11863,,H,,,1051,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,,Autocuration,,CHEMBL616252,In vivo,,,8,1,,F,,,BAO_0000218,16616
11863,,H,,,1052,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,,Autocuration,,CHEMBL616253,In vivo,,,8,1,,F,,,BAO_0000218,16616
11863,,H,,,1053,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,,Autocuration,,CHEMBL616254,In vivo,,,8,1,,F,,,BAO_0000218,16616
11863,,D,,,1054,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,,Expert,,CHEMBL616255,,10090.0,,9,1,,F,,,BAO_0000218,16616
11863,,D,,,1055,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,,Expert,,CHEMBL832872,,10090.0,,9,1,,F,,,BAO_0000218,16616
11863,,D,,,1056,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,,Expert,,CHEMBL616256,,10090.0,,9,1,,F,,,BAO_0000218,16616
11863,,D,,,1057,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,,Expert,,CHEMBL616257,,10090.0,,9,1,,F,,,BAO_0000218,16616
11863,,D,,,1058,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,,Expert,,CHEMBL616258,,10090.0,,9,1,,F,,,BAO_0000218,16616
11863,,D,,,1059,Mus musculus,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,,Expert,,CHEMBL616384,,10090.0,,9,1,,F,,,BAO_0000218,16616
11863,,H,10000000.0,,1060,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Hippocampus,Autocuration,,CHEMBL616385,,,,8,1,,B,,,BAO_0000221,10297
11863,,H,,,1061,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,,Expert,,CHEMBL616386,,,,8,1,,B,,,BAO_0000357,13704
11863,,D,10000000.0,,1062,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Hippocampus,Expert,,CHEMBL616387,,10090.0,,9,1,,B,,,BAO_0000221,10297
11863,,H,10000000.0,,1063,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Hippocampus,Autocuration,,CHEMBL616388,,,,8,1,,B,,,BAO_0000221,10297
11863,,D,10000000.0,,1064,Mus musculus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,Hippocampus,Expert,,CHEMBL616389,,10090.0,,9,1,,B,,,BAO_0000221,10297
11863,,H,10000000.0,,1065,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,Hippocampus,Autocuration,,CHEMBL616390,,,,8,1,,B,,,BAO_0000221,10297
11863,,H,,,1066,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,,Autocuration,,CHEMBL616391,,,,8,1,,B,,,BAO_0000357,217
11863,,D,10000000.0,,1067,Mus musculus,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,Hippocampus,Expert,,CHEMBL616392,,10090.0,,9,1,,B,,,BAO_0000221,10297
51,,H,,,1068,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616393,,9823.0,,8,1,,B,,,BAO_0000357,4921
51,,H,,,1069,Sus scrofa,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,,Autocuration,,CHEMBL616394,,9823.0,,8,1,,B,,,BAO_0000357,4921
51,,H,,,1070,Sus scrofa,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,,Autocuration,,CHEMBL616395,,9823.0,,8,1,,B,,,BAO_0000019,4996
51,,H,,,1071,Sus scrofa,Compound was evaluated for the binding affinity at 5- HT1A receptor,,Autocuration,,CHEMBL616396,,9823.0,,8,1,,B,,,BAO_0000357,12918
51,,H,,,1072,Sus scrofa,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,Autocuration,,CHEMBL872907,,9823.0,,8,1,,B,,,BAO_0000019,5333
51,,H,,,1073,Sus scrofa,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,,Autocuration,,CHEMBL616397,,9823.0,,8,1,,B,,,BAO_0000019,4437
51,,H,,,1074,Sus scrofa,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,,Autocuration,,CHEMBL616398,,9823.0,,8,1,,B,,,BAO_0000019,1742
51,,H,,,1075,Sus scrofa,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616399,,9823.0,,8,1,,B,,,BAO_0000357,16688
51,,H,,,1076,Sus scrofa,Binding activity radioligand.,,Autocuration,,CHEMBL857065,,9823.0,,8,1,,B,,,BAO_0000357,12861
51,,H,,,1077,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,Expert,,CHEMBL616400,,9823.0,,8,1,,B,,,BAO_0000019,12861
51,,H,,,1078,Sus scrofa,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,,Autocuration,,CHEMBL616401,,9823.0,,8,1,,B,,,BAO_0000019,12861
10624,,H,,,1079,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,,Expert,,CHEMBL616402,,,,8,1,,B,,,BAO_0000019,12490
51,,H,,,1080,Sus scrofa,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616403,,9823.0,,8,1,,B,,,BAO_0000019,11828
51,,H,10000000.0,,1081,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,Hippocampus,Autocuration,,CHEMBL616404,,9823.0,,8,1,,B,,,BAO_0000221,11866
51,,H,,,1082,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,,Autocuration,,CHEMBL616405,,9823.0,,8,1,,B,,,BAO_0000249,12827
51,,H,,,1083,Sus scrofa,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,,Autocuration,,CHEMBL616406,,9823.0,,8,1,,B,,,BAO_0000019,12918
51,,H,,,1084,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,,Expert,,CHEMBL616407,,9823.0,,8,1,,F,,,BAO_0000019,12919
51,,H,,,1085,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,,Autocuration,,CHEMBL616408,,9986.0,,8,1,,B,,,BAO_0000019,13047
10576,,D,,,1086,Rattus norvegicus,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,,Expert,,CHEMBL616409,,10116.0,,9,1,,B,,,BAO_0000249,15796
10576,,D,10000000.0,,1087,Rattus norvegicus,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",Hippocampus,Expert,,CHEMBL616410,,10116.0,,9,1,,B,,,BAO_0000221,3651
10576,,H,,,1088,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,,Autocuration,,CHEMBL616411,,,,8,1,,B,,,BAO_0000357,188
10576,,D,,,1089,Rattus norvegicus,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,Expert,,CHEMBL616412,,10116.0,,9,1,,F,,Membranes,BAO_0000249,16616
10576,,D,10000000.0,,1090,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Hippocampus,Expert,,CHEMBL616413,,10116.0,,9,1,,F,,Membranes,BAO_0000249,16616
10576,,H,10000000.0,,1091,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,Autocuration,,CHEMBL616414,,,,8,1,,B,,,BAO_0000221,12306
10576,,D,10000000.0,,1092,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,Hippocampus,Expert,,CHEMBL616415,,10116.0,,9,1,,B,,,BAO_0000221,17167
10576,,H,,,1093,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,,Autocuration,,CHEMBL616416,,,,8,1,,B,,,BAO_0000019,14776
10576,,H,,,1094,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,,Expert,,CHEMBL616417,,,,8,1,,B,,,BAO_0000357,12158
10576,,H,,,1095,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,,Autocuration,,CHEMBL616418,,,,8,1,,B,,,BAO_0000357,13481
10576,,H,,,1096,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,Autocuration,,CHEMBL616419,In vitro,,,8,1,,B,,,BAO_0000219,13427
10576,,H,,,1097,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,,Autocuration,,CHEMBL616420,,,,8,1,,B,,,BAO_0000357,10210
10576,,H,,,1098,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,Autocuration,,CHEMBL616421,,,,8,1,,B,,Membranes,BAO_0000249,10205
10576,,H,,,1099,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,,Autocuration,,CHEMBL616422,,,,8,1,,B,,Membranes,BAO_0000249,10205
10576,,H,,,1100,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,,Expert,,CHEMBL616423,,,,8,1,,B,,Membranes,BAO_0000249,10205
10576,,D,,,1101,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,,Expert,,CHEMBL616424,,10116.0,,9,1,,B,,,BAO_0000357,12280
10576,,H,,,1102,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616425,,,,8,1,,B,,,BAO_0000357,17386
10576,,H,,,1103,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,,Expert,,CHEMBL616426,,,,8,1,,B,,,BAO_0000357,13654
10576,,H,10000000.0,,1104,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,Hippocampus,Autocuration,,CHEMBL616427,,,,8,1,,B,,,BAO_0000221,14423
10576,,H,10000000.0,,1105,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,Hippocampus,Autocuration,,CHEMBL616428,,,,8,1,,B,,,BAO_0000221,15412
10576,,H,10000000.0,,1106,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Autocuration,,CHEMBL616290,,,,8,1,,B,,,BAO_0000221,12073
10576,,D,,,1107,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616052,,10116.0,,9,1,,B,,,BAO_0000357,4101
10576,,H,,,1108,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616053,,,,8,1,,B,,,BAO_0000357,10062
10576,,H,,,1109,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616054,,,,8,1,,B,,,BAO_0000249,6238
10576,,H,,,1110,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616055,,,,8,1,,B,,,BAO_0000357,16273
10576,,H,,,1111,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,,Autocuration,,CHEMBL616056,,,,8,1,,B,,,BAO_0000357,11139
10576,,H,,,1112,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,Expert,,CHEMBL616057,,,,8,1,,B,,,BAO_0000019,16796
10576,,D,955.0,,1113,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,Expert,,CHEMBL616058,,10116.0,,9,1,,B,,,BAO_0000221,9548
10576,,H,955.0,,1114,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,Autocuration,,CHEMBL616059,,,,8,1,,B,,,BAO_0000221,10381
10576,,H,,,1115,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616060,,,,8,1,,B,,,BAO_0000249,13408
10576,,D,10000000.0,,1116,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,Hippocampus,Expert,,CHEMBL616061,,10116.0,,9,1,,B,,,BAO_0000221,13825
10576,,H,10000000.0,,1117,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,Hippocampus,Expert,,CHEMBL616062,,,,8,1,,B,,,BAO_0000221,11147
10576,,H,,,1118,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616063,,,,8,1,,B,,,BAO_0000249,10552
10576,,H,2435.0,,1119,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Striatum,Autocuration,,CHEMBL616064,,,,8,1,,B,,,BAO_0000249,10552
10576,,D,,,1120,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,,Expert,,CHEMBL616065,,10116.0,,9,1,,B,,Membranes,BAO_0000249,17136
10576,,D,,,1121,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,,Expert,,CHEMBL616066,,10116.0,,9,1,,B,,Membranes,BAO_0000249,5778
10576,,H,10000000.0,,1122,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,Hippocampus,Autocuration,,CHEMBL616067,,,,8,1,,B,,,BAO_0000221,13481
10576,,H,10000000.0,,1123,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,Hippocampus,Autocuration,,CHEMBL616068,,,,8,1,,B,,,BAO_0000221,13481
10576,,H,10000000.0,,1124,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,Hippocampus,Intermediate,,CHEMBL616069,,,,8,1,,B,,,BAO_0000221,13630
10576,,H,,,1125,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,Expert,,CHEMBL616070,,,,8,1,,B,,,BAO_0000249,16245
10576,,H,10000000.0,,1126,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,Autocuration,,CHEMBL616071,,,,8,1,,B,,,BAO_0000221,14509
10576,,H,10000000.0,,1127,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,Hippocampus,Expert,,CHEMBL616072,,,,8,1,,B,,,BAO_0000221,14509
10576,,H,10000000.0,,1128,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,Hippocampus,Autocuration,,CHEMBL616073,,,,8,1,,B,,,BAO_0000221,14509
10576,,H,10000000.0,,1129,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,Hippocampus,Autocuration,,CHEMBL616074,,,,8,1,,B,,,BAO_0000221,14509
10576,,H,,,1130,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,,Expert,,CHEMBL616075,,,,8,1,,B,,,BAO_0000019,14256
10576,,H,,,1131,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616076,,,,8,1,,B,,,BAO_0000357,11139
10576,,D,,,1132,Rattus norvegicus,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,,Expert,,CHEMBL616077,,10116.0,,9,1,,B,,,BAO_0000019,11047
10576,,D,,,1133,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,,Expert,,CHEMBL616078,,10116.0,,9,1,,B,,,BAO_0000019,11047
10576,,D,,,1134,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,,Expert,,CHEMBL616079,,10116.0,,9,1,,B,,,BAO_0000019,11047
10576,,D,,,1135,Rattus norvegicus,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,Expert,,CHEMBL616080,,10116.0,485.0,9,1,CHO-K1,B,,,BAO_0000219,2395
10576,,H,,,1136,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616081,,,,8,1,,B,,,BAO_0000357,9699
10576,,D,10000000.0,,1137,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,Hippocampus,Expert,,CHEMBL616082,,10116.0,,9,1,,B,,,BAO_0000221,12028
10576,,H,10000000.0,,1138,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,Hippocampus,Autocuration,,CHEMBL616083,,,,8,1,,B,,,BAO_0000221,12028
10576,,H,,,1139,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,Autocuration,,CHEMBL616084,,,,8,1,,B,,,BAO_0000019,5815
10576,,H,,,1140,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,,Expert,,CHEMBL616085,,,,8,1,,B,,,BAO_0000019,16616
10576,,H,,,1141,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,,Autocuration,,CHEMBL616086,,,,8,1,,B,,,BAO_0000019,5815
10576,,H,10000000.0,,1142,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",Hippocampus,Autocuration,,CHEMBL616087,,,,8,1,,B,,,BAO_0000221,2761
10576,,H,,,1143,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,,Expert,,CHEMBL616088,,,,8,1,,B,,,BAO_0000357,13133
10576,,H,,,1144,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,,Autocuration,,CHEMBL616089,,,,8,1,,B,,,BAO_0000019,10444
10576,,D,,,1145,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,,Expert,,CHEMBL616090,,10116.0,,9,1,,B,,,BAO_0000357,13278
10576,,H,,,1146,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,,Autocuration,,CHEMBL616091,,,,8,1,,B,,,BAO_0000357,15874
10576,,H,2435.0,,1147,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",Striatum,Autocuration,,CHEMBL616092,,,,8,1,,B,,Membranes,BAO_0000249,10552
10576,,H,,,1148,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),,Autocuration,,CHEMBL616093,,,,8,1,,B,,,BAO_0000357,11130
10576,,H,,,1149,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),,Autocuration,,CHEMBL616094,In vivo,,,8,1,,B,,,BAO_0000218,11130
10576,,H,955.0,,1150,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,Brain,Autocuration,,CHEMBL616095,,,,8,1,,B,,,BAO_0000221,14542
10576,,D,,,1151,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616096,,10116.0,,9,1,,B,,,BAO_0000357,13670
10576,,H,,,1152,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,,Expert,,CHEMBL616097,,,,8,1,,B,,,BAO_0000249,9888
10576,,D,,,1153,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,,Expert,,CHEMBL616098,,10116.0,,9,1,,B,,Membranes,BAO_0000249,3678
10576,,H,10000000.0,,1154,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,Autocuration,,CHEMBL616099,,,,8,1,,B,,,BAO_0000221,11332
10576,,H,10000000.0,,1155,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,Autocuration,,CHEMBL616100,,,,8,1,,B,,,BAO_0000221,11332
10576,,H,,,1156,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616101,,,,8,1,,B,,,BAO_0000357,1185
10576,,H,,,1157,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,,Expert,,CHEMBL616102,,,,8,1,,B,,,BAO_0000249,2014
10576,,H,,,1158,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616103,,,,8,1,,B,,,BAO_0000357,1185
10576,,H,,,1159,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,,Expert,,CHEMBL616104,,,,8,1,,B,,,BAO_0000019,14429
10576,,H,,,1160,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",,Expert,,CHEMBL616105,,,,8,1,,B,,,BAO_0000019,16288
10576,,D,,,1161,Rattus norvegicus,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616106,,10116.0,,9,1,,B,,,BAO_0000019,5432
10576,,H,,,1162,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,,Autocuration,,CHEMBL616107,,,,8,1,,B,,,BAO_0000019,14429
10576,,H,,,1163,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,,Expert,,CHEMBL616108,,,,8,1,,B,,,BAO_0000357,13672
10576,,H,10000000.0,,1164,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,Expert,,CHEMBL616109,,,,8,1,,B,,,BAO_0000221,11296
10576,,H,,,1165,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,,Autocuration,,CHEMBL616110,,,,8,1,,B,,,BAO_0000357,11296
10576,,H,,,1166,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,,Expert,,CHEMBL616111,,,449.0,8,1,CHO,B,,,BAO_0000219,14749
10576,,H,,,1167,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,,Expert,,CHEMBL616112,,,,8,1,,B,,,BAO_0000019,15086
10576,,H,10000000.0,,1168,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,Hippocampus,Autocuration,,CHEMBL616113,,,,8,1,,B,,,BAO_0000221,13462
10576,,H,,,1169,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616114,,,,8,1,,B,,,BAO_0000019,15363
10576,,H,,,1170,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616115,,,,8,1,,B,,,BAO_0000019,15363
10576,,H,,,1171,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616116,,,,8,1,,B,,,BAO_0000357,10796
10576,,H,955.0,,1172,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,Brain,Expert,,CHEMBL615844,,,,8,1,,B,,,BAO_0000221,12816
10576,,H,10000000.0,,1173,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,Expert,,CHEMBL615939,,,,8,1,,B,,,BAO_0000221,13542
10576,,H,,,1174,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,,Expert,,CHEMBL615940,,,,8,1,,B,,,BAO_0000019,13308
10576,,H,10000000.0,,1175,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,Hippocampus,Expert,,CHEMBL615941,,,,8,1,,B,,,BAO_0000221,13541
10576,,H,10000000.0,,1176,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,Hippocampus,Autocuration,,CHEMBL615942,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1177,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,Autocuration,,CHEMBL615943,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1178,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,Hippocampus,Autocuration,,CHEMBL615944,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1179,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,Hippocampus,Autocuration,,CHEMBL615945,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1180,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,Hippocampus,Autocuration,,CHEMBL615946,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1181,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,Hippocampus,Autocuration,,CHEMBL615947,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1182,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,Hippocampus,Autocuration,,CHEMBL615948,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1183,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,Hippocampus,Autocuration,,CHEMBL615949,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1184,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,Hippocampus,Autocuration,,CHEMBL615950,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1185,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,Hippocampus,Autocuration,,CHEMBL615951,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1186,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,Hippocampus,Autocuration,,CHEMBL615952,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1187,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,Hippocampus,Autocuration,,CHEMBL615953,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1188,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,Hippocampus,Autocuration,,CHEMBL615954,,,,8,1,,B,,,BAO_0000221,10058
10576,,D,10000000.0,,1189,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,Expert,,CHEMBL615955,,10116.0,,9,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1190,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,Hippocampus,Autocuration,,CHEMBL615956,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1191,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,Hippocampus,Autocuration,,CHEMBL615957,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,,,1192,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,,Expert,,CHEMBL615958,,,,8,1,,B,,,BAO_0000019,12879
10576,,H,,,1193,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,,Expert,,CHEMBL615959,,,,8,1,,B,,,BAO_0000019,11964
10576,,H,,,1194,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),,Autocuration,,CHEMBL615960,,,,8,1,,B,,,BAO_0000019,11964
10576,,H,,,1195,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),,Autocuration,,CHEMBL615961,,,,8,1,,B,,,BAO_0000019,11964
10576,,H,955.0,,1196,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,Brain,Expert,,CHEMBL615962,,,,8,1,,B,,,BAO_0000221,9548
10576,,H,,,1197,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,,Expert,,CHEMBL615963,,,,8,1,,B,,,BAO_0000019,9098
10576,,H,,,1198,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,,Autocuration,,CHEMBL615964,,,,8,1,,B,,,BAO_0000019,9098
10576,,H,,,1199,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,,Autocuration,,CHEMBL615965,,,,8,1,,B,,,BAO_0000019,9098
10576,,H,,,1200,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,,Expert,,CHEMBL615966,,,449.0,8,1,CHO,B,,,BAO_0000219,13248
10576,,H,,,1201,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,,Expert,,CHEMBL615967,,,,8,1,,B,,,BAO_0000249,3147
10576,,H,,,1202,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,Expert,,CHEMBL615968,,,,8,1,,B,,,BAO_0000019,13949
10576,,H,,,1203,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),,Autocuration,,CHEMBL615969,,,449.0,8,1,CHO,B,,,BAO_0000218,11883
10576,,H,,,1204,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),,Autocuration,,CHEMBL615970,,,,8,1,,B,,,BAO_0000218,11883
10576,,D,,,1205,Rattus norvegicus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,,Expert,,CHEMBL615971,,10116.0,,9,1,,B,,,BAO_0000357,11883
10576,,H,,,1206,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,Expert,,CHEMBL615972,,,,8,1,,B,,Membranes,BAO_0000249,15535
10576,,H,,,1207,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,,Autocuration,,CHEMBL615973,,,,8,1,,B,,,BAO_0000249,15535
10576,,H,,,1208,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,,Autocuration,,CHEMBL615974,,,,8,1,,B,,,BAO_0000249,15535
51,,D,,,1209,Homo sapiens,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,,Expert,,CHEMBL615975,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,16372
10576,,H,,,1210,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,,Expert,,CHEMBL615976,,,,8,1,,B,,,BAO_0000249,14608
10576,,D,10000000.0,,1211,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,Hippocampus,Expert,,CHEMBL872106,,10116.0,,9,1,,B,,,BAO_0000221,4795
10576,,H,,,1212,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL615977,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1213,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,,Autocuration,,CHEMBL615978,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1214,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,,Autocuration,,CHEMBL616166,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1215,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,,Autocuration,,CHEMBL616167,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1216,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,,Autocuration,,CHEMBL616168,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1217,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,,Autocuration,,CHEMBL616169,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1218,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,,Autocuration,,CHEMBL616170,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1219,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,,Autocuration,,CHEMBL616171,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1220,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,,Autocuration,,CHEMBL616172,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1221,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,,Autocuration,,CHEMBL616173,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1222,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,,Autocuration,,CHEMBL616174,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1223,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,,Autocuration,,CHEMBL616175,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1224,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,,Autocuration,,CHEMBL616176,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1225,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,,Autocuration,,CHEMBL616177,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1226,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,,Autocuration,,CHEMBL616178,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1227,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,,Autocuration,,CHEMBL616179,,,,8,1,,B,,,BAO_0000019,9742
10576,,H,,,1228,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616180,,,,8,1,,B,,,BAO_0000357,12073
10576,,H,,,1229,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,,Autocuration,,CHEMBL616181,,,,8,1,,B,,,BAO_0000357,4101
10576,,H,,,1230,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,,Autocuration,,CHEMBL616182,,,,8,1,,B,,,BAO_0000019,15360
10576,,H,10000000.0,,1231,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,Autocuration,,CHEMBL616183,,,,8,1,,B,,,BAO_0000221,11576
10576,,H,,,1232,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,,Expert,,CHEMBL615874,,,,8,1,,B,,,BAO_0000019,5834
10576,,D,,,1233,Rattus norvegicus,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,,Expert,,CHEMBL615875,,10116.0,485.0,9,1,CHO-K1,B,,,BAO_0000219,2395
10576,,H,,,1234,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,,Autocuration,,CHEMBL615876,,,,8,1,,B,,,BAO_0000019,1375
10576,,H,,,1235,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,,Autocuration,,CHEMBL615877,,,,8,1,,B,,,BAO_0000019,1375
10576,,H,,,1236,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),,Autocuration,,CHEMBL615878,,,,8,1,,B,,,BAO_0000357,3967
10576,,H,,,1237,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,,Expert,,CHEMBL615879,,,,8,1,,B,,,BAO_0000357,12884
10576,,H,,,1238,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,,Expert,,CHEMBL615880,,,,8,1,,B,,,BAO_0000357,2343
10576,,H,,,1239,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,Autocuration,,CHEMBL615881,,,,8,1,,B,,,BAO_0000019,11511
10576,,D,,,1240,Rattus norvegicus,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",,Expert,,CHEMBL615882,,10116.0,,9,1,,B,,,BAO_0000019,11511
10576,,H,,,1241,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,,Autocuration,,CHEMBL615883,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1242,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),,Autocuration,,CHEMBL615884,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1243,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),,Autocuration,,CHEMBL615885,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1244,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),,Autocuration,,CHEMBL615886,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1245,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),,Autocuration,,CHEMBL615887,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1246,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),,Autocuration,,CHEMBL615888,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1247,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),,Autocuration,,CHEMBL615889,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1248,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),,Autocuration,,CHEMBL615890,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1249,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),,Autocuration,,CHEMBL615891,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1250,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),,Autocuration,,CHEMBL615892,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1251,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),,Autocuration,,CHEMBL615893,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1252,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),,Autocuration,,CHEMBL615894,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1253,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),,Autocuration,,CHEMBL615895,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1254,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),,Autocuration,,CHEMBL615896,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,H,,,1255,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,,Autocuration,,CHEMBL615897,In vivo,,,8,1,,F,,,BAO_0000218,16394
10576,,D,,,1256,Rattus norvegicus,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",,Expert,,CHEMBL615898,,10116.0,,9,1,,F,,Membranes,BAO_0000249,16616
10576,,H,,,1257,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,,Autocuration,,CHEMBL615899,,,,8,1,,B,,,BAO_0000019,16796
10576,,H,,,1258,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,,Autocuration,,CHEMBL616291,,,,8,1,,B,,,BAO_0000019,16796
10576,,H,,,1259,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,,Autocuration,,CHEMBL616292,,,,8,1,,B,,,BAO_0000357,15629
10576,,H,,,1260,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",,Autocuration,,CHEMBL616293,,,,8,1,,F,,,BAO_0000249,13241
10576,,H,10000000.0,,1261,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Expert,,CHEMBL616294,,,,8,1,,B,,,BAO_0000221,12073
10576,,H,10000000.0,,1262,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,Hippocampus,Autocuration,,CHEMBL616295,,,,8,1,,B,,,BAO_0000249,14286
10576,,H,955.0,,1263,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,Brain,Autocuration,,CHEMBL616296,,,,8,1,,B,,,BAO_0000221,14542
10576,,H,,,1264,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,Autocuration,,CHEMBL616297,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1265,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,,Autocuration,,CHEMBL616605,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1266,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,,Autocuration,,CHEMBL616606,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1267,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,Autocuration,,CHEMBL616607,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1268,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,,Expert,,CHEMBL616608,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1269,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,,Autocuration,,CHEMBL616609,,,,8,1,,F,,,BAO_0000019,13630
10576,,D,,,1270,Rattus norvegicus,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,,Expert,,CHEMBL616610,,10116.0,,9,1,,F,,,BAO_0000019,13630
10576,,H,,,1271,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,,Autocuration,,CHEMBL616611,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1272,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,,Expert,,CHEMBL616612,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1273,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,,Autocuration,,CHEMBL616613,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1274,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,,Expert,,CHEMBL616614,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1275,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,,Autocuration,,CHEMBL616615,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1276,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,Expert,,CHEMBL616616,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1277,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,,Autocuration,,CHEMBL616617,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1278,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,Autocuration,,CHEMBL616618,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1279,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,,Autocuration,,CHEMBL616619,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1280,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,,Expert,,CHEMBL616620,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1281,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,Expert,,CHEMBL616621,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1282,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,,Autocuration,,CHEMBL616622,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1283,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,,Expert,,CHEMBL616146,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1284,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,,Autocuration,,CHEMBL832873,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1285,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,,Autocuration,,CHEMBL616147,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1286,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,,Autocuration,,CHEMBL872872,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,,,1287,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,,Autocuration,,CHEMBL616148,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,10000000.0,,1288,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,Hippocampus,Autocuration,,CHEMBL616149,,,,8,1,,B,,,BAO_0000221,9783
10576,,H,10000000.0,,1289,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,Hippocampus,Expert,,CHEMBL616150,,,,8,1,,B,,,BAO_0000221,9783
10576,,D,,,1290,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,,Expert,,CHEMBL616151,,10116.0,,9,1,,B,,Membranes,BAO_0000249,14331
10576,,H,10000000.0,,1291,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,Hippocampus,Expert,,CHEMBL872873,,,,8,1,,B,,,BAO_0000221,15260
10576,,H,10000000.0,,1292,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,Hippocampus,Autocuration,,CHEMBL616670,,,,8,1,,B,,,BAO_0000221,15260
10576,,H,10000000.0,,1293,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,Hippocampus,Autocuration,,CHEMBL616671,,,,8,1,,B,,,BAO_0000221,15260
10576,,D,,,1294,Rattus norvegicus,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",,Expert,,CHEMBL884861,,10116.0,,9,1,,F,,,BAO_0000249,16616
10576,,H,,,1295,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,,Autocuration,,CHEMBL616672,,,,8,1,,B,,,BAO_0000357,15629
10576,,H,,,1296,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,Autocuration,,CHEMBL616673,,,,8,1,,B,,,BAO_0000019,15086
10576,,H,,,1297,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,,Expert,,CHEMBL616674,,,,8,1,,F,,,BAO_0000019,5717
10576,,H,,,1298,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,Autocuration,,CHEMBL616675,,,,8,1,,B,,,BAO_0000357,12652
10576,,H,10000000.0,,1299,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,Hippocampus,Autocuration,,CHEMBL616676,,,,8,1,,B,,,BAO_0000221,14608
10576,,H,10000000.0,,1300,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,Autocuration,,CHEMBL616677,,,,8,1,,B,,,BAO_0000221,12306
10576,,H,10000000.0,,1301,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,Autocuration,,CHEMBL616678,,,,8,1,,B,,,BAO_0000221,12306
10576,,D,,,1302,Rattus norvegicus,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616679,,10116.0,,9,1,,B,,,BAO_0000357,15247
10576,,H,10000000.0,,1303,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,Hippocampus,Expert,,CHEMBL616680,,,,8,1,,B,,,BAO_0000221,17529
10576,,H,10000000.0,,1304,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Autocuration,,CHEMBL616681,,,,8,1,,B,,,BAO_0000221,14826
10576,,H,10000000.0,,1305,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Autocuration,,CHEMBL616682,,,,8,1,,B,,,BAO_0000221,14826
10576,,H,10000000.0,,1306,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,Autocuration,,CHEMBL616683,,,,8,1,,B,,,BAO_0000221,13241
10576,,H,10000000.0,,1307,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,Hippocampus,Autocuration,,CHEMBL616684,,,,8,1,,B,,,BAO_0000221,14093
10576,,H,10000000.0,,1308,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,Hippocampus,Autocuration,,CHEMBL616685,,,,8,1,,B,,,BAO_0000221,14093
10576,,H,955.0,,1309,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,Brain,Autocuration,,CHEMBL616686,,,,8,1,,B,,,BAO_0000221,14442
10576,,H,,,1310,,Affinity for 5-hydroxytryptamine 1A receptor site,,Autocuration,,CHEMBL616687,,,,8,1,,B,,,BAO_0000357,9919
10576,,H,,,1311,,Affinity for 5-hydroxytryptamine 1A receptor site,,Autocuration,,CHEMBL616688,,,,8,1,,B,,,BAO_0000357,9919
10576,,H,10000000.0,,1312,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,Hippocampus,Autocuration,,CHEMBL616689,,,,8,1,,B,,,BAO_0000221,11440
10576,,H,,,1313,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,,Autocuration,,CHEMBL616690,,,,8,1,,B,,,BAO_0000357,11257
10576,,H,,,1314,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,,Expert,,CHEMBL616691,,,,8,1,,B,,,BAO_0000357,10330
10576,,D,10000000.0,,1315,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,Hippocampus,Expert,,CHEMBL616692,,10116.0,,9,1,,B,,,BAO_0000221,17331
10576,,H,,,1316,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,,Expert,,CHEMBL616693,,,,8,1,,B,,,BAO_0000249,16567
10576,,D,,,1317,Rattus norvegicus,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,Expert,,CHEMBL616694,,10116.0,,9,1,,B,,,BAO_0000019,12058
10576,,H,10000000.0,,1318,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,Hippocampus,Autocuration,,CHEMBL616695,,,,8,1,,B,,,BAO_0000221,9699
10576,,H,,,1319,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,,Autocuration,,CHEMBL616696,,,,8,1,,B,,,BAO_0000357,9547
10576,,H,,,1320,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,,Autocuration,,CHEMBL616697,,,,8,1,,B,,,BAO_0000357,10330
10576,,H,,,1321,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616698,,,,8,1,,B,,,BAO_0000357,14331
10576,,D,,,1322,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616949,,10116.0,,9,1,,B,,,BAO_0000019,14060
10576,,H,10000000.0,,1323,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,Hippocampus,Autocuration,,CHEMBL616950,,,,8,1,,B,,,BAO_0000221,14744
10576,,H,,,1324,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,,Autocuration,,CHEMBL832875,,,,8,1,,B,,,BAO_0000357,13506
10576,,H,955.0,,1325,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,Expert,,CHEMBL616951,,,,8,1,,B,,,BAO_0000221,10862
10576,,H,955.0,,1326,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,Expert,,CHEMBL616952,,,,8,1,,B,,,BAO_0000221,10862
10576,,H,,,1327,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,,Expert,,CHEMBL616953,,,,8,1,,B,,,BAO_0000357,10062
10576,,H,,,1328,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,,Autocuration,,CHEMBL616954,,,,8,1,,B,,,BAO_0000357,12073
106,,H,,,1329,,GTPgammaS radioligand binding assay,,Autocuration,,CHEMBL616955,,,,8,1,,B,,,BAO_0000357,14875
106,,H,,,1330,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,Autocuration,,CHEMBL616956,,,,8,1,,B,,,BAO_0000357,2391
106,,H,,,1331,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,,Autocuration,,CHEMBL616957,,,,8,1,,F,,,BAO_0000019,2391
106,,H,,,1332,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,,Autocuration,,CHEMBL616958,,,,8,1,,F,,,BAO_0000019,2391
106,,H,,,1333,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616959,,,,8,1,,B,,,BAO_0000357,2391
106,,H,,,1334,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,,Autocuration,,CHEMBL616960,,,,8,1,,B,,,BAO_0000357,2391
106,,H,,,1335,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,,Autocuration,,CHEMBL616961,,,,8,1,,F,,,BAO_0000019,2391
106,,H,,,1336,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616962,,,308.0,8,1,HeLa,B,,,BAO_0000219,17211
106,,H,,,1337,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,,Autocuration,,CHEMBL616963,,,308.0,8,1,HeLa,B,,,BAO_0000219,17211
106,,D,,,1338,Homo sapiens,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,,Expert,,CHEMBL616524,,9606.0,,9,1,,B,,,BAO_0000357,6491
106,,H,,,1339,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616525,,,449.0,8,1,CHO,B,,,BAO_0000219,16190
106,,H,,,1340,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,,Autocuration,,CHEMBL872908,,,,8,1,,B,,,BAO_0000019,14165
106,,H,,,1341,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,,Autocuration,,CHEMBL616526,,,,8,1,,B,,,BAO_0000019,14165
106,,D,,,1342,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616527,,9606.0,,9,1,,B,,,BAO_0000357,4234
106,,H,,,1343,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,Expert,,CHEMBL616528,,,,8,1,,B,,,BAO_0000219,6328
106,,H,,,1344,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL616529,,,,8,1,,B,,,BAO_0000357,14770
106,,H,,,1345,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,,Autocuration,,CHEMBL616530,,,,8,1,,B,,,BAO_0000357,2598
106,,H,,,1346,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616531,,,,8,1,,B,,,BAO_0000357,6897
106,,H,,,1347,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616532,,,,8,1,,B,,,BAO_0000357,6897
106,,H,,,1348,,Binding affinity towards 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616533,,,,8,1,,B,,,BAO_0000357,6013
106,,H,,,1349,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616534,,,,8,1,,B,,,BAO_0000357,5843
106,,H,,,1350,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,,Expert,,CHEMBL616535,,,,8,1,,B,,,BAO_0000357,14454
106,,H,,,1351,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,,Autocuration,,CHEMBL616536,,,,8,1,,B,,,BAO_0000357,16209
106,,H,,,1352,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616537,,,,8,1,,B,,,BAO_0000357,3935
106,,H,,,1353,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,,Expert,,CHEMBL616538,,,485.0,8,1,CHO-K1,F,,,BAO_0000219,13729
106,,H,,,1354,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616539,,,,8,1,,F,,,BAO_0000019,14251
106,,H,,,1355,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616540,,,,8,1,,B,,,BAO_0000019,17085
106,,H,,,1356,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,Autocuration,,CHEMBL616429,,,,8,1,,B,,,BAO_0000357,3025
106,,H,,,1357,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616430,,,,8,1,,B,,,BAO_0000357,15315
106,,D,,,1358,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,,Expert,,CHEMBL616431,,9606.0,,9,1,,B,,,BAO_0000219,14214
106,,D,,,1359,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616432,,9606.0,,9,1,,B,,,BAO_0000357,3804
106,,D,,,1360,Homo sapiens,Affinity for 5-hydroxytryptamine 1B receptor subtype,,Expert,,CHEMBL616433,,9606.0,,9,1,,B,,,BAO_0000357,2391
106,,D,,,1361,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616434,,9606.0,,9,1,,B,,,BAO_0000357,4175
106,,H,,,1362,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,,Autocuration,,CHEMBL616435,,,449.0,8,1,CHO,B,,,BAO_0000219,17296
106,,H,,,1363,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,,Expert,,CHEMBL616436,,,,8,1,,B,,,BAO_0000019,17085
106,,H,,,1364,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,Autocuration,,CHEMBL616437,,,308.0,8,1,HeLa,B,,,BAO_0000219,17211
106,,H,,,1365,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,,Autocuration,,CHEMBL616438,,,308.0,8,1,HeLa,B,,,BAO_0000219,17211
106,,H,,,1366,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,,Autocuration,,CHEMBL616439,,,308.0,8,1,HeLa,B,,,BAO_0000219,17211
106,,D,,,1367,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,,Expert,,CHEMBL616440,,9606.0,,9,1,,B,,,BAO_0000357,15926
106,,H,,,1368,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,,Autocuration,,CHEMBL616441,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,16312
106,,H,,,1369,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,,Expert,,CHEMBL616442,,,,8,1,,B,,,BAO_0000357,5843
106,,H,,,1370,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616443,,,,8,1,,B,,,BAO_0000357,5843
106,,H,,,1371,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616444,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,16312
106,,D,,,1372,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616445,,9606.0,,9,1,,B,,,BAO_0000357,15926
106,,D,,,1373,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616446,,9606.0,,9,1,,B,,,BAO_0000357,15926
106,,D,,,1374,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,,Expert,,CHEMBL616447,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,4540
106,,H,,,1375,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,,Autocuration,,CHEMBL616448,,,,8,1,,B,,,BAO_0000357,6166
106,,H,,,1376,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,,Autocuration,,CHEMBL616449,,,449.0,8,1,CHO,B,,,BAO_0000219,17296
106,,H,,,1377,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,,Autocuration,,CHEMBL616450,,,449.0,8,1,CHO,B,,,BAO_0000219,17296
106,,H,,,1378,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,,Autocuration,,CHEMBL857974,,,449.0,8,1,CHO,B,,,BAO_0000219,17296
106,,H,,,1379,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616451,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
106,,H,,,1380,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616452,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
106,,H,,,1381,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,,Autocuration,,CHEMBL616453,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
106,,H,,,1382,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,,Autocuration,,CHEMBL616454,,,449.0,8,1,CHO,B,,,BAO_0000219,4199
106,,D,,,1383,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616455,,9606.0,,9,1,,B,,,BAO_0000357,14875
106,,H,,,1384,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,Autocuration,,CHEMBL616456,,,449.0,8,1,CHO,B,,,BAO_0000219,15146
106,,H,,,1385,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,,Autocuration,,CHEMBL616457,,,,8,1,,B,,,BAO_0000357,5213
106,,H,,,1386,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,,Autocuration,,CHEMBL616458,,,449.0,8,1,CHO,B,,,BAO_0000219,14818
106,,H,,,1387,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",,Autocuration,,CHEMBL616459,,,449.0,8,1,CHO,B,,,BAO_0000219,4829
106,,H,,,1388,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,,Expert,,CHEMBL616460,,,,8,1,,F,,,BAO_0000019,14454
106,,H,,,1389,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,,Expert,,CHEMBL616461,,,,8,1,,F,,,BAO_0000019,14454
106,,H,,,1390,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",,Autocuration,,CHEMBL616462,,,449.0,8,1,CHO,F,,,BAO_0000219,14875
106,,H,,,1391,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",,Autocuration,,CHEMBL616463,,,449.0,8,1,CHO,F,,,BAO_0000219,14875
105,,H,,,1392,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",,Autocuration,,CHEMBL616464,,,,8,1,,F,,,BAO_0000019,15250
105,,H,,,1393,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,,Autocuration,,CHEMBL616465,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
17105,,H,,,1394,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL832874,,,,8,1,,B,,,BAO_0000357,15086
106,,H,,,1395,Oryctolagus cuniculus,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,,Autocuration,,CHEMBL616184,,9986.0,,8,1,,F,,,BAO_0000019,3025
106,,H,,,1396,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,,Autocuration,,CHEMBL616185,,9986.0,,8,1,,B,,,BAO_0000019,14998
106,,H,,,1397,Oryctolagus cuniculus,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",,Intermediate,,CHEMBL616186,,9986.0,,8,1,,B,,,BAO_0000019,14998
106,,H,,,1398,Oryctolagus cuniculus,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,,Autocuration,,CHEMBL616187,,9986.0,,8,1,,B,,,BAO_0000019,14998
10577,,H,,,1399,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,,Expert,,CHEMBL616188,,,,8,1,,B,,,BAO_0000357,13969
10577,,D,,,1400,,Binding affinity for 5-hydroxytryptamine 1B receptor,,Intermediate,,CHEMBL873475,,,,9,1,,B,,,BAO_0000357,13392
10577,,D,2435.0,,1401,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,Striatum,Expert,,CHEMBL616189,,10116.0,,9,1,,B,,,BAO_0000019,3651
10577,,H,,,1402,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,Expert,,CHEMBL616190,,,,8,1,,B,,,BAO_0000357,10025
10576,,H,,,1403,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,,Autocuration,,CHEMBL616191,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1404,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,,Autocuration,,CHEMBL616192,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1405,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,,Autocuration,,CHEMBL616193,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1406,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,,Autocuration,,CHEMBL616194,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1407,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,,Autocuration,,CHEMBL616195,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,,,1408,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,,Autocuration,,CHEMBL616196,,,,8,1,,B,,,BAO_0000357,13863
10576,,H,10000000.0,,1409,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,Hippocampus,Autocuration,,CHEMBL616197,,,,8,1,,B,,,BAO_0000249,4622
10576,,H,,,1410,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,,Intermediate,,CHEMBL616198,,,,8,1,,B,,,BAO_0000019,14911
10576,,H,10000000.0,,1411,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,Hippocampus,Autocuration,,CHEMBL616199,,,,8,1,,B,,,BAO_0000221,12678
10576,,H,10000000.0,,1412,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,Hippocampus,Expert,,CHEMBL616200,,,,8,1,,B,,,BAO_0000221,12678
10576,,H,10000000.0,,1413,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,Hippocampus,Expert,,CHEMBL616201,,,,8,1,,B,,,BAO_0000221,14235
10576,,H,10000000.0,,1414,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Hippocampus,Expert,,CHEMBL616202,,,,8,1,,B,,,BAO_0000221,14949
10576,,H,10000000.0,,1415,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,Hippocampus,Expert,,CHEMBL616203,,,,8,1,,B,,,BAO_0000221,14949
10576,,H,10000000.0,,1416,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,Hippocampus,Expert,,CHEMBL616204,,,,8,1,,B,,,BAO_0000221,14949
10576,,H,10000000.0,,1417,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,Hippocampus,Expert,,CHEMBL616205,,,,8,1,,B,,,BAO_0000221,14949
10576,,H,10000000.0,,1418,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,Hippocampus,Expert,,CHEMBL616206,,,,8,1,,B,,,BAO_0000221,14949
10576,,H,,,1419,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,,Expert,,CHEMBL616207,,,,8,1,,B,,,BAO_0000249,16118
10576,,H,,,1420,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,,Autocuration,,CHEMBL616208,,,,8,1,,B,,,BAO_0000249,3268
10576,,H,,,1421,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,,Autocuration,,CHEMBL616209,,,,8,1,,B,,,BAO_0000249,3268
10576,,H,,,1422,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,,Expert,,CHEMBL616210,,,,8,1,,B,,,BAO_0000357,16117
10576,,H,10000000.0,,1423,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,Hippocampus,Expert,,CHEMBL616211,,,,8,1,,B,,,BAO_0000221,9783
10576,,H,10000000.0,,1424,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,Hippocampus,Autocuration,,CHEMBL616504,,,,8,1,,B,,,BAO_0000221,9783
10576,,D,10000000.0,,1425,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,Expert,,CHEMBL616505,,10116.0,,9,1,,B,,,BAO_0000221,14356
10576,,H,,,1426,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616506,,,,8,1,,F,,,BAO_0000019,15740
10576,,H,10000000.0,,1427,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,Hippocampus,Autocuration,,CHEMBL872107,,,,8,1,,B,,,BAO_0000221,12306
10576,,D,10000000.0,,1428,Rattus norvegicus,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,Hippocampus,Expert,,CHEMBL616507,,10116.0,,9,1,,B,,,BAO_0000221,13348
10576,,H,,,1429,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,,Autocuration,,CHEMBL616303,,,,8,1,,B,,,BAO_0000249,10394
10576,,H,10000000.0,,1430,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,Hippocampus,Autocuration,,CHEMBL616304,,,,8,1,,B,,,BAO_0000221,15260
10576,,H,10000000.0,,1431,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,Expert,,CHEMBL616305,,,,8,1,,B,,,BAO_0000221,10046
10576,,H,10000000.0,,1432,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,Hippocampus,Intermediate,,CHEMBL616306,,,,8,1,,F,,,BAO_0000221,15260
10576,,H,,,1433,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616307,,,,8,1,,B,,,BAO_0000357,12851
10576,,D,10000000.0,,1434,Rattus norvegicus,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,Hippocampus,Expert,,CHEMBL881829,,10116.0,,9,1,,B,,,BAO_0000221,2148
10576,,H,,,1435,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,,Expert,,CHEMBL616308,,,,8,1,,B,,,BAO_0000357,13134
10576,,H,,,1436,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,,Autocuration,,CHEMBL616309,,,,8,1,,B,,,BAO_0000019,12462
10576,,H,,,1437,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,,Expert,,CHEMBL616310,,,,8,1,,B,,,BAO_0000019,12462
10576,,H,,,1438,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,,Autocuration,,CHEMBL616311,,,449.0,8,1,CHO,B,,,BAO_0000219,12462
10576,,H,,,1439,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,,Expert,,CHEMBL616312,,,,8,1,,B,,,BAO_0000357,11933
10576,,H,,,1440,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,,Autocuration,,CHEMBL616313,,,,8,1,,B,,,BAO_0000357,11933
10576,,D,10000000.0,,1441,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,Hippocampus,Expert,,CHEMBL616314,,10116.0,,9,1,,B,,,BAO_0000221,403
10576,,H,10000000.0,,1442,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Autocuration,,CHEMBL616315,,,,8,1,,B,,,BAO_0000221,15538
10576,,H,10000000.0,,1443,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,Hippocampus,Autocuration,,CHEMBL616567,,,,8,1,,B,,,BAO_0000221,15538
10576,,H,10000000.0,,1444,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,Hippocampus,Autocuration,,CHEMBL616568,,,,8,1,,B,,,BAO_0000221,15538
10576,,H,,,1445,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,,Intermediate,,CHEMBL616569,,,,8,1,,B,,,BAO_0000019,12464
10576,,H,,,1446,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,,Expert,,CHEMBL616570,,,,8,1,,B,,,BAO_0000357,1455
10576,,H,,,1447,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,,Autocuration,,CHEMBL616571,,,,8,1,,B,,,BAO_0000357,12652
10576,,H,10000000.0,,1448,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,Hippocampus,Autocuration,,CHEMBL616572,,,,8,1,,B,,,BAO_0000221,12639
10576,,H,,,1449,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,,Expert,,CHEMBL616573,,,,8,1,,B,,,BAO_0000249,13949
10576,,D,,,1450,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,,Expert,,CHEMBL616574,,10116.0,,9,1,,B,,,BAO_0000357,12463
10576,,H,10000000.0,,1451,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,Hippocampus,Expert,,CHEMBL616575,,,,8,1,,B,,,BAO_0000221,14829
10576,,H,10000000.0,,1452,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,Hippocampus,Autocuration,,CHEMBL872108,,,,8,1,,B,,,BAO_0000221,14829
10576,,H,,,1453,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,,Autocuration,,CHEMBL616576,,,,8,1,,B,,,BAO_0000357,12092
10576,,H,,,1454,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,,Autocuration,,CHEMBL616577,,,,8,1,,B,,,BAO_0000249,403
10576,,H,,,1455,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,,Autocuration,,CHEMBL616578,,,,8,1,,B,,,BAO_0000249,403
10576,,H,,,1456,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,,Expert,,CHEMBL616579,,,,8,1,,B,,,BAO_0000357,3967
10576,,D,,,1457,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,,Expert,,CHEMBL616580,,10116.0,,9,1,,B,,,BAO_0000019,12771
10576,,H,,,1458,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,,Autocuration,,CHEMBL616581,,,,8,1,,B,,,BAO_0000019,15086
10576,,H,10000000.0,,1459,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Autocuration,,CHEMBL616582,,,,8,1,,B,,,BAO_0000221,14909
10576,,H,10000000.0,,1460,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,Hippocampus,Expert,,CHEMBL616583,,,,8,1,,B,,,BAO_0000221,14949
10576,,D,10000000.0,,1461,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,Hippocampus,Expert,,CHEMBL616584,,10116.0,,9,1,,B,,,BAO_0000221,2309
10576,,H,,,1462,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616585,,,,8,1,,B,,,BAO_0000357,4170
10576,,D,10000000.0,,1463,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,Hippocampus,Expert,,CHEMBL616586,,10116.0,,9,1,,B,,,BAO_0000221,11642
10576,,H,10000000.0,,1464,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,Hippocampus,Autocuration,,CHEMBL616587,,,,8,1,,B,,,BAO_0000221,11642
10576,,H,10000000.0,,1465,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,Hippocampus,Autocuration,,CHEMBL616588,,,,8,1,,B,,,BAO_0000221,12953
10576,,H,10000000.0,,1466,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,Hippocampus,Autocuration,,CHEMBL616589,,,,8,1,,B,,,BAO_0000221,12953
10576,,H,10000000.0,,1467,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,Hippocampus,Expert,,CHEMBL616590,,,,8,1,,B,,,BAO_0000221,12953
10576,,H,,,1468,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",,Expert,,CHEMBL616591,,,449.0,8,1,CHO,B,,,BAO_0000219,12903
10576,,H,,,1469,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616592,,,,8,1,,B,,,BAO_0000357,12536
10576,,H,,,1470,,The inhibition activity of 5-HT1A at 1 uM,,Autocuration,,CHEMBL616593,,,,8,1,,B,,,BAO_0000357,10058
10576,,H,,,1471,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",,Expert,,CHEMBL616594,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,12902
10576,,H,,,1472,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,,Expert,,CHEMBL616595,,,,8,1,,B,,,BAO_0000249,14057
10576,,H,,,1473,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,,Autocuration,,CHEMBL616596,,,,8,1,,B,,,BAO_0000357,11296
10576,,H,10000000.0,,1474,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,Autocuration,,CHEMBL616597,,,,8,1,,B,,,BAO_0000221,11296
10576,,H,10000000.0,,1475,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,Hippocampus,Expert,,CHEMBL616598,,,,8,1,,B,,,BAO_0000221,11296
10576,,D,,,1476,Rattus norvegicus,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,,Expert,,CHEMBL616599,,10116.0,,9,1,,F,,Membranes,BAO_0000249,16616
10576,,D,10000000.0,,1477,Rattus norvegicus,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",Hippocampus,Expert,,CHEMBL616600,,10116.0,,9,1,,F,,Membranes,BAO_0000249,16616
10576,,H,,,1478,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,,Autocuration,,CHEMBL616601,,,,8,1,,B,,,BAO_0000019,16567
10576,,H,,,1479,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,,Autocuration,,CHEMBL616602,,,,8,1,,B,,,BAO_0000019,16567
10576,,H,,,1480,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,,Autocuration,,CHEMBL616603,,,,8,1,,B,,,BAO_0000019,16567
10576,,H,,,1481,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,,Autocuration,,CHEMBL616604,,,,8,1,,B,,,BAO_0000019,16567
10576,,H,,,1482,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,,Autocuration,,CHEMBL616316,,,,8,1,,B,,,BAO_0000249,17136
10576,,H,,,1483,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,,Autocuration,,CHEMBL616317,,,,8,1,,B,,,BAO_0000249,17136
10576,,D,,,1484,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,,Expert,,CHEMBL616318,,10116.0,,9,1,,B,,,BAO_0000019,16616
10576,,H,10000000.0,,1485,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,Hippocampus,Autocuration,,CHEMBL616319,,,,8,1,,B,,,BAO_0000221,17331
10576,,H,10000000.0,,1486,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,Hippocampus,Autocuration,,CHEMBL616320,,,,8,1,,B,,,BAO_0000221,17331
10576,,D,10000000.0,,1487,Rattus norvegicus,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,Hippocampus,Expert,,CHEMBL616321,,10116.0,,9,1,,B,,,BAO_0000221,17167
10576,,H,,,1488,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,Autocuration,,CHEMBL616322,,,,8,1,,F,,,BAO_0000019,15740
10576,,H,,,1489,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,,Autocuration,,CHEMBL616323,,,,8,1,,F,,,BAO_0000019,15740
10576,,H,,,1490,,Ratio of binding affinity to 5-HT 1A and D2 receptor,,Autocuration,,CHEMBL616324,,,,8,1,,B,,,BAO_0000357,4671
10576,,H,10000000.0,,1491,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Hippocampus,Autocuration,,CHEMBL616325,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1492,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,Hippocampus,Autocuration,,CHEMBL616326,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,10000000.0,,1493,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,Hippocampus,Autocuration,,CHEMBL616327,,,,8,1,,B,,,BAO_0000221,10058
10576,,H,,,1494,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616328,,,,8,1,,B,,,BAO_0000357,12073
10576,,H,,,1495,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,Autocuration,,CHEMBL858110,,,,8,1,,B,,,BAO_0000249,2759
10576,,H,,,1496,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),,Autocuration,,CHEMBL616329,,,,8,1,,F,,,BAO_0000249,2759
10576,,H,,,1497,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,Autocuration,,CHEMBL616330,,,,8,1,,B,,,BAO_0000249,2759
10576,,H,,,1498,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),,Autocuration,,CHEMBL616331,,,,8,1,,F,,,BAO_0000249,2759
10576,,H,,,1499,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,Autocuration,,CHEMBL616332,,,,8,1,,F,,,BAO_0000249,2759
10576,,H,955.0,,1500,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,Autocuration,,CHEMBL857063,,,,8,1,,B,,,BAO_0000249,9737
10576,,H,,,1501,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,,Autocuration,,CHEMBL616333,,,,8,1,,B,,,BAO_0000019,9737
10576,,H,,,1502,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,,Expert,,CHEMBL616334,,,,8,1,,F,,,BAO_0000019,5717
10576,,H,10000000.0,,1503,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,Autocuration,,CHEMBL616335,,,,8,1,,B,,,BAO_0000221,12253
10576,,H,,,1504,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,,Autocuration,,CHEMBL616336,,,,8,1,,B,,,BAO_0000019,14025
10576,,H,,,1505,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,,Expert,,CHEMBL616337,,,,8,1,,B,,,BAO_0000249,10425
10576,,H,,,1506,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,,Autocuration,,CHEMBL616338,,,,8,1,,B,,,BAO_0000019,14998
10576,,H,10000000.0,,1507,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,Hippocampus,Autocuration,,CHEMBL616339,,,,8,1,,B,,,BAO_0000221,13694
10576,,H,10000000.0,,1508,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,Hippocampus,Autocuration,,CHEMBL616340,,,,8,1,,B,,,BAO_0000221,13694
10576,,H,,,1509,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,,Autocuration,,CHEMBL616341,,,,8,1,,B,,,BAO_0000357,4342
10576,,D,,,1510,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616342,,10116.0,,9,1,,B,,,BAO_0000357,12936
10576,,D,,,1511,Rattus norvegicus,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,,Expert,,CHEMBL616343,,10116.0,,9,1,,B,,,BAO_0000019,13144
10576,,H,,,1512,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,,Expert,,CHEMBL616344,,,,8,1,,B,,,BAO_0000019,13343
10576,,H,,,1513,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,Expert,,CHEMBL616345,,,,8,1,,B,,,BAO_0000357,12132
10576,,H,,,1514,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,,Expert,,CHEMBL616346,,,,8,1,,B,,,BAO_0000019,15419
10576,,H,10000000.0,,1515,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,Hippocampus,Autocuration,,CHEMBL616347,,,,8,1,,B,,,BAO_0000221,1479
10576,,H,,,1516,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,,Expert,,CHEMBL616348,,,,8,1,,B,,,BAO_0000019,14287
10576,,H,,,1517,,Binding affinity at 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616349,,,,8,1,,B,,,BAO_0000357,13116
10576,,D,,,1518,Rattus norvegicus,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,,Expert,,CHEMBL616152,,10116.0,,9,1,,B,,Membranes,BAO_0000249,2759
10576,,H,,,1519,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,,Autocuration,,CHEMBL616153,,,,8,1,,B,,,BAO_0000249,2759
10576,,H,,,1520,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",,Expert,,CHEMBL616154,,,,8,1,,B,,,BAO_0000019,14748
10576,,H,,,1521,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,,Autocuration,,CHEMBL616155,,,,8,1,,B,,,BAO_0000019,12304
10576,,D,10000000.0,,1522,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,Hippocampus,Expert,,CHEMBL616156,,10116.0,,9,1,,B,,,BAO_0000221,12409
10576,,D,10000000.0,,1523,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,Hippocampus,Expert,,CHEMBL616157,,10116.0,,9,1,,B,,,BAO_0000221,12409
10576,,H,10000000.0,,1524,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,Hippocampus,Autocuration,,CHEMBL616158,,,,8,1,,B,,,BAO_0000221,13267
10576,,H,,,1525,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,,Autocuration,,CHEMBL616159,,,,8,1,,B,,,BAO_0000357,15194
10576,,H,,,1526,,pKi value against rat 5-hydroxytryptamine 1A receptor.,,Expert,,CHEMBL616160,,,,8,1,,B,,,BAO_0000357,14256
10576,,H,,,1527,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,,Autocuration,,CHEMBL616161,,,,8,1,,B,,,BAO_0000019,16567
10576,,H,,,1528,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,,Autocuration,,CHEMBL616162,,,,8,1,,F,,,BAO_0000019,15740
12687,,D,,,1529,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,Expert,,CHEMBL616163,,10116.0,,9,1,,B,,,BAO_0000357,13278
10626,,H,,,1530,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,,Expert,,CHEMBL616164,,,,8,1,,B,,Membranes,BAO_0000249,1970
10576,,H,955.0,,1531,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,Brain,Autocuration,,CHEMBL616165,,,,8,1,,B,,,BAO_0000221,10034
51,,H,,,1532,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,,Autocuration,,CHEMBL616355,,10116.0,,8,1,,B,,,BAO_0000019,13348
10576,,H,,,1533,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,,Autocuration,,CHEMBL616356,,,,8,1,,F,,,BAO_0000019,13630
10576,,H,955.0,,1534,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,Brain,Autocuration,,CHEMBL616357,,,,8,1,,B,,,BAO_0000221,10862
10576,,H,,,1535,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",,Autocuration,,CHEMBL616358,,,,8,1,,B,,,BAO_0000019,12058
51,,H,,,1536,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616359,,,,8,1,,B,,,BAO_0000357,4639
51,,H,,,1537,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,,Expert,,CHEMBL616360,,,,8,1,,B,,,BAO_0000357,15453
51,,H,,,1538,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616361,,,,8,1,,B,,,BAO_0000357,4820
51,,H,,,1539,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616362,,,,8,1,,B,,,BAO_0000357,1089
51,,H,,,1540,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,,Autocuration,,CHEMBL616363,,,,8,1,,B,,Brain membranes,BAO_0000249,386
51,,H,,,1541,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,,Autocuration,,CHEMBL616364,,,,8,1,,B,,,BAO_0000357,6011
51,,H,,,1542,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616365,,,,8,1,,B,,,BAO_0000357,5014
51,,H,,,1543,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,,Expert,,CHEMBL616366,,,,8,1,,B,,,BAO_0000357,4402
51,,H,,,1544,,Binding affinity towards 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL872906,,,,8,1,,B,,,BAO_0000357,17066
51,,H,,,1545,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,,Autocuration,,CHEMBL616367,,,,8,1,,B,,,BAO_0000357,17515
51,,H,,,1546,,Binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616368,,,,8,1,,B,,,BAO_0000357,2474
51,,H,,,1547,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,,Autocuration,,CHEMBL616369,,,,8,1,,B,,,BAO_0000357,4775
51,,D,,,1548,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,,Expert,,CHEMBL616370,,9606.0,,9,1,,B,,,BAO_0000357,14294
51,,D,,,1549,Homo sapiens,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,,Expert,,CHEMBL616371,,9606.0,,9,1,,B,,,BAO_0000357,14294
51,,H,,,1550,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,Autocuration,,CHEMBL616372,,,449.0,8,1,CHO,B,,,BAO_0000219,12249
51,,H,,,1551,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,,Expert,,CHEMBL616373,,,,8,1,,B,,,BAO_0000219,11376
51,,H,,,1552,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616374,In vivo,,,8,1,,B,,,BAO_0000218,2474
51,,H,10000000.0,,1553,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,Hippocampus,Autocuration,,CHEMBL616375,,,,8,1,,B,,,BAO_0000221,13311
51,,H,,,1554,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,,Autocuration,,CHEMBL616376,,,,8,1,,B,,,BAO_0000357,4373
51,,H,,,1555,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,,Expert,,CHEMBL857064,,,,8,1,,B,,,BAO_0000357,1633
51,,H,,,1556,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,Autocuration,,CHEMBL616377,,,,8,1,,B,,,BAO_0000357,11866
51,,H,,,1557,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,,Autocuration,,CHEMBL616378,,,,8,1,,B,,,BAO_0000357,4373
51,,H,,,1558,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616379,,,,8,1,,B,,,BAO_0000357,4687
11863,,H,,,1559,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616380,,,,8,1,,B,,,BAO_0000357,16946
11863,,H,,,1560,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,,Autocuration,,CHEMBL616381,,,,8,1,,B,,,BAO_0000357,13291
11863,,H,,,1561,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616382,,,,8,1,,B,,,BAO_0000357,14159
11863,,H,,,1562,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,,Autocuration,,CHEMBL616383,,,,8,1,,B,,,BAO_0000357,10812
11863,,D,,,1563,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,,Expert,,CHEMBL616350,,10090.0,449.0,9,1,CHO,B,,,BAO_0000219,3032
11863,,H,,,1564,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616351,,,,8,1,,B,,,BAO_0000357,16655
11863,,H,,,1565,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,,Autocuration,,CHEMBL616352,,,,8,1,,B,,,BAO_0000357,14532
11863,,H,,,1566,,Binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616353,,,,8,1,,B,,,BAO_0000357,13944
11863,,H,,,1567,,Binding affinity against serotonergic 5-HT1a receptor,,Autocuration,,CHEMBL616354,,,,8,1,,B,,,BAO_0000357,13033
11863,,H,,,1568,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616508,,,,8,1,,B,,,BAO_0000357,10321
11863,,D,,,1569,Mus musculus,Binding affinity for 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616559,,10090.0,,9,1,,B,,,BAO_0000357,2968
11863,,H,,,1570,,Binding affinity at 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616560,,,,8,1,,B,,,BAO_0000357,13964
11863,,H,,,1571,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",,Autocuration,,CHEMBL616561,,,,8,1,,B,,,BAO_0000357,15527
11863,,H,,,1572,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,Autocuration,,CHEMBL616562,,,449.0,8,1,CHO,B,,,BAO_0000219,12248
11863,,H,,,1573,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,,Autocuration,,CHEMBL616563,,,449.0,8,1,CHO,B,,,BAO_0000219,12249
11863,,H,,,1574,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616564,,,,8,1,,B,,,BAO_0000357,15120
11863,,H,,,1575,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616565,,,,8,1,,B,,,BAO_0000357,13313
11863,,H,,,1576,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616566,,,,8,1,,B,,,BAO_0000218,2613
11863,,H,,,1577,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,,Autocuration,,CHEMBL616989,,,,8,1,,B,,,BAO_0000357,16700
11863,,H,,,1578,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL857975,,,,8,1,,B,,,BAO_0000357,2201
11863,,D,,,1579,Mus musculus,Binding affinity against 5-hydroxytryptamine 1A receptor,,Expert,,CHEMBL616990,,10090.0,,9,1,,B,,,BAO_0000357,1274
11863,,H,,,1580,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,,Autocuration,,CHEMBL616991,,,,8,1,,B,,,BAO_0000357,1317
11863,,H,,,1581,,Tested against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616992,,,,8,1,,B,,,BAO_0000357,12146
11863,,H,,,1582,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL616993,,,,8,1,,B,,,BAO_0000357,14059
106,,H,,,1583,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,,Expert,,CHEMBL616994,,9986.0,,8,1,,B,,,BAO_0000019,14025
106,,H,,,1584,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,,Autocuration,,CHEMBL616995,,9986.0,,8,1,,B,,,BAO_0000019,14025
105571,,D,,,1585,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,Intermediate,,CHEMBL616996,,9593.0,722.0,9,1,HEK293,B,,,BAO_0000219,14447
106,,H,,,1586,Cavia porcellus,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,Autocuration,,CHEMBL616997,In vivo,10141.0,,8,1,,F,,,BAO_0000218,3025
106,,H,,,1587,Cavia porcellus,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,,Autocuration,,CHEMBL616998,In vivo,10141.0,,8,1,,F,,,BAO_0000218,3025
106,,H,,,1588,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,,Autocuration,,CHEMBL616999,,10141.0,,8,1,,F,,,BAO_0000019,15329
106,,H,,,1589,Cavia porcellus,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,,Autocuration,,CHEMBL617000,,10141.0,,8,1,,F,,,BAO_0000019,15329
106,,H,,,1590,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,,Autocuration,,CHEMBL617001,,10141.0,,8,1,,F,,,BAO_0000019,15847
106,,H,,,1591,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,,Autocuration,,CHEMBL858111,,10141.0,,8,1,,F,,,BAO_0000019,15847
106,,H,,,1592,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,,Autocuration,,CHEMBL617002,,,,8,1,,F,,,BAO_0000019,14165
106,,H,,,1593,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),,Autocuration,,CHEMBL617003,,,,8,1,,F,,,BAO_0000019,14214
106,,H,,,1594,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),,Autocuration,,CHEMBL617004,,,,8,1,,F,,,BAO_0000019,14214
106,,D,,,1595,Homo sapiens,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,,Expert,,CHEMBL617005,,9606.0,,9,1,,F,,,BAO_0000019,14214
106,,D,,,1596,Homo sapiens,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,,Expert,,CHEMBL616623,,9606.0,485.0,9,1,CHO-K1,F,,,BAO_0000219,13729
106,,H,,,1597,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,,Autocuration,,CHEMBL616624,,,449.0,8,1,CHO,F,,,BAO_0000219,3025
106,,H,,,1598,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL883243,,,,8,1,,B,,,BAO_0000357,2391
106,,H,,,1599,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,,Autocuration,,CHEMBL616625,,,,8,1,,F,,,BAO_0000019,2391
106,,H,,,1600,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",,Expert,,CHEMBL616626,,,449.0,8,1,CHO,F,,,BAO_0000219,14956
106,,H,,,1601,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,,Autocuration,,CHEMBL616627,,,449.0,8,1,CHO,F,,,BAO_0000219,2598
106,,H,,,1602,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,,Autocuration,,CHEMBL616628,,,449.0,8,1,CHO,F,,,BAO_0000219,2598
106,,H,,,1603,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,,Autocuration,,CHEMBL616629,,,449.0,8,1,CHO,F,,,BAO_0000219,2598
106,,H,,,1604,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,,Autocuration,,CHEMBL616630,,,449.0,8,1,CHO,F,,,BAO_0000219,2598
106,,H,,,1605,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",,Expert,,CHEMBL616631,,,,8,1,,F,,,BAO_0000019,14956
106,,H,,,1606,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",,Autocuration,,CHEMBL616632,,,,8,1,,F,,,BAO_0000019,14956
106,,D,,,1607,Homo sapiens,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616633,,9606.0,,9,1,,B,,,BAO_0000357,14214
106,,H,,,1608,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,,Expert,,CHEMBL616634,,,449.0,8,1,CHO,B,,,BAO_0000219,3463
106,,H,,,1609,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,,Autocuration,,CHEMBL616635,,,,8,1,,B,,,BAO_0000357,15331
106,,D,,,1610,Homo sapiens,Binding affinity against 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL885358,,9606.0,,9,1,,B,,,BAO_0000357,16146
106,,D,,,1611,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,Expert,,CHEMBL616636,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,14159
106,,H,,,1612,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,,Expert,,CHEMBL616637,,,449.0,8,1,CHO,B,,,BAO_0000219,14158
106,,H,,,1613,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616638,,,,8,1,,B,,,BAO_0000357,14159
106,,H,,,1614,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,Expert,,CHEMBL616639,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
106,,H,,,1615,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,,Expert,,CHEMBL616640,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
106,,H,,,1616,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,,Expert,,CHEMBL616641,,,449.0,8,1,CHO,B,,,BAO_0000219,15331
106,,H,,,1617,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,,Expert,,CHEMBL616642,,,449.0,8,1,CHO,B,,,BAO_0000219,15332
106,,H,,,1618,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,,Expert,,CHEMBL616643,,,449.0,8,1,CHO,B,,,BAO_0000219,14956
106,,H,,,1619,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),,Autocuration,,CHEMBL616644,,,,8,1,,B,,,BAO_0000357,3805
106,,H,,,1620,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,,Autocuration,,CHEMBL616645,,,,8,1,,B,,,BAO_0000357,14875
105,,H,,,1621,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Autocuration,,CHEMBL616646,,9986.0,,8,1,,F,,,BAO_0000019,14454
105,,H,,,1622,Oryctolagus cuniculus,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Expert,,CHEMBL616647,,9986.0,,8,1,,F,,,BAO_0000019,14454
105,,H,,,1623,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),,Autocuration,,CHEMBL616509,,,,8,1,,B,,,BAO_0000357,16288
105,,H,,,1624,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),,Autocuration,,CHEMBL616510,,,,8,1,,B,,,BAO_0000357,16288
105,,H,,,1625,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616511,,,,8,1,,B,,,BAO_0000357,16312
105,,H,,,1626,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,,Expert,,CHEMBL616512,,9913.0,,8,1,,B,,,BAO_0000357,1348
105,,H,,,1627,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,,Autocuration,,CHEMBL616513,,9913.0,,8,1,,B,,,BAO_0000357,5834
105,,H,2435.0,,1628,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Striatum,Autocuration,,CHEMBL616514,,9913.0,,8,1,,B,,,BAO_0000019,13366
105,,H,,,1629,Bos taurus,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,,Expert,,CHEMBL616515,,9913.0,,8,1,,B,,,BAO_0000357,1414
105,,H,,,1630,Bos taurus,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,,Autocuration,,CHEMBL616516,,9913.0,,8,1,,B,,,BAO_0000019,14998
105,,H,,,1631,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,Autocuration,,CHEMBL616517,,9913.0,,8,1,,B,,,BAO_0000357,11473
105,,H,,,1632,Bos taurus,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,,Autocuration,,CHEMBL616518,,9913.0,,8,1,,B,,,BAO_0000357,11473
105,,H,,,1633,Bos taurus,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,Autocuration,,CHEMBL616519,,9913.0,,8,1,,B,,,BAO_0000357,10639
105,,H,,,1634,Bos taurus,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,,Autocuration,,CHEMBL616520,,9913.0,,8,1,,B,,,BAO_0000357,10639
105,,H,,,1635,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,,Autocuration,,CHEMBL616521,,9913.0,,8,1,,B,,,BAO_0000357,1375
105,,H,,,1636,Bos taurus,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,,Autocuration,,CHEMBL616522,,9913.0,,8,1,,B,,,BAO_0000357,1375
105,,H,,,1637,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,Autocuration,,CHEMBL884531,,9913.0,,8,1,,B,,,BAO_0000357,16532
105,,H,,,1638,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616523,,9913.0,,8,1,,B,,,BAO_0000357,11147
105,,H,2435.0,,1639,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,Striatum,Autocuration,,CHEMBL616731,,9913.0,,8,1,,B,,,BAO_0000019,13366
105,,H,,,1640,Bos taurus,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,,Autocuration,,CHEMBL616732,,9913.0,,8,1,,B,,,BAO_0000019,10444
105,,H,,,1641,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,,Autocuration,,CHEMBL616733,,9913.0,,8,1,,B,,,BAO_0000357,16532
105,,H,,,1642,Bos taurus,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,,Autocuration,,CHEMBL616734,,9913.0,,8,1,,B,,,BAO_0000357,16532
105,,H,,,1643,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,,Autocuration,,CHEMBL616735,,9913.0,,8,1,,B,,,BAO_0000249,12827
105,,H,,,1644,Bos taurus,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,,Autocuration,,CHEMBL616736,,9913.0,,8,1,,B,,,BAO_0000249,12827
105,,H,,,1645,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Expert,,CHEMBL616737,,9913.0,,8,1,,F,,,BAO_0000019,12919
105,,H,,,1646,Bos taurus,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,,Autocuration,,CHEMBL616738,,9913.0,,8,1,,B,,,BAO_0000019,14025
105,,H,,,1647,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Expert,,CHEMBL616739,,9913.0,,8,1,,F,,,BAO_0000019,12919
105,,H,,,1648,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Expert,,CHEMBL616740,,9913.0,,8,1,,F,,,BAO_0000019,12919
105,,H,,,1649,Bos taurus,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,,Expert,,CHEMBL616741,,9913.0,,8,1,,F,,,BAO_0000019,12919
105,,H,,,1650,Gorilla gorilla,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,,Autocuration,,CHEMBL616742,,9593.0,722.0,8,1,HEK293,B,,,BAO_0000219,14447
105570,,D,,,1651,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,,Intermediate,,CHEMBL616743,,10141.0,,9,1,,B,,,BAO_0000019,1375
105570,,D,,,1652,Cavia porcellus,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,,Intermediate,,CHEMBL616744,,10141.0,,9,1,,B,,,BAO_0000019,1375
105570,,D,,,1653,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,,Intermediate,,CHEMBL616745,,10141.0,,9,1,,F,,,BAO_0000019,12409
105570,,D,,,1654,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Intermediate,,CHEMBL616746,,10141.0,,9,1,,F,,,BAO_0000019,12409
105570,,D,,,1655,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,,Intermediate,,CHEMBL616747,,10141.0,,9,1,,F,,,BAO_0000019,12409
105570,,D,,,1656,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,,Intermediate,,CHEMBL616748,,10141.0,,9,1,,F,,,BAO_0000019,12409
105570,,D,,,1657,Cavia porcellus,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,,Intermediate,,CHEMBL616648,,10141.0,,9,1,,F,,,BAO_0000019,12409
105570,,D,,,1658,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 1D receptor,,Intermediate,,CHEMBL616649,,10141.0,,9,1,,B,,,BAO_0000357,11574
105570,,D,,,1659,Cavia porcellus,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,,Intermediate,,CHEMBL616650,,10141.0,,9,1,,B,,,BAO_0000357,1558
105570,,D,,,1660,Cavia porcellus,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Intermediate,,CHEMBL616651,,10141.0,,9,1,,F,,,BAO_0000218,12409
105570,,D,,,1661,Cavia porcellus,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Intermediate,,CHEMBL616652,,10141.0,,9,1,,F,,,BAO_0000218,12409
105570,,D,,,1662,Cavia porcellus,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,,Intermediate,,CHEMBL616653,,10141.0,,9,1,,F,,,BAO_0000218,12409
105570,,D,,,1663,Cavia porcellus,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,,Intermediate,,CHEMBL616654,,10141.0,,9,1,,F,,,BAO_0000218,12409
105570,,D,,,1664,Cavia porcellus,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,,Intermediate,,CHEMBL616655,,10141.0,,9,1,,B,,,BAO_0000019,12253
105570,,D,,,1665,Cavia porcellus,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,,Intermediate,,CHEMBL616656,,10141.0,,9,1,,B,,,BAO_0000357,12936
105,,H,,,1666,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,,Autocuration,,CHEMBL616657,,10141.0,,8,1,,B,,,BAO_0000019,13181
105570,,D,2435.0,,1667,Cavia porcellus,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,Striatum,Intermediate,,CHEMBL616658,,10141.0,,9,1,,B,,,BAO_0000357,12409
105570,,D,,,1668,Cavia porcellus,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,,Intermediate,,CHEMBL616659,,10141.0,,9,1,,B,,,BAO_0000357,10639
51,,H,,,1669,,Binding affinity against 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616660,,,,8,1,,B,,,BAO_0000357,5254
106,,H,,,1670,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,,Autocuration,,CHEMBL616661,,,,8,1,,B,,,BAO_0000357,13051
105,,H,,,1671,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616662,,,,8,1,,F,,,BAO_0000019,3463
105,,H,,,1672,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616663,,,,8,1,,F,,,BAO_0000019,15315
105,,H,,,1673,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616664,,,,8,1,,F,,,BAO_0000019,6011
105,,D,,,1674,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",,Expert,,CHEMBL881820,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,14159
105,,H,,,1675,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",,Autocuration,,CHEMBL616665,,,449.0,8,1,CHO,F,,,BAO_0000219,14159
105,,H,,,1676,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616666,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
105,,H,,,1677,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616667,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
105,,H,,,1678,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,Expert,,CHEMBL616668,,,449.0,8,1,CHO,F,,,BAO_0000219,15331
105,,D,,,1679,Homo sapiens,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",,Expert,,CHEMBL616669,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,15332
105,,H,,,1680,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",,Expert,,CHEMBL617040,,,449.0,8,1,CHO,F,,,BAO_0000219,15332
105,,H,,,1681,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",,Autocuration,,CHEMBL617041,,,449.0,8,1,CHO,F,,,BAO_0000219,3294
105,,H,,,1682,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",,Expert,,CHEMBL617042,,,449.0,8,1,CHO,F,,,BAO_0000219,14158
105,,H,,,1683,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",,Expert,,CHEMBL617043,,,449.0,8,1,CHO,F,,,BAO_0000219,14956
105,,H,,,1684,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL617044,,,,8,1,,F,,,BAO_0000019,12469
105,,H,,,1685,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL617045,,,449.0,8,1,CHO,F,,,BAO_0000219,3463
105,,D,,,1686,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,Expert,,CHEMBL617046,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,15250
105,,D,,,1687,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",,Expert,,CHEMBL617047,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,15250
105,,H,,,1688,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",,Expert,,CHEMBL617048,,,,8,1,,F,,,BAO_0000019,14956
105,,H,,,1689,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",,Autocuration,,CHEMBL616897,,,,8,1,,F,,,BAO_0000019,14159
105,,D,,,1690,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",,Expert,,CHEMBL616898,,9606.0,,9,1,,F,,,BAO_0000019,14159
105,,D,,,1691,Homo sapiens,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,,Expert,,CHEMBL858201,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,14499
105,,H,,,1692,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616899,,,,8,1,,F,,,BAO_0000019,15315
105,,H,,,1693,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),,Autocuration,,CHEMBL616900,In vitro,,,8,1,,B,,,BAO_0000219,3294
105,,H,,,1694,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,,Expert,,CHEMBL616901,,,449.0,8,1,CHO,B,,,BAO_0000219,3463
105,,H,,,1695,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,,Autocuration,,CHEMBL616902,,,,8,1,,B,,,BAO_0000357,15331
105,,D,,,1696,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Expert,,CHEMBL616903,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,14159
105,,H,,,1697,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,,Expert,,CHEMBL616904,,,449.0,8,1,CHO,B,,,BAO_0000219,14158
105,,H,,,1698,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616905,,,,8,1,,B,,,BAO_0000357,14159
105,,H,,,1699,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,,Expert,,CHEMBL616906,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
105,,H,,,1700,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,Expert,,CHEMBL616907,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
105,,H,,,1701,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,Expert,,CHEMBL616908,,,449.0,8,1,CHO,B,,,BAO_0000219,15331
105,,D,,,1702,Homo sapiens,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Expert,,CHEMBL616909,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,15332
105,,D,,,1703,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Expert,,CHEMBL616910,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,14499
105,,H,,,1704,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,,Expert,,CHEMBL616911,,,449.0,8,1,CHO,B,,,BAO_0000219,15332
105,,H,,,1705,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,,Expert,,CHEMBL616912,,,449.0,8,1,CHO,B,,,BAO_0000219,14956
105,,H,,,1706,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),,Autocuration,,CHEMBL616913,,,,8,1,,B,,,BAO_0000357,3805
105,,D,,,1707,Homo sapiens,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,,Expert,,CHEMBL616914,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,6011
105,,H,,,1708,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616915,,,449.0,8,1,CHO,B,,,BAO_0000219,16190
105,,H,,,1709,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,,Autocuration,,CHEMBL616916,,,,8,1,,B,,,BAO_0000019,14165
105,,D,,,1710,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616917,,9606.0,,9,1,,B,,,BAO_0000357,4234
105,,H,,,1711,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",,Autocuration,,CHEMBL616918,,,,8,1,,B,,,BAO_0000357,15527
105,,H,,,1712,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,,Expert,,CHEMBL616919,,,,8,1,,B,,,BAO_0000219,6328
105,,H,,,1713,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616920,,,,8,1,,B,,,BAO_0000357,16209
105,,H,,,1714,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL872914,,,,8,1,,B,,,BAO_0000357,14770
105,,H,,,1715,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,,Autocuration,,CHEMBL616921,,,,8,1,,B,,,BAO_0000357,2598
105,,H,,,1716,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616922,,,,8,1,,B,,,BAO_0000357,6897
105,,H,,,1717,,Binding affinity towards 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616923,,,,8,1,,B,,,BAO_0000357,6013
105,,H,,,1718,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616924,,,,8,1,,B,,,BAO_0000357,5843
105,,H,,,1719,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,,Expert,,CHEMBL875909,,,,8,1,,B,,,BAO_0000357,14454
105,,H,,,1720,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,,Autocuration,,CHEMBL616925,,,,8,1,,B,,,BAO_0000357,14454
105,,H,,,1721,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,,Autocuration,,CHEMBL616926,,,,8,1,,B,,,BAO_0000357,14454
105,,H,,,1722,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616927,,,,8,1,,B,,,BAO_0000357,15818
105,,H,,,1723,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,,Expert,,CHEMBL616928,,,485.0,8,1,CHO-K1,F,,,BAO_0000219,13729
105,,D,,,1724,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),,Expert,,CHEMBL616929,In vitro,9606.0,,9,1,,B,,,BAO_0000219,6011
105,,D,,,1725,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616930,,9606.0,,9,1,,B,,,BAO_0000357,4234
105,,H,,,1726,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616931,,,,8,1,,B,,,BAO_0000019,17085
105,,H,,,1727,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,Autocuration,,CHEMBL616932,,,,8,1,,B,,,BAO_0000357,3025
105,,H,,,1728,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616933,,,,8,1,,B,,,BAO_0000357,15315
105,,D,,,1729,Homo sapiens,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,,Expert,,CHEMBL616934,,9606.0,,9,1,,B,,,BAO_0000219,14214
105,,D,,,1730,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616935,,9606.0,,9,1,,B,,,BAO_0000357,3804
105,,H,,,1731,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,,Autocuration,,CHEMBL616936,,,,8,1,,B,,,BAO_0000357,16700
105,,D,,,1732,Homo sapiens,Affinity for 5-hydroxytryptamine 1D receptor subtype,,Expert,,CHEMBL616937,,9606.0,,9,1,,B,,,BAO_0000357,2391
105,,D,,,1733,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616938,,9606.0,,9,1,,B,,,BAO_0000357,4175
105,,H,,,1734,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616939,,,,8,1,,B,,,BAO_0000019,17085
105,,H,,,1735,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,,Expert,,CHEMBL616940,,,,8,1,,B,,,BAO_0000019,17085
105,,D,,,1736,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,,Expert,,CHEMBL616941,,9606.0,,9,1,,B,,,BAO_0000357,15926
105,,H,,,1737,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,,Autocuration,,CHEMBL616942,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,16312
105,,H,,,1738,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,,Autocuration,,CHEMBL616943,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,16312
104802,,H,,,1739,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,,Autocuration,,CHEMBL616944,,,449.0,4,1,CHO,B,,,BAO_0000219,14956
105,,H,,,1740,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",,Autocuration,,CHEMBL616945,,,,8,1,,F,,,BAO_0000019,3294
105,,H,,,1741,,Binding activity radioligand.,,Autocuration,,CHEMBL616946,,,,8,1,,B,,,BAO_0000357,12861
105,,H,,,1742,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,Autocuration,,CHEMBL616947,,,,8,1,,B,,,BAO_0000019,12861
105,,H,,,1743,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616948,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,16312
105,,H,,,1744,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616851,,,,8,1,,B,,,BAO_0000357,5104
105,,H,,,1745,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616852,,,,8,1,,B,,,BAO_0000357,5105
105,,H,,,1746,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616853,,,,8,1,,B,,,BAO_0000357,14499
105,,D,,,1747,Homo sapiens,Binding activity against human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616854,,9606.0,,9,1,,B,,,BAO_0000357,15926
105,,D,,,1748,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,,Expert,,CHEMBL616855,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,4540
105,,H,,,1749,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,,Autocuration,,CHEMBL616856,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
105,,H,,,1750,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL616857,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
105,,H,,,1751,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616858,,,,8,1,,B,,,BAO_0000357,6166
105,,H,,,1752,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL616859,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
105,,H,,,1753,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,,Autocuration,,CHEMBL616860,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
105,,H,,,1754,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,Autocuration,,CHEMBL616861,,,722.0,8,1,HEK293,B,,,BAO_0000219,17451
105,,H,,,1755,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,,Autocuration,,CHEMBL616541,,,722.0,8,1,HEK293,B,,,BAO_0000219,17451
105,,H,,,1756,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,,Autocuration,,CHEMBL616542,,,722.0,8,1,HEK293,B,,,BAO_0000219,17451
105,,H,,,1757,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,,Autocuration,,CHEMBL616543,,,449.0,8,1,CHO,B,,,BAO_0000219,4199
105,,D,,,1758,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL616544,,9606.0,,9,1,,B,,,BAO_0000357,14875
105,,H,,,1759,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,,Autocuration,,CHEMBL616545,,,449.0,8,1,CHO,B,,,BAO_0000219,15146
105,,H,,,1760,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,,Autocuration,,CHEMBL616546,,,,8,1,,B,,,BAO_0000357,5213
105,,H,,,1761,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,,Autocuration,,CHEMBL616547,,,449.0,8,1,CHO,B,,,BAO_0000219,14818
105,,H,,,1762,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",,Autocuration,,CHEMBL616548,,,449.0,8,1,CHO,B,,,BAO_0000219,4829
105,,H,,,1763,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,,Expert,,CHEMBL616549,,,,8,1,,F,,,BAO_0000019,14454
105,,H,,,1764,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,,Expert,,CHEMBL616550,,,,8,1,,F,,,BAO_0000019,14454
108,,H,,,1765,,Binding affinity against 5-HT2C receptor,,Autocuration,,CHEMBL857066,,,,8,1,,B,,,BAO_0000357,5254
108,,H,,,1766,,Binding affinity against 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616551,,,,8,1,,B,,,BAO_0000357,5254
10577,,H,,,1767,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,Autocuration,,CHEMBL616552,,,,8,1,,B,,,BAO_0000357,10639
10577,,H,,,1768,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,,Autocuration,,CHEMBL832876,,,,8,1,,F,,,BAO_0000019,10639
10577,,H,,,1769,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",,Expert,,CHEMBL616553,,,,8,1,,B,,,BAO_0000019,12352
10577,,H,,,1770,,Binding affinity towards 5-HT1B was determined,,Autocuration,,CHEMBL616554,,,,8,1,,B,,,BAO_0000357,9098
10577,,H,,,1771,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,,Expert,,CHEMBL616555,,,,8,1,,B,,,BAO_0000019,14430
10577,,H,,,1772,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",,Expert,,CHEMBL616556,,,,8,1,,B,,,BAO_0000019,13657
10577,,H,,,1773,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",,Autocuration,,CHEMBL616557,,,,8,1,,B,,,BAO_0000019,13657
10577,,H,,,1774,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,Expert,,CHEMBL616558,,,,8,1,,B,,,BAO_0000019,15854
10577,,D,,,1775,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,,Expert,,CHEMBL616749,,10116.0,,9,1,,B,,,BAO_0000019,10639
10577,,H,,,1776,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,,Autocuration,,CHEMBL616750,,,,8,1,,B,,,BAO_0000357,10025
10577,,H,,,1777,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",,Autocuration,,CHEMBL616751,,,,8,1,,B,,,BAO_0000357,10025
10577,,H,,,1778,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,Autocuration,,CHEMBL616752,,,,8,1,,B,,,BAO_0000249,14286
10577,,H,2435.0,,1779,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,Striatum,Autocuration,,CHEMBL616753,,,,8,1,,B,,,BAO_0000019,3651
10577,,D,,,1780,Rattus norvegicus,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616754,,10116.0,,9,1,,B,,,BAO_0000357,14178
10577,,H,,,1781,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,,Autocuration,,CHEMBL616755,,,,8,1,,B,,,BAO_0000019,10639
10577,,H,2435.0,,1782,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,Striatum,Autocuration,,CHEMBL616756,,,,8,1,,B,,,BAO_0000019,13605
10577,,H,2435.0,,1783,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,Striatum,Autocuration,,CHEMBL616757,,,,8,1,,B,,,BAO_0000019,5834
10577,,H,2435.0,,1784,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,Striatum,Autocuration,,CHEMBL616758,,,,8,1,,B,,,BAO_0000357,10922
10577,,H,,,1785,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,,Autocuration,,CHEMBL616759,,,,8,1,,B,,,BAO_0000249,14286
10577,,H,,,1786,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,,Autocuration,,CHEMBL616760,,,,8,1,,B,,,BAO_0000357,11825
10577,,H,2435.0,,1787,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,Striatum,Autocuration,,CHEMBL616761,,,,8,1,,B,,,BAO_0000019,14826
10577,,H,2435.0,,1788,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,Striatum,Autocuration,,CHEMBL616762,,,,8,1,,B,,,BAO_0000019,9699
10577,,H,,,1789,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,,Autocuration,,CHEMBL616763,,,,8,1,,B,,,BAO_0000019,14423
10577,,H,,,1790,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,,Expert,,CHEMBL872909,,,,8,1,,B,,,BAO_0000357,10062
10577,,H,,,1791,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616764,,,,8,1,,B,,,BAO_0000357,10062
10577,,D,,,1792,Rattus norvegicus,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616765,,10116.0,,9,1,,B,,,BAO_0000357,12280
10577,,H,2435.0,,1793,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,Striatum,Autocuration,,CHEMBL616766,,,,8,1,,B,,,BAO_0000357,15412
10577,,H,2435.0,,1794,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,Striatum,Autocuration,,CHEMBL616767,,,,8,1,,B,,,BAO_0000357,15412
10577,,H,,,1795,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616768,,,,8,1,,B,,,BAO_0000357,10062
10577,,H,,,1796,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616769,,,,8,1,,B,,,BAO_0000357,11147
10577,,H,,,1797,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,,Autocuration,,CHEMBL616770,,,,8,1,,B,,,BAO_0000019,9547
10577,,H,,,1798,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,,Autocuration,,CHEMBL616771,,,,8,1,,B,,,BAO_0000019,10444
10577,,H,2435.0,,1799,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,Striatum,Autocuration,,CHEMBL616772,,,,8,1,,B,,,BAO_0000019,12469
10577,,H,,,1800,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,,Expert,,CHEMBL616773,,,,8,1,,B,,,BAO_0000019,9098
10577,,H,,,1801,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,,Autocuration,,CHEMBL616774,,,,8,1,,B,,,BAO_0000019,9098
10577,,H,,,1802,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616775,,,,8,1,,B,,,BAO_0000357,9699
10577,,H,,,1803,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,,Autocuration,,CHEMBL616776,,,,8,1,,B,,,BAO_0000249,10394
10577,,H,,,1804,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,,Autocuration,,CHEMBL616777,,,,8,1,,B,,,BAO_0000357,12092
10577,,H,,,1805,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,,Autocuration,,CHEMBL616778,,,,8,1,,B,,,BAO_0000357,16700
10577,,D,,,1806,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,,Expert,,CHEMBL616779,,10116.0,,9,1,,B,,,BAO_0000249,403
10577,,D,,,1807,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616780,,10116.0,,9,1,,B,,,BAO_0000357,12771
10577,,H,,,1808,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,,Autocuration,,CHEMBL616781,,,,8,1,,B,,,BAO_0000019,11642
10577,,H,,,1809,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616782,,,,8,1,,B,,,BAO_0000357,12953
10577,,H,,,1810,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL616783,,,,8,1,,B,,,BAO_0000357,12953
10577,,H,2435.0,,1811,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,Striatum,Expert,,CHEMBL616784,,,,8,1,,B,,,BAO_0000019,12953
10577,,H,,,1812,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,,Autocuration,,CHEMBL616785,,,,8,1,,B,,,BAO_0000357,12953
10577,,H,955.0,,1813,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,Autocuration,,CHEMBL857067,,,,8,1,,B,,,BAO_0000249,9737
10577,,H,,,1814,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,,Autocuration,,CHEMBL616786,,,,8,1,,B,,,BAO_0000019,9737
10577,,H,955.0,,1815,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,Autocuration,,CHEMBL616787,,,,8,1,,B,,,BAO_0000249,9737
10577,,H,,,1816,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,,Autocuration,,CHEMBL616788,,,,8,1,,B,,,BAO_0000357,12827
10577,,H,,,1817,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616789,,,,8,1,,B,,,BAO_0000357,5033
10577,,D,,,1818,Rattus norvegicus,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,,Expert,,CHEMBL616790,,10116.0,,9,1,,B,,,BAO_0000019,9786
10577,,H,,,1819,,Binding affinity at 5-hydroxytryptamine 1B receptor,,Expert,,CHEMBL616791,,,,8,1,,B,,,BAO_0000357,13116
10577,,H,,,1820,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,,Autocuration,,CHEMBL616792,,,,8,1,,B,,,BAO_0000019,16429
10577,,D,,,1821,Rattus norvegicus,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,,Expert,,CHEMBL616793,,10116.0,,9,1,,B,,,BAO_0000249,12409
10577,,H,,,1822,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616794,,,,8,1,,B,,,BAO_0000357,15194
10577,,H,,,1823,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL616795,,,,8,1,,B,,,BAO_0000357,15194
104686,,H,,,1824,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,,Autocuration,,CHEMBL616796,,,,4,1,,B,,,BAO_0000019,5486
106,,H,,,1825,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616797,,,,8,1,,B,,,BAO_0000357,4639
106,,H,,,1826,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,,Autocuration,,CHEMBL616798,,,,8,1,,B,,Brain membranes,BAO_0000249,386
106,,H,,,1827,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,,Autocuration,,CHEMBL616799,,,,8,1,,B,,,BAO_0000357,2474
106,,H,,,1828,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,,Autocuration,,CHEMBL616800,,,,8,1,,B,,,BAO_0000357,6011
106,,H,,,1829,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616801,,,,8,1,,B,,,BAO_0000357,5014
106,,H,,,1830,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,,Autocuration,,CHEMBL616802,,,,8,1,,B,,,BAO_0000357,17515
106,,H,,,1831,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,,Autocuration,,CHEMBL616803,,,,8,1,,B,,,BAO_0000357,4373
106,,H,,,1832,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,,Expert,,CHEMBL857068,,,,8,1,,B,,,BAO_0000357,1633
106,,H,,,1833,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,,Autocuration,,CHEMBL616804,,,,8,1,,B,,,BAO_0000357,1633
106,,H,,,1834,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,,Autocuration,,CHEMBL616805,,,,8,1,,B,,,BAO_0000357,4373
106,,H,,,1835,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616806,,,,8,1,,B,,,BAO_0000357,4687
106,,H,,,1836,,Binding affinity against 5-hydroxytryptamine 1B receptor,,Autocuration,,CHEMBL616807,,,,8,1,,B,,,BAO_0000357,11574
106,,H,,,1837,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616808,,,,8,1,,B,,,BAO_0000357,10321
106,,H,,,1838,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL616809,,,,8,1,,B,,,BAO_0000357,15527
106,,H,,,1839,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,,Autocuration,,CHEMBL616810,,,,8,1,,B,,,BAO_0000357,17200
104802,,H,,,1840,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,,Autocuration,,CHEMBL616811,,,,4,1,,B,,,BAO_0000224,14423
108,,H,,,1841,Bos taurus,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,,Autocuration,,CHEMBL616812,,9913.0,,8,1,,B,,,BAO_0000357,5834
108,,H,,,1842,Sus scrofa,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL616813,,9823.0,,8,1,,B,,,BAO_0000357,11473
108,,H,,,1843,Sus scrofa,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL616814,,9823.0,,8,1,,B,,,BAO_0000357,11473
108,,H,,,1844,Sus scrofa,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,Autocuration,,CHEMBL616815,,9823.0,,8,1,,B,,,BAO_0000357,10639
108,,H,,,1845,Sus scrofa,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,,Autocuration,,CHEMBL616816,,9823.0,,8,1,,B,,,BAO_0000357,10639
108,,H,,,1846,Sus scrofa,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,,Autocuration,,CHEMBL616817,,9823.0,,8,1,,B,,,BAO_0000357,14331
108,,H,,,1847,Sus scrofa,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,,Autocuration,,CHEMBL616818,,9823.0,,8,1,,B,,,BAO_0000357,10796
108,,H,,,1848,Sus scrofa,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,,Expert,,CHEMBL616819,,9823.0,,8,1,,B,,,BAO_0000357,9098
108,,H,,,1849,Sus scrofa,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,,Expert,,CHEMBL616820,,9823.0,,8,1,,B,,,BAO_0000357,14331
108,,H,,,1850,Sus scrofa,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,,Expert,,CHEMBL616821,,9823.0,,8,1,,B,,,BAO_0000019,11828
108,,H,,,1851,Sus scrofa,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,,Autocuration,,CHEMBL616822,,9823.0,,8,1,,B,,,BAO_0000357,11866
108,,H,,,1852,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,Autocuration,,CHEMBL616823,,9986.0,,8,1,,B,,,BAO_0000019,13047
12689,,D,,,1853,Rattus norvegicus,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,,Autocuration,,CHEMBL616824,,10116.0,,9,1,,B,,,BAO_0000357,188
12689,,D,,,1854,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,Autocuration,,CHEMBL616825,,10116.0,,9,1,,B,,,BAO_0000357,11825
12689,,D,,,1855,Rattus norvegicus,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,,Autocuration,,CHEMBL616826,,10116.0,,9,1,,B,,,BAO_0000357,11825
12689,,D,,,1856,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,,Expert,,CHEMBL616827,,10116.0,,9,1,,B,,,BAO_0000019,11624
12689,,D,,,1857,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,,Autocuration,,CHEMBL616828,,10116.0,,9,1,,B,,,BAO_0000357,11139
12689,,D,,,1858,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL616829,,10116.0,,9,1,,B,,,BAO_0000357,11147
12689,,D,,,1859,Rattus norvegicus,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,,Autocuration,,CHEMBL616830,,10116.0,,9,1,,B,,,BAO_0000019,10444
12689,,D,,,1860,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 1C receptor,,Expert,,CHEMBL616831,,10116.0,,9,1,,B,,,BAO_0000357,11624
12689,,D,,,1861,Rattus norvegicus,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Autocuration,,CHEMBL616832,,10116.0,,9,1,,B,,,BAO_0000019,11662
12689,,D,,,1862,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Autocuration,,CHEMBL616833,,10116.0,,9,1,,B,,,BAO_0000019,11662
12689,,D,,,1863,Rattus norvegicus,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Expert,,CHEMBL616834,,10116.0,,9,1,,B,,,BAO_0000019,11662
12689,,D,,,1864,Rattus norvegicus,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",,Autocuration,,CHEMBL829595,,10116.0,,9,1,,B,,,BAO_0000019,11662
12689,,D,,,1865,Rattus norvegicus,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,,Autocuration,,CHEMBL616835,,10116.0,,9,1,,B,,,BAO_0000357,9098
12689,,D,,,1866,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,,Autocuration,,CHEMBL872910,,10116.0,,9,1,,B,,,BAO_0000249,10394
12689,,H,,,1867,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,,Expert,,CHEMBL616836,,,,8,1,,B,,,BAO_0000357,11933
12689,,D,,,1868,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,,Autocuration,,CHEMBL616837,,10116.0,,9,1,,B,,,BAO_0000357,12092
12689,,D,,,1869,Rattus norvegicus,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,,Autocuration,,CHEMBL616466,,10116.0,,9,1,,B,,,BAO_0000019,12253
12689,,D,,,1870,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,,Autocuration,,CHEMBL616467,,10116.0,722.0,9,1,HEK293,B,,,BAO_0000219,12253
108,,H,,,1871,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,Autocuration,,CHEMBL616468,,,,8,1,,B,,,BAO_0000357,1558
108,,H,,,1872,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL616469,,,,8,1,,B,,,BAO_0000357,2474
108,,H,,,1873,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL616470,,,,8,1,,B,,,BAO_0000357,2474
12689,,H,,,1874,,Binding affinity against 5-hydroxytryptamine 1C receptor,,Autocuration,,CHEMBL616471,,,,8,1,,B,,,BAO_0000357,11574
12689,,H,,,1875,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,,Autocuration,,CHEMBL616472,,,,8,1,,B,,,BAO_0000357,1558
12689,,H,,,1876,,Binding affinity against 5-hydroxytryptamine 1C receptor,,Autocuration,,CHEMBL616473,,,,8,1,,B,,,BAO_0000357,13944
12689,,H,,,1877,,Binding affinity against serotonergic 5-HT1c receptor,,Autocuration,,CHEMBL616474,,,,8,1,,B,,,BAO_0000357,13033
12689,,H,,,1878,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,,Autocuration,,CHEMBL616475,,,,8,1,,B,,,BAO_0000357,10321
12689,,H,,,1879,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,,Autocuration,,CHEMBL616476,,,,8,1,,B,,,BAO_0000357,11866
105,,H,,,1880,Oryctolagus cuniculus,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),,Autocuration,,CHEMBL616477,,9986.0,,8,1,,B,,,BAO_0000019,14454
104686,,H,,,1881,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,,Autocuration,,CHEMBL616478,,,,4,1,,B,,,BAO_0000224,11574
104686,,H,,,1882,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,,Autocuration,,CHEMBL616479,,,,4,1,,B,,,BAO_0000224,11574
104686,,H,,,1883,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,,Autocuration,,CHEMBL616480,,,,4,1,,B,,,BAO_0000019,13631
104686,,D,,,1884,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,,Autocuration,,CHEMBL616481,,10116.0,,5,1,,B,,,BAO_0000019,9630
104686,,D,,,1885,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,,Autocuration,,CHEMBL616482,,10116.0,,5,1,,B,,,BAO_0000249,8822
104686,,D,955.0,,1886,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,Brain,Autocuration,,CHEMBL884713,,10116.0,,5,1,,B,,,BAO_0000221,9064
104686,,H,,,1887,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,,Autocuration,,CHEMBL616483,,,,4,1,,B,,,BAO_0000224,8868
104686,,H,,,1888,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,,Autocuration,,CHEMBL616484,,,,4,1,,B,,,BAO_0000224,9064
104686,,H,,,1889,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,,Autocuration,,CHEMBL616485,,,,4,1,,B,,,BAO_0000019,9806
104686,,H,,,1890,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,Autocuration,,CHEMBL616486,,,,4,1,,B,,,BAO_0000224,9098
104686,,H,,,1891,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,,Autocuration,,CHEMBL616487,,,,4,1,,B,,,BAO_0000224,8868
104686,,H,,,1892,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,Autocuration,,CHEMBL616488,,,,4,1,,B,,,BAO_0000224,12765
104686,,H,,,1893,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,Autocuration,,CHEMBL616489,,,,4,1,,B,,,BAO_0000019,11049
104686,,H,,,1894,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,Autocuration,,CHEMBL616490,,,,4,1,,B,,,BAO_0000019,11049
104686,,H,,,1895,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,,Autocuration,,CHEMBL616491,,,,4,1,,B,,,BAO_0000019,11049
104686,,H,,,1896,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,,Autocuration,,CHEMBL616492,,,,4,1,,B,,,BAO_0000019,11049
104686,,H,,,1897,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,Autocuration,,CHEMBL616493,,,,4,1,,B,,,BAO_0000019,11049
104686,,H,,,1898,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,,Autocuration,,CHEMBL616494,,,,4,1,,B,,,BAO_0000019,11473
104686,,H,,,1899,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL616495,,,,4,1,,B,,,BAO_0000019,11473
104686,,H,,,1900,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,,Autocuration,,CHEMBL616496,,,,4,1,,B,,,BAO_0000019,3086
104686,,H,,,1901,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,Autocuration,,CHEMBL616497,,,,4,1,,B,,,BAO_0000019,11049
104686,,H,,,1902,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,,Autocuration,,CHEMBL616498,,,,4,1,,B,,,BAO_0000019,11049
104686,,H,,,1903,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,,Autocuration,,CHEMBL616499,,,,4,1,,B,,,BAO_0000019,10639
104686,,H,,,1904,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,,Autocuration,,CHEMBL616500,,,,4,1,,B,,,BAO_0000019,10922
104686,,D,955.0,,1905,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Brain,Autocuration,,CHEMBL616501,,10116.0,,5,1,,B,,,BAO_0000221,9064
104686,,H,955.0,,1906,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,Brain,Autocuration,,CHEMBL616502,,,,4,1,,B,,,BAO_0000221,10748
104686,,H,,,1907,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,Autocuration,,CHEMBL884529,,,,4,1,,B,,Membranes,BAO_0000249,11614
104686,,H,,,1908,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,Autocuration,,CHEMBL616503,,,,4,1,,B,,Membranes,BAO_0000249,11615
104686,,H,,,1909,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL616964,,,,4,1,,B,,,BAO_0000224,11615
104686,,H,,,1910,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,,Autocuration,,CHEMBL616965,,,,4,1,,B,,Membranes,BAO_0000249,11614
104686,,H,,,1911,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,,Autocuration,,CHEMBL616966,,,,4,1,,B,,,BAO_0000224,11702
104686,,H,,,1912,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,,Autocuration,,CHEMBL616967,,,,4,1,,B,,,BAO_0000224,11702
104686,,D,,,1913,Rattus norvegicus,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL616968,,10116.0,,5,1,,B,,,BAO_0000224,11702
104686,,H,,,1914,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,,Autocuration,,CHEMBL616969,,,,4,1,,B,,,BAO_0000224,11702
104686,,H,,,1915,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,,Autocuration,,CHEMBL884530,,,,4,1,,B,,,BAO_0000019,13346
104686,,H,,,1916,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL616970,,,,4,1,,B,,,BAO_0000224,10025
104686,,H,,,1917,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,Autocuration,,CHEMBL616971,,,,4,1,,B,,,BAO_0000224,10025
104686,,H,,,1918,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,Autocuration,,CHEMBL616972,,,,4,1,,B,,,BAO_0000224,10025
104686,,H,,,1919,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,,Autocuration,,CHEMBL616973,,,,4,1,,B,,,BAO_0000224,9036
104686,,H,,,1920,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,,Autocuration,,CHEMBL616974,,,,4,1,,B,,,BAO_0000224,9036
104686,,H,,,1921,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,,Autocuration,,CHEMBL616975,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,1922,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,,Autocuration,,CHEMBL616976,,,,4,1,,B,,,BAO_0000019,12304
104686,,H,,,1923,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,,Autocuration,,CHEMBL616977,,,,4,1,,B,,,BAO_0000224,13276
104686,,H,,,1924,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,Autocuration,,CHEMBL616978,,,,4,1,,B,,,BAO_0000224,11825
104686,,H,,,1925,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,,Autocuration,,CHEMBL616979,,,,4,1,,B,,,BAO_0000224,12443
104686,,H,,,1926,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL616980,,,,4,1,,B,,,BAO_0000224,13830
104686,,H,,,1927,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,,Autocuration,,CHEMBL616981,,,,4,1,,B,,Membranes,BAO_0000249,9592
104686,,H,,,1928,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,,Autocuration,,CHEMBL616982,,,,4,1,,B,,Membranes,BAO_0000249,9592
104686,,H,,,1929,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,,Autocuration,,CHEMBL616983,,,,4,1,,B,,,BAO_0000224,10881
104686,,H,,,1930,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,,Autocuration,,CHEMBL616984,,,,4,1,,B,,,BAO_0000019,13605
104686,,D,,,1931,Rattus norvegicus,Inhibitory activity against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL616985,,10116.0,,5,1,,B,,,BAO_0000224,11624
104686,,H,,,1932,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,Autocuration,,CHEMBL616986,,,,4,1,,B,,,BAO_0000224,4101
104686,,H,,,1933,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,,Autocuration,,CHEMBL616987,,,,4,1,,B,,,BAO_0000224,4101
104686,,H,,,1934,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,,Autocuration,,CHEMBL616988,,,,4,1,,B,,,BAO_0000019,15360
104686,,H,,,1935,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,,Autocuration,,CHEMBL617243,,,,4,1,,B,,,BAO_0000019,11576
104686,,H,,,1936,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,,Autocuration,,CHEMBL617244,,,,4,1,,B,,,BAO_0000019,5834
104686,,D,,,1937,Rattus norvegicus,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Autocuration,,CHEMBL617245,,10116.0,485.0,5,1,CHO-K1,B,,,BAO_0000219,2395
104686,,H,,,1938,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,,Autocuration,,CHEMBL617246,,,,4,1,,B,,Membranes,BAO_0000249,11965
104686,,H,,,1939,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),,Autocuration,,CHEMBL617546,,,,4,1,,B,,,BAO_0000224,3967
104686,,H,,,1940,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),,Autocuration,,CHEMBL617547,,,,4,1,,B,,Brain membranes,BAO_0000249,11130
104686,,H,,,1941,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,Autocuration,,CHEMBL617548,In vitro,,,4,1,,B,,,BAO_0000219,13427
104686,,H,,,1942,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617549,,,,4,1,,B,,,BAO_0000224,9443
104686,,H,,,1943,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,Autocuration,,CHEMBL617550,,,,4,1,,B,,,BAO_0000224,9443
104686,,H,,,1944,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,,Autocuration,,CHEMBL617551,,,,4,1,,B,,,BAO_0000224,11825
104686,,H,,,1945,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,,Autocuration,,CHEMBL617552,,,,4,1,,B,,Membranes,BAO_0000249,12120
104686,,H,,,1946,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,,Autocuration,,CHEMBL617553,,,,4,1,,B,,Membranes,BAO_0000249,12120
104686,,H,1515.0,,1947,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,Thoracic aorta,Autocuration,,CHEMBL617554,,,,4,1,,F,,,BAO_0000019,11963
104686,,H,,,1948,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617555,,,,4,1,,B,,,BAO_0000019,9069
104686,,H,,,1949,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,Autocuration,,CHEMBL617556,,,,4,1,,B,,,BAO_0000224,8868
10624,,H,,,1950,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,,Autocuration,,CHEMBL617557,,,,8,1,,B,,,BAO_0000357,17200
10624,,H,,,1951,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,,Autocuration,,CHEMBL617558,,,,8,1,,B,,,BAO_0000357,17200
17106,,H,,,1952,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,,Expert,,CHEMBL617559,,,,8,1,,B,,,BAO_0000357,13969
17106,,D,,,1953,,Binding affinity for 5-hydroxytryptamine 1D receptor,,Expert,,CHEMBL617560,,,,9,1,,B,,,BAO_0000357,13392
17106,,H,,,1954,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,Autocuration,,CHEMBL617561,,,,8,1,,B,,,BAO_0000249,1742
17106,,H,,,1955,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,Autocuration,,CHEMBL617562,,,,8,1,,B,,,BAO_0000249,1742
17106,,H,2435.0,,1956,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,Striatum,Autocuration,,CHEMBL617563,,,,8,1,,B,,,BAO_0000357,14331
17106,,H,,,1957,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL617564,,,,8,1,,F,,,BAO_0000019,12861
17106,,H,,,1958,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,,Expert,,CHEMBL617565,,,,8,1,,B,,,BAO_0000019,12861
17106,,H,,,1959,,Binding activity radioligand.,,Autocuration,,CHEMBL856076,,,,8,1,,B,,,BAO_0000357,12861
17106,,H,,,1960,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,Autocuration,,CHEMBL617566,,,,8,1,,B,,,BAO_0000019,12861
17106,,H,,,1961,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,Expert,,CHEMBL875911,,,,8,1,,B,,,BAO_0000019,12861
17106,,H,,,1962,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,Autocuration,,CHEMBL617567,,,,8,1,,B,,,BAO_0000019,12861
17106,,H,,,1963,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,,Autocuration,,CHEMBL617568,,,,8,1,,B,,,BAO_0000249,675
17106,,H,,,1964,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,,Expert,,CHEMBL617569,,,,8,1,,B,,,BAO_0000019,12490
17106,,H,,,1965,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,,Expert,,CHEMBL617570,,,,8,1,,B,,,BAO_0000249,11828
17106,,H,,,1966,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,,Autocuration,,CHEMBL617571,,,,8,1,,B,,,BAO_0000357,11866
105,,H,,,1967,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,,Autocuration,,CHEMBL617572,,9823.0,,8,1,,B,,,BAO_0000357,773
105,,H,,,1968,Oryctolagus cuniculus,The compound was tested for intrinsic activity against 5-HT1D receptor,,Expert,,CHEMBL617573,,9986.0,,8,1,,B,,,BAO_0000357,13047
105,,H,,,1969,Oryctolagus cuniculus,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,,Autocuration,,CHEMBL617574,,9986.0,,8,1,,B,,,BAO_0000019,13047
105,,H,,,1970,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT1D receptor,,Expert,,CHEMBL617575,,9986.0,,8,1,,B,,,BAO_0000357,13047
10578,,H,,,1971,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,,Autocuration,,CHEMBL617576,,,,8,1,,B,,,BAO_0000357,188
10578,,H,,,1972,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,,Autocuration,,CHEMBL617577,,,,8,1,,F,,,BAO_0000019,10639
10578,,H,,,1973,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL617578,,,,8,1,,F,,,BAO_0000019,12438
10578,,H,,,1974,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL617579,,,,8,1,,B,,,BAO_0000357,12438
10578,,H,,,1975,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,,Expert,,CHEMBL617580,,,,8,1,,B,,,BAO_0000019,15854
10578,,H,,,1976,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,,Autocuration,,CHEMBL617581,,,,8,1,,B,,,BAO_0000249,10394
10578,,H,,,1977,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,,Autocuration,,CHEMBL617582,,,,8,1,,B,,,BAO_0000357,12092
10578,,H,,,1978,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,,Expert,,CHEMBL617583,,,,8,1,,B,,,BAO_0000019,3389
105,,H,,,1979,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,,Autocuration,,CHEMBL617584,,,,8,1,,B,,,BAO_0000357,6011
105,,H,,,1980,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL617585,,,,8,1,,B,,,BAO_0000357,4639
105,,H,,,1981,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,,Autocuration,,CHEMBL875912,,,,8,1,,B,,,BAO_0000357,2474
105,,H,,,1982,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL617586,,,,8,1,,B,,,BAO_0000357,5014
105,,H,,,1983,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,,Autocuration,,CHEMBL617587,,,,8,1,,B,,,BAO_0000357,17515
105,,H,,,1984,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,,Autocuration,,CHEMBL617588,,,,8,1,,B,,,BAO_0000357,11866
105,,H,,,1985,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL857980,,,,8,1,,B,,,BAO_0000357,4687
105,,H,,,1986,,Tested against 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL617589,,,,8,1,,B,,,BAO_0000357,12146
105,,H,,,1987,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,,Autocuration,,CHEMBL617590,,,,8,1,,B,,,BAO_0000357,10321
105,,H,,,1988,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617591,,,722.0,8,1,HEK293,B,,,BAO_0000219,13267
105,,D,,,1989,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 1D receptor,,Expert,,CHEMBL617592,,9606.0,,9,1,,B,,,BAO_0000357,1274
105,,H,,,1990,,,,Autocuration,,CHEMBL617593,,,,8,1,,B,,,BAO_0000357,15250
106,,H,,,1991,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,Autocuration,,CHEMBL617594,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,13706
105,,H,,,1992,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,Autocuration,,CHEMBL617595,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,13706
105,,H,,,1993,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,,Autocuration,,CHEMBL617596,,,722.0,8,1,HEK293,B,,,BAO_0000219,13706
105,,H,,,1994,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,Autocuration,,CHEMBL617597,,,722.0,8,1,HEK293,B,,,BAO_0000219,13706
105,,H,,,1995,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,Autocuration,,CHEMBL617598,,,,8,1,,B,,,BAO_0000019,13047
105,,H,,,1996,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,,Autocuration,,CHEMBL872916,,,,8,1,,B,,,BAO_0000357,13366
105,,H,,,1997,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,,Expert,,CHEMBL617599,,,,8,1,,B,,,BAO_0000357,13366
105,,H,,,1998,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,,Autocuration,,CHEMBL617091,,,,8,1,,B,,,BAO_0000357,1558
105,,H,,,1999,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",,Expert,,CHEMBL617092,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,12902
105,,H,,,2000,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,,Autocuration,,CHEMBL617093,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,13706
105,,H,,,2001,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,,Autocuration,,CHEMBL617094,,,,8,1,,F,,,BAO_0000019,13706
105,,H,,,2002,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,Autocuration,,CHEMBL617095,,,,8,1,,F,,,BAO_0000019,13706
105,,H,,,2003,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,Autocuration,,CHEMBL617096,,,,8,1,,F,,,BAO_0000019,14251
105,,H,,,2004,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,Autocuration,,CHEMBL617097,,,,8,1,,F,,,BAO_0000019,14251
105,,H,,,2005,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,,Autocuration,,CHEMBL617098,,,,8,1,,F,,,BAO_0000019,14251
105,,H,,,2006,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,,Autocuration,,CHEMBL617301,,,,8,1,,B,,,BAO_0000357,13313
105,,H,,,2007,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,,Autocuration,,CHEMBL617302,,,,8,1,,B,,,BAO_0000357,13313
105,,H,,,2008,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,,Autocuration,,CHEMBL617303,,,,8,1,,B,,,BAO_0000357,13366
105,,H,,,2009,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,,Expert,,CHEMBL617304,,,,8,1,,B,,,BAO_0000357,13051
105,,H,,,2010,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",,Expert,,CHEMBL617305,,,449.0,8,1,CHO,B,,,BAO_0000219,12903
105,,D,,,2011,Homo sapiens,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,,Autocuration,,CHEMBL617306,,9606.0,,9,1,,B,,,BAO_0000219,12469
17106,,H,,,2012,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,,Autocuration,,CHEMBL617307,,,,8,1,,B,,,BAO_0000357,5619
105,,H,,,2013,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,,Autocuration,,CHEMBL617308,,9986.0,,8,1,,B,,,BAO_0000019,13047
105,,H,,,2014,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,,Autocuration,,CHEMBL617309,,,,8,1,,B,,,BAO_0000357,16633
105,,H,,,2015,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,Autocuration,,CHEMBL617310,,,,8,1,,B,,,BAO_0000357,16633
105,,H,,,2016,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,,Autocuration,,CHEMBL617311,,,,8,1,,B,,,BAO_0000357,16633
105,,H,,,2017,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL617312,,,,8,1,,B,,,BAO_0000357,16633
105,,H,,,2018,,Affinity against 5-hydroxytryptamine 1D receptor alpha,,Autocuration,,CHEMBL617313,,,,8,1,,B,,,BAO_0000357,3269
105,,H,,,2019,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,,Expert,,CHEMBL617314,,,,8,1,,B,,,BAO_0000357,12409
106,,H,,,2020,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,Autocuration,,CHEMBL617315,,,,8,1,,F,,,BAO_0000019,13706
106,,H,,,2021,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,,Autocuration,,CHEMBL617316,,,722.0,8,1,HEK293,B,,,BAO_0000219,13706
106,,H,,,2022,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,,Autocuration,,CHEMBL617317,,,722.0,8,1,HEK293,B,,,BAO_0000219,13706
106,,H,,,2023,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,Autocuration,,CHEMBL617318,,,449.0,8,1,CHO,B,,,BAO_0000219,12903
106,,H,,,2024,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,,Autocuration,,CHEMBL617319,,,,8,1,,B,,,BAO_0000019,13047
106,,D,,,2025,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,Expert,,CHEMBL617320,,,,9,1,,B,,,BAO_0000357,13366
106,,D,,,2026,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,Expert,,CHEMBL617321,,,,9,1,,B,,,BAO_0000357,13366
106,,D,,,2027,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,,Expert,,CHEMBL617322,,,,9,1,,B,,,BAO_0000357,13366
106,,H,,,2028,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616862,,,,8,1,,B,,,BAO_0000357,13366
106,,H,,,2029,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL616863,,,,8,1,,B,,,BAO_0000357,13366
106,,H,,,2030,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,,Autocuration,,CHEMBL616864,,,449.0,8,1,CHO,B,,,BAO_0000219,12469
106,,H,,,2031,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,,Autocuration,,CHEMBL616865,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,13706
106,,H,,,2032,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,,Autocuration,,CHEMBL616866,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,13706
106,,H,,,2033,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,,Autocuration,,CHEMBL616867,,,,8,1,,F,,,BAO_0000019,13706
106,,H,,,2034,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",,Expert,,CHEMBL616868,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,12902
105,,H,,,2035,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,,Expert,,CHEMBL616869,,,,8,1,,B,,,BAO_0000357,13051
106,,H,,,2036,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",,Expert,,CHEMBL616870,,,449.0,8,1,CHO,B,,,BAO_0000219,12903
105,,H,,,2037,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,,Autocuration,,CHEMBL616871,,,485.0,8,1,CHO-K1,F,,,BAO_0000219,1558
105,,H,,,2038,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,,Autocuration,,CHEMBL616872,,,485.0,8,1,CHO-K1,F,,,BAO_0000219,1558
105,,H,,,2039,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,,Autocuration,,CHEMBL616873,,,485.0,8,1,CHO-K1,F,,,BAO_0000219,1558
105,,H,,,2040,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,,Autocuration,,CHEMBL616838,,,485.0,8,1,CHO-K1,F,,,BAO_0000219,1558
105,,H,,,2041,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,,Autocuration,,CHEMBL616839,,,,8,1,,B,,,BAO_0000357,1558
106,,H,,,2042,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,,Autocuration,,CHEMBL616840,,9986.0,,8,1,,B,,,BAO_0000019,13047
105,,H,,,2043,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,,Autocuration,,CHEMBL616841,,,,8,1,,B,,,BAO_0000357,13313
105,,H,,,2044,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616842,,,,8,1,,B,,,BAO_0000357,13313
105,,H,,,2045,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,,Expert,,CHEMBL857976,,,,8,1,,B,,,BAO_0000357,12409
10618,,H,,,2046,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,,Autocuration,,CHEMBL616843,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
10618,,D,,,2047,Homo sapiens,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,,Expert,,CHEMBL616844,,9606.0,,9,1,,B,,,BAO_0000357,1348
10618,,H,,,2048,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,,Autocuration,,CHEMBL616845,,,,8,1,,B,,,BAO_0000357,1348
10618,,D,,,2049,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,,Expert,,CHEMBL616846,,9606.0,,9,1,,B,,,BAO_0000357,4234
10618,,H,,,2050,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616847,,,,8,1,,B,,,BAO_0000357,16209
10618,,H,,,2051,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,,Autocuration,,CHEMBL616848,,,,8,1,,B,,,BAO_0000019,10444
10618,,H,,,2052,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,,Autocuration,,CHEMBL616849,,,,8,1,,B,,,BAO_0000357,3935
10618,,H,,,2053,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,,Autocuration,,CHEMBL872911,,,,8,1,,B,,,BAO_0000357,15818
10618,,H,,,2054,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,,Autocuration,,CHEMBL616850,,,,8,1,,B,,,BAO_0000019,17085
10618,,D,,,2055,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,,Expert,,CHEMBL616699,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,12936
10618,,H,,,2056,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,,Autocuration,,CHEMBL616700,,,,8,1,,B,,,BAO_0000357,6166
10618,,H,,,2057,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL616701,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
10618,,H,,,2058,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL616702,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
10618,,H,,,2059,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,,Autocuration,,CHEMBL616703,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
10618,,H,,,2060,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,,Autocuration,,CHEMBL616704,,,,8,1,,B,,,BAO_0000357,13181
10618,,H,,,2061,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,,Autocuration,,CHEMBL616705,,,449.0,8,1,CHO,B,,,BAO_0000219,4199
10618,,H,,,2062,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,,Autocuration,,CHEMBL616706,,,,8,1,,B,,,BAO_0000357,14875
10618,,H,,,2063,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,,Autocuration,,CHEMBL616707,,,449.0,8,1,CHO,B,,,BAO_0000219,15146
10618,,H,,,2064,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,,Autocuration,,CHEMBL616708,,,,8,1,,B,,,BAO_0000357,5213
10618,,H,,,2065,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616709,,,,8,1,,B,,,BAO_0000357,12146
10618,,H,,,2066,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,,Autocuration,,CHEMBL616710,,,449.0,8,1,CHO,B,,,BAO_0000219,13267
10618,,H,,,2067,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,,Autocuration,,CHEMBL616711,,,449.0,8,1,CHO,B,,,BAO_0000219,14818
10618,,H,,,2068,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",,Autocuration,,CHEMBL616712,,,449.0,8,1,CHO,B,,,BAO_0000219,4829
10618,,H,,,2069,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,,Autocuration,,CHEMBL616713,,,,8,1,,B,,,BAO_0000357,4373
10618,,H,,,2070,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,,Autocuration,,CHEMBL616714,,,,8,1,,B,,,BAO_0000357,4373
10618,,H,,,2071,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,,Autocuration,,CHEMBL616715,,,,8,1,,B,,,BAO_0000357,14159
10618,,H,,,2072,,Binding affinity towards 5-hydroxytryptamine 1E receptor,,Autocuration,,CHEMBL616716,,,,8,1,,B,,,BAO_0000357,16633
279,,H,,,2073,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",,Autocuration,,CHEMBL616717,,,,8,1,,F,,,BAO_0000019,17085
279,,H,,,2074,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",,Expert,,CHEMBL616718,,,,8,1,,F,,,BAO_0000019,17085
279,,H,,,2075,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,,Autocuration,,CHEMBL875905,,,,8,1,,F,,,BAO_0000019,16209
279,,H,,,2076,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,,Autocuration,,CHEMBL616719,,,,8,1,,F,,,BAO_0000019,16209
279,,H,,,2077,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",,Expert,,CHEMBL616720,,,,8,1,,F,,,BAO_0000019,17085
279,,H,,,2078,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,,Autocuration,,CHEMBL616721,,,,8,1,,B,,,BAO_0000357,14159
279,,H,,,2079,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,,Autocuration,,CHEMBL616722,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
279,,H,,,2080,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),,Autocuration,,CHEMBL616723,,,,8,1,,B,,,BAO_0000357,3805
279,,H,,,2081,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,,Autocuration,,CHEMBL616724,,,449.0,8,1,CHO,B,,,BAO_0000219,16190
279,,H,,,2082,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,,Autocuration,,CHEMBL616725,,,,8,1,,B,,,BAO_0000357,16190
279,,H,,,2083,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,,Autocuration,,CHEMBL616726,,,,8,1,,B,,,BAO_0000357,16209
279,,H,,,2084,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,,Autocuration,,CHEMBL616727,,,,8,1,,B,,,BAO_0000357,16209
279,,H,,,2085,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,,Autocuration,,CHEMBL616728,,,,8,1,,B,,,BAO_0000357,16209
279,,H,,,2086,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,,Autocuration,,CHEMBL616729,,,,8,1,,B,,,BAO_0000357,6866
279,,H,,,2087,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,,Expert,,CHEMBL616730,,,,8,1,,B,,,BAO_0000019,17085
279,,H,,,2088,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,,Autocuration,,CHEMBL617125,,,,8,1,,B,,,BAO_0000357,16312
279,,H,,,2089,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,,Autocuration,,CHEMBL857977,,,,8,1,,B,,,BAO_0000357,6166
279,,H,,,2090,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL617126,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
279,,H,,,2091,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,,Autocuration,,CHEMBL617127,,,449.0,8,1,CHO,B,,,BAO_0000219,4199
279,,H,,,2092,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,,Autocuration,,CHEMBL617128,,,,8,1,,B,,,BAO_0000357,14875
279,,H,,,2093,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,,Autocuration,,CHEMBL617129,,,449.0,8,1,CHO,B,,,BAO_0000219,15146
279,,H,,,2094,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,,Autocuration,,CHEMBL617130,,,,8,1,,B,,,BAO_0000357,5213
279,,H,,,2095,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,,Autocuration,,CHEMBL617131,,,449.0,8,1,CHO,B,,,BAO_0000219,14818
279,,H,,,2096,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,Autocuration,,CHEMBL617132,,,449.0,8,1,CHO,B,,,BAO_0000219,4829
279,,H,,,2097,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",,Autocuration,,CHEMBL617133,,,449.0,8,1,CHO,B,,,BAO_0000219,4829
279,,H,,,2098,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,,Autocuration,,CHEMBL617134,,,,8,1,,B,,,BAO_0000357,4373
279,,H,,,2099,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,,Autocuration,,CHEMBL617135,,,,8,1,,B,,,BAO_0000357,4373
279,,H,,,2100,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,,Autocuration,,CHEMBL617136,,,,8,1,,B,,,BAO_0000357,5014
104686,,H,,,2101,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",,Autocuration,,CHEMBL617137,,,,4,1,,B,,,BAO_0000019,11662
104686,,H,,,2102,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,Autocuration,,CHEMBL617138,,,,4,1,,B,,,BAO_0000019,11662
104686,,H,,,2103,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,Autocuration,,CHEMBL617139,,,,4,1,,B,,,BAO_0000019,11662
12687,,H,,,2104,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617140,,,,8,1,,B,,,BAO_0000019,14093
104686,,H,,,2105,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",,Autocuration,,CHEMBL617141,In vivo,,,4,1,,F,,,BAO_0000218,11200
104686,,H,,,2106,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,Autocuration,,CHEMBL858112,,,,4,1,,F,,,BAO_0000019,11200
17005,,H,,,2107,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,,Intermediate,,CHEMBL617142,,,,8,1,,B,,,BAO_0000019,12352
22226,,U,,,2108,Bos taurus,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",,Autocuration,,CHEMBL617143,,9913.0,,0,1,,B,,,BAO_0000019,13657
22226,,U,,,2109,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,,Autocuration,,CHEMBL617144,,9913.0,,0,1,,B,,,BAO_0000019,14331
22226,,U,,,2110,Bos taurus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,,Autocuration,,CHEMBL617145,,9913.0,,0,1,,B,,,BAO_0000019,14331
22226,,U,,,2111,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,,Autocuration,,CHEMBL617146,,,,0,1,,B,,,BAO_0000019,14331
104784,,H,,,2112,Cavia porcellus,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,,Autocuration,,CHEMBL617147,,10141.0,,4,1,,B,,,BAO_0000019,12685
104784,,H,,,2113,Cavia porcellus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,,Autocuration,,CHEMBL617148,,10141.0,,4,1,,B,,,BAO_0000019,14389
104784,,H,,,2114,Cavia porcellus,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,,Autocuration,,CHEMBL617149,,10141.0,,4,1,,B,,,BAO_0000019,14386
104784,,H,,,2115,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,,Autocuration,,CHEMBL617150,,,,4,1,,B,,,BAO_0000224,5732
104784,,H,,,2116,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,Autocuration,,CHEMBL617151,,,,4,1,,B,,,BAO_0000224,16293
104784,,H,,,2117,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617201,,,,4,1,,B,,,BAO_0000224,2078
10209,,H,,,2118,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,,Autocuration,,CHEMBL617202,,,,8,1,,B,,,BAO_0000357,5486
104826,,H,,,2119,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,Autocuration,,CHEMBL617203,In vivo,,,4,1,,B,,,BAO_0000218,11820
104826,,H,,,2120,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,Autocuration,,CHEMBL617204,,,,4,1,,B,,,BAO_0000019,10297
104826,,H,,,2121,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,,Autocuration,,CHEMBL617205,,,,4,1,,B,,,BAO_0000224,13704
104826,,D,,,2122,Mus musculus,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,,Autocuration,,CHEMBL617206,,10090.0,,5,1,,B,,,BAO_0000019,10297
104826,,H,,,2123,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,,Autocuration,,CHEMBL617207,In vivo,,,4,1,,B,,,BAO_0000218,11820
104826,,D,,,2124,Mus musculus,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,,Autocuration,,CHEMBL617208,,10090.0,,5,1,,B,,,BAO_0000019,10297
104826,,H,,,2125,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617209,,,,4,1,,B,,,BAO_0000224,11555
104826,,H,,,2126,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,,Autocuration,,CHEMBL617210,,,,4,1,,B,,,BAO_0000224,11555
104826,,H,,,2127,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,,Autocuration,,CHEMBL617211,,,,4,1,,B,,,BAO_0000224,11555
104826,,D,,,2128,Mus musculus,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,,Autocuration,,CHEMBL617212,,10090.0,,5,1,,B,,,BAO_0000019,10297
104784,,H,,,2129,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,,Autocuration,,CHEMBL617213,,9823.0,,4,1,,B,,,BAO_0000224,16688
104784,,H,,,2130,Sus scrofa,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,,Autocuration,,CHEMBL617214,,9823.0,,4,1,,B,,,BAO_0000224,16688
22226,,U,,,2131,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,Autocuration,,CHEMBL617215,,,,0,1,,B,,,BAO_0000221,5333
22226,,U,,,2132,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,,Autocuration,,CHEMBL617216,,,,0,1,,B,,,BAO_0000221,4437
17005,,H,,,2133,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617217,,9823.0,,8,1,,B,,,BAO_0000357,5033
104686,,H,,,2134,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617218,,,,4,1,,B,,,BAO_0000019,15267
104686,,H,,,2135,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL872913,,,,4,1,,B,,,BAO_0000019,15267
104826,,H,,,2136,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,,Autocuration,,CHEMBL617219,,,,4,1,,B,,,BAO_0000019,11820
104686,,H,,,2137,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL873482,,,,4,1,,B,,,BAO_0000224,9069
104686,,D,,,2138,Rattus norvegicus,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,,Autocuration,,CHEMBL617220,,10116.0,,5,1,,B,,,BAO_0000019,9162
104686,,H,,,2139,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,,Autocuration,,CHEMBL617221,,,,4,1,,B,,,BAO_0000019,9162
104686,,H,,,2140,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,,Autocuration,,CHEMBL617222,,,,4,1,,B,,,BAO_0000019,9162
104686,,H,,,2141,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,,Autocuration,,CHEMBL875906,,,,4,1,,F,,,BAO_0000019,10428
104686,,H,,,2142,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,,Autocuration,,CHEMBL617223,,,,4,1,,B,,,BAO_0000019,9628
104686,,H,,,2143,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617224,,,,4,1,,B,,,BAO_0000224,12704
104686,,D,,,2144,Rattus norvegicus,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,Autocuration,,CHEMBL617225,,10116.0,,5,1,,B,,,BAO_0000224,15453
104686,,H,,,2145,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,,Autocuration,,CHEMBL617226,,,,4,1,,B,,,BAO_0000224,188
104686,,H,,,2146,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,,Autocuration,,CHEMBL617227,,,,4,1,,B,,,BAO_0000224,10349
104686,,H,,,2147,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,,Autocuration,,CHEMBL617228,,,,4,1,,B,,,BAO_0000224,10349
104686,,H,,,2148,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,,Autocuration,,CHEMBL617229,,,,4,1,,B,,,BAO_0000224,8868
104686,,H,,,2149,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,,Autocuration,,CHEMBL617230,,,,4,1,,B,,,BAO_0000224,10025
104686,,H,,,2150,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",,Autocuration,,CHEMBL617231,,,,4,1,,B,,,BAO_0000224,10025
104686,,H,,,2151,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,,Autocuration,,CHEMBL617232,,,,4,1,,B,,,BAO_0000224,11702
104686,,H,,,2152,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617233,,,,4,1,,B,,,BAO_0000224,11702
104686,,H,,,2153,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,,Autocuration,,CHEMBL617234,,,,4,1,,B,,,BAO_0000224,11702
104686,,H,,,2154,,Compound was tested for the inhibition of quipazine induced head twitches in rats,,Autocuration,,CHEMBL617235,,,,4,1,,F,,,BAO_0000019,11702
104686,,H,,,2155,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,,Autocuration,,CHEMBL617236,,,,4,1,,F,,,BAO_0000019,11702
104686,,H,10000000.0,,2156,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,Hippocampus,Autocuration,,CHEMBL617237,,,,4,1,,B,,,BAO_0000221,10085
104686,,H,10000000.0,,2157,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,Hippocampus,Autocuration,,CHEMBL617238,,,,4,1,,B,,,BAO_0000221,10085
104686,,D,955.0,,2158,Rattus norvegicus,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,Brain,Autocuration,,CHEMBL617239,,10116.0,,5,1,,B,,,BAO_0000221,9630
104686,,H,,,2159,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,,Autocuration,,CHEMBL617240,,,,4,1,,B,,,BAO_0000019,11070
104686,,H,,,2160,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,Autocuration,,CHEMBL617241,,,,4,1,,B,,Membranes,BAO_0000249,9841
104686,,H,,,2161,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,,Autocuration,,CHEMBL875907,,,,4,1,,B,,Membranes,BAO_0000249,9841
104686,,H,,,2162,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,,Autocuration,,CHEMBL617242,,,,4,1,,B,,,BAO_0000019,13291
104686,,H,,,2163,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,,Autocuration,,CHEMBL617152,,,,4,1,,F,,,BAO_0000019,10590
104686,,D,955.0,,2164,Rattus norvegicus,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,Brain,Autocuration,,CHEMBL617153,,10116.0,,5,1,,B,,,BAO_0000221,9064
104686,,D,,,2165,Rattus norvegicus,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,,Autocuration,,CHEMBL617154,,10116.0,,5,1,,B,,Membranes,BAO_0000249,12268
104686,,H,955.0,,2166,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,Brain,Autocuration,,CHEMBL617155,,,,4,1,,B,,,BAO_0000221,13508
104686,,H,,,2167,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,Autocuration,,CHEMBL617156,,,,4,1,,F,,,BAO_0000019,11279
104686,,H,,,2168,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,,Autocuration,,CHEMBL617157,,,,4,1,,F,,,BAO_0000019,11200
104686,,H,,,2169,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,Autocuration,,CHEMBL617158,,,,4,1,,F,,,BAO_0000019,11200
104686,,H,,,2170,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,Autocuration,,CHEMBL617159,,,,4,1,,F,,,BAO_0000019,11200
104686,,H,,,2171,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,,Autocuration,,CHEMBL617160,,,,4,1,,F,,,BAO_0000019,11200
104686,,H,,,2172,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,Autocuration,,CHEMBL858113,,,,4,1,,F,,,BAO_0000019,11200
104686,,H,955.0,,2173,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,Brain,Autocuration,,CHEMBL617247,,,,4,1,,B,,,BAO_0000220,9231
104686,,H,,,2174,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617248,,,,4,1,,B,,,BAO_0000019,9737
104686,,H,955.0,,2175,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,Brain,Autocuration,,CHEMBL617249,,,,4,1,,B,,,BAO_0000249,9737
104686,,H,,,2176,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,,Autocuration,,CHEMBL617250,,,,4,1,,B,,,BAO_0000019,9737
104686,,H,,,2177,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617251,,,,4,1,,B,,,BAO_0000019,9737
104686,,D,,,2178,Rattus norvegicus,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617252,,10116.0,,5,1,,B,,,BAO_0000019,11828
104686,,H,,,2179,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,,Autocuration,,CHEMBL617006,,,,4,1,,B,,,BAO_0000019,12253
104686,,H,,,2180,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,,Autocuration,,CHEMBL617007,,,,4,1,,B,,,BAO_0000019,12253
104686,,H,,,2181,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",,Autocuration,,CHEMBL617008,,,,4,1,,F,,,BAO_0000019,11279
104686,,H,,,2182,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,,Autocuration,,CHEMBL617009,,,,4,1,,B,,,BAO_0000019,11866
104686,,D,,,2183,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,,Autocuration,,CHEMBL617010,,10116.0,,5,1,,B,,,BAO_0000224,14424
104686,,D,,,2184,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL857978,,10116.0,,5,1,,B,,,BAO_0000019,15180
104686,,D,,,2185,Rattus norvegicus,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617011,,10116.0,,5,1,,B,,,BAO_0000019,15180
104686,,D,,,2186,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,,Autocuration,,CHEMBL617012,,10116.0,,5,1,,B,,,BAO_0000019,9786
104686,,H,,,2187,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,,Autocuration,,CHEMBL617013,,,,4,1,,B,,,BAO_0000224,12132
104686,,H,,,2188,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,,Autocuration,,CHEMBL617014,,,,4,1,,B,,,BAO_0000249,5486
104686,,H,,,2189,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617015,,,,4,1,,B,,,BAO_0000019,15316
104686,,H,,,2190,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,,Autocuration,,CHEMBL617016,,,,4,1,,B,,,BAO_0000019,16429
104686,,H,,,2191,,pKi value for 5-hydroxytryptamine 2 receptor binding site,,Autocuration,,CHEMBL617017,,,,4,1,,B,,,BAO_0000224,14617
104686,,H,955.0,,2192,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,Brain,Autocuration,,CHEMBL617018,,,,4,1,,B,,,BAO_0000221,11351
104686,,H,,,2193,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,,Autocuration,,CHEMBL617019,,,,4,1,,F,,,BAO_0000019,11279
105075,,H,,,2194,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration,,CHEMBL617020,,,,4,1,,B,,,BAO_0000019,9523
105075,,H,,,2195,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration,,CHEMBL617021,,,,4,1,,B,,,BAO_0000019,9523
105075,,H,,,2196,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration,,CHEMBL617022,,,,4,1,,B,,,BAO_0000019,9523
105075,,H,,,2197,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration,,CHEMBL617023,,,,4,1,,B,,,BAO_0000019,9523
105075,,H,,,2198,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration,,CHEMBL617024,,,,4,1,,B,,,BAO_0000019,9523
105075,,H,,,2199,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,,Autocuration,,CHEMBL617025,,,,4,1,,B,,,BAO_0000019,9523
105075,,H,,,2200,,Hill coefficient of compound was determined,,Autocuration,,CHEMBL617026,,,,4,1,,B,,,BAO_0000224,9523
22226,,U,,,2201,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617027,,,,0,1,,B,,,BAO_0000019,4771
104686,,D,,,2202,Rattus norvegicus,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,,Autocuration,,CHEMBL617028,,10116.0,,5,1,,B,,,BAO_0000019,5033
12687,,H,,,2203,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,,Expert,,CHEMBL617029,,,,8,1,,B,,,BAO_0000019,10845
12687,,H,,,2204,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,,Expert,,CHEMBL875908,,,,8,1,,B,,,BAO_0000019,10845
12687,,H,,,2205,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),,Autocuration,,CHEMBL617030,,,,8,1,,B,,,BAO_0000357,16288
12687,,H,,,2206,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),,Autocuration,,CHEMBL617031,,,,8,1,,B,,,BAO_0000019,16288
12687,,H,,,2207,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,,Autocuration,,CHEMBL617032,,,,8,1,,B,,,BAO_0000019,16190
104686,,D,,,2208,Rattus norvegicus,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,,Autocuration,,CHEMBL617033,,10116.0,,5,1,,B,,,BAO_0000224,12463
104686,,H,,,2209,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",,Autocuration,,CHEMBL617034,,,,4,1,,B,,,BAO_0000224,9699
104686,,H,,,2210,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,,Autocuration,,CHEMBL617035,,,,4,1,,B,,,BAO_0000224,9699
104686,,H,,,2211,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,Autocuration,,CHEMBL617036,,,,4,1,,B,,,BAO_0000019,11662
104784,,H,,,2212,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617037,,,,4,1,,B,,,BAO_0000224,1205
22226,,U,,,2213,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,,Autocuration,,CHEMBL617038,,,,0,1,,B,,,BAO_0000219,11376
104784,,H,,,2214,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",,Autocuration,,CHEMBL617039,,,,4,1,,B,,,BAO_0000219,11376
104784,,H,,,2215,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617161,,,,4,1,,B,,,BAO_0000224,4639
104784,,H,,,2216,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617162,,,,4,1,,B,,,BAO_0000224,2222
104784,,H,,,2217,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617163,,,,4,1,,B,,,BAO_0000224,1558
104784,,H,,,2218,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617164,,,,4,1,,B,,,BAO_0000224,1089
104784,,H,,,2219,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,,Autocuration,,CHEMBL617165,,,,4,1,,B,,Brain membranes,BAO_0000249,386
104784,,H,,,2220,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617166,,,,4,1,,B,,,BAO_0000224,2474
104784,,H,,,2221,,Binding affinity towards 5-HT2 receptor,,Autocuration,,CHEMBL617167,,,,4,1,,B,,,BAO_0000224,17066
104784,,H,,,2222,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL872912,,,,4,1,,B,,,BAO_0000224,959
104784,,H,,,2223,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,,Autocuration,,CHEMBL617168,,,,4,1,,B,,,BAO_0000224,6398
104686,,H,,,2224,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,,Autocuration,,CHEMBL617169,,,,4,1,,B,,,BAO_0000224,11889
104784,,H,,,2225,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617170,,,,4,1,,B,,,BAO_0000224,4221
104784,,H,,,2226,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,,Autocuration,,CHEMBL617171,,,,4,1,,B,,,BAO_0000224,11026
104784,,H,,,2227,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,,Autocuration,,CHEMBL617172,,,,4,1,,B,,,BAO_0000224,11866
104784,,H,,,2228,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617173,,,,4,1,,B,,,BAO_0000224,4221
22226,,U,,,2229,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617174,,,,0,1,,B,,,BAO_0000019,13950
104784,,H,,,2230,,5-hydroxytryptamine 2 receptor binding affinity,,Autocuration,,CHEMBL617175,,,,4,1,,B,,,BAO_0000224,1263
17005,,H,,,2231,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,,Autocuration,,CHEMBL617176,,,,8,1,,B,,,BAO_0000357,13291
17005,,H,,,2232,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617177,,,,8,1,,B,,,BAO_0000357,10812
104784,,H,,,2233,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,Autocuration,,CHEMBL617178,,,,4,1,,B,,,BAO_0000224,13020
104784,,H,,,2234,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,,Autocuration,,CHEMBL617179,,,,4,1,,B,,,BAO_0000224,13021
104784,,H,,,2235,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,,Autocuration,,CHEMBL617180,,,,4,1,,B,,,BAO_0000224,13020
17005,,H,,,2236,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,,Autocuration,,CHEMBL617181,,,,8,1,,B,,,BAO_0000357,14532
17005,,H,,,2237,,Binding affinity against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617182,,,,8,1,,B,,,BAO_0000357,13944
17005,,H,,,2238,,Binding affinity against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617183,,,,8,1,,B,,,BAO_0000357,14331
17005,,H,,,2239,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617184,,,,8,1,,B,,,BAO_0000357,14118
17005,,H,,,2240,,Binding affinity against serotonergic 5-HT2 receptor,,Autocuration,,CHEMBL617185,,,,8,1,,B,,,BAO_0000357,13033
17005,,H,,,2241,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617186,,,,8,1,,B,,,BAO_0000357,10321
17005,,H,,,2242,,Compound was evaluated for the binding affinity at 5- HT2 receptor,,Autocuration,,CHEMBL617187,,,,8,1,,B,,,BAO_0000357,12918
17005,,H,,,2243,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617188,,,,8,1,,B,,,BAO_0000357,15120
17005,,H,,,2244,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617189,,,,8,1,,B,,,BAO_0000218,2613
104784,,D,,,2245,Homo sapiens,Inhibitory activity against cloned human 5-HT2 receptor,,Autocuration,,CHEMBL617190,,9606.0,,5,1,,B,,,BAO_0000224,13378
104784,,D,,,2246,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",,Autocuration,,CHEMBL617191,,9606.0,449.0,5,1,CHO,B,,,BAO_0000219,2331
104784,,D,,,2247,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",,Autocuration,,CHEMBL617192,,9606.0,449.0,5,1,CHO,B,,,BAO_0000219,2331
104784,,D,,,2248,Homo sapiens,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",,Autocuration,,CHEMBL617193,,9606.0,449.0,5,1,CHO,B,,,BAO_0000219,2331
104784,,D,,,2249,Homo sapiens,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",,Autocuration,,CHEMBL617194,,9606.0,449.0,5,1,CHO,B,,,BAO_0000219,2331
104784,,H,,,2250,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617195,,,,4,1,,B,,,BAO_0000224,4170
104784,,H,,,2251,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,,Autocuration,,CHEMBL881830,,,,4,1,,B,,,BAO_0000224,15453
17005,,H,,,2252,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617196,,,,8,1,,B,,,BAO_0000357,1479
104686,,H,,,2253,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,,Autocuration,,CHEMBL617197,,,,4,1,,B,,,BAO_0000224,11139
17005,,H,,,2254,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,,Expert,,CHEMBL617198,,,,8,1,,B,,,BAO_0000357,13969
17005,,H,,,2255,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL873476,,,,8,1,,B,,,BAO_0000357,13392
17005,,H,,,2256,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,,Expert,,CHEMBL617199,,,,8,1,,B,,,BAO_0000019,14430
107,,H,,,2257,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617200,,10141.0,,8,1,,B,,,BAO_0000357,13181
51,,H,,,2258,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Autocuration,,CHEMBL617484,,,,8,1,,B,,,BAO_0000357,17200
107,,H,,,2259,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Autocuration,,CHEMBL617485,,,,8,1,,B,,,BAO_0000357,17200
51,,H,,,2260,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Autocuration,,CHEMBL617486,,,,8,1,,B,,,BAO_0000357,17200
107,,H,,,2261,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL858022,,,,8,1,,B,,,BAO_0000357,13463
107,,H,,,2262,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,Autocuration,,CHEMBL617049,,,449.0,8,1,CHO,B,,,BAO_0000219,6347
107,,D,,,2263,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,,Expert,,CHEMBL617050,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,6857
107,,H,,,2264,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,Autocuration,,CHEMBL617051,,,,8,1,,F,,,BAO_0000219,4176
107,,H,,,2265,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,,Autocuration,,CHEMBL617052,,,,8,1,,F,,,BAO_0000219,4176
107,,H,,,2266,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,,Autocuration,,CHEMBL617053,,,,8,1,,F,,,BAO_0000219,4176
107,,H,,,2267,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",,Autocuration,,CHEMBL617054,,,449.0,8,1,CHO,B,,,BAO_0000219,6347
107,,H,,,2268,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",,Autocuration,,CHEMBL617055,,,449.0,8,1,CHO,B,,,BAO_0000219,6347
107,,H,,,2269,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,,Autocuration,,CHEMBL882924,,,,8,1,,B,,,BAO_0000357,15331
107,,D,,,2270,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617056,,9606.0,,9,1,,B,,,BAO_0000357,16146
107,,H,,,2271,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,Autocuration,,CHEMBL617057,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
107,,H,,,2272,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,,Expert,,CHEMBL617058,,,,8,1,,B,,,BAO_0000219,13631
107,,H,,,2273,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),,Autocuration,,CHEMBL617059,,,,8,1,,B,,,BAO_0000357,3805
107,,H,,,2274,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,,Autocuration,,CHEMBL617060,,,449.0,8,1,CHO,B,,,BAO_0000219,4011
107,,H,,,2275,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,,Expert,,CHEMBL617061,,,449.0,8,1,CHO,B,,,BAO_0000219,4012
107,,H,,,2276,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,,Expert,,CHEMBL617062,,,307.0,8,1,L929,B,,,BAO_0000219,6366
107,,H,,,2277,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,Expert,,CHEMBL617063,,,449.0,8,1,CHO,B,,,BAO_0000219,15949
107,,H,,,2278,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,,Autocuration,,CHEMBL617064,,,,8,1,,F,,,BAO_0000019,14093
107,,H,,,2279,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,Autocuration,,CHEMBL617065,,,,8,1,,F,,,BAO_0000019,13481
107,,H,,,2280,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,,Autocuration,,CHEMBL617066,,,449.0,8,1,CHO,B,,,BAO_0000219,6347
107,,H,,,2281,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,,Autocuration,,CHEMBL617067,,,449.0,8,1,CHO,B,,,BAO_0000219,6347
107,,H,,,2282,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,,Autocuration,,CHEMBL617068,,,,8,1,,F,,,BAO_0000019,14093
107,,H,,,2283,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,,Autocuration,,CHEMBL617069,,,,8,1,,F,,,BAO_0000019,14093
107,,H,,,2284,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617070,,,,8,1,,F,,,BAO_0000019,13481
107,,H,,,2285,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,,Autocuration,,CHEMBL617071,,,,8,1,,B,,,BAO_0000357,14442
107,,H,,,2286,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL872915,,,,8,1,,B,,,BAO_0000357,14442
107,,H,,,2287,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,,Autocuration,,CHEMBL617072,,,,8,1,,B,,,BAO_0000357,14755
107,,H,,,2288,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,,Autocuration,,CHEMBL617073,,,,8,1,,B,,,BAO_0000357,16441
107,,H,,,2289,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,,Autocuration,,CHEMBL617074,,,,8,1,,B,,,BAO_0000357,14744
107,,H,,,2290,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,Expert,,CHEMBL617075,,,449.0,8,1,CHO,B,,,BAO_0000219,16659
107,,H,,,2291,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617076,,,,8,1,,B,,,BAO_0000357,3307
107,,D,,,2292,Homo sapiens,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,,Expert,,CHEMBL617077,,9606.0,,9,1,,B,,,BAO_0000019,6857
107,,H,,,2293,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,,Expert,,CHEMBL617078,,,,8,1,,B,,,BAO_0000357,5635
107,,D,,,2294,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617079,,9606.0,,9,1,,B,,,BAO_0000357,4234
107,,H,,,2295,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL617080,,,,8,1,,B,,,BAO_0000357,15527
107,,H,,,2296,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,,Expert,,CHEMBL617081,,,449.0,8,1,CHO,B,,,BAO_0000219,6588
107,,H,,,2297,,Binding affinity towards human 5-HT2A receptor in BEK cells,,Expert,,CHEMBL617082,,,,8,1,,B,,,BAO_0000219,13631
107,,H,,,2298,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617083,,,,8,1,,B,,,BAO_0000357,17723
107,,H,,,2299,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL617084,,,,8,1,,B,,,BAO_0000357,14770
107,,D,,,2300,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617085,,9606.0,,9,1,,B,,,BAO_0000357,16293
107,,H,,,2301,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,Autocuration,,CHEMBL617086,,,,8,1,,B,,,BAO_0000357,16209
107,,H,,,2302,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,,Autocuration,,CHEMBL617087,,,,8,1,,B,,,BAO_0000219,12469
107,,H,,,2303,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617088,,,,8,1,,B,,,BAO_0000357,15363
107,,H,,,2304,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617089,,,,8,1,,B,,,BAO_0000357,15363
107,,H,,,2305,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",,Expert,,CHEMBL617090,,,,8,1,,B,,,BAO_0000019,16441
107,,H,,,2306,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617513,,,,8,1,,B,,,BAO_0000357,8
107,,H,,,2307,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617514,,,722.0,8,1,HEK293,B,,,BAO_0000219,4176
107,,H,,,2308,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617515,,,,8,1,,B,,,BAO_0000019,17085
107,,H,,,2309,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Autocuration,,CHEMBL617516,,,,8,1,,B,,,BAO_0000357,17200
107,,D,,,2310,Homo sapiens,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,,Expert,,CHEMBL617517,,9606.0,,9,1,,B,,,BAO_0000357,17200
107,,D,,,2311,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,,Expert,,CHEMBL617518,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,4013
107,,H,,,2312,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617519,,,,8,1,,B,,,BAO_0000357,5088
107,,D,,,2313,Homo sapiens,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617520,,9606.0,,9,1,,B,,,BAO_0000357,5088
107,,H,,,2314,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,,Autocuration,,CHEMBL617521,,,,8,1,,B,,,BAO_0000357,5088
107,,D,,,2315,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617522,,9606.0,,9,1,,B,,,BAO_0000357,5088
107,,H,,,2316,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL617523,,,,8,1,,B,,,BAO_0000357,5088
107,,H,,,2317,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,Autocuration,,CHEMBL617524,,,,8,1,,B,,,BAO_0000357,5088
104686,,H,,,2318,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,,Autocuration,,CHEMBL617525,,,,4,1,,B,,,BAO_0000019,9786
104686,,D,,,2319,Rattus norvegicus,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,,Autocuration,,CHEMBL617526,,10116.0,,5,1,,B,,,BAO_0000019,9205
104686,,H,,,2320,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,,Autocuration,,CHEMBL617527,,,,4,1,,B,,,BAO_0000224,11257
104686,,H,,,2321,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,Autocuration,,CHEMBL617528,,,,4,1,,B,,,BAO_0000019,9362
104686,,H,,,2322,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,,Autocuration,,CHEMBL617529,,,,4,1,,B,,,BAO_0000019,9362
104686,,H,,,2323,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,,Autocuration,,CHEMBL617530,,,,4,1,,B,,,BAO_0000224,10590
104686,,H,,,2324,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,Autocuration,,CHEMBL617531,,,,4,1,,B,,,BAO_0000019,10468
104686,,H,,,2325,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,,Autocuration,,CHEMBL617532,,,,4,1,,B,,,BAO_0000019,13050
104686,,H,,,2326,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617533,,,,4,1,,B,,,BAO_0000019,11624
104686,,H,,,2327,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,,Autocuration,,CHEMBL617534,,,,4,1,,B,,,BAO_0000019,10468
104686,,H,,,2328,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617535,,,,4,1,,B,,,BAO_0000224,10330
104686,,H,,,2329,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,,Autocuration,,CHEMBL617536,,,,4,1,,B,,,BAO_0000224,10062
104686,,H,,,2330,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617537,,,,4,1,,B,,,BAO_0000224,11642
104686,,H,,,2331,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617538,,,,4,1,,B,,,BAO_0000224,10062
104686,,H,,,2332,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,,Autocuration,,CHEMBL617539,In vitro,,,4,1,,B,,,BAO_0000219,13427
104686,,D,,,2333,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617540,,10116.0,,5,1,,B,,,BAO_0000224,12280
104686,,D,,,2334,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,,Autocuration,,CHEMBL617541,,10116.0,,5,1,,B,,,BAO_0000224,4101
104686,,H,,,2335,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617542,,,,4,1,,B,,,BAO_0000224,10062
104686,,H,,,2336,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,,Autocuration,,CHEMBL617543,,,,4,1,,B,,,BAO_0000224,11147
104686,,D,,,2337,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Autocuration,,CHEMBL617544,,10116.0,485.0,5,1,CHO-K1,B,,,BAO_0000219,2395
104686,,D,,,2338,Rattus norvegicus,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,,Autocuration,,CHEMBL617545,,10116.0,485.0,5,1,CHO-K1,B,,,BAO_0000219,2395
104686,,D,,,2339,Rattus norvegicus,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,,Autocuration,,CHEMBL617413,,10116.0,,5,1,,B,,,BAO_0000019,9098
104686,,H,,,2340,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,,Autocuration,,CHEMBL617414,,,,4,1,,B,,,BAO_0000019,9098
104686,,D,,,2341,Rattus norvegicus,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,,Autocuration,,CHEMBL617415,,10116.0,,5,1,,B,,,BAO_0000019,9098
104686,,H,,,2342,,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617416,,,,4,1,,B,,,BAO_0000224,9443
104686,,H,,,2343,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,,Autocuration,,CHEMBL617417,,,,4,1,,B,,,BAO_0000224,9443
104686,,H,,,2344,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",,Autocuration,,CHEMBL617418,,,,4,1,,B,,,BAO_0000019,9699
104686,,H,,,2345,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,,Autocuration,,CHEMBL617419,,,,4,1,,B,,,BAO_0000019,9699
104686,,H,,,2346,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,,Autocuration,,CHEMBL617420,,,,4,1,,B,,,BAO_0000224,9098
104686,,D,,,2347,Rattus norvegicus,Affinity for 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617421,,10116.0,,5,1,,B,,,BAO_0000224,3070
104686,,H,,,2348,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,,Autocuration,,CHEMBL617422,,,,4,1,,B,,,BAO_0000224,9547
104686,,H,,,2349,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,,Autocuration,,CHEMBL617423,,,,4,1,,B,,,BAO_0000019,10444
104686,,H,,,2350,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,,Autocuration,,CHEMBL617424,,,,4,1,,B,,,BAO_0000019,14617
104686,,H,,,2351,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,,Autocuration,,CHEMBL617425,,,,4,1,,B,,,BAO_0000019,14617
104686,,H,,,2352,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),,Autocuration,,CHEMBL617426,,,,4,1,,B,,,BAO_0000224,11130
104686,,H,,,2353,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),,Autocuration,,CHEMBL617427,In vivo,,,4,1,,B,,,BAO_0000218,11130
104686,,H,955.0,,2354,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,Brain,Autocuration,,CHEMBL617428,,,,4,1,,B,,,BAO_0000221,14542
104686,,H,,,2355,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,,Autocuration,,CHEMBL617429,,,,4,1,,B,,,BAO_0000224,2797
104686,,H,,,2356,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,Autocuration,,CHEMBL617430,,,,4,1,,B,,,BAO_0000019,11332
104686,,H,,,2357,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,,Autocuration,,CHEMBL617431,,,,4,1,,B,,,BAO_0000019,11332
104686,,H,1870.0,,2358,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,Frontal cortex,Autocuration,,CHEMBL617432,,,,4,1,,B,,,BAO_0000019,10752
104686,,H,,,2359,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617433,,,,4,1,,B,,,BAO_0000224,1185
104686,,H,,,2360,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617434,,,,4,1,,B,,,BAO_0000224,1185
104686,,D,,,2361,Rattus norvegicus,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,,Autocuration,,CHEMBL617435,,10116.0,,5,1,,B,,,BAO_0000224,11624
104686,,H,,,2362,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,,Autocuration,,CHEMBL617436,,,,4,1,,B,,,BAO_0000019,1344
104686,,D,2435.0,,2363,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,Striatum,Autocuration,,CHEMBL617437,,10116.0,,5,1,,B,,,BAO_0000019,15453
104686,,H,,,2364,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",,Autocuration,,CHEMBL617438,,,,4,1,,B,,,BAO_0000019,11662
104686,,H,,,2365,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",,Autocuration,,CHEMBL617439,,,,4,1,,B,,,BAO_0000019,11662
104686,,H,,,2366,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617440,,,,4,1,,B,,,BAO_0000224,10796
104686,,H,,,2367,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617441,,,,4,1,,B,,,BAO_0000224,9069
104686,,D,,,2368,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,,Autocuration,,CHEMBL872918,,10116.0,,5,1,,B,,,BAO_0000019,8814
104686,,D,,,2369,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,,Autocuration,,CHEMBL617442,,10116.0,,5,1,,B,,,BAO_0000019,8908
104686,,H,,,2370,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,Autocuration,,CHEMBL617443,,,,4,1,,B,,,BAO_0000019,9098
104686,,H,,,2371,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,,Autocuration,,CHEMBL617444,,,,4,1,,B,,,BAO_0000019,9098
104686,,H,,,2372,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,,Autocuration,,CHEMBL617445,,,,4,1,,B,,,BAO_0000019,9098
104686,,H,,,2373,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,,Autocuration,,CHEMBL617446,,,,4,1,,B,,,BAO_0000019,9098
104686,,H,,,2374,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,,Autocuration,,CHEMBL617447,,,,4,1,,B,,,BAO_0000249,9098
104686,,H,,,2375,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,,Autocuration,,CHEMBL617448,,,,4,1,,B,,,BAO_0000019,9098
104686,,H,,,2376,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,,Autocuration,,CHEMBL617449,,,,4,1,,B,,,BAO_0000019,9098
104686,,H,,,2377,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,,Autocuration,,CHEMBL617450,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2378,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,,Autocuration,,CHEMBL617451,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2379,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,,Autocuration,,CHEMBL617452,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2380,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,,Autocuration,,CHEMBL617453,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2381,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,,Autocuration,,CHEMBL617660,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2382,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,,Autocuration,,CHEMBL617661,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2383,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,,Autocuration,,CHEMBL617662,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2384,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,,Autocuration,,CHEMBL872919,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2385,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,,Autocuration,,CHEMBL617663,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2386,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,,Autocuration,,CHEMBL617664,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2387,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,,Autocuration,,CHEMBL617665,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2388,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,,Autocuration,,CHEMBL617666,,,,4,1,,B,,,BAO_0000019,9161
104686,,H,,,2389,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,,Autocuration,,CHEMBL617667,,,,4,1,,B,,,BAO_0000019,12094
104686,,H,,,2390,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,,Autocuration,,CHEMBL617668,,,,4,1,,B,,,BAO_0000249,12018
104686,,H,,,2391,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,,Autocuration,,CHEMBL617669,,,,4,1,,B,,,BAO_0000249,10394
104686,,H,,,2392,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617670,,,,4,1,,B,,,BAO_0000224,15260
104686,,D,,,2393,Rattus norvegicus,Inhibitory constant against 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617671,,10116.0,,5,1,,B,,,BAO_0000224,11624
104686,,H,,,2394,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617672,,,,4,1,,B,,,BAO_0000224,13654
104686,,H,,,2395,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,,Autocuration,,CHEMBL617673,,,,4,1,,B,,,BAO_0000019,9541
104686,,H,,,2396,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617674,,,,4,1,,B,,,BAO_0000224,11933
104686,,H,,,2397,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,,Autocuration,,CHEMBL617675,,,,4,1,,B,,,BAO_0000019,15538
104686,,H,,,2398,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,,Autocuration,,CHEMBL617676,,,,4,1,,B,,,BAO_0000019,15538
104686,,H,,,2399,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,,Autocuration,,CHEMBL617677,,,,4,1,,B,,,BAO_0000019,15538
104686,,D,,,2400,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617678,,,,5,1,,B,,,BAO_0000019,8841
104686,,H,,,2401,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,,Autocuration,,CHEMBL617679,,,,4,1,,B,,,BAO_0000224,1455
104686,,H,,,2402,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,,Autocuration,,CHEMBL617680,,,,4,1,,B,,,BAO_0000224,1455
104686,,H,,,2403,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,,Autocuration,,CHEMBL617681,,,,4,1,,B,,,BAO_0000019,11752
104686,,H,955.0,,2404,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,Brain,Autocuration,,CHEMBL617682,,,,4,1,,B,,,BAO_0000221,11642
104686,,H,,,2405,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,,Autocuration,,CHEMBL617683,,,,4,1,,B,,,BAO_0000224,12092
104686,,H,,,2406,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,,Autocuration,,CHEMBL617684,,,,4,1,,B,,,BAO_0000224,3967
104686,,D,,,2407,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617685,,10116.0,,5,1,,B,,,BAO_0000224,12771
104686,,H,,,2408,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,,Autocuration,,CHEMBL617686,,,,4,1,,B,,,BAO_0000019,11642
104686,,H,,,2409,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,,Autocuration,,CHEMBL617687,,,,4,1,,B,,,BAO_0000224,11628
104686,,H,,,2410,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,,Autocuration,,CHEMBL617688,,,,4,1,,B,,,BAO_0000224,13654
104686,,H,,,2411,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,Autocuration,,CHEMBL617689,,,,4,1,,F,,,BAO_0000019,11200
104686,,H,,,2412,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,,Autocuration,,CHEMBL617690,,,,4,1,,F,,,BAO_0000019,11200
104686,,H,,,2413,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,Autocuration,,CHEMBL617691,In vivo,,,4,1,,F,,,BAO_0000218,11200
104686,,H,,,2414,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,Autocuration,,CHEMBL617692,In vivo,,,4,1,,F,,,BAO_0000218,11200
104686,,H,,,2415,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",,Autocuration,,CHEMBL617693,In vivo,,,4,1,,F,,,BAO_0000218,11200
104686,,H,,,2416,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",,Autocuration,,CHEMBL617694,In vivo,,,4,1,,F,,,BAO_0000218,11200
12687,,H,955.0,,2417,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,Brain,Expert,,CHEMBL857985,,,,8,1,,B,,,BAO_0000221,15436
12687,,D,,,2418,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Expert,,CHEMBL617695,,10116.0,,9,1,,B,,,BAO_0000019,15436
12687,,H,,,2419,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,,Autocuration,,CHEMBL617696,,,,8,1,,B,,,BAO_0000019,14025
12687,,H,,,2420,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,,Autocuration,,CHEMBL617697,,,,8,1,,B,,,BAO_0000357,4342
12687,,D,,,2421,Rattus norvegicus,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,,Expert,,CHEMBL617257,,10116.0,,9,1,,B,,,BAO_0000019,13735
12687,,D,,,2422,Rattus norvegicus,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,Expert,,CHEMBL617258,,10116.0,,9,1,,B,,,BAO_0000357,5816
12687,,H,,,2423,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,,Expert,,CHEMBL617259,,,,8,1,,B,,,BAO_0000019,14287
12687,,H,,,2424,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,,Autocuration,,CHEMBL617260,,,,8,1,,B,,,BAO_0000357,15738
12687,,D,,,2425,Rattus norvegicus,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617261,,10116.0,,9,1,,B,,,BAO_0000357,15738
12687,,H,,,2426,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,,Autocuration,,CHEMBL617262,,,,8,1,,B,,,BAO_0000019,15026
12687,,H,,,2427,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,Expert,,CHEMBL617263,,,,8,1,,B,,,BAO_0000019,16647
12687,,H,,,2428,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,,Autocuration,,CHEMBL617264,,,,8,1,,B,,,BAO_0000019,16647
12687,,D,,,2429,Rattus norvegicus,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617265,,10116.0,,9,1,,B,,,BAO_0000019,13345
12687,,H,,,2430,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617266,,,,8,1,,B,,Membranes,BAO_0000249,1543
12687,,H,,,2431,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,,Autocuration,,CHEMBL617267,,,,8,1,,B,,,BAO_0000019,12444
12687,,H,,,2432,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,,Expert,,CHEMBL617268,,,,8,1,,B,,,BAO_0000019,16404
12687,,H,,,2433,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,Autocuration,,CHEMBL617269,,,449.0,8,1,CHO,B,,,BAO_0000219,16404
12687,,H,,,2434,,Kinetic inhibition constant evaluated by measuring serotonergic activity,,Expert,,CHEMBL617323,,,,8,1,,B,,,BAO_0000357,15577
12687,,H,,,2435,,Serotonergic activity of the compound.,,Autocuration,,CHEMBL617324,,,,8,1,,B,,,BAO_0000357,15577
12687,,H,,,2436,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,,Autocuration,,CHEMBL617325,,,,8,1,,B,,,BAO_0000249,2495
12687,,D,,,2437,Rattus norvegicus,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,,Expert,,CHEMBL617326,,10116.0,,9,1,,B,,,BAO_0000019,15042
12687,,H,,,2438,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,,Expert,,CHEMBL617327,,,,8,1,,B,,,BAO_0000249,15026
12687,,D,,,2439,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Expert,,CHEMBL617328,,10116.0,,9,1,,F,,,BAO_0000019,12919
12687,,D,,,2440,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Expert,,CHEMBL617329,,10116.0,,9,1,,F,,,BAO_0000019,12919
12687,,D,,,2441,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Expert,,CHEMBL617330,,10116.0,,9,1,,F,,,BAO_0000019,12919
12687,,H,,,2442,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617331,,,,8,1,,B,,,BAO_0000357,15194
12687,,H,,,2443,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,,Autocuration,,CHEMBL617332,,,,8,1,,B,,,BAO_0000357,15194
107,,H,,,2444,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617333,,,,8,1,,B,,,BAO_0000357,4820
107,,H,,,2445,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,,Autocuration,,CHEMBL617334,,,,8,1,,B,,,BAO_0000357,6736
107,,H,,,2446,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,,Autocuration,,CHEMBL617335,,,,8,1,,B,,,BAO_0000357,5163
107,,H,,,2447,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,,Autocuration,,CHEMBL617336,,,,8,1,,B,,,BAO_0000357,5163
107,,H,,,2448,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,,Autocuration,,CHEMBL617337,,,,8,1,,B,,,BAO_0000357,6011
107,,D,,,2449,Homo sapiens,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,,Expert,,CHEMBL617338,,9606.0,,9,1,,B,,,BAO_0000357,14294
107,,H,,,2450,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617339,,,,8,1,,B,,,BAO_0000357,5014
107,,H,,,2451,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617340,,,,8,1,,B,,,BAO_0000357,17066
107,,H,,,2452,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,,Autocuration,,CHEMBL617341,,,,8,1,,B,,,BAO_0000357,17515
107,,H,,,2453,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617342,,,,8,1,,B,,,BAO_0000357,6736
107,,H,,,2454,,Affinity for 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617343,,,,8,1,,B,,,BAO_0000357,5163
107,,H,,,2455,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,,Expert,,CHEMBL617344,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,16911
107,,H,,,2456,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,,Expert,,CHEMBL617345,,,,8,1,,B,,,BAO_0000357,6841
107,,H,,,2457,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,,Expert,,CHEMBL617346,,,,8,1,,B,,,BAO_0000357,6119
107,,H,,,2458,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617347,,,,8,1,,B,,,BAO_0000357,3962
107,,H,,,2459,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,,Autocuration,,CHEMBL617348,,,,8,1,,B,,,BAO_0000357,4373
107,,H,,,2460,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,,Autocuration,,CHEMBL617349,,,,8,1,,B,,,BAO_0000357,4373
107,,H,,,2461,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617350,,,,8,1,,F,,,BAO_0000019,3962
107,,H,,,2462,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,,Expert,,CHEMBL872339,,,,8,1,,B,,,BAO_0000357,1633
107,,H,,,2463,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,,Autocuration,,CHEMBL617351,,,,8,1,,B,,,BAO_0000357,4373
107,,H,,,2464,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617352,,,,8,1,,B,,,BAO_0000357,6576
107,,H,,,2465,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617353,,,,8,1,,B,,,BAO_0000357,4687
107,,H,,,2466,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617354,,,,8,1,,B,,,BAO_0000357,16946
107,,H,,,2467,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617355,,,,8,1,,B,,,BAO_0000357,14159
107,,H,,,2468,Mus musculus,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,,Expert,,CHEMBL617356,,10090.0,449.0,8,1,CHO,B,,,BAO_0000219,3032
107,,H,,,2469,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617357,,,,8,1,,B,,,BAO_0000357,16655
107,,H,,,2470,,Binding affinity at 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617358,,,,8,1,,B,,,BAO_0000357,13964
107,,H,,,2471,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617359,,,,8,1,,B,,,BAO_0000357,16989
107,,H,,,2472,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,,Autocuration,,CHEMBL617360,,,,8,1,,B,,,BAO_0000357,16117
107,,H,,,2473,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,,Autocuration,,CHEMBL875913,,,,8,1,,B,,,BAO_0000357,16700
107,,H,,,2474,,Affinity against 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617361,,,,8,1,,B,,,BAO_0000357,3269
107,,D,,,2475,Homo sapiens,Binding affinity against 5-Hydroxytryptamine 2A receptor,,Expert,,CHEMBL617362,,9606.0,,9,1,,B,,,BAO_0000357,1274
107,,H,,,2476,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,,Autocuration,,CHEMBL617363,,,,8,1,,B,,,BAO_0000357,1317
107,,H,,,2477,,Tested against 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617364,,,,8,1,,B,,,BAO_0000357,12146
105075,,H,,,2478,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,Autocuration,,CHEMBL617365,,,,4,1,,B,,,BAO_0000224,12652
105075,,H,,,2479,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,,Autocuration,,CHEMBL617366,,,,4,1,,B,,,BAO_0000224,12652
105075,,H,,,2480,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,,Autocuration,,CHEMBL617367,,,,4,1,,B,,,BAO_0000224,12652
105075,,H,,,2481,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,,Autocuration,,CHEMBL617368,,,,4,1,,B,,,BAO_0000224,12652
107,,H,,,2482,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),,Autocuration,,CHEMBL617369,,,,8,1,,B,,,BAO_0000357,16647
227,,D,,,2483,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,,Expert,,CHEMBL617370,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,15851
227,,D,,,2484,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,,Expert,,CHEMBL617371,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,6857
227,,H,,,2485,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),,Autocuration,,CHEMBL617372,,,,8,1,,B,,,BAO_0000357,3805
227,,D,,,2486,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,,Expert,,CHEMBL617373,,9606.0,,9,1,,B,,,BAO_0000357,6491
227,,H,,,2487,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,,Autocuration,,CHEMBL617374,,,,8,1,,F,,,BAO_0000019,14093
227,,H,,,2488,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,,Autocuration,,CHEMBL617375,,,,8,1,,F,,,BAO_0000019,13481
227,,H,,,2489,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,,Autocuration,,CHEMBL617376,,,,8,1,,F,,,BAO_0000019,14093
227,,H,,,2490,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,,Autocuration,,CHEMBL617377,,,,8,1,,F,,,BAO_0000019,14093
227,,H,,,2491,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,,Autocuration,,CHEMBL617378,,,,8,1,,F,,,BAO_0000019,14093
227,,H,,,2492,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,Autocuration,,CHEMBL617379,,,,8,1,,F,,,BAO_0000019,13481
227,,H,,,2493,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,,Autocuration,,CHEMBL617380,,,,8,1,,B,,,BAO_0000357,14442
227,,H,,,2494,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,,Autocuration,,CHEMBL617381,,,,8,1,,B,,,BAO_0000357,14442
227,,H,,,2495,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,,Autocuration,,CHEMBL617382,,,,8,1,,B,,,BAO_0000357,14442
107,,H,,,2496,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617383,,,,8,1,,B,,,BAO_0000357,12369
107,,H,,,2497,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,,Expert,,CHEMBL617384,,,,8,1,,B,,,BAO_0000357,12369
107,,H,,,2498,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,,Expert,,CHEMBL617385,,,,8,1,,B,,,BAO_0000357,12369
107,,H,,,2499,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,,Autocuration,,CHEMBL617386,,,,8,1,,B,,,BAO_0000019,14447
107,,H,,,2500,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,,Autocuration,,CHEMBL617387,,,,8,1,,B,,,BAO_0000019,14447
107,,H,,,2501,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,Autocuration,,CHEMBL617388,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,17451
107,,H,,,2502,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Autocuration,,CHEMBL617389,,,449.0,8,1,CHO,F,,,BAO_0000219,6857
107,,D,,,2503,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Expert,,CHEMBL617390,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,6857
104817,,H,,,2504,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,,Autocuration,,CHEMBL617391,,,,4,1,,B,,,BAO_0000224,5635
107,,H,,,2505,,Binding activity radioligand.,,Autocuration,,CHEMBL617392,,,,8,1,,B,,,BAO_0000357,12861
107,,H,,,2506,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,Autocuration,,CHEMBL617393,,,,8,1,,B,,,BAO_0000019,12861
107,,H,,,2507,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,Autocuration,,CHEMBL617394,,,307.0,8,1,L929,B,,,BAO_0000219,5105
107,,H,,,2508,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,,Expert,,CHEMBL617395,,,307.0,8,1,L929,B,,,BAO_0000219,5104
107,,H,,,2509,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,,Expert,,CHEMBL617396,,,307.0,8,1,L929,B,,,BAO_0000219,5105
107,,H,,,2510,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,,Autocuration,,CHEMBL617397,,,307.0,8,1,L929,B,,,BAO_0000219,5105
107,,H,,,2511,,Binding affinity against 5-HT2A receptor,,Autocuration,,CHEMBL617398,,,,8,1,,B,,,BAO_0000357,5254
107,,H,,,2512,,Binding affinity against 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617399,,,,8,1,,B,,,BAO_0000357,5254
107,,H,,,2513,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617400,,,722.0,8,1,HEK293,B,,,BAO_0000219,13267
107,,H,,,2514,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL617401,,,722.0,8,1,HEK293,B,,,BAO_0000219,13267
107,,D,,,2515,Homo sapiens,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,,Expert,,CHEMBL617402,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,14157
107,,D,,,2516,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Expert,,CHEMBL617403,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,12936
107,,H,,,2517,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,,Expert,,CHEMBL617404,,,,8,1,,B,,,BAO_0000357,14068
107,,D,,,2518,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Expert,,CHEMBL857981,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,12936
107,,D,,,2519,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Expert,,CHEMBL617405,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,12936
107,,D,,,2520,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,,Expert,,CHEMBL617253,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,4540
107,,H,,,2521,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,,Expert,,CHEMBL617254,,,,8,1,,B,,,BAO_0000357,6166
107,,H,,,2522,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617255,,,722.0,8,1,HEK293,B,,,BAO_0000219,17296
107,,H,,,2523,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617256,,,722.0,8,1,HEK293,B,,,BAO_0000219,17296
107,,H,,,2524,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL616874,,,722.0,8,1,HEK293,B,,,BAO_0000219,17296
107,,D,,,2525,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,,Expert,,CHEMBL616875,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,15779
107,,H,,,2526,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,,Expert,,CHEMBL616876,,,722.0,8,1,HEK293,B,,,BAO_0000219,14391
107,,H,,,2527,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",,Expert,,CHEMBL616877,,,722.0,8,1,HEK293,B,,,BAO_0000219,15851
107,,D,,,2528,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,,Expert,,CHEMBL616878,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,15851
107,,H,,,2529,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,,Expert,,CHEMBL616879,,,722.0,8,1,HEK293,B,,,BAO_0000219,3832
107,,H,,,2530,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,,Expert,,CHEMBL616880,,,722.0,8,1,HEK293,B,,,BAO_0000219,3833
107,,D,,,2531,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,,Expert,,CHEMBL616881,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,12936
107,,H,,,2532,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,Autocuration,,CHEMBL616882,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,17451
107,,H,,,2533,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,Autocuration,,CHEMBL616883,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,17451
107,,H,,,2534,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,Autocuration,,CHEMBL616884,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,17451
107,,H,,,2535,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,,Autocuration,,CHEMBL616885,,,722.0,8,1,HEK293,B,,,BAO_0000219,4199
107,,H,,,2536,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,,Autocuration,,CHEMBL616886,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,1883
107,,H,,,2537,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,,Expert,,CHEMBL616887,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,1883
107,,D,,,2538,Homo sapiens,Binding affinity for human 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL616888,,9606.0,,9,1,,B,,,BAO_0000357,14875
107,,H,,,2539,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,,Autocuration,,CHEMBL616889,,,722.0,8,1,HEK293,B,,,BAO_0000219,15146
107,,H,,,2540,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,,Autocuration,,CHEMBL616890,,,722.0,8,1,HEK293,B,,,BAO_0000219,5213
107,,D,,,2541,Homo sapiens,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,,Expert,,CHEMBL616891,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,16404
107,,H,,,2542,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,,Autocuration,,CHEMBL616892,,,722.0,8,1,HEK293,B,,,BAO_0000219,14818
107,,H,,,2543,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",,Autocuration,,CHEMBL616893,,,722.0,8,1,HEK293,B,,,BAO_0000219,4829
10620,,H,,,2544,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,,Autocuration,,CHEMBL616894,,,723.0,8,1,NIH3T3,F,,,BAO_0000219,12652
107,,H,,,2545,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,,Expert,,CHEMBL616895,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,4682
10620,,H,,,2546,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL616896,,,,8,1,,F,,,BAO_0000019,12652
10621,,H,,,2547,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617099,,,,8,1,,B,,,BAO_0000357,4921
10621,,H,,,2548,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,,Autocuration,,CHEMBL617100,,,,8,1,,B,,,BAO_0000357,4921
107,,H,,,2549,Oryctolagus cuniculus,Binding affinity against rabbit aorta 5-HT2A receptor,,Autocuration,,CHEMBL884532,,9986.0,,8,1,,B,,,BAO_0000357,16312
107,,H,,,2550,Oryctolagus cuniculus,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,,Expert,,CHEMBL617101,,9986.0,,8,1,,B,,,BAO_0000357,14998
107,,H,,,2551,Oryctolagus cuniculus,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,,Expert,,CHEMBL617102,,9986.0,,8,1,,B,,,BAO_0000357,14025
107,,H,,,2552,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,,Autocuration,,CHEMBL617103,,9986.0,,8,1,,B,,,BAO_0000019,13047
107,,H,,,2553,Oryctolagus cuniculus,The compound was tested for binding affinity against 5-HT2A receptor,,Expert,,CHEMBL617104,,9986.0,,8,1,,B,,,BAO_0000357,13047
10576,,H,,,2554,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,,Autocuration,,CHEMBL857979,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,1883
12687,,H,,,2555,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,,Autocuration,,CHEMBL857502,,,,8,1,,B,,,BAO_0000019,13463
12687,,H,,,2556,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,Autocuration,,CHEMBL617105,,,,8,1,,B,,,BAO_0000019,13463
12687,,H,945.0,,2557,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,Stomach,Autocuration,,CHEMBL858021,,,,8,1,,B,,,BAO_0000019,13463
12687,,D,945.0,,2558,Rattus norvegicus,Binding affinity for 5-HT 2A in rat stomach fundus,Stomach,Expert,,CHEMBL875910,,10116.0,,9,1,,B,,,BAO_0000019,13463
12687,,H,,,2559,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,,Autocuration,,CHEMBL617106,,,,8,1,,B,,,BAO_0000019,13463
12687,,H,,,2560,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617107,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,16326
12687,,H,,,2561,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617108,,,,8,1,,F,,,BAO_0000019,14093
12687,,H,,,2562,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617109,,,,8,1,,F,,,BAO_0000019,14093
12687,,H,,,2563,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617110,,,,8,1,,B,,,BAO_0000357,15740
12687,,H,,,2564,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,,Autocuration,,CHEMBL617111,,,,8,1,,B,,,BAO_0000357,16633
12687,,D,,,2565,Rattus norvegicus,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,,Expert,,CHEMBL617112,,10116.0,,9,1,,F,,,BAO_0000019,17200
12687,,H,,,2566,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617113,,,,8,1,,B,,,BAO_0000357,17133
12687,,H,,,2567,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617114,,,,8,1,,B,,,BAO_0000357,17133
12687,,H,,,2568,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617115,,,,8,1,,B,,,BAO_0000357,17133
12687,,H,,,2569,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,Autocuration,,CHEMBL617116,,,,8,1,,F,,,BAO_0000219,17200
12687,,H,,,2570,,Efficacy at 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617117,,,,8,1,,F,,,BAO_0000019,15363
12687,,H,,,2571,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,Autocuration,,CHEMBL617118,,,,8,1,,B,,,BAO_0000357,17200
12687,,D,,,2572,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),,Expert,,CHEMBL617119,,10116.0,,9,1,,B,,,BAO_0000357,17200
12687,,D,,,2573,Rattus norvegicus,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),,Expert,,CHEMBL617120,,10116.0,,9,1,,B,,,BAO_0000357,17200
12687,,D,,,2574,Rattus norvegicus,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,Expert,,CHEMBL617121,,10116.0,,9,1,,F,,,BAO_0000219,17200
12687,,H,,,2575,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,,Autocuration,,CHEMBL617122,,,,8,1,,F,,,BAO_0000219,17200
12687,,H,,,2576,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617123,,,,8,1,,B,,,BAO_0000019,17211
12687,,H,,,2577,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,,Expert,,CHEMBL617124,,,,8,1,,B,,,BAO_0000019,17331
12687,,H,,,2578,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,,Expert,,CHEMBL617600,,,,8,1,,B,,,BAO_0000249,13565
12687,,H,,,2579,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,,Expert,,CHEMBL617601,,,,8,1,,B,,,BAO_0000357,13730
12687,,H,,,2580,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,,Expert,,CHEMBL882923,,,,8,1,,B,,,BAO_0000019,12416
12687,,H,,,2581,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617602,,,,8,1,,B,,,BAO_0000357,15295
12687,,H,,,2582,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,,Autocuration,,CHEMBL617603,,,,8,1,,B,,,BAO_0000019,1742
12687,,H,,,2583,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617604,,,,8,1,,B,,,BAO_0000357,15295
12687,,H,,,2584,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,,Expert,,CHEMBL617605,,,,8,1,,B,,,BAO_0000019,14970
12687,,H,,,2585,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,,Expert,,CHEMBL617606,,,,8,1,,B,,,BAO_0000019,16693
12687,,D,,,2586,Rattus norvegicus,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617607,,10116.0,,9,1,,B,,,BAO_0000019,14776
12687,,H,,,2587,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Autocuration,,CHEMBL617455,,,,8,1,,B,,,BAO_0000249,14286
12687,,D,,,2588,Rattus norvegicus,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,Expert,,CHEMBL617456,,10116.0,,9,1,,B,,,BAO_0000019,17200
12687,,H,,,2589,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),,Expert,,CHEMBL617457,,,,8,1,,B,,,BAO_0000357,15306
12687,,D,,,2590,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617458,,10116.0,,9,1,,B,,,BAO_0000357,14178
12687,,D,,,2591,Rattus norvegicus,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,,Expert,,CHEMBL617459,,10116.0,,9,1,,B,,,BAO_0000019,14229
12687,,H,,,2592,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,,Expert,,CHEMBL617460,,,,8,1,,B,,,BAO_0000357,12884
12687,,H,,,2593,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",,Expert,,CHEMBL617461,,,,8,1,,B,,,BAO_0000357,13149
12687,,D,,,2594,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,,Expert,,CHEMBL617462,,10116.0,,9,1,,B,,,BAO_0000019,15295
12687,,H,,,2595,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,,Autocuration,,CHEMBL617463,,,,8,1,,B,,,BAO_0000357,15740
12687,,H,,,2596,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",,Autocuration,,CHEMBL617464,,,,8,1,,B,,,BAO_0000019,15185
12687,,H,,,2597,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",,Autocuration,,CHEMBL617465,,,,8,1,,B,,,BAO_0000019,15185
12687,,H,,,2598,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,,Expert,,CHEMBL617466,,,,8,1,,B,,,BAO_0000019,17529
12687,,H,,,2599,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,Autocuration,,CHEMBL617467,,,,8,1,,B,,,BAO_0000019,14826
12687,,H,,,2600,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,,Expert,,CHEMBL617468,,,,8,1,,B,,,BAO_0000019,17211
12687,,H,,,2601,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,,Autocuration,,CHEMBL617469,,,,8,1,,B,,,BAO_0000019,14826
12687,,H,,,2602,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617470,,,,8,1,,B,,,BAO_0000019,14093
12687,,H,,,2603,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,,Autocuration,,CHEMBL617471,,,,8,1,,B,,,BAO_0000019,14093
12687,,H,,,2604,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,,Expert,,CHEMBL617472,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,13246
12687,,H,,,2605,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,,Expert,,CHEMBL617473,,,,8,1,,B,,,BAO_0000357,13246
12687,,D,,,2606,Rattus norvegicus,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Expert,,CHEMBL617474,,10116.0,,9,1,,B,,,BAO_0000019,15436
12687,,D,,,2607,Rattus norvegicus,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,,Expert,,CHEMBL617475,,10116.0,,9,1,,B,,,BAO_0000019,15436
12687,,H,955.0,,2608,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,Brain,Autocuration,,CHEMBL617476,,,,8,1,,B,,,BAO_0000221,14442
12687,,H,,,2609,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617477,,,,8,1,,B,,,BAO_0000357,12457
12687,,H,,,2610,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617478,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,12457
12687,,H,,,2611,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",,Autocuration,,CHEMBL617479,,,,8,1,,F,,,BAO_0000221,14755
12687,,H,,,2612,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,,Autocuration,,CHEMBL617480,,,,8,1,,B,,,BAO_0000357,4707
12687,,H,,,2613,,Binding affinity against 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617481,,,,8,1,,B,,,BAO_0000357,13297
12687,,H,,,2614,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,,Expert,,CHEMBL617482,,,,8,1,,B,,,BAO_0000019,17331
12687,,H,,,2615,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617483,,,,8,1,,B,,,BAO_0000019,4664
12687,,H,,,2616,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,Autocuration,,CHEMBL621528,,,,8,1,,B,,,BAO_0000357,16633
12687,,D,,,2617,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,,Expert,,CHEMBL621529,,10116.0,723.0,9,1,NIH3T3,B,,,BAO_0000219,4664
12687,,H,,,2618,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,Expert,,CHEMBL621530,,,,8,1,,B,,,BAO_0000357,16133
12687,,H,,,2619,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Expert,,CHEMBL621531,,,,8,1,,B,,,BAO_0000357,16133
12687,,D,,,2620,Rattus norvegicus,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL621532,,10116.0,,9,1,,B,,,BAO_0000019,14060
12687,,H,,,2621,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,Expert,,CHEMBL621533,,,,8,1,,B,,,BAO_0000357,16326
12687,,H,,,2622,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,,Expert,,CHEMBL621534,,,449.0,8,1,CHO,B,,,BAO_0000219,16659
12687,,H,,,2623,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,,Autocuration,,CHEMBL621535,,,,8,1,,B,,,BAO_0000019,14776
12687,,H,,,2624,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,,Autocuration,,CHEMBL621536,,,,8,1,,B,,,BAO_0000357,13481
12687,,H,,,2625,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL621537,,,,8,1,,B,,,BAO_0000357,17386
12687,,D,,,2626,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL621538,,10116.0,,9,1,,B,,,BAO_0000357,6611
12687,,H,,,2627,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,,Autocuration,,CHEMBL621539,,,,8,1,,B,,,BAO_0000019,14423
12687,,H,,,2628,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,,Autocuration,,CHEMBL621540,,,,8,1,,B,,,BAO_0000019,15412
12687,,H,,,2629,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,,Autocuration,,CHEMBL621541,,,,8,1,,B,,,BAO_0000019,15412
12687,,H,,,2630,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL621542,,,,8,1,,B,,,BAO_0000019,6238
12687,,H,,,2631,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,,Expert,,CHEMBL621543,,,,8,1,,B,,,BAO_0000357,6648
12687,,H,,,2632,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,,Expert,,CHEMBL621544,,,,8,1,,B,,,BAO_0000357,5667
12687,,D,,,2633,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,,Expert,,CHEMBL621545,,10116.0,,9,1,,B,,,BAO_0000357,6611
12687,,H,,,2634,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL621546,,,,8,1,,B,,,BAO_0000357,13481
12687,,H,,,2635,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,,Autocuration,,CHEMBL621547,,,,8,1,,B,,,BAO_0000357,13481
12687,,H,,,2636,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL618692,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,15558
12687,,H,,,2637,,Binding affinity towards 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL618693,,,,8,1,,B,,,BAO_0000357,6013
12687,,H,,,2638,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,,Autocuration,,CHEMBL872922,,,,8,1,,B,,,BAO_0000357,16633
12687,,H,,,2639,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL618694,,,,8,1,,B,,,BAO_0000357,6013
12687,,D,,,2640,Rattus norvegicus,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,,Expert,,CHEMBL618695,,10116.0,,9,1,,B,,,BAO_0000357,6013
12687,,H,,,2641,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,,Autocuration,,CHEMBL618696,,,,8,1,,B,,,BAO_0000357,6013
12687,,H,,,2642,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,,Expert,,CHEMBL618697,,,,8,1,,B,,,BAO_0000357,6013
12687,,H,,,2643,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,,Autocuration,,CHEMBL618892,,,,8,1,,B,,,BAO_0000357,6013
12687,,H,,,2644,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL618893,,,,8,1,,B,,,BAO_0000357,6013
12687,,H,,,2645,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL618894,,,,8,1,,B,,,BAO_0000357,16293
12687,,H,,,2646,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,,Expert,,CHEMBL618895,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,17175
12687,,D,,,2647,Rattus norvegicus,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,,Expert,,CHEMBL618896,,10116.0,,9,1,,B,,,BAO_0000357,13278
12687,,H,5383.0,,2648,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,Caudate-putamen,Autocuration,,CHEMBL618897,,,,8,1,,B,,,BAO_0000019,3682
12687,,H,,,2649,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,,Autocuration,,CHEMBL618898,,,,8,1,,B,,,BAO_0000357,2014
12687,,H,,,2650,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,,Autocuration,,CHEMBL618899,,,,8,1,,B,,,BAO_0000357,2014
12687,,H,,,2651,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,,Autocuration,,CHEMBL618900,,,,8,1,,B,,,BAO_0000357,4932
12687,,H,,,2652,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,,Autocuration,,CHEMBL618901,,,,8,1,,B,,,BAO_0000019,4932
12687,,H,,,2653,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL618902,,,,8,1,,B,,,BAO_0000357,3935
12687,,D,10000000.0,,2654,Rattus norvegicus,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,Hippocampus,Expert,,CHEMBL618903,,10116.0,,9,1,,B,,,BAO_0000221,5432
12687,,H,,,2655,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL618904,,,,8,1,,B,,,BAO_0000357,15818
12687,,H,,,2656,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,,Autocuration,,CHEMBL618905,,,,8,1,,B,,,BAO_0000357,13672
12687,,H,,,2657,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,,Autocuration,,CHEMBL618906,,,,8,1,,B,,,BAO_0000357,13672
12687,,H,,,2658,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,,Expert,,CHEMBL618907,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,14749
12687,,H,,,2659,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,,Autocuration,,CHEMBL618908,,,,8,1,,B,,,BAO_0000019,13462
12687,,H,,,2660,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617909,,,,8,1,,B,,,BAO_0000357,15740
12687,,H,,,2661,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,,Expert,,CHEMBL617910,,,,8,1,,B,,,BAO_0000019,16647
12687,,H,955.0,,2662,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,Brain,Autocuration,,CHEMBL617911,,,,8,1,,B,,,BAO_0000221,13345
12687,,H,,,2663,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Autocuration,,CHEMBL872923,,,,8,1,,B,,,BAO_0000249,16740
12687,,H,,,2664,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Autocuration,,CHEMBL617912,,,,8,1,,B,,,BAO_0000249,16740
12687,,D,,,2665,Rattus norvegicus,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,,Expert,,CHEMBL617913,,10116.0,,9,1,,B,,,BAO_0000019,15535
12687,,H,,,2666,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Expert,,CHEMBL617914,,,,8,1,,B,,,BAO_0000249,16740
12687,,H,,,2667,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Autocuration,,CHEMBL617915,,,,8,1,,B,,,BAO_0000249,16740
12687,,H,,,2668,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,,Autocuration,,CHEMBL617916,,,,8,1,,B,,,BAO_0000249,16740
12687,,D,,,2669,Rattus norvegicus,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,,Expert,,CHEMBL617917,,10116.0,,9,1,,B,,,BAO_0000019,4795
12687,,H,,,2670,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,,Expert,,CHEMBL617918,,,,8,1,,B,,,BAO_0000019,8
12687,,H,,,2671,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,,Autocuration,,CHEMBL617919,,,,8,1,,B,,,BAO_0000019,8
12687,,D,,,2672,Rattus norvegicus,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,,Expert,,CHEMBL617920,,10116.0,,9,1,,B,,,BAO_0000019,17200
12687,,D,,,2673,Rattus norvegicus,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,,Expert,,CHEMBL617921,,10116.0,,9,1,,B,,,BAO_0000019,2148
105102,,D,,,2674,Rattus norvegicus,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",,Expert,,CHEMBL617922,,10116.0,,5,1,,B,,,BAO_0000224,13345
12687,,H,,,2675,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,,Autocuration,,CHEMBL617923,,,,8,1,,B,,,BAO_0000357,5088
12687,,H,,,2676,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,,Autocuration,,CHEMBL617924,,,,8,1,,B,,,BAO_0000357,5088
12687,,H,,,2677,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,,Autocuration,,CHEMBL617925,,,,8,1,,B,,,BAO_0000357,17133
12687,,D,,,2678,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,,Expert,,CHEMBL617926,,10116.0,,9,1,,B,,,BAO_0000357,17133
12687,,H,,,2679,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,,Autocuration,,CHEMBL617927,,,,8,1,,B,,,BAO_0000357,16532
12687,,H,,,2680,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617928,,,,8,1,,B,,,BAO_0000357,15086
12687,,D,,,2681,Rattus norvegicus,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,,Expert,,CHEMBL617929,,10116.0,,9,1,,B,,,BAO_0000019,2309
12687,,H,,,2682,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,,Expert,,CHEMBL617930,,,,8,1,,B,,,BAO_0000019,12953
12687,,H,,,2683,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,,Autocuration,,CHEMBL617931,,,,8,1,,B,,,BAO_0000019,12953
12687,,H,,,2684,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,,Autocuration,,CHEMBL617932,,,,8,1,,B,,,BAO_0000019,12953
12687,,H,,,2685,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,,Autocuration,,CHEMBL617933,,,449.0,8,1,CHO,B,,,BAO_0000219,16659
12687,,H,,,2686,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,Autocuration,,CHEMBL617934,,,,8,1,,B,,,BAO_0000019,16740
12687,,H,,,2687,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,,Autocuration,,CHEMBL617935,,,,8,1,,B,,,BAO_0000019,16740
12687,,H,,,2688,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,,Autocuration,,CHEMBL617936,,,,8,1,,B,,,BAO_0000357,17133
12687,,H,,,2689,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,,Autocuration,,CHEMBL617937,,,,8,1,,B,,,BAO_0000019,17211
12687,,H,,,2690,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,,Autocuration,,CHEMBL617938,,,,8,1,,B,,,BAO_0000019,17331
12687,,H,,,2691,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,,Autocuration,,CHEMBL617939,,,,8,1,,B,,,BAO_0000218,16633
12687,,H,,,2692,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,,Autocuration,,CHEMBL617940,,,,8,1,,B,,,BAO_0000218,16633
12687,,H,,,2693,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,,Autocuration,,CHEMBL617941,,,,8,1,,B,,,BAO_0000218,16633
12687,,H,,,2694,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,,Expert,,CHEMBL617942,,,,8,1,,B,,,BAO_0000357,15026
12687,,H,,,2695,,Ratio of pKi of 5-HT2A to that of D2 receptor,,Expert,,CHEMBL617943,,,,8,1,,B,,,BAO_0000357,15026
105093,,H,,,2696,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,Expert,,CHEMBL617944,,,,4,1,,B,,,BAO_0000224,16404
105093,,H,,,2697,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,,Expert,,CHEMBL617945,,,,4,1,,B,,,BAO_0000224,16404
105075,,H,,,2698,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617946,,,,4,1,,B,,,BAO_0000224,16404
12687,,H,,,2699,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,,Autocuration,,CHEMBL617947,,,,8,1,,B,,,BAO_0000357,16404
12687,,H,,,2700,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,,Expert,,CHEMBL617948,,,,8,1,,B,,,BAO_0000357,16326
12687,,H,,,2701,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,,Autocuration,,CHEMBL858116,,,,8,1,,F,,,BAO_0000019,15847
12687,,H,,,2702,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,,Autocuration,,CHEMBL617949,,,,8,1,,F,,,BAO_0000019,15847
12687,,H,,,2703,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,,Autocuration,,CHEMBL617950,,,,8,1,,F,,,BAO_0000019,15329
12687,,H,1515.0,,2704,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,Thoracic aorta,Expert,,CHEMBL617951,,,,8,1,,F,,,BAO_0000019,16404
12687,,H,1515.0,,2705,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,Thoracic aorta,Expert,,CHEMBL617952,,,,8,1,,F,,,BAO_0000019,16404
12687,,H,1515.0,,2706,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,Thoracic aorta,Autocuration,,CHEMBL617953,,,,8,1,,F,,,BAO_0000019,16404
12687,,H,,,2707,,Binding activity radioligand.,,Autocuration,,CHEMBL617954,,,,8,1,,B,,,BAO_0000357,12861
12687,,H,,,2708,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,Expert,,CHEMBL617955,,,,8,1,,B,,,BAO_0000019,12861
12687,,H,,,2709,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,Autocuration,,CHEMBL857071,,,,8,1,,B,,,BAO_0000019,12861
12687,,H,,,2710,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,,Expert,,CHEMBL617270,,,,8,1,,B,,,BAO_0000019,12490
12687,,H,,,2711,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,,Autocuration,,CHEMBL617271,,,339.0,8,1,N1E-115,B,,,BAO_0000219,12827
12687,,H,,,2712,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,,Autocuration,,CHEMBL617272,,,339.0,8,1,N1E-115,B,,,BAO_0000219,12827
12687,,H,,,2713,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,,Autocuration,,CHEMBL617273,,,,8,1,,B,,,BAO_0000019,12918
12687,,D,,,2714,Rattus norvegicus,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,,Expert,,CHEMBL617274,,10116.0,,9,1,,F,,,BAO_0000019,12919
108,,H,,,2715,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617275,,,,8,1,,B,,,BAO_0000357,17723
108,,H,,,2716,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617276,,,,8,1,,B,,,BAO_0000357,6013
108,,H,,,2717,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617277,,,,8,1,,B,,,BAO_0000357,16293
108,,H,,,2718,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617278,,,,8,1,,B,,,BAO_0000019,3857
108,,H,,,2719,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,,Expert,,CHEMBL617279,,,,8,1,,B,,,BAO_0000019,3857
108,,H,,,2720,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617280,,,,8,1,,B,,,BAO_0000019,3857
108,,H,,,2721,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617281,,,,8,1,,B,,,BAO_0000357,15363
108,,H,,,2722,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617282,,,,8,1,,B,,,BAO_0000357,15363
108,,H,,,2723,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,,Expert,,CHEMBL617283,,,,8,1,,B,,,BAO_0000019,16441
108,,H,,,2724,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,,Expert,,CHEMBL617284,,,,8,1,,B,,,BAO_0000019,16441
108,,H,,,2725,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL617285,,,722.0,8,1,HEK293,B,,,BAO_0000219,4176
108,,H,,,2726,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617286,,,,8,1,,B,,,BAO_0000019,17085
108,,D,,,2727,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,,Expert,,CHEMBL617287,,9606.0,,9,1,,B,,,BAO_0000357,17200
108,,H,,,2728,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,,Expert,,CHEMBL617288,,,,8,1,,B,,,BAO_0000357,5088
108,,H,,,2729,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,,Autocuration,,CHEMBL617289,,,,8,1,,B,,,BAO_0000357,5088
108,,H,,,2730,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL872917,,,,8,1,,B,,,BAO_0000357,5088
108,,H,,,2731,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL617290,,,,8,1,,B,,,BAO_0000357,5088
108,,H,,,2732,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,Autocuration,,CHEMBL617291,,,449.0,8,1,CHO,B,,,BAO_0000219,16659
108,,H,,,2733,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,,Autocuration,,CHEMBL617292,,,449.0,8,1,CHO,B,,,BAO_0000219,16659
108,,H,,,2734,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,,Autocuration,,CHEMBL617293,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,17451
108,,D,,,2735,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Expert,,CHEMBL617294,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,6857
108,,H,,,2736,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,Expert,,CHEMBL617295,,,,8,1,,B,,,BAO_0000019,3857
108,,H,,,2737,,Binding activity radioligand.,,Autocuration,,CHEMBL617296,,,,8,1,,B,,,BAO_0000357,12861
108,,H,,,2738,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,,Autocuration,,CHEMBL617297,,,,8,1,,B,,,BAO_0000019,12861
108,,H,,,2739,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,,Expert,,CHEMBL617298,,,449.0,8,1,CHO,B,,,BAO_0000219,5104
108,,H,,,2740,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,,Expert,,CHEMBL617299,,,449.0,8,1,CHO,B,,,BAO_0000219,5105
108,,H,,,2741,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,,Autocuration,,CHEMBL617300,,,449.0,8,1,CHO,B,,,BAO_0000219,5105
108,,H,,,2742,,Binding affinity against 5-HT2C receptor,,Autocuration,,CHEMBL617454,,,,8,1,,B,,,BAO_0000357,5254
108,,H,,,2743,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL617505,,,722.0,8,1,HEK293,B,,,BAO_0000219,13267
108,,D,,,2744,Homo sapiens,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,,Expert,,CHEMBL617506,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,14157
108,,D,,,2745,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,Expert,,CHEMBL617507,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,12936
108,,H,,,2746,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,,Expert,,CHEMBL617508,,,,8,1,,B,,,BAO_0000357,14068
108,,D,,,2747,Homo sapiens,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,,Expert,,CHEMBL857982,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,12936
108,,D,,,2748,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,,Expert,,CHEMBL617509,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,4540
108,,D,,,2749,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,,Expert,,CHEMBL617510,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,4540
108,,H,,,2750,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,,Autocuration,,CHEMBL617511,,,,8,1,,B,,,BAO_0000357,6166
108,,H,,,2751,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL617512,,,722.0,8,1,HEK293,B,,,BAO_0000219,17296
108,,H,,,2752,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL617749,,,722.0,8,1,HEK293,B,,,BAO_0000219,17296
108,,H,,,2753,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,Autocuration,,CHEMBL617750,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
108,,H,,,2754,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,Autocuration,,CHEMBL617751,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
108,,H,,,2755,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,,Expert,,CHEMBL617752,,,722.0,8,1,HEK293,B,,,BAO_0000219,14391
108,,H,,,2756,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",,Autocuration,,CHEMBL617753,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
108,,H,,,2757,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",,Expert,,CHEMBL617754,,,722.0,8,1,HEK293,B,,,BAO_0000219,15851
108,,D,,,2758,Homo sapiens,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,,Expert,,CHEMBL617755,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,15851
108,,H,,,2759,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",,Autocuration,,CHEMBL617756,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
108,,H,,,2760,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,,Expert,,CHEMBL617757,,,722.0,8,1,HEK293,B,,,BAO_0000219,3832
108,,H,,,2761,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,,Expert,,CHEMBL617758,,,722.0,8,1,HEK293,B,,,BAO_0000219,3833
108,,H,,,2762,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,,Autocuration,,CHEMBL617759,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,17451
108,,H,,,2763,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,,Autocuration,,CHEMBL617760,,,722.0,8,1,HEK293,B,,,BAO_0000219,4199
108,,H,,,2764,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,,Expert,,CHEMBL617761,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,1883
108,,D,,,2765,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617762,,9606.0,,9,1,,B,,,BAO_0000357,4321
108,,H,,,2766,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617763,,,,8,1,,B,,,BAO_0000357,14875
108,,H,,,2767,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,,Autocuration,,CHEMBL857983,,,722.0,8,1,HEK293,B,,,BAO_0000219,15146
108,,H,,,2768,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,,Autocuration,,CHEMBL617764,,,722.0,8,1,HEK293,B,,,BAO_0000219,5213
108,,H,,,2769,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,,Autocuration,,CHEMBL617765,,,308.0,8,1,HeLa,B,,,BAO_0000219,16404
108,,H,,,2770,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,,Autocuration,,CHEMBL617766,,,,8,1,,F,,,BAO_0000019,13267
108,,H,10000000.0,,2771,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,Hippocampus,Autocuration,,CHEMBL617767,,,,8,1,,F,,,BAO_0000221,13267
108,,H,,,2772,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,,Autocuration,,CHEMBL617768,,,722.0,8,1,HEK293,B,,,BAO_0000219,14818
108,,H,,,2773,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",,Autocuration,,CHEMBL617769,,,722.0,8,1,HEK293,B,,,BAO_0000219,4829
11864,,H,,,2774,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL858023,,,,8,1,,B,,,BAO_0000357,13463
11864,,H,945.0,,2775,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,Stomach,Autocuration,,CHEMBL617770,,,,8,1,,B,,,BAO_0000019,13463
11864,,H,945.0,,2776,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,Stomach,Autocuration,,CHEMBL617771,,,,8,1,,B,,,BAO_0000019,13463
11864,,H,,,2777,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,,Autocuration,,CHEMBL617772,,,625.0,8,1,A9,F,,,BAO_0000219,12652
11864,,H,,,2778,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,Autocuration,,CHEMBL617773,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,4682
11864,,H,,,2779,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,,Autocuration,,CHEMBL617850,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,4682
11864,,H,,,2780,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,,Autocuration,,CHEMBL617851,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,4682
11864,,H,,,2781,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617852,,,,8,1,,F,,,BAO_0000019,12652
12689,,H,945.0,,2782,Mus musculus,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,Stomach,Autocuration,,CHEMBL858024,,10090.0,,8,1,,B,,,BAO_0000019,13463
12689,,D,945.0,,2783,Rattus norvegicus,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,Stomach,Expert,,CHEMBL617853,,10116.0,,9,1,,B,,,BAO_0000019,13463
108,,H,,,2784,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,,Expert,,CHEMBL617854,,,,8,1,,B,,,BAO_0000357,13969
108,,H,,,2785,Sus scrofa,Binding affinity for 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL873477,,9823.0,,8,1,,B,,,BAO_0000357,13392
108,,H,,,2786,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617855,,,,8,1,,B,,,BAO_0000357,13392
108,,H,,,2787,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,,Expert,,CHEMBL617856,,,,8,1,,B,,,BAO_0000019,14430
108,,H,,,2788,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,,Autocuration,,CHEMBL617857,,,,8,1,,B,,,BAO_0000019,1742
108,,H,,,2789,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,,Autocuration,,CHEMBL617858,,,,8,1,,B,,,BAO_0000249,14286
108,,H,,,2790,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617859,,,,8,1,,B,,,BAO_0000357,5619
108,,H,,,2791,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617860,,,,8,1,,B,,,BAO_0000357,15086
108,,H,,,2792,,Binding activity radioligand.,,Autocuration,,CHEMBL617861,,,,8,1,,B,,,BAO_0000357,12861
108,,H,,,2793,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,Expert,,CHEMBL617862,,,,8,1,,B,,,BAO_0000019,12861
108,,H,,,2794,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,,Autocuration,,CHEMBL617863,,,,8,1,,B,,,BAO_0000019,12861
108,,H,,,2795,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,,Autocuration,,CHEMBL617864,,,,8,1,,B,,,BAO_0000249,12827
108,,H,,,2796,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,,Autocuration,,CHEMBL617649,,,,8,1,,B,,,BAO_0000249,12827
108,,H,,,2797,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,Expert,,CHEMBL617650,,9823.0,,8,1,,F,,,BAO_0000019,12919
108,,H,,,2798,Sus scrofa,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,,Expert,,CHEMBL617651,,9823.0,,8,1,,F,,,BAO_0000019,12919
108,,H,,,2799,Sus scrofa,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,,Autocuration,,CHEMBL617652,,9823.0,,8,1,,B,,,BAO_0000357,16429
108,,H,,,2800,Sus scrofa,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,,Autocuration,,CHEMBL857072,,9823.0,,8,1,,B,,,BAO_0000019,773
108,,H,,,2801,Sus scrofa,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617653,,9823.0,,8,1,,B,,,BAO_0000357,5033
12687,,H,,,2802,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,,Autocuration,,CHEMBL617654,,,,8,1,,B,,,BAO_0000019,12861
12689,,H,,,2803,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617655,,,,8,1,,F,,,BAO_0000019,14093
12689,,H,,,2804,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,,Expert,,CHEMBL617656,,,,8,1,,B,,,BAO_0000357,14970
12689,,H,,,2805,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL617657,,,,8,1,,B,,,BAO_0000357,14970
12689,,H,,,2806,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,,Autocuration,,CHEMBL617658,,,,8,1,,B,,,BAO_0000357,14970
12689,,D,,,2807,Rattus norvegicus,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617659,,10116.0,,9,1,,B,,,BAO_0000357,14178
12689,,D,,,2808,Rattus norvegicus,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617838,,10116.0,,9,1,,B,,,BAO_0000357,14178
12689,,D,,,2809,Rattus norvegicus,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,,Expert,,CHEMBL617839,,10116.0,,9,1,,B,,Brain membranes,BAO_0000249,14229
12689,,H,,,2810,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,,Autocuration,,CHEMBL617840,,,,8,1,,B,,,BAO_0000357,16532
12689,,H,,,2811,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,,Autocuration,,CHEMBL617841,,,,8,1,,B,,,BAO_0000019,14826
12689,,H,,,2812,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,,Autocuration,,CHEMBL875915,,,,8,1,,B,,,BAO_0000019,17211
12689,,H,,,2813,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,,Expert,,CHEMBL617842,In vitro,,,8,1,,B,,,BAO_0000219,17211
12689,,H,,,2814,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,,Expert,,CHEMBL617843,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,13246
12689,,H,,,2815,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,,Expert,,CHEMBL617844,,,,8,1,,B,,,BAO_0000357,13246
12689,,H,,,2816,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617845,,,,8,1,,B,,,BAO_0000357,12457
12689,,H,,,2817,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617846,,,723.0,8,1,NIH3T3,B,,,BAO_0000219,12457
12689,,H,,,2818,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,,Autocuration,,CHEMBL617847,,,,8,1,,B,,,BAO_0000357,4707
12689,,H,,,2819,,Binding affinity against 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617848,,,,8,1,,B,,,BAO_0000357,13297
12689,,H,,,2820,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,Autocuration,,CHEMBL617849,,,,8,1,,B,,,BAO_0000357,16633
12689,,H,,,2821,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,Expert,,CHEMBL621507,,,,8,1,,B,,,BAO_0000357,16133
12689,,H,,,2822,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,,Expert,,CHEMBL621508,,,,8,1,,B,,,BAO_0000357,16326
12689,,H,,,2823,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,,Autocuration,,CHEMBL621509,,,,8,1,,B,,,BAO_0000019,14423
12689,,H,,,2824,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,,Autocuration,,CHEMBL621510,,,,8,1,,B,,,BAO_0000019,15412
12689,,H,,,2825,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,,Autocuration,,CHEMBL621511,,,,8,1,,B,,,BAO_0000019,15412
12689,,H,,,2826,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL621512,,,625.0,8,1,A9,B,,,BAO_0000219,15558
12689,,H,,,2827,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,Autocuration,,CHEMBL621513,,,,8,1,,B,,,BAO_0000357,16633
12689,,H,,,2828,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,,Expert,,CHEMBL621514,,,,8,1,,B,,,BAO_0000357,6013
12689,,H,,,2829,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,,Expert,,CHEMBL621515,In vitro,,,8,1,,B,,,BAO_0000219,17175
12689,,H,,,2830,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,,Autocuration,,CHEMBL621516,,,,8,1,,B,,,BAO_0000219,12469
12689,,H,5383.0,,2831,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,Caudate-putamen,Autocuration,,CHEMBL621517,,,,8,1,,B,,,BAO_0000019,3682
12689,,H,,,2832,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,,Autocuration,,CHEMBL621518,,,,8,1,,B,,,BAO_0000357,4932
12689,,H,,,2833,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,,Autocuration,,CHEMBL621519,,,,8,1,,B,,,BAO_0000019,4932
12689,,H,,,2834,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL621520,,,,8,1,,B,,,BAO_0000357,3935
12689,,H,,,2835,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL621521,,,,8,1,,B,,,BAO_0000357,15818
12689,,H,,,2836,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL621522,,,,8,1,,B,,,BAO_0000357,15818
12689,,H,,,2837,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,,Expert,,CHEMBL621523,,,,8,1,,B,,,BAO_0000219,14749
12689,,H,,,2838,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL621524,,,,8,1,,B,,,BAO_0000357,15740
12689,,D,,,2839,Rattus norvegicus,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,,Expert,,CHEMBL621525,,10116.0,,9,1,,B,,,BAO_0000357,17133
12689,,H,,,2840,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,,Autocuration,,CHEMBL872921,,,,8,1,,B,,,BAO_0000357,16532
12689,,H,,,2841,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL621526,,,,8,1,,B,,,BAO_0000357,12369
12689,,H,,,2842,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,,Expert,,CHEMBL621527,,,,8,1,,B,,,BAO_0000219,12369
12689,,D,,,2843,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,,Expert,,CHEMBL617865,,10116.0,,9,1,,B,,,BAO_0000019,2309
12689,,H,,,2844,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617866,,,,8,1,,B,,,BAO_0000357,12953
12689,,H,,,2845,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,,Autocuration,,CHEMBL617867,,,,8,1,,B,,,BAO_0000019,12953
12689,,H,,,2846,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,,Autocuration,,CHEMBL617487,,,,8,1,,B,,,BAO_0000357,12953
12689,,H,,,2847,,Binding affinity for 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617488,,,,8,1,,B,,,BAO_0000357,12953
12689,,H,,,2848,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,,Autocuration,,CHEMBL617489,,,,8,1,,B,,,BAO_0000357,17133
12689,,H,,,2849,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,,Autocuration,,CHEMBL617490,,,,8,1,,B,,,BAO_0000019,17211
12689,,H,,,2850,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,,Autocuration,,CHEMBL617491,,,,8,1,,B,,,BAO_0000019,17211
12689,,H,,,2851,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,,Autocuration,,CHEMBL617492,,,,8,1,,B,,,BAO_0000019,14025
12689,,H,,,2852,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,,Autocuration,,CHEMBL617493,,,,8,1,,B,,,BAO_0000019,14998
12689,,H,,,2853,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,,Autocuration,,CHEMBL617494,,,,8,1,,B,,,BAO_0000357,4342
12689,,D,,,2854,Rattus norvegicus,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,,Expert,,CHEMBL617495,,10116.0,,9,1,,B,,,BAO_0000019,13735
12689,,H,,,2855,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL617496,,,,8,1,,B,,,BAO_0000357,13181
12689,,H,,,2856,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,,Autocuration,,CHEMBL617497,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,1883
12689,,H,,,2857,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL617498,,,,8,1,,B,,,BAO_0000357,15194
12689,,H,,,2858,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,,Autocuration,,CHEMBL617499,,,,8,1,,B,,,BAO_0000357,15194
12689,,H,,,2859,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617500,,,,8,1,,F,,,BAO_0000019,14579
108,,H,,,2860,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617501,,,,8,1,,B,,,BAO_0000357,4639
108,,H,,,2861,,Binding affinity towards 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617502,,,,8,1,,B,,,BAO_0000357,4820
227,,H,,,2862,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,,Autocuration,,CHEMBL617503,,,,8,1,,B,,,BAO_0000357,14442
227,,H,,,2863,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,,Autocuration,,CHEMBL617504,,,,8,1,,B,,,BAO_0000357,14755
227,,H,,,2864,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,,Autocuration,,CHEMBL617406,,,,8,1,,B,,,BAO_0000357,14744
227,,D,,,2865,Homo sapiens,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,,Expert,,CHEMBL617407,,9606.0,,9,1,,B,,,BAO_0000019,6857
227,,H,,,2866,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL617408,,,,8,1,,B,,,BAO_0000357,16209
227,,H,,,2867,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,Autocuration,,CHEMBL617409,,,,8,1,,B,,,BAO_0000357,15363
227,,H,,,2868,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,,Autocuration,,CHEMBL617410,,,,8,1,,B,,,BAO_0000357,15363
227,,H,,,2869,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,,Autocuration,,CHEMBL617411,,,,8,1,,B,,,BAO_0000357,15363
227,,H,,,2870,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,,Autocuration,,CHEMBL617412,,,,8,1,,B,,,BAO_0000019,17085
227,,D,,,2871,Homo sapiens,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,,Expert,,CHEMBL617774,,9606.0,,9,1,,B,,,BAO_0000357,17200
227,,D,,,2872,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,Expert,,CHEMBL617775,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,15851
227,,D,,,2873,Homo sapiens,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,,Expert,,CHEMBL617776,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,15851
227,,D,,,2874,Homo sapiens,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Expert,,CHEMBL617777,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,6857
227,,D,,,2875,Homo sapiens,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,,Expert,,CHEMBL617778,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,6857
227,,H,,,2876,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,Autocuration,,CHEMBL617779,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
227,,H,,,2877,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,,Expert,,CHEMBL617780,,,722.0,8,1,HEK293,B,,,BAO_0000219,15851
227,,H,,,2878,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",,Autocuration,,CHEMBL617781,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
227,,D,,,2879,Homo sapiens,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,,Expert,,CHEMBL617782,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,14157
227,,D,,,2880,Homo sapiens,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,,Expert,,CHEMBL617783,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,4540
227,,H,,,2881,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,,Autocuration,,CHEMBL617784,,,,8,1,,B,,,BAO_0000357,6166
227,,H,,,2882,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,,Autocuration,,CHEMBL617785,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
227,,H,,,2883,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,,Expert,,CHEMBL857984,,,722.0,8,1,HEK293,B,,,BAO_0000219,14391
227,,H,,,2884,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,,Expert,,CHEMBL617786,,,722.0,8,1,HEK293,B,,,BAO_0000219,3832
227,,H,,,2885,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,,Expert,,CHEMBL617787,,,722.0,8,1,HEK293,B,,,BAO_0000219,3833
227,,D,,,2886,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,,Expert,,CHEMBL617788,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,15851
227,,D,,,2887,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,,Expert,,CHEMBL617789,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,15851
227,,H,,,2888,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,,Autocuration,,CHEMBL617790,,,722.0,8,1,HEK293,B,,,BAO_0000219,4199
227,,H,,,2889,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,,Expert,,CHEMBL617791,,,485.0,8,1,CHO-K1,B,,,BAO_0000219,1883
227,,H,,,2890,,Binding affinity against 5-hydroxytryptamine 2B receptor,,Expert,,CHEMBL617608,,,,8,1,,B,,,BAO_0000357,4321
227,,H,,,2891,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,,Autocuration,,CHEMBL617609,,,722.0,8,1,HEK293,B,,,BAO_0000219,15146
227,,H,,,2892,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,,Autocuration,,CHEMBL617610,,,722.0,8,1,HEK293,B,,,BAO_0000219,5213
227,,H,,,2893,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,,Autocuration,,CHEMBL617611,,,722.0,8,1,HEK293,B,,,BAO_0000219,14818
227,,H,,,2894,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,Autocuration,,CHEMBL617612,,,722.0,8,1,HEK293,B,,,BAO_0000219,4829
227,,H,,,2895,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",,Autocuration,,CHEMBL617613,,,722.0,8,1,HEK293,B,,,BAO_0000219,4829
227,,H,,,2896,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,,Autocuration,,CHEMBL617614,,9986.0,,8,1,,B,,,BAO_0000019,14025
12688,,H,945.0,,2897,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,Stomach,Expert,,CHEMBL617615,,,,8,1,,B,,,BAO_0000019,13463
12688,,H,945.0,,2898,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,Stomach,Expert,,CHEMBL858114,,,,8,1,,B,,,BAO_0000357,7259
12688,,H,945.0,,2899,,Affinity against serotonergic receptor in the isolated rat stomach fundus,Stomach,Autocuration,,CHEMBL617616,,,,8,1,,B,,,BAO_0000357,7259
12688,,D,945.0,,2900,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,Stomach,Expert,,CHEMBL617617,,10116.0,,9,1,,F,,,BAO_0000019,7185
12688,,D,,,2901,Rattus norvegicus,Antagonistic against 5-hydroxytryptamine 2B receptor,,Expert,,CHEMBL875914,,10116.0,,9,1,,F,,,BAO_0000019,7185
12688,,H,945.0,,2902,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,Stomach,Autocuration,,CHEMBL617618,,,,8,1,,F,,,BAO_0000019,13267
12688,,D,945.0,,2903,Rattus norvegicus,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,Stomach,Expert,,CHEMBL617619,,10116.0,,9,1,,B,,,BAO_0000357,13735
12688,,H,,,2904,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,,Autocuration,,CHEMBL617620,,,,8,1,,F,,,BAO_0000019,15738
12688,,H,,,2905,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,,Autocuration,,CHEMBL617621,,,,8,1,,F,,,BAO_0000019,15738
12688,,H,,,2906,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,,Autocuration,,CHEMBL617622,,,,8,1,,F,,,BAO_0000019,15738
12688,,D,945.0,,2907,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,Expert,,CHEMBL617623,,10116.0,,9,1,,B,,,BAO_0000357,12936
12688,,D,945.0,,2908,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,Expert,,CHEMBL617624,,10116.0,,9,1,,B,,,BAO_0000357,12936
12688,,D,945.0,,2909,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,Expert,,CHEMBL617625,,10116.0,,9,1,,B,,,BAO_0000357,12936
12688,,D,945.0,,2910,Rattus norvegicus,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,Stomach,Expert,,CHEMBL617626,,10116.0,,9,1,,B,,,BAO_0000357,12936
12688,,H,945.0,,2911,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,Autocuration,,CHEMBL617627,,,,8,1,,F,,,BAO_0000019,16404
12688,,H,945.0,,2912,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,Expert,,CHEMBL617628,,,,8,1,,F,,,BAO_0000019,16404
12688,,H,945.0,,2913,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,Stomach,Autocuration,,CHEMBL617629,,,,8,1,,F,,,BAO_0000019,16404
12688,,H,945.0,,2914,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,Stomach,Autocuration,,CHEMBL858115,,,,8,1,,F,,,BAO_0000019,16404
12688,,D,945.0,,2915,Rattus norvegicus,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,Stomach,Expert,,CHEMBL617630,,10116.0,,9,1,,F,,,BAO_0000019,16404
12688,,H,1515.0,,2916,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,Thoracic aorta,Autocuration,,CHEMBL617631,,,,8,1,,F,,,BAO_0000019,16404
12688,,H,,,2917,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,Autocuration,,CHEMBL617632,,,,8,1,,B,,,BAO_0000357,7483
12688,,H,,,2918,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,,Expert,,CHEMBL617633,,,,8,1,,B,,,BAO_0000357,7483
12688,,H,,,2919,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,,Autocuration,,CHEMBL617634,,,,8,1,,B,,,BAO_0000357,7483
12688,,H,,,2920,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,,Autocuration,,CHEMBL617635,,,,8,1,,B,,,BAO_0000357,7483
12688,,D,945.0,,2922,Rattus norvegicus,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,Stomach,Autocuration,,CHEMBL617637,,10116.0,,9,1,,F,,,BAO_0000019,16404
227,,H,,,2923,,Binding affinity against 5-hydroxytryptamine 1A receptor,,Autocuration,,CHEMBL617638,,,,8,1,,B,,,BAO_0000357,6347
227,,H,,,2924,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,,Autocuration,,CHEMBL617639,,,,8,1,,B,,,BAO_0000357,4373
227,,H,,,2925,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,,Autocuration,,CHEMBL617640,,,,8,1,,B,,,BAO_0000357,4373
227,,H,,,2926,,Evaluated for the binding affinity to 5-HT 2B receptor,,Autocuration,,CHEMBL617641,,,,8,1,,B,,,BAO_0000357,4687
227,,H,,,2927,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,,Autocuration,,CHEMBL617642,,,,8,1,,B,,,BAO_0000357,16946
227,,H,,,2928,,Binding affinities against 5-hydroxytryptamine 2B receptor,,Autocuration,,CHEMBL617643,,,,8,1,,B,,,BAO_0000357,16633
227,,H,,,2929,,Binding affinities towards 5-hydroxytryptamine 2B receptor,,Autocuration,,CHEMBL617644,,,,8,1,,B,,,BAO_0000357,16633
227,,H,,,2930,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,,Autocuration,,CHEMBL617645,,,,8,1,,B,,,BAO_0000357,16633
108,,H,,,2931,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,Expert,,CHEMBL617646,,,,8,1,,B,,,BAO_0000357,15026
108,,H,,,2932,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,Autocuration,,CHEMBL617647,,9913.0,,8,1,,B,,,BAO_0000357,15738
108,,H,,,2933,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,,Autocuration,,CHEMBL617648,,9913.0,,8,1,,B,,,BAO_0000357,15738
108,,H,,,2934,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,,Autocuration,,CHEMBL617875,,9913.0,,8,1,,B,,,BAO_0000357,15738
108,,H,,,2935,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,,Autocuration,,CHEMBL617876,,9913.0,,8,1,,B,,,BAO_0000357,15738
108,,H,,,2936,Bos taurus,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,,Expert,,CHEMBL617877,,9913.0,,8,1,,B,,,BAO_0000357,16404
108,,H,,,2937,Bos taurus,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,,Expert,,CHEMBL617878,,9913.0,,8,1,,B,,,BAO_0000357,15026
108,,H,,,2938,Bos taurus,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,,Autocuration,,CHEMBL617879,,9913.0,,8,1,,B,,,BAO_0000357,15738
108,,H,,,2939,Cavia porcellus,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,,Autocuration,,CHEMBL617880,,10141.0,,8,1,,B,,,BAO_0000019,16312
20033,,D,2435.0,,2940,Cavia porcellus,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,Striatum,Intermediate,,CHEMBL617881,,10141.0,,9,1,,B,,,BAO_0000357,5486
51,,H,,,2941,,Binding affinity against 5-HT1A receptor,,Autocuration,,CHEMBL857073,,,,8,1,,B,,,BAO_0000357,5254
108,,H,,,2942,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,,Expert,,CHEMBL617882,,,449.0,8,1,CHO,F,,,BAO_0000219,3857
108,,D,,,2943,Homo sapiens,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,,Expert,,CHEMBL617883,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,6857
108,,H,,,2944,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,,Autocuration,,CHEMBL617884,,,,8,1,,F,,,BAO_0000219,4176
108,,H,,,2945,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,,Autocuration,,CHEMBL617885,,,449.0,8,1,CHO,B,,,BAO_0000219,6347
108,,H,,,2946,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",,Autocuration,,CHEMBL617886,,,449.0,8,1,CHO,B,,,BAO_0000219,6347
108,,D,,,2947,Homo sapiens,Inhibition of human 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL617887,,9606.0,,9,1,,B,,,BAO_0000357,16146
108,,H,,,2948,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),,Autocuration,,CHEMBL617888,,,,8,1,,B,,,BAO_0000357,3805
108,,H,,,2949,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,,Autocuration,,CHEMBL617889,,,,8,1,,B,,,BAO_0000019,3857
108,,H,,,2950,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617890,,,,8,1,,B,,,BAO_0000357,5635
108,,H,,,2951,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,Autocuration,,CHEMBL617891,,,,8,1,,B,,,BAO_0000357,5635
108,,H,,,2952,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,,Autocuration,,CHEMBL617892,,,,8,1,,B,,,BAO_0000357,5635
108,,H,,,2953,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,,Expert,,CHEMBL617893,,,449.0,8,1,CHO,B,,,BAO_0000219,4012
108,,H,,,2954,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,,Expert,,CHEMBL617894,,,449.0,8,1,CHO,B,,,BAO_0000219,6366
108,,H,,,2955,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,Expert,,CHEMBL617895,,,449.0,8,1,CHO,B,,,BAO_0000219,15949
108,,H,,,2956,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL617896,,,449.0,8,1,CHO,B,,,BAO_0000219,17211
108,,D,,,2957,Homo sapiens,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,,Expert,,CHEMBL617897,,9606.0,,9,1,,B,,,BAO_0000357,6491
108,,H,,,2958,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,,Autocuration,,CHEMBL617898,,,,8,1,,F,,,BAO_0000019,14093
108,,H,,,2959,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,,Autocuration,,CHEMBL617899,,,,8,1,,F,,,BAO_0000019,13481
108,,H,,,2960,Rattus norvegicus,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,,Expert,,CHEMBL617900,,10116.0,449.0,8,1,CHO,B,,,BAO_0000219,6347
108,,H,,,2961,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,,Autocuration,,CHEMBL617901,,,,8,1,,F,,,BAO_0000019,14093
108,,H,,,2962,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,,Autocuration,,CHEMBL617902,,,,8,1,,F,,,BAO_0000019,14093
108,,H,,,2963,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL617903,,,,8,1,,F,,,BAO_0000019,13481
108,,H,,,2964,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,,Autocuration,,CHEMBL617904,,,,8,1,,B,,,BAO_0000357,14442
108,,H,,,2965,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,,Autocuration,,CHEMBL617905,,,,8,1,,B,,,BAO_0000357,14442
108,,H,,,2966,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,,Autocuration,,CHEMBL617906,,,,8,1,,B,,,BAO_0000357,14442
108,,H,,,2967,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,,Autocuration,,CHEMBL617907,,,,8,1,,B,,,BAO_0000357,14755
108,,H,,,2968,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,,Autocuration,,CHEMBL617908,,,,8,1,,B,,,BAO_0000357,14744
108,,H,,,2969,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,,Expert,,CHEMBL620617,,,449.0,8,1,CHO,B,,,BAO_0000219,16659
108,,D,,,2970,Homo sapiens,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,,Expert,,CHEMBL620618,,9606.0,,9,1,,B,,,BAO_0000019,6857
108,,H,,,2971,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,,Expert,,CHEMBL620619,,,,8,1,,B,,,BAO_0000357,5635
108,,D,,,2972,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL620620,,9606.0,,9,1,,B,,,BAO_0000357,4234
108,,H,,,2973,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,,Autocuration,,CHEMBL620621,,,,8,1,,B,,,BAO_0000357,16209
104698,,D,,,2974,Rattus norvegicus,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,,Autocuration,,CHEMBL872920,,10116.0,,7,1,,B,,Membranes,BAO_0000249,5778
104698,,H,,,2975,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,,Autocuration,,CHEMBL620622,,,,6,1,,B,,,BAO_0000223,5094
104698,,D,,,2976,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,,Autocuration,,CHEMBL620623,,10116.0,,7,1,,B,,,BAO_0000019,809
104698,,H,,,2977,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,,Autocuration,,CHEMBL620624,,,,6,1,,B,,,BAO_0000019,1578
104698,,H,,,2978,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,,Autocuration,,CHEMBL620625,,,,6,1,,B,,,BAO_0000019,809
104698,,H,,,2979,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,,Autocuration,,CHEMBL620626,,,,6,1,,B,,,BAO_0000219,12469
104698,,H,,,2980,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,,Autocuration,,CHEMBL621307,,,,6,1,,B,,,BAO_0000019,14290
104698,,H,,,2981,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,,Autocuration,,CHEMBL621308,,,,6,1,,B,,,BAO_0000019,14290
104698,,H,,,2982,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,,Autocuration,,CHEMBL621309,,,,6,1,,B,,,BAO_0000223,10609
104698,,H,,,2983,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,,Autocuration,,CHEMBL621310,,,,6,1,,B,,,BAO_0000223,10609
104698,,H,,,2984,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,,Autocuration,,CHEMBL621311,,,,6,1,,B,,,BAO_0000223,10609
104698,,H,,,2985,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,Autocuration,,CHEMBL621502,,,,6,1,,B,,,BAO_0000249,15253
104698,,H,,,2986,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",,Autocuration,,CHEMBL621503,,,,6,1,,B,,,BAO_0000249,15253
104698,,H,,,2987,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,,Autocuration,,CHEMBL621504,,,,6,1,,B,,Membranes,BAO_0000249,11683
104698,,H,,,2988,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL621505,,,,6,1,,B,,,BAO_0000223,12092
104698,,H,,,2989,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,Autocuration,,CHEMBL621506,,,,6,1,,B,,,BAO_0000019,1946
104698,,H,,,2990,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,,Autocuration,,CHEMBL619781,,,,6,1,,B,,,BAO_0000223,11623
104698,,H,,,2991,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,,Autocuration,,CHEMBL619782,,,,6,1,,B,,,BAO_0000223,11623
104698,,H,,,2992,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,,Autocuration,,CHEMBL619783,,,,6,1,,B,,,BAO_0000019,14788
104698,,D,,,2993,Rattus norvegicus,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,,Autocuration,,CHEMBL619784,,10116.0,,7,1,,B,,,BAO_0000019,5432
104698,,H,,,2994,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,Autocuration,,CHEMBL619785,,,,6,1,,B,,,BAO_0000249,14826
104698,,H,,,2995,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL619786,,,,6,1,,B,,,BAO_0000223,2222
104698,,H,,,2996,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,,Autocuration,,CHEMBL619787,,,,6,1,,B,,,BAO_0000019,11963
104698,,H,,,2997,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,,Autocuration,,CHEMBL872925,,,,6,1,,B,,,BAO_0000019,14145
104698,,H,,,2998,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,,Autocuration,,CHEMBL619788,,,,6,1,,B,,,BAO_0000019,17819
104698,,H,,,2999,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,Autocuration,,CHEMBL619789,,,,6,1,,B,,,BAO_0000249,10394
104698,,H,,,3000,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,,Autocuration,,CHEMBL619790,,,,6,1,,B,,,BAO_0000249,10394
104698,,H,,,3001,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,Autocuration,,CHEMBL619791,,,,6,1,,B,,,BAO_0000019,15034
104698,,H,,,3002,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,,Autocuration,,CHEMBL619792,,,,6,1,,B,,,BAO_0000019,691
104698,,H,,,3003,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,,Autocuration,,CHEMBL619793,,,,6,1,,B,,Membranes,BAO_0000249,12092
104698,,D,,,3004,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL619794,,10116.0,,7,1,,B,,,BAO_0000223,11752
104698,,H,955.0,,3005,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,Brain,Autocuration,,CHEMBL619795,,,,6,1,,B,,,BAO_0000221,11752
104698,,H,,,3006,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,,Autocuration,,CHEMBL619796,,,,6,1,,B,,,BAO_0000019,301
104698,,H,,,3007,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,,Autocuration,,CHEMBL620448,,,,6,1,,B,,,BAO_0000223,16532
104698,,H,,,3008,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,Autocuration,,CHEMBL620449,,,,6,1,,B,,,BAO_0000223,16532
104698,,H,,,3009,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,,Autocuration,,CHEMBL620450,,,,6,1,,B,,,BAO_0000223,12092
104698,,H,,,3010,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,,Autocuration,,CHEMBL620451,,,,6,1,,B,,,BAO_0000223,11684
104698,,H,,,3011,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,,Autocuration,,CHEMBL620631,,,,6,1,,B,,,BAO_0000223,11684
104698,,H,,,3012,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,,Autocuration,,CHEMBL620632,,,,6,1,,B,,,BAO_0000019,12953
104698,,H,,,3013,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,,Autocuration,,CHEMBL620633,,,,6,1,,B,,,BAO_0000019,12953
104698,,H,,,3014,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,,Autocuration,,CHEMBL620634,,,,6,1,,B,,,BAO_0000223,12953
104698,,H,,,3015,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,,Autocuration,,CHEMBL620635,,,,6,1,,B,,,BAO_0000019,12861
104698,,H,,,3016,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620636,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3017,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,,Autocuration,,CHEMBL620637,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3018,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620638,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3019,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620639,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3020,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620640,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3021,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,,Autocuration,,CHEMBL620641,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3022,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620642,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3023,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620643,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3024,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620644,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3025,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620645,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3026,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,,Autocuration,,CHEMBL620646,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3027,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620647,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3028,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620648,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3029,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620649,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3030,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL620650,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3031,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,,Autocuration,,CHEMBL620651,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3032,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,,Autocuration,,CHEMBL872875,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3033,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,,Autocuration,,CHEMBL620652,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3034,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,,Autocuration,,CHEMBL620653,,,,6,1,,F,,,BAO_0000019,10609
104698,,H,,,3035,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,,Autocuration,,CHEMBL857076,,,,6,1,,B,,,BAO_0000019,12861
104698,,D,,,3036,Rattus norvegicus,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL620654,,10116.0,,7,1,,B,,,BAO_0000019,12861
104698,,H,,,3037,,Binding activity radioligand.,,Autocuration,,CHEMBL620655,,,,6,1,,B,,,BAO_0000223,12861
104698,,H,,,3038,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,,Autocuration,,CHEMBL620656,,,,6,1,,B,,Brain membranes,BAO_0000249,10728
104698,,H,,,3039,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,,Autocuration,,CHEMBL620657,,,,6,1,,B,,Brain membranes,BAO_0000249,10728
108,,H,,,3040,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,,Autocuration,,CHEMBL620658,,,,8,1,,B,,,BAO_0000357,5163
108,,H,,,3041,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,,Autocuration,,CHEMBL620659,,,,8,1,,B,,,BAO_0000357,5163
108,,H,,,3042,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,,Autocuration,,CHEMBL620660,,,,8,1,,B,,,BAO_0000357,6011
108,,H,,,3043,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL620661,,,,8,1,,B,,,BAO_0000357,5014
108,,H,,,3044,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL620662,,,,8,1,,B,,,BAO_0000357,5635
108,,H,,,3045,,Affinity for 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL620663,,,,8,1,,B,,,BAO_0000357,5163
108,,H,,,3046,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,,Autocuration,,CHEMBL620664,,,,8,1,,B,,,BAO_0000357,6841
108,,H,,,3047,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,,Expert,,CHEMBL620665,,,,8,1,,B,,,BAO_0000357,6119
108,,H,,,3048,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,,Autocuration,,CHEMBL620666,,,,8,1,,B,,,BAO_0000357,4373
108,,H,,,3049,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,,Autocuration,,CHEMBL620667,,,,8,1,,B,,,BAO_0000357,1633
108,,H,,,3050,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,,Expert,,CHEMBL620668,,,,8,1,,B,,,BAO_0000357,1633
108,,H,,,3051,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,,Autocuration,,CHEMBL620669,,,,8,1,,B,,,BAO_0000357,4373
108,,H,,,3052,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL620670,,,,8,1,,B,,,BAO_0000357,6576
108,,H,,,3053,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL620671,,,,8,1,,B,,,BAO_0000357,4687
108,,H,,,3054,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,,Autocuration,,CHEMBL620672,,,,8,1,,B,,,BAO_0000357,12146
108,,H,,,3055,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,,Autocuration,,CHEMBL620673,,,,8,1,,B,,,BAO_0000357,12146
108,,H,,,3056,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL620674,,,,8,1,,B,,,BAO_0000357,16946
108,,H,,,3057,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL620675,,,,8,1,,B,,,BAO_0000357,14159
108,,H,,,3058,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,,Autocuration,,CHEMBL620676,,,,8,1,,B,,,BAO_0000357,16700
108,,H,,,3059,,Affinity against 5-hydroxytryptamine 2C receptor,,Autocuration,,CHEMBL621382,,,,8,1,,B,,,BAO_0000357,3269
108,,D,,,3060,Homo sapiens,Binding affinity against 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL621383,,9606.0,,9,1,,B,,,BAO_0000357,1274
108,,H,,,3061,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,,Autocuration,,CHEMBL621384,,,,8,1,,B,,,BAO_0000357,1317
144,,H,,,3062,Bos taurus,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,,Autocuration,,CHEMBL621385,,9913.0,,8,1,,B,,,BAO_0000357,5834
144,,H,,,3063,Bos taurus,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,,Autocuration,,CHEMBL617989,,9913.0,,8,1,,B,,,BAO_0000357,11147
104714,,H,,,3064,Cavia porcellus,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,,Expert,,CHEMBL617990,,10141.0,,4,1,,F,,,BAO_0000019,14145
104714,,H,2116.0,,3065,Cavia porcellus,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Ileum,Autocuration,,CHEMBL875085,,10141.0,,4,1,,B,,,BAO_0000221,10561
104714,,H,,,3066,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,,Autocuration,,CHEMBL617991,,10141.0,,4,1,,F,,,BAO_0000019,15847
104714,,H,,,3067,Cavia porcellus,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,,Autocuration,,CHEMBL617992,,10141.0,,4,1,,F,,,BAO_0000019,15847
104714,,H,2116.0,,3068,Cavia porcellus,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,Ileum,Autocuration,,CHEMBL617993,,10141.0,,4,1,,B,,,BAO_0000221,10561
104714,,H,2116.0,,3069,Cavia porcellus,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,Ileum,Autocuration,,CHEMBL617994,,10141.0,,4,1,,B,,,BAO_0000221,11454
104714,,H,,,3070,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,,Autocuration,,CHEMBL617995,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3071,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,,Autocuration,,CHEMBL617996,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3072,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,,Autocuration,,CHEMBL617997,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3073,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,,Autocuration,,CHEMBL617998,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3074,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,,Autocuration,,CHEMBL617999,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3075,Cavia porcellus,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,,Autocuration,,CHEMBL618000,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,2116.0,,3076,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",Ileum,Autocuration,,CHEMBL617815,,10141.0,,4,1,,F,,,BAO_0000221,15253
104714,,H,2116.0,,3077,Cavia porcellus,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",Ileum,Autocuration,,CHEMBL617816,,10141.0,,4,1,,F,,,BAO_0000221,15253
104714,,H,2116.0,,3078,Cavia porcellus,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,Ileum,Autocuration,,CHEMBL617817,,10141.0,,4,1,,F,,,BAO_0000221,11963
104714,,H,2116.0,,3079,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,Ileum,Autocuration,,CHEMBL617818,,10141.0,,4,1,,B,,,BAO_0000221,1946
104714,,H,2116.0,,3080,Cavia porcellus,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,Ileum,Autocuration,,CHEMBL617819,,10141.0,,4,1,,B,,,BAO_0000221,1946
104714,,H,,,3081,Cavia porcellus,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,,Autocuration,,CHEMBL617820,,10141.0,,4,1,,B,,,BAO_0000223,12045
104714,,H,2116.0,,3082,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,Autocuration,,CHEMBL617821,,10141.0,,4,1,,B,,,BAO_0000221,1559
104714,,H,2116.0,,3083,Cavia porcellus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,Autocuration,,CHEMBL617822,,10141.0,,4,1,,F,,,BAO_0000221,273
104714,,H,2116.0,,3084,Cavia porcellus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),Ileum,Autocuration,,CHEMBL617823,,10141.0,,4,1,,F,,,BAO_0000221,273
104714,,H,2116.0,,3085,Cavia porcellus,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,Ileum,Autocuration,,CHEMBL617824,,10141.0,,4,1,,F,,,BAO_0000221,188
104714,,H,2116.0,,3086,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,Ileum,Autocuration,,CHEMBL617825,,10141.0,,4,1,,F,,,BAO_0000221,12919
104714,,H,2116.0,,3087,Cavia porcellus,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,Ileum,Autocuration,,CHEMBL617826,,10141.0,,4,1,,F,,,BAO_0000221,12918
104714,,H,2116.0,,3088,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,Autocuration,,CHEMBL617827,,10141.0,,4,1,,B,,,BAO_0000221,1559
104714,,H,2116.0,,3089,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,Autocuration,,CHEMBL617828,,10141.0,,4,1,,F,,,BAO_0000221,273
104714,,H,2116.0,,3090,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,Ileum,Autocuration,,CHEMBL617829,,10141.0,,4,1,,B,,,BAO_0000221,1559
104714,,H,2116.0,,3091,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,Ileum,Autocuration,,CHEMBL617830,,10141.0,,4,1,,B,,,BAO_0000221,1559
104714,,H,2116.0,,3092,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,Ileum,Autocuration,,CHEMBL617831,,10141.0,,4,1,,B,,,BAO_0000221,1559
104714,,H,2116.0,,3093,Cavia porcellus,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,Ileum,Autocuration,,CHEMBL617832,,10141.0,,4,1,,B,,,BAO_0000221,14424
22226,,U,,,3094,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,,Autocuration,,CHEMBL617833,,10141.0,,0,1,,B,,,BAO_0000019,13181
51,,H,,,3095,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,,Autocuration,,CHEMBL617834,,,,8,1,,B,,,BAO_0000357,5486
104714,,D,,,3096,Homo sapiens,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,,Expert,,CHEMBL617835,,9606.0,,5,1,,B,,,BAO_0000223,6491
104714,,H,,,3097,,Binding affinity towards 5-HT3 receptor,,Autocuration,,CHEMBL617836,,,,4,1,,B,,,BAO_0000223,6013
104714,,H,,,3098,,Binding activity radioligand.,,Autocuration,,CHEMBL617837,,,,4,1,,B,,,BAO_0000223,12861
104714,,H,,,3099,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,,Autocuration,,CHEMBL620392,,,,4,1,,B,,,BAO_0000019,12861
104714,,H,,,3100,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL620393,,,,4,1,,B,,,BAO_0000223,5104
104714,,H,,,3101,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL620394,,,,4,1,,B,,,BAO_0000223,5105
104714,,H,,,3102,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,,Autocuration,,CHEMBL620395,,,,4,1,,B,,,BAO_0000223,5104
22226,,U,,,3103,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL620396,,,,0,1,,B,,,BAO_0000019,3935
105030,,H,,,3104,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,,Expert,,CHEMBL620582,,,433.0,4,1,NG108-15,B,,,BAO_0000219,13657
105030,,H,,,3105,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",,Autocuration,,CHEMBL620583,In vivo,,,4,1,,B,,,BAO_0000218,10369
105030,,H,,,3106,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,Autocuration,,CHEMBL620584,,,,4,1,,B,,,BAO_0000019,10369
105030,,H,,,3107,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,,Autocuration,,CHEMBL620585,,,,4,1,,B,,,BAO_0000224,12918
105030,,H,,,3108,,Compound was evaluated for the binding affinity at 5- HT3 receptor,,Autocuration,,CHEMBL620586,,,,4,1,,B,,,BAO_0000224,12918
105030,,H,,,3109,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),,Autocuration,,CHEMBL620587,,,,4,1,,B,,,BAO_0000019,10369
105030,,H,,,3110,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,Autocuration,,CHEMBL620588,,,,4,1,,B,,,BAO_0000019,773
105030,,H,,,3111,,5-hydroxytryptamine 3 receptor agonism in mouse,,Autocuration,,CHEMBL620589,,,,4,1,,F,,,BAO_0000218,12918
105030,,H,,,3112,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,,Autocuration,,CHEMBL620590,,,,4,1,,B,,,BAO_0000219,10561
105030,,H,,,3113,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,Autocuration,,CHEMBL617956,,,,4,1,,B,,,BAO_0000019,12827
105030,,H,,,3114,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,,Autocuration,,CHEMBL617957,,,,4,1,,B,,,BAO_0000019,12827
105030,,H,,,3115,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,,Autocuration,,CHEMBL617958,,,,4,1,,B,,,BAO_0000224,12918
105030,,H,,,3116,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,Autocuration,,CHEMBL617959,,,,4,1,,B,,,BAO_0000219,273
105030,,H,,,3117,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,,Autocuration,,CHEMBL617960,,,,4,1,,B,,,BAO_0000219,273
105030,,H,,,3118,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,Autocuration,,CHEMBL617961,,,,4,1,,B,,,BAO_0000224,10561
105030,,H,,,3119,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,,Autocuration,,CHEMBL617962,In vitro,,,4,1,,B,,,BAO_0000219,5033
105030,,H,,,3120,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,,Autocuration,,CHEMBL617963,,,339.0,4,1,N1E-115,B,,,BAO_0000219,16429
11765,,H,,,3121,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,Autocuration,,CHEMBL617964,,,,8,1,,B,,,BAO_0000019,10322
11765,,H,,,3122,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,,Autocuration,,CHEMBL617965,,,,8,1,,B,,,BAO_0000219,14331
10630,,D,,,3123,Mus musculus,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,,Autocuration,,CHEMBL617966,,10090.0,,9,1,,B,,,BAO_0000357,13462
17106,,H,,,3124,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,,Autocuration,,CHEMBL857074,,,,8,1,,B,,,BAO_0000019,12861
144,,H,,,3125,Sus scrofa,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL617967,,9823.0,,8,1,,B,,,BAO_0000357,15086
144,,H,,,3126,Sus scrofa,Binding activity radioligand.,,Autocuration,,CHEMBL617968,,9823.0,,8,1,,B,,,BAO_0000357,12861
104714,,H,,,3127,Oryctolagus cuniculus,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,,Autocuration,,CHEMBL617969,,9986.0,,4,1,,B,,,BAO_0000223,10561
104714,,H,,,3128,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,,Autocuration,,CHEMBL617970,,9986.0,,4,1,,B,,,BAO_0000223,10561
104714,,H,,,3129,Oryctolagus cuniculus,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,,Autocuration,,CHEMBL617971,,9986.0,,4,1,,B,,,BAO_0000223,10561
104714,,H,,,3130,Oryctolagus cuniculus,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,Autocuration,,CHEMBL617972,,9986.0,,4,1,,B,,,BAO_0000019,10561
104714,,H,,,3131,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Autocuration,,CHEMBL617973,,9986.0,,4,1,,F,,,BAO_0000019,273
104714,,H,,,3132,Oryctolagus cuniculus,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Autocuration,,CHEMBL617974,,9986.0,,4,1,,F,,,BAO_0000019,273
104714,,H,2116.0,,3133,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),Ileum,Autocuration,,CHEMBL617975,,9986.0,,4,1,,F,,,BAO_0000221,273
104714,,H,,,3134,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Autocuration,,CHEMBL617976,,9986.0,,4,1,,F,,,BAO_0000019,273
104714,,H,,,3135,Oryctolagus cuniculus,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Autocuration,,CHEMBL617977,,9986.0,,4,1,,F,,,BAO_0000019,273
104714,,H,,,3136,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),,Autocuration,,CHEMBL617978,,9986.0,,4,1,,F,,,BAO_0000019,273
104714,,H,,,3137,Oryctolagus cuniculus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),,Autocuration,,CHEMBL617979,,9986.0,,4,1,,F,,,BAO_0000019,273
104714,,H,,,3138,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,,Autocuration,,CHEMBL617980,,9986.0,449.0,4,1,CHO,B,,,BAO_0000219,13047
104698,,D,,,3139,Rattus norvegicus,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL617981,,10116.0,,7,1,,B,,,BAO_0000019,1650
12020,,H,,,3140,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),,Autocuration,,CHEMBL617982,,,,8,1,,B,,,BAO_0000019,16288
12020,,H,,,3141,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),,Autocuration,,CHEMBL617983,,,,8,1,,B,,,BAO_0000357,16288
104698,,D,,,3142,Rattus norvegicus,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,,Autocuration,,CHEMBL617984,,10116.0,,7,1,,B,,,BAO_0000019,10254
104698,,H,,,3143,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",,Autocuration,,CHEMBL617985,,,,6,1,,B,,,BAO_0000019,14532
104698,,H,948.0,,3144,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Heart,Autocuration,,CHEMBL617986,In vivo,,,6,1,,F,,,BAO_0000218,13392
104698,,H,948.0,,3145,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Heart,Autocuration,,CHEMBL617987,,,,6,1,,F,,,BAO_0000019,13392
104698,,H,948.0,,3146,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",Heart,Autocuration,,CHEMBL617988,,,,6,1,,F,,,BAO_0000019,13392
104698,,H,948.0,,3147,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",Heart,Autocuration,,CHEMBL617792,,,,6,1,,F,,,BAO_0000019,13392
104698,,H,948.0,,3148,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",Heart,Autocuration,,CHEMBL617793,,,,6,1,,F,,,BAO_0000019,13392
104698,,H,,,3149,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",,Autocuration,,CHEMBL617794,,,,6,1,,F,,,BAO_0000019,13392
104698,,H,,,3150,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,Autocuration,,CHEMBL617795,,,,6,1,,F,,,BAO_0000019,13392
104698,,H,,,3151,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",,Autocuration,,CHEMBL617796,,,,6,1,,F,,,BAO_0000019,13392
104698,,H,,,3152,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",,Autocuration,,CHEMBL617797,,,,6,1,,F,,,BAO_0000019,13392
104698,,D,,,3153,Rattus norvegicus,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),,Autocuration,,CHEMBL617798,In vivo,10116.0,,7,1,,F,,,BAO_0000218,1089
104698,,H,,,3154,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),,Autocuration,,CHEMBL617799,In vivo,,,6,1,,F,,,BAO_0000218,1089
104698,,D,,,3155,Rattus norvegicus,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617800,In vivo,10116.0,,7,1,,F,,,BAO_0000218,11454
104698,,D,,,3156,Rattus norvegicus,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,,Autocuration,,CHEMBL617801,,10116.0,,7,1,,F,,,BAO_0000019,11454
104698,,D,,,3157,Rattus norvegicus,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,,Autocuration,,CHEMBL617802,In vivo,10116.0,,7,1,,F,,,BAO_0000218,12205
104698,,D,,,3158,Rattus norvegicus,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),,Autocuration,,CHEMBL617803,,10116.0,,7,1,,F,,,BAO_0000019,1089
104698,,H,,,3159,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,Autocuration,,CHEMBL617804,,,,6,1,,B,,,BAO_0000019,5094
104698,,D,,,3160,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL617805,,10116.0,,7,1,,B,,,BAO_0000019,2622
104698,,H,,,3161,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL617806,,,,6,1,,B,,,BAO_0000223,245
104698,,H,,,3162,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,,Autocuration,,CHEMBL617807,,,,6,1,,B,,,BAO_0000019,14788
104698,,H,,,3163,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,,Autocuration,,CHEMBL617808,,,,6,1,,B,,,BAO_0000019,14788
104698,,H,,,3164,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,,Autocuration,,CHEMBL617809,,,,6,1,,B,,,BAO_0000249,3020
104698,,H,,,3165,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,,Autocuration,,CHEMBL617810,,,,6,1,,B,,,BAO_0000019,1742
104698,,H,955.0,,3166,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,Brain,Autocuration,,CHEMBL617811,,,,6,1,,B,,,BAO_0000249,17394
104698,,H,955.0,,3167,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,Brain,Autocuration,,CHEMBL617812,,,,6,1,,B,,,BAO_0000221,17394
104698,,H,,,3168,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,,Autocuration,,CHEMBL617813,,,,6,1,,B,,,BAO_0000249,17394
104698,,H,,,3169,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,,Autocuration,,CHEMBL617814,,,,6,1,,B,,,BAO_0000249,14286
104698,,H,,,3170,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,,Autocuration,,CHEMBL617698,,,,6,1,,B,,,BAO_0000019,14178
104698,,D,,,3171,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,,Autocuration,,CHEMBL617699,,10116.0,,7,1,,B,,,BAO_0000019,14178
104698,,D,,,3172,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,,Autocuration,,CHEMBL617700,,10116.0,,7,1,,B,,,BAO_0000019,14178
104698,,D,,,3173,Rattus norvegicus,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL617701,,10116.0,,7,1,,B,,,BAO_0000223,14178
104698,,H,,,3174,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,,Autocuration,,CHEMBL617702,,,,6,1,,B,,,BAO_0000019,15034
104698,,H,,,3175,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",,Autocuration,,CHEMBL617703,,,,6,1,,B,,Membranes,BAO_0000249,1089
104698,,D,,,3176,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,,Autocuration,,CHEMBL617704,,10116.0,,7,1,,B,,,BAO_0000019,1089
104698,,H,,,3177,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,,Autocuration,,CHEMBL617705,,,,6,1,,B,,,BAO_0000223,16532
104698,,D,,,3178,Rattus norvegicus,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL617706,,10116.0,,7,1,,B,,,BAO_0000223,12801
104698,,H,,,3179,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),,Autocuration,,CHEMBL617707,,,433.0,6,1,NG108-15,B,,,BAO_0000219,15194
104698,,H,,,3180,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,,Autocuration,,CHEMBL617708,,,433.0,6,1,NG108-15,B,,,BAO_0000219,15194
104698,,H,,,3181,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,,Autocuration,,CHEMBL617709,,,,6,1,,B,,,BAO_0000019,15194
104698,,H,,,3182,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,,Autocuration,,CHEMBL617710,,,,6,1,,B,,,BAO_0000019,15194
104698,,H,,,3183,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,,Autocuration,,CHEMBL882925,,,,6,1,,B,,,BAO_0000019,15194
104698,,H,,,3184,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,,Autocuration,,CHEMBL617711,,,,6,1,,B,,,BAO_0000019,15194
104698,,H,,,3185,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,,Autocuration,,CHEMBL617712,,,,6,1,,F,,,BAO_0000019,10610
104698,,D,,,3186,Rattus norvegicus,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,,Autocuration,,CHEMBL617713,,10116.0,,7,1,,F,,,BAO_0000019,10355
104698,,H,,,3187,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",,Autocuration,,CHEMBL617714,,,,6,1,,F,,,BAO_0000019,691
104698,,H,,,3188,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,,Autocuration,,CHEMBL617715,,,,6,1,,F,,,BAO_0000218,10611
104698,,H,,,3189,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,,Autocuration,,CHEMBL617716,In vivo,,,6,1,,F,,,BAO_0000218,12801
104698,,H,,,3190,,Inhibition of 5-HT evoked reflex bradycardia in rat.,,Autocuration,,CHEMBL617717,,,,6,1,,F,,,BAO_0000218,10609
104698,,H,,,3191,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617718,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3192,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617719,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3193,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),,Autocuration,,CHEMBL617720,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,D,,,3194,Rattus norvegicus,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617721,In vivo,10116.0,,7,1,,F,,,BAO_0000218,11454
104698,,H,,,3195,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617722,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3196,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,,Autocuration,,CHEMBL617723,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3197,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617724,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3198,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617725,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3199,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617726,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3200,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617727,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3201,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617728,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3202,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617729,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3203,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617730,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3204,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617731,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3205,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617732,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3206,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617733,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3207,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617734,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3208,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,,Autocuration,,CHEMBL872874,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3209,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,,Autocuration,,CHEMBL617735,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3210,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,,Autocuration,,CHEMBL617736,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3211,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,,Autocuration,,CHEMBL617737,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3212,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,,Autocuration,,CHEMBL617738,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3213,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617739,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3214,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617740,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3215,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617741,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3216,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617742,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3217,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617743,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3218,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617744,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3219,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,,Autocuration,,CHEMBL617745,In vivo,,,6,1,,F,,,BAO_0000218,11454
104698,,H,,,3220,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",,Autocuration,,CHEMBL617746,,,,6,1,,F,,,BAO_0000218,670
104698,,H,,,3221,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",,Autocuration,,CHEMBL617747,,,,6,1,,F,,,BAO_0000218,670
104698,,H,,,3222,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,,Autocuration,,CHEMBL617748,In vivo,,,6,1,,F,,,BAO_0000218,10321
104698,,H,,,3223,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,,Autocuration,,CHEMBL618909,In vivo,,,6,1,,F,,,BAO_0000218,10321
104698,,H,,,3224,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,,Autocuration,,CHEMBL618910,In vivo,,,6,1,,F,,,BAO_0000218,10321
104698,,H,,,3225,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,,Autocuration,,CHEMBL618911,In vivo,,,6,1,,F,,,BAO_0000218,10321
104698,,H,,,3226,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,,Autocuration,,CHEMBL618912,In vivo,,,6,1,,F,,,BAO_0000218,10321
104698,,H,,,3227,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),,Autocuration,,CHEMBL618913,In vivo,,,6,1,,F,,,BAO_0000218,10322
104698,,H,,,3228,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,Autocuration,,CHEMBL618914,,,,6,1,,F,,,BAO_0000019,15412
104698,,H,,,3229,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,,Autocuration,,CHEMBL618915,,,,6,1,,F,,,BAO_0000019,15412
104698,,D,,,3230,Rattus norvegicus,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618916,,10116.0,,7,1,,B,,,BAO_0000223,15412
104698,,H,,,3231,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,,Autocuration,,CHEMBL618917,,,,6,1,,F,,,BAO_0000019,15412
104698,,D,10000000.0,,3232,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,Hippocampus,Intermediate,,CHEMBL618918,,,,7,1,,B,,,BAO_0000221,15412
104698,,D,,,3233,Rattus norvegicus,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,,Autocuration,,CHEMBL618919,,10116.0,,7,1,,B,,,BAO_0000019,15412
104698,,D,,,3234,Rattus norvegicus,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618920,,10116.0,,7,1,,B,,,BAO_0000019,17394
104698,,H,,,3235,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618921,,,,6,1,,B,,,BAO_0000223,12457
104698,,H,,,3236,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618922,,,,6,1,,B,,,BAO_0000019,12457
104698,,H,,,3237,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,,Autocuration,,CHEMBL618923,,,,6,1,,B,,,BAO_0000019,12205
104698,,H,,,3238,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,,Autocuration,,CHEMBL618924,,,,6,1,,B,,,BAO_0000019,14532
104698,,H,,,3239,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,,Autocuration,,CHEMBL618925,,,,6,1,,B,,,BAO_0000019,1122
104698,,H,,,3240,,Binding affinity towards 5-HT3 receptor in rat was evaluated,,Autocuration,,CHEMBL618926,,,,6,1,,B,,,BAO_0000019,5094
20033,,D,2116.0,,3241,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,Ileum,Intermediate,,CHEMBL618927,,10141.0,,9,1,,F,,,BAO_0000221,809
20033,,D,2116.0,,3242,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,Ileum,Intermediate,,CHEMBL618928,,10141.0,,9,1,,F,,,BAO_0000221,809
20033,,D,2116.0,,3243,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",Ileum,Intermediate,,CHEMBL618929,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,2116.0,,3244,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",Ileum,Intermediate,,CHEMBL618930,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,2116.0,,3245,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Ileum,Intermediate,,CHEMBL618931,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,2116.0,,3246,Cavia porcellus,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",Ileum,Intermediate,,CHEMBL619594,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,2116.0,,3247,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",Ileum,Intermediate,,CHEMBL619595,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,2116.0,,3248,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,Ileum,Intermediate,,CHEMBL619596,,10141.0,,9,1,,F,,,BAO_0000221,13961
20033,,D,2116.0,,3249,Cavia porcellus,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,Ileum,Intermediate,,CHEMBL619755,,10141.0,,9,1,,F,,,BAO_0000221,13961
20033,,D,2116.0,,3250,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,Ileum,Intermediate,,CHEMBL619756,,10141.0,,9,1,,F,,,BAO_0000221,809
20033,,D,2116.0,,3251,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,Ileum,Intermediate,,CHEMBL619757,,10141.0,,9,1,,F,,,BAO_0000221,809
20033,,D,2116.0,,3252,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,Ileum,Intermediate,,CHEMBL619758,,10141.0,,9,1,,F,,,BAO_0000221,809
20033,,D,2116.0,,3253,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",Ileum,Intermediate,,CHEMBL619759,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,2116.0,,3254,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",Ileum,Intermediate,,CHEMBL619760,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,2116.0,,3255,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",Ileum,Intermediate,,CHEMBL619761,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,2116.0,,3256,Cavia porcellus,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,Ileum,Intermediate,,CHEMBL619762,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,2116.0,,3257,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Ileum,Intermediate,,CHEMBL619763,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,2116.0,,3258,Cavia porcellus,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",Ileum,Intermediate,,CHEMBL617868,,10141.0,,9,1,,F,,,BAO_0000221,14290
20033,,D,,,3259,Cavia porcellus,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,,Intermediate,,CHEMBL617869,,10141.0,,9,1,,B,,,BAO_0000357,15034
20033,,D,2435.0,,3260,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,Intermediate,,CHEMBL882926,,10141.0,,9,1,,B,,,BAO_0000249,5094
20033,,D,2435.0,,3261,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,Intermediate,,CHEMBL617870,,10141.0,,9,1,,B,,,BAO_0000249,5094
20033,,D,2435.0,,3262,Cavia porcellus,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,Striatum,Intermediate,,CHEMBL617871,,10141.0,,9,1,,B,,,BAO_0000357,5399
20033,,D,2435.0,,3263,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,Striatum,Intermediate,,CHEMBL617872,,10141.0,,9,1,,B,,,BAO_0000357,17394
20033,,D,2435.0,,3264,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Striatum,Intermediate,,CHEMBL617873,,10141.0,,9,1,,B,,,BAO_0000357,17394
20033,,D,2435.0,,3265,Cavia porcellus,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,Striatum,Intermediate,,CHEMBL617874,,10141.0,,9,1,,B,,,BAO_0000357,17394
20033,,D,2116.0,,3266,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,Ileum,Intermediate,,CHEMBL619067,,10141.0,,9,1,,F,,,BAO_0000221,13961
20033,,D,2116.0,,3267,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,Ileum,Intermediate,,CHEMBL619068,,10141.0,,9,1,,F,,,BAO_0000221,13961
20033,,D,2116.0,,3268,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Ileum,Intermediate,,CHEMBL619069,,10141.0,,9,1,,F,,,BAO_0000221,13961
20033,,D,,,3269,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,,Intermediate,,CHEMBL619070,,10141.0,,9,1,,B,,,BAO_0000357,16946
20033,,D,,,3270,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,,Intermediate,,CHEMBL619071,,10141.0,,9,1,,B,,,BAO_0000357,16946
20033,,D,,,3271,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor,,Intermediate,,CHEMBL619072,,10141.0,,9,1,,F,,,BAO_0000019,15034
20033,,D,,,3272,Cavia porcellus,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,,Intermediate,,CHEMBL619073,,10141.0,,9,1,,F,,,BAO_0000019,15034
20033,,D,,,3273,Cavia porcellus,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,,Intermediate,,CHEMBL619074,,10141.0,,9,1,,F,,,BAO_0000019,12918
20033,,D,,,3274,Cavia porcellus,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,,Intermediate,,CHEMBL619075,,10141.0,,9,1,,B,,,BAO_0000357,16946
20033,,D,2435.0,,3275,Cavia porcellus,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,Striatum,Intermediate,,CHEMBL619076,,10141.0,,9,1,,B,,,BAO_0000357,17394
20033,,D,2435.0,,3276,Cavia porcellus,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,Striatum,Intermediate,,CHEMBL619077,,10141.0,,9,1,,B,,,BAO_0000357,15034
20033,,D,2435.0,,3277,Cavia porcellus,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,Intermediate,,CHEMBL619078,,10141.0,,9,1,,B,,,BAO_0000249,5094
20033,,D,2435.0,,3278,Cavia porcellus,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,Striatum,Intermediate,,CHEMBL619079,,10141.0,,9,1,,B,,,BAO_0000249,5094
20033,,D,2116.0,,3279,Cavia porcellus,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,Ileum,Intermediate,,CHEMBL619080,,10141.0,,9,1,,B,,,BAO_0000221,17358
20033,,D,,,3280,Cavia porcellus,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,,Expert,,CHEMBL619081,,10141.0,,9,1,,B,,,BAO_0000357,12953
20033,,D,,,3281,Cavia porcellus,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,Intermediate,,CHEMBL619082,,10141.0,,9,1,,B,,,BAO_0000357,12953
20033,,D,,,3282,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,,Intermediate,,CHEMBL619083,,10141.0,,9,1,,B,,,BAO_0000357,12953
20033,,D,,,3283,Cavia porcellus,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,,Intermediate,,CHEMBL619084,,10141.0,,9,1,,B,,,BAO_0000357,12953
20033,,D,2116.0,,3284,Cavia porcellus,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,Intermediate,,CHEMBL859397,,10141.0,,9,1,,F,,,BAO_0000221,273
20033,,D,2116.0,,3285,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,Ileum,Intermediate,,CHEMBL619085,,10141.0,,9,1,,F,,,BAO_0000221,12918
20033,,D,2116.0,,3286,Cavia porcellus,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,Ileum,Intermediate,,CHEMBL619086,,10141.0,,9,1,,F,,,BAO_0000221,12919
20033,,D,2116.0,,3287,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,Ileum,Intermediate,,CHEMBL619087,,10141.0,,9,1,,F,,,BAO_0000221,273
20033,,D,2116.0,,3288,Cavia porcellus,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,Ileum,Intermediate,,CHEMBL619088,,10141.0,,9,1,,F,,,BAO_0000221,273
20033,,D,,,3289,Cavia porcellus,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,,Intermediate,,CHEMBL619089,,10141.0,,9,1,,B,,,BAO_0000357,13181
168,,H,,,3290,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL619090,,10141.0,,8,1,,B,,,BAO_0000357,13181
20033,,D,,,3291,Cavia porcellus,Antagonistic activity against 5-hydroxytryptamine 4 receptor,,Intermediate,,CHEMBL619091,,10141.0,,9,1,,F,,,BAO_0000019,15034
20033,,D,,,3292,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,,Intermediate,,CHEMBL619092,,10141.0,,9,1,,B,,,BAO_0000357,5033
20033,,D,,,3293,Cavia porcellus,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,,Intermediate,,CHEMBL619093,,10141.0,,9,1,,B,,,BAO_0000019,1980
168,,H,,,3294,Cavia porcellus,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,,Autocuration,,CHEMBL619094,,10141.0,722.0,8,1,HEK293,B,,,BAO_0000219,13181
20033,,D,,,3295,Cavia porcellus,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,,Intermediate,,CHEMBL619095,,10141.0,,9,1,,B,,,BAO_0000019,14287
20033,,D,,,3296,Cavia porcellus,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,,Intermediate,,CHEMBL857988,,10141.0,,9,1,,B,,,BAO_0000357,1317
20033,,D,,,3297,Cavia porcellus,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,,Intermediate,,CHEMBL619096,,10141.0,,9,1,,B,,,BAO_0000357,15316
20033,,D,2435.0,,3298,Cavia porcellus,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,Striatum,Intermediate,,CHEMBL619097,,10141.0,,9,1,,B,,,BAO_0000357,16429
20033,,D,10000000.0,,3299,Cavia porcellus,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,Hippocampus,Intermediate,,CHEMBL619098,,10141.0,,9,1,,B,,,BAO_0000221,14818
20033,,D,,,3300,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,,Intermediate,,CHEMBL619751,,10141.0,,9,1,,B,,,BAO_0000357,15194
20033,,D,,,3301,Cavia porcellus,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,,Intermediate,,CHEMBL619752,,10141.0,,9,1,,B,,,BAO_0000357,15194
20033,,D,2116.0,,3302,Cavia porcellus,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,Ileum,Intermediate,,CHEMBL875096,,10141.0,,9,1,,F,,,BAO_0000221,13961
108,,H,,,3303,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,,Autocuration,,CHEMBL619004,,,,8,1,,B,,,BAO_0000357,5486
168,,H,,,3304,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL619005,,,,8,1,,B,,,BAO_0000357,16209
168,,H,,,3305,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,,Autocuration,,CHEMBL619006,,,,8,1,,B,,,BAO_0000019,17085
168,,H,,,3306,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,,Autocuration,,CHEMBL619007,,,308.0,8,1,HeLa,B,,,BAO_0000219,4199
168,,H,,,3307,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,,Autocuration,,CHEMBL619008,,,,8,1,,B,,,BAO_0000357,15146
168,,H,,,3308,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,,Autocuration,,CHEMBL619009,,,,8,1,,B,,,BAO_0000357,5213
168,,H,,,3309,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",,Autocuration,,CHEMBL619010,,,308.0,8,1,HeLa,B,,,BAO_0000219,4829
10622,,H,,,3310,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,,Autocuration,,CHEMBL619011,,,,8,1,,B,,,BAO_0000357,17358
10622,,H,,,3311,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,,Autocuration,,CHEMBL619012,,,,8,1,,B,,,BAO_0000357,17358
10622,,H,,,3312,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,,Autocuration,,CHEMBL619013,,,,8,1,,B,,,BAO_0000219,16946
10622,,H,,,3313,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,,Autocuration,,CHEMBL619014,,,,8,1,,B,,,BAO_0000357,17358
11249,,H,2081.0,,3314,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,Cardiac atrium,Autocuration,,CHEMBL857503,,,,8,1,,F,,,BAO_0000019,268
11249,,H,2081.0,,3315,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,Cardiac atrium,Autocuration,,CHEMBL619015,,,,8,1,,F,,,BAO_0000019,268
11249,,H,,,3316,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,,Autocuration,,CHEMBL619016,,,,8,1,,B,,,BAO_0000357,15086
11249,,H,10000000.0,,3317,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,Hippocampus,Autocuration,,CHEMBL619017,,,,8,1,,B,,,BAO_0000221,14875
168,,H,10000000.0,,3318,Sus scrofa,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,Hippocampus,Autocuration,,CHEMBL619018,,9823.0,,8,1,,B,,,BAO_0000221,13267
168,,H,,,3319,Oryctolagus cuniculus,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,,Autocuration,,CHEMBL619019,,9986.0,,8,1,,B,,,BAO_0000019,13047
10623,,D,,,3320,Rattus norvegicus,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,,Expert,,CHEMBL619020,,10116.0,,9,1,,B,,,BAO_0000357,1650
10623,,H,,,3321,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,Autocuration,,CHEMBL619021,,,,8,1,,F,,,BAO_0000019,567
10623,,H,,,3322,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,,Autocuration,,CHEMBL619022,,,,8,1,,B,,,BAO_0000357,17358
10623,,H,,,3323,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,,Autocuration,,CHEMBL619023,,,,8,1,,B,,,BAO_0000357,188
10623,,H,,,3324,,lntrinsic activity relative to 5-HT receptor,,Autocuration,,CHEMBL619024,,,,8,1,,F,,,BAO_0000019,670
10623,,H,,,3325,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,,Autocuration,,CHEMBL619025,,,,8,1,,F,,,BAO_0000019,204
10623,,H,,,3326,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,,Expert,,CHEMBL619026,,,,8,1,,F,,,BAO_0000019,1946
10623,,H,,,3327,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,,Autocuration,,CHEMBL619027,,,,8,1,,F,,,BAO_0000019,6398
10623,,H,,,3328,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,,Autocuration,,CHEMBL619028,,,,8,1,,F,,,BAO_0000019,6398
10623,,H,,,3329,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,,Autocuration,,CHEMBL619029,,,,8,1,,F,,,BAO_0000019,17358
10623,,H,,,3330,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,,Autocuration,,CHEMBL619030,,,,8,1,,F,,,BAO_0000019,6398
10623,,H,,,3331,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,,Expert,,CHEMBL619031,,,,8,1,,B,,,BAO_0000357,11752
10623,,H,,,3332,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,,Autocuration,,CHEMBL619032,,,,8,1,,F,,,BAO_0000019,809
10623,,D,,,3333,Rattus norvegicus,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,,Expert,,CHEMBL619033,,10116.0,,9,1,,B,,,BAO_0000357,14178
10623,,H,,,3334,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,,Autocuration,,CHEMBL619034,,,,8,1,,B,,,BAO_0000357,567
10623,,H,,,3335,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,,Autocuration,,CHEMBL619035,,,,8,1,,B,,,BAO_0000357,1946
10623,,H,,,3336,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,,Autocuration,,CHEMBL619036,,,,8,1,,B,,,BAO_0000357,1946
10623,,D,,,3337,Rattus norvegicus,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,,Expert,,CHEMBL619037,,10116.0,,9,1,,B,,,BAO_0000019,13961
10623,,H,2435.0,,3338,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,Striatum,Autocuration,,CHEMBL619038,,,,8,1,,B,,,BAO_0000249,6238
10623,,H,,,3339,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,,Autocuration,,CHEMBL619039,,,,8,1,,B,,,BAO_0000249,14290
10623,,H,,,3340,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,,Expert,,CHEMBL619040,,,,8,1,,B,,,BAO_0000249,14290
10623,,D,2435.0,,3341,Rattus norvegicus,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Striatum,Expert,,CHEMBL619041,,10116.0,,9,1,,B,,,BAO_0000019,809
10623,,H,2435.0,,3342,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,Striatum,Autocuration,,CHEMBL619042,,,,8,1,,B,,,BAO_0000019,1578
10623,,H,2435.0,,3343,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,Striatum,Expert,,CHEMBL619043,,,,8,1,,B,,,BAO_0000249,16709
10623,,H,2435.0,,3344,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,Striatum,Expert,,CHEMBL619044,,,,8,1,,B,,,BAO_0000019,1946
10623,,H,2435.0,,3345,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,Striatum,Expert,,CHEMBL619045,,,,8,1,,B,,,BAO_0000249,15253
10623,,H,2435.0,,3346,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,Striatum,Expert,,CHEMBL619046,,,,8,1,,B,,,BAO_0000249,4535
10623,,H,,,3347,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,,Expert,,CHEMBL619047,,,,8,1,,B,,,BAO_0000249,13961
10623,,H,955.0,,3348,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,Brain,Autocuration,,CHEMBL619048,,,,8,1,,F,,,BAO_0000221,17358
10623,,H,,,3349,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,,Autocuration,,CHEMBL859398,,,,8,1,,F,,,BAO_0000019,15847
10623,,H,,,3350,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,,Autocuration,,CHEMBL619049,,,,8,1,,F,,,BAO_0000019,15847
10623,,H,,,3351,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,,Autocuration,,CHEMBL857886,,,,8,1,,F,,,BAO_0000019,670
10623,,H,,,3352,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,,Autocuration,,CHEMBL619050,,,,8,1,,F,,,BAO_0000019,670
10623,,H,,,3353,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,,Autocuration,,CHEMBL620591,,,,8,1,,F,,,BAO_0000019,1317
10623,,D,,,3354,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 4 receptor,,Expert,,CHEMBL620592,,10116.0,,9,1,,B,,,BAO_0000357,12936
10623,,H,2435.0,,3355,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,Striatum,Expert,,CHEMBL620593,,,,8,1,,B,,,BAO_0000249,4535
10623,,D,,,3356,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,,Expert,,CHEMBL620594,,10116.0,,9,1,,F,,,BAO_0000019,14424
10623,,H,,,3357,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,,Expert,,CHEMBL875079,,,,8,1,,F,,,BAO_0000019,14424
10623,,H,,,3358,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,Expert,,CHEMBL620595,,,,8,1,,F,,,BAO_0000019,14424
10623,,D,,,3359,Rattus norvegicus,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,,Expert,,CHEMBL620596,,10116.0,,9,1,,F,,,BAO_0000019,14424
10623,,H,,,3360,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,,Autocuration,,CHEMBL620597,,,,8,1,,F,,,BAO_0000019,14424
10623,,H,,,3361,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,,Expert,,CHEMBL620598,,,,8,1,,F,,,BAO_0000019,14424
10623,,H,,,3362,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),,Expert,,CHEMBL620599,,,,8,1,,F,,,BAO_0000218,14424
10623,,H,,,3363,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,,Autocuration,,CHEMBL620600,,,,8,1,,F,,,BAO_0000019,14424
168,,H,,,3364,Rattus norvegicus,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,,Autocuration,,CHEMBL620601,,10116.0,,8,1,,F,,,BAO_0000019,1980
168,,H,,,3365,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,,Autocuration,,CHEMBL620602,,,,8,1,,F,,,BAO_0000019,4639
168,,H,,,3366,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,,Autocuration,,CHEMBL620603,,,,8,1,,B,,,BAO_0000357,17358
168,,H,,,3367,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,,Autocuration,,CHEMBL620604,,,,8,1,,B,,,BAO_0000357,17358
168,,H,,,3368,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,,Autocuration,,CHEMBL620605,,,,8,1,,B,,,BAO_0000357,17358
168,,H,,,3369,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,,Autocuration,,CHEMBL620606,,,,8,1,,B,,,BAO_0000357,1558
168,,H,,,3370,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,Autocuration,,CHEMBL620607,,,,8,1,,F,,,BAO_0000019,17358
168,,H,,,3371,,In vitro binding affinity towards 5-HT4 receptor was determined,,Autocuration,,CHEMBL620608,,,,8,1,,B,,,BAO_0000357,16117
168,,H,,,3372,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,Autocuration,,CHEMBL620609,,,,8,1,,F,,,BAO_0000019,17358
168,,H,,,3373,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,,Autocuration,,CHEMBL620610,,,,8,1,,F,,,BAO_0000019,17358
168,,H,,,3374,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,,Autocuration,,CHEMBL620611,,,,8,1,,B,,,BAO_0000357,17358
168,,H,,,3375,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,,Autocuration,,CHEMBL620612,,,,8,1,,B,,,BAO_0000357,17358
168,,H,,,3376,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,,Autocuration,,CHEMBL620613,,,,8,1,,B,,,BAO_0000357,17358
168,,H,,,3377,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,,Autocuration,,CHEMBL620614,,,,8,1,,B,,,BAO_0000357,17358
168,,H,,,3378,,Binding affinity against 5-Hydroxytryptamine 4 receptor,,Expert,,CHEMBL620615,,,,8,1,,B,,,BAO_0000357,1274
104698,,H,,,3379,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,,Autocuration,,CHEMBL857075,,,,6,1,,B,,Brain membranes,BAO_0000249,10728
104698,,H,,,3380,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,,Autocuration,,CHEMBL620616,,,,6,1,,B,,Brain membranes,BAO_0000249,11695
104698,,H,,,3381,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,,Autocuration,,CHEMBL619411,,,,6,1,,B,,Brain membranes,BAO_0000249,11695
104698,,H,,,3382,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,,Autocuration,,CHEMBL619412,,,,6,1,,B,,,BAO_0000019,12490
104698,,D,,,3383,Rattus norvegicus,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL619413,,10116.0,,7,1,,B,,,BAO_0000019,11828
104698,,H,10000000.0,,3384,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,Hippocampus,Autocuration,,CHEMBL619414,,,,6,1,,B,,,BAO_0000221,12253
104698,,H,,,3385,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,,Autocuration,,CHEMBL619415,,,,6,1,,B,,,BAO_0000019,10561
104698,,H,,,3386,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,,Autocuration,,CHEMBL619416,,,,6,1,,B,,,BAO_0000019,10561
104698,,H,,,3387,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,,Autocuration,,CHEMBL619417,,,,6,1,,F,,,BAO_0000019,14432
104698,,D,,,3388,Rattus norvegicus,Binding affinity against rat 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL619418,,10116.0,,7,1,,B,,,BAO_0000223,12936
104698,,D,,,3389,Rattus norvegicus,Binding affinity against 5-Hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL619419,,10116.0,,7,1,,B,,,BAO_0000223,1274
104698,,H,,,3390,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,,Autocuration,,CHEMBL619420,,,,6,1,,B,,,BAO_0000019,1980
104698,,H,,,3391,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,,Autocuration,,CHEMBL619421,,,,6,1,,B,,,BAO_0000249,670
104698,,D,,,3392,Rattus norvegicus,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,,Autocuration,,CHEMBL619422,,10116.0,,7,1,,B,,,BAO_0000019,968
104698,,H,,,3393,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,,Autocuration,,CHEMBL619423,,,,6,1,,B,,,BAO_0000019,14287
104698,,H,,,3394,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,,Autocuration,,CHEMBL875080,,,,6,1,,B,,,BAO_0000019,567
104698,,H,,,3395,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,,Autocuration,,CHEMBL619424,,,,6,1,,B,,,BAO_0000019,13267
104698,,H,,,3396,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,,Autocuration,,CHEMBL619425,,,,6,1,,B,,,BAO_0000249,14826
104698,,H,,,3397,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,,Autocuration,,CHEMBL619426,,,,6,1,,B,,,BAO_0000223,15194
104698,,H,,,3398,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,,Autocuration,,CHEMBL619427,,,,6,1,,B,,,BAO_0000223,15194
104698,,D,,,3399,Rattus norvegicus,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL619645,,10116.0,,7,1,,B,,,BAO_0000223,10394
10576,,D,,,3400,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",,Expert,,CHEMBL619646,,,,9,1,,B,,,BAO_0000249,13657
12020,,H,955.0,,3401,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,Brain,Autocuration,,CHEMBL619647,,,,8,1,,F,,,BAO_0000221,1879
12020,,H,,,3402,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL619648,,,,8,1,,F,,,BAO_0000019,1879
12020,,H,,,3403,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,,Autocuration,,CHEMBL619165,,,,8,1,,F,,,BAO_0000019,1879
12020,,H,,,3404,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL620719,In vivo,,,8,1,,F,,,BAO_0000218,204
12020,,H,,,3405,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,Autocuration,,CHEMBL872924,,,,8,1,,B,,,BAO_0000019,1879
12020,,H,,,3406,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL620720,,,,8,1,,B,,,BAO_0000357,1879
12020,,H,,,3407,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,,Autocuration,,CHEMBL620721,,,,8,1,,B,,,BAO_0000019,1879
12020,,H,,,3408,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,,Autocuration,,CHEMBL620722,,,,8,1,,B,,,BAO_0000019,1879
104698,,H,,,3409,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",,Autocuration,,CHEMBL620723,,,,6,1,,B,,,BAO_0000019,10641
12020,,H,,,3410,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,,Autocuration,,CHEMBL620724,,,,8,1,,B,,,BAO_0000019,773
104698,,H,,,3411,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,,Autocuration,,CHEMBL620725,,,,6,1,,B,,,BAO_0000249,11952
12020,,D,,,3412,Rattus norvegicus,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,,Autocuration,,CHEMBL620726,,10116.0,,9,1,,F,,,BAO_0000019,14145
144,,H,,,3413,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,Expert,,CHEMBL620727,,,,8,1,,B,,,BAO_0000357,17066
104714,,H,,,3414,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,,Autocuration,,CHEMBL620728,,,,4,1,,B,,,BAO_0000223,6398
22226,,U,,,3415,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,Autocuration,,CHEMBL620729,,,,0,1,,B,,,BAO_0000019,10321
104714,,H,,,3416,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,,Autocuration,,CHEMBL858288,,,,4,1,,F,,,BAO_0000019,511
104714,,H,,,3417,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL620730,,,,4,1,,B,,,BAO_0000223,4639
104714,,H,,,3418,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL620731,,,,4,1,,B,,,BAO_0000223,4639
104714,,H,,,3419,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,,Autocuration,,CHEMBL620732,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3420,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,Autocuration,,CHEMBL618042,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3421,Cavia porcellus,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,,Autocuration,,CHEMBL618043,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3422,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618044,,,,4,1,,B,,,BAO_0000223,1558
104714,,H,,,3423,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,,Autocuration,,CHEMBL618045,,,,4,1,,F,,,BAO_0000019,268
104714,,H,,,3424,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,,Autocuration,,CHEMBL618046,,,,4,1,,B,,,BAO_0000223,2474
104714,,H,,,3425,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,,Autocuration,,CHEMBL618047,,,,4,1,,F,,,BAO_0000019,5067
104714,,H,,,3426,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,,Autocuration,,CHEMBL875084,,,,4,1,,F,,,BAO_0000019,5067
104714,,H,,,3427,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,,Autocuration,,CHEMBL618048,,,,4,1,,F,,,BAO_0000019,5067
104714,,H,,,3428,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,,Autocuration,,CHEMBL618049,,,,4,1,,B,,,BAO_0000223,5067
104714,,H,,,3429,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,,Autocuration,,CHEMBL619764,,,,4,1,,F,,,BAO_0000019,5067
104714,,H,,,3430,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,,Autocuration,,CHEMBL619765,,,,4,1,,F,,,BAO_0000019,5067
104714,,H,,,3431,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,,Autocuration,,CHEMBL619766,,,,4,1,,F,,,BAO_0000019,5067
104714,,H,,,3432,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,,Autocuration,,CHEMBL619767,,,,4,1,,B,,,BAO_0000223,5067
104714,,H,,,3433,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,,Autocuration,,CHEMBL619768,,,,4,1,,B,,,BAO_0000223,5067
104714,,H,,,3434,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,,Autocuration,,CHEMBL619769,,,,4,1,,F,,,BAO_0000019,5067
104714,,H,,,3435,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,,Autocuration,,CHEMBL619770,,,,4,1,,B,,,BAO_0000223,5067
104714,,H,,,3436,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL619771,,,,4,1,,B,,,BAO_0000223,5067
104714,,H,,,3437,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,,Autocuration,,CHEMBL619772,,,,4,1,,B,,,BAO_0000219,14331
104714,,H,,,3438,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,,Autocuration,,CHEMBL619773,,,,4,1,,B,,,BAO_0000223,5067
104714,,H,,,3439,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,,Autocuration,,CHEMBL619774,,,433.0,4,1,NG108-15,B,,,BAO_0000219,6179
104714,,H,,,3440,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,,Autocuration,,CHEMBL875083,,,,4,1,,B,,,BAO_0000019,4265
104714,,H,,,3441,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,,Autocuration,,CHEMBL620718,,,433.0,4,1,NG108-15,B,,,BAO_0000219,4265
104714,,H,,,3442,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,Autocuration,,CHEMBL618127,,,,4,1,,B,,,BAO_0000223,17358
104714,,H,,,3443,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,,Autocuration,,CHEMBL618128,,,,4,1,,B,,,BAO_0000223,17358
104714,,H,,,3444,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,,Autocuration,,CHEMBL618129,In vitro,,,4,1,,B,,,BAO_0000219,13628
104714,,H,,,3445,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,Autocuration,,CHEMBL618130,,,,4,1,,B,,,BAO_0000223,4612
104714,,H,,,3446,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,,Autocuration,,CHEMBL618131,,,,4,1,,F,,,BAO_0000019,17358
104714,,H,,,3447,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,,Autocuration,,CHEMBL618132,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3448,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,,Autocuration,,CHEMBL618133,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3449,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,,Autocuration,,CHEMBL618134,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3450,Cavia porcellus,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,,Autocuration,,CHEMBL618135,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3451,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,,Autocuration,,CHEMBL618136,,,,4,1,,B,,,BAO_0000223,511
104714,,H,,,3452,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618137,,,,4,1,,B,,,BAO_0000223,1479
104714,,H,,,3453,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,,Autocuration,,CHEMBL618138,,,,4,1,,B,,,BAO_0000223,1317
104714,,H,,,3454,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,,Autocuration,,CHEMBL618139,,,,4,1,,B,,,BAO_0000223,12146
104714,,H,,,3455,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,,Autocuration,,CHEMBL618140,,,,4,1,,B,,,BAO_0000223,12146
104714,,H,,,3456,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,,Autocuration,,CHEMBL618141,,,,4,1,,B,,,BAO_0000223,13969
108,,H,,,3457,,Binding affinity for 5-hydroxytryptamine 2C receptor,,Expert,,CHEMBL873478,,,,8,1,,B,,,BAO_0000357,13392
104698,,H,,,3458,,Binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618142,,,,6,1,,B,,,BAO_0000223,13392
144,,H,,,3459,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618143,,,,8,1,,B,,,BAO_0000357,14159
144,,H,,,3460,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618144,,,,8,1,,B,,,BAO_0000357,1558
144,,H,,,3461,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618145,,,,8,1,,B,,,BAO_0000357,16655
104714,,H,,,3462,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,Autocuration,,CHEMBL618146,,,,4,1,,B,,,BAO_0000223,13020
104714,,H,,,3463,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,,Autocuration,,CHEMBL618147,,,,4,1,,B,,,BAO_0000223,13021
104714,,H,,,3464,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,,Autocuration,,CHEMBL618148,,,,4,1,,B,,,BAO_0000223,13020
144,,H,,,3465,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,,Autocuration,,CHEMBL618149,,,,8,1,,B,,,BAO_0000019,10321
144,,H,,,3466,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL872927,,,,8,1,,B,,,BAO_0000357,15818
144,,H,,,3467,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL618150,,,,8,1,,B,,,BAO_0000357,15818
144,,H,,,3468,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,,Autocuration,,CHEMBL618151,,,,8,1,,B,,,BAO_0000357,17358
144,,H,,,3469,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL875094,,,,8,1,,B,,,BAO_0000357,2222
144,,H,,,3470,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,,Autocuration,,CHEMBL618152,,,,8,1,,B,,,BAO_0000019,10322
144,,H,,,3471,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,,Autocuration,,CHEMBL618153,,,,8,1,,B,,,BAO_0000357,16117
144,,H,,,3472,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,,Autocuration,,CHEMBL618888,,,,8,1,,B,,,BAO_0000357,17200
144,,H,,,3473,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,,Autocuration,,CHEMBL618889,,,,8,1,,F,,,BAO_0000019,17358
144,,H,,,3474,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,,Autocuration,,CHEMBL618890,,,,8,1,,B,,,BAO_0000357,16700
144,,H,,,3475,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,,Autocuration,,CHEMBL618891,,,,8,1,,B,,,BAO_0000019,1980
144,,H,,,3476,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,,Autocuration,,CHEMBL619054,,,,8,1,,B,,,BAO_0000019,1980
104714,,H,,,3477,,Binding affinity against the 5-hydroxytryptamine 3 receptor,,Autocuration,,CHEMBL619055,,,,4,1,,B,,,BAO_0000223,12409
144,,H,,,3478,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,Autocuration,,CHEMBL619056,,,,8,1,,B,,,BAO_0000357,4365
144,,H,,,3479,,Percent efficacy against 5-hydroxytryptamine 3A receptor,,Autocuration,,CHEMBL619057,,,,8,1,,F,,,BAO_0000019,4365
144,,H,,,3480,,Binding affinity against human 5-hydroxytryptamine 3A receptor,,Autocuration,,CHEMBL619058,,,,8,1,,B,,,BAO_0000357,4365
12020,,D,,,3481,Rattus norvegicus,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,,Expert,,CHEMBL619059,,10116.0,,9,1,Oocytes,F,,,BAO_0000219,6769
12020,,D,,,3482,Rattus norvegicus,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,,Expert,,CHEMBL619060,,10116.0,,9,1,Oocytes,F,,,BAO_0000219,6769
12020,,D,,,3483,Rattus norvegicus,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,,Expert,,CHEMBL875095,,10116.0,,9,1,Oocytes,F,,,BAO_0000219,6769
20033,,D,2116.0,,3484,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,Ileum,Intermediate,,CHEMBL619061,,10141.0,,9,1,,F,,,BAO_0000221,809
20033,,D,2116.0,,3485,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,Ileum,Intermediate,,CHEMBL619062,,10141.0,,9,1,,F,,,BAO_0000221,809
20033,,D,,,3486,Cavia porcellus,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,,Intermediate,,CHEMBL619063,,10141.0,,9,1,,F,,,BAO_0000019,14290
20033,,D,2116.0,,3487,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,Ileum,Intermediate,,CHEMBL619064,,10141.0,,9,1,,B,,,BAO_0000221,17358
20033,,D,,,3488,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,,Intermediate,,CHEMBL619065,,10141.0,,9,1,,B,,,BAO_0000357,17358
20033,,D,2116.0,,3489,Cavia porcellus,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,Ileum,Intermediate,,CHEMBL619066,,10141.0,,9,1,,B,,,BAO_0000221,17358
10209,,H,2116.0,,3490,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Ileum,Autocuration,,CHEMBL619775,,,,8,1,,B,,,BAO_0000221,17386
10209,,H,,,3491,,Affinity against 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL619776,,,,8,1,,B,,,BAO_0000357,3269
104841,,H,,,3492,Cavia porcellus,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,Autocuration,,CHEMBL619777,,10141.0,,4,1,,B,,,BAO_0000224,7721
104841,,H,,,3493,Cavia porcellus,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,,Autocuration,,CHEMBL619778,,10141.0,,4,1,,B,,,BAO_0000224,7721
104841,,H,2116.0,,3494,Cavia porcellus,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,Ileum,Autocuration,,CHEMBL619779,,10141.0,,4,1,,B,,,BAO_0000221,9117
104841,,H,,,3495,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",,Autocuration,,CHEMBL619780,,10141.0,,4,1,,B,,,BAO_0000224,7721
104841,,H,,,3496,Cavia porcellus,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",,Autocuration,,CHEMBL619166,,10141.0,,4,1,,B,,,BAO_0000224,7721
104841,,H,,,3497,Cavia porcellus,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,Autocuration,,CHEMBL619167,,10141.0,,4,1,,F,,,BAO_0000019,15796
104841,,H,,,3498,Cavia porcellus,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,,Autocuration,,CHEMBL619168,,10141.0,,4,1,,F,,,BAO_0000019,15796
168,,D,2081.0,,3499,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,Cardiac atrium,Expert,,CHEMBL619169,,9606.0,,9,1,,B,,,BAO_0000219,15650
168,,D,2081.0,,3500,Homo sapiens,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,Cardiac atrium,Expert,,CHEMBL619170,,9606.0,,9,1,,B,,,BAO_0000219,15650
104841,,D,,,3501,Homo sapiens,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",,Autocuration,,CHEMBL619171,,9606.0,,5,1,,F,,,BAO_0000019,6866
168,,D,2081.0,,3502,Homo sapiens,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",Cardiac atrium,Expert,,CHEMBL619172,,9606.0,,9,1,,F,,,BAO_0000219,15650
22226,,U,,,3503,Mus musculus,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,,Autocuration,,CHEMBL619173,,10090.0,,0,1,,B,,,BAO_0000019,10063
22226,,U,,,3504,Mus musculus,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,,Autocuration,,CHEMBL619174,,10090.0,,0,1,,B,,,BAO_0000019,12665
104705,,H,,,3505,,5-hydroxytryptamine receptor binding affinity was determined in rats,,Autocuration,,CHEMBL619175,,,,4,1,,B,,,BAO_0000019,7504
104705,,H,,,3506,,Binding affinity at rat 5-hydroxytryptamine receptor.,,Autocuration,,CHEMBL619176,,,,4,1,,B,,,BAO_0000224,7504
104705,,H,,,3507,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,,Autocuration,,CHEMBL619177,,,,4,1,,B,,,BAO_0000019,7038
104705,,H,,,3508,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,,Autocuration,,CHEMBL619178,,,,4,1,,B,,,BAO_0000224,7626
104705,,H,,,3509,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,,Autocuration,,CHEMBL619179,,,,4,1,,B,,,BAO_0000224,7626
104705,,H,945.0,,3510,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,Stomach,Autocuration,,CHEMBL619180,,,,4,1,,F,,,BAO_0000019,7185
104705,,H,945.0,,3511,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,Stomach,Autocuration,,CHEMBL619181,,,,4,1,,F,,,BAO_0000019,7185
104705,,H,,,3512,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,,Autocuration,,CHEMBL619182,,,,4,1,,F,,,BAO_0000019,7185
104705,,H,,,3513,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,,Autocuration,,CHEMBL619183,,,,4,1,,B,,,BAO_0000224,6960
104705,,H,,,3514,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",,Autocuration,,CHEMBL619184,,,,4,1,,B,,,BAO_0000224,6960
10576,,H,10000000.0,,3515,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,Hippocampus,Autocuration,,CHEMBL619185,,,,8,1,,B,,,BAO_0000221,12416
12198,,H,,,3516,,Binding affinity for rat 5-hydroxytryptamine transporter.,,Expert,,CHEMBL619186,,,,8,1,,B,,,BAO_0000357,15753
104705,,H,,,3517,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,,Autocuration,,CHEMBL619187,,,,4,1,,B,,,BAO_0000019,8062
104705,,D,,,3518,Rattus norvegicus,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,,Autocuration,,CHEMBL619188,,10116.0,,5,1,,B,,,BAO_0000019,9036
104705,,D,,,3519,Rattus norvegicus,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,,Autocuration,,CHEMBL619189,,10116.0,,5,1,,B,,,BAO_0000224,15067
12198,,D,955.0,,3520,Rattus norvegicus,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,Brain,Expert,,CHEMBL619190,,10116.0,,9,1,,F,,,BAO_0000019,15753
12198,,D,2037.0,,3521,Rattus norvegicus,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,Cerebellum,Expert,,CHEMBL619191,,10116.0,,9,1,,F,,,BAO_0000221,15753
104705,,D,,,3522,Rattus norvegicus,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,,Autocuration,,CHEMBL619192,,10116.0,,5,1,,B,,,BAO_0000019,15295
104705,,D,,,3523,Rattus norvegicus,Percent binding affinity against 5-hydroxytryptamine receptor,,Autocuration,,CHEMBL619193,,10116.0,,5,1,,B,,,BAO_0000224,6347
22226,,U,,,3524,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,,Autocuration,,CHEMBL619194,,,,0,1,,B,,,BAO_0000019,6763
104705,,D,,,3525,Rattus norvegicus,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,,Autocuration,,CHEMBL619195,,10116.0,,5,1,,B,,,BAO_0000224,12092
104705,,D,,,3526,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined,,Autocuration,,CHEMBL619196,,10116.0,,5,1,,B,,,BAO_0000224,1579
104705,,D,945.0,,3527,Rattus norvegicus,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,Stomach,Autocuration,,CHEMBL619197,,10116.0,,5,1,,B,,,BAO_0000019,1579
121,,D,,,3528,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,Expert,,CHEMBL619198,In vitro,9606.0,,9,1,,B,,,BAO_0000219,5963
121,,D,,,3529,Homo sapiens,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,,Expert,,CHEMBL875081,In vitro,9606.0,,9,1,,B,,,BAO_0000219,5963
18065,,H,,,3530,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,,Autocuration,,CHEMBL884712,,,,8,1,,B,,,BAO_0000357,5030
121,,H,,,3531,,Inhibition of 5-hydroxytryptamine reuptake,,Expert,,CHEMBL884710,,,,8,1,,B,,,BAO_0000357,15796
18065,,H,,,3532,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",,Autocuration,,CHEMBL619199,,,,8,1,,F,,,BAO_0000019,15413
18065,,H,,,3533,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",,Autocuration,,CHEMBL619200,,,,8,1,,F,,,BAO_0000019,15413
18065,,H,,,3534,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",,Autocuration,,CHEMBL619201,,,,8,1,,F,,,BAO_0000019,15413
18065,,H,,,3535,,Tested for 5-hydroxytryptamine receptor uptake,,Autocuration,,CHEMBL619202,,,,8,1,,F,,,BAO_0000019,12409
51,,D,,,3536,Homo sapiens,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,,Expert,,CHEMBL619203,,9606.0,449.0,9,1,CHO,B,,,BAO_0000219,16909
51,,D,,,3537,Homo sapiens,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,,Expert,,CHEMBL619204,,9606.0,,9,1,,F,,,BAO_0000019,16909
10576,,H,,,3538,Homo sapiens,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,,Autocuration,,CHEMBL619205,,9606.0,,8,1,,B,,,BAO_0000249,15629
10576,,H,,,3539,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,,Autocuration,,CHEMBL619206,,,,8,1,,B,,,BAO_0000357,15629
10576,,H,,,3540,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,,Expert,,CHEMBL619207,,,,8,1,,B,,,BAO_0000249,15629
10825,,H,2435.0,,3541,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,Striatum,Autocuration,,CHEMBL619208,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,2435.0,,3542,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,Striatum,Autocuration,,CHEMBL619209,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,2435.0,,3543,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,Striatum,Autocuration,,CHEMBL619210,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,2435.0,,3544,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,Striatum,Autocuration,,CHEMBL619211,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,2435.0,,3545,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,Striatum,Autocuration,,CHEMBL619212,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,2435.0,,3546,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,Striatum,Autocuration,,CHEMBL620681,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,2435.0,,3547,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,Striatum,Autocuration,,CHEMBL620682,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,2435.0,,3548,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,Striatum,Autocuration,,CHEMBL620683,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,2435.0,,3549,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,Striatum,Autocuration,,CHEMBL620684,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,2435.0,,3550,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,Striatum,Autocuration,,CHEMBL620685,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,2435.0,,3551,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,Striatum,Autocuration,,CHEMBL620686,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,349.0,,3552,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,Limbic system,Autocuration,,CHEMBL620687,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,349.0,,3553,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Limbic system,Autocuration,,CHEMBL620688,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,349.0,,3554,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,Limbic system,Autocuration,,CHEMBL620689,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,349.0,,3555,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,Limbic system,Autocuration,,CHEMBL620690,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,349.0,,3556,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,Limbic system,Autocuration,,CHEMBL620691,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,349.0,,3557,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,Limbic system,Autocuration,,CHEMBL620692,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,349.0,,3558,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,Limbic system,Autocuration,,CHEMBL620693,,,,8,1,,F,,,BAO_0000019,10034
168,,H,,,3559,,Binding affinity against 5-hydroxytryptamine 4 receptor,,Expert,,CHEMBL620694,,,,8,1,,B,,,BAO_0000357,1274
168,,H,,,3560,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,,Autocuration,,CHEMBL857986,,,,8,1,,F,,,BAO_0000019,17358
168,,H,,,3561,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,,Autocuration,,CHEMBL620695,,,,8,1,,B,,,BAO_0000357,14532
168,,H,,,3562,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,,Expert,,CHEMBL620696,,,,8,1,,B,,,BAO_0000357,16989
168,,H,,,3563,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,,Autocuration,,CHEMBL620697,,,,8,1,,B,,,BAO_0000357,17200
168,,H,,,3564,,Binding affinity towards 5-hydroxytryptamine 4 receptor,,Autocuration,,CHEMBL620698,,,,8,1,,B,,,BAO_0000357,15779
168,,H,,,3565,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,Autocuration,,CHEMBL620699,,,,8,1,,B,,,BAO_0000357,15779
168,,H,,,3566,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,,Autocuration,,CHEMBL620700,,,,8,1,,B,,,BAO_0000357,15779
168,,H,,,3567,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,,Autocuration,,CHEMBL620701,,,643.0,8,1,COS-7,B,,,BAO_0000219,15650
168,,H,,,3568,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,,Autocuration,,CHEMBL875082,,,643.0,8,1,COS-7,B,,,BAO_0000219,15650
168,,H,,,3569,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,,Autocuration,,CHEMBL620702,,,643.0,8,1,COS-7,B,,,BAO_0000219,15650
168,,H,,,3570,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,,Autocuration,,CHEMBL620703,,,643.0,8,1,COS-7,B,,,BAO_0000219,15650
168,,H,,,3571,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,Autocuration,,CHEMBL620704,,,673.0,8,1,C6,B,,,BAO_0000219,17046
168,,H,,,3572,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,,Expert,,CHEMBL620705,,,673.0,8,1,C6,B,,,BAO_0000219,17046
168,,H,,,3573,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,,Expert,,CHEMBL620706,,,673.0,8,1,C6,B,,,BAO_0000219,15650
168,,H,,,3574,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,,Expert,,CHEMBL620707,,,673.0,8,1,C6,B,,,BAO_0000219,17046
10624,,H,,,3575,,Binding affinity towards 5-hydroxytryptamine 5 receptor,,Expert,,CHEMBL620708,,,,8,1,,B,,,BAO_0000357,17066
105,,H,,,3576,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,,Autocuration,,CHEMBL620709,,,,8,1,,B,,,BAO_0000357,17200
10624,,D,,,3577,Homo sapiens,Binding affinity against 5-hydroxytryptamine 5A receptor,,Expert,,CHEMBL620710,,9606.0,,9,1,,B,,,BAO_0000357,16146
10624,,H,,,3578,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,,Autocuration,,CHEMBL620711,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
10624,,D,,,3579,Homo sapiens,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,,Expert,,CHEMBL620712,,9606.0,,9,1,,B,,,BAO_0000357,6491
10624,,D,,,3580,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor,,Expert,,CHEMBL620713,,9606.0,,9,1,,B,,,BAO_0000357,17066
10624,,D,,,3581,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,,Expert,,CHEMBL620714,,9606.0,,9,1,,B,,,BAO_0000357,17066
10624,,D,,,3582,Homo sapiens,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,,Expert,,CHEMBL620715,,9606.0,,9,1,,B,,,BAO_0000357,4234
10624,,H,,,3583,,Binding affinity towards 5-HT5A receptor,,Autocuration,,CHEMBL620716,,,,8,1,,B,,,BAO_0000357,6013
10624,,H,,,3584,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,,Expert,,CHEMBL620717,,,,8,1,,B,,,BAO_0000357,17175
10624,,H,,,3585,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,,Autocuration,,CHEMBL618072,,,,8,1,,B,,,BAO_0000357,15818
10624,,H,,,3586,,Binding affinity towards cloned human 5-HT5A receptor was determined,,Autocuration,,CHEMBL857987,,,,8,1,,B,,,BAO_0000357,6166
10624,,H,,,3587,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,Autocuration,,CHEMBL618073,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
10624,,H,,,3588,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,Autocuration,,CHEMBL618074,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
10624,,H,,,3589,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),,Autocuration,,CHEMBL618075,,,722.0,8,1,HEK293,B,,,BAO_0000219,5213
10625,,D,,,3590,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,,Expert,,CHEMBL618076,,10090.0,,9,1,,B,,,BAO_0000357,17066
10625,,D,,,3591,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,,Expert,,CHEMBL618077,,10090.0,,9,1,,B,,,BAO_0000357,17066
10625,,D,,,3592,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,,Expert,,CHEMBL618078,,10090.0,,9,1,,B,,,BAO_0000357,17066
10625,,D,,,3593,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,,Expert,,CHEMBL881821,,10090.0,,9,1,,B,,,BAO_0000357,17066
10625,,D,,,3594,Mus musculus,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,,Expert,,CHEMBL618079,,10090.0,,9,1,,B,,,BAO_0000357,17066
10625,,H,,,3595,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,,Expert,,CHEMBL618080,,,,8,1,,B,,,BAO_0000357,17175
10576,,H,,,3596,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,Autocuration,,CHEMBL618081,,,722.0,8,1,HEK293,B,,,BAO_0000219,16190
10626,,H,,,3597,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,,Autocuration,,CHEMBL618082,,,722.0,8,1,HEK293,B,,,BAO_0000219,16190
10624,,H,,,3598,,Binding affinity towards 5-HT5a receptor,,Expert,,CHEMBL618083,,,,8,1,,B,,,BAO_0000357,4820
10624,,D,,,3599,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 5A receptor,,Expert,,CHEMBL618084,,9606.0,,9,1,,B,,,BAO_0000357,17066
10624,,H,,,3600,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,,Expert,,CHEMBL618085,,,,8,1,,B,,,BAO_0000357,17066
10624,,H,,,3601,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,,Expert,,CHEMBL618086,,,,8,1,,B,,,BAO_0000357,17175
10624,,H,,,3602,,Binding affinities against 5-hydroxytryptamine 5A receptor,,Autocuration,,CHEMBL875092,,,,8,1,,B,,,BAO_0000357,16633
10624,,H,,,3603,,Binding affinities towards 5-hydroxytryptamine 5A receptor,,Autocuration,,CHEMBL618087,,,,8,1,,B,,,BAO_0000357,16633
10624,,H,,,3604,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,,Autocuration,,CHEMBL872926,,,,8,1,,B,,,BAO_0000357,16700
104714,,H,,,3605,Cavia porcellus,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,,Autocuration,,CHEMBL618088,,10141.0,,4,1,,F,,,BAO_0000019,4639
104714,,H,,,3606,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,,Autocuration,,CHEMBL618089,,,,4,1,,B,,,BAO_0000223,5486
10627,,D,,,3607,Homo sapiens,Inhibition of human 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL618090,,9606.0,,9,1,,B,,,BAO_0000357,16146
10627,,D,,,3608,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,,Expert,,CHEMBL618091,,9606.0,,9,1,,B,,,BAO_0000357,17273
10627,,H,,,3609,,Inhibition against human 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL618092,,,,8,1,,B,,,BAO_0000357,17687
10627,,D,,,3610,Homo sapiens,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,,Expert,,CHEMBL618093,,9606.0,,9,1,,B,,,BAO_0000357,6491
10627,,H,,,3611,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,,Expert,,CHEMBL618094,,,308.0,8,1,HeLa,B,,,BAO_0000219,16190
10627,,D,,,3612,Homo sapiens,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL618095,,9606.0,,9,1,,B,,,BAO_0000357,17066
10627,,D,,,3613,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL875093,,9606.0,,9,1,,B,,,BAO_0000357,17066
10627,,D,,,3614,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,,Expert,,CHEMBL618096,,9606.0,,9,1,,B,,,BAO_0000357,17066
10627,,D,,,3615,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,,Expert,,CHEMBL618118,,9606.0,,9,1,,B,,,BAO_0000357,17066
10627,,D,,,3616,Homo sapiens,Binding affinity against 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL618119,,9606.0,,9,1,,B,,,BAO_0000357,3555
10627,,H,,,3617,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL618120,,,,8,1,,B,,,BAO_0000357,5808
10627,,H,,,3618,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL618121,,,,8,1,,B,,,BAO_0000357,6013
10627,,H,,,3619,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",,Expert,,CHEMBL618122,,,722.0,8,1,HEK293,B,,,BAO_0000219,15818
10627,,H,,,3620,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,,Autocuration,,CHEMBL618123,,,,8,1,,B,,,BAO_0000357,16209
10627,,H,,,3621,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,,Expert,,CHEMBL618124,,,722.0,8,1,HEK293,B,,,BAO_0000219,3935
10627,,H,,,3622,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL618125,,,,8,1,,B,,,BAO_0000357,15818
10627,,D,,,3623,Homo sapiens,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,Expert,,CHEMBL618126,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,3805
10627,,H,,,3624,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,,Expert,,CHEMBL618236,,,,8,1,,B,,,BAO_0000019,16441
10627,,H,,,3625,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,Expert,,CHEMBL618237,,,,8,1,,B,,,BAO_0000019,16441
10627,,H,,,3626,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,,Expert,,CHEMBL618238,,,643.0,8,1,COS-7,B,,,BAO_0000219,6786
10627,,D,,,3627,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL618239,,9606.0,,9,1,,B,,,BAO_0000357,4234
10627,,H,,,3628,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL618240,,,,8,1,,B,,,BAO_0000019,17085
10627,,H,,,3629,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,,Autocuration,,CHEMBL618241,,,,8,1,,B,,,BAO_0000357,17200
10627,,H,,,3630,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,,Autocuration,,CHEMBL859399,,,722.0,8,1,HEK293,B,,,BAO_0000219,17451
10627,,H,,,3631,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,,Autocuration,,CHEMBL618242,,,,8,1,,F,,,BAO_0000019,3935
10627,,H,,,3632,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL857991,,,,8,1,,B,,,BAO_0000357,5033
10627,,H,,,3633,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL619951,,,,8,1,,B,,,BAO_0000357,4540
10627,,D,,,3634,Homo sapiens,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,,Expert,,CHEMBL619952,,9606.0,308.0,9,1,HeLa,B,,,BAO_0000219,4540
10627,,D,,,3635,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,,Expert,,CHEMBL619953,,9606.0,308.0,9,1,HeLa,B,,,BAO_0000219,4540
10627,,H,,,3636,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,,Autocuration,,CHEMBL619954,,,308.0,8,1,HeLa,B,,,BAO_0000219,17296
10627,,H,,,3637,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,Autocuration,,CHEMBL619955,,,308.0,8,1,HeLa,B,,,BAO_0000219,17296
10627,,H,,,3638,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,,Autocuration,,CHEMBL619956,,,308.0,8,1,HeLa,B,,,BAO_0000219,17296
10627,,H,,,3639,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,,Autocuration,,CHEMBL619957,,,449.0,8,1,CHO,B,,,BAO_0000219,15779
10627,,H,,,3640,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,,Autocuration,,CHEMBL619958,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
10627,,H,,,3641,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,,Autocuration,,CHEMBL620627,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
10627,,H,,,3642,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,,Autocuration,,CHEMBL620628,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
10627,,H,,,3643,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,,Autocuration,,CHEMBL620629,,,308.0,8,1,HeLa,B,,,BAO_0000219,15779
10627,,H,,,3644,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL620630,,,,8,1,,B,,,BAO_0000357,6166
10627,,H,,,3645,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,,Autocuration,,CHEMBL620782,,,308.0,8,1,HeLa,B,,,BAO_0000219,17451
10627,,H,,,3646,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL620783,,,,8,1,,B,,,BAO_0000357,15316
10627,,H,,,3647,,Binding affinity against human 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL620784,,,,8,1,,B,,,BAO_0000357,4199
10627,,H,,,3648,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,,Expert,,CHEMBL620785,,,308.0,8,1,HeLa,B,,,BAO_0000219,15146
10627,,H,,,3649,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),,Autocuration,,CHEMBL857992,,,,8,1,,B,,,BAO_0000357,5213
10627,,H,,,3650,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,,Autocuration,,CHEMBL620786,,,,8,1,,B,,,BAO_0000219,16429
10627,,H,,,3651,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,,Autocuration,,CHEMBL620787,,,308.0,8,1,HeLa,B,,,BAO_0000219,14818
10627,,H,,,3652,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",,Autocuration,,CHEMBL620788,,,308.0,8,1,HeLa,B,,,BAO_0000219,4829
10627,,H,,,3653,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",,Autocuration,,CHEMBL620789,,,308.0,8,1,HeLa,B,,,BAO_0000219,4829
10627,,H,,,3654,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",,Autocuration,,CHEMBL620790,,,308.0,8,1,HeLa,B,,,BAO_0000219,4829
10628,,H,,,3655,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,,Autocuration,,CHEMBL620791,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
10628,,H,,,3656,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,,Autocuration,,CHEMBL620792,,,,8,1,,B,,,BAO_0000019,14423
10628,,H,,,3657,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL620793,,,,8,1,,B,,,BAO_0000357,15086
10628,,H,,,3658,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,,Autocuration,,CHEMBL620794,,,,8,1,,B,,,BAO_0000357,4342
10627,,D,,,3659,Homo sapiens,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,,Autocuration,,CHEMBL620795,,9606.0,308.0,9,1,HeLa,B,,,BAO_0000219,16190
10627,,H,,,3660,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL620796,,,,8,1,,B,,,BAO_0000357,4820
10627,,H,,,3661,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,,Autocuration,,CHEMBL620797,,,,8,1,,B,,,BAO_0000357,4639
10627,,D,,,3662,Homo sapiens,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,Expert,,CHEMBL620798,,9606.0,,9,1,,F,,,BAO_0000019,17066
10627,,H,,,3663,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,,Autocuration,,CHEMBL620799,,,,8,1,,B,,,BAO_0000357,6011
10627,,H,,,3664,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL620800,,,,8,1,,B,,,BAO_0000357,17066
10627,,H,,,3665,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,,Autocuration,,CHEMBL620801,,,,8,1,,B,,,BAO_0000357,17515
10627,,H,,,3666,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL875100,,,,8,1,,B,,,BAO_0000357,5014
10627,,H,,,3667,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,,Autocuration,,CHEMBL620802,,,,8,1,,B,,,BAO_0000357,4373
10627,,H,,,3668,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL620803,,,,8,1,,F,,,BAO_0000019,17066
10627,,H,,,3669,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,,Expert,,CHEMBL620804,,,,8,1,,F,,,BAO_0000019,17066
10627,,H,,,3670,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,,Autocuration,,CHEMBL620805,,,,8,1,,B,,,BAO_0000357,4373
10627,,H,,,3671,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL620806,,,,8,1,,B,,,BAO_0000357,4687
10627,,H,,,3672,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,,Autocuration,,CHEMBL620807,,,,8,1,,B,,,BAO_0000357,16946
10627,,H,,,3673,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,,Autocuration,,CHEMBL620808,,,,8,1,,B,,,BAO_0000357,16946
10627,,H,,,3674,,Binding affinities against 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL620809,,,,8,1,,B,,,BAO_0000357,16633
10627,,H,,,3675,,Binding affinities towards 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL620810,,,,8,1,,B,,,BAO_0000357,16633
10627,,D,,,3676,Homo sapiens,Binding affinity towards 5-hydroxytryptamine 6 receptor,,Expert,,CHEMBL620811,,9606.0,,9,1,,B,,,BAO_0000357,17066
10627,,H,,,3677,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,,Autocuration,,CHEMBL620812,,,,8,1,,B,,,BAO_0000357,16700
10627,,H,,,3678,,Affinity against 5-hydroxytryptamine 6 receptor,,Autocuration,,CHEMBL620813,,,,8,1,,B,,,BAO_0000357,3269
10627,,H,,,3679,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],,Autocuration,,CHEMBL620814,,,,8,1,,B,,,BAO_0000357,5486
10209,,D,,,3680,Homo sapiens,Inhibition of human 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL620815,,9606.0,,9,1,,B,,,BAO_0000357,16146
10209,,H,,,3681,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,,Autocuration,,CHEMBL620816,,,722.0,8,1,HEK293,B,,,BAO_0000219,5014
10209,,H,,,3682,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL620817,,,,8,1,,B,,,BAO_0000357,15463
10209,,H,,,3683,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),,Autocuration,,CHEMBL620818,,,,8,1,,B,,,BAO_0000357,3805
10209,,H,,,3684,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,,Expert,,CHEMBL620819,,,722.0,8,1,HEK293,B,,,BAO_0000219,5014
10209,,D,,,3685,Homo sapiens,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,,Expert,,CHEMBL620820,,9606.0,,9,1,,B,,,BAO_0000357,6491
10209,,H,,,3686,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,,Autocuration,,CHEMBL620821,,,449.0,8,1,CHO,B,,,BAO_0000219,16190
10209,,D,,,3687,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL620822,,9606.0,,9,1,,B,,,BAO_0000357,17066
10209,,D,,,3688,Homo sapiens,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL620823,,9606.0,,9,1,,B,,,BAO_0000357,17066
10209,,D,,,3689,Homo sapiens,Binding affinity against 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL620824,,9606.0,,9,1,,B,,,BAO_0000357,3555
10209,,H,,,3690,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,,Expert,,CHEMBL620825,,,449.0,8,1,CHO,B,,,BAO_0000219,6588
10209,,H,,,3691,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,,Autocuration,,CHEMBL872930,,,,8,1,,B,,,BAO_0000357,15463
10209,,H,,,3692,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL620826,,,,8,1,,B,,,BAO_0000357,6013
10209,,H,,,3693,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL620827,,,,8,1,,B,,,BAO_0000357,16209
10209,,H,,,3694,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL620828,,,,8,1,,B,,,BAO_0000357,3935
10209,,H,,,3695,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL620829,,,,8,1,,B,,,BAO_0000357,15818
10209,,H,,,3696,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,,Expert,,CHEMBL620830,,,722.0,8,1,HEK293,B,,,BAO_0000219,5014
10209,,H,,,3697,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,,Expert,,CHEMBL620831,,,,8,1,,B,,,BAO_0000019,16441
10209,,H,,,3698,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,,Expert,,CHEMBL620832,,,,8,1,,B,,,BAO_0000019,16441
10209,,D,,,3699,Homo sapiens,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL621548,,9606.0,,9,1,,B,,,BAO_0000357,4234
10209,,H,,,3700,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL621549,,,,8,1,,B,,,BAO_0000019,17085
10209,,H,,,3701,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,,Autocuration,,CHEMBL621550,,,,8,1,,B,,,BAO_0000357,17200
10209,,H,,,3702,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,,Autocuration,,CHEMBL621551,,,449.0,8,1,CHO,B,,,BAO_0000219,17451
10209,,H,,,3703,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,,Autocuration,,CHEMBL621552,,,,8,1,,B,,,BAO_0000019,17085
10209,,H,,,3704,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL857077,,,,8,1,,B,,,BAO_0000357,5104
10209,,H,,,3705,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,,Autocuration,,CHEMBL618158,,,,8,1,,B,,,BAO_0000357,5104
10209,,D,,,3706,Homo sapiens,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,Expert,,CHEMBL618159,,9606.0,643.0,9,1,COS-7,B,,,BAO_0000219,5033
10209,,H,,,3707,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,,Autocuration,,CHEMBL875101,,,643.0,8,1,COS-7,B,,,BAO_0000219,5486
10209,,D,,,3708,Homo sapiens,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,,Expert,,CHEMBL618160,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,4540
10209,,H,,,3709,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,,Expert,,CHEMBL618161,,,,8,1,,B,,,BAO_0000357,6166
10209,,H,,,3710,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,,Expert,,CHEMBL618162,,,722.0,8,1,HEK293,B,,,BAO_0000219,17342
10209,,H,,,3711,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,,Expert,,CHEMBL618163,,,,8,1,,B,,,BAO_0000357,17342
10209,,H,,,3712,,Binding affinity against 5-hydroxytryptamine 7 human receptors,,Autocuration,,CHEMBL618164,,,,8,1,,B,,,BAO_0000357,17296
10209,,H,,,3713,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,,Expert,,CHEMBL618165,,,,8,1,,B,,,BAO_0000219,16429
10209,,H,,,3714,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,,Autocuration,,CHEMBL618166,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
10209,,H,,,3715,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,Autocuration,,CHEMBL857989,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
10209,,H,,,3716,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,Autocuration,,CHEMBL619888,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
10209,,H,,,3717,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,,Autocuration,,CHEMBL619889,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
10209,,H,,,3718,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,,Autocuration,,CHEMBL619890,,,722.0,8,1,HEK293,B,,,BAO_0000219,15779
10209,,H,,,3719,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,,Autocuration,,CHEMBL619891,,,449.0,8,1,CHO,B,,,BAO_0000219,17451
10209,,H,,,3720,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),,Autocuration,,CHEMBL619892,,,722.0,8,1,HEK293,B,,,BAO_0000219,4199
10209,,D,,,3721,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,,Expert,,CHEMBL619893,,,722.0,9,1,HEK293,B,,,BAO_0000219,4199
10209,,H,,,3722,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),,Autocuration,,CHEMBL619894,,,722.0,8,1,HEK293,B,,,BAO_0000219,4199
10209,,D,,,3723,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,,Intermediate,,CHEMBL619895,,,722.0,9,1,HEK293,B,,,BAO_0000219,3680
10209,,D,,,3724,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,,Intermediate,,CHEMBL619896,,,,9,1,,B,,,BAO_0000357,3680
10209,,H,,,3725,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,,Autocuration,,CHEMBL619897,,,643.0,8,1,COS-7,B,,,BAO_0000219,15316
10209,,H,,,3726,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,,Autocuration,,CHEMBL619898,,,722.0,8,1,HEK293,B,,,BAO_0000219,15146
10209,,H,,,3727,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,,Expert,,CHEMBL619899,,,722.0,8,1,HEK293,B,,,BAO_0000219,5213
10209,,H,,,3728,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),,Autocuration,,CHEMBL619900,,,722.0,8,1,HEK293,B,,,BAO_0000219,5213
10209,,D,,,3729,Homo sapiens,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,,Expert,,CHEMBL619901,,9606.0,722.0,9,1,HEK293,B,,,BAO_0000219,14818
10209,,H,,,3730,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,,Autocuration,,CHEMBL620580,,,722.0,8,1,HEK293,B,,,BAO_0000219,14818
10209,,H,,,3731,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,,Autocuration,,CHEMBL620581,,,722.0,8,1,HEK293,B,,,BAO_0000219,14818
10209,,H,,,3732,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",,Autocuration,,CHEMBL620733,,,722.0,8,1,HEK293,B,,,BAO_0000219,4829
10209,,D,,,3733,Homo sapiens,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,,Autocuration,,CHEMBL620734,,9606.0,,9,1,,B,,,BAO_0000357,17200
10022,,D,,,3734,Mus musculus,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,Expert,,CHEMBL620735,,10090.0,,9,1,,B,,,BAO_0000357,17066
10209,,H,,,3735,Oryctolagus cuniculus,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,,Autocuration,,CHEMBL620736,,9986.0,,8,1,,B,,,BAO_0000019,14025
11923,,H,,,3736,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,,Autocuration,,CHEMBL620737,,,449.0,8,1,CHO,B,,,BAO_0000219,15250
11923,,H,,,3737,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,,Autocuration,,CHEMBL620738,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3738,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,,Autocuration,,CHEMBL620739,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3739,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,,Autocuration,,CHEMBL620740,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3740,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,,Autocuration,,CHEMBL620741,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3741,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,,Autocuration,,CHEMBL620742,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3742,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,,Autocuration,,CHEMBL620743,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3743,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,,Autocuration,,CHEMBL620744,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3744,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,,Autocuration,,CHEMBL620745,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3745,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,,Autocuration,,CHEMBL620746,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3746,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,,Autocuration,,CHEMBL620747,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3747,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,,Autocuration,,CHEMBL620748,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3748,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,,Autocuration,,CHEMBL620749,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3749,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL620750,,,,8,1,,B,,,BAO_0000357,17066
11923,,D,,,3750,Rattus norvegicus,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,,Expert,,CHEMBL620751,,10116.0,,9,1,,B,,,BAO_0000357,17066
11923,,H,,,3751,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL620752,,,,8,1,,B,,,BAO_0000357,17386
11923,,H,,,3752,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,,Autocuration,,CHEMBL872929,,,,8,1,,B,,,BAO_0000019,14423
11923,,D,,,3753,Rattus norvegicus,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,,Expert,,CHEMBL620753,,10116.0,,9,1,,B,,,BAO_0000357,15874
11923,,D,,,3754,Rattus norvegicus,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL620754,,10116.0,,9,1,,B,,,BAO_0000357,15874
11923,,D,,,3755,Rattus norvegicus,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,,Expert,,CHEMBL620755,,10116.0,449.0,9,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3756,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,,Autocuration,,CHEMBL620756,,,,8,1,,B,,,BAO_0000357,4622
11923,,H,,,3757,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL620757,,,,8,1,,B,,,BAO_0000357,15086
11923,,H,,,3758,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",,Autocuration,,CHEMBL620758,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3759,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",,Autocuration,,CHEMBL620759,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3760,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,,Autocuration,,CHEMBL620760,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,,,3761,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,,Autocuration,,CHEMBL620761,,,449.0,8,1,CHO,B,,,BAO_0000219,16372
11923,,H,2116.0,,3762,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Ileum,Autocuration,,CHEMBL620762,,,,8,1,,F,,,BAO_0000221,17386
11923,,H,2116.0,,3763,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,Ileum,Autocuration,,CHEMBL620763,,,,8,1,,F,,,BAO_0000221,17386
11923,,H,2116.0,,3764,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,Ileum,Autocuration,,CHEMBL620764,,,,8,1,,F,,,BAO_0000221,17386
11923,,D,,,3765,Rattus norvegicus,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,,Expert,,CHEMBL857990,,10116.0,,9,1,,B,,Membranes,BAO_0000249,5831
11923,,H,,,3766,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,,Autocuration,,CHEMBL620765,,,,8,1,,B,,,BAO_0000357,4342
11923,,H,,,3767,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,,Expert,,CHEMBL620766,,,,8,1,,B,,,BAO_0000357,17319
11923,,H,1898.0,,3768,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,Hypothalamus,Expert,,CHEMBL620767,,,,8,1,,B,,,BAO_0000019,17342
11923,,H,,,3769,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,,Autocuration,,CHEMBL620768,,,,8,1,,B,,,BAO_0000357,17342
11923,,H,1898.0,,3770,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,Hypothalamus,Expert,,CHEMBL619051,,,,8,1,,B,,,BAO_0000249,3680
11923,,H,,,3771,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL619052,,,,8,1,,B,,,BAO_0000357,3680
11923,,D,,,3772,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,,Expert,,CHEMBL619053,,10116.0,722.0,9,1,HEK293,F,,,BAO_0000219,17319
11923,,D,,,3773,Rattus norvegicus,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,,Expert,,CHEMBL619703,,10116.0,722.0,9,1,HEK293,F,,,BAO_0000219,17319
11923,,D,,,3774,Rattus norvegicus,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,,Autocuration,,CHEMBL619704,,10116.0,722.0,9,1,HEK293,F,,,BAO_0000219,17319
10209,,H,,,3775,,Binding affinity towards 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL619851,,,,8,1,,B,,,BAO_0000357,4820
10209,,H,,,3776,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,,Autocuration,,CHEMBL619852,,,,8,1,,B,,,BAO_0000357,4639
10209,,H,,,3777,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,,Autocuration,,CHEMBL619853,,,,8,1,,B,,,BAO_0000357,6011
10209,,D,,,3778,Homo sapiens,Binding affinity towards human 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL619854,,9606.0,,9,1,,B,,,BAO_0000357,17066
10209,,H,,,3779,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL619855,,,,8,1,,B,,,BAO_0000357,17066
10209,,H,,,3780,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,,Autocuration,,CHEMBL619856,,,,8,1,,B,,,BAO_0000357,17515
10209,,H,,,3781,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,Autocuration,,CHEMBL619857,,,,8,1,,B,,,BAO_0000357,4373
10209,,H,,,3782,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,,Expert,,CHEMBL619858,,,,8,1,,F,,,BAO_0000019,17066
10209,,H,,,3783,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,,Autocuration,,CHEMBL619859,,,,8,1,,B,,,BAO_0000357,4373
10209,,H,,,3784,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,,Autocuration,,CHEMBL619860,,,,8,1,,B,,,BAO_0000357,4373
10209,,H,,,3785,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL619861,,,,8,1,,B,,,BAO_0000357,4687
10209,,H,,,3786,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL619862,,,,8,1,,B,,,BAO_0000357,17342
10209,,H,,,3787,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,,Autocuration,,CHEMBL619863,,,,8,1,,B,,,BAO_0000357,16946
10209,,H,,,3788,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,,Autocuration,,CHEMBL619864,,,,8,1,,B,,,BAO_0000357,16946
10209,,H,,,3789,,Binding affinities against 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL872928,,,,8,1,,B,,,BAO_0000357,16633
10209,,H,,,3790,,Binding affinities towards 5-hydroxytryptamine 7 receptor,,Autocuration,,CHEMBL619865,,,,8,1,,B,,,BAO_0000357,16633
10209,,H,,,3791,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,,Expert,,CHEMBL619866,,,,8,1,,B,,,BAO_0000357,17066
10209,,H,,,3792,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,,Autocuration,,CHEMBL619867,,,,8,1,,B,,,BAO_0000357,16700
10209,,H,2116.0,,3793,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,Ileum,Autocuration,,CHEMBL619868,,,,8,1,,B,,,BAO_0000221,17386
55,,H,,,3794,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,,Autocuration,,CHEMBL619869,,,,8,1,,F,,,BAO_0000019,14080
55,,D,,,3795,Homo sapiens,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,,Expert,,CHEMBL619870,,9606.0,,9,1,,F,,,BAO_0000019,14080
55,,H,,,3796,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,,Autocuration,,CHEMBL619871,,,,8,1,,B,,,BAO_0000357,409
55,,H,,,3797,,In vitro inhibition of human recombinant lipoxygenase enzyme,,Autocuration,,CHEMBL619872,,,,8,1,,B,,,BAO_0000357,409
55,,H,,,3798,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,,Autocuration,,CHEMBL619873,,,,8,1,,B,,,BAO_0000357,409
55,,H,178.0,,3799,,Inhibition of 5-lipoxygenase in human whole blood.,Blood,Expert,,CHEMBL619874,,,,8,1,,B,,,BAO_0000357,11090
55,,H,178.0,,3800,,Inhibition of 5-lipoxygenase in human whole blood.,Blood,Expert,,CHEMBL619875,,,,8,1,,B,,,BAO_0000357,11090
55,,H,,,3801,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,,Autocuration,,CHEMBL619876,,,,8,1,,B,,,BAO_0000357,948
55,,H,,,3802,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),,Autocuration,,CHEMBL619877,,,,8,1,,B,,,BAO_0000357,948
55,,H,,,3803,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,,Expert,,CHEMBL619878,,,,8,1,,F,,,BAO_0000219,13622
55,,H,178.0,,3804,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,Blood,Autocuration,,CHEMBL619879,,,,8,1,,F,,,BAO_0000019,13622
55,,H,,,3805,,In vitro inhibition of 5-lipoxygenase from human polymorphs,,Autocuration,,CHEMBL619880,,,,8,1,,B,,,BAO_0000357,9637
55,,H,,,3806,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),,Autocuration,,CHEMBL619881,,,,8,1,,B,,,BAO_0000357,11320
55,,H,,,3807,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,,Expert,,CHEMBL619882,,,,8,1,,B,,,BAO_0000357,11320
55,,H,,,3808,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,,Autocuration,,CHEMBL619883,,,,8,1,,B,,,BAO_0000357,6838
55,,D,178.0,,3809,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),Blood,Expert,,CHEMBL619884,,9606.0,,9,1,,B,,,BAO_0000357,17667
55,,H,,,3810,,In vitro potency against human 5-Lipoxygenase,,Autocuration,,CHEMBL619885,,,,8,1,,B,,,BAO_0000357,12703
55,,D,,,3811,Homo sapiens,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,,Expert,,CHEMBL619886,,9606.0,,9,1,,F,,,BAO_0000019,14312
55,,H,178.0,,3812,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,Blood,Autocuration,,CHEMBL619887,,,,8,1,,F,,,BAO_0000019,14312
55,,H,,,3813,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,Autocuration,,CHEMBL875097,,,,8,1,,F,,,BAO_0000019,5364
55,,H,,,3814,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,,Autocuration,,CHEMBL618001,,,,8,1,,B,,,BAO_0000219,951
55,,H,,,3815,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,,Autocuration,,CHEMBL618002,,,,8,1,,B,,,BAO_0000219,951
55,,H,,,3816,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,,Autocuration,,CHEMBL618003,,,,8,1,,B,,,BAO_0000219,951
55,,H,,,3817,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,,Autocuration,,CHEMBL618004,,,,8,1,,B,,,BAO_0000219,951
55,,H,,,3818,,Inhibition of human 5-lipoxygenase in human cells,,Autocuration,,CHEMBL618005,,,,8,1,,B,,,BAO_0000219,12365
55,,H,,,3819,,Inhibition of human neutrophil 5-lipoxygenase,,Expert,,CHEMBL618006,,,,8,1,,B,,,BAO_0000357,10603
55,,H,,,3820,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,,Autocuration,,CHEMBL875086,,,,8,1,,B,,,BAO_0000019,10501
55,,H,178.0,,3821,,Inhibition of 5-lipoxygenase from human whole blood,Blood,Expert,,CHEMBL618007,,,,8,1,,B,,,BAO_0000357,12281
55,,H,,,3822,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,Autocuration,,CHEMBL618008,,,,8,1,,B,,,BAO_0000357,2567
55,,H,,,3823,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,,Autocuration,,CHEMBL618009,,,,8,1,,B,,,BAO_0000219,2567
55,,H,,,3824,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,,Expert,,CHEMBL618010,,,,8,1,,B,,,BAO_0000357,10193
55,,H,,,3825,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,Autocuration,,CHEMBL618011,,,,8,1,,B,,,BAO_0000357,10193
55,,H,,,3826,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,,Expert,,CHEMBL618012,,,,8,1,,B,,,BAO_0000357,13623
55,,H,,,3827,,Tested against 5-lipoxygenase,,Autocuration,,CHEMBL882927,,,,8,1,,B,,,BAO_0000357,12780
55,,H,,,3828,,Tested for activity against 5-Lipoxygenase (5-LO),,Autocuration,,CHEMBL618013,,,,8,1,,B,,,BAO_0000357,12780
55,,H,,,3829,,Tested for activity against 5-lipoxygenase,,Autocuration,,CHEMBL618014,,,,8,1,,B,,,BAO_0000357,12780
55,,H,,,3830,,Tested for inhibition of 5-HPETE production by human 5-LO,,Autocuration,,CHEMBL618015,,,,8,1,,B,,,BAO_0000357,11966
55,,H,,,3831,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,,Autocuration,,CHEMBL618016,,,,8,1,,F,,,BAO_0000019,5364
55,,H,,,3832,,Inhibition of Human 5-lipoxygenase,,Expert,,CHEMBL618017,,,,8,1,,B,,,BAO_0000357,13165
55,,H,,,3833,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,,Autocuration,,CHEMBL618018,,,,8,1,,B,,,BAO_0000019,5364
55,,H,,,3834,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],,Autocuration,,CHEMBL875087,,,,8,1,,B,,,BAO_0000219,11311
55,,H,,,3835,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],,Autocuration,,CHEMBL618019,,,,8,1,,B,,,BAO_0000219,11311
55,,H,,,3836,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,,Autocuration,,CHEMBL618020,,,,8,1,,B,,,BAO_0000019,14863
55,,H,,,3837,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,,Autocuration,,CHEMBL618021,,,,8,1,,B,,,BAO_0000019,14863
55,,H,178.0,,3838,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),Blood,Autocuration,,CHEMBL618022,,,,8,1,,B,,,BAO_0000357,11087
55,,H,,,3839,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,,Autocuration,,CHEMBL618023,,,,8,1,,B,,,BAO_0000357,455
55,,H,,,3840,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,Autocuration,,CHEMBL618024,,,,8,1,,B,,,BAO_0000357,13183
55,,H,,,3841,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,,Expert,,CHEMBL873950,,,,8,1,,B,,,BAO_0000019,10319
55,,H,,,3842,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,Autocuration,,CHEMBL618025,,,,8,1,,B,,,BAO_0000357,10193
55,,H,,,3843,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,,Autocuration,,CHEMBL618026,,,,8,1,,B,,,BAO_0000219,951
55,,H,,,3844,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,,Autocuration,,CHEMBL618027,,,,8,1,,B,,,BAO_0000219,951
55,,H,,,3845,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,,Autocuration,,CHEMBL618028,,,,8,1,,B,,,BAO_0000219,951
55,,H,,,3846,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,,Autocuration,,CHEMBL618029,,,,8,1,,B,,,BAO_0000219,951
55,,H,,,3847,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,,Expert,,CHEMBL618030,,,,8,1,,B,,,BAO_0000357,9859
55,,H,,,3848,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,,Expert,,CHEMBL618031,,,,8,1,,B,,,BAO_0000357,9859
55,,H,,,3849,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,,Autocuration,,CHEMBL618032,,,,8,1,,B,,,BAO_0000357,9859
55,,H,,,3850,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,,Autocuration,,CHEMBL618033,,,,8,1,,B,,,BAO_0000357,2567
55,,H,,,3851,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,,Autocuration,,CHEMBL618034,,,,8,1,,B,,,BAO_0000357,10193
55,,H,,,3852,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,,Autocuration,,CHEMBL875088,,,,8,1,,B,,,BAO_0000357,10193
55,,H,,,3853,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,,Autocuration,,CHEMBL618035,,,,8,1,,B,,,BAO_0000019,949
55,,H,,,3854,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,,Autocuration,,CHEMBL618036,,,,8,1,,B,,,BAO_0000019,949
55,,H,,,3855,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,,Expert,,CHEMBL618037,,,,8,1,,B,,,BAO_0000357,10603
55,,H,,,3856,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,Expert,,CHEMBL618038,,,,8,1,,B,,,BAO_0000357,10603
55,,H,,,3857,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,,Autocuration,,CHEMBL618761,,,,8,1,,F,,,BAO_0000019,10603
55,,H,,,3858,,Inhibition of lipoxygenase at the concentration of 0.1 uM,,Expert,,CHEMBL618762,,,,8,1,,B,,,BAO_0000357,10603
55,,H,,,3859,,Inhibition of lipoxygenase at the concentration of 1 uM,,Expert,,CHEMBL618763,,,,8,1,,B,,,BAO_0000357,10603
55,,H,,,3860,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,,Autocuration,,CHEMBL618764,,,,8,1,,B,,,BAO_0000357,10193
55,,D,,,3861,Homo sapiens,Inhibition of 5-Lipoxygenase (5-LOX),,Expert,,CHEMBL618765,,9606.0,,9,1,,B,,,BAO_0000357,14580
17087,,H,,,3862,,Inhibition of 5-lipoxygenase in mouse macrophages.,,Expert,,CHEMBL618766,,,,8,1,,B,,,BAO_0000357,11090
17087,,H,,,3863,,Inhibition of 5-lipoxygenase in mouse macrophages.,,Expert,,CHEMBL618767,,,,8,1,,B,,,BAO_0000357,11090
17087,,H,,,3864,,Inhibitory activity against lipoxygenase-2 in mice,,Autocuration,,CHEMBL619380,,,,8,1,,B,,,BAO_0000357,6339
17087,,H,,,3865,,Inhibitory activity against murine lipoxygenase-2.,,Expert,,CHEMBL619381,,,,8,1,,B,,,BAO_0000357,6339
17087,,D,,,3866,Mus musculus,Inhibition of 5-lipoxygenase from mouse macrophage,,Expert,,CHEMBL619382,,10090.0,,9,1,,B,,,BAO_0000357,12281
17087,,H,,,3867,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,,Autocuration,,CHEMBL619383,,,,8,1,,B,,,BAO_0000357,11311
55,,H,,,3868,Sus scrofa,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,,Autocuration,,CHEMBL619384,,9823.0,,8,1,,B,,,BAO_0000019,11089
55,,H,,,3869,Sus scrofa,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,,Autocuration,,CHEMBL619385,,9823.0,,8,1,,B,,,BAO_0000019,10091
55,,H,,,3870,Oryctolagus cuniculus,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,,Autocuration,,CHEMBL882928,,9986.0,,8,1,,B,,,BAO_0000019,14352
12166,,D,,,3871,Rattus norvegicus,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,,Expert,,CHEMBL619386,,10116.0,,9,1,,B,,,BAO_0000019,13329
12166,,H,,,3872,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",,Autocuration,,CHEMBL619387,,,,8,1,,B,,,BAO_0000019,13329
12166,,H,,,3873,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,Autocuration,,CHEMBL619388,,,,8,1,,B,,,BAO_0000019,13329
12166,,H,,,3874,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",,Autocuration,,CHEMBL619389,,,,8,1,,B,,,BAO_0000019,13329
12166,,H,,,3875,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),,Expert,,CHEMBL619390,,,,8,1,,B,,,BAO_0000019,13329
12166,,H,,,3876,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",,Expert,,CHEMBL619391,,,,8,1,,B,,,BAO_0000019,13329
12166,,H,,,3877,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,,Autocuration,,CHEMBL619392,,,,8,1,,B,,,BAO_0000019,13329
12166,,H,,,3878,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),,Autocuration,,CHEMBL619393,,,,8,1,,B,,,BAO_0000019,11311
12166,,H,,,3879,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,,Autocuration,,CHEMBL619394,,,,8,1,,B,,,BAO_0000019,11311
12166,,H,,,3880,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,Autocuration,,CHEMBL619395,,,702.0,8,1,RBL-1,B,,,BAO_0000219,105
12166,,H,,,3881,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",,Autocuration,,CHEMBL619396,,,702.0,8,1,RBL-1,B,,,BAO_0000219,105
12166,,H,,,3882,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),,Autocuration,,CHEMBL619397,,,,8,1,,B,,,BAO_0000357,9138
12166,,H,,,3883,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",,Autocuration,,CHEMBL619398,,,,8,1,,B,,,BAO_0000357,9138
12166,,H,,,3884,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",,Autocuration,,CHEMBL619399,,,,8,1,,B,,,BAO_0000357,9138
12166,,H,,,3885,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,Autocuration,,CHEMBL619400,,,,8,1,,B,,,BAO_0000357,14427
12166,,H,,,3886,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",,Autocuration,,CHEMBL619401,,,,8,1,,B,,,BAO_0000019,13329
12166,,H,,,3887,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",,Autocuration,,CHEMBL619402,,,,8,1,,B,,,BAO_0000019,13329
12166,,D,,,3888,Rattus norvegicus,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,,Expert,,CHEMBL619403,,10116.0,663.0,9,1,RBL-2H3,B,,,BAO_0000219,14427
12166,,H,,,3889,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,,Autocuration,,CHEMBL619404,,,,8,1,,B,,,BAO_0000357,14427
12166,,H,,,3890,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,,Autocuration,,CHEMBL619405,,,,8,1,,B,,,BAO_0000357,14427
12166,,H,,,3891,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,,Expert,,CHEMBL619406,,,702.0,8,1,RBL-1,B,,,BAO_0000219,10293
12166,,D,,,3892,Rattus norvegicus,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,,Expert,,CHEMBL619407,,10116.0,702.0,9,1,RBL-1,B,,,BAO_0000219,338
12166,,H,,,3893,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),,Autocuration,,CHEMBL619408,,,,8,1,,B,,,BAO_0000357,303
12166,,H,,,3894,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,,Autocuration,,CHEMBL619409,,,702.0,8,1,RBL-1,B,,,BAO_0000219,303
12166,,H,,,3895,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,,Expert,,CHEMBL619410,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9247
12166,,H,,,3896,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,Autocuration,,CHEMBL619753,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9247
12166,,H,,,3897,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,,Autocuration,,CHEMBL619754,,,702.0,8,1,RBL-1,B,,,BAO_0000219,137
12166,,H,,,3898,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,,Expert,,CHEMBL619903,,,,8,1,,B,,,BAO_0000357,11481
12166,,H,,,3899,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",,Expert,,CHEMBL619904,,,,8,1,,B,,,BAO_0000357,11481
12166,,H,,,3900,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,,Expert,,CHEMBL619905,,,,8,1,,B,,,BAO_0000357,9029
12166,,H,,,3901,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,,Autocuration,,CHEMBL619906,,,,8,1,,B,,,BAO_0000019,1701
12166,,H,,,3902,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,,Autocuration,,CHEMBL619907,,,,8,1,,B,,,BAO_0000019,1701
12166,,H,,,3903,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,,Autocuration,,CHEMBL619908,,,,8,1,,B,,,BAO_0000019,1701
12166,,H,,,3904,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,,Autocuration,,CHEMBL619909,,,,8,1,,B,,,BAO_0000019,1701
12166,,H,,,3905,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,,Expert,,CHEMBL619910,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13358
12166,,H,,,3906,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,,Expert,,CHEMBL882929,,,702.0,8,1,RBL-1,B,,,BAO_0000219,1175
12166,,H,,,3907,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,,Expert,,CHEMBL619911,,,702.0,8,1,RBL-1,B,,,BAO_0000219,8797
12166,,H,,,3908,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,,Autocuration,,CHEMBL619912,,,,8,1,,B,,,BAO_0000019,8797
12166,,D,,,3909,Rattus norvegicus,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,,Expert,,CHEMBL619913,,10116.0,,9,1,,B,,,BAO_0000357,577
12166,,H,,,3910,,In vitro inhibitory activity against RBL-1 5-LO,,Expert,,CHEMBL619914,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9295
12166,,H,,,3911,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),,Autocuration,,CHEMBL619915,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9295
12166,,H,,,3912,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),,Autocuration,,CHEMBL619916,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9295
12166,,H,,,3913,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,,Autocuration,,CHEMBL619917,,,,8,1,,B,,,BAO_0000218,9295
12166,,H,,,3914,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,,Autocuration,,CHEMBL619918,,,,8,1,,B,,,BAO_0000357,9295
12166,,H,,,3915,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,,Autocuration,,CHEMBL619919,,,,8,1,,B,,,BAO_0000218,216
12166,,H,,,3916,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,,Autocuration,,CHEMBL883710,,,702.0,8,1,RBL-1,B,,,BAO_0000219,11090
12166,,H,178.0,,3917,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,Blood,Autocuration,,CHEMBL619920,,,,8,1,,B,,,BAO_0000019,11090
12166,,H,,,3918,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,,Expert,,CHEMBL619921,,,,8,1,,B,,,BAO_0000357,10091
12166,,H,,,3919,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,,Autocuration,,CHEMBL619922,,,,8,1,,F,,,BAO_0000019,10274
12166,,H,,,3920,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,,Autocuration,,CHEMBL619923,,,,8,1,,F,,,BAO_0000219,13622
12166,,H,,,3921,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,,Expert,,CHEMBL619924,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12118
12166,,H,,,3922,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,,Expert,,CHEMBL619925,,,,8,1,,B,,,BAO_0000357,12576
12166,,H,,,3923,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,,Expert,,CHEMBL619926,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9546
12166,,H,,,3924,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,,Autocuration,,CHEMBL619927,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9521
12166,,H,,,3925,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,,Expert,,CHEMBL619928,,,702.0,8,1,RBL-1,B,,,BAO_0000219,10626
12166,,H,,,3926,,In vitro inhibition of RBL-1 5-lipoxygenase,,Autocuration,,CHEMBL619929,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3927,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,,Autocuration,,CHEMBL875089,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3928,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,,Autocuration,,CHEMBL619930,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3929,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,,Autocuration,,CHEMBL619931,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3930,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,,Autocuration,,CHEMBL619932,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3931,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,,Autocuration,,CHEMBL619933,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3932,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,,Autocuration,,CHEMBL619934,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3933,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,,Autocuration,,CHEMBL619935,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3934,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,,Autocuration,,CHEMBL619936,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3935,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,,Autocuration,,CHEMBL619937,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3936,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,,Autocuration,,CHEMBL619938,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3937,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,,Autocuration,,CHEMBL619939,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3938,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,,Autocuration,,CHEMBL619940,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3939,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,,Autocuration,,CHEMBL875090,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3940,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,,Autocuration,,CHEMBL619941,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3941,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,,Autocuration,,CHEMBL619942,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3942,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,,Autocuration,,CHEMBL883711,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3943,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,,Autocuration,,CHEMBL619943,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3944,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,,Autocuration,,CHEMBL619944,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3945,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,,Autocuration,,CHEMBL619945,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3946,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,,Autocuration,,CHEMBL619946,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3947,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,,Autocuration,,CHEMBL619947,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3948,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,,Autocuration,,CHEMBL619948,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3949,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,,Autocuration,,CHEMBL619949,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,3950,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,,Expert,,CHEMBL619950,,,,8,1,,B,,,BAO_0000019,9401
12166,,H,,,3951,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,,Autocuration,,CHEMBL618050,,,,8,1,,B,,,BAO_0000019,10325
12166,,H,,,3952,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,,Expert,,CHEMBL875091,,,663.0,8,1,RBL-2H3,F,,,BAO_0000219,1556
12166,,H,,,3953,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,,Expert,,CHEMBL618051,,,663.0,8,1,RBL-2H3,F,,,BAO_0000219,1556
12166,,D,,,3954,Rattus norvegicus,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,,Expert,,CHEMBL618052,,10116.0,702.0,9,1,RBL-1,B,,,BAO_0000219,961
12166,,H,,,3955,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,,Autocuration,,CHEMBL618053,,,,8,1,,B,,,BAO_0000019,6838
12166,,H,,,3956,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),,Expert,,CHEMBL618054,,,,8,1,,B,,,BAO_0000019,10325
12166,,D,,,3957,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,Expert,,CHEMBL618055,,10116.0,702.0,9,1,RBL-1,B,,,BAO_0000219,9209
12166,,H,,,3958,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,,Expert,,CHEMBL618056,,,702.0,8,1,RBL-1,B,,,BAO_0000219,11520
12166,,H,,,3959,,In vitro inhibitory activity against 5-lipoxygenase was determined,,Autocuration,,CHEMBL618057,,,,8,1,,B,,,BAO_0000357,137
12166,,H,,,3960,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,,Autocuration,,CHEMBL618058,,,702.0,8,1,RBL-1,B,,,BAO_0000219,4717
12166,,H,,,3961,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,,Expert,,CHEMBL618059,,,702.0,8,1,RBL-1,B,,,BAO_0000219,10636
12166,,D,,,3962,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,,Expert,,CHEMBL618060,,10116.0,,9,1,,F,,,BAO_0000019,14312
12166,,H,,,3963,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,,Autocuration,,CHEMBL618061,,,702.0,8,1,RBL-1,B,,,BAO_0000219,1203
12166,,H,,,3964,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,,Autocuration,,CHEMBL618062,,,,8,1,,B,,,BAO_0000019,1203
12166,,H,,,3965,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,,Expert,,CHEMBL618063,,,702.0,8,1,RBL-1,B,,,BAO_0000219,13622
12166,,H,,,3966,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,,Autocuration,,CHEMBL618064,,,,8,1,,B,,,BAO_0000357,9793
12166,,D,,,3967,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,,Expert,,CHEMBL618065,,10116.0,702.0,9,1,RBL-1,B,,,BAO_0000219,1143
12166,,D,,,3968,Rattus norvegicus,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,,Expert,,CHEMBL618066,,10116.0,702.0,9,1,RBL-1,B,,,BAO_0000219,11854
12166,,H,,,3969,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,Autocuration,,CHEMBL618067,,,702.0,8,1,RBL-1,B,,,BAO_0000219,3595
12166,,H,,,3970,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,Autocuration,,CHEMBL618068,,,702.0,8,1,RBL-1,B,,,BAO_0000219,3595
12166,,D,,,3971,Rattus norvegicus,Inhibition of 5-lipoxygenase in rat RBL-1 cells,,Expert,,CHEMBL618069,,10116.0,702.0,9,1,RBL-1,B,,,BAO_0000219,10501
12166,,H,,,3972,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,Expert,,CHEMBL618070,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12526
10825,,H,349.0,,3973,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,Limbic system,Autocuration,,CHEMBL618071,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,349.0,,3974,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,Limbic system,Autocuration,,CHEMBL619247,,,,8,1,,F,,,BAO_0000019,10034
10825,,H,,,3975,,Approximate dose levels for a half maximal reduction of 5-HTP levels,,Autocuration,,CHEMBL619248,,,,8,1,,F,,,BAO_0000019,10034
10576,,H,10000000.0,,3976,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,Autocuration,,CHEMBL619249,,,,8,1,,B,,,BAO_0000221,10046
10576,,H,10000000.0,,3977,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,Hippocampus,Autocuration,,CHEMBL619250,,,,8,1,,B,,,BAO_0000221,10046
10577,,H,,,3978,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,,Autocuration,,CHEMBL619251,,,,8,1,,B,,,BAO_0000019,10046
55,,H,178.0,,3979,Canis lupus familiaris,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,Blood,Autocuration,,CHEMBL619252,,9615.0,,8,1,,F,,,BAO_0000019,12079
55,,H,178.0,,3980,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,Blood,Autocuration,,CHEMBL619253,,,,8,1,,F,,,BAO_0000019,12079
12166,,H,,,3981,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,Autocuration,,CHEMBL619254,,,,8,1,,B,,,BAO_0000219,11311
17140,,H,,,3982,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,,Expert,,CHEMBL619255,,,,8,1,,B,,,BAO_0000219,12338
17140,,H,,,3983,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,,Expert,,CHEMBL619256,,,,8,1,,B,,,BAO_0000219,12143
17140,,H,,,3984,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),,Autocuration,,CHEMBL875418,,,,8,1,,B,,,BAO_0000219,12143
17140,,H,,,3985,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,Expert,,CHEMBL619257,,,,8,1,,B,,,BAO_0000219,12143
17140,,H,,,3986,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,,Autocuration,,CHEMBL619258,,,,8,1,,B,,,BAO_0000219,12143
17140,,H,,,3987,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,,Expert,,CHEMBL619259,,,,8,1,,B,,,BAO_0000357,12365
17140,,H,,,3988,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,,Expert,,CHEMBL619260,,,,8,1,,B,,,BAO_0000357,13500
55,,H,178.0,,3989,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619261,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,3990,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619263,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,3991,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619264,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,3992,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619265,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,3993,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619266,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,3994,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619902,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,3995,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620058,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,3996,Canis lupus familiaris,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620059,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,3997,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620060,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,3998,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620061,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,3999,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",Blood,Autocuration,,CHEMBL620062,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4000,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620063,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4001,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",Blood,Autocuration,,CHEMBL620064,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4002,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620065,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4003,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",Blood,Autocuration,,CHEMBL620066,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4004,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620067,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4005,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",Blood,Autocuration,,CHEMBL620068,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4006,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620069,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4007,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,Autocuration,,CHEMBL620070,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4008,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620071,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4009,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,Autocuration,,CHEMBL620072,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4010,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620036,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4011,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",Blood,Autocuration,,CHEMBL857702,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4012,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620037,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4013,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",Blood,Autocuration,,CHEMBL620038,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4014,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620039,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4015,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,Autocuration,,CHEMBL620040,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4016,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620041,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4017,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,Autocuration,,CHEMBL620042,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4018,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620043,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4019,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,Autocuration,,CHEMBL620044,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4020,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620045,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4021,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,Autocuration,,CHEMBL620046,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4022,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620047,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4023,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",Blood,Autocuration,,CHEMBL620048,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4024,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL857703,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4025,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",Blood,Autocuration,,CHEMBL620049,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4026,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620050,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4027,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620051,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4028,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619213,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4029,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619214,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4030,Canis lupus familiaris,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619804,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4031,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619805,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4032,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619806,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4033,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619807,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,178.0,,4034,Canis lupus familiaris,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL619808,In vivo,9615.0,,8,1,,F,,,BAO_0000218,12832
55,,H,,,4035,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,,Autocuration,,CHEMBL619809,,9615.0,,8,1,,B,,,BAO_0000218,3595
55,,H,,,4036,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,,Autocuration,,CHEMBL619810,,9615.0,,8,1,,B,,,BAO_0000218,3595
55,,H,,,4037,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,,Autocuration,,CHEMBL619811,,9615.0,,8,1,,B,,,BAO_0000218,3595
55,,H,,,4038,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,,Autocuration,,CHEMBL620769,,9615.0,,8,1,,B,,,BAO_0000218,3595
55,,H,,,4039,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,,Autocuration,,CHEMBL620770,,9615.0,,8,1,,B,,,BAO_0000218,3595
55,,H,,,4040,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,,Autocuration,,CHEMBL620771,,9615.0,,8,1,,B,,,BAO_0000218,3595
55,,H,,,4041,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,,Autocuration,,CHEMBL620772,,9615.0,,8,1,,B,,,BAO_0000218,3595
55,,H,,,4042,Canis lupus familiaris,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,,Autocuration,,CHEMBL620773,,9615.0,,8,1,,B,,,BAO_0000218,3595
55,,H,,,4043,Cavia porcellus,Ability to inhibit 5-lipoxygenase in guinea pig,,Autocuration,,CHEMBL620774,,10141.0,,8,1,,B,,,BAO_0000357,9203
55,,H,,,4044,Cavia porcellus,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),,Expert,,CHEMBL620775,,10141.0,,8,1,,B,,,BAO_0000357,82
55,,H,,,4045,Cavia porcellus,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,,Autocuration,,CHEMBL620776,,10141.0,,8,1,,B,,,BAO_0000357,11090
55,,H,178.0,,4046,Cavia porcellus,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",Blood,Autocuration,,CHEMBL620777,,10141.0,,8,1,,B,,,BAO_0000218,12832
55,,H,,,4047,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,,Autocuration,,CHEMBL620778,,10141.0,,8,1,,B,,,BAO_0000357,1065
55,,H,,,4048,Cavia porcellus,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,,Autocuration,,CHEMBL620779,,10141.0,,8,1,,B,,,BAO_0000357,1065
55,,H,,,4049,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,,Expert,,CHEMBL621500,,10141.0,,8,1,,B,,,BAO_0000019,12832
55,,H,,,4050,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,Expert,,CHEMBL621501,,10141.0,,8,1,,B,,,BAO_0000019,12832
55,,H,,,4051,Cavia porcellus,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,,Autocuration,,CHEMBL618098,,10141.0,,8,1,,B,,,BAO_0000019,12832
55,,H,,,4052,Cavia porcellus,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,Autocuration,,CHEMBL618099,,10141.0,,8,1,,B,,,BAO_0000019,10504
55,,H,,,4053,Cavia porcellus,Inhibitory activity against 5-lipoxygenase,,Autocuration,,CHEMBL618100,,10141.0,,8,1,,B,,,BAO_0000357,7788
55,,H,,,4054,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,,Autocuration,,CHEMBL618101,,10141.0,,8,1,,B,,,BAO_0000357,10001
55,,H,,,4055,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,,Autocuration,,CHEMBL618102,,10141.0,,8,1,,B,,,BAO_0000357,10193
55,,H,,,4056,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,,Autocuration,,CHEMBL618103,,10141.0,,8,1,,B,,,BAO_0000357,13243
55,,H,,,4057,Cavia porcellus,Inhibitory activity uM,,Autocuration,,CHEMBL618104,,10141.0,,8,1,,B,,,BAO_0000357,13243
55,,H,,,4058,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,,Autocuration,,CHEMBL883712,,10141.0,,8,1,,B,,,BAO_0000219,969
55,,H,,,4059,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at 10 uM,,Autocuration,,CHEMBL618105,,10141.0,,8,1,,B,,,BAO_0000357,10001
55,,H,,,4060,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,Autocuration,,CHEMBL618106,,10141.0,,8,1,,B,,,BAO_0000357,7788
55,,H,,,4061,Cavia porcellus,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,,Autocuration,,CHEMBL618107,,10141.0,,8,1,,B,,,BAO_0000357,10001
55,,H,,,4062,Cavia porcellus,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,,Autocuration,,CHEMBL618108,,10141.0,,8,1,,B,,,BAO_0000357,10193
55,,H,,,4063,Cavia porcellus,Inhibitory activity uM,,Autocuration,,CHEMBL618109,,10141.0,,8,1,,B,,,BAO_0000357,13243
55,,H,,,4064,Cavia porcellus,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,,Autocuration,,CHEMBL618110,,10141.0,,8,1,,B,,,BAO_0000357,13243
55,,H,,,4065,Cavia porcellus,Inhibitory activity uM,,Expert,,CHEMBL618111,,10141.0,,8,1,,B,,,BAO_0000357,13243
55,,H,,,4066,Cavia porcellus,Inhibitory activity uM,,Autocuration,,CHEMBL618112,,10141.0,,8,1,,F,,,BAO_0000019,13243
55,,H,,,4067,Cavia porcellus,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,,Autocuration,,CHEMBL618113,,10141.0,,8,1,,B,,,BAO_0000019,10504
55,,H,,,4068,Cavia porcellus,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,,Autocuration,,CHEMBL618114,,10141.0,,8,1,,B,,,BAO_0000357,7788
55,,H,2116.0,,4069,Cavia porcellus,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,Ileum,Expert,,CHEMBL620871,,10141.0,,8,1,,F,,,BAO_0000221,10546
55,,H,,,4070,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,Autocuration,,CHEMBL620872,,,,8,1,,B,,,BAO_0000357,13183
55,,H,,,4071,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),,Autocuration,,CHEMBL620873,,,,8,1,,B,,,BAO_0000357,13183
55,,H,,,4072,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),,Autocuration,,CHEMBL620874,,,,8,1,,B,,,BAO_0000357,2578
55,,H,,,4073,,In vitro inhibition of human 5-Lipoxygenase.,,Expert,,CHEMBL620875,,,,8,1,,B,,,BAO_0000357,12780
22226,,U,2107.0,,4074,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Liver,Autocuration,,CHEMBL620876,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4075,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Liver,Autocuration,,CHEMBL620877,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4076,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Liver,Autocuration,,CHEMBL857854,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4077,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,Liver,Autocuration,,CHEMBL620878,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4078,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Liver,Autocuration,,CHEMBL620879,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4079,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,Autocuration,,CHEMBL620880,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4080,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,Autocuration,,CHEMBL620881,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4081,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Liver,Autocuration,,CHEMBL620882,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4082,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Liver,Autocuration,,CHEMBL620883,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4083,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Liver,Autocuration,,CHEMBL620884,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4084,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Liver,Autocuration,,CHEMBL620885,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4085,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,Liver,Autocuration,,CHEMBL620886,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4086,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Liver,Autocuration,,CHEMBL620887,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4087,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,Autocuration,,CHEMBL618039,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4088,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Liver,Autocuration,,CHEMBL618040,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4089,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,Autocuration,,CHEMBL618041,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4090,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,Autocuration,,CHEMBL618216,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4091,Rattus norvegicus,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,Autocuration,,CHEMBL618217,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4092,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,Liver,Autocuration,,CHEMBL618218,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4093,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,Liver,Autocuration,,CHEMBL618219,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4094,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,Liver,Autocuration,,CHEMBL618220,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4095,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,Liver,Autocuration,,CHEMBL618221,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4096,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,Liver,Autocuration,,CHEMBL618222,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4097,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Liver,Autocuration,,CHEMBL618223,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4098,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Liver,Autocuration,,CHEMBL618224,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4099,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,Liver,Autocuration,,CHEMBL618225,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4100,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,Liver,Autocuration,,CHEMBL618226,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4101,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,Autocuration,,CHEMBL618227,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4102,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Liver,Autocuration,,CHEMBL618228,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4103,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Liver,Autocuration,,CHEMBL618229,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4104,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,Liver,Autocuration,,CHEMBL618230,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4105,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,Liver,Autocuration,,CHEMBL618231,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4106,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,Liver,Autocuration,,CHEMBL618232,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4107,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,Liver,Autocuration,,CHEMBL618233,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4108,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,Liver,Autocuration,,CHEMBL618234,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4109,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,Liver,Autocuration,,CHEMBL618235,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4110,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,Liver,Autocuration,,CHEMBL618115,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4111,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,Liver,Autocuration,,CHEMBL618116,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4112,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,Liver,Autocuration,,CHEMBL618117,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4113,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,Liver,Autocuration,,CHEMBL619968,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4114,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,Autocuration,,CHEMBL619969,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4115,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,Liver,Autocuration,,CHEMBL619970,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4116,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,Liver,Autocuration,,CHEMBL619971,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4117,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,Liver,Autocuration,,CHEMBL619972,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4118,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,Liver,Autocuration,,CHEMBL619973,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4119,Rattus norvegicus,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,Liver,Autocuration,,CHEMBL619974,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4120,Rattus norvegicus,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,Liver,Autocuration,,CHEMBL619975,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,,,4121,Rattus norvegicus,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,,Autocuration,,CHEMBL619976,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4122,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,Autocuration,,CHEMBL619977,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4123,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,Autocuration,,CHEMBL619978,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4124,Rattus norvegicus,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",Liver,Autocuration,,CHEMBL619979,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4125,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",Liver,Autocuration,,CHEMBL619980,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4126,Rattus norvegicus,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",Liver,Autocuration,,CHEMBL619981,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
80433,,N,,,4127,Homo sapiens,In vitro inhibition of 7226/S myeloma cancer cell line,,Intermediate,,CHEMBL619982,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,10797
80698,,N,,,4128,Homo sapiens,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),,Intermediate,,CHEMBL619983,,9606.0,993.0,1,1,BEL-7404 tumor cell line,F,,,BAO_0000219,6881
80640,,N,,,4129,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,Intermediate,,CHEMBL620031,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,3838
80640,,N,,,4130,Homo sapiens,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,,Intermediate,,CHEMBL620032,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,3838
81264,,N,,,4131,Cricetulus griseus,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,,Expert,,CHEMBL620033,,10029.0,505.0,1,1,V79,F,,,BAO_0000219,12981
81264,,N,,,4132,Cricetulus griseus,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,,Expert,,CHEMBL620034,,10029.0,505.0,1,1,V79,F,,,BAO_0000219,12981
80635,,N,,,4133,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,,Intermediate,,CHEMBL620035,,10116.0,1119.0,1,1,7800C1 cell line,F,,,BAO_0000219,7653
80635,,N,,,4134,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,,Intermediate,,CHEMBL618318,,10116.0,1119.0,1,1,7800C1 cell line,F,,,BAO_0000219,7653
80635,,N,,,4135,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,,Intermediate,,CHEMBL618319,,10116.0,1119.0,1,1,7800C1 cell line,F,,,BAO_0000219,7653
80635,,N,,,4136,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,,Intermediate,,CHEMBL618320,,10116.0,1119.0,1,1,7800C1 cell line,F,,,BAO_0000219,7653
80635,,N,,,4137,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,,Intermediate,,CHEMBL618321,,10116.0,1119.0,1,1,7800C1 cell line,F,,,BAO_0000219,7653
80635,,N,,,4138,Rattus norvegicus,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,,Intermediate,,CHEMBL883118,,10116.0,1119.0,1,1,7800C1 cell line,F,,,BAO_0000219,7653
80640,,N,,,4139,Homo sapiens,In vitro antitumor activity against renal 786-0 tumor cell lines,,Intermediate,,CHEMBL883795,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,17229
80640,,N,,,4140,Homo sapiens,Cytotoxic activity against 786-0 Renal cancer cell line,,Intermediate,,CHEMBL618322,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,12858
80640,,N,,,4141,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,,Intermediate,,CHEMBL618323,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,16325
80640,,N,,,4142,Homo sapiens,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,,Intermediate,,CHEMBL618324,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,16325
80640,,N,,,4143,Homo sapiens,In vitro antitumor activity against human renal 786-0 cell line,,Intermediate,,CHEMBL618325,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,5858
80640,,N,,,4144,Homo sapiens,Inhibition of Renal cancer in 786-0 cancer cell lines,,Intermediate,,CHEMBL875416,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,16325
80640,,N,,,4145,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,,Intermediate,,CHEMBL618326,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14696
80640,,N,,,4146,Homo sapiens,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,,Intermediate,,CHEMBL618327,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,3786
80640,,N,,,4147,Homo sapiens,inhibition of the growth of renal cancer(786-0) cell line,,Intermediate,,CHEMBL619215,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14696
80640,,N,,,4148,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,Intermediate,,CHEMBL619216,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14769
80640,,N,,,4149,Homo sapiens,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,,Intermediate,,CHEMBL619217,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,15354
80640,,N,,,4150,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor,,Intermediate,,CHEMBL619218,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14255
80640,,N,,,4151,Homo sapiens,The IC50 value was measured on 786-0 cell line in ovarian tumor t,,Intermediate,,CHEMBL619219,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14255
80640,,N,,,4152,Homo sapiens,The IC50 value was measured on 786-0 cell line in renal tumor type.,,Intermediate,,CHEMBL619220,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14255
80640,,N,,,4153,Homo sapiens,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,,Intermediate,,CHEMBL619221,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14696
80640,,N,,,4154,Homo sapiens,Tested for cytotoxic activity against renal cancer 786-0 cell line,,Intermediate,,CHEMBL619222,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,12016
80640,,N,,,4155,Homo sapiens,Compound was tested for growth inhibitory activity against 786-0 cell line,,Intermediate,,CHEMBL857454,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,2597
12166,,H,,,4156,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,,Autocuration,,CHEMBL619223,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12526
12166,,H,,,4157,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,,Autocuration,,CHEMBL619224,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12526
12166,,H,,,4158,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,Autocuration,,CHEMBL619225,,,,8,1,,B,,,BAO_0000019,14799
12166,,H,,,4159,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),,Expert,,CHEMBL619226,,,702.0,8,1,RBL-1,B,,,BAO_0000219,3595
12166,,H,,,4160,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),,Expert,,CHEMBL619227,,,702.0,8,1,RBL-1,B,,,BAO_0000219,3595
12166,,H,,,4161,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,,Autocuration,,CHEMBL619228,,,,8,1,,B,,,BAO_0000357,12767
12166,,H,,,4162,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,,Autocuration,,CHEMBL619229,,,,8,1,,B,,,BAO_0000219,10997
12166,,H,,,4163,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,,Autocuration,,CHEMBL619230,,,702.0,8,1,RBL-1,B,,,BAO_0000219,11388
12166,,H,,,4164,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,,Autocuration,,CHEMBL619231,,,,8,1,,B,,,BAO_0000357,167
12166,,H,,,4165,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",,Autocuration,,CHEMBL619232,,,,8,1,,B,,,BAO_0000357,167
12166,,H,,,4166,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,,Expert,,CHEMBL619233,,,,8,1,,B,,,BAO_0000357,13744
12166,,H,,,4167,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,,Autocuration,,CHEMBL619234,,,,8,1,,B,,,BAO_0000357,1630
12166,,H,,,4168,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),,Autocuration,,CHEMBL619235,,,,8,1,,B,,,BAO_0000357,1630
12166,,D,,,4169,Rattus norvegicus,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",,Expert,,CHEMBL619236,,10116.0,,9,1,,B,,,BAO_0000019,969
12166,,H,,,4170,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,,Autocuration,,CHEMBL619237,,,702.0,8,1,RBL-1,B,,,BAO_0000219,13621
12166,,H,,,4171,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,,Autocuration,,CHEMBL619238,,,,8,1,,B,,,BAO_0000357,10089
12166,,H,,,4172,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,,Expert,,CHEMBL619239,,,,8,1,,B,,,BAO_0000357,10193
12166,,H,,,4173,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,,Autocuration,,CHEMBL619240,,,,8,1,,B,,,BAO_0000357,11966
12166,,H,,,4174,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,Autocuration,,CHEMBL875417,,,,8,1,,B,,,BAO_0000019,12251
12166,,H,,,4175,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),,Autocuration,,CHEMBL619241,,,702.0,8,1,RBL-1,B,,,BAO_0000219,211
12166,,H,,,4176,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,,Expert,,CHEMBL619242,,,,8,1,,F,,,BAO_0000019,12251
12166,,H,,,4177,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,,Autocuration,,CHEMBL883796,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12495
12166,,H,,,4178,,Tested for its inhibitory activity against 5-lipoxygenase,,Autocuration,,CHEMBL619243,,,,8,1,,B,,,BAO_0000357,414
12166,,H,,,4179,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,,Autocuration,,CHEMBL619244,,,,8,1,,B,,,BAO_0000357,414
12166,,H,,,4180,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",,Expert,,CHEMBL619245,,,,8,1,,B,,,BAO_0000019,10325
12166,,H,,,4181,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,Expert,,CHEMBL619246,,,,8,1,,B,,,BAO_0000019,11966
12166,,H,,,4182,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,,Expert,,CHEMBL619984,,,702.0,8,1,RBL-1,B,,,BAO_0000219,165
12166,,H,,,4183,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,,Autocuration,,CHEMBL619985,,,702.0,8,1,RBL-1,B,,,BAO_0000219,165
12166,,H,,,4184,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,Autocuration,,CHEMBL619986,,,702.0,8,1,RBL-1,B,,,BAO_0000219,165
12166,,H,,,4185,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,,Expert,,CHEMBL619987,,,702.0,8,1,RBL-1,B,,,BAO_0000219,165
12166,,H,,,4186,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,,Autocuration,,CHEMBL619988,,,,8,1,,B,,,BAO_0000218,11311
12166,,H,,,4187,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,,Autocuration,,CHEMBL619989,,,702.0,8,1,RBL-1,B,,,BAO_0000219,11311
12166,,H,,,4188,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,,Autocuration,,CHEMBL619990,,,702.0,8,1,RBL-1,B,,,BAO_0000219,11311
12166,,H,,,4189,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],,Autocuration,,CHEMBL619991,,,,8,1,,B,,,BAO_0000219,11311
12166,,H,,,4190,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),,Autocuration,,CHEMBL619992,,,,8,1,,B,,,BAO_0000219,11311
12166,,H,,,4191,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),,Autocuration,,CHEMBL619993,In vivo,,,8,1,,B,,,BAO_0000218,11311
12166,,H,,,4192,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,,Autocuration,,CHEMBL619994,,,663.0,8,1,RBL-2H3,F,,,BAO_0000219,11311
12166,,H,,,4193,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,,Autocuration,,CHEMBL619995,,,663.0,8,1,RBL-2H3,F,,,BAO_0000219,11311
12166,,H,,,4194,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],,Autocuration,,CHEMBL619996,,,,8,1,,B,,,BAO_0000019,11311
12166,,H,,,4195,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,,Autocuration,,CHEMBL619997,,,,8,1,,B,,,BAO_0000019,11732
12166,,H,,,4196,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,,Expert,,CHEMBL619998,,,,8,1,,B,,,BAO_0000019,11732
12166,,H,,,4197,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,,Expert,,CHEMBL619999,,,,8,1,,B,,,BAO_0000019,11087
12166,,H,,,4198,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,,Autocuration,,CHEMBL620000,,,,8,1,,B,,,BAO_0000019,11087
12166,,H,,,4199,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,,Autocuration,,CHEMBL620001,,,702.0,8,1,RBL-1,B,,,BAO_0000219,11087
12166,,D,,,4200,Rattus norvegicus,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,,Expert,,CHEMBL620002,,10116.0,,9,1,,B,,,BAO_0000357,11087
12166,,H,,,4201,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,,Autocuration,,CHEMBL620003,,,702.0,8,1,RBL-1,B,,,BAO_0000219,496
12166,,H,,,4202,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,,Expert,,CHEMBL620004,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13986
12166,,H,,,4203,,Compound was evaluated for the inhibition of 5-lipoxygenase,,Autocuration,,CHEMBL874063,,,,8,1,,B,,,BAO_0000357,11520
12166,,H,,,4204,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,,Autocuration,,CHEMBL620005,,,702.0,8,1,RBL-1,B,,,BAO_0000219,10293
12166,,H,,,4205,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,,Autocuration,,CHEMBL620006,,,702.0,8,1,RBL-1,B,,,BAO_0000219,303
12166,,H,,,4206,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,,Autocuration,,CHEMBL620007,,,702.0,8,1,RBL-1,B,,,BAO_0000219,303
12166,,H,,,4207,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,,Autocuration,,CHEMBL620008,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9247
12166,,D,,,4208,Rattus norvegicus,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,,Expert,,CHEMBL620009,,10116.0,702.0,9,1,RBL-1,B,,,BAO_0000219,9247
12166,,H,,,4209,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,,Autocuration,,CHEMBL620010,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9247
12166,,H,,,4210,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,,Autocuration,,CHEMBL620011,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9247
12166,,H,,,4211,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,,Autocuration,,CHEMBL620677,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9247
12166,,H,,,4212,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,,Autocuration,,CHEMBL620678,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9247
12166,,H,,,4213,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,,Autocuration,,CHEMBL620679,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9247
12166,,H,,,4214,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,,Autocuration,,CHEMBL620680,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9247
12166,,D,,,4215,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase at 10 uM,,Expert,,CHEMBL620838,,10116.0,,9,1,,B,,,BAO_0000357,11481
12166,,H,,,4216,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,,Autocuration,,CHEMBL620839,,,,8,1,,B,,,BAO_0000357,105
12166,,H,,,4217,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,,Expert,,CHEMBL620840,,,,8,1,,B,,,BAO_0000357,9029
12166,,H,,,4218,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,,Expert,,CHEMBL620841,,,702.0,8,1,RBL-1,B,,,BAO_0000219,1175
12166,,H,,,4219,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,,Autocuration,,CHEMBL620842,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12118
12166,,H,,,4220,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,,Autocuration,,CHEMBL620843,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12118
12166,,H,,,4221,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,,Autocuration,,CHEMBL620844,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12118
12166,,H,,,4222,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,,Autocuration,,CHEMBL620845,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9225
12166,,H,,,4223,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,,Autocuration,,CHEMBL620846,,,,8,1,,B,,,BAO_0000019,9401
12166,,H,,,4224,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,Autocuration,,CHEMBL873951,,,,8,1,,B,,,BAO_0000357,137
12166,,H,,,4225,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,,Autocuration,,CHEMBL620847,,,,8,1,,B,,,BAO_0000357,137
12166,,H,,,4226,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,Autocuration,,CHEMBL620848,,,702.0,8,1,RBL-1,B,,,BAO_0000219,4717
12166,,H,,,4227,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,Autocuration,,CHEMBL620849,,,702.0,8,1,RBL-1,B,,,BAO_0000219,3595
12166,,H,,,4228,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,,Autocuration,,CHEMBL620850,,,702.0,8,1,RBL-1,B,,,BAO_0000219,10501
12166,,H,,,4229,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,,Autocuration,,CHEMBL620851,,,702.0,8,1,RBL-1,B,,,BAO_0000219,10501
12166,,H,,,4230,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,,Autocuration,,CHEMBL620852,,,702.0,8,1,RBL-1,B,,,BAO_0000219,10501
12166,,H,,,4231,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,Autocuration,,CHEMBL875098,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12526
12166,,D,,,4232,Rattus norvegicus,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,,Expert,,CHEMBL620853,,10116.0,702.0,9,1,RBL-1,B,,,BAO_0000219,14799
12166,,H,,,4233,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,,Autocuration,,CHEMBL620854,,,,8,1,,B,,,BAO_0000019,14799
12166,,H,,,4234,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,,Autocuration,,CHEMBL620855,,,702.0,8,1,RBL-1,B,,,BAO_0000219,3595
12166,,H,,,4235,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,,Expert,,CHEMBL839884,,,702.0,8,1,RBL-1,B,,,BAO_0000219,3595
12166,,H,,,4236,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,Autocuration,,CHEMBL620856,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12526
12166,,H,,,4237,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,,Autocuration,,CHEMBL620857,,,702.0,8,1,RBL-1,B,,,BAO_0000219,12526
12166,,H,,,4238,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,Autocuration,,CHEMBL620858,,,,8,1,,B,,,BAO_0000019,10193
12166,,H,,,4239,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,Autocuration,,CHEMBL620859,,,,8,1,,B,,,BAO_0000019,10193
12166,,H,,,4240,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,,Autocuration,,CHEMBL620860,,,,8,1,,B,,,BAO_0000019,10193
12166,,H,,,4241,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,,Autocuration,,CHEMBL620861,,,,8,1,,B,,,BAO_0000019,10193
12166,,H,,,4242,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),,Expert,,CHEMBL620862,,,,8,1,,B,,,BAO_0000357,9138
12166,,H,,,4243,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,,Autocuration,,CHEMBL620863,,,,8,1,,B,,,BAO_0000357,9138
12166,,H,,,4244,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,,Autocuration,,CHEMBL620864,,,,8,1,,B,,,BAO_0000019,11966
12166,,H,,,4245,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,,Autocuration,,CHEMBL620865,,,702.0,8,1,RBL-1,B,,,BAO_0000219,165
12166,,H,,,4246,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,,Autocuration,,CHEMBL620866,,,702.0,8,1,RBL-1,B,,,BAO_0000219,165
12166,,H,,,4247,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,,Autocuration,,CHEMBL620867,,,663.0,8,1,RBL-2H3,B,,,BAO_0000219,11311
12166,,H,,,4248,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,Autocuration,,CHEMBL620868,,,663.0,8,1,RBL-2H3,B,,,BAO_0000219,11311
12166,,H,,,4249,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,,Autocuration,,CHEMBL620869,,,663.0,8,1,RBL-2H3,F,,,BAO_0000219,11311
12166,,H,,,4250,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,,Autocuration,,CHEMBL873952,,,,8,1,,F,,,BAO_0000019,11311
12166,,H,,,4251,,The compound was tested for inhibition of isolated 5-lipoxygenase,,Autocuration,,CHEMBL875099,,,,8,1,,B,,,BAO_0000357,11311
12166,,H,,,4252,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,,Autocuration,,CHEMBL620870,,,663.0,8,1,RBL-2H3,F,,,BAO_0000219,11311
12166,,H,,,4253,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,,Autocuration,,CHEMBL618261,,,,8,1,,B,,,BAO_0000019,11087
12166,,H,,,4254,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,,Autocuration,,CHEMBL618262,,,,8,1,,B,,,BAO_0000019,11087
12166,,H,,,4255,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,,Autocuration,,CHEMBL619428,,,,8,1,,B,,,BAO_0000019,11087
12166,,H,,,4256,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,Autocuration,,CHEMBL619429,,,,8,1,,B,,,BAO_0000019,11087
12166,,H,,,4257,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,,Autocuration,,CHEMBL619430,,,,8,1,,B,,,BAO_0000019,11087
12166,,H,,,4258,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,,Autocuration,,CHEMBL620017,,,702.0,8,1,RBL-1,B,,,BAO_0000219,496
12166,,H,,,4259,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,,Autocuration,,CHEMBL620018,,,702.0,8,1,RBL-1,B,,,BAO_0000219,496
12166,,H,,,4260,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,,Autocuration,,CHEMBL620019,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13986
12166,,H,,,4261,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,,Autocuration,,CHEMBL620020,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13986
12166,,H,,,4262,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,,Autocuration,,CHEMBL620021,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13986
12166,,H,,,4263,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,,Autocuration,,CHEMBL620022,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13986
12166,,H,,,4264,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,,Autocuration,,CHEMBL620023,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13986
12166,,H,,,4265,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,,Autocuration,,CHEMBL620024,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13986
12166,,H,,,4266,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,,Autocuration,,CHEMBL620025,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13986
12166,,H,,,4267,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,,Autocuration,,CHEMBL620026,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13986
12166,,H,,,4268,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,,Autocuration,,CHEMBL620027,,,702.0,8,1,RBL-1,F,,,BAO_0000219,13986
12166,,D,,,4269,Rattus norvegicus,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,,Expert,,CHEMBL620028,,10116.0,,9,1,,F,,,BAO_0000019,13986
12166,,H,,,4270,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,,Autocuration,,CHEMBL620029,,,,8,1,,B,,,BAO_0000357,10193
12166,,H,,,4271,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,,Autocuration,,CHEMBL620030,,,,8,1,,B,,,BAO_0000357,9295
12166,,H,,,4272,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,,Autocuration,,CHEMBL875415,,,702.0,8,1,RBL-1,B,,,BAO_0000219,4717
12166,,H,,,4273,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,,Autocuration,,CHEMBL618256,,,702.0,8,1,RBL-1,B,,,BAO_0000219,4717
12166,,H,,,4274,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,,Autocuration,,CHEMBL618257,,,702.0,8,1,RBL-1,B,,,BAO_0000219,11854
12166,,H,,,4275,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,,Autocuration,,CHEMBL618258,,,702.0,8,1,RBL-1,B,,,BAO_0000219,11854
12166,,H,,,4276,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,,Autocuration,,CHEMBL618259,,,702.0,8,1,RBL-1,B,,,BAO_0000219,11854
12166,,H,,,4277,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,,Autocuration,,CHEMBL618260,,,,8,1,,B,,,BAO_0000019,10193
12166,,H,,,4278,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,,Autocuration,,CHEMBL618215,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9295
12166,,H,,,4279,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,,Autocuration,,CHEMBL618390,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9295
12166,,H,,,4280,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,,Autocuration,,CHEMBL618391,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9295
12166,,H,,,4281,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,,Autocuration,,CHEMBL618392,,,702.0,8,1,RBL-1,B,,,BAO_0000219,9295
12166,,H,,,4282,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,,Autocuration,,CHEMBL618393,,,702.0,8,1,RBL-1,B,,,BAO_0000219,165
12166,,H,,,4283,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,,Autocuration,,CHEMBL618394,,,,8,1,,B,,,BAO_0000219,11311
12166,,H,,,4284,Homo sapiens,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,Expert,,CHEMBL618395,,9606.0,702.0,8,1,RBL-1,B,,,BAO_0000219,10489
12166,,D,,,4285,Rattus norvegicus,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),,Expert,,CHEMBL618396,,10116.0,702.0,9,1,RBL-1,B,,,BAO_0000219,10489
12166,,D,,,4286,Rattus norvegicus,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),,Expert,,CHEMBL858253,,10116.0,702.0,9,1,RBL-1,B,,,BAO_0000219,10489
12166,,D,,,4287,Rattus norvegicus,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,,Autocuration,,CHEMBL618397,,10116.0,,9,1,,B,,,BAO_0000019,14799
12054,,H,,,4288,Glycine max,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),,Autocuration,,CHEMBL618398,,3847.0,,8,1,,B,,,BAO_0000357,9295
22226,,U,,,4289,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",,Autocuration,,CHEMBL618399,,,,0,1,,B,,,BAO_0000019,16811
55,,H,,,4290,,In vitro inhibition of 5-Lipoxygenase; Inactive.,,Expert,,CHEMBL618400,,,,8,1,,B,,,BAO_0000357,168
55,,H,,,4291,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,,Autocuration,,CHEMBL618401,,,,8,1,,B,,,BAO_0000357,6309
55,,H,,,4292,,Inhibitory concentration against 5-lipoxygenase; No inhibition,,Autocuration,,CHEMBL618402,,,,8,1,,B,,,BAO_0000357,6309
55,,H,,,4293,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,,Autocuration,,CHEMBL876400,,,702.0,8,1,RBL-1,B,,,BAO_0000219,3092
55,,H,,,4294,,Inhibitory activity against 5-lipoxygenase.,,Expert,,CHEMBL618403,,,,8,1,,B,,,BAO_0000357,168
55,,H,,,4295,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,,Autocuration,,CHEMBL618404,,,,8,1,,B,,,BAO_0000357,168
55,,H,,,4296,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,,Autocuration,,CHEMBL618405,,,,8,1,,B,,,BAO_0000357,168
55,,H,,,4297,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,,Autocuration,,CHEMBL618406,,,,8,1,,B,,,BAO_0000357,168
55,,H,,,4298,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,,Expert,,CHEMBL618407,,,,8,1,,F,,,BAO_0000019,12338
55,,H,,,4299,,Tested for the inhibitory activity against 5-lipoxygenase,,Autocuration,,CHEMBL618408,,,,8,1,,B,,,BAO_0000357,4501
55,,H,,,4300,,Compound was tested for its inhibitory activity against 5-lipoxygenase,,Autocuration,,CHEMBL618409,,,,8,1,,B,,,BAO_0000357,1132
55,,H,,,4301,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,,Autocuration,,CHEMBL618410,,,,8,1,,B,,,BAO_0000357,2117
55,,H,,,4302,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,,Autocuration,,CHEMBL618411,,,,8,1,,B,,,BAO_0000357,168
55,,H,,,4303,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,,Autocuration,,CHEMBL618412,,,,8,1,,B,,,BAO_0000357,168
12166,,H,,,4304,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,,Autocuration,,CHEMBL618413,,,702.0,8,1,RBL-1,B,,,BAO_0000219,13575
12166,,H,,,4305,,,,Autocuration,,CHEMBL618414,,,,8,1,,B,,,BAO_0000357,11089
10102,,H,,,4306,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),,Autocuration,,CHEMBL618415,,,,8,1,,B,,,BAO_0000357,216
10102,,H,,,4307,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,,Autocuration,,CHEMBL618416,,,,8,1,,B,,,BAO_0000019,13165
10102,,H,,,4308,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,,Autocuration,,CHEMBL876401,,,,8,1,,B,,,BAO_0000357,3278
10102,,H,,,4309,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,,Expert,,CHEMBL618417,,,,8,1,,B,,,BAO_0000357,3278
10102,,H,,,4310,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,,Autocuration,,CHEMBL618418,,,,8,1,,B,,,BAO_0000357,11966
10102,,H,,,4311,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",,Autocuration,,CHEMBL618419,,,,8,1,,B,,,BAO_0000357,175
10102,,H,,,4312,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",,Autocuration,,CHEMBL618420,,,,8,1,,B,,,BAO_0000357,175
10102,,H,,,4313,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,,Autocuration,,CHEMBL618421,,,,8,1,,B,,,BAO_0000357,13449
11238,,H,,,4314,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,,Autocuration,,CHEMBL618422,,,,8,1,,B,,,BAO_0000019,12014
11238,,H,,,4315,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),,Autocuration,,CHEMBL618423,,,,8,1,,B,,,BAO_0000019,12014
11238,,H,,,4316,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),,Autocuration,,CHEMBL618424,,,,8,1,,B,,,BAO_0000019,12014
100284,,S,,,4317,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,,Intermediate,,CHEMBL618425,,,,2,1,,B,,,BAO_0000220,99
22226,,U,,,4318,Homo sapiens,The dark toxicity against 543 human galactophore carcinoma cells,,Autocuration,,CHEMBL618426,,9606.0,,0,1,,F,,,BAO_0000019,4349
80623,,N,,,4319,Homo sapiens,Tested in vitro for cytotoxicity against 56 human tumor cell lines,,Expert,,CHEMBL618427,,9606.0,390.0,1,1,Panel (56 tumour cell lines),F,,,BAO_0000219,4071
80008,,N,,,4320,Homo sapiens,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,,Expert,,CHEMBL618428,,9606.0,345.0,1,1,5637,F,,,BAO_0000219,17589
80008,,N,,,4321,Homo sapiens,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,,Intermediate,,CHEMBL618429,,9606.0,345.0,1,1,5637,F,,,BAO_0000219,15002
80008,,N,,,4322,Homo sapiens,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",,Intermediate,,CHEMBL618430,,9606.0,345.0,1,1,5637,F,,,BAO_0000219,13958
80008,,N,,,4323,Homo sapiens,Growth inhibition against human 5637 cell lines,,Expert,,CHEMBL618431,,9606.0,345.0,1,1,5637,F,,,BAO_0000219,17589
80008,,N,,,4324,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells.,,Expert,,CHEMBL883799,,9606.0,345.0,1,1,5637,F,,,BAO_0000219,16748
80008,,N,,,4325,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,,Intermediate,,CHEMBL618432,,9606.0,345.0,1,1,5637,F,,,BAO_0000219,16747
80008,,N,,,4326,Homo sapiens,Antitumor activity against human bladder carcinoma 5637 cells,,Intermediate,,CHEMBL618433,,9606.0,345.0,1,1,5637,F,,,BAO_0000219,16747
10443,,D,,,4327,Bos taurus,In vitro inhibition of bovine trypsin(Trp).,,Expert,,CHEMBL618434,,9913.0,,9,1,,B,,,BAO_0000357,15285
240,,H,,,4328,Cercopithecidae,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,,Expert,,CHEMBL618435,,9527.0,407.0,8,1,CV-1,B,,,BAO_0000219,3726
10577,,H,,,4329,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,,Autocuration,,CHEMBL876402,,,,8,1,,B,,,BAO_0000357,5033
104698,,H,,,4330,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,,Autocuration,,CHEMBL618436,,,,6,1,,F,,,BAO_0000019,11756
22226,,U,,,4331,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,,Autocuration,,CHEMBL618437,In vivo,,,0,1,,F,,,BAO_0000218,11953
20033,,D,,,4332,Cavia porcellus,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,,Intermediate,,CHEMBL618438,,10141.0,,9,1,,B,,,BAO_0000357,5033
17045,,H,,,4333,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,Expert,,CHEMBL883800,,10116.0,,8,1,,A,,Microsomes,BAO_0000251,11347
17045,,H,,,4334,Rattus norvegicus,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,,Expert,,CHEMBL618439,,10116.0,,8,1,,A,,Microsomes,BAO_0000251,11347
22226,,U,,,4335,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,Intermediate,,CHEMBL618440,,,,0,1,,F,,,BAO_0000019,1229
22226,,U,,,4336,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,,Intermediate,,CHEMBL618441,,,,0,1,,F,,,BAO_0000019,1229
11938,,H,,,4337,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,,Expert,,CHEMBL618442,,5691.0,,8,1,,B,,,BAO_0000019,17588
11938,,H,,,4338,Trypanosoma brucei,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,,Autocuration,,CHEMBL618443,,5691.0,,8,1,,B,,,BAO_0000019,17588
11938,,H,,,4339,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,,Expert,,CHEMBL619158,,9940.0,,8,1,,B,,,BAO_0000019,17588
11938,,H,,,4340,Ovis aries,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,,Autocuration,,CHEMBL620974,,9940.0,,8,1,,B,,,BAO_0000019,17588
11938,,H,,,4341,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,,Autocuration,,CHEMBL620975,,,,8,1,,B,,,BAO_0000357,16485
22226,,U,,,4342,Homo sapiens,Average inhibitory concentration against 60 human cell lines was reported,,Intermediate,,CHEMBL620976,,9606.0,,0,1,,F,,,BAO_0000019,4337
22226,,U,,,4343,Homo sapiens,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,,Expert,,CHEMBL620977,,9606.0,,0,1,,F,,,BAO_0000019,4112
80315,,N,,,4344,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,,Intermediate,,CHEMBL620978,,9606.0,542.0,1,1,Panel NCI-60 (60 carcinoma cell lines),F,,,BAO_0000219,16160
80315,,N,,,4345,Homo sapiens,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,,Intermediate,,CHEMBL620979,,9606.0,542.0,1,1,Panel NCI-60 (60 carcinoma cell lines),F,,,BAO_0000219,16160
80315,,N,,,4346,,In vitro mean growth inhibitory activity against 60-cell panel,,Expert,,CHEMBL620980,,,542.0,1,1,Panel NCI-60 (60 carcinoma cell lines),F,,,BAO_0000219,17376
80315,,N,,,4347,,In vitro mean growth lethal concentration against 60-cell panel,,Expert,,CHEMBL620981,,,542.0,1,1,Panel NCI-60 (60 carcinoma cell lines),F,,,BAO_0000219,17376
80315,,N,,,4348,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,,Expert,,CHEMBL620982,,,542.0,1,1,Panel NCI-60 (60 carcinoma cell lines),F,,,BAO_0000219,17376
80315,,N,,,4349,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,,Expert,,CHEMBL620983,,,542.0,1,1,Panel NCI-60 (60 carcinoma cell lines),F,,,BAO_0000219,17376
104775,,H,,,4350,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,Autocuration,,CHEMBL620984,,,,4,1,,F,,,BAO_0000019,3241
104775,,H,,,4351,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,,Autocuration,,CHEMBL620985,,,,4,1,,F,,,BAO_0000019,3241
275,,H,,,4352,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,,Expert,,CHEMBL620986,,,,8,1,,B,,,BAO_0000357,3725
50425,,N,,,4353,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,,Expert,,CHEMBL620987,,5833.0,,1,1,,F,,,BAO_0000218,10805
50425,,N,,,4354,Plasmodium falciparum,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,,Expert,,CHEMBL620988,,5833.0,,1,1,,F,,,BAO_0000218,10805
50425,,N,,,4355,Plasmodium falciparum,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,,Expert,,CHEMBL620989,,5833.0,,1,1,,F,,,BAO_0000218,10805
50425,,N,,,4356,Plasmodium falciparum,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,,Expert,,CHEMBL620990,,5833.0,,1,1,,F,,,BAO_0000218,10805
50425,,N,,,4357,Plasmodium falciparum,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,,Intermediate,,CHEMBL620991,,5833.0,,1,1,,F,,,BAO_0000218,10805
80628,,N,,,4358,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,Intermediate,,CHEMBL620992,,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,10144
80628,,N,,,4359,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,Intermediate,,CHEMBL620993,,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,10144
80628,,N,,,4360,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,,Intermediate,,CHEMBL620994,,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,10144
80628,,N,,,4361,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,Intermediate,,CHEMBL620995,,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,10144
80628,,N,,,4362,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,Intermediate,,CHEMBL620996,,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,10144
80628,,N,,,4363,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,,Intermediate,,CHEMBL875581,,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,10144
22224,,U,,,4364,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,,Autocuration,,CHEMBL620997,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4365,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,,Autocuration,,CHEMBL620998,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4366,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),,Autocuration,,CHEMBL620999,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4367,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,,Autocuration,,CHEMBL621000,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4368,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,,Autocuration,,CHEMBL621001,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4369,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,,Autocuration,,CHEMBL621002,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4370,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,,Autocuration,,CHEMBL621003,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4371,Mus musculus,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",,Autocuration,,CHEMBL621004,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4372,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),,Autocuration,,CHEMBL621005,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4373,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),,Autocuration,,CHEMBL621006,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4374,Mus musculus,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,,Autocuration,,CHEMBL621007,In vivo,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4375,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,,Autocuration,,CHEMBL621008,,10090.0,,0,1,,F,,,BAO_0000218,10144
22224,,U,,,4376,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,,Autocuration,,CHEMBL621009,,10090.0,,0,1,,F,,,BAO_0000218,10144
22224,,U,,,4377,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,,Autocuration,,CHEMBL857705,,10090.0,,0,1,,F,,,BAO_0000218,10144
22224,,U,,,4378,Mus musculus,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,,Autocuration,,CHEMBL619828,,10090.0,,0,1,,F,,,BAO_0000218,10144
22224,,U,,,4379,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,,Autocuration,,CHEMBL619829,,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4380,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,,Autocuration,,CHEMBL619830,,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4381,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,,Autocuration,,CHEMBL619831,,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4382,Mus musculus,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,,Autocuration,,CHEMBL619832,,10090.0,,0,1,,F,,,BAO_0000218,10685
22224,,U,,,4383,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,,Autocuration,,CHEMBL619833,,10090.0,,0,1,,A,,,BAO_0000218,10685
22224,,U,,,4384,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,,Autocuration,,CHEMBL619834,,10090.0,,0,1,,A,,,BAO_0000218,10685
22224,,U,,,4385,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,,Autocuration,,CHEMBL619835,,10090.0,,0,1,,A,,,BAO_0000218,10685
22224,,U,,,4386,Mus musculus,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,,Autocuration,,CHEMBL619836,,10090.0,,0,1,,A,,,BAO_0000218,10685
80628,,N,,,4387,Mus musculus,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",,Intermediate,,CHEMBL619837,,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,8831
22224,,U,,,4388,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,,Autocuration,,CHEMBL619838,In vivo,,,0,1,,F,,,BAO_0000218,11704
50594,,N,,,4389,Mus musculus,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,,Intermediate,,CHEMBL619839,,10090.0,,1,1,,A,,,BAO_0000218,11704
80628,,N,,,4390,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,,Intermediate,,CHEMBL619840,In vivo,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,10685
80628,,N,,,4391,Mus musculus,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,,Intermediate,,CHEMBL619841,In vivo,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,10685
80628,,N,,,4392,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),,Expert,,CHEMBL857704,,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,11368
80628,,N,,,4393,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),,Intermediate,,CHEMBL619842,,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,11368
80628,,N,,,4394,Mus musculus,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),,Expert,,CHEMBL619843,,10090.0,850.0,1,1,6C3HED,F,,,BAO_0000218,11368
22226,,U,,,4395,Staphylococcus aureus,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",,Autocuration,,CHEMBL619844,,1280.0,,0,1,,B,,,BAO_0000019,17763
22226,,U,2107.0,,4396,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,Liver,Autocuration,,CHEMBL857855,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4397,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,Liver,Autocuration,,CHEMBL619845,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4398,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,Liver,Autocuration,,CHEMBL619846,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4399,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,Liver,Autocuration,,CHEMBL619847,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4400,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,Liver,Autocuration,,CHEMBL619848,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4401,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,Liver,Autocuration,,CHEMBL620893,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4402,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,Liver,Autocuration,,CHEMBL620894,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4403,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,Liver,Autocuration,,CHEMBL620895,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4404,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,Liver,Autocuration,,CHEMBL620896,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4405,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,Liver,Autocuration,,CHEMBL620897,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4406,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,Liver,Autocuration,,CHEMBL620898,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22226,,U,2107.0,,4407,Rattus norvegicus,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,Liver,Autocuration,,CHEMBL620899,,10116.0,,0,1,,B,,Microsomes,BAO_0000251,7411
22224,,U,1969.0,,4408,Cercopithecidae,The apparent total plasma clearance in monkey,Plasma,Autocuration,,CHEMBL620900,In vivo,9527.0,,0,1,,A,,,BAO_0000218,347
22224,,U,,,4409,Cercopithecidae,Compound was evaluated for Hepatic clearance in monkey,,Autocuration,,CHEMBL620901,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3341
22224,,U,,,4410,Cercopithecidae,Lower clearance in monkey (i.v.) at 0.5 mpk,,Autocuration,,CHEMBL620902,In vivo,9527.0,,0,1,,A,,,BAO_0000218,17853
22224,,U,,,4411,Cercopithecidae,Plasma clearance in rhesus monkey,,Autocuration,,CHEMBL620903,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4514
22224,,U,,,4412,Cercopithecidae,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,,Autocuration,,CHEMBL620904,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6062
22224,,U,,,4413,Cercopithecidae,Plasma clearance of compound was determined in monkey,,Autocuration,,CHEMBL620905,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6821
22224,,U,,,4414,Cercopithecidae,Plasma clearance was calculated in rhesus monkey,,Autocuration,,CHEMBL620906,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6057
22224,,U,,,4415,Cercopithecidae,Plasma clearance in rhesus monkey,,Autocuration,,CHEMBL875420,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5145
22224,,U,,,4416,Cercopithecidae,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Autocuration,,CHEMBL620907,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6641
22224,,U,,,4417,Cercopithecidae,Plasma clearance was evaluated in rhesus,,Autocuration,,CHEMBL620908,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5472
22224,,U,,,4418,Cercopithecidae,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,,Autocuration,,CHEMBL620909,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4257
22224,,U,,,4419,Cercopithecidae,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,Autocuration,,CHEMBL620910,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5546
22224,,U,,,4420,Cercopithecidae,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,Autocuration,,CHEMBL620911,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5334
22224,,U,,,4421,Cercopithecidae,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,Autocuration,,CHEMBL620912,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5334
22224,,U,,,4422,Cercopithecidae,Cmax 24 hr after 2 mg/kg oral administration in monkeys,,Autocuration,,CHEMBL620913,In vivo,9527.0,,0,1,,A,,,BAO_0000218,17509
22224,,U,,,4423,Cercopithecidae,Cmax in monkey after administration of 1 mg/kg iv,,Autocuration,,CHEMBL620914,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6535
22224,,U,,,4424,Cercopithecidae,Cmax was determine after peroral administration at 10 mpk in Rhesus,,Autocuration,,CHEMBL620915,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5668
22224,,U,,,4425,Cercopithecidae,Cmax in cynomolgus monkey by iv administration,,Autocuration,,CHEMBL620916,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5922
22224,,U,,,4426,Cercopithecidae,Cmax in cynomolgus monkey by po administration,,Autocuration,,CHEMBL620917,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5922
22224,,U,,,4427,Cercopithecidae,Cmax value evaluated in monkey,,Autocuration,,CHEMBL620918,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6078
22224,,U,,,4428,Cercopithecidae,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Autocuration,,CHEMBL620919,In vivo,9527.0,,0,1,,A,,,BAO_0000218,2661
22224,,U,1969.0,,4429,Cercopithecidae,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,Plasma,Autocuration,,CHEMBL620920,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3249
22224,,U,1969.0,,4430,Cercopithecidae,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,Plasma,Autocuration,,CHEMBL620921,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3249
22224,,U,1969.0,,4431,Cercopithecidae,Maximal plasma concentration in squirrel monkeys,Plasma,Autocuration,,CHEMBL620922,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5553
22224,,U,,,4432,Cercopithecidae,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Autocuration,,CHEMBL620923,In vivo,9527.0,,0,1,,A,,,BAO_0000218,1916
22224,,U,1969.0,,4433,Cercopithecidae,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,Plasma,Autocuration,,CHEMBL620924,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6227
22224,,U,,,4434,Cercopithecidae,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Autocuration,,CHEMBL620925,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4809
22224,,U,,,4435,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,Autocuration,,CHEMBL620926,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4436,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,,Autocuration,,CHEMBL620927,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4437,Cercopithecidae,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,,Autocuration,,CHEMBL620928,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4438,Cercopithecidae,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,,Autocuration,,CHEMBL620929,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,1969.0,,4439,Cercopithecidae,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,Plasma,Autocuration,,CHEMBL620930,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6221
22224,,U,,,4440,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,,Autocuration,,CHEMBL620931,,9527.0,,0,1,,A,,,BAO_0000218,167
22224,,U,,,4441,Cercopithecidae,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,,Autocuration,,CHEMBL620932,,9527.0,,0,1,,A,,,BAO_0000218,167
22224,,U,,,4442,monkey,Absolute bioavailability was evaluated in monkey,,Autocuration,,CHEMBL620933,In vivo,9443.0,,0,1,,A,,,BAO_0000218,4257
22224,,U,,,4443,monkey,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,,Autocuration,,CHEMBL620934,In vivo,9443.0,,0,1,,A,,,BAO_0000218,6221
22224,,U,,,4444,monkey,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,,Autocuration,,CHEMBL620935,In vivo,9443.0,,0,1,,A,,,BAO_0000218,17667
22224,,U,,,4445,Macaca mulatta,Bioavailability of compound was determined in rhesus monkey,,Autocuration,,CHEMBL620936,In vivo,9544.0,,0,1,,A,,,BAO_0000218,17267
22224,,U,,,4446,marmosets,Bioavailability determined after oral administration in marmoset,,Autocuration,,CHEMBL620937,In vivo,38020.0,,0,1,,A,,,BAO_0000218,4256
22224,,U,,,4447,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,,Autocuration,,CHEMBL620938,In vivo,9541.0,,0,1,,A,,,BAO_0000218,4256
22224,,U,,,4448,monkey,Bioavailability in monkey (p.o.) at 2.0 mpk,,Autocuration,,CHEMBL620939,In vivo,9443.0,,0,1,,A,,,BAO_0000218,17853
22224,,U,,,4449,monkey,Bioavailability was evaluated after oral administration in monkey,,Autocuration,,CHEMBL620940,In vivo,9443.0,,0,1,,A,,,BAO_0000218,16365
22224,,U,,,4450,Macaca fascicularis,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Autocuration,,CHEMBL620941,In vivo,9541.0,,0,1,,A,,,BAO_0000218,1916
22224,,U,,,4451,Macaca mulatta,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,Autocuration,,CHEMBL620942,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5334
22224,,U,,,4452,Macaca mulatta,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,Autocuration,,CHEMBL620943,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5334
22224,,U,,,4453,monkey,Bioavailability of the compound was determined in monkey,,Autocuration,,CHEMBL620944,In vivo,9443.0,,0,1,,A,,,BAO_0000218,17592
22224,,U,,,4454,Saimiri sciureus,Bioavailability in squirrel monkey (dose 5 mg/kg),,Autocuration,,CHEMBL620945,In vivo,9521.0,,0,1,,A,,,BAO_0000218,1399
22224,,U,,,4455,monkey,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Autocuration,,CHEMBL620946,In vivo,9443.0,,0,1,,A,,,BAO_0000218,4809
22224,,U,,,4456,monkey,Oral bioavailability in monkey,,Autocuration,,CHEMBL620947,In vivo,9443.0,,0,1,,A,,,BAO_0000218,3341
22224,,U,,,4457,Saimiri sciureus,Compound was tested for bioavailability in squirrel monkey,,Autocuration,,CHEMBL620948,In vivo,9521.0,,0,1,,A,,,BAO_0000218,64
22224,,U,,,4458,Macaca mulatta,Oral bioavailability in Rhesus monkey,,Autocuration,,CHEMBL620949,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5005
22224,,U,,,4459,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),,Autocuration,,CHEMBL620950,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5005
22224,,U,,,4460,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,,Autocuration,,CHEMBL620951,In vivo,9541.0,,0,1,,A,,,BAO_0000218,5237
22224,,U,,,4461,Macaca fascicularis,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,,Autocuration,,CHEMBL620952,In vivo,9541.0,,0,1,,A,,,BAO_0000218,5237
22224,,U,,,4462,monkey,Oral bioavailability in monkey (dose 5 mg/kg),,Autocuration,,CHEMBL875421,In vivo,9443.0,,0,1,,A,,,BAO_0000218,5302
22224,,U,,,4463,monkey,Oral bioavailability of compound at 5 mg/kg in monkey,,Autocuration,,CHEMBL620953,In vivo,9443.0,,0,1,,A,,,BAO_0000218,17667
50588,,N,,,4464,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,,Intermediate,,CHEMBL873491,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6161
50588,,N,,,4465,Canis lupus familiaris,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,,Intermediate,,CHEMBL620954,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6161
50588,,N,1969.0,,4466,Canis lupus familiaris,Plasma half life determined,Plasma,Intermediate,,CHEMBL620955,,9615.0,,1,1,,A,,,BAO_0000218,3854
50588,,N,1969.0,,4467,Canis lupus familiaris,Plasma half life in dog,Plasma,Intermediate,,CHEMBL618097,,9615.0,,1,1,,A,,,BAO_0000218,993
50588,,N,1969.0,,4468,Canis lupus familiaris,Plasma half-life in Beagle dogs,Plasma,Intermediate,,CHEMBL618268,,9615.0,,1,1,,A,,,BAO_0000218,4514
50588,,N,1969.0,,4469,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),Plasma,Intermediate,,CHEMBL618269,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5334
50588,,N,1969.0,,4470,Canis lupus familiaris,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),Plasma,Intermediate,,CHEMBL618270,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5334
50588,,N,,,4471,Canis lupus familiaris,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,,Intermediate,,CHEMBL618271,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1466
50588,,N,,,4472,Canis lupus familiaris,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,,Intermediate,,CHEMBL873493,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1466
50588,,N,,,4473,Canis lupus familiaris,Tested for the half life period in dog,,Intermediate,,CHEMBL621031,,9615.0,,1,1,,A,,,BAO_0000218,5313
50588,,N,,,4474,Canis lupus familiaris,Tested for the half life period in dog at dosage of 10 mpk,,Intermediate,,CHEMBL621032,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5313
50588,,N,,,4475,Canis lupus familiaris,The compound was tested for half life in dog,,Intermediate,,CHEMBL621033,,9615.0,,1,1,,A,,,BAO_0000218,3880
50588,,N,1969.0,,4476,Canis lupus familiaris,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",Plasma,Intermediate,,CHEMBL621034,,9615.0,,1,1,,A,,,BAO_0000218,3639
50588,,N,,,4477,Canis lupus familiaris,The half life was determined,,Intermediate,,CHEMBL621035,,9615.0,,1,1,,A,,,BAO_0000218,3880
50588,,N,1969.0,,4478,Canis lupus familiaris,The plasma half-life in dogs,Plasma,Intermediate,,CHEMBL621036,,9615.0,,1,1,,A,,,BAO_0000218,3918
50588,,N,1969.0,,4479,Canis lupus familiaris,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,Plasma,Intermediate,,CHEMBL621037,,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,4480,Canis lupus familiaris,Half life in dog,,Intermediate,,CHEMBL619812,,9615.0,,1,1,,A,,,BAO_0000218,17796
50588,,N,,,4481,Canis lupus familiaris,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,,Intermediate,,CHEMBL619813,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5983
50588,,N,,,4482,Canis lupus familiaris,tmax upon peroral administration of 10.0 mg/Kg dose in dog,,Intermediate,,CHEMBL873335,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1466
50588,,N,,,4483,Canis lupus familiaris,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Intermediate,,CHEMBL619814,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16456
50506,,N,,,4484,Mustela putorius furo,Cmax in ferrets after 30 mg/kg oral dose,,Expert,,CHEMBL619815,In vivo,9669.0,,1,1,,A,,,BAO_0000218,6113
50506,,N,,,4485,Mustela putorius furo,Emesis in ferrets at 30 mg/kg oral dose,,Expert,,CHEMBL619816,In vivo,9669.0,,1,1,,F,,,BAO_0000218,6113
22224,,U,,,4486,Macaca fascicularis,Bioavailability in cynomolgus monkey,,Autocuration,,CHEMBL619817,In vivo,9541.0,,0,1,,A,,,BAO_0000218,17796
100710,,N,,,4487,Macaca fascicularis,Volume of distribution in cynomolgus,,Intermediate,,CHEMBL619818,In vivo,9541.0,,1,1,,A,,,BAO_0000218,17796
22224,,U,1969.0,,4488,Cavia porcellus,AUC tested in guinea pig when 3 mg/kg dose was given perorally,Plasma,Autocuration,,CHEMBL619819,,10141.0,,0,1,,A,,,BAO_0000218,5308
22224,,U,,,4489,Cavia porcellus,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,,Autocuration,,CHEMBL619820,,10141.0,,0,1,,A,,,BAO_0000218,4877
22224,,U,,,4490,Cavia porcellus,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",,Autocuration,,CHEMBL875419,,10141.0,,0,1,,A,,,BAO_0000218,4876
22224,,U,1969.0,,4491,Cavia porcellus,AUC in guinea pig after 3mg/kg oral dose,Plasma,Autocuration,,CHEMBL619821,In vivo,10141.0,,0,1,,A,,,BAO_0000218,4878
22224,,U,,,4492,Cavia porcellus,Bioavailability in guinea pig was tested,,Autocuration,,CHEMBL619822,In vivo,10141.0,,0,1,,A,,,BAO_0000218,5308
22224,,U,,,4493,Cavia porcellus,Tested for oral bioavailability in guinea pig at 5 mg/kg,,Autocuration,,CHEMBL619823,In vivo,10141.0,,0,1,,A,,,BAO_0000218,4877
22224,,U,,,4494,Cavia porcellus,Tested for the oral bioavailability of the compound,,Autocuration,,CHEMBL619824,In vivo,10141.0,,0,1,,A,,,BAO_0000218,4876
22224,,U,,,4495,Cavia porcellus,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,,Autocuration,,CHEMBL619825,In vivo,10141.0,,0,1,,A,,,BAO_0000218,4876
22224,,U,,,4496,Cavia porcellus,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,,Autocuration,,CHEMBL619826,In vivo,10141.0,,0,1,,A,,,BAO_0000218,5308
22224,,U,2048.0,,4497,Cavia porcellus,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,Lung,Autocuration,,CHEMBL619827,In vivo,10141.0,,0,1,,A,,,BAO_0000218,4877
22224,,U,,,4498,Cavia porcellus,Cmax in guinea pig after 3mg/kg oral dose,,Autocuration,,CHEMBL618167,In vivo,10141.0,,0,1,,A,,,BAO_0000218,4878
22224,,U,178.0,,4499,Cavia porcellus,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,Blood,Autocuration,,CHEMBL618168,,10141.0,,0,1,,A,,,BAO_0000019,5689
22224,,U,955.0,,4500,Cavia porcellus,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,Brain,Autocuration,,CHEMBL618169,,10141.0,,0,1,,A,,,BAO_0000019,5689
22224,,U,,,4501,Cavia porcellus,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,,Autocuration,,CHEMBL618170,,10141.0,,0,1,,A,,,BAO_0000019,5689
22224,,U,160.0,,4502,Cavia porcellus,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,Intestine,Autocuration,,CHEMBL618171,,10141.0,,0,1,,A,,,BAO_0000019,5689
22224,,U,2113.0,,4503,Cavia porcellus,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,Kidney,Autocuration,,CHEMBL618172,,10141.0,,0,1,,A,,,BAO_0000019,5689
22224,,U,2107.0,,4504,Cavia porcellus,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,Liver,Autocuration,,CHEMBL618173,,10141.0,,0,1,,A,,,BAO_0000019,5689
22224,,U,,,4505,Cavia porcellus,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,,Autocuration,,CHEMBL618174,,10141.0,,0,1,,A,,,BAO_0000019,5689
22224,,U,2106.0,,4506,Cavia porcellus,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,Spleen,Autocuration,,CHEMBL875408,,10141.0,,0,1,,A,,,BAO_0000019,5689
22224,,U,,,4507,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),,Autocuration,,CHEMBL839827,In vivo,10141.0,,0,1,,A,,,BAO_0000218,14465
22224,,U,,,4508,Cavia porcellus,Partition coefficient was measured as -log (counts per min ),,Autocuration,,CHEMBL618175,,10141.0,,0,1,,A,,,BAO_0000019,5689
22224,,U,,,4509,Cavia porcellus,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,,Autocuration,,CHEMBL618176,In vivo,10141.0,,0,1,,A,,,BAO_0000218,611
22224,,U,,,4510,Cavia porcellus,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,,Autocuration,,CHEMBL618177,In vivo,10141.0,,0,1,,A,,,BAO_0000218,611
22224,,U,,,4511,Cavia porcellus,Elimination T1/2 in Guinea pig (PO dose),,Autocuration,,CHEMBL618178,In vivo,10141.0,,0,1,,A,,,BAO_0000218,14465
22224,,U,,,4512,Cavia porcellus,"Tested for the half life period of the compound, intravenously",,Autocuration,,CHEMBL618179,In vivo,10141.0,,0,1,,A,,,BAO_0000218,4876
22224,,U,,,4513,Cavia porcellus,Half-life was measured,,Autocuration,,CHEMBL873489,,10141.0,,0,1,,A,,,BAO_0000019,5689
22224,,U,,,4514,Cavia porcellus,The time required for onset of inotropy after addition of a single dose of delta F75,,Autocuration,,CHEMBL618180,,10141.0,,0,1,,A,,,BAO_0000019,7515
22224,,U,,,4515,Cavia porcellus,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,,Autocuration,,CHEMBL618181,In vivo,10141.0,,0,1,,A,,,BAO_0000218,17667
22224,,U,,,4516,Cavia porcellus,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,,Autocuration,,CHEMBL618182,In vivo,10141.0,,0,1,,A,,,BAO_0000218,17667
22224,,U,,,4517,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,Autocuration,,CHEMBL618183,In vivo,10029.0,,0,1,,A,,,BAO_0000218,4727
50594,,N,,,4518,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,,Intermediate,,CHEMBL618184,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,,,4519,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,,Intermediate,,CHEMBL618185,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,,,4520,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,,Intermediate,,CHEMBL618186,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,,,4521,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,,Intermediate,,CHEMBL618187,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,,,4522,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,,Intermediate,,CHEMBL618188,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,,,4523,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,,Intermediate,,CHEMBL875409,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,,,4524,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,,Intermediate,,CHEMBL618189,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,178.0,,4525,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,Blood,Intermediate,,CHEMBL618190,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,178.0,,4526,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,Blood,Intermediate,,CHEMBL618191,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,178.0,,4527,Mus musculus,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,Blood,Intermediate,,CHEMBL618192,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,10000001.0,,4528,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,Bone,Intermediate,,CHEMBL618193,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,10000001.0,,4529,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,Bone,Intermediate,,CHEMBL618194,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,10000001.0,,4530,Mus musculus,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,Bone,Intermediate,,CHEMBL618195,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,955.0,,4531,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,Brain,Intermediate,,CHEMBL618196,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,955.0,,4532,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,Brain,Intermediate,,CHEMBL618197,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,955.0,,4533,Mus musculus,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,Brain,Intermediate,,CHEMBL618198,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,948.0,,4534,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,Heart,Intermediate,,CHEMBL618199,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,948.0,,4535,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,Heart,Intermediate,,CHEMBL618200,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,948.0,,4536,Mus musculus,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,Heart,Intermediate,,CHEMBL618201,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,160.0,,4537,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,Intestine,Intermediate,,CHEMBL618202,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,160.0,,4538,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,Intestine,Intermediate,,CHEMBL618203,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,160.0,,4539,Mus musculus,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,Intestine,Intermediate,,CHEMBL618204,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2113.0,,4540,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,Kidney,Intermediate,,CHEMBL618205,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2113.0,,4541,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,Kidney,Intermediate,,CHEMBL618206,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2113.0,,4542,Mus musculus,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,Kidney,Intermediate,,CHEMBL618207,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2107.0,,4543,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,Liver,Intermediate,,CHEMBL618208,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2107.0,,4544,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,Liver,Intermediate,,CHEMBL618932,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2107.0,,4545,Mus musculus,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,Liver,Intermediate,,CHEMBL618933,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2048.0,,4546,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,Lung,Intermediate,,CHEMBL618934,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2048.0,,4547,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,Lung,Intermediate,,CHEMBL618935,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2048.0,,4548,Mus musculus,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,Lung,Intermediate,,CHEMBL618936,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2385.0,,4549,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,Muscle tissue,Intermediate,,CHEMBL618937,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2385.0,,4550,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,Muscle tissue,Intermediate,,CHEMBL618938,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2385.0,,4551,Mus musculus,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,Muscle tissue,Intermediate,,CHEMBL619104,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2106.0,,4552,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,Spleen,Intermediate,,CHEMBL619105,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2106.0,,4553,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,Spleen,Intermediate,,CHEMBL619106,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,2106.0,,4554,Mus musculus,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,Spleen,Intermediate,,CHEMBL619107,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,945.0,,4555,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,Stomach,Intermediate,,CHEMBL875410,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,945.0,,4556,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,Stomach,Intermediate,,CHEMBL619108,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,945.0,,4557,Mus musculus,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,Stomach,Intermediate,,CHEMBL619109,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3655
50594,,N,,,4558,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,Intermediate,,CHEMBL619110,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4559,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,,Intermediate,,CHEMBL619111,In vivo,10090.0,,1,1,,F,,,BAO_0000218,16597
50594,,N,,,4560,Mus musculus,MRT value at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate,,CHEMBL619112,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4561,Mus musculus,MRT value at a dose of 10 mg/kg peroral administration in mice.,,Intermediate,,CHEMBL619113,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4562,Mus musculus,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,,Intermediate,,CHEMBL619114,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17764
50594,,N,,,4563,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,Intermediate,,CHEMBL619115,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
81034,,N,,,4564,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,,Intermediate,,CHEMBL619116,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,3830
81034,,N,,,4565,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,,Intermediate,,CHEMBL619117,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,3829
81034,,N,,,4566,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell lines.,,Intermediate,,CHEMBL619118,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,2040
81034,,N,,,4567,Homo sapiens,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,,Intermediate,,CHEMBL619119,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4568,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,Intermediate,,CHEMBL619120,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4569,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,Intermediate,,CHEMBL619121,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4570,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,Intermediate,,CHEMBL619122,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4571,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,Intermediate,,CHEMBL619123,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4572,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,Intermediate,,CHEMBL619124,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4573,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,,Intermediate,,CHEMBL619125,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,2859
81034,,N,,,4574,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780,,Intermediate,,CHEMBL875411,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,5618
81034,,N,,,4575,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,,Intermediate,,CHEMBL619126,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4576,Homo sapiens,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,,Intermediate,,CHEMBL619127,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4577,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,,Intermediate,,CHEMBL619128,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4578,Homo sapiens,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,,Intermediate,,CHEMBL619129,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4579,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,,Intermediate,,CHEMBL619130,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,2113
81034,,N,,,4580,Homo sapiens,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,,Intermediate,,CHEMBL619131,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,2113
81034,,N,,,4581,Homo sapiens,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,,Intermediate,,CHEMBL619132,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16745
81034,,N,,,4582,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Expert,,CHEMBL619133,,9606.0,478.0,1,1,A2780,F,,,BAO_0000218,16597
81034,,N,,,4583,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,,Intermediate,,CHEMBL619134,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4584,Homo sapiens,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,,Intermediate,,CHEMBL619135,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15684
81034,,N,,,4585,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,,Intermediate,,CHEMBL619136,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,2040
81034,,N,,,4586,Homo sapiens,Relative resistance factor in A2780 cisplatin-resistant line,,Intermediate,,CHEMBL619137,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,2040
81034,,N,,,4587,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,,Intermediate,,CHEMBL883713,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16165
81034,,N,,,4588,Homo sapiens,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,,Intermediate,,CHEMBL875412,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16165
81034,,N,,,4589,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Expert,,CHEMBL619138,,9606.0,478.0,1,1,A2780,F,,,BAO_0000218,16597
81034,,N,,,4590,Homo sapiens,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,,Expert,,CHEMBL619262,,9606.0,478.0,1,1,A2780,F,,,BAO_0000218,16597
81034,,N,,,4591,Homo sapiens,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,,Intermediate,,CHEMBL619139,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,3992
81034,,N,,,4592,Homo sapiens,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,,Intermediate,,CHEMBL619140,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,10553
81034,,N,,,4593,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,,Intermediate,,CHEMBL619141,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15608
81034,,N,,,4594,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,,Intermediate,,CHEMBL619142,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15608
81034,,N,,,4595,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,,Intermediate,,CHEMBL619143,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15608
81034,,N,,,4596,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,,Intermediate,,CHEMBL619144,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15608
81034,,N,,,4597,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,,Intermediate,,CHEMBL619145,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15608
81034,,N,,,4598,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,,Intermediate,,CHEMBL619146,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15608
81034,,N,,,4599,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,,Intermediate,,CHEMBL619147,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15569
81034,,N,,,4600,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line,,Intermediate,,CHEMBL619148,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17420
81034,,N,,,4601,Homo sapiens,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,,Intermediate,,CHEMBL619149,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17420
81034,,N,,,4602,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),,Intermediate,,CHEMBL619150,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15099
81034,,N,,,4603,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),,Intermediate,,CHEMBL619151,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15099
81034,,N,,,4604,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,,Intermediate,,CHEMBL883794,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17672
81034,,N,,,4605,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,,Intermediate,,CHEMBL619152,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17672
81034,,N,,,4606,Homo sapiens,In vitro cytotoxicity against A2780ADR cell line,,Intermediate,,CHEMBL619153,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17270
81034,,N,,,4607,Homo sapiens,In vitro cytotoxicity against A2780CIS cell line,,Intermediate,,CHEMBL619154,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17270
81034,,N,,,4608,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,,Intermediate,,CHEMBL619155,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,5574
81034,,N,,,4609,Homo sapiens,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,,Intermediate,,CHEMBL619156,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,2113
81034,,N,,,4610,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",,Intermediate,,CHEMBL619157,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16913
81034,,N,,,4611,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",,Intermediate,,CHEMBL619797,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16913
22224,,U,,,4612,Macaca mulatta,Oral bioavailability of compound in rhesus macaques,,Autocuration,,CHEMBL619798,In vivo,9544.0,,0,1,,A,,,BAO_0000218,17839
22224,,U,,,4613,monkey,Oral bioavailability in monkey,,Autocuration,,CHEMBL619799,In vivo,9443.0,,0,1,,A,,,BAO_0000218,6821
22224,,U,,,4614,monkey,Oral bioavailability evaluated in monkey,,Autocuration,,CHEMBL619800,In vivo,9443.0,,0,1,,A,,,BAO_0000218,6078
22224,,U,,,4615,monkey,Oral bioavailability in monkey (dose 1 mg/kg p.o.),,Autocuration,,CHEMBL619801,In vivo,9443.0,,0,1,,A,,,BAO_0000218,6535
22224,,U,,,4616,Macaca mulatta,Oral bioavailability in Rhesus monkey,,Autocuration,,CHEMBL619802,In vivo,9544.0,,0,1,,A,,,BAO_0000218,4449
22224,,U,,,4617,Macaca mulatta,Oral bioavailability was calculated in rhesus monkey,,Autocuration,,CHEMBL619803,In vivo,9544.0,,0,1,,A,,,BAO_0000218,6057
22224,,U,,,4618,Macaca fascicularis,Oral bioavailability in cynomolgus monkey,,Autocuration,,CHEMBL619965,In vivo,9541.0,,0,1,,A,,,BAO_0000218,5922
22224,,U,,,4619,monkey,Oral bioavailability in monkey,,Autocuration,,CHEMBL619966,In vivo,9443.0,,0,1,,A,,,BAO_0000218,5940
22224,,U,,,4620,monkey,Oral bioavailability in monkey,,Autocuration,,CHEMBL619967,In vivo,9443.0,,0,1,,A,,,BAO_0000218,6265
22224,,U,,,4621,monkey,Oral bioavailability in monkey (dose 1 mg/kg),,Autocuration,,CHEMBL620073,In vivo,9443.0,,0,1,,A,,,BAO_0000218,6265
22224,,U,,,4622,monkey,Oral bioavailability in monkey (dose 5 mg/kg),,Autocuration,,CHEMBL620074,In vivo,9443.0,,0,1,,A,,,BAO_0000218,6265
22224,,U,,,4623,monkey,Oral bioavailability in monkey,,Autocuration,,CHEMBL620075,In vivo,9443.0,,0,1,,A,,,BAO_0000218,5940
22224,,U,,,4624,monkey,Oral bioavailability in monkey,,Autocuration,,CHEMBL620076,In vivo,9443.0,,0,1,,A,,,BAO_0000218,5940
22224,,U,,,4625,Macaca mulatta,Oral bioavailability in rhesus monkey,,Autocuration,,CHEMBL620077,In vivo,9544.0,,0,1,,A,,,BAO_0000218,4514
22224,,U,,,4626,Macaca mulatta,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,,Autocuration,,CHEMBL620078,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5546
22224,,U,,,4627,Saimiri sciureus,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,,Autocuration,,CHEMBL620079,In vivo,9521.0,,0,1,,A,,,BAO_0000218,5553
22224,,U,,,4628,monkey,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Autocuration,,CHEMBL620080,In vivo,9443.0,,0,1,,A,,,BAO_0000218,6641
22224,,U,,,4629,Macaca mulatta,Oral bioavailability in Rhesus monkey,,Autocuration,,CHEMBL620081,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5472
22224,,U,,,4630,Macaca mulatta,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),,Autocuration,,CHEMBL620082,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5668
22224,,U,,,4631,monkey,Oral bioavailability in monkey at 10 mg/kg of the compound,,Autocuration,,CHEMBL620083,In vivo,9443.0,,0,1,,A,,,BAO_0000218,5711
22224,,U,,,4632,Macaca mulatta,Bioavailability in Rhesus monkey,,Autocuration,,CHEMBL620084,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5145
22224,,U,,,4633,Cercopithecidae,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration,,CHEMBL620085,,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,4634,Cercopithecidae,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration,,CHEMBL874595,,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,4635,Cercopithecidae,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,,Autocuration,,CHEMBL873352,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3249
22224,,U,,,4636,Cercopithecidae,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,,Autocuration,,CHEMBL620086,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3249
22224,,U,,,4637,Cercopithecidae,Mean residence time was determined after intravenous administration in cynomolgus monkeys,,Autocuration,,CHEMBL620087,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4638,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,Autocuration,,CHEMBL620088,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4639,Cercopithecidae,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,,Autocuration,,CHEMBL620089,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4640,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Autocuration,,CHEMBL620090,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4809
22224,,U,,,4641,Cercopithecidae,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Autocuration,,CHEMBL620091,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4809
22224,,U,,,4642,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),,Autocuration,,CHEMBL620092,,9527.0,,0,1,,A,,Microsomes,BAO_0000251,14294
22224,,U,,,4643,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),,Autocuration,,CHEMBL620093,,9527.0,,0,1,,A,,Microsomes,BAO_0000251,14294
22224,,U,,,4644,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),,Autocuration,,CHEMBL620094,,9527.0,,0,1,,A,,Microsomes,BAO_0000251,14294
22224,,U,,,4645,Cercopithecidae,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),,Autocuration,,CHEMBL620095,,9527.0,,0,1,,A,,Microsomes,BAO_0000251,14294
22224,,U,,,4646,Cercopithecidae,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration,,CHEMBL620096,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,4647,Cercopithecidae,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration,,CHEMBL620097,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,4648,Cercopithecidae,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,,Autocuration,,CHEMBL620098,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,4649,Cercopithecidae,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration,,CHEMBL620099,,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,4650,Cercopithecidae,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration,,CHEMBL620100,,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,4651,Cercopithecidae,Elimination Half-life of compound was determined in monkey,,Autocuration,,CHEMBL620101,,9527.0,,0,1,,A,,,BAO_0000019,6821
22224,,U,,,4652,Cercopithecidae,Half life of compound was determined in rhesus monkey,,Autocuration,,CHEMBL620102,,9527.0,,0,1,,A,,,BAO_0000019,17267
22224,,U,1969.0,,4653,Cercopithecidae,Half life in monkey plasma,Plasma,Autocuration,,CHEMBL620103,,9527.0,,0,1,,A,,,BAO_0000366,5819
22224,,U,1969.0,,4654,Cercopithecidae,Half life in monkey plasma; Not detected,Plasma,Autocuration,,CHEMBL620104,,9527.0,,0,1,,A,,,BAO_0000366,5819
22224,,U,,,4655,Cercopithecidae,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Autocuration,,CHEMBL874596,In vivo,9527.0,,0,1,,A,,,BAO_0000218,1916
22224,,U,,,4656,Cercopithecidae,Half-life 24 hr after 2 mg/kg iv administration in monkeys,,Autocuration,,CHEMBL873490,In vivo,9527.0,,0,1,,A,,,BAO_0000218,17509
22224,,U,,,4657,Cercopithecidae,Terminal half life of the compound.,,Autocuration,,CHEMBL620105,,9527.0,,0,1,,A,,,BAO_0000019,1399
22224,,U,,,4658,Cercopithecidae,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Autocuration,,CHEMBL620780,In vivo,9527.0,,0,1,,A,,,BAO_0000218,1916
22224,,U,,,4659,Cercopithecidae,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),,Autocuration,,CHEMBL620781,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4809
22224,,U,,,4660,Cercopithecidae,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,Autocuration,,CHEMBL620956,,9527.0,,0,1,,A,,,BAO_0000218,5546
22224,,U,1088.0,,4661,Cercopithecidae,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Urine,Autocuration,,CHEMBL620957,,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,1088.0,,4662,Cercopithecidae,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Urine,Autocuration,,CHEMBL620958,,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,4663,Cercopithecidae,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,,Autocuration,,CHEMBL620959,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4257
22224,,U,,,4664,Cercopithecidae,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,,Autocuration,,CHEMBL620960,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6221
22224,,U,,,4665,Cercopithecidae,Volume of distribution was evaluated in rhesus,,Autocuration,,CHEMBL620961,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5472
22224,,U,,,4666,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,,Autocuration,,CHEMBL620962,In vivo,10029.0,,0,1,,A,,,BAO_0000218,4727
22224,,U,,,4667,Cricetulus griseus,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,,Autocuration,,CHEMBL620963,In vivo,10029.0,,0,1,,A,,,BAO_0000218,4727
22224,,U,,,4668,Cricetulus griseus,Bioavailability in hamster was determined,,Autocuration,,CHEMBL620964,In vivo,10029.0,,0,1,,A,,,BAO_0000218,4727
22224,,U,,,4669,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,,Autocuration,,CHEMBL620965,In vivo,10029.0,,0,1,,A,,,BAO_0000218,4727
22224,,U,,,4670,Cricetulus griseus,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,,Autocuration,,CHEMBL620966,In vivo,10029.0,,0,1,,A,,,BAO_0000218,4727
22224,,U,178.0,,4671,Cricetulus griseus,Half life of compound was determined in hamster blood,Blood,Autocuration,,CHEMBL620967,,10029.0,,0,1,,A,,,BAO_0000221,4727
22224,,U,,,4672,Sus scrofa,Michaelis-Menten constant of the compound.,,Autocuration,,CHEMBL620968,,9823.0,,0,1,,A,,,BAO_0000019,1452
22224,,U,,,4673,Sus scrofa,Vmax value was measured at 0 uM concentration of silyl ether.,,Autocuration,,CHEMBL874597,,9823.0,,0,1,,A,,,BAO_0000019,1452
22224,,U,,,4674,Sus scrofa,Vmax value was measured at 10 uM concentration of silyl ether.,,Autocuration,,CHEMBL620969,,9823.0,,0,1,,A,,,BAO_0000019,1452
22224,,U,,,4675,Sus scrofa,Vmax value was measured at 5 uM concentration of silyl ether.,,Autocuration,,CHEMBL620970,,9823.0,,0,1,,A,,,BAO_0000019,1452
235,,D,,,4676,Homo sapiens,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,,Expert,,CHEMBL620971,,9606.0,,9,1,,B,,,BAO_0000357,11706
22224,,U,,,4677,Homo sapiens,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,,Autocuration,,CHEMBL620972,,9606.0,,0,1,,A,,,BAO_0000218,1916
22224,,U,,,4678,Homo sapiens,Compound was evaluated for area under the curve expressed as (h*ug/ml),,Autocuration,,CHEMBL620973,,9606.0,,0,1,,A,,,BAO_0000019,17791
22224,,U,,,4679,Homo sapiens,Active metabolite of ifosfamide determined in humans; A-Active,,Autocuration,,CHEMBL618243,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,,,4680,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,,Autocuration,,CHEMBL618244,,9606.0,,0,1,,A,,,BAO_0000019,6567
22224,,U,,,4681,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,,Autocuration,,CHEMBL618245,,9606.0,,0,1,,A,,,BAO_0000019,6567
22224,,U,,,4682,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,,Autocuration,,CHEMBL618246,,9606.0,,0,1,,A,,,BAO_0000019,6567
22224,,U,,,4683,Homo sapiens,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,,Autocuration,,CHEMBL618247,,9606.0,,0,1,,A,,,BAO_0000019,6567
22224,,U,,,4684,Homo sapiens,Compound was evaluated for oral bioavailability in human,,Autocuration,,CHEMBL618248,,9606.0,,0,1,,A,,,BAO_0000218,17791
22224,,U,1088.0,,4685,Homo sapiens,Metabolite of ifosfamide determined in urine; NF-Not found,Urine,Autocuration,,CHEMBL618249,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,,,4686,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),,Autocuration,,CHEMBL618250,,9606.0,,0,1,,A,,,BAO_0000019,6852
22224,,U,,,4687,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,,Autocuration,,CHEMBL874598,,9606.0,,0,1,,A,,,BAO_0000019,6852
22224,,U,,,4688,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,,Autocuration,,CHEMBL618251,,9606.0,,0,1,,A,,,BAO_0000019,6852
22224,,U,,,4689,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,,Autocuration,,CHEMBL618252,,9606.0,,0,1,,A,,,BAO_0000019,6852
22224,,U,,,4690,Homo sapiens,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,,Autocuration,,CHEMBL618253,,9606.0,,0,1,,A,,,BAO_0000019,6852
22224,,U,,,4691,Homo sapiens,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),,Autocuration,,CHEMBL618254,,9606.0,,0,1,,A,,,BAO_0000019,6852
22224,,U,,,4692,Homo sapiens,Percent of compound in healthy individuals (Group D),,Autocuration,,CHEMBL618255,,9606.0,,0,1,,A,,,BAO_0000019,6852
22224,,U,2107.0,,4693,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Liver,Autocuration,,CHEMBL618983,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,4397
22224,,U,,,4694,Homo sapiens,Binding towards human plasma protein at 10 uM,,Autocuration,,CHEMBL618984,,9606.0,,0,1,,A,,,BAO_0000019,17409
22224,,U,,,4695,Homo sapiens,Binding towards human plasma protein at 100 uM,,Autocuration,,CHEMBL618985,,9606.0,,0,1,,A,,,BAO_0000019,17409
22224,,U,,,4696,Homo sapiens,Human plasma protein binding activity was determined,,Autocuration,,CHEMBL618986,,9606.0,,0,1,,A,,,BAO_0000019,17176
22224,,U,,,4697,Homo sapiens,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),,Autocuration,,CHEMBL618987,,9606.0,,0,1,,A,,,BAO_0000019,15444
22224,,U,,,4698,Homo sapiens,Percent binding of compound towards human plasma protein was determined,,Autocuration,,CHEMBL618988,,9606.0,,0,1,,A,,,BAO_0000019,17267
22224,,U,2107.0,,4699,Homo sapiens,Plasma clearance in human liver microsomes,Liver,Autocuration,,CHEMBL618989,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5944
22224,,U,2107.0,,4700,Homo sapiens,In vitro intrinsic clearance in human liver microsome,Liver,Autocuration,,CHEMBL618990,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5668
22224,,U,2107.0,,4701,Homo sapiens,In vitro intrinsic clearance in human liver microsome,Liver,Autocuration,,CHEMBL618991,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5669
22224,,U,,,4702,Homo sapiens,In vitro microsome metabolism clearance in human was determined,,Autocuration,,CHEMBL876725,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5041
22224,,U,,,4703,Homo sapiens,In vitro microsome metabolism clearance in human was determined; High,,Autocuration,,CHEMBL618992,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5041
22224,,U,,,4704,Homo sapiens,In vitro microsome metabolism clearance in human was determined; ND denotes no data,,Autocuration,,CHEMBL618993,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5041
22224,,U,2107.0,,4705,Homo sapiens,Pharmacokinetic property (clearance) in human liver microsome,Liver,Autocuration,,CHEMBL618994,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5676
22224,,U,2107.0,,4706,Homo sapiens,Plasma clearance in human liver microsomes,Liver,Autocuration,,CHEMBL618995,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5944
22224,,U,2107.0,,4707,Homo sapiens,In vitro clearance in human liver microsomes,Liver,Autocuration,,CHEMBL618996,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,17538
22224,,U,2107.0,,4708,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,Liver,Autocuration,,CHEMBL618997,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,6331
22224,,U,2107.0,,4709,Homo sapiens,Intrinsic clearance in human liver microsomes was determined,Liver,Autocuration,,CHEMBL618998,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5948
22224,,U,,,4710,Homo sapiens,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,,Autocuration,,CHEMBL618999,In vivo,9606.0,,0,1,,A,,,BAO_0000218,5965
22224,,U,,,4711,Homo sapiens,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,,Autocuration,,CHEMBL620223,In vivo,9606.0,,0,1,,A,,,BAO_0000218,1916
22224,,U,,,4712,Homo sapiens,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,,Autocuration,,CHEMBL620224,,9606.0,,0,1,,A,,,BAO_0000218,5965
22224,,U,,,4713,Homo sapiens,Stability in human plasma 2 hr after incubation expressed as percent concentration,,Autocuration,,CHEMBL620225,,9606.0,,0,1,,A,,,BAO_0000019,1299
22224,,U,,,4714,Homo sapiens,Stability in human plasma 4 hr after incubation expressed as percent concentration,,Autocuration,,CHEMBL620226,,9606.0,,0,1,,A,,,BAO_0000019,1299
22224,,U,1088.0,,4715,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,Autocuration,,CHEMBL620227,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,4716,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,Autocuration,,CHEMBL876726,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,4717,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,Autocuration,,CHEMBL620228,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,4718,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,Autocuration,,CHEMBL620229,,9606.0,,0,1,,A,,,BAO_0000019,7766
50594,,N,,,4719,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,Intermediate,,CHEMBL620230,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4720,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,Intermediate,,CHEMBL620231,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4721,Mus musculus,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,Intermediate,,CHEMBL620232,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4722,Mus musculus,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,,Intermediate,,CHEMBL620233,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4723,Mus musculus,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),,Intermediate,,CHEMBL620234,,10090.0,,1,1,,A,,,BAO_0000218,14294
50594,,N,,,4724,Mus musculus,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),,Intermediate,,CHEMBL620235,,10090.0,,1,1,,A,,,BAO_0000218,14294
50594,,N,,,4725,Mus musculus,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),,Intermediate,,CHEMBL620236,,10090.0,,1,1,,A,,,BAO_0000218,14294
50594,,N,2107.0,,4726,Mus musculus,In vitro metabolic potential in mouse liver microsomes,Liver,Intermediate,,CHEMBL620237,,10090.0,,1,1,,A,,,BAO_0000218,6251
50594,,N,,,4727,Mus musculus,Ability of compound to bind to plasma protein was evaluated in HSA cells,,Intermediate,,CHEMBL620238,,10090.0,,1,1,,A,,,BAO_0000218,17582
50594,,N,2369.0,,4728,Mus musculus,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),Adrenal gland,Intermediate,,CHEMBL620239,,10090.0,,1,1,,A,,,BAO_0000218,17811
50594,,N,955.0,,4729,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,Brain,Intermediate,,CHEMBL620240,,10090.0,,1,1,,A,,,BAO_0000218,17811
50594,,N,955.0,,4730,Mus musculus,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,Brain,Intermediate,,CHEMBL620241,,10090.0,,1,1,,A,,,BAO_0000218,17811
50594,,N,,,4731,Mus musculus,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),,Intermediate,,CHEMBL876727,,10090.0,,1,1,,A,,,BAO_0000218,17811
50594,,N,2113.0,,4732,Mus musculus,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),Kidney,Intermediate,,CHEMBL620242,,10090.0,,1,1,,A,,,BAO_0000218,17811
50594,,N,,,4733,Mus musculus,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),,Intermediate,,CHEMBL620243,,10090.0,,1,1,,A,,,BAO_0000218,17811
50594,,N,,,4734,Mus musculus,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,,Intermediate,,CHEMBL620244,,10090.0,,1,1,,A,,,BAO_0000218,5288
50594,,N,1977.0,,4735,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,Serum,Intermediate,,CHEMBL620245,,10090.0,,1,1,,A,,,BAO_0000218,2717
50594,,N,1977.0,,4736,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,Serum,Intermediate,,CHEMBL620246,,10090.0,,1,1,,A,,,BAO_0000218,2717
50594,,N,1977.0,,4737,Mus musculus,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,Serum,Intermediate,,CHEMBL620247,,10090.0,,1,1,,A,,,BAO_0000218,2717
50594,,N,1969.0,,4738,Mus musculus,Half life of compound was determined in plasma of mice at 24 mg/Kg,Plasma,Intermediate,,CHEMBL620248,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,1969.0,,4739,Mus musculus,Half life of compound was determined in plasma of mice at 40 mg/Kg,Plasma,Intermediate,,CHEMBL873497,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,1969.0,,4740,Mus musculus,Half life of compound was determined in plasma of mice at 5 mg/Kg,Plasma,Intermediate,,CHEMBL620249,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,4741,Mus musculus,Half life after intraperitoneal administration in mice at 18 uM/kg,,Intermediate,,CHEMBL620250,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4742,Mus musculus,Half life after intraperitoneal administration in mice at 23 uM/kg,,Intermediate,,CHEMBL620251,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4743,Mus musculus,Half life after intraperitoneal administration in mice at 25 uM/kg,,Intermediate,,CHEMBL620252,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4744,Mus musculus,Half life after intraperitoneal administration in mice at 26 uM/kg,,Intermediate,,CHEMBL620253,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4745,Mus musculus,Half life after intravenous administration in mice at 23 uM/kg,,Intermediate,,CHEMBL620254,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4746,Mus musculus,Half life after intravenous administration in mice at 24 uM/kg,,Intermediate,,CHEMBL620255,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17764
50594,,N,,,4747,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,Intermediate,,CHEMBL620256,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4748,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,,Intermediate,,CHEMBL876728,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,,,4749,Mus musculus,Maximum time required to reach Cp max was evaluated in mice after oral administration,,Intermediate,,CHEMBL620257,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,,,4750,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),,Intermediate,,CHEMBL620258,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4751,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",,Intermediate,,CHEMBL620259,In vivo,10090.0,,1,1,,A,,,BAO_0000218,4890
50594,,N,,,4752,Mus musculus,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,,Intermediate,,CHEMBL620260,In vivo,10090.0,,1,1,,A,,,BAO_0000218,429
50594,,N,178.0,,4753,Mus musculus,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,Blood,Intermediate,,CHEMBL620261,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17837
50594,,N,,,4754,Mus musculus,Half life at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate,,CHEMBL620262,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4755,Mus musculus,Half life at a dose of 10 mg/kg peroral administration in mice.,,Intermediate,,CHEMBL620263,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4756,Mus musculus,Half life in ob/ob mice,,Intermediate,,CHEMBL620264,,10090.0,,1,1,,A,,,BAO_0000218,6619
50594,,N,,,4757,Mus musculus,Half-life at a single subcutaneous administration of 40 mg/kg in mice,,Intermediate,,CHEMBL620265,In vivo,10090.0,,1,1,,A,,,BAO_0000218,4066
50594,,N,,,4758,Mus musculus,Half-life was measured in mouse,,Intermediate,,CHEMBL620266,,10090.0,,1,1,,A,,,BAO_0000218,4239
50594,,N,,,4759,Mus musculus,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,,Intermediate,,CHEMBL620267,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,4760,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,,Intermediate,,CHEMBL619364,,10090.0,,1,1,,A,,,BAO_0000218,8999
50594,,N,,,4761,Mus musculus,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,,Intermediate,,CHEMBL619365,,10090.0,,1,1,,A,,,BAO_0000218,8999
50594,,N,955.0,,4762,Mus musculus,T2 in brain of mice at the oral dose of 50 mg/kg,Brain,Intermediate,,CHEMBL619366,,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2113.0,,4763,Mus musculus,T2 in kidney of mice at the oral dose of 50 mg/kg,Kidney,Intermediate,,CHEMBL619367,,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2107.0,,4764,Mus musculus,T2 in liver of mice at the oral dose of 50 mg/kg,Liver,Intermediate,,CHEMBL619368,,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2048.0,,4765,Mus musculus,T2 in lungs of mice at the oral dose of 50 mg/kg,Lung,Intermediate,,CHEMBL619369,,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2106.0,,4766,Mus musculus,T2 in spleen of mice at the oral dose of 50 mg/kg,Spleen,Intermediate,,CHEMBL876729,,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,,,4767,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,,Intermediate,,CHEMBL619370,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4768,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",,Intermediate,,CHEMBL619371,In vivo,10090.0,,1,1,,A,,,BAO_0000218,4890
50594,,N,,,4769,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,,Intermediate,,CHEMBL619372,In vivo,10090.0,,1,1,,A,,,BAO_0000218,429
50594,,N,,,4770,Mus musculus,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,,Intermediate,,CHEMBL620012,In vivo,10090.0,,1,1,,A,,,BAO_0000218,429
50594,,N,,,4771,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,,Intermediate,,CHEMBL620013,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
81034,,N,,,4772,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,Intermediate,,CHEMBL620014,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16913
81034,,N,,,4773,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",,Intermediate,,CHEMBL620015,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16913
81034,,N,,,4774,Homo sapiens,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Intermediate,,CHEMBL621010,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16913
81034,,N,,,4775,Homo sapiens,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Intermediate,,CHEMBL621011,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16913
81034,,N,,,4776,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Intermediate,,CHEMBL621012,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16913
81034,,N,,,4777,Homo sapiens,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",,Intermediate,,CHEMBL621013,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16913
81034,,N,,,4778,Homo sapiens,In vitro cytotoxicity against A2780TAX cell line,,Intermediate,,CHEMBL621014,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17270
80017,,N,,,4779,Homo sapiens,In vitro inhibitory activity against human tumor cell line A2780cis,,Intermediate,,CHEMBL618154,,9606.0,481.0,1,1,A2780cisR,F,,,BAO_0000219,5618
81034,,N,,,4780,Homo sapiens,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,,Expert,,CHEMBL618155,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17777
80017,,N,,,4781,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,,Intermediate,,CHEMBL618156,,9606.0,481.0,1,1,A2780cisR,F,,,BAO_0000219,16112
80017,,N,,,4782,Homo sapiens,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,Intermediate,,CHEMBL618157,,9606.0,481.0,1,1,A2780cisR,F,,,BAO_0000219,15748
81034,,N,,,4783,Homo sapiens,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,,Intermediate,,CHEMBL618328,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,6633
81034,,N,,,4784,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,,Intermediate,,CHEMBL618329,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16930
81034,,N,,,4785,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,,Intermediate,,CHEMBL618330,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17496
81034,,N,,,4786,Homo sapiens,In vitro antitumor activity against A2780cisR cell line.,,Expert,,CHEMBL618331,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,12989
81034,,N,,,4787,Homo sapiens,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),,Intermediate,,CHEMBL618332,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,4840
81034,,N,,,4788,Homo sapiens,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,,Expert,,CHEMBL618333,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,12989
80017,,N,,,4789,Homo sapiens,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,,Intermediate,,CHEMBL618334,,9606.0,481.0,1,1,A2780cisR,F,,,BAO_0000219,16745
81034,,N,,,4790,Homo sapiens,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,,Expert,,CHEMBL618335,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16597
11736,,D,,,4791,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,,Expert,,CHEMBL618336,,10116.0,,9,1,,B,,,BAO_0000019,16547
11736,,H,,,4792,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,Expert,,CHEMBL618337,,,,8,1,,F,,,BAO_0000019,16547
11736,,D,,,4793,Rattus norvegicus,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),,Expert,,CHEMBL618338,,10116.0,,9,1,,F,,,BAO_0000019,16547
278,,D,,,4794,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,,Expert,,CHEMBL618339,,9606.0,722.0,9,1,HEK293,F,,,BAO_0000219,15856
278,,D,,,4795,Homo sapiens,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,,Expert,,CHEMBL618340,,9606.0,722.0,9,1,HEK293,F,,,BAO_0000219,15856
11831,,D,,,4796,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,,Expert,,CHEMBL618341,,10090.0,,9,1,,B,,,BAO_0000019,16547
11831,,H,,,4797,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,Expert,,CHEMBL618342,,,,8,1,,F,,,BAO_0000019,16547
11831,,D,,,4798,Mus musculus,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),,Expert,,CHEMBL618343,,10090.0,,9,1,,F,,,BAO_0000019,16547
280,,H,,,4799,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,,Expert,,CHEMBL621038,,,,8,1,,B,,,BAO_0000357,17402
22226,,U,,,4800,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),,Autocuration,,CHEMBL621039,,9606.0,574.0,0,1,T-cells,F,,,BAO_0000219,11746
22226,,U,,,4801,Homo sapiens,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,,Autocuration,,CHEMBL621040,,9606.0,574.0,0,1,T-cells,F,,,BAO_0000219,11746
80018,,N,,,4802,Homo sapiens,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,,Intermediate,,CHEMBL621041,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,5455
80018,,N,,,4803,Homo sapiens,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,,Intermediate,,CHEMBL621042,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,2068
80018,,N,,,4804,Homo sapiens,In vitro antitumor activity against A375cell line extracted form melanoma,,Intermediate,,CHEMBL621043,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,2683
80018,,N,,,4805,Homo sapiens,Inhibition of cell growth in (A375) melan cell line,,Expert,,CHEMBL621044,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,15313
80018,,N,,,4806,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,,Intermediate,,CHEMBL621045,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,13739
80018,,N,,,4807,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,,Intermediate,,CHEMBL621046,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,13739
80018,,N,,,4808,Homo sapiens,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,,Intermediate,,CHEMBL621047,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,14750
80019,,N,,,4809,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,,Intermediate,,CHEMBL621048,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,14777
80019,,N,,,4810,Homo sapiens,Antiproliferative activity measured against A427 human lung carcinoma,,Intermediate,,CHEMBL883798,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,14777
80019,,N,,,4811,Homo sapiens,Cytotoxicity against lung carcinoma A427 tumor cell lines,,Intermediate,,CHEMBL621049,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,17672
80019,,N,,,4812,Homo sapiens,Inhibition of large cell lung carcinoma (A427),,Intermediate,,CHEMBL621050,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,14368
80019,,N,,,4813,Homo sapiens,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,,Intermediate,,CHEMBL621051,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,14368
80019,,N,,,4814,Homo sapiens,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,Intermediate,,CHEMBL621052,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,13866
80019,,N,,,4815,Homo sapiens,Inhibitory concentration in human lung carcinoma A427 cell line,,Intermediate,,CHEMBL621053,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,2545
80019,,N,,,4816,Homo sapiens,Inhibitory concentration in human lung carcinoma A427/VCR cell line,,Intermediate,,CHEMBL621054,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,2545
22224,,U,,,4817,Cercopithecidae,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,Autocuration,,CHEMBL621055,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6062
22224,,U,,,4818,Cercopithecidae,Tested for volume of distribution upon iv administration to african green monkey,,Autocuration,,CHEMBL876398,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4578
22224,,U,,,4819,Cercopithecidae,Volume of distribution in monkey,,Autocuration,,CHEMBL621056,In vivo,9527.0,,0,1,,A,,,BAO_0000218,17592
22224,,U,,,4820,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,,Autocuration,,CHEMBL621057,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5005
22224,,U,,,4821,Macaca mulatta,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,,Autocuration,,CHEMBL621058,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5005
22224,,U,,,4822,Cercopithecidae,Pharmacokinetic property(Vdss) in cynomolgus monkey,,Autocuration,,CHEMBL621059,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5922
22224,,U,,,4823,Cercopithecidae,The distribution volume after intravenous administration in cynomolgus monkeys,,Autocuration,,CHEMBL621060,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4824,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,,Autocuration,,CHEMBL621061,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4825,Cercopithecidae,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,,Autocuration,,CHEMBL621062,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4826,Cercopithecidae,Volume displacement was calculated in rhesus monkey,,Autocuration,,CHEMBL621063,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6057
22224,,U,,,4827,Cercopithecidae,Volume of distribution in steady state was determined in rhesus monkey,,Autocuration,,CHEMBL621064,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5145
22224,,U,,,4828,Cercopithecidae,Volume of distribution of compound was determined in monkey,,Autocuration,,CHEMBL621065,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6821
22224,,U,,,4829,Cercopithecidae,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),,Autocuration,,CHEMBL621066,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5334
22224,,U,,,4830,Cercopithecidae,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),,Autocuration,,CHEMBL621067,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5334
22224,,U,,,4831,Cercopithecidae,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Autocuration,,CHEMBL621068,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6641
22224,,U,,,4832,Cercopithecidae,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Autocuration,,CHEMBL876399,In vivo,9527.0,,0,1,,A,,,BAO_0000218,2661
22224,,U,,,4833,Cercopithecidae,Volume distribution in monkey after administration of 1 mg/kg iv,,Autocuration,,CHEMBL621069,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6535
22224,,U,,,4834,Cercopithecidae,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Autocuration,,CHEMBL621070,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4809
22224,,U,,,4835,Cercopithecidae,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,,Autocuration,,CHEMBL621071,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6062
22224,,U,,,4836,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration,,CHEMBL621072,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,4837,Cercopithecidae,Oral systemic bioavailability upon iv administration to african green monkey,,Autocuration,,CHEMBL618209,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4578
22224,,U,,,4838,Cercopithecidae,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Autocuration,,CHEMBL618210,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4809
22224,,U,,,4839,Cercopithecidae,Baboon plasma free fraction. ,,Autocuration,,CHEMBL618211,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,4840,Cercopithecidae,Area under the curve was calculated in rhesus monkey after iv administration,,Autocuration,,CHEMBL618212,,9527.0,,0,1,,A,,,BAO_0000218,6057
22224,,U,,,4841,Cercopithecidae,Area under the curve was calculated in rhesus monkey after peroral administration,,Autocuration,,CHEMBL618213,,9527.0,,0,1,,A,,,BAO_0000019,6057
22224,,U,,,4842,Cercopithecidae,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,,Autocuration,,CHEMBL618214,,9527.0,,0,1,,A,,,BAO_0000019,17853
22224,,U,,,4843,Cercopithecidae,Half life period in monkey after 5 mg/kg dose,,Autocuration,,CHEMBL873492,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5302
22224,,U,,,4844,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose,,Autocuration,,CHEMBL618272,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4257
22224,,U,,,4845,Cercopithecidae,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,,Autocuration,,CHEMBL618273,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4257
22224,,U,1969.0,,4846,Cercopithecidae,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,Plasma,Autocuration,,CHEMBL618274,In vivo,9527.0,,0,1,,A,,,BAO_0000218,13501
22224,,U,,,4847,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,,Autocuration,,CHEMBL618275,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5394
22224,,U,,,4848,Cercopithecidae,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Autocuration,,CHEMBL618276,In vivo,9527.0,,0,1,,A,,,BAO_0000218,2661
22224,,U,,,4849,Cercopithecidae,Compound was evaluated for terminal half life in monkey,,Autocuration,,CHEMBL618277,,9527.0,,0,1,,A,,,BAO_0000019,3341
22224,,U,,,4850,Cercopithecidae,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,,Autocuration,,CHEMBL618278,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3045
22224,,U,1969.0,,4851,Macaca mulatta,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,Autocuration,,CHEMBL618279,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5005
22224,,U,,,4852,Cercopithecidae,Half life of compound was determined in squirrel monkey,,Autocuration,,CHEMBL618280,,9527.0,,0,1,,A,,,BAO_0000019,4847
22224,,U,,,4853,Macaca fascicularis,Half life after iv administration in cynomolgus monkey,,Autocuration,,CHEMBL618281,In vivo,9541.0,,0,1,,A,,,BAO_0000218,4256
22224,,U,1969.0,,4854,Cercopithecidae,Half life in monkey plasma after administration of 1 mg/kg iv,Plasma,Autocuration,,CHEMBL618282,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6535
22224,,U,,,4855,Cercopithecidae,Half life was calculated in rhesus monkey,,Autocuration,,CHEMBL618283,,9527.0,,0,1,,A,,,BAO_0000019,6057
22224,,U,,,4856,Cercopithecidae,Half life in monkey,,Autocuration,,CHEMBL618284,,9527.0,,0,1,,A,,,BAO_0000019,17592
22224,,U,,,4857,Cercopithecidae,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),,Autocuration,,CHEMBL618285,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6641
22224,,U,,,4858,Cercopithecidae,Half life was evaluated in rhesus,,Autocuration,,CHEMBL618286,,9527.0,,0,1,,A,,,BAO_0000019,5472
22224,,U,,,4859,Cercopithecidae,Half life period after oral administration (2.5 mg/kg) in monkey was determined,,Autocuration,,CHEMBL618287,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6221
22224,,U,,,4860,Cercopithecidae,Half life period was determine after peroral administration at 10 mpk in Rhesus,,Autocuration,,CHEMBL618288,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5668
22224,,U,,,4861,Cercopithecidae,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),,Autocuration,,CHEMBL876393,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4809
22224,,U,,,4862,Cercopithecidae,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,,Autocuration,,CHEMBL618289,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5546
22224,,U,,,4863,Cercopithecidae,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,,Autocuration,,CHEMBL618290,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5553
22224,,U,,,4864,Cercopithecidae,Half-life was calculated in monkey,,Autocuration,,CHEMBL618291,,9527.0,,0,1,,A,,,BAO_0000019,6078
22224,,U,,,4865,Cercopithecidae,Half-life in Squirrel monkey,,Autocuration,,CHEMBL618292,,9527.0,,0,1,,A,,,BAO_0000019,5147
22224,,U,,,4866,Cercopithecidae,Half-life in rhesus monkey,,Autocuration,,CHEMBL618293,,9527.0,,0,1,,A,,,BAO_0000019,5145
22224,,U,,,4867,Cercopithecidae,Half-life was measured in monkey after an iv dose of 1 mg/kg,,Autocuration,,CHEMBL618294,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6062
22224,,U,,,4868,Cercopithecidae,Half-life period after intravenous administration in cynomolgus monkeys,,Autocuration,,CHEMBL618295,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4869,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys,,Autocuration,,CHEMBL618296,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,4870,Cercopithecidae,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,,Autocuration,,CHEMBL618297,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,1088.0,,4871,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,Autocuration,,CHEMBL618298,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,4872,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,Autocuration,,CHEMBL618299,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,4873,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,Autocuration,,CHEMBL618300,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,4874,Homo sapiens,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,Urine,Autocuration,,CHEMBL618301,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,4875,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Urine,Autocuration,,CHEMBL618302,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,4876,Homo sapiens,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Urine,Autocuration,,CHEMBL876394,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,4877,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,Urine,Autocuration,,CHEMBL618303,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,4878,Homo sapiens,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,Urine,Autocuration,,CHEMBL618304,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,,,4879,Homo sapiens,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,,Autocuration,,CHEMBL618305,In vivo,9606.0,,0,1,,A,,,BAO_0000218,1916
22224,,U,,,4880,Homo sapiens,Oral bioavailability in human,,Autocuration,,CHEMBL618306,In vivo,9606.0,,0,1,,A,,,BAO_0000218,16643
22224,,U,,,4881,Homo sapiens,Compound was tested for human plasma protein binding,,Autocuration,,CHEMBL618307,,9606.0,,0,1,,A,,,BAO_0000019,17248
22224,,U,,,4882,Homo sapiens,Compound was tested for human plasma protein binding; Not determined,,Autocuration,,CHEMBL618308,,9606.0,,0,1,,A,,,BAO_0000019,17248
22224,,U,,,4883,Homo sapiens,Protein binding activity of compound in human plasma; % Free,,Autocuration,,CHEMBL618309,,9606.0,,0,1,,A,,,BAO_0000019,6241
22224,,U,,,4884,Homo sapiens,Unbound fraction (plasma),,Autocuration,,CHEMBL618310,,9606.0,,0,1,,A,,,BAO_0000019,17716
22224,,U,1969.0,,4885,Homo sapiens,Half life for the hydrolysis of compound in human blood serum,Plasma,Autocuration,,CHEMBL873353,,9606.0,,0,1,,A,,,BAO_0000366,17605
22224,,U,1969.0,,4886,Homo sapiens,Half life period in human plasma using phosphate buffer (0.08 M),Plasma,Autocuration,,CHEMBL618311,,9606.0,,0,1,,A,,,BAO_0000366,17625
22224,,U,1969.0,,4887,Homo sapiens,Half life period in human plasma using phosphate buffer (0.1 M),Plasma,Autocuration,,CHEMBL618312,,9606.0,,0,1,,A,,,BAO_0000366,17625
22224,,U,1969.0,,4888,Homo sapiens,Half-life in human plasma was determined,Plasma,Autocuration,,CHEMBL618313,,9606.0,,0,1,,A,,,BAO_0000366,17747
22224,,U,,,4889,Homo sapiens,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,,Autocuration,,CHEMBL618314,,9606.0,,0,1,,A,,,BAO_0000019,15613
22224,,U,,,4890,Homo sapiens,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),,Autocuration,,CHEMBL618315,,9606.0,,0,1,,A,,,BAO_0000019,354
22224,,U,,,4891,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",,Autocuration,,CHEMBL618316,,9606.0,,0,1,,A,,,BAO_0000019,3741
22224,,U,,,4892,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",,Autocuration,,CHEMBL618317,,9606.0,,0,1,,A,,,BAO_0000019,3741
22224,,U,,,4893,Homo sapiens,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",,Autocuration,,CHEMBL620138,,9606.0,,0,1,,A,,,BAO_0000019,3741
22224,,U,,,4894,Homo sapiens,Partition coefficient (logP),,Autocuration,,CHEMBL858280,,9606.0,,0,1,,A,,,BAO_0000019,17599
22224,,U,,,4895,Homo sapiens,In vitro metabolic stability in human was measured as pmol/min/mg/protein,,Autocuration,,CHEMBL620139,,9606.0,,0,1,,A,,,BAO_0000019,5486
22224,,U,,,4896,Homo sapiens,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,,Autocuration,,CHEMBL620140,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5600
22224,,U,,,4897,Homo sapiens,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),,Autocuration,,CHEMBL620141,,9606.0,,0,1,,A,,,BAO_0000019,14294
22224,,U,,,4898,Homo sapiens,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),,Autocuration,,CHEMBL620142,,9606.0,,0,1,,A,,,BAO_0000019,14294
22224,,U,,,4899,Homo sapiens,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),,Autocuration,,CHEMBL620143,,9606.0,,0,1,,A,,,BAO_0000019,14294
22224,,U,,,4900,Homo sapiens,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),,Autocuration,,CHEMBL620144,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,14294
22224,,U,,,4901,Homo sapiens,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),,Autocuration,,CHEMBL620145,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,14294
22224,,U,,,4902,Homo sapiens,Metabolism of compound in human microsomes; Trace,,Autocuration,,CHEMBL620146,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,14294
22224,,U,2107.0,,4903,Homo sapiens,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,Liver,Autocuration,,CHEMBL620147,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,6260
22224,,U,,,4904,Homo sapiens,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,,Autocuration,,CHEMBL620148,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,6187
22224,,U,2107.0,,4905,Homo sapiens,In vitro metabolic potential in human liver microsomes,Liver,Autocuration,,CHEMBL620149,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,6251
22224,,U,,,4906,Homo sapiens,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,,Autocuration,,CHEMBL876412,,9606.0,,0,1,,A,,,BAO_0000019,3246
22224,,U,,,4907,Homo sapiens,Tested for human plasma protein binding of the compound; Not tested,,Autocuration,,CHEMBL619352,,9606.0,,0,1,,A,,,BAO_0000019,17313
22224,,U,,,4908,Homo sapiens,Compound was tested for percent protein binding (PB) in human,,Autocuration,,CHEMBL619353,,9606.0,,0,1,,A,,,BAO_0000019,6227
22224,,U,1969.0,,4909,Homo sapiens,Protein binding in human plasma,Plasma,Autocuration,,CHEMBL619354,,9606.0,,0,1,,A,,,BAO_0000019,5530
22224,,U,,,4910,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,,Autocuration,,CHEMBL619355,,9606.0,,0,1,,A,,,BAO_0000019,6108
22224,,U,,,4911,Homo sapiens,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,,Autocuration,,CHEMBL619356,,9606.0,,0,1,,A,,,BAO_0000019,6108
22224,,U,,,4912,Homo sapiens,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),,Autocuration,,CHEMBL619357,,9606.0,,0,1,,A,,,BAO_0000019,2774
22224,,U,,,4913,Homo sapiens,In vitro rate of absorption observed as Caco-2 permeability in humans,,Autocuration,,CHEMBL619358,,9606.0,,0,1,,A,,,BAO_0000019,16643
22224,,U,,,4914,Homo sapiens,Cellular permeability of compound was determined in Caco-2 cells; High,,Autocuration,,CHEMBL619359,,9606.0,495.0,0,1,Caco-2,A,,,BAO_0000219,17582
22224,,U,,,4915,Homo sapiens,Permeability in Caco-2 cells of compound,,Autocuration,,CHEMBL619360,,9606.0,495.0,0,1,Caco-2,A,,,BAO_0000219,6838
22224,,U,,,4916,Homo sapiens,Permeability coefficient (A to B) in Caco-2 cell,,Autocuration,,CHEMBL619361,,9606.0,,0,1,,A,,,BAO_0000019,6108
22224,,U,,,4917,Homo sapiens,Permeability coefficient (B to A) in Caco-2 cell,,Autocuration,,CHEMBL619362,,9606.0,,0,1,,A,,,BAO_0000019,6108
22224,,U,,,4918,Homo sapiens,Permeability coefficient (Papp) (Caco-2 cell monolayer),,Autocuration,,CHEMBL619363,,9606.0,,0,1,,A,,,BAO_0000019,6108
22224,,U,,,4919,Homo sapiens,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,,Autocuration,,CHEMBL618942,,9606.0,,0,1,,A,,,BAO_0000019,2146
22224,,U,,,4920,Homo sapiens,Compound was tested for protein binding in human plasma,,Autocuration,,CHEMBL618943,,9606.0,,0,1,,A,,,BAO_0000019,4514
22224,,U,,,4921,Homo sapiens,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,,Autocuration,,CHEMBL618944,,9606.0,,0,1,,A,,,BAO_0000019,6108
22224,,U,1088.0,,4922,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,Urine,Autocuration,,CHEMBL618945,,9606.0,,0,1,,A,,,BAO_0000019,7766
50594,,N,,,4923,Mus musculus,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,,Intermediate,,CHEMBL618946,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,4924,Mus musculus,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,Intermediate,,CHEMBL876413,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3277
50594,,N,,,4925,Mus musculus,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,,Intermediate,,CHEMBL618947,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3802
50594,,N,1969.0,,4926,Mus musculus,Time taken to reach maximum concentration in plasma upon oral administration in mouse,Plasma,Intermediate,,CHEMBL618948,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2862
50594,,N,1969.0,,4927,Mus musculus,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Plasma,Intermediate,,CHEMBL618949,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6348
50594,,N,,,4928,Mus musculus,Tmax after intraperitoneal administration in mice at 23 uM/kg,,Intermediate,,CHEMBL618950,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4929,Mus musculus,Tmax after oral administration at 30 mg/kg in ICR mouse,,Intermediate,,CHEMBL618951,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5781
50594,,N,,,4930,Mus musculus,Tmax after peroral administration in mice at 2.4 uM/kg,,Intermediate,,CHEMBL618952,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17764
50594,,N,,,4931,Mus musculus,Tmax at a single subcutaneous administration of 40 mg/kg in mice,,Intermediate,,CHEMBL618953,In vivo,10090.0,,1,1,,A,,,BAO_0000218,4066
50594,,N,955.0,,4932,Mus musculus,Tmax in brain of mice at the oral dose of 50 mg/kg,Brain,Intermediate,,CHEMBL618954,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2113.0,,4933,Mus musculus,Tmax in kidney of mice at the oral dose of 50 mg/kg,Kidney,Intermediate,,CHEMBL618955,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2107.0,,4934,Mus musculus,Tmax in liver of mice at the oral dose of 50 mg/kg,Liver,Intermediate,,CHEMBL618956,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2048.0,,4935,Mus musculus,Tmax in lungs of mice at the oral dose of 50 mg/kg,Lung,Intermediate,,CHEMBL618957,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,,,4936,Mus musculus,Tmax in mice at 18 uM/kg i.p. administration,,Intermediate,,CHEMBL618958,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4937,Mus musculus,Tmax in mice at 23 uM/kg i.v. administration,,Intermediate,,CHEMBL618959,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4938,Mus musculus,Tmax in mice at 25 uM/kg i.p. administration,,Intermediate,,CHEMBL618960,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,4939,Mus musculus,Tmax in mice at 26 uM/kg i.p. administration,,Intermediate,,CHEMBL876723,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,2106.0,,4940,Mus musculus,Tmax in spleen of mice at the oral dose of 50 mg/kg,Spleen,Intermediate,,CHEMBL618961,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,,,4941,Mus musculus,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate,,CHEMBL618962,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4942,Mus musculus,Tmax value at a dose of 10 mg/kg peroral administration in mice.,,Intermediate,,CHEMBL618963,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4943,Mus musculus,Tmax value in IRC mice,,Intermediate,,CHEMBL618964,,10090.0,,1,1,,A,,,BAO_0000218,5951
50594,,N,,,4944,Mus musculus,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,Intermediate,,CHEMBL618965,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5506
50594,,N,,,4945,Mus musculus,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,Intermediate,,CHEMBL618966,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5506
50594,,N,1088.0,,4946,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),Urine,Intermediate,,CHEMBL618967,,10090.0,,1,1,,A,,,BAO_0000218,429
50594,,N,1088.0,,4947,Mus musculus,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),Urine,Intermediate,,CHEMBL618968,,10090.0,,1,1,,A,,,BAO_0000218,429
50594,,N,1088.0,,4948,Mus musculus,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),Urine,Intermediate,,CHEMBL618969,,10090.0,,1,1,,A,,,BAO_0000218,4066
50594,,N,,,4949,Mus musculus,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Intermediate,,CHEMBL618970,,10090.0,,1,1,,A,,,BAO_0000218,17734
50594,,N,,,4950,Mus musculus,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Intermediate,,CHEMBL618971,,10090.0,,1,1,,A,,,BAO_0000218,17734
50594,,N,,,4951,Mus musculus,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,Intermediate,,CHEMBL618972,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6062
50594,,N,,,4952,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,,Intermediate,,CHEMBL618973,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,4953,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,,Intermediate,,CHEMBL618974,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,4954,Mus musculus,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,Intermediate,,CHEMBL618975,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,4955,Mus musculus,Vd in mice,,Intermediate,,CHEMBL618976,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5980
50594,,N,,,4956,Mus musculus,Volume of distribution in mouse,,Intermediate,,CHEMBL618977,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17592
50594,,N,,,4957,Mus musculus,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Intermediate,,CHEMBL876724,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6348
50594,,N,,,4958,Mus musculus,Volume of distribution of compound in plasma was determined at 24 mg/Kg,,Intermediate,,CHEMBL618978,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,4959,Mus musculus,Volume of distribution of compound in plasma was determined at 40 mg/Kg,,Intermediate,,CHEMBL618979,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,4960,Mus musculus,Volume of distribution of compound in plasma was determined at 5 mg/Kg,,Intermediate,,CHEMBL618980,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,4961,Mus musculus,Pharmacokinetic property (vdss) was measured in mouse,,Intermediate,,CHEMBL618981,In vivo,10090.0,,1,1,,A,,,BAO_0000218,4239
50594,,N,,,4962,Mus musculus,Value distribution upon iv administration in mouse,,Intermediate,,CHEMBL618982,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2862
50594,,N,,,4963,Mus musculus,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,,Intermediate,,CHEMBL620150,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17734
50594,,N,,,4964,Mus musculus,Volume of distribution was evaluated in mice after intravenous administration,,Intermediate,,CHEMBL620151,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,,,4965,Mus musculus,Volume of distribution was evaluated in mice after oral administration,,Intermediate,,CHEMBL620152,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,,,4966,Mus musculus,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,,Intermediate,,CHEMBL620153,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17837
50594,,N,,,4967,Mus musculus,Steady state volume of distribution was determined in mice,,Intermediate,,CHEMBL876395,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5727
50594,,N,,,4968,Mus musculus,Volume distribution (steady state) of compound was determined in mouse,,Intermediate,,CHEMBL620154,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17852
50594,,N,,,4969,Mus musculus,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,,Intermediate,,CHEMBL620155,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17764
50594,,N,,,4970,Mus musculus,Vss value at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate,,CHEMBL620156,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,4971,Mus musculus,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,,Intermediate,,CHEMBL620157,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6062
50594,,N,2113.0,,4972,Mus musculus,Biodistribution of compound (oxidized form) in in kidney tissue,Kidney,Intermediate,,CHEMBL620158,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,178.0,,4973,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,Blood,Intermediate,,CHEMBL620159,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,178.0,,4974,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Blood,Intermediate,,CHEMBL620160,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,178.0,,4975,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Blood,Intermediate,,CHEMBL620161,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
80019,,N,,,4976,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,,Intermediate,,CHEMBL620162,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,10708
80852,,N,,,4977,Homo sapiens,Inhibition of A431 human squamous cell carcinoma cell proliferation,,Expert,,CHEMBL620163,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,16597
80852,,N,,,4978,Homo sapiens,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,,Expert,,CHEMBL620833,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,16062
80852,,N,,,4979,Homo sapiens,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,,Expert,,CHEMBL876396,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,16062
80852,,N,,,4980,Homo sapiens,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,,Expert,,CHEMBL620834,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,16958
80852,,N,,,4981,Homo sapiens,Inhibition of A431 human carcinoma cell proliferation,,Expert,,CHEMBL620835,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,6700
80852,,N,,,4982,Homo sapiens,In vitro inhibition of A431 (human carcinoma) cell basal growth.,,Expert,,CHEMBL620836,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,17226
80852,,N,,,4983,Homo sapiens,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,,Intermediate,,CHEMBL620837,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,6828
80852,,N,,,4984,Homo sapiens,In vitro cytotoxicity against epidermoid carcinoma cell line,,Intermediate,,CHEMBL621017,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,12314
9,,D,,,4985,Homo sapiens,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",,Expert,,CHEMBL621018,,9606.0,500.0,9,1,A-431,F,,,BAO_0000218,13412
80852,,N,,,4986,Homo sapiens,Antiproliferative activity of compound was measured on human tumor cell line A431.,,Intermediate,,CHEMBL621019,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,13299
80852,,N,,,4987,Homo sapiens,Antiproliferative effect of compound on A431 cell line expressing mutant p53,,Intermediate,,CHEMBL621020,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,17420
80852,,N,,,4988,Homo sapiens,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,,Intermediate,,CHEMBL621021,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,13678
9,,H,,,4989,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,,Expert,,CHEMBL621022,,,500.0,8,1,A-431,F,,,BAO_0000219,14171
80852,,N,,,4990,Homo sapiens,Tested for antiproliferative activity against human A431 cells,,Expert,,CHEMBL621023,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,6333
9,,D,,,4991,Homo sapiens,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,,Expert,,CHEMBL621024,,9606.0,500.0,9,1,A-431,F,,,BAO_0000219,2356
80852,,N,,,4992,Homo sapiens,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,,Expert,,CHEMBL621025,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,15578
80852,,N,,,4993,Homo sapiens,Inhibition of A431 cell proliferation,,Expert,,CHEMBL621026,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,5126
80852,,N,,,4994,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells,,Expert,,CHEMBL621027,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,6844
80852,,N,,,4995,Homo sapiens,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),,Expert,,CHEMBL876397,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,6844
80852,,N,,,4996,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,,Intermediate,,CHEMBL883797,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,4925
80852,,N,,,4997,Homo sapiens,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,,Intermediate,,CHEMBL621028,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,4925
80852,,N,,,4998,Homo sapiens,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,,Intermediate,,CHEMBL621029,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,13978
80852,,N,,,4999,Homo sapiens,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,,Intermediate,,CHEMBL621030,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,16786
9,,H,,,5000,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,,Expert,,CHEMBL621147,,,500.0,8,1,A-431,F,,,BAO_0000219,13412
80852,,N,,,5001,Homo sapiens,In vivo antiproliferative activity against A431 cell line,,Intermediate,,CHEMBL621148,,9606.0,500.0,1,1,A-431,F,,,BAO_0000218,17824
9,,D,,,5002,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,,Expert,,CHEMBL621149,,9606.0,500.0,9,1,A-431,F,,,BAO_0000219,12751
80852,,N,,,5003,Homo sapiens,Inhibition of A431 human epidermoid carcinoma cell proliferation,,Expert,,CHEMBL621150,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,12380
9,,D,,,5004,Homo sapiens,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,,Expert,,CHEMBL621151,,9606.0,500.0,9,1,A-431,F,,,BAO_0000219,4959
80852,,N,,,5005,Homo sapiens,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),,Intermediate,,CHEMBL621152,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,6333
80852,,N,,,5006,Homo sapiens,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),,Intermediate,,CHEMBL621153,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,6333
80852,,N,,,5007,Homo sapiens,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),,Intermediate,,CHEMBL884000,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,6333
9,,D,,,5008,Homo sapiens,Inhibition of EGFR overexpressing A431 cell proliferation,,Expert,,CHEMBL621154,,9606.0,,9,1,,F,,,BAO_0000019,5296
80852,,N,,,5009,Homo sapiens,Inhibition of A431 cell proliferation,,Expert,,CHEMBL621155,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,12624
9,,D,,,5010,Homo sapiens,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,,Expert,,CHEMBL621156,,9606.0,500.0,9,1,A-431,F,,,BAO_0000219,14926
9,,D,,,5011,Homo sapiens,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",,Expert,,CHEMBL621157,,9606.0,500.0,9,1,A-431,F,,,BAO_0000219,14926
9,,H,,,5012,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),,Expert,,CHEMBL621158,,,500.0,8,1,A-431,F,,,BAO_0000219,14926
80852,,N,,,5013,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,Intermediate,,CHEMBL621159,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,15144
80852,,N,,,5014,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,,Intermediate,,CHEMBL621160,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,15144
80852,,N,,,5015,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,,Intermediate,,CHEMBL621161,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,5245
80852,,N,,,5016,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,,Intermediate,,CHEMBL621162,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,5245
80852,,N,,,5017,Homo sapiens,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,Intermediate,,CHEMBL621163,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,5245
80852,,N,,,5018,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,,Intermediate,,CHEMBL621164,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,5245
80852,,N,,,5019,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,,Intermediate,,CHEMBL621165,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,5245
22224,,U,,,5020,Cercopithecidae,Half-life period in cynomolgus monkey,,Autocuration,,CHEMBL619159,,9527.0,,0,1,,A,,,BAO_0000019,5922
22224,,U,1969.0,,5021,Cercopithecidae,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",Plasma,Autocuration,,CHEMBL619160,In vitro,9527.0,,0,1,,A,,,BAO_0000366,1116
22224,,U,,,5022,Cercopithecidae,Longer half-life in monkey (i.v.) at 0.5 mpk,,Autocuration,,CHEMBL619161,In vivo,9527.0,,0,1,,A,,,BAO_0000218,17853
22224,,U,1969.0,,5023,Cercopithecidae,Plasma half life in monkey,Plasma,Autocuration,,CHEMBL619162,,9527.0,,0,1,,A,,,BAO_0000366,993
22224,,U,1969.0,,5024,Cercopithecidae,Plasma half-life in rhesus monkey,Plasma,Autocuration,,CHEMBL619163,,9527.0,,0,1,,A,,,BAO_0000366,4514
22224,,U,1969.0,,5025,Cercopithecidae,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),Plasma,Autocuration,,CHEMBL619164,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5334
22224,,U,1969.0,,5026,Cercopithecidae,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),Plasma,Autocuration,,CHEMBL619320,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5334
22224,,U,,,5027,Cercopithecidae,Tested for half life upon iv administration to african green monkey,,Autocuration,,CHEMBL619321,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4578
22224,,U,,,5028,Cercopithecidae,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Autocuration,,CHEMBL873336,In vivo,9527.0,,0,1,,A,,,BAO_0000218,2661
22224,,U,,,5029,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,,Autocuration,,CHEMBL619322,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,5030,Cercopithecidae,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,,Autocuration,,CHEMBL619323,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,5031,Cercopithecidae,The time for peak concentration value after oral administration in cynomolgus monkeys,,Autocuration,,CHEMBL619324,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,5032,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,,Autocuration,,CHEMBL619325,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5033,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,,Autocuration,,CHEMBL876411,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5034,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,,Autocuration,,CHEMBL619326,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5035,Cercopithecidae,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,,Autocuration,,CHEMBL619327,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5036,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,,Autocuration,,CHEMBL619328,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5037,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,,Autocuration,,CHEMBL619329,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5038,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,,Autocuration,,CHEMBL619330,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5039,Cercopithecidae,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,,Autocuration,,CHEMBL619331,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5040,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,,Autocuration,,CHEMBL619332,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5041,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,,Autocuration,,CHEMBL619333,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5042,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,,Autocuration,,CHEMBL619334,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5043,Cercopithecidae,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,,Autocuration,,CHEMBL619335,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5044,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,,Autocuration,,CHEMBL619336,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5045,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,,Autocuration,,CHEMBL619337,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5046,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,,Autocuration,,CHEMBL619338,,9527.0,,0,1,,A,,,BAO_0000019,11271
22224,,U,,,5047,Cercopithecidae,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,,Autocuration,,CHEMBL619339,,9527.0,,0,1,,A,,,BAO_0000019,11271
50597,,N,,,5048,Rattus norvegicus,Bioavailability in rat (cannulated) (dose 2 mg/kg),,Intermediate,,CHEMBL619340,In vivo,10116.0,,1,1,,A,,,BAO_0000218,5809
50597,,N,1969.0,,5049,Rattus norvegicus,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,Plasma,Intermediate,,CHEMBL873496,In vivo,10116.0,,1,1,,A,,,BAO_0000218,17720
50597,,N,1969.0,,5050,Rattus norvegicus,AUC value in rat after IV administration at a dose of 10 mg/kg,Plasma,Intermediate,,CHEMBL619341,,10116.0,,1,1,,A,,,BAO_0000218,3546
50597,,N,1969.0,,5051,Rattus norvegicus,AUC value in rat after oral administration at a dose of 10 mg/kg,Plasma,Intermediate,,CHEMBL619342,,10116.0,,1,1,,A,,,BAO_0000218,3546
50597,,N,,,5052,Rattus norvegicus,Cmax value in rat after oral administration at a dose of 10 mg/kg,,Intermediate,,CHEMBL619343,In vivo,10116.0,,1,1,,A,,,BAO_0000218,3546
50597,,N,,,5053,Rattus norvegicus,Bioavailability in rat after oral administration at a dose of 10 mg/kg,,Intermediate,,CHEMBL619344,In vivo,10116.0,,1,1,,A,,,BAO_0000218,3546
50597,,N,,,5054,Rattus norvegicus,Tmax value in rat after oral administration at a dose of 10 mg/kg,,Intermediate,,CHEMBL619345,In vivo,10116.0,,1,1,,A,,,BAO_0000218,3546
50597,,N,,,5055,Rattus norvegicus,Vc value in rat after IV administration at a dose of 10 mg/kg,,Intermediate,,CHEMBL619346,,10116.0,,1,1,,A,,,BAO_0000218,3546
50597,,N,,,5056,Rattus norvegicus,Half life period in rat after IV administration at a dose of 10 mg/kg,,Intermediate,,CHEMBL619347,In vivo,10116.0,,1,1,,A,,,BAO_0000218,3546
22224,,U,,,5057,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,Autocuration,,CHEMBL619348,,9557.0,,0,1,,A,,,BAO_0000019,10625
22224,,U,,,5058,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),,Autocuration,,CHEMBL619349,,9557.0,,0,1,,A,,,BAO_0000019,10625
22224,,U,,,5059,Papio hamadryas,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),,Autocuration,,CHEMBL619350,,9557.0,,0,1,,A,,,BAO_0000019,10625
22224,,U,,,5060,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,,Autocuration,,CHEMBL619351,,9557.0,,0,1,,A,,,BAO_0000019,10625
22224,,U,,,5061,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,,Autocuration,,CHEMBL875953,,9557.0,,0,1,,A,,,BAO_0000019,10625
22224,,U,,,5062,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,,Autocuration,,CHEMBL621716,,9557.0,,0,1,,A,,,BAO_0000019,10625
22224,,U,,,5063,Papio hamadryas,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,,Autocuration,,CHEMBL621717,,9557.0,,0,1,,A,,,BAO_0000019,10625
22224,,U,,,5064,Papio hamadryas,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,,Autocuration,,CHEMBL621718,,9557.0,,0,1,,A,,,BAO_0000019,10625
22224,,U,,,5065,beagle,Area under curve after 1 mpk peroral administration to beagles,,Autocuration,,CHEMBL621719,,9615.0,,0,1,,A,,,BAO_0000019,3510
22224,,U,,,5066,beagle,Area under curve after 2 mpk peroral administration to beagles,,Autocuration,,CHEMBL621720,,9615.0,,0,1,,A,,,BAO_0000019,3510
22224,,U,,,5067,beagle,Cmax value after 1 mpk peroral administration to beagles,,Autocuration,,CHEMBL621721,In vivo,9615.0,,0,1,,A,,,BAO_0000218,3510
22224,,U,1088.0,,5068,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,Urine,Autocuration,,CHEMBL621722,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,5069,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,Urine,Autocuration,,CHEMBL621723,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,5070,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,Urine,Autocuration,,CHEMBL621724,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,5071,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,Urine,Autocuration,,CHEMBL623443,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,5072,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,Urine,Autocuration,,CHEMBL623444,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,5073,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,Urine,Autocuration,,CHEMBL623445,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,1088.0,,5074,Homo sapiens,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,Urine,Autocuration,,CHEMBL623446,,9606.0,,0,1,,A,,,BAO_0000019,7766
22224,,U,2107.0,,5075,Homo sapiens,Metabolic stability observed at 30 min after administration in human liver microsomes,Liver,Autocuration,,CHEMBL623447,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,16643
22224,,U,,,5076,Homo sapiens,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,,Autocuration,,CHEMBL623448,,9606.0,,0,1,,A,,,BAO_0000019,6852
22224,,U,,,5077,Homo sapiens,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,,Autocuration,,CHEMBL623449,,9606.0,,0,1,,A,,,BAO_0000019,6852
22224,,U,,,5078,Homo sapiens,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,,Autocuration,,CHEMBL623450,,9606.0,,0,1,,A,,,BAO_0000019,6852
22224,,U,2107.0,,5079,Homo sapiens,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",Liver,Autocuration,,CHEMBL623451,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,6567
22224,,U,,,5080,Homo sapiens,Metabolic stability (% remaining at 30 mins) in human S9.,,Autocuration,,CHEMBL623452,,9606.0,,0,1,,A,,,BAO_0000019,6570
22224,,U,,,5081,Homo sapiens,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,,Autocuration,,CHEMBL623453,,9606.0,,0,1,,A,,,BAO_0000019,6570
22224,,U,2107.0,,5082,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes,Liver,Autocuration,,CHEMBL623454,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5237
22224,,U,2107.0,,5083,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,Liver,Autocuration,,CHEMBL623455,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5237
22224,,U,2107.0,,5084,Homo sapiens,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,Liver,Autocuration,,CHEMBL624371,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5237
22224,,U,,,5085,Homo sapiens,First pass metabolism and metabolic bioavailability using human hepatic microsomes,,Autocuration,,CHEMBL624372,,9606.0,,0,1,,A,,,BAO_0000218,5202
22224,,U,,,5086,Homo sapiens,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,,Autocuration,,CHEMBL624373,,9606.0,,0,1,,A,,,BAO_0000019,5481
22224,,U,,,5087,Homo sapiens,Percent remaining in human plasma after incubation for 60 min at 37 C.,,Autocuration,,CHEMBL624374,,9606.0,,0,1,,A,,,BAO_0000019,5481
22224,,U,,,5088,Homo sapiens,The percent remaining in human plasma after 30 min was determined,,Autocuration,,CHEMBL624556,,9606.0,,0,1,,A,,,BAO_0000019,3956
22224,,U,1969.0,,5089,Homo sapiens,Conversion rate of the prodrug in human plasma,Plasma,Autocuration,,CHEMBL624557,,9606.0,,0,1,,A,,,BAO_0000366,5074
22224,,U,1969.0,,5090,Homo sapiens,Conversion rate of the prodrug in human plasma; ND means no data,Plasma,Autocuration,,CHEMBL624558,,9606.0,,0,1,,A,,,BAO_0000366,5074
22224,,U,178.0,,5091,Homo sapiens,Half life of compound was determined in human blood,Blood,Autocuration,,CHEMBL624559,,9606.0,,0,1,,A,,,BAO_0000221,4727
22224,,U,,,5092,Homo sapiens,Half life of compound was determined in man with once daily dosing,,Autocuration,,CHEMBL624560,,9606.0,,0,1,,A,,,BAO_0000019,5965
22224,,U,,,5093,Homo sapiens,Half life in human microsomes,,Autocuration,,CHEMBL624561,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5732
22224,,U,1969.0,,5094,Homo sapiens,Half life in human plasma,Plasma,Autocuration,,CHEMBL624562,,9606.0,,0,1,,A,,,BAO_0000366,5819
22224,,U,1969.0,,5095,Homo sapiens,Half life in human plasma; Not detected,Plasma,Autocuration,,CHEMBL624563,,9606.0,,0,1,,A,,,BAO_0000366,5819
22224,,U,,,5096,Homo sapiens,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,,Autocuration,,CHEMBL624564,In vivo,9606.0,,0,1,,A,,,BAO_0000218,1916
22224,,U,2107.0,,5097,Homo sapiens,Half-life for oxidative metabolic stability was determined using rat liver microsomes,Liver,Autocuration,,CHEMBL624565,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,6597
22224,,U,1969.0,,5098,Homo sapiens,Half-life in human plasma,Plasma,Autocuration,,CHEMBL875152,,9606.0,,0,1,,A,,,BAO_0000366,5229
22224,,U,1969.0,,5099,Homo sapiens,Half-life of the parent prodrug in plasma,Plasma,Autocuration,,CHEMBL624566,,9606.0,,0,1,,A,,,BAO_0000366,5229
22224,,U,1969.0,,5100,Homo sapiens,In vitro half life in human plasma was determined,Plasma,Autocuration,,CHEMBL873805,In vitro,9606.0,,0,1,,A,,,BAO_0000366,2192
22224,,U,2107.0,,5101,Homo sapiens,The compound was tested In Vitro for half life in human liver microsomes.,Liver,Autocuration,,CHEMBL624567,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,3032
22224,,U,,,5102,Homo sapiens,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,,Autocuration,,CHEMBL624568,In vivo,9606.0,,0,1,,A,,,BAO_0000218,1916
22224,,U,,,5103,Homo sapiens,Observed volume of distribution,,Autocuration,,CHEMBL624569,In vivo,9606.0,,0,1,,A,,,BAO_0000218,17716
22224,,U,,,5104,Homo sapiens,Oral bioavailability in human,,Autocuration,,CHEMBL624570,In vivo,9606.0,,0,1,,A,,,BAO_0000218,15778
22224,,U,,,5105,Homo sapiens,Tested for human plasma protein binding of the compound,,Autocuration,,CHEMBL624571,,9606.0,,0,1,,A,,,BAO_0000019,17313
22224,,U,,,5106,Homo sapiens,"First order rate constant, k was determined in human plasma",,Autocuration,,CHEMBL624572,,9606.0,,0,1,,A,,,BAO_0000019,4231
22224,,U,,,5107,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,,Autocuration,,CHEMBL624573,,9606.0,,0,1,,A,,,BAO_0000019,4755
22224,,U,,,5108,Homo sapiens,Observed rate constant in 80% human plasma at 37 degree Centigrade,,Autocuration,,CHEMBL875153,,9606.0,,0,1,,A,,,BAO_0000019,4755
22224,,U,2107.0,,5109,Homo sapiens,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Liver,Autocuration,,CHEMBL624574,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,16907
22224,,U,,,5110,Homo sapiens,The compound was tested for the plasma binding in human,,Autocuration,,CHEMBL624575,,9606.0,,0,1,,A,,,BAO_0000019,10839
22224,,U,,,5111,Homo sapiens,Plasma protein binding (human),,Autocuration,,CHEMBL624576,,9606.0,,0,1,,A,,,BAO_0000019,10839
22224,,U,2107.0,,5112,Homo sapiens,Compound was evaluated for half-life in human liver microsomes,Liver,Autocuration,,CHEMBL624577,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,3199
22224,,U,178.0,,5113,Homo sapiens,Half life measured in vitro for its stability in human blood,Blood,Autocuration,,CHEMBL624578,In vitro,9606.0,,0,1,,A,,,BAO_0000221,1345
22224,,U,1977.0,,5114,Homo sapiens,Half life in human serum,Serum,Autocuration,,CHEMBL622796,,9606.0,,0,1,,A,,,BAO_0000019,4297
22224,,U,1977.0,,5115,Homo sapiens,Half life in human serum; ND=not determined,Serum,Autocuration,,CHEMBL622797,,9606.0,,0,1,,A,,,BAO_0000019,4297
22224,,U,,,5116,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 1,,Autocuration,,CHEMBL622798,,9606.0,,0,1,,A,,,BAO_0000019,4297
22224,,U,,,5117,Homo sapiens,Half life were determined in CEM-SS cell extract in decomposition step 2,,Autocuration,,CHEMBL622799,,9606.0,,0,1,,A,,,BAO_0000019,4297
22224,,U,1969.0,,5118,Homo sapiens,Half life of the in human plasma,Plasma,Autocuration,,CHEMBL622800,,9606.0,,0,1,,A,,,BAO_0000366,4231
22224,,U,,,5119,Homo sapiens,Half life period in human hepatic S9 fraction was determined,,Autocuration,,CHEMBL622801,In vitro,9606.0,,0,1,,A,,S9,BAO_0000220,5633
22224,,U,2107.0,,5120,Homo sapiens,Half life period in human liver microsome was determined,Liver,Autocuration,,CHEMBL622802,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5633
22224,,U,,,5121,Homo sapiens,Half life period was determined; 6-7,,Autocuration,,CHEMBL622803,,9606.0,,0,1,,A,,,BAO_0000019,17791
22224,,U,,,5122,Homo sapiens,Half life period was evaluated in human,,Autocuration,,CHEMBL875154,,9606.0,,0,1,,A,,,BAO_0000019,17791
22224,,U,1969.0,,5123,Homo sapiens,Half life time in human plasma,Plasma,Autocuration,,CHEMBL622804,,9606.0,,0,1,,A,,,BAO_0000366,3160
50594,,N,955.0,,5124,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Brain,Intermediate,,CHEMBL622805,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,948.0,,5125,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,Intermediate,,CHEMBL622611,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,948.0,,5126,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Heart,Intermediate,,CHEMBL622612,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2113.0,,5127,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Kidney,Intermediate,,CHEMBL875160,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2113.0,,5128,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Kidney,Intermediate,,CHEMBL622613,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2113.0,,5129,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Kidney,Intermediate,,CHEMBL622614,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2107.0,,5130,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",Liver,Intermediate,,CHEMBL622615,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2107.0,,5131,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,Liver,Intermediate,,CHEMBL622616,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2107.0,,5132,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Liver,Intermediate,,CHEMBL622617,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2106.0,,5133,Mus musculus,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,Spleen,Intermediate,,CHEMBL622618,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2106.0,,5134,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",Spleen,Intermediate,,CHEMBL622619,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2106.0,,5135,Mus musculus,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Spleen,Intermediate,,CHEMBL622620,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,955.0,,5136,Mus musculus,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,Intermediate,,CHEMBL622621,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,178.0,,5137,Mus musculus,Biodistribution of compound (oxidized form) in blood tissue,Blood,Intermediate,,CHEMBL622622,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,178.0,,5138,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Blood,Intermediate,,CHEMBL622623,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,178.0,,5139,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Blood,Intermediate,,CHEMBL622624,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,178.0,,5140,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Blood,Intermediate,,CHEMBL622625,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,178.0,,5141,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Blood,Intermediate,,CHEMBL622626,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,178.0,,5142,Mus musculus,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",Blood,Intermediate,,CHEMBL622627,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,955.0,,5143,Mus musculus,Biodistribution of compound (oxidized form) in brain tissue of mice,Brain,Intermediate,,CHEMBL622628,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,955.0,,5144,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Brain,Intermediate,,CHEMBL622629,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,955.0,,5145,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Brain,Intermediate,,CHEMBL622630,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,955.0,,5146,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Brain,Intermediate,,CHEMBL622631,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,955.0,,5147,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Brain,Intermediate,,CHEMBL622632,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,955.0,,5148,Mus musculus,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",Brain,Intermediate,,CHEMBL622633,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,948.0,,5149,Mus musculus,Biodistribution of compound (oxidized form) in heart tissue of mice,Heart,Intermediate,,CHEMBL622634,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,948.0,,5150,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,Intermediate,,CHEMBL622635,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,948.0,,5151,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Heart,Intermediate,,CHEMBL875161,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,948.0,,5152,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Heart,Intermediate,,CHEMBL622636,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,948.0,,5153,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Heart,Intermediate,,CHEMBL623335,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,948.0,,5154,Mus musculus,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Heart,Intermediate,,CHEMBL623336,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2113.0,,5155,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Kidney,Intermediate,,CHEMBL623337,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2113.0,,5156,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",Kidney,Intermediate,,CHEMBL623338,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2113.0,,5157,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",Kidney,Intermediate,,CHEMBL623339,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2113.0,,5158,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",Kidney,Intermediate,,CHEMBL623524,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2113.0,,5159,Mus musculus,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",Kidney,Intermediate,,CHEMBL623525,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2107.0,,5160,Mus musculus,Biodistribution of compound (oxidized form) in liver tissue,Liver,Intermediate,,CHEMBL623526,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2107.0,,5161,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",Liver,Intermediate,,CHEMBL623527,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
50594,,N,2107.0,,5162,Mus musculus,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",Liver,Intermediate,,CHEMBL623528,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16438
80852,,N,,,5163,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,,Intermediate,,CHEMBL624615,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,5245
80852,,N,,,5164,Homo sapiens,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,,Intermediate,,CHEMBL621672,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,5245
80852,,N,,,5165,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",,Expert,,CHEMBL621673,,,500.0,1,1,A-431,F,,,BAO_0000218,16289
80852,,N,,,5166,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",,Expert,,CHEMBL621674,,,500.0,1,1,A-431,F,,,BAO_0000218,16289
9,,D,,,5167,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,Expert,,CHEMBL884002,,9606.0,500.0,9,1,A-431,F,,,BAO_0000219,16093
80852,,N,,,5168,Homo sapiens,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",,Intermediate,,CHEMBL621850,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,16825
80852,,N,,,5169,Homo sapiens,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,,Intermediate,,CHEMBL621851,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,4848
9,,D,,,5170,Homo sapiens,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,,Expert,,CHEMBL621852,,9606.0,500.0,9,1,A-431,F,,,BAO_0000219,14827
9,,D,,,5171,Homo sapiens,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,,Expert,,CHEMBL621853,,9606.0,500.0,9,1,A-431,F,,,BAO_0000219,14827
80852,,N,,,5172,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",,Expert,,CHEMBL621854,,,500.0,1,1,A-431,F,,,BAO_0000218,16289
80852,,N,,,5173,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,Expert,,CHEMBL621855,,,500.0,1,1,A-431,F,,,BAO_0000218,16289
80852,,N,,,5174,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",,Expert,,CHEMBL623724,,,500.0,1,1,A-431,F,,,BAO_0000218,16289
80852,,N,,,5175,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",,Expert,,CHEMBL623725,,,500.0,1,1,A-431,F,,,BAO_0000218,16289
80852,,N,,,5176,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",,Expert,,CHEMBL623726,,,500.0,1,1,A-431,F,,,BAO_0000218,16289
9,,D,,,5177,Homo sapiens,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",,Expert,,CHEMBL623727,,9606.0,500.0,9,1,A-431,F,,,BAO_0000219,16289
9,,H,,,5178,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,,Expert,,CHEMBL623728,,,500.0,8,1,A-431,F,,,BAO_0000219,16289
80852,,N,,,5179,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",,Expert,,CHEMBL623729,,,500.0,1,1,A-431,F,,,BAO_0000218,16289
80852,,N,,,5180,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,Expert,,CHEMBL623730,,,500.0,1,1,A-431,F,,,BAO_0000218,16289
80852,,N,,,5181,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",,Expert,,CHEMBL623731,,,500.0,1,1,A-431,F,,,BAO_0000218,16289
80852,,N,,,5182,Mus musculus,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",,Expert,,CHEMBL623732,,10090.0,500.0,1,1,A-431,F,,,BAO_0000218,14555
80852,,N,,,5183,Mus musculus,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",,Expert,,CHEMBL623733,,10090.0,500.0,1,1,A-431,F,,,BAO_0000218,14555
80852,,N,,,5184,Mus musculus,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,Expert,,CHEMBL623734,,10090.0,500.0,1,1,A-431,F,,,BAO_0000218,14555
80852,,N,,,5185,Mus musculus,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",,Expert,,CHEMBL623735,,10090.0,500.0,1,1,A-431,F,,,BAO_0000218,14555
80852,,N,,,5186,Homo sapiens,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,,Expert,,CHEMBL623736,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,1937
80852,,N,,,5187,Homo sapiens,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,,Intermediate,,CHEMBL623737,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,13739
80852,,N,,,5188,Homo sapiens,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,,Intermediate,,CHEMBL623738,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,3558
80852,,N,,,5189,Homo sapiens,Dose giving a 50% decrease in the living cell number (A437 cells),,Intermediate,,CHEMBL875168,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,3558
80682,,N,,,5190,Homo sapiens,In vitro inhibitory concentration against proliferation of A459 cell line.,,Expert,,CHEMBL623739,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17686
80682,,N,,,5191,Homo sapiens,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,,Intermediate,,CHEMBL623740,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5305
80682,,N,,,5192,Homo sapiens,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,,Intermediate,,CHEMBL624424,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3614
80021,,N,,,5193,Homo sapiens,In vitro antitumor activity against renal A498 tumor cell lines,,Intermediate,,CHEMBL624425,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,17229
80021,,N,,,5194,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",,Intermediate,,CHEMBL624426,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,15935
80021,,N,,,5195,Homo sapiens,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",,Intermediate,,CHEMBL624427,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,15935
80021,,N,,,5196,Homo sapiens,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,,Intermediate,,CHEMBL624428,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,15560
80021,,N,,,5197,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,,Intermediate,,CHEMBL624429,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,13891
80021,,N,,,5198,Homo sapiens,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,,Intermediate,,CHEMBL624620,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,13891
80021,,N,,,5199,Homo sapiens,Cytotoxicity on kidney carcinoma (A-498) cell line,,Intermediate,,CHEMBL624621,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,13788
80021,,N,,,5200,Homo sapiens,Compound was evaluated against Human cell line renal A498,,Intermediate,,CHEMBL624622,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,15403
80021,,N,,,5201,Homo sapiens,Compound was tested for inhibition of A498 human renal cancer cell line,,Intermediate,,CHEMBL624623,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,1009
80021,,N,,,5202,Homo sapiens,Growth inhibitory activity against A498 human cancer cell line,,Intermediate,,CHEMBL874365,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,1043
80021,,N,,,5203,Homo sapiens,In vitro antitumor activity against human renal A498 cell line,,Intermediate,,CHEMBL624624,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,5858
80021,,N,,,5204,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line,,Intermediate,,CHEMBL624625,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,5958
80021,,N,,,5205,Homo sapiens,In vitro cytotoxic activity against human renal cancer (A498) cell line,,Intermediate,,CHEMBL624626,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,5506
80021,,N,,,5206,Homo sapiens,Tested for cytostatic activity against renal A498 cell line,,Intermediate,,CHEMBL624627,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,12781
80021,,N,,,5207,Homo sapiens,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,,Intermediate,,CHEMBL883157,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,14399
80021,,N,,,5208,Homo sapiens,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,,Expert,,CHEMBL624628,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,5958
22224,,U,,,5209,beagle,Cmax value after 2 mpk peroral administration to beagles,,Autocuration,,CHEMBL624629,In vivo,9615.0,,0,1,,A,,,BAO_0000218,3510
22224,,U,,beagle,5210,Canis lupus familiaris,Bioavailability,,Autocuration,,CHEMBL623551,In vivo,9615.0,,0,1,,A,,,BAO_0000218,3510
22224,,U,,beagle,5211,Canis lupus familiaris,Bioavailability after 1 mpk peroral administration to beagles,,Autocuration,,CHEMBL623552,In vivo,9615.0,,0,1,,A,,,BAO_0000218,3510
22224,,U,,beagle,5212,Canis lupus familiaris,Bioavailability after 2 mpk peroral administration to beagles,,Autocuration,,CHEMBL623553,In vivo,9615.0,,0,1,,A,,,BAO_0000218,3510
22224,,U,,,5213,Bos taurus,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,,Autocuration,,CHEMBL623554,,9913.0,,0,1,,A,,,BAO_0000019,3085
22224,,U,,,5214,Bos taurus,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,,Autocuration,,CHEMBL623555,,9913.0,,0,1,,A,,,BAO_0000019,3085
22224,,U,,,5215,Bos taurus,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,,Autocuration,,CHEMBL623556,,9913.0,,0,1,,A,,,BAO_0000019,3085
22224,,U,,,5216,Bos taurus,Solubility against bovine alpha-chymotrypsin,,Autocuration,,CHEMBL623557,,9913.0,,0,1,,A,,,BAO_0000019,9372
22224,,U,,,5217,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,Autocuration,,CHEMBL623558,,9913.0,,0,1,,A,,,BAO_0000019,3085
22224,,U,,,5218,Bos taurus,Rate constant of the bovine serum albumin catalyzed reaction of the compound,,Autocuration,,CHEMBL623559,,9913.0,,0,1,,A,,,BAO_0000019,3085
22224,,U,2106.0,,5219,Bos taurus,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,Spleen,Autocuration,,CHEMBL623560,,9913.0,,0,1,,A,,,BAO_0000221,1469
22224,,U,,,5220,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum,,Autocuration,,CHEMBL623561,,9913.0,,0,1,,A,,,BAO_0000019,4297
22224,,U,,,5221,Bos taurus,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,,Autocuration,,CHEMBL623562,,9913.0,,0,1,,A,,,BAO_0000019,4297
22224,,U,,,5222,Bos taurus,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,,Autocuration,,CHEMBL623563,,9913.0,,0,1,,A,,,BAO_0000019,17585
22224,,U,2106.0,,5223,Bos taurus,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,Spleen,Autocuration,,CHEMBL623564,,9913.0,,0,1,,A,,,BAO_0000221,1336
22224,,U,,,5224,Bos taurus,Half life in presence of 2 mg/mL BSA at pH 8.8,,Autocuration,,CHEMBL873806,,9913.0,,0,1,,A,,,BAO_0000019,3085
22224,,U,,,5225,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,,Autocuration,,CHEMBL623565,,9913.0,,0,1,,A,,,BAO_0000019,2857
22224,,U,,,5226,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,,Autocuration,,CHEMBL623566,,9913.0,,0,1,,A,,,BAO_0000019,2857
22224,,U,,,5227,Bos taurus,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,,Autocuration,,CHEMBL623567,,9913.0,,0,1,,A,,,BAO_0000019,2857
22224,,U,,,5228,Bos taurus,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),,Autocuration,,CHEMBL623568,,9913.0,,0,1,,A,,,BAO_0000019,1540
50588,,N,1969.0,,5229,Canis lupus familiaris,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,Plasma,Intermediate,,CHEMBL623569,,9615.0,,1,1,,A,,,BAO_0000218,6316
50588,,N,1969.0,,5230,Canis lupus familiaris,AUC after administration at 100 mg/kg/day in dogs,Plasma,Intermediate,,CHEMBL623570,,9615.0,,1,1,,A,,,BAO_0000218,17594
50588,,N,1969.0,,5231,Canis lupus familiaris,AUC in dog at 0-24 hr by peroral administration at 3 mpk,Plasma,Intermediate,,CHEMBL624254,,9615.0,,1,1,,A,,,BAO_0000218,4953
50588,,N,1969.0,,5232,Canis lupus familiaris,AUC value after 15 mg/kg iv dose in Dogs,Plasma,Intermediate,,CHEMBL624255,,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,1969.0,,5233,Canis lupus familiaris,AUC value after 30 mg/kg po dose in Dogs,Plasma,Intermediate,,CHEMBL624256,,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,1969.0,,5234,Canis lupus familiaris,AUC value after administration of 4 mg/Kg oral dose in dog,Plasma,Intermediate,,CHEMBL624257,,9615.0,,1,1,,A,,,BAO_0000218,2959
50588,,N,1969.0,,5235,Canis lupus familiaris,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,Plasma,Intermediate,,CHEMBL624258,,9615.0,,1,1,,A,,,BAO_0000218,17594
50588,,N,,,5236,Canis lupus familiaris,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,,Intermediate,,CHEMBL875277,,9615.0,,1,1,,A,,,BAO_0000218,5356
50588,,N,,,5237,Canis lupus familiaris,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,,Intermediate,,CHEMBL622667,,9615.0,,1,1,,A,,,BAO_0000218,16807
50588,,N,,,5238,Canis lupus familiaris,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,,Intermediate,,CHEMBL622668,,9615.0,,1,1,,A,,,BAO_0000218,4527
50588,,N,,,5239,Canis lupus familiaris,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,,Intermediate,,CHEMBL622669,,9615.0,,1,1,,A,,,BAO_0000218,4527
50588,,N,,,5240,Canis lupus familiaris,Area under curve determined in dogs after intravenous administration of 3 mg/kg,,Intermediate,,CHEMBL622670,,9615.0,,1,1,,A,,,BAO_0000218,15660
50588,,N,,,5241,Canis lupus familiaris,Area under curve determined in dogs after oral administration of 10 mg/kg,,Intermediate,,CHEMBL622671,,9615.0,,1,1,,A,,,BAO_0000218,15660
50588,,N,,,5242,Canis lupus familiaris,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Intermediate,,CHEMBL622672,,9615.0,,1,1,,A,,,BAO_0000218,5802
50588,,N,,,5243,Canis lupus familiaris,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,,Expert,,CHEMBL622673,,9615.0,,1,1,,A,,,BAO_0000218,3598
50588,,N,,,5244,Canis lupus familiaris,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,,Expert,,CHEMBL622674,,9615.0,,1,1,,A,,,BAO_0000218,3598
50588,,N,,,5245,Canis lupus familiaris,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,Intermediate,,CHEMBL622675,,9615.0,,1,1,,A,,,BAO_0000218,5944
50588,,N,,,5246,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,,Intermediate,,CHEMBL622676,,9615.0,,1,1,,A,,,BAO_0000218,5944
50588,,N,,,5247,Canis lupus familiaris,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,Intermediate,,CHEMBL622677,,9615.0,,1,1,,A,,,BAO_0000218,5944
50588,,N,,,5248,Canis lupus familiaris,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,,Intermediate,,CHEMBL622678,,9615.0,,1,1,,A,,,BAO_0000218,5944
50588,,N,,,5249,Canis lupus familiaris,Area under curve in dog after administration of 20 mg/kg dose through peroral route,,Intermediate,,CHEMBL622679,,9615.0,,1,1,,A,,,BAO_0000218,4186
50588,,N,,,5250,Canis lupus familiaris,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Intermediate,,CHEMBL622680,,9615.0,,1,1,,A,,,BAO_0000218,5007
50588,,N,,,5251,Canis lupus familiaris,Area under curve was determine after peroral administration at 10 mpk in dog,,Intermediate,,CHEMBL622681,,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,5252,Canis lupus familiaris,Area under curve was determine after peroral administration at 5 mpk in dog,,Intermediate,,CHEMBL875278,,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,5253,Canis lupus familiaris,Area under curve was determined,,Intermediate,,CHEMBL622682,,9615.0,,1,1,,A,,,BAO_0000218,5006
50588,,N,,,5254,Canis lupus familiaris,Area under curve in dogs,,Intermediate,,CHEMBL622683,,9615.0,,1,1,,A,,,BAO_0000218,5006
50588,,N,,,5255,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration,,Intermediate,,CHEMBL622684,,9615.0,,1,1,,A,,,BAO_0000218,3771
50588,,N,,,5256,Canis lupus familiaris,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),,Intermediate,,CHEMBL622685,,9615.0,,1,1,,A,,,BAO_0000218,3771
50588,,N,,,5257,Canis lupus familiaris,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,,Intermediate,,CHEMBL622686,,9615.0,,1,1,,A,,,BAO_0000218,3771
50588,,N,,,5258,Canis lupus familiaris,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Intermediate,,CHEMBL618344,,9615.0,,1,1,,A,,,BAO_0000218,1916
50588,,N,,,5259,Canis lupus familiaris,Area under curve value in dog at a dose of 5 mg/kg,,Intermediate,,CHEMBL875582,,9615.0,,1,1,,A,,,BAO_0000218,5302
50588,,N,,,5260,Canis lupus familiaris,Area under curve was determined after 0.1 mg/kg iv administration in dog,,Intermediate,,CHEMBL618345,,9615.0,,1,1,,A,,,BAO_0000218,5600
50588,,N,,,5261,Canis lupus familiaris,Area under curve was determined after 0.3 mg/kg po administration in dog,,Intermediate,,CHEMBL618346,,9615.0,,1,1,,A,,,BAO_0000218,5600
50588,,N,,,5262,Canis lupus familiaris,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,,Intermediate,,CHEMBL618347,,9615.0,,1,1,,A,,,BAO_0000218,17764
50588,,N,,,5263,Canis lupus familiaris,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,,Intermediate,,CHEMBL618348,,9615.0,,1,1,,A,,,BAO_0000218,4368
22224,,U,,,5264,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,,Autocuration,,CHEMBL618349,,9606.0,,0,1,,A,,,BAO_0000019,5318
22224,,U,,,5265,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,Autocuration,,CHEMBL618350,,9606.0,,0,1,,A,,,BAO_0000019,5318
22224,,U,,,5266,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,,Autocuration,,CHEMBL618351,,9606.0,,0,1,,A,,,BAO_0000019,5318
22224,,U,,,5267,Homo sapiens,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,,Autocuration,,CHEMBL618352,,9606.0,,0,1,,A,,,BAO_0000019,5318
22224,,U,178.0,,5268,Homo sapiens,Time taken to reduce 50% of the concentration of compound in blood plasma,Blood,Autocuration,,CHEMBL873494,,9606.0,,0,1,,A,,,BAO_0000221,14518
22224,,U,1969.0,,5269,Homo sapiens,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Plasma,Autocuration,,CHEMBL618353,,9606.0,,0,1,,A,,,BAO_0000366,2209
22224,,U,1969.0,,5270,Homo sapiens,Half life in human plasma,Plasma,Autocuration,,CHEMBL618354,,9606.0,,0,1,,A,,,BAO_0000366,6787
22224,,U,1969.0,,5271,Homo sapiens,Half life in human plasma was reported,Plasma,Autocuration,,CHEMBL875583,,9606.0,,0,1,,A,,,BAO_0000366,4898
22224,,U,1977.0,,5272,Homo sapiens,Half life in human serum,Serum,Autocuration,,CHEMBL618355,,9606.0,,0,1,,A,,,BAO_0000019,6072
22224,,U,1969.0,,5273,Homo sapiens,Half life upon exposure to human plasma,Plasma,Autocuration,,CHEMBL618356,,9606.0,,0,1,,A,,,BAO_0000366,16907
22224,,U,,,5274,Homo sapiens,t1/2 in human microsomes,,Autocuration,,CHEMBL618357,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,5656
22224,,U,1969.0,,5275,Homo sapiens,Half life period in 80% human plasma at 37 degree Centigrade,Plasma,Autocuration,,CHEMBL618358,,9606.0,,0,1,,A,,,BAO_0000366,4755
22224,,U,14.0,,5276,Homo sapiens,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),Zone of skin,Autocuration,,CHEMBL618359,,9606.0,,0,1,,A,,,BAO_0000221,17503
22224,,U,1969.0,,5277,Homo sapiens,Half-life measured in in vitro Cathepsin B assay in human plasma,Plasma,Autocuration,,CHEMBL618360,In vitro,9606.0,,0,1,,A,,,BAO_0000366,12357
22224,,U,,,5278,Homo sapiens,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,,Autocuration,,CHEMBL618361,,9606.0,,0,1,,A,,,BAO_0000019,3076
22224,,U,2107.0,,5279,Homo sapiens,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,Liver,Autocuration,,CHEMBL618362,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,6410
22224,,U,1969.0,,5280,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",Plasma,Autocuration,,CHEMBL618363,,9606.0,,0,1,,A,,,BAO_0000366,3741
22224,,U,1969.0,,5281,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",Plasma,Autocuration,,CHEMBL618364,,9606.0,,0,1,,A,,,BAO_0000366,3741
22224,,U,1969.0,,5282,Homo sapiens,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",Plasma,Autocuration,,CHEMBL875584,,9606.0,,0,1,,A,,,BAO_0000366,3741
22224,,U,,,5283,Homo sapiens,Half-life in the CEM cell extracts,,Autocuration,,CHEMBL618365,,9606.0,,0,1,,A,,,BAO_0000019,1540
22224,,U,1969.0,,5284,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,Plasma,Autocuration,,CHEMBL873495,,9606.0,,0,1,,A,,,BAO_0000366,2905
22224,,U,1969.0,,5285,Homo sapiens,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,Plasma,Autocuration,,CHEMBL618366,,9606.0,,0,1,,A,,,BAO_0000366,2905
22224,,U,,,5286,Homo sapiens,Half-life was determined,,Autocuration,,CHEMBL618367,,9606.0,,0,1,,A,,,BAO_0000019,5523
22224,,U,178.0,,5287,Homo sapiens,Half-life (human blood stability),Blood,Autocuration,,CHEMBL618368,,9606.0,,0,1,,A,,,BAO_0000221,1499
22224,,U,178.0,,5288,Homo sapiens,Half-life (human blood stability); no data,Blood,Autocuration,,CHEMBL618369,,9606.0,,0,1,,A,,,BAO_0000221,1499
22224,,U,1969.0,,5289,Homo sapiens,Half-life in human plasma,Plasma,Autocuration,,CHEMBL618370,,9606.0,,0,1,,A,,,BAO_0000366,17065
22224,,U,,,5290,Homo sapiens,CYP3A4 metabolism half-life (t1/2),,Autocuration,,CHEMBL618371,,9606.0,,0,1,,A,,,BAO_0000019,6861
22224,,U,178.0,,5291,Homo sapiens,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),Blood,Autocuration,,CHEMBL618372,,9606.0,,0,1,,A,,,BAO_0000221,1499
22224,,U,1969.0,,5292,Homo sapiens,In vitro half life in human plasma,Plasma,Autocuration,,CHEMBL618373,In vitro,9606.0,,0,1,,A,,,BAO_0000366,530
22224,,U,1969.0,,5293,Homo sapiens,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",Plasma,Autocuration,,CHEMBL618374,In vitro,9606.0,,0,1,,A,,,BAO_0000366,1116
22224,,U,1969.0,,5294,Homo sapiens,In vitro hydrolysis in human plasma,Plasma,Autocuration,,CHEMBL618375,In vitro,9606.0,,0,1,,A,,,BAO_0000366,6695
22224,,U,1969.0,,5295,Homo sapiens,In vitro hydrolysis in human plasma; no data,Plasma,Autocuration,,CHEMBL618376,In vitro,9606.0,,0,1,,A,,,BAO_0000366,6695
22224,,U,2107.0,,5296,Homo sapiens,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,Liver,Autocuration,,CHEMBL618377,In vitro,9606.0,,0,1,,A,,Microsomes,BAO_0000251,10
22224,,U,1969.0,,5297,Homo sapiens,Plasma half life in human,Plasma,Autocuration,,CHEMBL618378,,9606.0,,0,1,,A,,,BAO_0000366,993
22224,,U,1969.0,,5298,Homo sapiens,Stability after incubation with human plasma (at 37 degree C),Plasma,Autocuration,,CHEMBL618379,,9606.0,,0,1,,A,,,BAO_0000366,15429
22224,,U,1969.0,,5299,Homo sapiens,T1/2 was evaluated in human plasma,Plasma,Autocuration,,CHEMBL618380,,9606.0,,0,1,,A,,,BAO_0000366,1675
22224,,U,1969.0,,5300,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",Plasma,Autocuration,,CHEMBL618381,,9606.0,,0,1,,A,,,BAO_0000366,2209
22224,,U,1969.0,,5301,Homo sapiens,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",Plasma,Autocuration,,CHEMBL618382,,9606.0,,0,1,,A,,,BAO_0000366,2209
22224,,U,,,5302,Homo sapiens,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,,Autocuration,,CHEMBL618383,,9606.0,,0,1,,A,,,BAO_0000019,5318
22224,,U,,,5303,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,,Autocuration,,CHEMBL618384,In vitro,9606.0,,0,1,,A,,,BAO_0000019,2412
22224,,U,,,5304,Homo sapiens,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,,Autocuration,,CHEMBL618385,In vitro,9606.0,,0,1,,A,,,BAO_0000019,2412
22224,,U,1969.0,,5305,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,Plasma,Autocuration,,CHEMBL619099,,9606.0,,0,1,,A,,,BAO_0000366,2906
22224,,U,1969.0,,5306,Homo sapiens,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,Plasma,Autocuration,,CHEMBL619100,,9606.0,,0,1,,A,,,BAO_0000366,2906
22224,,U,,,5307,Homo sapiens,Time taken for 50% to be consumed by serum PON1 was determined,,Autocuration,,CHEMBL619101,,9606.0,,0,1,,A,,,BAO_0000019,5495
22224,,U,,,5308,Homo sapiens,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,,Autocuration,,CHEMBL619102,,9606.0,,0,1,,A,,,BAO_0000019,5495
22224,,U,2107.0,,5309,Homo sapiens,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,Liver,Autocuration,,CHEMBL619103,,9606.0,,0,1,,A,,Microsomes,BAO_0000251,4397
22224,,U,,,5310,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration,,CHEMBL619268,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5311,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration,,CHEMBL619269,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5312,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration,,CHEMBL619270,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5313,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration,,CHEMBL619271,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5314,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration,,CHEMBL875585,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5315,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Autocuration,,CHEMBL619272,,10095.0,,0,1,,A,,,BAO_0000218,2413
80640,,N,,,5316,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line 786-0,,Intermediate,,CHEMBL619273,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,6058
80640,,N,,,5317,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,,Intermediate,,CHEMBL619274,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,17708
80640,,N,,,5318,Homo sapiens,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,,Expert,,CHEMBL619275,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14017
80640,,N,,,5319,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",,Intermediate,,CHEMBL619276,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,16818
80640,,N,,,5320,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",,Intermediate,,CHEMBL619277,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,16818
80640,,N,,,5321,Homo sapiens,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",,Intermediate,,CHEMBL619278,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,16818
80640,,N,,,5322,Homo sapiens,Tested for cytotoxicity against 786-0 cell lines in renal cancer,,Intermediate,,CHEMBL619279,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,11970
80640,,N,,,5323,Homo sapiens,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,,Intermediate,,CHEMBL858458,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,12400
80640,,N,,,5324,Homo sapiens,Cytotoxic effect on renal cancer line 786-0,,Expert,,CHEMBL619280,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,12888
80640,,N,,,5325,Homo sapiens,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,,Intermediate,,CHEMBL619281,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,15300
80640,,N,,,5326,Homo sapiens,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),,Intermediate,,CHEMBL619282,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14769
80640,,N,,,5327,Homo sapiens,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",,Intermediate,,CHEMBL619283,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,15895
80640,,N,,,5328,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,,Intermediate,,CHEMBL619284,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,17376
80640,,N,,,5329,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,Intermediate,,CHEMBL619285,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14882
80640,,N,,,5330,Homo sapiens,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),,Intermediate,,CHEMBL619286,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,14882
80640,,N,,,5331,Homo sapiens,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,,Intermediate,,CHEMBL619287,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,15176
80640,,N,,,5332,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,Intermediate,,CHEMBL857455,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,12696
80640,,N,,,5333,Homo sapiens,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),,Intermediate,,CHEMBL883801,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,2496
80641,,N,,,5334,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,,Intermediate,,CHEMBL619288,,9606.0,972.0,1,1,791T cell line,F,,,BAO_0000219,11831
80641,,N,,,5335,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),,Intermediate,,CHEMBL619289,,9606.0,972.0,1,1,791T cell line,F,,,BAO_0000219,11831
80641,,N,,,5336,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,,Intermediate,,CHEMBL619290,,9606.0,972.0,1,1,791T cell line,F,,,BAO_0000219,11831
80641,,N,,,5337,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),,Intermediate,,CHEMBL619291,,9606.0,972.0,1,1,791T cell line,F,,,BAO_0000219,11831
80641,,N,,,5338,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),,Intermediate,,CHEMBL619292,,9606.0,972.0,1,1,791T cell line,F,,,BAO_0000219,11831
80641,,N,,,5339,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,,Intermediate,,CHEMBL619293,,9606.0,972.0,1,1,791T cell line,F,,,BAO_0000219,11831
80641,,N,,,5340,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),,Intermediate,,CHEMBL619294,,9606.0,972.0,1,1,791T cell line,F,,,BAO_0000219,11831
80641,,N,,,5341,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),,Intermediate,,CHEMBL619295,,9606.0,972.0,1,1,791T cell line,F,,,BAO_0000219,11831
80641,,N,,,5342,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),,Intermediate,,CHEMBL619296,,9606.0,972.0,1,1,791T cell line,F,,,BAO_0000219,11831
80641,,N,,,5343,Homo sapiens,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,,Intermediate,,CHEMBL619297,,9606.0,972.0,1,1,791T cell line,F,,,BAO_0000219,11831
80640,,N,,,5344,Homo sapiens,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,,Intermediate,,CHEMBL619298,,9606.0,391.0,1,1,786-0,F,,,BAO_0000219,12782
22226,,U,,,5345,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,,Intermediate,,CHEMBL619299,,,,0,1,,F,,,BAO_0000019,1229
80433,,N,,,5346,Homo sapiens,Inhibition of cell growth in drug resistant 8226 myeloma cell line,,Expert,,CHEMBL619300,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,15313
80433,,N,,,5347,Homo sapiens,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,,Expert,,CHEMBL619301,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,15313
80433,,N,,,5348,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,,Intermediate,,CHEMBL619302,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,11544
80433,,N,,,5349,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Intermediate,,CHEMBL619303,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5350,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Intermediate,,CHEMBL619304,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5351,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Intermediate,,CHEMBL857706,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5352,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Intermediate,,CHEMBL619305,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5353,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Intermediate,,CHEMBL619306,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5354,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Intermediate,,CHEMBL619307,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5355,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Intermediate,,CHEMBL619308,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5356,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Intermediate,,CHEMBL619309,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5357,Homo sapiens,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Intermediate,,CHEMBL619310,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80021,,N,,,5358,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,Intermediate,,CHEMBL619311,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,14769
80021,,N,,,5359,Homo sapiens,Compound was tested for the growth inhibition of A498 renal tumor cell line,,Intermediate,,CHEMBL619312,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,15354
80021,,N,,,5360,Homo sapiens,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),,Intermediate,,CHEMBL619313,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,17445
80021,,N,,,5361,Homo sapiens,In vitro inhibitory concentration against renal cancer cell line A498,,Intermediate,,CHEMBL619314,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,4337
80021,,N,,,5362,Homo sapiens,Cytotoxicity against A 498 tumor cell line,,Intermediate,,CHEMBL619959,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,15277
80021,,N,,,5363,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line,,Intermediate,,CHEMBL619960,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,4812
80021,,N,,,5364,Homo sapiens,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),,Intermediate,,CHEMBL619961,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,4812
80021,,N,,,5365,Homo sapiens,Inhibitory dose required against A498 human tumor cell lines,,Intermediate,,CHEMBL619962,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,4995
80021,,N,,,5366,Homo sapiens,Anticancer activity against one renal cancer (A498 cell line),,Intermediate,,CHEMBL875586,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,5847
80021,,N,,,5367,Homo sapiens,In vitro cytotoxicity against melanoma A498 cell line,,Intermediate,,CHEMBL619963,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,6557
80021,,N,,,5368,Homo sapiens,Compound was tested for growth inhibitory activity against A498 cell line,,Intermediate,,CHEMBL619964,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,2597
80021,,N,,,5369,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line A498,,Intermediate,,CHEMBL620108,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,6058
80021,,N,,,5370,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,,Intermediate,,CHEMBL620109,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,17708
80021,,N,,,5371,Homo sapiens,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,,Intermediate,,CHEMBL620110,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,15176
80021,,N,,,5372,Homo sapiens,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,,Intermediate,,CHEMBL620111,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,15300
80021,,N,,,5373,Homo sapiens,Tested for cytotoxicity against A498 cell lines in renal cancer,,Intermediate,,CHEMBL620112,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,11970
80021,,N,,,5374,Homo sapiens,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,,Intermediate,,CHEMBL620113,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,12400
80021,,N,,,5375,Homo sapiens,Cytotoxic effect on renal cancer lines A498,,Expert,,CHEMBL620114,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,12888
80021,,N,,,5376,Homo sapiens,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,,Intermediate,,CHEMBL620115,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,3030
80021,,N,,,5377,Homo sapiens,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),,Intermediate,,CHEMBL620116,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,14769
80021,,N,,,5378,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,,Intermediate,,CHEMBL620117,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,17376
80021,,N,,,5379,Homo sapiens,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,,Intermediate,,CHEMBL620118,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,16558
80021,,N,,,5380,Homo sapiens,Cytotoxicity against human kidney carcinoma cell lines A4982LM,,Intermediate,,CHEMBL620119,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,5194
80021,,N,,,5381,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,,Intermediate,,CHEMBL620120,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,10708
80682,,N,,,5382,Homo sapiens,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,,Expert,,CHEMBL620121,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16880
80682,,N,,,5383,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line,,Intermediate,,CHEMBL620122,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,10196
80682,,N,,,5384,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,,Intermediate,,CHEMBL620123,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,10196
80682,,N,,,5385,Homo sapiens,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,,Intermediate,,CHEMBL620124,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,10196
80682,,N,,,5386,Homo sapiens,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",,Intermediate,,CHEMBL620125,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12083
80682,,N,,,5387,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,,Expert,,CHEMBL620126,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16464
80682,,N,,,5388,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate,,CHEMBL883027,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16464
80682,,N,,,5389,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line,,Expert,,CHEMBL620127,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16470
80682,,N,,,5390,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),,Intermediate,,CHEMBL620128,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16470
80682,,N,,,5391,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line),,Intermediate,,CHEMBL620129,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16470
80682,,N,,,5392,Homo sapiens,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,,Intermediate,,CHEMBL620130,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16470
80682,,N,,,5393,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A549.,,Expert,,CHEMBL620131,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16582
80682,,N,,,5394,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",,Intermediate,,CHEMBL620132,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15935
80682,,N,,,5395,Homo sapiens,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",,Intermediate,,CHEMBL620133,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15935
80682,,N,,,5396,Homo sapiens,Inhibition of A549 human lung carcinoma cell proliferation,,Expert,,CHEMBL620134,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16597
80682,,N,,,5397,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,,Intermediate,,CHEMBL620135,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17376
80682,,N,,,5398,Homo sapiens,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,,Intermediate,,CHEMBL620136,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16496
80682,,N,,,5399,Homo sapiens,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,,Intermediate,,CHEMBL620137,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16152
80682,,N,,,5400,Homo sapiens,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,,Intermediate,,CHEMBL620268,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16152
80682,,N,,,5401,Homo sapiens,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate,,CHEMBL620269,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16464
80682,,N,,,5402,Homo sapiens,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,,Intermediate,,CHEMBL620270,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2288
80682,,N,,,5403,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,Intermediate,,CHEMBL620271,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17350
80682,,N,,,5404,Homo sapiens,Inhibition of A549 cancer cell proliferation,,Expert,,CHEMBL620272,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4090
80682,,N,,,5405,Homo sapiens,Inhibition of A549 cancer cell proliferation (Not tested),,Expert,,CHEMBL620273,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4090
80682,,N,,,5406,Homo sapiens,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,,Intermediate,,CHEMBL620274,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17350
80682,,N,,,5407,Homo sapiens,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,,Intermediate,,CHEMBL620275,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4197
80682,,N,,,5408,Homo sapiens,Antiproliferative potency determined as inhibitory concentration against A549 cells,,Intermediate,,CHEMBL620276,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17072
80682,,N,,,5409,Homo sapiens,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,,Intermediate,,CHEMBL620277,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17072
80682,,N,,,5410,Homo sapiens,Cytotoxicity against Renal cell lines A549 was determined,,Intermediate,,CHEMBL620278,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5194
50588,,N,,,5411,Canis lupus familiaris,Area under curve was determined in dog after a 3 mg/kg of oral dose,,Intermediate,,CHEMBL620279,,9615.0,,1,1,,A,,,BAO_0000218,4257
50588,,N,,,5412,Canis lupus familiaris,Area under curve was determined in dog after oral administration at 1 mg/kg,,Intermediate,,CHEMBL620280,,9615.0,,1,1,,A,,,BAO_0000218,6123
50588,,N,,,5413,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,,Intermediate,,CHEMBL620281,,9615.0,,1,1,,A,,,BAO_0000218,1337
50588,,N,,,5414,Canis lupus familiaris,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,,Intermediate,,CHEMBL620282,,9615.0,,1,1,,A,,,BAO_0000218,1337
50588,,N,,,5415,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),,Intermediate,,CHEMBL621134,,9615.0,,1,1,,A,,,BAO_0000218,8833
50588,,N,,,5416,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),,Intermediate,,CHEMBL621135,,9615.0,,1,1,,A,,,BAO_0000218,8833
50588,,N,,,5417,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),,Intermediate,,CHEMBL621136,,9615.0,,1,1,,A,,,BAO_0000218,8833
50588,,N,,,5418,Canis lupus familiaris,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),,Intermediate,,CHEMBL621137,,9615.0,,1,1,,A,,,BAO_0000218,8833
50588,,N,1969.0,,5419,Canis lupus familiaris,Area under plasma concentration time curve in dog upon oral administration,Plasma,Intermediate,,CHEMBL621138,,9615.0,,1,1,,A,,,BAO_0000218,17657
50588,,N,1969.0,,5420,Canis lupus familiaris,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,Plasma,Intermediate,,CHEMBL875587,,9615.0,,1,1,,A,,,BAO_0000218,17650
50588,,N,,,5421,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,,Intermediate,,CHEMBL621139,,9615.0,,1,1,,A,,,BAO_0000218,1977
50588,,N,,,5422,Canis lupus familiaris,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,,Intermediate,,CHEMBL621140,,9615.0,,1,1,,A,,,BAO_0000218,1977
50588,,N,,,5423,Canis lupus familiaris,Area under the curve for the compound was obtained when tested in dog,,Intermediate,,CHEMBL621141,,9615.0,,1,1,,A,,,BAO_0000218,3132
50588,,N,,,5424,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg,,Intermediate,,CHEMBL621142,,9615.0,,1,1,,A,,,BAO_0000218,5473
50588,,N,,,5425,Canis lupus familiaris,Area under the curve at a dose of 1 mg/kg (oral),,Intermediate,,CHEMBL621143,,9615.0,,1,1,,A,,,BAO_0000218,5474
50588,,N,,,5426,Canis lupus familiaris,Area under the curve at i.v. dose of 0.2 mg/kg,,Intermediate,,CHEMBL621144,,9615.0,,1,1,,A,,,BAO_0000218,5474
50588,,N,,,5427,Canis lupus familiaris,Area under the curve was measured in dog after an iv dose of 1 mg/kg,,Intermediate,,CHEMBL621145,,9615.0,,1,1,,A,,,BAO_0000218,6062
50588,,N,,,5428,Canis lupus familiaris,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,,Intermediate,,CHEMBL621146,,9615.0,,1,1,,A,,,BAO_0000218,4709
50588,,N,,,5429,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,,Intermediate,,CHEMBL622567,,9615.0,,1,1,,A,,,BAO_0000218,2652
50588,,N,,,5430,Canis lupus familiaris,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,,Intermediate,,CHEMBL622568,,9615.0,,1,1,,A,,,BAO_0000218,2652
50588,,N,,,5431,Canis lupus familiaris,Compound was evaluated for area under the curve in dog blood.,,Intermediate,,CHEMBL622569,,9615.0,,1,1,,A,,,BAO_0000218,2877
50588,,N,,,5432,Canis lupus familiaris,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,,Intermediate,,CHEMBL622570,,9615.0,,1,1,,A,,,BAO_0000218,5444
50588,,N,1969.0,,5433,Canis lupus familiaris,AUC in dog after oral dose (1 mg/kg),Plasma,Intermediate,,CHEMBL622571,,9615.0,,1,1,,A,,,BAO_0000218,5130
50588,,N,,,5434,Canis lupus familiaris,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,,Intermediate,,CHEMBL622572,,9615.0,,1,1,,A,,,BAO_0000218,6265
50588,,N,,,5435,Canis lupus familiaris,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",,Intermediate,,CHEMBL622573,,9615.0,,1,1,,A,,,BAO_0000218,4657
50588,,N,,,5436,Canis lupus familiaris,Pharmacokinetic parameter AUC after intravenous administration to dogs,,Intermediate,,CHEMBL622574,,9615.0,,1,1,,A,,,BAO_0000218,16367
50588,,N,,,5437,Canis lupus familiaris,Pharmacokinetic parameter AUC after oral administration to dogs,,Intermediate,,CHEMBL622575,,9615.0,,1,1,,A,,,BAO_0000218,16367
50588,,N,,,5438,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,,Intermediate,,CHEMBL622576,,9615.0,,1,1,,A,,,BAO_0000218,9579
50588,,N,,,5439,Canis lupus familiaris,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,,Intermediate,,CHEMBL622577,,9615.0,,1,1,,A,,,BAO_0000218,9579
50588,,N,,,5440,Canis lupus familiaris,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,,Intermediate,,CHEMBL622578,,9615.0,,1,1,,A,,,BAO_0000218,5983
50588,,N,,,5441,Canis lupus familiaris,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,,Intermediate,,CHEMBL622579,,9615.0,,1,1,,A,,,BAO_0000218,6241
50588,,N,,,5442,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",,Intermediate,,CHEMBL622580,,9615.0,,1,1,,A,,,BAO_0000218,5313
50588,,N,,,5443,Canis lupus familiaris,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",,Intermediate,,CHEMBL622581,,9615.0,,1,1,,A,,,BAO_0000218,5313
50588,,N,,,5444,Canis lupus familiaris,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Intermediate,,CHEMBL622582,,9615.0,,1,1,,A,,,BAO_0000218,6642
50588,,N,,,5445,Canis lupus familiaris,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Intermediate,,CHEMBL622583,,9615.0,,1,1,,A,,,BAO_0000218,6642
50588,,N,,,5446,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),,Intermediate,,CHEMBL622584,,9615.0,,1,1,,A,,,BAO_0000218,6641
50588,,N,,,5447,Canis lupus familiaris,Oral AUCN in dog (dosed at 0.5 mpk iv ),,Intermediate,,CHEMBL622585,,9615.0,,1,1,,A,,,BAO_0000218,6642
50588,,N,,,5448,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dog; 90-100,,Intermediate,,CHEMBL622586,,9615.0,,1,1,,A,,,BAO_0000218,17791
50588,,N,,,5449,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,,Intermediate,,CHEMBL623281,,9615.0,,1,1,,A,,,BAO_0000218,17655
50588,,N,,,5450,Canis lupus familiaris,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,,Intermediate,,CHEMBL623282,,9615.0,,1,1,,A,,,BAO_0000218,17655
50588,,N,,,5451,Canis lupus familiaris,PAPP (membrane permeability) in dog kidney cell monolayer assay,,Intermediate,,CHEMBL623283,,9615.0,,1,1,,A,,,BAO_0000218,6596
50588,,N,,,5452,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623284,,9615.0,,1,1,,A,,,BAO_0000218,3880
50588,,N,,,5453,Canis lupus familiaris,Bioavailability administered orally at a dose of 10 mg/kg to dogs,,Intermediate,,CHEMBL623285,,9615.0,,1,1,,A,,,BAO_0000218,16367
50588,,N,1969.0,,5454,Canis lupus familiaris,Plasma protein binding towards dog plasma at 10 uM,Plasma,Intermediate,,CHEMBL623463,,9615.0,,1,1,,A,,,BAO_0000218,17409
50588,,N,1969.0,,5455,Canis lupus familiaris,Plasma protein binding towards dog plasma at 100 uM,Plasma,Intermediate,,CHEMBL875952,,9615.0,,1,1,,A,,,BAO_0000218,17409
50588,,N,,,5456,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),,Intermediate,,CHEMBL621705,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2959
50588,,N,,,5457,Canis lupus familiaris,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,,Intermediate,,CHEMBL621706,In vivo,9615.0,,1,1,,A,,,BAO_0000218,13501
50588,,N,,,5458,Canis lupus familiaris,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,,Intermediate,,CHEMBL621707,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4527
50588,,N,,,5459,Canis lupus familiaris,Bioavailability in dogs,,Intermediate,,CHEMBL621708,In vivo,9615.0,,1,1,,A,,,BAO_0000218,15145
50588,,N,,,5460,Canis lupus familiaris,Bioavailability,,Intermediate,,CHEMBL621709,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4219
50588,,N,,,5461,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate,,CHEMBL621710,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17538
50588,,N,,,5462,Canis lupus familiaris,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,,Intermediate,,CHEMBL621711,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17538
50588,,N,,,5463,Canis lupus familiaris,Bioavailability in dog (dose 10.0 mg/kg p.o.),,Intermediate,,CHEMBL621712,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1466
50588,,N,,,5464,Canis lupus familiaris,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,,Intermediate,,CHEMBL621713,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17650
50588,,N,,,5465,Canis lupus familiaris,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,,Intermediate,,CHEMBL621714,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3132
22224,,U,,,5466,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration,,CHEMBL621715,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,2107.0,,5467,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,Liver,Autocuration,,CHEMBL623717,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,2107.0,,5468,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,Liver,Autocuration,,CHEMBL623718,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,2107.0,,5469,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,Liver,Autocuration,,CHEMBL623719,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5470,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration,,CHEMBL623720,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5471,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration,,CHEMBL623721,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,2385.0,,5472,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,Muscle tissue,Autocuration,,CHEMBL623722,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,2385.0,,5473,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,Muscle tissue,Autocuration,,CHEMBL623723,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,2385.0,,5474,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,Muscle tissue,Autocuration,,CHEMBL618543,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,2106.0,,5475,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,Spleen,Autocuration,,CHEMBL618544,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,2106.0,,5476,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,Spleen,Autocuration,,CHEMBL875155,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5477,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,,Autocuration,,CHEMBL618545,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5478,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Autocuration,,CHEMBL618546,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5479,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration,,CHEMBL623529,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5480,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,,Autocuration,,CHEMBL623530,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5481,Mus sp.,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,,Autocuration,,CHEMBL621764,,10095.0,,0,1,,A,,,BAO_0000218,2413
22224,,U,,,5482,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,Autocuration,,CHEMBL621765,,9527.0,,0,1,,A,,,BAO_0000019,17827
22224,,U,2037.0,,5483,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cerebellum,Autocuration,,CHEMBL621766,,9527.0,,0,1,,A,,,BAO_0000019,17827
22224,,U,1870.0,,5484,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Frontal cortex,Autocuration,,CHEMBL621767,,9527.0,,0,1,,A,,,BAO_0000019,17827
22224,,U,,,5485,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),,Autocuration,,CHEMBL621768,,9527.0,,0,1,,A,,,BAO_0000019,17827
22224,,U,2435.0,,5486,Cercopithecidae,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),Striatum,Autocuration,,CHEMBL621769,,9527.0,,0,1,,A,,,BAO_0000019,17827
22224,,U,,,5487,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),,Autocuration,,CHEMBL621770,,9527.0,,0,1,,A,,,BAO_0000019,17827
22224,,U,2037.0,,5488,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),Cerebellum,Autocuration,,CHEMBL621771,,9527.0,,0,1,,A,,,BAO_0000019,17827
22224,,U,1870.0,,5489,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),Frontal cortex,Autocuration,,CHEMBL621772,,9527.0,,0,1,,A,,,BAO_0000019,17827
22224,,U,,,5490,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),,Autocuration,,CHEMBL621773,,9527.0,,0,1,,A,,,BAO_0000019,17827
22224,,U,2435.0,,5491,Cercopithecidae,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),Striatum,Autocuration,,CHEMBL621774,,9527.0,,0,1,,A,,,BAO_0000019,17827
22224,,U,,,5492,Cercopithecidae,Compound was evaluated for oral bioavailability in rats,,Autocuration,,CHEMBL621775,,9527.0,,0,1,,A,,,BAO_0000218,17791
22224,,U,1969.0,,5493,Cercopithecidae,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,Plasma,Autocuration,,CHEMBL621776,In vivo,9527.0,,0,1,,A,,,BAO_0000218,17667
22224,,U,,,5494,Cercopithecidae,Half life period was evaluated in monkey,,Autocuration,,CHEMBL621777,,9527.0,,0,1,,A,,,BAO_0000019,17791
22224,,U,,,5495,Cercopithecidae,Half-life in rhesus monkeys by intravenous administration of dose,,Autocuration,,CHEMBL875162,In vivo,9527.0,,0,1,,A,,,BAO_0000218,110
50594,,N,1969.0,,5496,Mus musculus,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,Plasma,Intermediate,,CHEMBL621778,,10090.0,,1,1,,A,,,BAO_0000218,5781
50594,,N,1969.0,,5497,Mus musculus,AUC after intraperitoneal administration of 100 mg/kg in mice,Plasma,Intermediate,,CHEMBL621779,,10090.0,,1,1,,A,,,BAO_0000218,17734
50594,,N,1969.0,,5498,Mus musculus,AUC value was determined after oral administration,Plasma,Intermediate,,CHEMBL622479,,10090.0,,1,1,,A,,,BAO_0000218,17718
50594,,N,,,5499,Mus musculus,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,,Intermediate,,CHEMBL622480,,10090.0,,1,1,,A,,,BAO_0000218,4573
50594,,N,,,5500,Mus musculus,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),,Intermediate,,CHEMBL622481,,10090.0,,1,1,,A,,,BAO_0000218,3277
50594,,N,,,5501,Mus musculus,Area under curve by ioral administration in mouse,,Intermediate,,CHEMBL622482,,10090.0,,1,1,,A,,,BAO_0000218,2862
50594,,N,,,5502,Mus musculus,Area under curve by iv administration in mouse,,Intermediate,,CHEMBL622483,,10090.0,,1,1,,A,,,BAO_0000218,2862
50594,,N,,,5503,Mus musculus,Area under curve at 0-8 hr in IRC mice after peroral administration,,Intermediate,,CHEMBL622484,,10090.0,,1,1,,A,,,BAO_0000218,5951
50594,,N,,,5504,Mus musculus,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,,Intermediate,,CHEMBL622641,,10090.0,,1,1,,A,,,BAO_0000218,17729
50594,,N,,,5505,Mus musculus,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,,Intermediate,,CHEMBL622642,,10090.0,,1,1,,A,,,BAO_0000218,17728
50594,,N,,,5506,Mus musculus,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,,Intermediate,,CHEMBL622643,,10090.0,,1,1,,A,,,BAO_0000218,17728
50594,,N,,,5507,Mus musculus,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,,Intermediate,,CHEMBL622644,,10090.0,,1,1,,A,,,BAO_0000218,17729
80433,,N,,,5508,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Intermediate,,CHEMBL622645,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5509,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Intermediate,,CHEMBL622646,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5510,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Intermediate,,CHEMBL621238,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5511,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Intermediate,,CHEMBL621239,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5512,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Intermediate,,CHEMBL621240,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5513,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Intermediate,,CHEMBL621241,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5514,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Intermediate,,CHEMBL621242,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5515,Homo sapiens,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Intermediate,,CHEMBL620350,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5516,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,,Intermediate,,CHEMBL620351,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5517,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,,Intermediate,,CHEMBL620352,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5518,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),,Intermediate,,CHEMBL620353,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5519,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),,Intermediate,,CHEMBL620354,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5520,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),,Intermediate,,CHEMBL620355,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5521,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),,Intermediate,,CHEMBL620356,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5522,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),,Intermediate,,CHEMBL620357,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5523,Homo sapiens,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),,Intermediate,,CHEMBL620358,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5524,Homo sapiens,In vitro inhibition of human 8226 myeloma tumor cell line growth.,,Expert,,CHEMBL620359,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,9424
80433,,N,,,5525,Homo sapiens,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,,Intermediate,,CHEMBL620360,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,11544
80433,,N,,,5526,Homo sapiens,Cytotoxicity of compound against 8226/DOX1V cells,,Intermediate,,CHEMBL620361,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,17378
80433,,N,,,5527,Homo sapiens,Cytotoxicity of compound against 8226/S cells,,Intermediate,,CHEMBL620362,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,17378
80433,,N,,,5528,Homo sapiens,Inhibitory concentration against 8226 myeloma cancer cell line,,Intermediate,,CHEMBL620363,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,17079
80433,,N,,,5529,Homo sapiens,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,,Intermediate,,CHEMBL620364,,9606.0,741.0,1,1,RPMI-8226,F,,,BAO_0000219,17079
80647,,N,,,5530,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K).,,Intermediate,,CHEMBL620365,,9606.0,854.0,1,1,833K,F,,,BAO_0000219,13466
80647,,N,,,5531,Homo sapiens,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',,Intermediate,,CHEMBL620366,,9606.0,854.0,1,1,833K,F,,,BAO_0000219,13466
80647,,N,,,5532,Homo sapiens,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,,Expert,,CHEMBL620367,,9606.0,854.0,1,1,833K,F,,,BAO_0000219,2392
80647,,N,,,5533,Homo sapiens,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,,Intermediate,,CHEMBL620368,,9606.0,854.0,1,1,833K,F,,,BAO_0000219,2392
22226,,U,,,5534,,Inhibitory activity against caspase-1,,Autocuration,,CHEMBL620369,,,,0,1,,B,,,BAO_0000019,6608
45,,H,,,5535,Enterococcus faecalis,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,,Autocuration,,CHEMBL620370,,1351.0,,8,1,,B,,,BAO_0000357,10199
80648,,N,,,5536,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,,Intermediate,,CHEMBL620371,,9606.0,705.0,1,1,8701-BC,F,,,BAO_0000219,17749
80648,,N,,,5537,Homo sapiens,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,,Intermediate,,CHEMBL620372,,9606.0,705.0,1,1,8701-BC,F,,,BAO_0000219,17749
22226,,U,,,5538,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,,Intermediate,,CHEMBL876492,,,,0,1,,F,,,BAO_0000019,1229
22226,,U,,,5539,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,,Intermediate,,CHEMBL620373,,,,0,1,,F,,,BAO_0000019,1229
22226,,U,,,5540,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,,Intermediate,,CHEMBL620374,,,,0,1,,F,,,BAO_0000019,1229
22226,,U,,,5541,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,,Autocuration,,CHEMBL620375,,,,0,1,,B,,,BAO_0000019,6390
22226,,U,,,5542,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,Autocuration,,CHEMBL857902,,1314.0,,0,1,,F,,,BAO_0000019,16219
22226,,U,,,5543,Streptococcus pyogenes,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,,Autocuration,,CHEMBL620376,,1314.0,,0,1,,F,,,BAO_0000019,16219
11922,,H,,,5544,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,,Autocuration,,CHEMBL620377,,,,8,1,,B,,,BAO_0000357,17043
81115,,N,,,5545,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,,Intermediate,,CHEMBL620378,,9606.0,324.0,1,1,KB ,F,,,BAO_0000219,6929
81115,,N,,,5546,Homo sapiens,Tested for in vitro cytotoxic potency of compound in 9KB assay,,Intermediate,,CHEMBL620379,,9606.0,324.0,1,1,KB ,A,,,BAO_0000219,6929
22226,,U,,,5547,Homo sapiens,In vitro cytotoxicity of compound was tested against 9KB cells.,,Autocuration,,CHEMBL620380,,9606.0,,0,1,,F,,,BAO_0000219,7083
80653,,N,,,5548,Rattus norvegicus,Cytotoxic concentration against 9L cells was determined on day 3,,Intermediate,,CHEMBL884006,,10116.0,392.0,1,1,9L,F,,,BAO_0000219,12446
80653,,N,,,5549,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells,,Expert,,CHEMBL620381,,10116.0,392.0,1,1,9L,F,,,BAO_0000219,15345
80653,,N,,,5550,Rattus norvegicus,Tested in vitro for anticancer activity against 9L cells; Not determined,,Expert,,CHEMBL620382,,10116.0,392.0,1,1,9L,F,,,BAO_0000219,15345
80682,,N,,,5551,Homo sapiens,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,,Intermediate,,CHEMBL620383,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6301
80682,,N,,,5552,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,,Intermediate,,CHEMBL876493,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4833
80682,,N,,,5553,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,,Intermediate,,CHEMBL620384,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4833
80682,,N,,,5554,Homo sapiens,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,,Intermediate,,CHEMBL620385,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4833
80682,,N,,,5555,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line,,Expert,,CHEMBL620386,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13330
25,,D,,,5556,Homo sapiens,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,,Expert,,CHEMBL620387,,9606.0,646.0,9,1,A549,F,,,BAO_0000219,17517
25,,D,,,5557,Homo sapiens,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",,Expert,,CHEMBL621404,,9606.0,646.0,9,1,A549,F,,,BAO_0000219,17517
80682,,N,,,5558,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma",,Intermediate,,CHEMBL621405,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14425
80682,,N,,,5559,Homo sapiens,"In vitro growth inhibition of A549, lung carcinoma.",,Intermediate,,CHEMBL621406,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14425
80682,,N,,,5560,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Expert,,CHEMBL621407,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5228
80682,,N,,,5561,Homo sapiens,Cytotoxic activity against human lung cancer A549 cell line was determined,,Intermediate,,CHEMBL621408,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5351
80682,,N,,,5562,Homo sapiens,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,,Expert,,CHEMBL885345,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12198
80682,,N,,,5563,Homo sapiens,Cytotoxicity concentration against human lung carcinoma A-549 cell line,,Intermediate,,CHEMBL621409,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13891
80682,,N,,,5564,Homo sapiens,Cytotoxicity in A549 (human carcinoma) cell line.,,Expert,,CHEMBL876034,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5677
80682,,N,,,5565,Homo sapiens,Cytotoxicity on lung carcinoma (A-549) cell line,,Intermediate,,CHEMBL621410,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13788
80682,,N,,,5566,Homo sapiens,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,,Expert,,CHEMBL621411,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13384
80682,,N,,,5567,Homo sapiens,Effective dose of compound against replication of A549 cell line was evaluated,,Intermediate,,CHEMBL621412,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6726
80682,,N,,,5568,Homo sapiens,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,,Expert,,CHEMBL621413,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3455
80682,,N,,,5569,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),,Intermediate,,CHEMBL621414,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5726
80682,,N,,,5570,Homo sapiens,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,,Intermediate,,CHEMBL621415,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5726
80682,,N,,,5571,Homo sapiens,The compound was evaluated for antiproliferative activity against A549 cell line,,Intermediate,,CHEMBL621416,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3936
80682,,N,,,5572,Homo sapiens,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,,Intermediate,,CHEMBL621417,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14991
80682,,N,,,5573,Homo sapiens,Concentration required for growth inhibition of human lung carcinoma cell line A549,,Intermediate,,CHEMBL621418,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5243
80682,,N,,,5574,Homo sapiens,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,,Intermediate,,CHEMBL621419,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12858
80682,,N,,,5575,Homo sapiens,Growth inhibition against A549 cell line was evaluated,,Intermediate,,CHEMBL621420,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6776
80682,,N,,,5576,Homo sapiens,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,,Intermediate,,CHEMBL875823,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16558
80682,,N,,,5577,Homo sapiens,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,,Expert,,CHEMBL621421,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4583
80682,,N,,,5578,Homo sapiens,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,,Intermediate,,CHEMBL621422,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13514
80682,,N,,,5579,Homo sapiens,Chemosensitivity against DT-diaphorase rich A549 cell lines,,Expert,,CHEMBL884014,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15166
80682,,N,,,5580,Homo sapiens,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,,Intermediate,,CHEMBL621423,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13873
80682,,N,,,5581,Homo sapiens,In vitro cytotoxicity against human A549 (lung cancer) cell line.,,Expert,,CHEMBL621424,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6447
80682,,N,,,5582,Homo sapiens,In vitro antitumor activity against A549 (lung) human tumor cell lines.,,Intermediate,,CHEMBL621425,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2068
80682,,N,,,5583,Homo sapiens,In vitro cytotoxic activity against human lung carcinoma A549 cell line,,Expert,,CHEMBL621426,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1863
80682,,N,,,5584,Homo sapiens,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,,Intermediate,,CHEMBL621427,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13873
80682,,N,,,5585,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,Intermediate,,CHEMBL621428,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13873
80682,,N,,,5586,Homo sapiens,Tested against A549 lung carcinoma in the sulforhodamine B assay.,,Expert,,CHEMBL621429,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13873
80682,,N,,,5587,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),,Intermediate,,CHEMBL621430,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,579
80682,,N,,,5588,Homo sapiens,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,,Intermediate,,CHEMBL621431,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,579
80682,,N,,,5589,Homo sapiens,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,,Intermediate,,CHEMBL621432,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4584
80682,,N,,,5590,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,,Expert,,CHEMBL621433,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5421
80682,,N,,,5591,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,Intermediate,,CHEMBL875824,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5421
80682,,N,,,5592,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,Intermediate,,CHEMBL621434,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5421
80682,,N,,,5593,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,,Intermediate,,CHEMBL621435,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5421
80682,,N,,,5594,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,,Intermediate,,CHEMBL621436,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14188
80682,,N,,,5595,Homo sapiens,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,,Intermediate,,CHEMBL621437,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14188
80682,,N,,,5596,Homo sapiens,Compound was tested for the growth inhibition of A549 lung tumor cell line,,Intermediate,,CHEMBL621438,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15354
80682,,N,,,5597,Homo sapiens,Growth inhibition of human non-small-lung carcinoma (A549) cell line,,Expert,,CHEMBL621439,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14253
80682,,N,,,5598,Homo sapiens,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,,Intermediate,,CHEMBL621440,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13873
50588,,N,,,5599,Canis lupus familiaris,Oral bioavailability in dog (conscious),,Intermediate,,CHEMBL621441,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3043
50588,,N,,,5600,Canis lupus familiaris,Compound was evaluated for the oral bioavailability after oral administration in dog.,,Intermediate,,CHEMBL621442,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3045
50588,,N,,,5601,Canis lupus familiaris,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,,Intermediate,,CHEMBL621443,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3022
50588,,N,,,5602,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621444,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4453
50588,,N,,,5603,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL625133,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1696
50588,,N,,,5604,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL625134,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5045
50588,,N,,,5605,Canis lupus familiaris,Oral bioavailability in dog (fasted),,Intermediate,,CHEMBL625135,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5356
50588,,N,,,5606,Canis lupus familiaris,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,,Intermediate,,CHEMBL625136,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17764
50588,,N,,,5607,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL625137,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6448
50588,,N,,,5608,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL625138,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1475
50588,,N,,,5609,Canis lupus familiaris,Percent bioavailability in dog,,Intermediate,,CHEMBL625139,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3788
50588,,N,,,5610,Canis lupus familiaris,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,,Intermediate,,CHEMBL872264,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3639
50588,,N,,,5611,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL625140,In vivo,9615.0,,1,1,,A,,,BAO_0000218,13397
50588,,N,,,5612,Canis lupus familiaris,The compound was evaluated for bioavailability in dogs; 34-44,,Intermediate,,CHEMBL624436,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2137
50588,,N,,,5613,Canis lupus familiaris,Bioavailability in dog (dose 4 mg/kg p.o.),,Intermediate,,CHEMBL624437,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2959
50588,,N,,,5614,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL872261,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6448
50588,,N,,,5615,Canis lupus familiaris,8 hour trough Blood level in dog was measured after administration of compound,,Intermediate,,CHEMBL624438,,9615.0,,1,1,,A,,,BAO_0000218,6084
50588,,N,1969.0,,5616,Canis lupus familiaris,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,Plasma,Intermediate,,CHEMBL624439,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3639
50588,,N,,,5617,Canis lupus familiaris,C24 after oral administration at 5 mg/kg,,Intermediate,,CHEMBL624440,,9615.0,,1,1,,A,,,BAO_0000218,6316
50588,,N,,,5618,Canis lupus familiaris,Clearance after oral and iv dosing in dogs,,Intermediate,,CHEMBL624441,,9615.0,,1,1,,A,,,BAO_0000218,5238
50588,,N,1969.0,,5619,Canis lupus familiaris,Clearance of the drug was measured in the plasma of dog,Plasma,Intermediate,,CHEMBL624442,,9615.0,,1,1,,A,,,BAO_0000218,17796
50588,,N,,,5620,Canis lupus familiaris,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,,Intermediate,,CHEMBL624443,,9615.0,,1,1,,A,,,BAO_0000218,2652
50588,,N,,,5621,Canis lupus familiaris,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,Intermediate,,CHEMBL624444,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5654
50588,,N,,,5622,Canis lupus familiaris,Clearance of compound was determined in dogs,,Intermediate,,CHEMBL624445,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6621
50588,,N,,,5623,Canis lupus familiaris,Clearance on i.v. administration of 2 mg/kg was measured in dog,,Intermediate,,CHEMBL624446,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6505
50588,,N,,,5624,Canis lupus familiaris,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Intermediate,,CHEMBL624447,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5802
50588,,N,,,5625,Canis lupus familiaris,Plasma clearance in dog was determined,,Intermediate,,CHEMBL624448,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17267
50588,,N,,,5626,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Intermediate,,CHEMBL624449,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4521
50588,,N,,,5627,Canis lupus familiaris,Plasma clearance in dog after administration of 0.25 mg/kg iv,,Intermediate,,CHEMBL624450,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,,,5628,Canis lupus familiaris,Plasma clearance in dog after administration of 1 mg/kg iv,,Intermediate,,CHEMBL875942,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,,,5629,Canis lupus familiaris,Plasma clearance in dogs,,Intermediate,,CHEMBL624451,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,,,5630,Canis lupus familiaris,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,,Intermediate,,CHEMBL624452,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5542
50588,,N,,,5631,Canis lupus familiaris,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,Intermediate,,CHEMBL624453,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5199
50588,,N,,,5632,Canis lupus familiaris,Plasma clearance after 15 mg/kg iv dose in Dogs,,Intermediate,,CHEMBL624454,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,5633,Canis lupus familiaris,Plasma clearance after 30 mg/kg po dose in Dogs,,Intermediate,,CHEMBL624455,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,5634,Canis lupus familiaris,Plasma administration to dogs,,Intermediate,,CHEMBL624456,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16367
50588,,N,,,5635,Canis lupus familiaris,Plasma clearance was determined,,Intermediate,,CHEMBL624457,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5505
50588,,N,,,5636,Canis lupus familiaris,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,,Intermediate,,CHEMBL624458,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6215
50588,,N,,,5637,Canis lupus familiaris,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,,Intermediate,,CHEMBL624459,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1466
102164,,S,2107.0,,5638,Homo sapiens,Intrinsic clearance in human liver microsomes,Liver,Intermediate,,CHEMBL624460,In vitro,9606.0,,2,1,,A,,Microsomes,BAO_0000251,5007
102164,,S,2107.0,,5639,Homo sapiens,Intrinsic clearance in human liver microsomes,Liver,Intermediate,,CHEMBL624461,In vitro,9606.0,,2,1,,A,,Microsomes,BAO_0000251,5007
50588,,N,,,5640,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Intermediate,,CHEMBL875943,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,5641,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,Intermediate,,CHEMBL624462,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,5642,Canis lupus familiaris,Clearance in dog (dose 1 mg/kg i.v.),,Intermediate,,CHEMBL624463,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,5643,Canis lupus familiaris,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,,Intermediate,,CHEMBL624464,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6221
50588,,N,,,5644,Canis lupus familiaris,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Intermediate,,CHEMBL624465,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5007
50588,,N,,,5645,Canis lupus familiaris,Plasma clearance after peroral administration at 10 mpk in dog,,Intermediate,,CHEMBL624466,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,5646,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mpk in dog,,Intermediate,,CHEMBL624467,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,5647,Canis lupus familiaris,Plasma clearance after peroral administration at 5 mg/kg in dog,,Intermediate,,CHEMBL624468,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,5648,Canis lupus familiaris,Plasma clearance was measured in dog,,Intermediate,,CHEMBL624469,In vivo,9615.0,,1,1,,A,,,BAO_0000218,15660
50588,,N,,,5649,Canis lupus familiaris,Plasma clearance was measured in dog,,Intermediate,,CHEMBL624470,In vivo,9615.0,,1,1,,A,,,BAO_0000218,15660
50588,,N,,,5650,Canis lupus familiaris,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,,Intermediate,,CHEMBL624471,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5983
50588,,N,,,5651,Canis lupus familiaris,Total clearance was determined after 0.1 mg/kg iv administration in dog,,Intermediate,,CHEMBL624472,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5600
50588,,N,,,5652,Canis lupus familiaris,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,,Intermediate,,CHEMBL622775,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17764
50588,,N,,,5653,Canis lupus familiaris,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,,Intermediate,,CHEMBL622776,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6039
50588,,N,,,5654,Canis lupus familiaris,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,,Intermediate,,CHEMBL622777,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6039
50588,,N,,,5655,Canis lupus familiaris,Clearance after peroral administration of 0.2 mg/kg in dog was determined,,Intermediate,,CHEMBL622778,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6039
50588,,N,,,5656,Canis lupus familiaris,Clearance by intravenous administration of 1.2 mg/kg in dog,,Intermediate,,CHEMBL622779,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4368
50588,,N,,,5657,Canis lupus familiaris,Clearance by iv administration in dogs at a dose of 1 mg/kg,,Intermediate,,CHEMBL622780,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4305
50588,,N,1969.0,,5658,Canis lupus familiaris,Clearance value was evaluated in dog plasma,Plasma,Intermediate,,CHEMBL622781,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1918
50588,,N,,,5659,Canis lupus familiaris,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,Intermediate,,CHEMBL622782,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6005
50588,,N,1969.0,,5660,Canis lupus familiaris,Compound was tested for plasma clearance in dog,Plasma,Intermediate,,CHEMBL622783,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4839
50588,,N,,,5661,Canis lupus familiaris,Pharmacokinetic property (Plasma clearance) was measured in dog,,Intermediate,,CHEMBL622784,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4239
50594,,N,,,5662,Mus musculus,Area under curve when injected perorally in mice at a dose of 50 mg/kg,,Intermediate,,CHEMBL622785,,10090.0,,1,1,,A,,,BAO_0000218,17729
50594,,N,,,5663,Mus musculus,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,,Intermediate,,CHEMBL622786,,10090.0,,1,1,,A,,,BAO_0000218,17728
50594,,N,,,5664,Mus musculus,Area under curve value in mouse at a dose of 10 mg/kg,,Intermediate,,CHEMBL622787,,10090.0,,1,1,,A,,,BAO_0000218,5302
50594,,N,,,5665,Mus musculus,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,,Intermediate,,CHEMBL875949,,10090.0,,1,1,,A,,,BAO_0000218,5506
50594,,N,,,5666,Mus musculus,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,,Intermediate,,CHEMBL622788,,10090.0,,1,1,,A,,,BAO_0000218,5506
50594,,N,,,5667,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,,Intermediate,,CHEMBL622789,,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,5668,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,,Intermediate,,CHEMBL622790,,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,5669,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,,Intermediate,,CHEMBL622791,,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,5670,Mus musculus,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,,Intermediate,,CHEMBL622792,,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,5671,Mus musculus,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,,Intermediate,,CHEMBL622793,,10090.0,,1,1,,A,,,BAO_0000218,17764
50594,,N,,,5672,Mus musculus,Area under curve was determined for the compound at 24 mg/Kg,,Intermediate,,CHEMBL622794,,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,5673,Mus musculus,Area under curve was determined for the compound at 40 mg/Kg,,Intermediate,,CHEMBL622795,,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,5674,Mus musculus,Area under curve was determined for the compound at 5 mg/Kg,,Intermediate,,CHEMBL621803,,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,5675,Mus musculus,Area under the curve for the compound is obtained at dose 25 mg/kg,,Intermediate,,CHEMBL621804,,10090.0,,1,1,,A,,,BAO_0000218,3132
50594,,N,,,5676,Mus musculus,Area under the curve for the compound was obtained when tested in mouse,,Intermediate,,CHEMBL621805,,10090.0,,1,1,,A,,,BAO_0000218,3132
50594,,N,,,5677,Mus musculus,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,,Intermediate,,CHEMBL621806,,10090.0,,1,1,,A,,,BAO_0000218,17837
50594,,N,,,5678,Mus musculus,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,,Intermediate,,CHEMBL621807,,10090.0,,1,1,,A,,,BAO_0000218,17837
50594,,N,,,5679,Mus musculus,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,,Intermediate,,CHEMBL621808,,10090.0,,1,1,,A,,,BAO_0000218,6062
50594,,N,,,5680,Mus musculus,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,,Intermediate,,CHEMBL621809,,10090.0,,1,1,,A,,,BAO_0000218,4066
50594,,N,,,5681,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,Intermediate,,CHEMBL621810,,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,5682,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,,Intermediate,,CHEMBL875164,,10090.0,,1,1,,A,,,BAO_0000218,14239
50594,,N,,,5683,Mus musculus,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,,Intermediate,,CHEMBL621811,,10090.0,,1,1,,A,,,BAO_0000218,14239
50594,,N,,,5684,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, area under curve",,Intermediate,,CHEMBL621812,,10090.0,,1,1,,A,,,BAO_0000218,4890
50594,,N,,,5685,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),,Intermediate,,CHEMBL621813,,10090.0,,1,1,,A,,,BAO_0000218,429
50594,,N,,,5686,Mus musculus,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),,Intermediate,,CHEMBL621814,,10090.0,,1,1,,A,,,BAO_0000218,429
50594,,N,,,5687,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,,Intermediate,,CHEMBL621815,,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,5688,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,,Intermediate,,CHEMBL621816,,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,5689,Mus musculus,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,Intermediate,,CHEMBL621817,,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,5690,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,,Intermediate,,CHEMBL621818,,10090.0,,1,1,,A,,,BAO_0000218,6091
50594,,N,,,5691,Mus musculus,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,,Intermediate,,CHEMBL621819,,10090.0,,1,1,,A,,,BAO_0000218,6091
50594,,N,,,5692,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,,Intermediate,,CHEMBL621820,,10090.0,,1,1,,A,,,BAO_0000218,6091
50594,,N,,,5693,Mus musculus,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,,Intermediate,,CHEMBL621821,,10090.0,,1,1,,A,,,BAO_0000218,6091
50594,,N,,,5694,Mus musculus,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,,Intermediate,,CHEMBL621822,,10090.0,,1,1,,A,,,BAO_0000218,6178
50594,,N,,,5695,Mus musculus,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,,Intermediate,,CHEMBL619474,,10090.0,,1,1,,A,,,BAO_0000218,6178
50594,,N,,,5696,Mus musculus,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,Intermediate,,CHEMBL619475,,10090.0,,1,1,,A,,,BAO_0000218,6619
50594,,N,,,5697,Mus musculus,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",,Intermediate,,CHEMBL619476,,10090.0,,1,1,,A,,,BAO_0000218,6619
50594,,N,,,5698,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",,Intermediate,,CHEMBL619477,,10090.0,,1,1,,A,,,BAO_0000218,3760
50594,,N,,,5699,Mus musculus,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",,Intermediate,,CHEMBL619478,,10090.0,,1,1,,A,,,BAO_0000218,3760
50594,,N,,,5700,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",,Intermediate,,CHEMBL619479,,10090.0,,1,1,,A,,,BAO_0000218,3760
50594,,N,,,5701,Mus musculus,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",,Intermediate,,CHEMBL619480,,10090.0,,1,1,,A,,,BAO_0000218,3760
50594,,N,,,5702,Mus musculus,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,,Intermediate,,CHEMBL619481,,10090.0,,1,1,,A,,,BAO_0000218,3192
50594,,N,,,5703,Mus musculus,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,,Intermediate,,CHEMBL619482,,10090.0,,1,1,,A,,,BAO_0000218,3192
50594,,N,,,5704,Mus musculus,Area under the curve was evaluated in mice after intravenous administration,,Intermediate,,CHEMBL619483,,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,,,5705,Mus musculus,Area under the curve was evaluated in mice after oral administration,,Intermediate,,CHEMBL619484,,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,1969.0,,5706,Mus musculus,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,Plasma,Intermediate,,CHEMBL619485,,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,1969.0,,5707,Mus musculus,AUC total value at a dose of 10 mg/kg peroral administration in mice.,Plasma,Intermediate,,CHEMBL619486,,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,5708,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),,Intermediate,,CHEMBL619487,,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,5709,Mus musculus,AUMC after intraperitoneal administration of 100 mg/kg in mice,,Intermediate,,CHEMBL619488,,10090.0,,1,1,,A,,,BAO_0000218,17734
50594,,N,178.0,,5710,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,Blood,Intermediate,,CHEMBL620106,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
80653,,N,,,5711,,The compound was tested in vitro for anticancer activity against 9L cells,,Intermediate,,CHEMBL620107,,,392.0,1,1,9L,F,,,BAO_0000219,15345
22226,,U,,,5712,Rattus norvegicus,Anti proliferation activity determined; Weak effect,,Autocuration,,CHEMBL620283,,10116.0,,0,1,,F,,,BAO_0000019,2181
22226,,U,,,5713,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,,Autocuration,,CHEMBL875176,,10116.0,,0,1,,F,,,BAO_0000219,2181
22226,,U,,,5714,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,,Autocuration,,CHEMBL620284,,10116.0,,0,1,,F,,,BAO_0000219,2181
22226,,U,,,5715,Rattus norvegicus,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,,Autocuration,,CHEMBL623515,,10116.0,,0,1,,F,,,BAO_0000219,2181
22226,,U,,,5716,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method,,Autocuration,,CHEMBL623516,,10090.0,,0,1,,F,,,BAO_0000019,10486
22226,,U,,,5717,Mus musculus,The cytotoxic activity was in vitro tested by 9PS assay method.,,Autocuration,,CHEMBL623517,,10090.0,,0,1,,F,,,BAO_0000019,10486
22224,,U,,,5718,,Partition coefficient (logD6.5),,Autocuration,,CHEMBL857878,,,,0,1,,A,,,BAO_0000019,15508
81034,,N,,,5719,Homo sapiens,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,,Expert,,CHEMBL623518,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,5242
80018,,N,,,5720,Homo sapiens,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),,Intermediate,,CHEMBL624195,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,16167
80852,,N,,,5721,Homo sapiens,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,,Expert,,CHEMBL624196,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,4782
9,,D,,,5722,Homo sapiens,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,,Expert,,CHEMBL624197,,9606.0,500.0,9,1,A-431,F,,,BAO_0000219,16093
80021,,N,,,5723,Homo sapiens,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,,Intermediate,,CHEMBL624198,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,2596
80021,,N,,,5724,Homo sapiens,in vitro cytotoxicity against A 498 cancer cell line,,Intermediate,,CHEMBL621287,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,2596
80021,,N,,,5725,Homo sapiens,In vitro cytotoxic activity against renal (A 498) cancer cell line.,,Intermediate,,CHEMBL621288,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,3239
80021,,N,,,5726,Homo sapiens,Cytotoxic activity against A 498 renal cancer cell lines.,,Intermediate,,CHEMBL876496,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,1847
80021,,N,,,5727,Homo sapiens,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,,Intermediate,,CHEMBL621289,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,10553
22226,,U,,,5728,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,Autocuration,,CHEMBL621290,,1280.0,,0,1,,F,,,BAO_0000019,16219
22226,,U,,,5729,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,,Autocuration,,CHEMBL621291,,1280.0,,0,1,,F,,,BAO_0000019,16219
22226,,U,,,5730,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,Autocuration,,CHEMBL621292,,1280.0,,0,1,,F,,,BAO_0000019,16219
22226,,U,,,5731,Staphylococcus aureus,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,,Autocuration,,CHEMBL621293,,1280.0,,0,1,,F,,,BAO_0000019,16219
80682,,N,,,5732,Homo sapiens,Inhibitory concentration required against A 549 lung cancer cell line,,Intermediate,,CHEMBL621294,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4782
80682,,N,,,5733,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,,Intermediate,,CHEMBL621295,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,11805
80682,,N,,,5734,Homo sapiens,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,,Intermediate,,CHEMBL884007,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,11805
80682,,N,,,5735,Homo sapiens,In vitro cytotoxicity against lung cancer A 549 cell lines,,Intermediate,,CHEMBL621296,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2007
80682,,N,,,5736,Homo sapiens,Compound was tested for its cytotoxicity against A 549 cell line,,Intermediate,,CHEMBL621297,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4594
80682,,N,,,5737,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",,Expert,,CHEMBL839828,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6018
80682,,N,,,5738,Homo sapiens,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",,Intermediate,,CHEMBL620397,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6018
80682,,N,,,5739,Homo sapiens,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,,Expert,,CHEMBL620398,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3599
80682,,N,,,5740,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,Intermediate,,CHEMBL620399,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2551
80682,,N,,,5741,Homo sapiens,In vitro inhibition of A549 (human lung cancer) cell growth.,,Expert,,CHEMBL620400,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16132
80682,,N,,,5742,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,,Intermediate,,CHEMBL620401,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16132
80682,,N,,,5743,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,,Expert,,CHEMBL620402,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2551
80682,,N,,,5744,Homo sapiens,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),,Expert,,CHEMBL620403,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2551
22226,,U,,,5745,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,,Autocuration,,CHEMBL620404,,,,0,1,,F,,,BAO_0000218,11913
104694,,H,,,5746,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,,Autocuration,,CHEMBL620405,In vivo,,,4,1,,F,,,BAO_0000218,12621
104694,,H,,,5747,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,,Autocuration,,CHEMBL620406,In vivo,,,4,1,,F,,,BAO_0000218,12621
104694,,H,,,5748,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,,Autocuration,,CHEMBL620407,In vivo,,,4,1,,F,,,BAO_0000218,12621
104694,,H,,,5749,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,,Autocuration,,CHEMBL620408,In vivo,,,4,1,,F,,,BAO_0000218,12621
104694,,H,,,5750,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,,Autocuration,,CHEMBL620409,In vivo,,,4,1,,F,,,BAO_0000218,12621
80021,,N,,,5751,Homo sapiens,Inhibition of A-498 human Renal cell proliferation,,Expert,,CHEMBL620410,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,3600
22226,,U,,,5752,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",,Autocuration,,CHEMBL620411,,10116.0,,0,1,,F,,,BAO_0000019,1796
22226,,U,,,5753,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",,Autocuration,,CHEMBL620412,,10116.0,,0,1,,F,,,BAO_0000019,1796
22226,,U,,,5754,Rattus norvegicus,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",,Autocuration,,CHEMBL876596,,10116.0,,0,1,,F,,,BAO_0000019,1796
80012,,N,,,5755,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,,Expert,,CHEMBL620413,,9606.0,622.0,1,1,A 172,F,,,BAO_0000219,16464
80012,,N,,,5756,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate,,CHEMBL620414,,9606.0,622.0,1,1,A 172,F,,,BAO_0000219,16464
80012,,N,,,5757,Homo sapiens,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate,,CHEMBL620415,,9606.0,622.0,1,1,A 172,F,,,BAO_0000219,16464
80682,,N,,,5758,Homo sapiens,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,,Expert,,CHEMBL620416,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13617
80682,,N,,,5759,Homo sapiens,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,,Intermediate,,CHEMBL620417,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4584
80682,,N,,,5760,Homo sapiens,Cytotoxic activity evaluated against A549 tumor cells,,Expert,,CHEMBL620418,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13799
80682,,N,,,5761,Homo sapiens,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,,Intermediate,,CHEMBL620419,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16726
80682,,N,,,5762,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,,Intermediate,,CHEMBL620420,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16109
80682,,N,,,5763,Homo sapiens,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,,Intermediate,,CHEMBL620421,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16109
80682,,N,,,5764,Homo sapiens,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,,Intermediate,,CHEMBL620422,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15474
80682,,N,,,5765,Homo sapiens,Cytotoxicity of compound against A549 cell line,,Intermediate,,CHEMBL620423,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6851
80682,,N,,,5766,Homo sapiens,Cytotoxicity against human lung cell carcinoma A549 cell line,,Expert,,CHEMBL620424,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17534
80682,,N,,,5767,Homo sapiens,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,,Intermediate,,CHEMBL620425,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2621
80682,,N,,,5768,Homo sapiens,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,,Intermediate,,CHEMBL620426,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,830
80682,,N,,,5769,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,,Intermediate,,CHEMBL620427,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14255
80682,,N,,,5770,Homo sapiens,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,,Intermediate,,CHEMBL620428,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14255
80682,,N,,,5771,Homo sapiens,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,,Intermediate,,CHEMBL620429,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1590
80682,,N,,,5772,Homo sapiens,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,,Expert,,CHEMBL620430,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6146
80682,,N,,,5773,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Expert,,CHEMBL839887,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17427
80682,,N,,,5774,Homo sapiens,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,,Intermediate,,CHEMBL620431,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5280
80682,,N,,,5775,Homo sapiens,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,,Intermediate,,CHEMBL884010,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16786
80682,,N,,,5776,Homo sapiens,In vitro cytotoxicity against A549 (human lung cancer),,Intermediate,,CHEMBL620538,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5895
80682,,N,,,5777,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,Expert,,CHEMBL620539,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14297
80682,,N,,,5778,Homo sapiens,In vivo antiproliferative activity against A549 cell line,,Intermediate,,CHEMBL623373,,9606.0,646.0,1,1,A549,F,,,BAO_0000218,17824
80682,,N,,,5779,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549),,Intermediate,,CHEMBL623374,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14368
80682,,N,,,5780,Homo sapiens,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,,Intermediate,,CHEMBL623375,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14368
80682,,N,,,5781,Homo sapiens,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,,Intermediate,,CHEMBL623376,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14254
80682,,N,,,5782,Homo sapiens,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),,Intermediate,,CHEMBL623377,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15897
80682,,N,,,5783,Homo sapiens,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,,Intermediate,,CHEMBL623378,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13866
80682,,N,,,5784,Homo sapiens,Inhibitory activity of compound against human A549 lung carcinoma cell line.,,Intermediate,,CHEMBL623379,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13370
80682,,N,,,5785,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,,Intermediate,,CHEMBL623380,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4862
80682,,N,,,5786,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,,Intermediate,,CHEMBL623381,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4862
80682,,N,,,5787,Homo sapiens,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,,Intermediate,,CHEMBL623382,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4862
80682,,N,,,5788,Homo sapiens,Inhibitory concentration against A549 (lung cancer) cell line,,Intermediate,,CHEMBL623383,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15970
80682,,N,,,5789,Homo sapiens,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,,Expert,,CHEMBL623384,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17713
80682,,N,,,5790,Homo sapiens,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,,Intermediate,,CHEMBL623385,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4833
80682,,N,,,5791,Homo sapiens,Activity against A549 cancer cell line.,,Expert,,CHEMBL623386,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,13736
80682,,N,,,5792,Homo sapiens,The compound was evaluated for cytotoxicity against A549 cell line,,Intermediate,,CHEMBL884105,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4312
80682,,N,,,5793,Homo sapiens,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,,Intermediate,,CHEMBL623387,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5421
80682,,N,,,5794,Homo sapiens,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,,Intermediate,,CHEMBL621568,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5421
80682,,N,,,5795,Homo sapiens,Growth inhibitory activity was measured for human A549 tumor cell line.,,Intermediate,,CHEMBL621569,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14717
80682,,N,,,5796,Homo sapiens,Inhibitory activity against A549 lung cancer cell line,,Intermediate,,CHEMBL621570,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4634
80682,,N,,,5797,Homo sapiens,Inhibitory activity against A549 cell line; inactive,,Intermediate,,CHEMBL621571,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1149
80682,,N,,,5798,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,Expert,,CHEMBL621572,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5421
80682,,N,,,5799,Homo sapiens,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,,Expert,,CHEMBL621573,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5421
80682,,N,,,5800,Homo sapiens,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,,Intermediate,,CHEMBL621574,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5421
80682,,N,,,5801,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),,Intermediate,,CHEMBL621575,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3320
80682,,N,,,5802,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),,Intermediate,,CHEMBL621576,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3320
80682,,N,,,5803,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),,Intermediate,,CHEMBL621577,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3320
80682,,N,,,5804,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),,Intermediate,,CHEMBL621578,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3320
80682,,N,,,5805,Homo sapiens,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),,Intermediate,,CHEMBL621579,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3320
80682,,N,,,5806,Homo sapiens,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,,Intermediate,,CHEMBL621580,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5726
50588,,N,,,5807,Canis lupus familiaris,Plasma clearance (in vivo) in mongrel dogs was determined,,Intermediate,,CHEMBL621581,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17800
50588,,N,,,5808,Canis lupus familiaris,Plasma clearance was measured in dog,,Intermediate,,CHEMBL621582,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5985
50588,,N,,,5809,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,Intermediate,,CHEMBL621583,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5530
50588,,N,,,5810,Canis lupus familiaris,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,,Intermediate,,CHEMBL621584,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5530
50588,,N,1969.0,,5811,Canis lupus familiaris,Tested for plasma clearance in dog,Plasma,Intermediate,,CHEMBL621585,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4839
50588,,N,,,5812,Canis lupus familiaris,The compound was tested for clearance in dog plasma.,,Intermediate,,CHEMBL621586,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3639
50588,,N,,,5813,Canis lupus familiaris,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",,Intermediate,,CHEMBL875835,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4838
50588,,N,,,5814,Canis lupus familiaris,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,,Intermediate,,CHEMBL621587,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4137
50588,,N,1969.0,,5815,Canis lupus familiaris,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Plasma,Intermediate,,CHEMBL621588,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5017
50588,,N,2107.0,,5816,Canis lupus familiaris,In vitro clearance in dog liver microsomes,Liver,Intermediate,,CHEMBL621589,In vitro,9615.0,,1,1,,A,,Microsomes,BAO_0000218,17538
50588,,N,,,5817,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,,Intermediate,,CHEMBL621590,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6161
50588,,N,,,5818,Canis lupus familiaris,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,,Intermediate,,CHEMBL621591,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6161
50588,,N,,,5819,Canis lupus familiaris,Plasma clearance in dog,,Intermediate,,CHEMBL621592,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1696
50588,,N,,,5820,Canis lupus familiaris,Clearance rate in dog,,Intermediate,,CHEMBL621593,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6762
50588,,N,1969.0,,5821,Canis lupus familiaris,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,Plasma,Intermediate,,CHEMBL621594,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5932
50588,,N,,,5822,Canis lupus familiaris,Clearance in dogs,,Intermediate,,CHEMBL621595,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6305
50588,,N,,,5823,Canis lupus familiaris,Plasma clearance in dogs,,Intermediate,,CHEMBL621596,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4942
50588,,N,,,5824,Canis lupus familiaris,Plasma clearance was determined,,Intermediate,,CHEMBL621597,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4219
50588,,N,,,5825,Canis lupus familiaris,Lower clearance in dog (i.v.) at 0.5 mpk,,Intermediate,,CHEMBL621598,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17853
50588,,N,,,5826,Canis lupus familiaris,Plasma clearance in Beagle dogs,,Intermediate,,CHEMBL621599,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4514
50588,,N,,,5827,Canis lupus familiaris,Plasma clearance (Clp) in dog,,Intermediate,,CHEMBL875836,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6448
50588,,N,,,5828,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,,Intermediate,,CHEMBL621600,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,5829,Canis lupus familiaris,Plasma clearance (pharmacokinetic parameter) in dog was determined,,Intermediate,,CHEMBL621601,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,5830,Canis lupus familiaris,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,,Intermediate,,CHEMBL618474,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6062
50588,,N,,,5831,Canis lupus familiaris,Plasma clearance of compound was determined in dog,,Intermediate,,CHEMBL618475,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6821
50588,,N,,,5832,Canis lupus familiaris,Plasma clearance after intravenous administration of 1 mg/kg in dog,,Intermediate,,CHEMBL624524,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4709
50588,,N,,,5833,Canis lupus familiaris,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,Intermediate,,CHEMBL624525,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4521
50588,,N,,,5834,Canis lupus familiaris,Plasma clearance in dog was determined,,Intermediate,,CHEMBL624526,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5374
50588,,N,,,5835,Canis lupus familiaris,Plasma clearance was calculated in dog,,Intermediate,,CHEMBL624527,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6057
50588,,N,,,5836,Canis lupus familiaris,Plasma clearance at the dose of 2 mg/kg in dog,,Intermediate,,CHEMBL624528,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4727
50588,,N,,,5837,Canis lupus familiaris,Plasma clearance in dog,,Intermediate,,CHEMBL624529,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5145
50588,,N,,,5838,Canis lupus familiaris,Plasma clearance in dog,,Intermediate,,CHEMBL624530,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17657
50588,,N,,,5839,Canis lupus familiaris,Plasma clearance in dog; Unable to calculate,,Intermediate,,CHEMBL624531,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17657
50588,,N,,,5840,Canis lupus familiaris,Plasma clearance in rhesus monkey,,Intermediate,,CHEMBL624532,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5145
50588,,N,,,5841,Canis lupus familiaris,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Intermediate,,CHEMBL624533,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6642
50588,,N,,,5842,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate,,CHEMBL624534,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6641
50588,,N,,,5843,Canis lupus familiaris,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate,,CHEMBL624535,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6642
50588,,N,,,5844,Canis lupus familiaris,Plasma clearance was evaluated in dog,,Intermediate,,CHEMBL624536,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5472
50588,,N,,,5845,Canis lupus familiaris,Plasma clearance was evaluated in dog; Not tested,,Intermediate,,CHEMBL624537,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5472
50588,,N,,,5846,Canis lupus familiaris,Plasma clearance was evaluated in rhesus,,Intermediate,,CHEMBL624538,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5472
50588,,N,,,5847,Canis lupus familiaris,Plasma clearance was evaluated in rhesus; Not tested,,Intermediate,,CHEMBL624539,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5472
50588,,N,,,5848,Canis lupus familiaris,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,,Intermediate,,CHEMBL624540,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4257
50588,,N,,,5849,Canis lupus familiaris,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Intermediate,,CHEMBL624541,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6679
50588,,N,,,5850,Canis lupus familiaris,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,Intermediate,,CHEMBL624542,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5546
50588,,N,,,5851,Canis lupus familiaris,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Intermediate,,CHEMBL624543,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6348
50588,,N,,,5852,Canis lupus familiaris,Clearance value at a dose of 0.2 mg/kg i.v.,,Intermediate,,CHEMBL624544,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5474
50588,,N,1969.0,,5853,Canis lupus familiaris,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,Plasma,Intermediate,,CHEMBL624545,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6316
50588,,N,,,5854,Canis lupus familiaris,Cmax after oral dose of compound at 3 mg/kg in dogs,,Intermediate,,CHEMBL624546,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17594
50588,,N,,,5855,Canis lupus familiaris,Cmax after single intravenous bolus of 1 mg/kg in dogs,,Intermediate,,CHEMBL875957,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17594
50588,,N,,,5856,Canis lupus familiaris,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Intermediate,,CHEMBL624547,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5802
50588,,N,,,5857,Canis lupus familiaris,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,,Intermediate,,CHEMBL624548,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,,,5858,Canis lupus familiaris,Cmax in dog after administration of 1 mg/kg iv,,Intermediate,,CHEMBL624549,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,1969.0,,5859,Canis lupus familiaris,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,Plasma,Intermediate,,CHEMBL624550,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1466
50588,,N,,,5860,Canis lupus familiaris,Cmax on p.o. administration of 10 mg/kg was measured in dog,,Intermediate,,CHEMBL621613,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6505
50588,,N,,,5861,Canis lupus familiaris,Cmax was determine after peroral administration at 10 mpk in dog,,Intermediate,,CHEMBL621614,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,5862,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mpk in dog,,Intermediate,,CHEMBL623431,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,5863,Canis lupus familiaris,Cmax was determine after peroral administration at 5 mg/kg in dog,,Intermediate,,CHEMBL623432,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,5864,Canis lupus familiaris,Cmax after 0.3 mg/kg po administration in dog,,Intermediate,,CHEMBL623433,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5600
50588,,N,,,5865,Canis lupus familiaris,Cmax after peroral administration in dogs at 2.4 uM/kg,,Intermediate,,CHEMBL623434,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17764
50588,,N,,,5866,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg,,Intermediate,,CHEMBL623435,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6123
50588,,N,,,5867,Canis lupus familiaris,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,,Intermediate,,CHEMBL623436,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6123
50588,,N,,,5868,Canis lupus familiaris,Cmax upon oral administration in male Beagle dog at 10 mg/kg,,Intermediate,,CHEMBL875958,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6757
50588,,N,,,5869,Canis lupus familiaris,Cmax value after 15 mg/kg iv dose in Dogs,,Intermediate,,CHEMBL623437,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50594,,N,178.0,,5870,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Blood,Intermediate,,CHEMBL623438,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,178.0,,5871,Mus musculus,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Blood,Intermediate,,CHEMBL623439,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,10000001.0,,5872,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Bone,Intermediate,,CHEMBL623440,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,10000001.0,,5873,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Bone,Intermediate,,CHEMBL623441,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,10000001.0,,5874,Mus musculus,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Bone,Intermediate,,CHEMBL623442,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,,,5875,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate,,CHEMBL623469,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,,,5876,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate,,CHEMBL623470,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,,,5877,Mus musculus,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate,,CHEMBL623471,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,948.0,,5878,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Heart,Intermediate,,CHEMBL623472,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,948.0,,5879,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Heart,Intermediate,,CHEMBL623473,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,948.0,,5880,Mus musculus,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Heart,Intermediate,,CHEMBL623474,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2113.0,,5881,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Kidney,Intermediate,,CHEMBL623475,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2113.0,,5882,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Kidney,Intermediate,,CHEMBL623476,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2113.0,,5883,Mus musculus,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Kidney,Intermediate,,CHEMBL623477,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,160.0,,5884,Mus musculus,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intestine,Intermediate,,CHEMBL621896,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,160.0,,5885,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intestine,Intermediate,,CHEMBL621897,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,160.0,,5886,Mus musculus,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intestine,Intermediate,,CHEMBL621898,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2107.0,,5887,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Liver,Intermediate,,CHEMBL621899,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2107.0,,5888,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Liver,Intermediate,,CHEMBL621900,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2107.0,,5889,Mus musculus,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Liver,Intermediate,,CHEMBL621901,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2048.0,,5890,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Lung,Intermediate,,CHEMBL621902,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2048.0,,5891,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Lung,Intermediate,,CHEMBL621903,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2048.0,,5892,Mus musculus,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Lung,Intermediate,,CHEMBL622587,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2385.0,,5893,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Muscle tissue,Intermediate,,CHEMBL620285,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2385.0,,5894,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Muscle tissue,Intermediate,,CHEMBL875285,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2385.0,,5895,Mus musculus,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Muscle tissue,Intermediate,,CHEMBL620286,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,,,5896,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,,Intermediate,,CHEMBL620287,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,,,5897,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,,Intermediate,,CHEMBL620288,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,,,5898,Mus musculus,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,,Intermediate,,CHEMBL620289,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,160.0,,5899,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Intestine,Intermediate,,CHEMBL620290,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,160.0,,5900,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Intestine,Intermediate,,CHEMBL620291,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,160.0,,5901,Mus musculus,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Intestine,Intermediate,,CHEMBL620292,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2106.0,,5902,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Spleen,Intermediate,,CHEMBL620293,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2106.0,,5903,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Spleen,Intermediate,,CHEMBL620294,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,2106.0,,5904,Mus musculus,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Spleen,Intermediate,,CHEMBL618614,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,945.0,,5905,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Stomach,Intermediate,,CHEMBL618615,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,945.0,,5906,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,Stomach,Intermediate,,CHEMBL618616,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
80012,,N,,,5907,Homo sapiens,Cytotoxicity against A-172 human tumor cell lines,,Expert,,CHEMBL618617,,9606.0,622.0,1,1,A 172,F,,,BAO_0000219,2036
80012,,N,,,5908,Homo sapiens,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,,Intermediate,,CHEMBL618618,,9606.0,622.0,1,1,A 172,F,,,BAO_0000219,2357
80014,,N,,,5909,Homo sapiens,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,,Intermediate,,CHEMBL618619,,9606.0,623.0,1,1,A204,F,,,BAO_0000219,1457
81034,,N,,,5910,Homo sapiens,Tested for antiproliferative activity against A-2780 tumoral cell line,,Intermediate,,CHEMBL618620,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,4379
80018,,N,,,5911,Homo sapiens,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,,Intermediate,,CHEMBL618621,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,1093
80018,,N,,,5912,Homo sapiens,Tested in vitro against A-375 cell line human melanoma,,Intermediate,,CHEMBL618622,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,12152
80019,,N,,,5913,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,,Expert,,CHEMBL618623,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,16464
80019,,N,,,5914,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate,,CHEMBL618624,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,16464
80019,,N,,,5915,Homo sapiens,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,,Expert,,CHEMBL618625,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,16582
80019,,N,,,5916,Homo sapiens,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,,Intermediate,,CHEMBL618626,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,16464
80019,,N,,,5917,Homo sapiens,Antitumor activity on A-427 lung carcinoma cell lines,,Intermediate,,CHEMBL618627,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,10413
80019,,N,,,5918,Homo sapiens,Cytotoxic activity against human A-427 lung tumor cell line,,Intermediate,,CHEMBL618628,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,6418
80019,,N,,,5919,Homo sapiens,In vitro antitumor effects against human A-427 cell lines.,,Expert,,CHEMBL618629,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,17134
80019,,N,,,5920,Homo sapiens,In vitro inhibition of A-427 (human lung cancer) cell growth.,,Expert,,CHEMBL618630,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,16132
80019,,N,,,5921,Homo sapiens,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,,Intermediate,,CHEMBL618631,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,16132
80019,,N,,,5922,Homo sapiens,Cytotoxic activity of compound against A-427 lung human tumor cell line,,Intermediate,,CHEMBL618632,,9606.0,797.0,1,1,A-427,F,,,BAO_0000219,16780
80852,,N,,,5923,Homo sapiens,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,,Expert,,CHEMBL618633,,9606.0,500.0,1,1,A-431,F,,,BAO_0000219,4085
80021,,N,,,5924,Homo sapiens,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,,Intermediate,,CHEMBL619315,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,1276
80021,,N,,,5925,Homo sapiens,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,,Expert,,CHEMBL619316,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,3498
80021,,N,,,5926,Homo sapiens,Cytotoxicity against human kidney carcinoma A-498cell lines,,Intermediate,,CHEMBL619317,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,1169
80021,,N,,,5927,Homo sapiens,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,,Intermediate,,CHEMBL619318,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,4450
80021,,N,,,5928,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,,Intermediate,,CHEMBL619319,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,3311
80021,,N,,,5929,Homo sapiens,Antitumor cytotoxic activity against A-498 cell line was determined,,Intermediate,,CHEMBL619739,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,4461
80021,,N,,,5930,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,,Intermediate,,CHEMBL619740,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,3311
80021,,N,,,5931,Homo sapiens,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,,Intermediate,,CHEMBL883158,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,3311
80021,,N,,,5932,Homo sapiens,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,,Intermediate,,CHEMBL884012,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,1457
80021,,N,,,5933,Homo sapiens,In vitro inhibitory activity against A-498 ovarian cancer cell lines,,Intermediate,,CHEMBL619741,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,3664
80021,,N,,,5934,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",,Intermediate,,CHEMBL619742,,9606.0,624.0,1,1,A498,F,,,BAO_0000219,15895
80682,,N,,,5935,Homo sapiens,Inhibition of growth lung non-small cell carcinoma A-549 cell line,,Intermediate,,CHEMBL876610,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,11843
80682,,N,,,5936,Homo sapiens,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,,Intermediate,,CHEMBL619743,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,11843
80682,,N,,,5937,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line,,Intermediate,,CHEMBL619744,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17705
80682,,N,,,5938,Homo sapiens,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,,Intermediate,,CHEMBL619745,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17705
80682,,N,,,5939,Homo sapiens,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,,Intermediate,,CHEMBL619746,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4369
80682,,N,,,5940,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,,Intermediate,,CHEMBL619747,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4369
80682,,N,,,5941,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,,Intermediate,,CHEMBL619748,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4369
80682,,N,,,5942,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,,Intermediate,,CHEMBL619749,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4369
80682,,N,,,5943,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,,Intermediate,,CHEMBL619750,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4369
80682,,N,,,5944,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,,Intermediate,,CHEMBL624014,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4369
80682,,N,,,5945,Homo sapiens,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,,Intermediate,,CHEMBL624015,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4369
80682,,N,,,5946,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,,Expert,,CHEMBL885344,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4787
80682,,N,,,5947,Homo sapiens,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,,Intermediate,,CHEMBL623224,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4787
80682,,N,,,5948,Homo sapiens,Cytotoxic activity against A-549 cell line,,Intermediate,,CHEMBL623225,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6513
80682,,N,,,5949,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,,Intermediate,,CHEMBL622698,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6690
80682,,N,,,5950,Homo sapiens,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,,Intermediate,,CHEMBL622699,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6690
80682,,N,,,5951,Homo sapiens,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",,Expert,,CHEMBL622700,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12263
80682,,N,,,5952,Homo sapiens,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),,Intermediate,,CHEMBL622701,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1054
80682,,N,,,5953,Homo sapiens,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),,Intermediate,,CHEMBL622702,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1359
80682,,N,,,5954,Homo sapiens,Cytotoxic activity against human lung carcinoma (A-549) cell line,,Intermediate,,CHEMBL622703,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3547
80682,,N,,,5955,Homo sapiens,Cytotoxic activity towards A-549 cells,,Expert,,CHEMBL622704,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5771
80682,,N,,,5956,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",,Intermediate,,CHEMBL622705,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14425
80682,,N,,,5957,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma",,Intermediate,,CHEMBL622706,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14425
80682,,N,,,5958,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.",,Intermediate,,CHEMBL622707,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14425
80682,,N,,,5959,Homo sapiens,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",,Intermediate,,CHEMBL622708,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14425
80682,,N,,,5960,Homo sapiens,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,,Intermediate,,CHEMBL622709,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5280
80682,,N,,,5961,Homo sapiens,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,,Intermediate,,CHEMBL622710,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15176
80682,,N,,,5962,Homo sapiens,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,,Intermediate,,CHEMBL622711,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15300
80682,,N,,,5963,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Intermediate,,CHEMBL622712,,9606.0,646.0,1,1,A549,F,,,BAO_0000218,17824
80682,,N,,,5964,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Intermediate,,CHEMBL622713,,9606.0,646.0,1,1,A549,F,,,BAO_0000218,17824
80682,,N,,,5965,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Intermediate,,CHEMBL622714,,9606.0,646.0,1,1,A549,F,,,BAO_0000218,17824
80682,,N,,,5966,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Intermediate,,CHEMBL622715,,9606.0,646.0,1,1,A549,F,,,BAO_0000218,17824
80682,,N,,,5967,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",,Intermediate,,CHEMBL622716,,9606.0,646.0,1,1,A549,F,,,BAO_0000218,17824
80682,,N,,,5968,Homo sapiens,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",,Intermediate,,CHEMBL622717,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17824
80682,,N,,,5969,Homo sapiens,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),,Intermediate,,CHEMBL622718,,9606.0,646.0,1,1,A549,F,,,BAO_0000218,17528
80682,,N,,,5970,Homo sapiens,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,,Expert,,CHEMBL622719,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6870
80682,,N,,,5971,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,Intermediate,,CHEMBL622720,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6870
80682,,N,,,5972,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,,Intermediate,,CHEMBL622721,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6870
80682,,N,,,5973,Homo sapiens,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,,Intermediate,,CHEMBL622722,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6870
80682,,N,,,5974,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,Intermediate,,CHEMBL876030,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16726
80682,,N,,,5975,Homo sapiens,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",,Intermediate,,CHEMBL620206,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6170
80682,,N,,,5976,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,,Expert,,CHEMBL620207,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6583
80682,,N,,,5977,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,,Expert,,CHEMBL620208,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6583
80682,,N,,,5978,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,,Expert,,CHEMBL620209,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6583
80682,,N,,,5979,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,,Expert,,CHEMBL620210,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6583
80682,,N,,,5980,Homo sapiens,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,,Expert,,CHEMBL621639,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6583
80682,,N,,,5981,Homo sapiens,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,,Intermediate,,CHEMBL621640,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17321
80682,,N,,,5982,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,Expert,,CHEMBL621641,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17528
80682,,N,,,5983,Homo sapiens,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,,Expert,,CHEMBL621642,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12888
80682,,N,,,5984,Homo sapiens,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,,Intermediate,,CHEMBL621643,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4312
80682,,N,,,5985,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,,Intermediate,,CHEMBL621644,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4312
80682,,N,,,5986,Homo sapiens,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,,Intermediate,,CHEMBL621645,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4312
80682,,N,,,5987,Mus musculus,In vitro antiproliferative activity against A549 cell line,,Intermediate,,CHEMBL621646,,10090.0,646.0,1,1,A549,F,,,BAO_0000219,17737
80682,,N,,,5988,,Synergism with indomethacin in A549 cells,,Intermediate,,CHEMBL621647,,,646.0,1,1,A549,F,,,BAO_0000219,6630
80682,,N,,,5989,,Synergism with tolmetin in A549 cells,,Intermediate,,CHEMBL621648,,,646.0,1,1,A549,F,,,BAO_0000219,6630
80682,,N,,,5990,,Synergism with sulindac in A549 cells,,Intermediate,,CHEMBL621649,,,646.0,1,1,A549,F,,,BAO_0000219,6630
80682,,N,,,5991,,Antagonism of indomethacin in A549 cells,,Intermediate,,CHEMBL621650,,,646.0,1,1,A549,F,,,BAO_0000219,6630
80682,,N,,,5992,,Antagonism of sulindac in A549 cells,,Intermediate,,CHEMBL621651,,,646.0,1,1,A549,F,,,BAO_0000219,6630
80682,,N,,,5993,,Antagonism of tolmetin in A549 cells,,Intermediate,,CHEMBL621652,,,646.0,1,1,A549,F,,,BAO_0000219,6630
80682,,N,,,5994,,Synergism with indomethacin in A549 cells,,Intermediate,,CHEMBL621653,,,646.0,1,1,A549,F,,,BAO_0000219,6630
80682,,N,,,5995,,Synergism with sulindac in A549 cells,,Intermediate,,CHEMBL621654,,,646.0,1,1,A549,F,,,BAO_0000219,6630
80682,,N,,,5996,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,,Intermediate,,CHEMBL621655,,,646.0,1,1,A549,F,,,BAO_0000219,6630
50588,,N,,,5997,Canis lupus familiaris,Cmax value after 30 mg/kg po dose in Dogs,,Intermediate,,CHEMBL621656,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,5998,Canis lupus familiaris,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),,Intermediate,,CHEMBL621657,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5944
50588,,N,,,5999,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,,Intermediate,,CHEMBL621658,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5944
50588,,N,,,6000,Canis lupus familiaris,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),,Intermediate,,CHEMBL621659,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5944
50588,,N,,,6001,Canis lupus familiaris,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,,Intermediate,,CHEMBL621660,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5944
50588,,N,,,6002,Canis lupus familiaris,Cmax value after administration of 4 mg/Kg oral dose in dog,,Intermediate,,CHEMBL621661,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2959
50588,,N,,,6003,Canis lupus familiaris,Cmax value in dog,,Intermediate,,CHEMBL621662,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6241
50588,,N,,,6004,Canis lupus familiaris,Cmax value in dogs after oral administration at 1 mg/kg,,Intermediate,,CHEMBL621663,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6241
50588,,N,,,6005,Canis lupus familiaris,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,,Intermediate,,CHEMBL621664,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2652
50588,,N,1969.0,,6006,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,Plasma,Intermediate,,CHEMBL621665,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1806
50588,,N,1969.0,,6007,Canis lupus familiaris,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,Plasma,Intermediate,,CHEMBL621666,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1806
50588,,N,,,6008,Canis lupus familiaris,Concentration maxima after oral dosing in dogs,,Intermediate,,CHEMBL621667,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1021
50588,,N,,,6009,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,,Intermediate,,CHEMBL876738,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1021
50588,,N,,,6010,Canis lupus familiaris,Concentration maxima after oral dosing in dogs; not available,,Intermediate,,CHEMBL621668,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1021
50588,,N,,,6011,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,,Intermediate,,CHEMBL621669,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5444
50588,,N,,,6012,Canis lupus familiaris,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,,Intermediate,,CHEMBL621670,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5444
50588,,N,,,6013,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog,,Intermediate,,CHEMBL621671,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5444
50588,,N,,,6014,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,,Intermediate,,CHEMBL622360,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5444
50588,,N,,,6015,Canis lupus familiaris,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,,Intermediate,,CHEMBL622361,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5444
50588,,N,1969.0,,6016,Canis lupus familiaris,Cmax in dog plasma after oral dose (1 mg/kg),Plasma,Intermediate,,CHEMBL622362,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5130
50588,,N,1969.0,,6017,Canis lupus familiaris,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,Plasma,Intermediate,,CHEMBL622363,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3249
50588,,N,1969.0,,6018,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg,Plasma,Intermediate,,CHEMBL622364,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5473
50588,,N,1969.0,,6019,Canis lupus familiaris,Maximal plasma concentration at a dose of 1 mg/kg (oral),Plasma,Intermediate,,CHEMBL622365,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5474
50588,,N,1969.0,,6020,Canis lupus familiaris,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,Plasma,Intermediate,,CHEMBL622533,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4657
50588,,N,,,6021,Canis lupus familiaris,Maximum concentration of compound in dog was evaluated.,,Intermediate,,CHEMBL622534,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3031
50588,,N,,,6022,Canis lupus familiaris,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,,Intermediate,,CHEMBL622535,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4527
50588,,N,,,6023,Canis lupus familiaris,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,,Intermediate,,CHEMBL876739,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4186
50588,,N,,,6024,Canis lupus familiaris,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Intermediate,,CHEMBL622536,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5007
50588,,N,1969.0,,6025,Canis lupus familiaris,Maximum concentration obtained in dog plasma was determined,Plasma,Intermediate,,CHEMBL622537,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3132
50588,,N,,,6026,Canis lupus familiaris,Maximum concentration was determined,,Intermediate,,CHEMBL622538,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5006
50588,,N,,,6027,Canis lupus familiaris,Maximum concentration at the dose of 2 mg/kg in dog,,Intermediate,,CHEMBL627867,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4727
50588,,N,,,6028,Canis lupus familiaris,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Intermediate,,CHEMBL627868,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1916
50588,,N,1969.0,,6029,Canis lupus familiaris,Maximum concentration was evaluated in dog plasma,Plasma,Intermediate,,CHEMBL627869,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1918
50588,,N,,,6030,Canis lupus familiaris,Maximum concentration was evaluated after 75 min after administration in dog,,Intermediate,,CHEMBL627870,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3045
50588,,N,1969.0,,6031,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 17b,Plasma,Intermediate,,CHEMBL627871,In vivo,9615.0,,1,1,,A,,,BAO_0000218,9579
50588,,N,1969.0,,6032,Canis lupus familiaris,Maximum plasma concentration determined in dog after oral administration of 2b,Plasma,Intermediate,,CHEMBL627872,In vivo,9615.0,,1,1,,A,,,BAO_0000218,9579
50588,,N,1969.0,,6033,Canis lupus familiaris,Maximum plasma concentration in dog,Plasma,Intermediate,,CHEMBL627873,In vivo,9615.0,,1,1,,A,,,BAO_0000218,933
50588,,N,1969.0,,6034,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,Plasma,Intermediate,,CHEMBL627874,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,1969.0,,6035,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,Plasma,Intermediate,,CHEMBL627875,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,1969.0,,6036,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,Plasma,Intermediate,,CHEMBL627876,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,1969.0,,6037,Canis lupus familiaris,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,Plasma,Intermediate,,CHEMBL627877,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,1969.0,,6038,Canis lupus familiaris,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Plasma,Intermediate,,CHEMBL627878,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6348
50588,,N,1969.0,,6039,Canis lupus familiaris,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,Plasma,Intermediate,,CHEMBL627879,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16367
50588,,N,1969.0,,6040,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Plasma,Intermediate,,CHEMBL875355,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1337
50588,,N,1969.0,,6041,Canis lupus familiaris,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Plasma,Intermediate,,CHEMBL627880,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1337
50588,,N,1969.0,,6042,Canis lupus familiaris,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Plasma,Intermediate,,CHEMBL627881,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5199
50588,,N,1969.0,,6043,Canis lupus familiaris,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Plasma,Intermediate,,CHEMBL627882,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17650
50588,,N,1969.0,,6044,Canis lupus familiaris,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,Plasma,Intermediate,,CHEMBL627883,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6679
50588,,N,1969.0,,6045,Canis lupus familiaris,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,Plasma,Intermediate,,CHEMBL628526,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5356
50588,,N,1969.0,,6046,Canis lupus familiaris,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,Plasma,Intermediate,,CHEMBL628527,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5356
50588,,N,1969.0,,6047,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,Plasma,Intermediate,,CHEMBL628528,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,1969.0,,6048,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,Plasma,Intermediate,,CHEMBL628529,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,1969.0,,6049,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,Plasma,Intermediate,,CHEMBL628530,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,1969.0,,6050,Canis lupus familiaris,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,Plasma,Intermediate,,CHEMBL625243,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,1969.0,,6051,Canis lupus familiaris,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,Plasma,Expert,,CHEMBL625244,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3598
50588,,N,,,6052,Canis lupus familiaris,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,,Intermediate,,CHEMBL625245,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4368
50588,,N,,,6053,Canis lupus familiaris,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,,Intermediate,,CHEMBL625246,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6265
50594,,N,945.0,,6054,Mus musculus,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,Stomach,Intermediate,,CHEMBL625247,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,1088.0,,6055,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,Urine,Intermediate,,CHEMBL625248,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,1088.0,,6056,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,Urine,Intermediate,,CHEMBL625249,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,1088.0,,6057,Mus musculus,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,Urine,Intermediate,,CHEMBL625250,In vivo,10090.0,,1,1,,A,,,BAO_0000218,7767
50594,,N,,,6058,Mus musculus,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,,Intermediate,,CHEMBL625251,,10090.0,,1,1,,A,,,BAO_0000218,17811
50594,,N,,,6059,Mus musculus,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,,Intermediate,,CHEMBL875356,,10090.0,,1,1,,A,,,BAO_0000218,17811
50594,,N,,,6060,Mus musculus,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),,Intermediate,,CHEMBL625252,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,178.0,,6061,Mus musculus,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Blood,Intermediate,,CHEMBL625253,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,,,6062,Mus musculus,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),,Intermediate,,CHEMBL625254,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,,,6063,Mus musculus,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),,Intermediate,,CHEMBL625255,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,,,6064,Mus musculus,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),,Intermediate,,CHEMBL625256,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,178.0,,6065,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),Blood,Intermediate,,CHEMBL625257,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,178.0,,6066,Mus musculus,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),Blood,Intermediate,,CHEMBL625258,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,,,6067,Mus musculus,Compound was evaluated for washout rate in mice (Radiolabeled compound),,Intermediate,,CHEMBL625259,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,,,6068,Mus musculus,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,,Intermediate,,CHEMBL625260,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,,,6069,Mus musculus,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Intermediate,,CHEMBL625261,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,,,6070,Mus musculus,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Intermediate,,CHEMBL625262,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,,,6071,Mus musculus,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",,Intermediate,,CHEMBL622639,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,,,6072,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,,Intermediate,,CHEMBL622640,,10090.0,,1,1,,A,,,BAO_0000218,17257
50594,,N,,,6073,Mus musculus,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,,Intermediate,,CHEMBL622812,,10090.0,,1,1,,A,,,BAO_0000218,17257
50594,,N,,,6074,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,,Intermediate,,CHEMBL622813,,10090.0,,1,1,,A,,,BAO_0000218,17257
50594,,N,,,6075,Mus musculus,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,,Intermediate,,CHEMBL622814,,10090.0,,1,1,,A,,,BAO_0000218,17257
50594,,N,,,6076,Mus musculus,Time at maximum activity in mice (Radiolabeled compound),,Intermediate,,CHEMBL622815,,10090.0,,1,1,,A,,,BAO_0000218,17827
50594,,N,,,6077,Mus musculus,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,,Intermediate,,CHEMBL625342,,10090.0,,1,1,,A,,,BAO_0000218,3760
50594,,N,,,6078,Mus musculus,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,,Intermediate,,CHEMBL625343,,10090.0,,1,1,,A,,,BAO_0000218,3760
50594,,N,,,6079,Mus musculus,Binding towards mouse plasma protein at 10 uM,,Intermediate,,CHEMBL877591,,10090.0,,1,1,,A,,,BAO_0000218,17409
50594,,N,,,6080,Mus musculus,Binding towards mouse plasma protein at 100 uM,,Intermediate,,CHEMBL625344,,10090.0,,1,1,,A,,,BAO_0000218,17409
50594,,N,,,6081,Mus musculus,Bioavailability was evaluated in mice after intravenous administration,,Intermediate,,CHEMBL625345,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,,,6082,Mus musculus,Bioavailability was evaluated in mice after oral administration,,Intermediate,,CHEMBL625346,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,,,6083,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,,Intermediate,,CHEMBL625347,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3132
50594,,N,,,6084,Mus musculus,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,,Intermediate,,CHEMBL625348,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3132
50594,,N,,,6085,Mus musculus,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,,Intermediate,,CHEMBL625349,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,6086,Mus musculus,Oral bioavailability in mouse,,Intermediate,,CHEMBL625350,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2862
50594,,N,,,6087,Mus musculus,Oral bioavailability after intravenous administration in mice at 24 uM/kg,,Intermediate,,CHEMBL882952,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17764
50594,,N,955.0,,6088,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Brain,Intermediate,,CHEMBL625351,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,955.0,,6089,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Brain,Intermediate,,CHEMBL625352,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,955.0,,6090,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Brain,Intermediate,,CHEMBL877592,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,955.0,,6091,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Brain,Intermediate,,CHEMBL625353,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,955.0,,6092,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Brain,Intermediate,,CHEMBL625354,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,955.0,,6093,Mus musculus,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Brain,Intermediate,,CHEMBL626019,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,948.0,,6094,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Heart,Intermediate,,CHEMBL626020,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,948.0,,6095,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Heart,Intermediate,,CHEMBL626021,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,948.0,,6096,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Heart,Intermediate,,CHEMBL626022,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,948.0,,6097,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Heart,Intermediate,,CHEMBL626192,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
80682,,N,,,6098,Homo sapiens,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),,Intermediate,,CHEMBL626193,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1276
80682,,N,,,6099,Homo sapiens,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,,Expert,,CHEMBL626194,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3498
80682,,N,,,6100,Homo sapiens,Cytotoxicity against human lung carcinoma A-549 cell lines,,Intermediate,,CHEMBL626195,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1169
80682,,N,,,6101,Homo sapiens,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,,Intermediate,,CHEMBL626196,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4450
80682,,N,,,6102,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549,,Intermediate,,CHEMBL626197,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,358
80682,,N,,,6103,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,,Intermediate,,CHEMBL626198,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,358
80682,,N,,,6104,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,,Intermediate,,CHEMBL626199,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,358
80682,,N,,,6105,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,,Intermediate,,CHEMBL626200,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,358
80682,,N,,,6106,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,,Intermediate,,CHEMBL626201,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,358
80682,,N,,,6107,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,,Intermediate,,CHEMBL626202,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,358
80682,,N,,,6108,Homo sapiens,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,,Intermediate,,CHEMBL626203,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,358
80682,,N,,,6109,Homo sapiens,In vitro cytotoxicity against A-549 human lung cancer cells,,Intermediate,,CHEMBL626204,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15167
80682,,N,,,6110,Homo sapiens,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,,Intermediate,,CHEMBL624701,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4139
80682,,N,,,6111,Homo sapiens,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,,Intermediate,,CHEMBL624702,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,833
80682,,N,,,6112,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,Expert,,CHEMBL624703,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15718
80682,,N,,,6113,Homo sapiens,Tested in vitro for cytotoxicity against A-549 lung cancer cells,,Intermediate,,CHEMBL624704,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12373
80682,,N,,,6114,Homo sapiens,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,,Intermediate,,CHEMBL624705,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,637
80682,,N,,,6115,Homo sapiens,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,,Expert,,CHEMBL624706,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14867
80682,,N,,,6116,Homo sapiens,Antitumor cytotoxic activity against A-549 cell line was determined,,Intermediate,,CHEMBL624707,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4461
80682,,N,,,6117,Homo sapiens,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",,Intermediate,,CHEMBL624708,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5406
80682,,N,,,6118,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,Intermediate,,CHEMBL624709,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4457
80682,,N,,,6119,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,Expert,,CHEMBL884107,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1386
80682,,N,,,6120,Homo sapiens,Antitumoral activity was assayed against A-549 cell line,,Intermediate,,CHEMBL624710,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3265
80682,,N,,,6121,Homo sapiens,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,,Intermediate,,CHEMBL624711,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2359
80682,,N,,,6122,Homo sapiens,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,,Intermediate,,CHEMBL624712,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4457
80682,,N,,,6123,Homo sapiens,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,,Expert,,CHEMBL624713,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12454
80682,,N,,,6124,Homo sapiens,Compound was tested for inhibition of cell growth of A-549 cells,,Intermediate,,CHEMBL624714,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1481
80682,,N,,,6125,Homo sapiens,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,,Intermediate,,CHEMBL624715,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1750
80682,,N,,,6126,Homo sapiens,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,,Intermediate,,CHEMBL624716,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5065
80682,,N,,,6127,Homo sapiens,In vitro cytotoxicity against A549-human lung carcinoma cells.,,Expert,,CHEMBL619505,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,808
80682,,N,,,6128,Homo sapiens,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,,Expert,,CHEMBL619506,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16364
80682,,N,,,6129,Homo sapiens,Cytotoxic activity against A-549 cell lines.,,Intermediate,,CHEMBL619507,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1847
80682,,N,,,6130,Homo sapiens,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,,Expert,,CHEMBL619508,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1747
80682,,N,,,6131,Homo sapiens,Cytotoxicity against human A549 non small cell lung cell lines,,Intermediate,,CHEMBL619509,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1003
80682,,N,,,6132,Homo sapiens,Inhibition of cell growth in (A-549) lung cell line,,Expert,,CHEMBL619510,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15313
80682,,N,,,6133,Homo sapiens,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,,Intermediate,,CHEMBL619511,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3122
80682,,N,,,6134,Homo sapiens,In vitro antitumor activity against A-549 tumor cells.,,Intermediate,,CHEMBL619512,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16049
80682,,N,,,6135,Homo sapiens,In vitro antitumor effects against human A-549 cell lines.,,Expert,,CHEMBL619513,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17134
80682,,N,,,6136,Homo sapiens,In vitro cytotoxic activity of compound against A-549 cell line,,Intermediate,,CHEMBL619514,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6406
80682,,N,,,6137,Homo sapiens,In vitro cytotoxicity against human lung carcinoma A-549 cell line,,Intermediate,,CHEMBL619515,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,627
80682,,N,,,6138,Homo sapiens,In vitro cytotoxicity against human non-small cell lung carcinoma A549,,Intermediate,,CHEMBL619516,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12307
80682,,N,,,6139,Homo sapiens,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,,Intermediate,,CHEMBL884005,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17861
80682,,N,,,6140,Homo sapiens,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,,Expert,,CHEMBL619517,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6682
80682,,N,,,6141,Homo sapiens,Inhibitory concentration of compound against A-549 cell line,,Intermediate,,CHEMBL619518,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6142,Homo sapiens,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,,Intermediate,,CHEMBL619519,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2454
80682,,N,,,6143,Homo sapiens,cytotoxic activity against leukemia (A-549) cancer cell line,,Intermediate,,CHEMBL876489,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14709
80682,,N,,,6144,Homo sapiens,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,,Expert,,CHEMBL619520,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15718
80682,,N,,,6145,Homo sapiens,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,,Intermediate,,CHEMBL619521,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15718
80682,,N,,,6146,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),,Intermediate,,CHEMBL619522,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17130
80682,,N,,,6147,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),,Intermediate,,CHEMBL619523,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17130
80682,,N,,,6148,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),,Intermediate,,CHEMBL619524,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17130
80682,,N,,,6149,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),,Intermediate,,CHEMBL619525,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17130
80682,,N,,,6150,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,,Intermediate,,CHEMBL619526,,,646.0,1,1,A549,F,,,BAO_0000219,6630
80682,,N,,,6151,Homo sapiens,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,,Intermediate,,CHEMBL619527,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16726
80682,,N,,,6152,Homo sapiens,Cytotoxicity against A549 cells; No cytotoxicity,,Intermediate,,CHEMBL619528,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17846
80682,,N,,,6153,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines,,Expert,,CHEMBL619529,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3415
80682,,N,,,6154,Homo sapiens,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,,Expert,,CHEMBL619530,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3415
80682,,N,,,6155,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,,Intermediate,,CHEMBL876490,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5609
80682,,N,,,6156,Homo sapiens,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,,Intermediate,,CHEMBL619531,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6157,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,,Intermediate,,CHEMBL619532,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6158,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,,Intermediate,,CHEMBL619533,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6159,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,,Intermediate,,CHEMBL619534,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6160,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,,Intermediate,,CHEMBL620164,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6161,Homo sapiens,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,Intermediate,,CHEMBL620165,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6162,Homo sapiens,Inhibition of A549 human lung tumor cell proliferation,,Expert,,CHEMBL620166,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16295
80682,,N,,,6163,Homo sapiens,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",,Intermediate,,CHEMBL620167,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16825
80682,,N,,,6164,Homo sapiens,In vitro cytotoxicity against human tumor cell line A549,,Expert,,CHEMBL620168,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3439
80682,,N,,,6165,Homo sapiens,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,,Intermediate,,CHEMBL620338,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,10870
80682,,N,,,6166,Homo sapiens,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,,Intermediate,,CHEMBL620339,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4845
80682,,N,,,6167,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,,Intermediate,,CHEMBL620340,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5822
80682,,N,,,6168,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,,Intermediate,,CHEMBL620341,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5822
80682,,N,,,6169,Homo sapiens,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,,Intermediate,,CHEMBL876491,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5822
80682,,N,,,6170,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,Intermediate,,CHEMBL620342,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16381
80682,,N,,,6171,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,Intermediate,,CHEMBL620343,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16381
80682,,N,,,6172,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,Intermediate,,CHEMBL620344,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16381
80682,,N,,,6173,Homo sapiens,In vitro anticancer activity against human lung (A549) cell line,,Intermediate,,CHEMBL620345,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5609
80682,,N,,,6174,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,,Intermediate,,CHEMBL620346,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4644
80682,,N,,,6175,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,,Intermediate,,CHEMBL620347,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4644
80682,,N,,,6176,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,,Intermediate,,CHEMBL620348,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4644
80682,,N,,,6177,Homo sapiens,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,,Intermediate,,CHEMBL620349,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4644
80682,,N,,,6178,Homo sapiens,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,,Intermediate,,CHEMBL618667,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5822
80682,,N,,,6179,Homo sapiens,Percentage inhibition of human lung carcinoma (A549) cell lines,,Expert,,CHEMBL618668,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3415
80682,,N,,,6180,Homo sapiens,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,,Intermediate,,CHEMBL876031,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16726
80682,,N,,,6181,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",,Intermediate,,CHEMBL618759,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6182,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,Intermediate,,CHEMBL618760,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6183,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,,Intermediate,,CHEMBL619000,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6184,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",,Intermediate,,CHEMBL619001,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6185,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",,Intermediate,,CHEMBL619002,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6186,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",,Intermediate,,CHEMBL619003,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6187,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",,Intermediate,,CHEMBL619597,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6188,Homo sapiens,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",,Intermediate,,CHEMBL619598,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6189,Homo sapiens,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,,Intermediate,,CHEMBL619599,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6190,Homo sapiens,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,,Intermediate,,CHEMBL619600,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6191,Homo sapiens,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,,Intermediate,,CHEMBL619601,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16726
80682,,N,,,6192,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,,Intermediate,,CHEMBL619602,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6193,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,,Intermediate,,CHEMBL619603,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6194,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,,Intermediate,,CHEMBL619604,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6195,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,,Intermediate,,CHEMBL619605,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
50588,,N,,,6196,Canis lupus familiaris,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,,Intermediate,,CHEMBL619606,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6084
50588,,N,,,6197,Canis lupus familiaris,Pharmacokinetic activity (Cmax) in dog,,Intermediate,,CHEMBL876032,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6084
50588,,N,,,6198,Canis lupus familiaris,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,Intermediate,,CHEMBL619607,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4809
50588,,N,,,6199,Canis lupus familiaris,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,,Intermediate,,CHEMBL619608,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5983
50588,,N,,,6200,Canis lupus familiaris,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,,Intermediate,,CHEMBL619609,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6251
50588,,N,1969.0,,6201,Canis lupus familiaris,Cmax in dog plasma after 30mg/kg oral dose,Plasma,Intermediate,,CHEMBL619610,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5932
50588,,N,178.0,,6202,Canis lupus familiaris,Tested for the peak blood level in dog,Blood,Intermediate,,CHEMBL619611,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4273
50588,,N,,,6203,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",,Intermediate,,CHEMBL619612,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5313
50588,,N,,,6204,Canis lupus familiaris,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",,Intermediate,,CHEMBL619613,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5313
50588,,N,178.0,,6205,Canis lupus familiaris,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,Blood,Intermediate,,CHEMBL619614,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6221
50588,,N,,,6206,Canis lupus familiaris,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,,Intermediate,,CHEMBL619615,,9615.0,,1,1,,A,,,BAO_0000218,4709
50588,,N,,,6207,Canis lupus familiaris,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,,Intermediate,,CHEMBL619616,,9615.0,,1,1,,A,,,BAO_0000218,167
50588,,N,1969.0,,6208,Canis lupus familiaris,Final plasma concentration in dogs after oral administration at 1 mg/kg,Plasma,Intermediate,,CHEMBL619617,,9615.0,,1,1,,A,,,BAO_0000218,6241
50588,,N,,,6209,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,,Intermediate,,CHEMBL619618,,9615.0,,1,1,,A,,,BAO_0000218,344
50588,,N,,,6210,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,,Intermediate,,CHEMBL876033,,9615.0,,1,1,,A,,,BAO_0000218,344
50588,,N,,,6211,Canis lupus familiaris,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,,Intermediate,,CHEMBL619619,,9615.0,,1,1,,A,,,BAO_0000218,344
50588,,N,,,6212,Canis lupus familiaris,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,,Intermediate,,CHEMBL619620,,9615.0,,1,1,,A,,,BAO_0000218,2189
50588,,N,1088.0,,6213,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,Urine,Intermediate,,CHEMBL619621,,9615.0,,1,1,,A,,,BAO_0000218,2189
50588,,N,1088.0,,6214,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,Urine,Intermediate,,CHEMBL619622,,9615.0,,1,1,,A,,,BAO_0000218,2189
50588,,N,1088.0,,6215,Canis lupus familiaris,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,Urine,Intermediate,,CHEMBL618874,,9615.0,,1,1,,A,,,BAO_0000218,2189
50588,,N,,,6216,Canis lupus familiaris,Absolute bioavailability was evaluated in dog,,Intermediate,,CHEMBL618875,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4257
50588,,N,,,6217,Canis lupus familiaris,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,,Intermediate,,CHEMBL618876,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6221
50588,,N,,,6218,Canis lupus familiaris,Bioavailability after peroral administration (1 mg/kg) was determined in dog,,Intermediate,,CHEMBL618877,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6215
50588,,N,,,6219,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL618878,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17267
50588,,N,,,6220,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL618879,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6621
50588,,N,,,6221,Canis lupus familiaris,Bioavailability after intravenous administration in dogs,,Intermediate,,CHEMBL618880,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3854
50588,,N,,,6222,Canis lupus familiaris,Bioavailability after peroral administration in dogs,,Intermediate,,CHEMBL618881,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3854
50588,,N,,,6223,Canis lupus familiaris,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,Intermediate,,CHEMBL618882,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5007
50588,,N,,,6224,Canis lupus familiaris,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,,Intermediate,,CHEMBL624226,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4333
50588,,N,1969.0,,6225,Canis lupus familiaris,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,Plasma,Intermediate,,CHEMBL624227,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4333
50588,,N,,,6226,Canis lupus familiaris,Bioavailability,,Intermediate,,CHEMBL624228,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5006
50588,,N,,,6227,Canis lupus familiaris,Bioavailability,,Intermediate,,CHEMBL624229,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5199
50588,,N,,,6228,Canis lupus familiaris,Bioavailability by intravenous administration of 1.2 mg/kg in dog,,Intermediate,,CHEMBL624230,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4368
50588,,N,,,6229,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL624231,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3771
50588,,N,,,6230,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL624232,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4953
50588,,N,,,6231,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL625127,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5064
50588,,N,,,6232,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL625128,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17657
50588,,N,,,6233,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL621675,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17796
50588,,N,,,6234,Canis lupus familiaris,Bioavailability in dog (p.o.) at 2.0 mpk,,Intermediate,,CHEMBL621676,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17853
50588,,N,,,6235,Canis lupus familiaris,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),,Intermediate,,CHEMBL621677,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4521
50588,,N,,,6236,Canis lupus familiaris,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Intermediate,,CHEMBL621678,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4521
50588,,N,,,6237,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL621679,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5006
50588,,N,,,6238,Canis lupus familiaris,Bioavailability was evaluated after oral administration in dog,,Intermediate,,CHEMBL621680,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16365
50588,,N,,,6239,Canis lupus familiaris,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Intermediate,,CHEMBL621681,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1916
50588,,N,,,6240,Canis lupus familiaris,Bioavailability was evaluated in dog,,Intermediate,,CHEMBL876740,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1918
50588,,N,,,6241,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL621682,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4239
50588,,N,,,6242,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL621683,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6505
50588,,N,,,6243,Canis lupus familiaris,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,Intermediate,,CHEMBL621684,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5334
50588,,N,,,6244,Canis lupus familiaris,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,Intermediate,,CHEMBL621685,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5334
50588,,N,,,6245,Canis lupus familiaris,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,Intermediate,,CHEMBL621686,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4809
50588,,N,,,6246,Canis lupus familiaris,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Intermediate,,CHEMBL621687,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6348
50588,,N,,,6247,Canis lupus familiaris,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,,Intermediate,,CHEMBL621688,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6005
50588,,N,,,6248,Canis lupus familiaris,Bioavailability of compound in dog was determined after peroral administration,,Intermediate,,CHEMBL621689,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17804
50588,,N,,,6249,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621690,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3184
50588,,N,,,6250,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,,Intermediate,,CHEMBL621691,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1806
50588,,N,,,6251,Canis lupus familiaris,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,,Intermediate,,CHEMBL875941,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1806
50588,,N,,,6252,Canis lupus familiaris,Compound was evaluated for oral bioavailability in dogs; 37-38 %,,Intermediate,,CHEMBL621692,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1806
50588,,N,,,6253,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL621693,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4839
50588,,N,,,6254,Canis lupus familiaris,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),,Intermediate,,CHEMBL621694,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5017
50594,,N,948.0,,6255,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Heart,Intermediate,,CHEMBL621695,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,948.0,,6256,Mus musculus,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Heart,Intermediate,,CHEMBL621696,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2113.0,,6257,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Kidney,Intermediate,,CHEMBL621697,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2113.0,,6258,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Kidney,Intermediate,,CHEMBL621698,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2113.0,,6259,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Kidney,Intermediate,,CHEMBL623420,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2113.0,,6260,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Kidney,Intermediate,,CHEMBL623421,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2113.0,,6261,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Kidney,Intermediate,,CHEMBL623422,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2113.0,,6262,Mus musculus,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Kidney,Intermediate,,CHEMBL623423,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2107.0,,6263,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Liver,Intermediate,,CHEMBL623424,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2107.0,,6264,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Liver,Intermediate,,CHEMBL623425,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2107.0,,6265,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Liver,Intermediate,,CHEMBL623426,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2107.0,,6266,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Liver,Intermediate,,CHEMBL623427,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2107.0,,6267,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Liver,Intermediate,,CHEMBL623428,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2107.0,,6268,Mus musculus,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Liver,Intermediate,,CHEMBL875947,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2048.0,,6269,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,Lung,Intermediate,,CHEMBL623429,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2048.0,,6270,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,Lung,Intermediate,,CHEMBL623430,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2048.0,,6271,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,Lung,Intermediate,,CHEMBL622588,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2048.0,,6272,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,Lung,Intermediate,,CHEMBL622589,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2048.0,,6273,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,Lung,Intermediate,,CHEMBL622751,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,2048.0,,6274,Mus musculus,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,Lung,Intermediate,,CHEMBL622752,In vivo,10090.0,,1,1,,A,,,BAO_0000218,846
50594,,N,,,6275,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,,Intermediate,,CHEMBL622753,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6276,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,,Intermediate,,CHEMBL622647,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6277,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,,Intermediate,,CHEMBL875163,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6278,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,,Intermediate,,CHEMBL622648,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6279,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,,Intermediate,,CHEMBL622649,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,955.0,,6280,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,Brain,Intermediate,,CHEMBL622650,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,955.0,,6281,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,Brain,Intermediate,,CHEMBL622651,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,955.0,,6282,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,Brain,Intermediate,,CHEMBL622652,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,955.0,,6283,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,Brain,Intermediate,,CHEMBL622653,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,955.0,,6284,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,Brain,Intermediate,,CHEMBL622654,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,948.0,,6285,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,Heart,Intermediate,,CHEMBL622655,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,948.0,,6286,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,Heart,Intermediate,,CHEMBL622656,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,948.0,,6287,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,Heart,Intermediate,,CHEMBL622657,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,948.0,,6288,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,Heart,Intermediate,,CHEMBL622658,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,948.0,,6289,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,Heart,Intermediate,,CHEMBL622659,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2113.0,,6290,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,Kidney,Intermediate,,CHEMBL624630,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2113.0,,6291,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,Kidney,Intermediate,,CHEMBL624631,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2113.0,,6292,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,Kidney,Intermediate,,CHEMBL624632,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
80682,,N,,,6293,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,,Intermediate,,CHEMBL624633,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17130
80682,,N,,,6294,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,,Intermediate,,CHEMBL624634,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17130
80682,,N,,,6295,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),,Intermediate,,CHEMBL624635,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17130
80682,,N,,,6296,Homo sapiens,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),,Intermediate,,CHEMBL624636,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17130
80682,,N,,,6297,Homo sapiens,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,,Expert,,CHEMBL857055,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3263
80682,,N,,,6298,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,,Expert,,CHEMBL624637,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6299,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,,Expert,,CHEMBL624638,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6300,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,,Expert,,CHEMBL874366,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6301,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,,Expert,,CHEMBL624639,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6302,Homo sapiens,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,,Expert,,CHEMBL624640,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6303,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,,Intermediate,,CHEMBL624641,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6304,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,,Intermediate,,CHEMBL624642,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6305,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,,Intermediate,,CHEMBL624643,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6306,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,,Intermediate,,CHEMBL624644,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6307,Homo sapiens,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,,Intermediate,,CHEMBL624645,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6663
80682,,N,,,6308,Homo sapiens,The compound was evaluated for its cytotoxic potency against A-549 cell line,,Intermediate,,CHEMBL619445,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3983
80682,,N,,,6309,Homo sapiens,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,,Expert,,CHEMBL839886,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,11141
80682,,N,,,6310,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line.,,Intermediate,,CHEMBL619446,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5076
80682,,N,,,6311,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,,Intermediate,,CHEMBL619447,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3311
80682,,N,,,6312,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,,Intermediate,,CHEMBL619448,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3311
80682,,N,,,6313,Homo sapiens,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,,Intermediate,,CHEMBL619449,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3311
80682,,N,,,6314,Homo sapiens,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,,Intermediate,,CHEMBL619450,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5076
80682,,N,,,6315,Homo sapiens,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),,Intermediate,,CHEMBL619451,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4150
80682,,N,,,6316,Homo sapiens,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,,Expert,,CHEMBL619452,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2150
80682,,N,,,6317,Homo sapiens,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,,Intermediate,,CHEMBL619453,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4644
80682,,N,,,6318,Homo sapiens,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,,Intermediate,,CHEMBL874367,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,263
80682,,N,,,6319,Homo sapiens,Cytotoxic concentration against A-549 tumor cells.,,Intermediate,,CHEMBL619454,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,11333
80682,,N,,,6320,Homo sapiens,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,,Intermediate,,CHEMBL619455,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,11333
80682,,N,,,6321,Homo sapiens,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",,Intermediate,,CHEMBL619456,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,15895
50191,,N,,,6322,Acinetobacter baumannii,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,,Expert,,CHEMBL619457,,470.0,,1,1,,F,,,BAO_0000218,16677
50192,,N,,,6323,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),,Intermediate,,CHEMBL619458,,471.0,,1,1,,F,,,BAO_0000218,10624
50274,,N,,,6324,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,,Expert,,CHEMBL619459,,5059.0,,1,1,,F,,,BAO_0000218,16717
50274,,N,,,6325,Aspergillus flavus,In vitro antifungal activity against Aspergillus flavus CM74,,Expert,,CHEMBL619460,,5059.0,,1,1,,F,,,BAO_0000218,16717
50416,,N,,,6326,Aspergillus fumigatus,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,,Intermediate,,CHEMBL619461,,746128.0,,1,1,,F,,,BAO_0000218,5513
50416,,N,,,6327,Aspergillus fumigatus,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),,Intermediate,,CHEMBL619462,,746128.0,,1,1,,F,,,BAO_0000218,15962
50416,,N,,,6328,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),,Intermediate,,CHEMBL620388,,746128.0,,1,1,,F,,,BAO_0000218,15962
50416,,N,,,6329,Aspergillus fumigatus,Antimicrobial activity against Aspergillus fumigatus (MIC),,Intermediate,,CHEMBL620389,,746128.0,,1,1,,F,,,BAO_0000218,15962
50416,,N,,,6330,Aspergillus fumigatus,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),,Intermediate,,CHEMBL620390,,746128.0,,1,1,,F,,,BAO_0000218,15962
50416,,N,,,6331,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,,Expert,,CHEMBL620391,,746128.0,,1,1,,F,,,BAO_0000218,16717
50416,,N,,,6332,Aspergillus fumigatus,In vitro antifungal activity against Aspergillus fumigatus 48238E,,Expert,,CHEMBL621073,,746128.0,,1,1,,F,,,BAO_0000218,16717
50296,,N,,,6333,Actinomyces naeslundii,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,,Intermediate,,CHEMBL621074,,1655.0,,1,1,,F,,,BAO_0000218,8117
50366,,N,,,6334,Actinomyces viscosus,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,,Intermediate,,CHEMBL621075,,1656.0,,1,1,,F,,,BAO_0000218,8117
50535,,N,,,6335,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,Intermediate,,CHEMBL619554,,6277.0,,1,1,,F,,,BAO_0000218,15472
50535,,N,,,6336,Acanthocheilonema viteae,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),,Intermediate,,CHEMBL619555,,6277.0,,1,1,,F,,,BAO_0000218,15472
50169,,N,,,6337,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,,Intermediate,,CHEMBL619556,,714.0,,1,1,,F,,,BAO_0000218,16443
50169,,N,,,6338,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,,Intermediate,,CHEMBL619557,,714.0,,1,1,,F,,,BAO_0000218,16443
50169,,N,,,6339,Aggregatibacter actinomycetemcomitans,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,,Intermediate,,CHEMBL619558,,714.0,,1,1,,F,,,BAO_0000218,16443
80682,,N,,,6340,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,,Intermediate,,CHEMBL619559,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6341,Homo sapiens,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,,Intermediate,,CHEMBL619560,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6342,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,,Intermediate,,CHEMBL619561,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16381
80682,,N,,,6343,Homo sapiens,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,,Intermediate,,CHEMBL619562,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16381
80682,,N,,,6344,Homo sapiens,% inhibition against A549 cells (lung cancer) at 4 ug/mL,,Intermediate,,CHEMBL619563,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16381
80682,,N,,,6345,Homo sapiens,GI values against A549 cells (lung cancer),,Intermediate,,CHEMBL857457,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16381
80682,,N,,,6346,Homo sapiens,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,,Intermediate,,CHEMBL619564,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17206
80682,,N,,,6347,Homo sapiens,Inhibitory activity against A549 human adenocarcinoma,,Intermediate,,CHEMBL619565,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16325
80682,,N,,,6348,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,,Intermediate,,CHEMBL619566,,9606.0,646.0,1,1,A549,F,,,BAO_0000218,10708
80682,,N,,,6349,Homo sapiens,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,,Intermediate,,CHEMBL619567,,9606.0,646.0,1,1,A549,F,,,BAO_0000218,10708
80682,,N,,,6350,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line,,Intermediate,,CHEMBL619568,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17376
80682,,N,,,6351,Homo sapiens,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,,Intermediate,,CHEMBL619569,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17376
80682,,N,,,6352,Homo sapiens,Cytotoxicity against human A549 lung cells,,Intermediate,,CHEMBL619570,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17488
80682,,N,,,6353,Homo sapiens,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,,Intermediate,,CHEMBL619571,,9606.0,646.0,1,1,A549,F,,,BAO_0000218,17404
80682,,N,,,6354,Homo sapiens,Growth inhibition of A549 (human lung carcinoma) cell line.,,Expert,,CHEMBL619572,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,10958
80682,,N,,,6355,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line.,,Expert,,CHEMBL619573,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17099
80682,,N,,,6356,Homo sapiens,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,,Intermediate,,CHEMBL619574,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17099
80682,,N,,,6357,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,,Intermediate,,CHEMBL619575,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4096
80682,,N,,,6358,Homo sapiens,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,,Expert,,CHEMBL619576,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4096
80682,,N,,,6359,Homo sapiens,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,,Intermediate,,CHEMBL619577,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,4096
80682,,N,,,6360,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture,,Intermediate,,CHEMBL619578,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2525
80682,,N,,,6361,Homo sapiens,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,,Intermediate,,CHEMBL884009,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,2525
80682,,N,,,6362,Homo sapiens,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),,Intermediate,,CHEMBL619579,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,5302
80682,,N,,,6363,Homo sapiens,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,,Intermediate,,CHEMBL619580,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16325
80682,,N,,,6364,Homo sapiens,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,,Intermediate,,CHEMBL619581,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,16939
80682,,N,,,6365,Homo sapiens,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,,Intermediate,,CHEMBL619582,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17229
80682,,N,,,6366,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,,Intermediate,,CHEMBL619583,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17380
80682,,N,,,6367,Homo sapiens,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,,Intermediate,,CHEMBL876502,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17380
80682,,N,,,6368,Homo sapiens,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,,Intermediate,,CHEMBL619584,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1903
80682,,N,,,6369,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,Intermediate,,CHEMBL619585,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3838
80682,,N,,,6370,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,Intermediate,,CHEMBL619586,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14696
80682,,N,,,6371,Homo sapiens,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,,Intermediate,,CHEMBL619587,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3838
80682,,N,,,6372,Homo sapiens,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,,Intermediate,,CHEMBL619588,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1522
80682,,N,,,6373,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell lines,,Intermediate,,CHEMBL619589,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12400
80682,,N,,,6374,Homo sapiens,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,,Intermediate,,CHEMBL619590,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14696
80682,,N,,,6375,Homo sapiens,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),,Intermediate,,CHEMBL619591,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14769
80682,,N,,,6376,Homo sapiens,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,,Intermediate,,CHEMBL619592,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,14696
80682,,N,,,6377,Homo sapiens,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,,Intermediate,,CHEMBL619593,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,1888
80682,,N,,,6378,Homo sapiens,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,,Intermediate,,CHEMBL620217,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12016
80682,,N,,,6379,Homo sapiens,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,,Intermediate,,CHEMBL620218,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,6058
80682,,N,,,6380,Homo sapiens,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,,Intermediate,,CHEMBL620219,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17708
80682,,N,,,6381,Homo sapiens,Antitumor activity against A549/ATCC cell line,,Intermediate,,CHEMBL620220,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12301
80682,,N,,,6382,Homo sapiens,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,,Intermediate,,CHEMBL625141,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,11970
80682,,N,,,6383,Homo sapiens,In vitro cytotoxicity against A549/ATCC cell line.,,Expert,,CHEMBL625142,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,11818
80682,,N,,,6384,Homo sapiens,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,,Intermediate,,CHEMBL625143,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,12400
80682,,N,,,6385,Homo sapiens,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,,Intermediate,,CHEMBL625144,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,3381
80682,,N,,,6386,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,,Intermediate,,CHEMBL622474,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,17376
80682,,N,,,6387,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,,Intermediate,,CHEMBL884104,,9606.0,646.0,1,1,A549,F,,,BAO_0000219,10708
22226,,U,,,6388,Homo sapiens,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,,Autocuration,,CHEMBL622475,,9606.0,,0,1,,F,,,BAO_0000219,2964
22224,,U,,,6389,Canis lupus familiaris,Compound was tested for oral bioavailability in dogs,,Intermediate,,CHEMBL622476,In vivo,9615.0,,0,1,,A,,,BAO_0000218,5005
50588,,N,,,6390,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,,Intermediate,,CHEMBL875831,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6229
50588,,N,,,6391,Canis lupus familiaris,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,,Intermediate,,CHEMBL622477,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6229
50588,,N,,,6392,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL622478,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5374
50588,,N,,,6393,Canis lupus familiaris,Compound was tested for the oral bioavailability in dog; No availability,,Intermediate,,CHEMBL623172,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5374
50588,,N,,,6394,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),,Intermediate,,CHEMBL623173,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6265
50588,,N,,,6395,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,Intermediate,,CHEMBL623174,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5654
50588,,N,,,6396,Canis lupus familiaris,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,,Intermediate,,CHEMBL623175,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5654
50588,,N,,,6397,Canis lupus familiaris,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),,Intermediate,,CHEMBL623340,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16456
50588,,N,,,6398,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),,Intermediate,,CHEMBL623341,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5302
50588,,N,,,6399,Canis lupus familiaris,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),,Intermediate,,CHEMBL623342,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3624
50588,,N,,,6400,Canis lupus familiaris,Oral bioavailability of active FTIs in dogs,,Intermediate,,CHEMBL623343,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,6401,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),,Intermediate,,CHEMBL623344,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5802
50588,,N,,,6402,Canis lupus familiaris,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,,Expert,,CHEMBL623345,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3598
50588,,N,,,6403,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL875832,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,,,6404,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623346,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6762
50588,,N,,,6405,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623347,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6821
50588,,N,,,6406,Canis lupus familiaris,Oral bioavailability of compound was determined in dog; Not tested,,Intermediate,,CHEMBL623348,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6821
50588,,N,,,6407,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623349,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5210
50588,,N,,,6408,Canis lupus familiaris,Oral bioavailability (10 mg/kg) was determined in dog,,Intermediate,,CHEMBL623350,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,6409,Canis lupus familiaris,Oral bioavailability,,Intermediate,,CHEMBL623351,In vivo,9615.0,,1,1,,A,,,BAO_0000218,761
50588,,N,,,6410,Canis lupus familiaris,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),,Intermediate,,CHEMBL623352,In vivo,9615.0,,1,1,,A,,,BAO_0000218,761
50588,,N,,,6411,Canis lupus familiaris,Oral bioavailability administered in solution in rats,,Intermediate,,CHEMBL623353,In vivo,9615.0,,1,1,,A,,,BAO_0000218,761
50588,,N,,,6412,Canis lupus familiaris,Oral bioavailability after 30 mg/kg po dose in Dogs,,Intermediate,,CHEMBL875833,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,6413,Canis lupus familiaris,Oral bioavailability at a dose of 1 mg/kg in dogs,,Intermediate,,CHEMBL623354,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5474
50588,,N,,,6414,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg p.o.),,Intermediate,,CHEMBL623355,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,,,6415,Canis lupus familiaris,Oral bioavailability in Dog; ND = not determined,,Intermediate,,CHEMBL623356,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,,,6416,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623357,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3352
50588,,N,,,6417,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623358,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6168
50588,,N,,,6418,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623359,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5988
50588,,N,,,6419,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623360,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4942
50588,,N,,,6420,Canis lupus familiaris,Oral bioavailability in dogs; No data,,Intermediate,,CHEMBL623361,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4942
50588,,N,,,6421,Canis lupus familiaris,Oral bioavailability measured in dogs,,Intermediate,,CHEMBL623362,In vivo,9615.0,,1,1,,A,,,BAO_0000218,14541
50588,,N,,,6422,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623363,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4449
50588,,N,,,6423,Canis lupus familiaris,Oral bioavailability was calculated in dog,,Intermediate,,CHEMBL623364,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6057
50588,,N,,,6424,Canis lupus familiaris,Oral bioavailability after 0.3 mg/kg po administration in dog,,Intermediate,,CHEMBL875834,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5600
50588,,N,,,6425,Canis lupus familiaris,Oral bioavailability in dog (i.v. dosing),,Intermediate,,CHEMBL623365,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5542
50588,,N,,,6426,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623366,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5542
50588,,N,,,6427,Canis lupus familiaris,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,,Intermediate,,CHEMBL623367,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5546
50588,,N,,,6428,Canis lupus familiaris,Oral bioavailability in Beagle dogs,,Intermediate,,CHEMBL623368,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4514
50588,,N,,,6429,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623369,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3624
50588,,N,,,6430,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623370,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3854
50588,,N,,,6431,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623371,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5836
50588,,N,,,6432,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL623372,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5940
50588,,N,,,6433,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621351,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6168
50588,,N,,,6434,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621352,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,6435,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621353,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6251
50588,,N,,,6436,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621354,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6448
50588,,N,,,6437,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621355,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6647
50588,,N,,,6438,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621356,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5940
50588,,N,,,6439,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621357,In vivo,9615.0,,1,1,,A,,,BAO_0000218,933
50588,,N,,,6440,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621358,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5210
50588,,N,,,6441,Canis lupus familiaris,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),,Intermediate,,CHEMBL621359,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6642
50588,,N,,,6442,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,Intermediate,,CHEMBL621360,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6641
50588,,N,,,6443,Canis lupus familiaris,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),,Intermediate,,CHEMBL621361,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6642
50588,,N,,,6444,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621362,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5472
50588,,N,,,6445,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621363,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5985
50588,,N,,,6446,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621364,In vivo,9615.0,,1,1,,A,,,BAO_0000218,15660
50588,,N,,,6447,Canis lupus familiaris,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),,Intermediate,,CHEMBL621166,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5530
50588,,N,,,6448,Canis lupus familiaris,Oral bioavailability in dog (dose 1 mg/kg i.v.),,Intermediate,,CHEMBL621167,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5530
50588,,N,,,6449,Canis lupus familiaris,Oral bioavailability (F) in dogs,,Intermediate,,CHEMBL621168,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6305
50588,,N,,,6450,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL621169,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5210
50588,,N,,,6451,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL875950,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5238
50588,,N,,,6452,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate,,CHEMBL621170,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,6453,Canis lupus familiaris,Oral bioavailability after peroral administration at 5 mpk in Dog,,Intermediate,,CHEMBL621171,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,6454,Canis lupus familiaris,Oral bioavailability in dog (dose 5 mg/kg),,Intermediate,,CHEMBL621172,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,6455,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate,,CHEMBL621173,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6084
50594,,N,2113.0,,6456,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,Kidney,Intermediate,,CHEMBL621174,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2113.0,,6457,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,Kidney,Intermediate,,CHEMBL621175,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2107.0,,6458,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,Liver,Intermediate,,CHEMBL621176,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2107.0,,6459,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,Liver,Intermediate,,CHEMBL621177,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2107.0,,6460,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,Liver,Intermediate,,CHEMBL621178,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2107.0,,6461,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,Liver,Intermediate,,CHEMBL621179,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2107.0,,6462,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,Liver,Intermediate,,CHEMBL621180,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2048.0,,6463,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,Lung,Intermediate,,CHEMBL875951,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2048.0,,6464,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,Lung,Intermediate,,CHEMBL621181,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2048.0,,6465,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,Lung,Intermediate,,CHEMBL621182,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2048.0,,6466,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,Lung,Intermediate,,CHEMBL621183,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2048.0,,6467,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,Lung,Intermediate,,CHEMBL621184,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6468,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,,Intermediate,,CHEMBL621185,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6469,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,,Intermediate,,CHEMBL621186,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6470,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,,Intermediate,,CHEMBL621187,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6471,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,,Intermediate,,CHEMBL621188,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6472,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,,Intermediate,,CHEMBL621189,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2106.0,,6473,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,Spleen,Intermediate,,CHEMBL621190,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2106.0,,6474,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,Spleen,Intermediate,,CHEMBL618520,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2106.0,,6475,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,Spleen,Intermediate,,CHEMBL621739,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2106.0,,6476,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,Spleen,Intermediate,,CHEMBL621740,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2106.0,,6477,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,Spleen,Intermediate,,CHEMBL621741,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6478,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,,Intermediate,,CHEMBL621742,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6479,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,,Intermediate,,CHEMBL621743,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6480,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,,Intermediate,,CHEMBL621744,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6481,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,,Intermediate,,CHEMBL621745,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6482,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,,Intermediate,,CHEMBL621746,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6483,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,,Intermediate,,CHEMBL621747,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6484,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,,Intermediate,,CHEMBL621748,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6485,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,,Intermediate,,CHEMBL621749,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6486,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,,Intermediate,,CHEMBL621750,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6487,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,,Intermediate,,CHEMBL621751,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,948.0,,6488,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,Heart,Intermediate,,CHEMBL621752,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,948.0,,6489,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,Heart,Intermediate,,CHEMBL621753,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,948.0,,6490,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,Heart,Intermediate,,CHEMBL875955,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,948.0,,6491,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,Heart,Intermediate,,CHEMBL621754,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,948.0,,6492,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,Heart,Intermediate,,CHEMBL621755,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2107.0,,6493,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,Liver,Intermediate,,CHEMBL621756,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2107.0,,6494,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,Liver,Intermediate,,CHEMBL624199,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2107.0,,6495,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,Liver,Intermediate,,CHEMBL624200,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2107.0,,6496,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,Liver,Intermediate,,CHEMBL624375,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2107.0,,6497,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,Liver,Intermediate,,CHEMBL624376,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2048.0,,6498,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,Lung,Intermediate,,CHEMBL624377,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2048.0,,6499,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,Lung,Intermediate,,CHEMBL624378,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50067,,N,,,6500,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Intermediate,,CHEMBL857901,,107673.0,,1,1,,F,,,BAO_0000218,12269
50067,,N,,,6501,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Intermediate,,CHEMBL875274,,107673.0,,1,1,,F,,,BAO_0000218,12269
50067,,N,,,6502,Acinetobacter calcoaceticus subsp. anitratus,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Intermediate,,CHEMBL624379,,107673.0,,1,1,,F,,,BAO_0000218,12269
50067,,N,,,6503,aeinetobacter anitrotap,Compound tested for the antimicrobial activity against Acinetobacter anitratus,,Intermediate,,CHEMBL624380,,107673.0,,1,1,,F,,,BAO_0000218,12269
50192,,N,,,6504,Acinetobacter calcoaceticus,Activity against Acinetobacter calcoaceticus (AC54),,Intermediate,,CHEMBL624381,,471.0,,1,1,,F,,,BAO_0000218,10624
50714,,N,,,6505,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,,Intermediate,,CHEMBL624382,,28377.0,,1,1,,F,,,BAO_0000218,17216
50714,,N,,,6506,Anolis carolinensis,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,,Intermediate,,CHEMBL624383,,28377.0,,1,1,,F,,,BAO_0000218,17216
50296,,N,,,6507,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii 631,,Intermediate,,CHEMBL624384,,1655.0,,1,1,,F,,,BAO_0000218,9560
50296,,N,,,6508,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii B74,,Intermediate,,CHEMBL624385,,1655.0,,1,1,,F,,,BAO_0000218,9560
50296,,N,,,6509,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/3,,Intermediate,,CHEMBL624386,,1655.0,,1,1,,F,,,BAO_0000218,9560
50296,,N,,,6510,Actinomyces naeslundii,Chlorohexidine coefficient for Actinomyces naeslundii N/9,,Intermediate,,CHEMBL624387,,1655.0,,1,1,,F,,,BAO_0000218,9560
50296,,N,,,6511,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii 631,,Intermediate,,CHEMBL624388,,1655.0,,1,1,,F,,,BAO_0000218,9560
50296,,N,,,6512,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/9,,Intermediate,,CHEMBL624389,,1655.0,,1,1,,F,,,BAO_0000218,9560
50296,,N,,,6513,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii B74,,Intermediate,,CHEMBL624390,,1655.0,,1,1,,F,,,BAO_0000218,9560
50296,,N,,,6514,Actinomyces naeslundii,Plaque bactericidal index against Actinomyces naeslundii N/3,,Intermediate,,CHEMBL875275,,1655.0,,1,1,,F,,,BAO_0000218,9560
50056,,N,,,6515,Artemia salina,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,,Intermediate,,CHEMBL624391,,85549.0,,1,1,,F,,,BAO_0000218,114
50056,,N,,,6516,Artemia salina,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",,Intermediate,,CHEMBL623636,,85549.0,,1,1,,F,,,BAO_0000218,114
50532,,N,,,6517,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,,Intermediate,,CHEMBL623637,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6518,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,,Intermediate,,CHEMBL623638,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6519,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,,Intermediate,,CHEMBL623639,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6520,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,,Intermediate,,CHEMBL623640,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6521,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,,Intermediate,,CHEMBL623641,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6522,Ascaris suum,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,,Intermediate,,CHEMBL623642,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6523,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,,Intermediate,,CHEMBL623643,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6524,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,,Intermediate,,CHEMBL623644,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6525,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,,Intermediate,,CHEMBL623645,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6526,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,,Intermediate,,CHEMBL623646,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6527,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,,Intermediate,,CHEMBL623647,,6253.0,,1,1,,F,,,BAO_0000218,10841
50532,,N,,,6528,Ascaris suum,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,,Intermediate,,CHEMBL623648,,6253.0,,1,1,,F,,,BAO_0000218,10841
50366,,N,,,6529,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,Intermediate,,CHEMBL623649,,1656.0,,1,1,,F,,,BAO_0000218,8117
50366,,N,,,6530,Actinomyces viscosus,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,,Intermediate,,CHEMBL623650,,1656.0,,1,1,,F,,,BAO_0000218,8117
50366,,N,,,6531,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus 8A06,,Intermediate,,CHEMBL623651,,1656.0,,1,1,,F,,,BAO_0000218,9560
50366,,N,,,6532,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-100,,Expert,,CHEMBL623652,,1656.0,,1,1,,F,,,BAO_0000218,9560
50366,,N,,,6533,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus M-626,,Intermediate,,CHEMBL623653,,1656.0,,1,1,,F,,,BAO_0000218,9560
50366,,N,,,6534,Actinomyces viscosus,Chlorohexidine coefficient for Actinomyces viscosus T14V,,Intermediate,,CHEMBL623654,,1656.0,,1,1,,F,,,BAO_0000218,9560
50366,,N,,,6535,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 8A06,,Intermediate,,CHEMBL623655,,1656.0,,1,1,,F,,,BAO_0000218,9560
50366,,N,,,6536,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100,,Intermediate,,CHEMBL623656,,1656.0,,1,1,,F,,,BAO_0000218,9560
50366,,N,,,6537,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,,Expert,,CHEMBL623657,,1656.0,,1,1,,F,,,BAO_0000218,9560
50366,,N,,,6538,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,Intermediate,,CHEMBL623658,,1656.0,,1,1,,F,,,BAO_0000218,9560
50366,,N,,,6539,Actinomyces viscosus,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",,Intermediate,,CHEMBL623659,,1656.0,,1,1,,F,,,BAO_0000218,9560
50366,,N,,,6540,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus 626,,Intermediate,,CHEMBL623660,,1656.0,,1,1,,F,,,BAO_0000218,9560
50366,,N,,,6541,Actinomyces viscosus,Plaque bactericidal index against Actinomyces viscosus T14V,,Intermediate,,CHEMBL623661,,1656.0,,1,1,,F,,,BAO_0000218,9560
50535,,N,,,6542,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,,Intermediate,,CHEMBL875281,,6277.0,,1,1,,F,,,BAO_0000218,10986
50535,,N,,,6543,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,,Intermediate,,CHEMBL623662,,6277.0,,1,1,,F,,,BAO_0000218,10986
50535,,N,,,6544,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,,Intermediate,,CHEMBL623663,,6277.0,,1,1,,F,,,BAO_0000218,10986
50535,,N,,,6545,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,,Intermediate,,CHEMBL623664,,6277.0,,1,1,,F,,,BAO_0000218,10986
50535,,N,,,6546,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,,Intermediate,,CHEMBL623665,,6277.0,,1,1,,F,,,BAO_0000218,10986
80023,,N,,,6547,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,,Intermediate,,CHEMBL621856,,9606.0,165.0,1,1,A673,F,,,BAO_0000219,10708
80661,,N,,,6548,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,,Intermediate,,CHEMBL620432,,9606.0,645.0,1,1,A704,F,,,BAO_0000219,10708
22226,,U,,,6549,Rattus norvegicus,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,,Autocuration,,CHEMBL620433,,10116.0,,0,1,,F,,,BAO_0000219,416
80024,,N,,,6550,Mus musculus,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,Intermediate,,CHEMBL620434,,10090.0,625.0,1,1,A9,F,,,BAO_0000219,14354
80024,,N,,,6551,Mus musculus,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,,Intermediate,,CHEMBL620435,,10090.0,625.0,1,1,A9,F,,,BAO_0000219,14354
80024,,N,,,6552,Homo sapiens,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,,Intermediate,,CHEMBL620436,,9606.0,625.0,1,1,A9,F,,,BAO_0000219,5116
80024,,N,,,6553,Homo sapiens,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,,Intermediate,,CHEMBL876597,,9606.0,625.0,1,1,A9,F,,,BAO_0000219,5116
81037,,N,,,6554,Homo sapiens,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,,Expert,,CHEMBL620437,,9606.0,874.0,1,1,Human ovarian carcinoma cell line,F,,,BAO_0000219,15694
80024,,N,,,6555,Mus musculus,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",,Expert,,CHEMBL620438,,10090.0,625.0,1,1,A9,F,,,BAO_0000219,13038
80024,,N,,,6556,Mus musculus,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,,Expert,,CHEMBL620439,,10090.0,625.0,1,1,A9,F,,,BAO_0000219,13038
80024,,N,,,6557,Mus musculus,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,,Expert,,CHEMBL619657,,10090.0,625.0,1,1,A9,F,,,BAO_0000219,10923
80024,,N,,,6558,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,,Intermediate,,CHEMBL619658,,10090.0,625.0,1,1,A9,F,,,BAO_0000219,10923
80024,,N,,,6559,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,,Intermediate,,CHEMBL619659,,10090.0,625.0,1,1,A9,F,,,BAO_0000219,10923
10649,,H,,,6560,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",,Expert,,CHEMBL619660,,,,8,1,,F,,,BAO_0000019,10923
80024,,N,,,6561,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,,Intermediate,,CHEMBL619661,,10090.0,625.0,1,1,A9,F,,,BAO_0000219,10923
80024,,N,,,6562,Mus musculus,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,,Intermediate,,CHEMBL619662,,10090.0,625.0,1,1,A9,F,,,BAO_0000219,10923
80663,,N,,,6563,Cricetulus griseus,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,,Intermediate,,CHEMBL619663,,10029.0,975.0,1,1,AA6,F,,,BAO_0000219,8158
22226,,U,,,6564,Homo sapiens,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,,Autocuration,,CHEMBL619664,,9606.0,,0,1,,F,,,BAO_0000219,15494
22226,,U,,,6565,Homo sapiens,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",,Autocuration,,CHEMBL619665,,9606.0,,0,1,,F,,,BAO_0000219,15494
80662,,N,,,6566,Homo sapiens,Anti -HIV activity was measured against AA5/HIV-1(IIIB),,Intermediate,,CHEMBL883244,,9606.0,974.0,1,1,AA5,F,,,BAO_0000219,12348
80662,,N,,,6567,Homo sapiens,Cytotoxicity was measured against AA5/HIV-1(IIIB),,Intermediate,,CHEMBL884011,,9606.0,974.0,1,1,AA5,F,,,BAO_0000219,12348
80662,,N,,,6568,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,,Intermediate,,CHEMBL619666,,9606.0,974.0,1,1,AA5,F,,,BAO_0000219,2726
80566,,N,,,6569,Homo sapiens,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,,Intermediate,,CHEMBL619667,,9606.0,379.0,1,1,U-937,F,,,BAO_0000219,2726
80578,,N,,,6570,Cricetulus griseus,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,,Intermediate,,CHEMBL619668,,10029.0,274.0,1,1,UV4,F,,,BAO_0000219,10747
80089,,N,,,6571,Cricetulus griseus,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,Expert,,CHEMBL619669,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,11005
80089,,N,,,6572,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6,,Intermediate,,CHEMBL876608,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12687
80089,,N,,,6573,Cricetulus griseus,Average intracellular compound concentration when the hypoxic SER=1.6.,,Intermediate,,CHEMBL619670,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12687
80089,,N,,,6574,Cricetulus griseus,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,,Intermediate,,CHEMBL619671,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12687
80089,,N,,,6575,Cricetulus griseus,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,,Intermediate,,CHEMBL619672,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12687
80089,,N,,,6576,Cricetulus griseus,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,,Intermediate,,CHEMBL619673,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12687
80089,,N,,,6577,Cricetulus griseus,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",,Intermediate,,CHEMBL619674,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,13436
80089,,N,,,6578,Cricetulus griseus,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",,Intermediate,,CHEMBL619675,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,13435
80089,,N,,,6579,Cricetulus griseus,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,,Intermediate,,CHEMBL619676,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,13302
80089,,N,,,6580,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,Intermediate,,CHEMBL619677,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12687
80089,,N,,,6581,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,,Intermediate,,CHEMBL619678,,10029.0,185.0,1,1,CHO-AA8,A,,,BAO_0000219,12687
80089,,N,,,6582,Cricetulus griseus,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,,Intermediate,,CHEMBL619679,,10029.0,185.0,1,1,CHO-AA8,A,,,BAO_0000219,12687
80089,,N,,,6583,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,,Expert,,CHEMBL619680,,10029.0,185.0,1,1,CHO-AA8,A,,,BAO_0000219,12878
80089,,N,,,6584,Cricetulus griseus,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,,Intermediate,,CHEMBL621457,,10029.0,185.0,1,1,CHO-AA8,A,,,BAO_0000219,12878
80089,,N,,,6585,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,,Expert,,CHEMBL876609,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,14367
80089,,N,,,6586,Cricetulus griseus,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,,Intermediate,,CHEMBL621458,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,14367
80089,,N,,,6587,hampster,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,,Expert,,CHEMBL621459,,36483.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12398
80089,,N,,,6588,Cricetulus griseus,Aerobic growth inhibition in Chinese hamster cell line AA8,,Expert,,CHEMBL621460,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12878
80089,,N,,,6589,Cricetulus griseus,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,,Expert,,CHEMBL621461,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,13820
80089,,N,,,6590,Cricetulus griseus,Inhibition of growth under aerobic conditions in AA8 cells,,Expert,,CHEMBL621462,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,13436
50588,,N,,,6591,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate,,CHEMBL621463,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6084
50588,,N,,,6592,Canis lupus familiaris,Oral bioavailability in dog at 10 mg/kg of the compound,,Intermediate,,CHEMBL621464,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5711
50588,,N,,,6593,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),,Intermediate,,CHEMBL621465,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4353
50588,,N,,,6594,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),,Intermediate,,CHEMBL621466,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4353
50588,,N,,,6595,Canis lupus familiaris,Oral bioavailability in dog (mongrel),,Intermediate,,CHEMBL621467,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17800
50588,,N,,,6596,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate,,CHEMBL621468,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3994
50588,,N,,,6597,Canis lupus familiaris,Oral bioavailability in dog (dose 10 mg/kg),,Intermediate,,CHEMBL876734,In vivo,9615.0,,1,1,,F,,,BAO_0000218,3994
50588,,N,,,6598,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL618476,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5145
50588,,N,,,6599,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),,Intermediate,,CHEMBL618477,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,6600,Canis lupus familiaris,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),,Intermediate,,CHEMBL618478,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,6601,Canis lupus familiaris,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,,Intermediate,,CHEMBL618479,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5983
50588,,N,,,6602,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL618480,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4273
50588,,N,,,6603,Canis lupus familiaris,Bioavailability in dog (dose 3-10 mg/kg),,Intermediate,,CHEMBL618481,In vivo,9615.0,,1,1,,A,,,BAO_0000218,12500
50588,,N,1969.0,,6604,Canis lupus familiaris,The compound was tested for bioavailability of compound in plasma of dog; Complete,Plasma,Intermediate,,CHEMBL618482,In vivo,9615.0,,1,1,,A,,,BAO_0000218,12500
50588,,N,,,6605,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL618483,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3639
50588,,N,,,6606,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL618484,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3880
50588,,N,,,6607,Canis lupus familiaris,Bioavailability in dog,,Intermediate,,CHEMBL618485,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4838
50588,,N,,,6608,Canis lupus familiaris,oral bioavailability was measured in dogs,,Intermediate,,CHEMBL618486,In vivo,9615.0,,1,1,,A,,,BAO_0000218,15600
50588,,N,,,6609,Canis lupus familiaris,Compound was tested for plasma protein binding in dog; Not determined,,Intermediate,,CHEMBL618487,,9615.0,,1,1,,A,,,BAO_0000218,17248
50588,,N,,,6610,Canis lupus familiaris,Compound was tested for plasma protein binding of dog,,Intermediate,,CHEMBL618488,,9615.0,,1,1,,A,,,BAO_0000218,17248
50588,,N,,,6611,Canis lupus familiaris,Compound was tested for plasma protein binding of dog; Not determined,,Intermediate,,CHEMBL876735,,9615.0,,1,1,,A,,,BAO_0000218,17248
50588,,N,,,6612,Canis lupus familiaris,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,,Intermediate,,CHEMBL618489,,9615.0,,1,1,,A,,,BAO_0000218,17443
50588,,N,,,6613,Canis lupus familiaris,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,,Intermediate,,CHEMBL618490,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4186
50588,,N,,,6614,Canis lupus familiaris,Half life was determined,,Intermediate,,CHEMBL618491,,9615.0,,1,1,,A,,,BAO_0000218,3749
50588,,N,,,6615,Canis lupus familiaris,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,,Intermediate,,CHEMBL618492,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3249
50588,,N,,,6616,Canis lupus familiaris,Half life was evaluated in dog,,Intermediate,,CHEMBL873354,,9615.0,,1,1,,A,,,BAO_0000218,3022
50588,,N,,,6617,Canis lupus familiaris,Half life was determined,,Intermediate,,CHEMBL618493,,9615.0,,1,1,,A,,,BAO_0000218,3749
50588,,N,,,6618,Canis lupus familiaris,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),,Intermediate,,CHEMBL618494,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2517
50588,,N,948.0,,6619,Canis lupus familiaris,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),Heart,Intermediate,,CHEMBL618495,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2517
50588,,N,2113.0,,6620,Canis lupus familiaris,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),Kidney,Intermediate,,CHEMBL618496,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2517
50588,,N,2107.0,,6621,Canis lupus familiaris,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),Liver,Intermediate,,CHEMBL618497,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2517
50588,,N,2048.0,,6622,Canis lupus familiaris,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),Lung,Intermediate,,CHEMBL618498,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2517
50588,,N,2106.0,,6623,Canis lupus familiaris,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),Spleen,Intermediate,,CHEMBL618499,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2517
50588,,N,,,6624,Canis lupus familiaris,LogP in dog,,Intermediate,,CHEMBL876736,,9615.0,,1,1,,A,,,BAO_0000218,3639
50588,,N,,,6625,Canis lupus familiaris,Partition coefficient (logP),,Intermediate,,CHEMBL618500,,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,6626,Canis lupus familiaris,Partition coefficient in dog,,Intermediate,,CHEMBL857831,,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,6627,Canis lupus familiaris,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,,Intermediate,,CHEMBL618501,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17764
50588,,N,,,6628,Canis lupus familiaris,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),,Intermediate,,CHEMBL618502,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4809
50588,,N,,,6629,Canis lupus familiaris,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,,Intermediate,,CHEMBL618503,,9615.0,,1,1,,A,,,BAO_0000218,5600
50588,,N,,,6630,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),,Intermediate,,CHEMBL618504,,9615.0,,1,1,,A,,,BAO_0000218,14294
50588,,N,,,6631,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),,Intermediate,,CHEMBL618505,,9615.0,,1,1,,A,,,BAO_0000218,14294
50588,,N,,,6632,Canis lupus familiaris,Metabolism of compound in dog S9 microsomes; Trace,,Intermediate,,CHEMBL618506,,9615.0,,1,1,,A,,,BAO_0000218,14294
50588,,N,2107.0,,6633,Canis lupus familiaris,In vitro metabolic potential in dog liver microsomes,Liver,Intermediate,,CHEMBL618507,,9615.0,,1,1,,A,,,BAO_0000218,6251
50588,,N,,,6634,Canis lupus familiaris,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,,Intermediate,,CHEMBL876737,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3748
50588,,N,,,6635,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL618508,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2713
50588,,N,,,6636,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL618509,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6512
50588,,N,,,6637,Canis lupus familiaris,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Intermediate,,CHEMBL618510,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6679
50588,,N,,,6638,Canis lupus familiaris,The compound was tested for bioavailability in dogs,,Intermediate,,CHEMBL618511,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3749
50588,,N,,,6639,Canis lupus familiaris,The compound was tested for oral bioavailability in dogs,,Intermediate,,CHEMBL618512,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3749
50588,,N,,,6640,Canis lupus familiaris,Oral bioavailability in dog,,Intermediate,,CHEMBL618513,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6742
50588,,N,,,6641,Canis lupus familiaris,Compound was tested for percent protein binding (PB) in dog,,Intermediate,,CHEMBL618514,,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,6642,Canis lupus familiaris,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,,Intermediate,,CHEMBL620052,,9615.0,,1,1,,A,,,BAO_0000218,6874
50588,,N,1969.0,,6643,Canis lupus familiaris,Compound was evaluated for plasma clearance.,Plasma,Intermediate,,CHEMBL620053,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2877
50588,,N,1969.0,,6644,Canis lupus familiaris,The compound was tested for plasma clearance in dog,Plasma,Intermediate,,CHEMBL620054,In vivo,9615.0,,1,1,,A,,,BAO_0000218,12500
50588,,N,1969.0,,6645,Canis lupus familiaris,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,Plasma,Intermediate,,CHEMBL620055,In vivo,9615.0,,1,1,,A,,,BAO_0000218,12500
50588,,N,,,6646,Canis lupus familiaris,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,,Intermediate,,CHEMBL620056,,9615.0,,1,1,,A,,,BAO_0000218,4709
50588,,N,2107.0,,6647,Canis lupus familiaris,In vitro relative rate of metabolism was determined in dog liver microsomes,Liver,Intermediate,,CHEMBL620057,,9615.0,,1,1,,A,,,BAO_0000218,5542
50588,,N,,,6648,Canis lupus familiaris,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,,Intermediate,,CHEMBL618939,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17594
50588,,N,,,6649,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,Intermediate,,CHEMBL618940,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2652
50588,,N,,,6650,Canis lupus familiaris,Half life after intravenous administration in dogs at 1.2 uM/kg,,Intermediate,,CHEMBL618941,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17764
50594,,N,2048.0,,6651,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,Lung,Intermediate,,CHEMBL624473,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2048.0,,6652,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,Lung,Intermediate,,CHEMBL624474,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,2048.0,,6653,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,Lung,Intermediate,,CHEMBL624475,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6654,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,,Intermediate,,CHEMBL624476,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6655,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,,Intermediate,,CHEMBL623478,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6656,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,,Intermediate,,CHEMBL623479,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6657,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,,Intermediate,,CHEMBL623480,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,,,6658,Mus musculus,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,,Intermediate,,CHEMBL623481,,10090.0,42.0,1,1,CCRF S-180,A,,,BAO_0000218,6599
50594,,N,955.0,,6659,Mus musculus,C2 in brain of mice at the oral dose of 50 mg/kg,Brain,Intermediate,,CHEMBL623482,,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2113.0,,6660,Mus musculus,C2 in kidney of mice at the oral dose of 50 mg/kg,Kidney,Intermediate,,CHEMBL623483,,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2107.0,,6661,Mus musculus,C2 in liver of mice at the oral dose of 50 mg/kg,Liver,Intermediate,,CHEMBL623484,,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2048.0,,6662,Mus musculus,C2 in lungs of mice at the oral dose of 50 mg/kg,Lung,Intermediate,,CHEMBL623485,,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2106.0,,6663,Mus musculus,C2 in spleen of mice at the oral dose of 50 mg/kg,Spleen,Intermediate,,CHEMBL623486,,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,,,6664,Mus musculus,Plasma clearance in mouse,,Intermediate,,CHEMBL623487,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17852
50594,,N,,,6665,Mus musculus,Clearance of compound after intravenous administration in mice at 24 uM/kg,,Intermediate,,CHEMBL623488,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17764
50594,,N,,,6666,Mus musculus,Clearance from mouse blood following i.v. administration of 10 mg/kg,,Intermediate,,CHEMBL623489,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17837
50594,,N,,,6667,Mus musculus,Clearance was evaluated in mice after intravenous administration,,Intermediate,,CHEMBL875157,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,,,6668,Mus musculus,Clearance was evaluated in mice after oral administration,,Intermediate,,CHEMBL623490,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,,,6669,Mus musculus,Pharmacokinetic property (Plasma clearance) was measured in mouse,,Intermediate,,CHEMBL623491,In vivo,10090.0,,1,1,,A,,,BAO_0000218,4239
50594,,N,,,6670,Mus musculus,Plasma clearance of compound was determined at 40 mg/Kg,,Intermediate,,CHEMBL623492,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,6671,Mus musculus,Plasma clearance of at 24 mg/Kg,,Intermediate,,CHEMBL623493,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,6672,Mus musculus,Plasma clearance at 24 mg/Kg,,Intermediate,,CHEMBL623494,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,6673,Mus musculus,Plasma clearance at 5 mg/Kg,,Intermediate,,CHEMBL623495,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,6674,Mus musculus,Plasma clearance in mice,,Intermediate,,CHEMBL623496,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5727
50594,,N,,,6675,Mus musculus,Plasma clearance value upon iv administration in mouse,,Intermediate,,CHEMBL623497,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2862
50594,,N,1969.0,,6676,Mus musculus,Total plasma clearance in mice,Plasma,Intermediate,,CHEMBL623498,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5980
50594,,N,,,6677,Mus musculus,Clearance in mouse,,Intermediate,,CHEMBL623499,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17592
50594,,N,,,6678,Mus musculus,Clearance value was determined,,Intermediate,,CHEMBL623500,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17718
50594,,N,,,6679,Mus musculus,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate,,CHEMBL623501,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
22229,,U,,,6680,,Calculated partition coefficient (clogP),,Intermediate,,CHEMBL875158,,,,0,1,,P,,,BAO_0000100,17384
50594,,N,,,6681,Mus musculus,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,,Intermediate,,CHEMBL623502,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6062
50594,,N,,,6682,Mus musculus,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,,Intermediate,,CHEMBL623503,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17734
50594,,N,,,6683,Mus musculus,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Intermediate,,CHEMBL623504,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6348
50594,,N,,,6684,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,,Intermediate,,CHEMBL623505,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,6685,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,,Intermediate,,CHEMBL623506,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,6686,Mus musculus,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,,Intermediate,,CHEMBL623507,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,6687,Mus musculus,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,,Intermediate,,CHEMBL623508,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,6688,Mus musculus,Cmax after oral administration at 30 mg/kg in ICR mouse,,Intermediate,,CHEMBL623509,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5781
50594,,N,,,6689,Mus musculus,Cmax after peroral administration in mice at 2.4 uM/kg,,Intermediate,,CHEMBL875159,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17764
50594,,N,955.0,,6690,Mus musculus,Cmax in brain of mice at the oral dose of 50 mg/kg,Brain,Intermediate,,CHEMBL623510,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2113.0,,6691,Mus musculus,Cmax in kidney of mice at the oral dose of 50 mg/kg,Kidney,Intermediate,,CHEMBL623511,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2107.0,,6692,Mus musculus,Cmax in liver of mice at the oral dose of 50 mg/kg,Liver,Intermediate,,CHEMBL623512,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,2048.0,,6693,Mus musculus,Cmax in lungs of mice at the oral dose of 50 mg/kg,Lung,Intermediate,,CHEMBL623513,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,,,6694,Mus musculus,Cmax in mice at 18 uM/kg i.p. administration,,Intermediate,,CHEMBL623514,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,6695,Mus musculus,Cmax in mice at 23 uM/kg i.v. administration,,Intermediate,,CHEMBL622609,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,6696,Mus musculus,Cmax in mice at 24 uM/kg i.p. administration,,Intermediate,,CHEMBL622610,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,6697,Mus musculus,Cmax in mice at 25 uM/kg i.p. administration,,Intermediate,,CHEMBL621823,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,,,6698,Mus musculus,Cmax in mice at 26 uM/kg i.p. administration,,Intermediate,,CHEMBL621824,In vivo,10090.0,,1,1,,F,,,BAO_0000218,17764
50594,,N,2106.0,,6699,Mus musculus,Cmax in spleen of mice at the oral dose of 50 mg/kg,Spleen,Intermediate,,CHEMBL621825,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17641
50594,,N,,,6700,Mus musculus,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,,Intermediate,,CHEMBL621826,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,6701,Mus musculus,Cmax value at a dose of 10 mg/kg peroral administration in mice.,,Intermediate,,CHEMBL621827,In vivo,10090.0,,1,1,,A,,,BAO_0000218,16597
50594,,N,,,6702,Mus musculus,Cmax value was determined,,Intermediate,,CHEMBL621828,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5727
50594,,N,,,6703,Mus musculus,Cmax value in IRC mice,,Intermediate,,CHEMBL621829,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5951
50594,,N,,,6704,Mus musculus,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,,Intermediate,,CHEMBL621830,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5506
50594,,N,,,6705,Mus musculus,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,,Intermediate,,CHEMBL621831,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5506
50594,,N,1969.0,,6706,Mus musculus,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,Plasma,Intermediate,,CHEMBL621832,In vivo,10090.0,,1,1,,A,,,BAO_0000218,14239
50594,,N,1969.0,,6707,Mus musculus,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",Plasma,Intermediate,,CHEMBL624579,In vivo,10090.0,,1,1,,A,,,BAO_0000218,4890
50594,,N,,,6708,Mus musculus,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,,Intermediate,,CHEMBL624580,In vivo,10090.0,,1,1,,A,,,BAO_0000218,429
50535,,N,,,6709,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,,Intermediate,,CHEMBL624581,,6277.0,,1,1,,F,,,BAO_0000218,10986
50535,,N,,,6710,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,,Intermediate,,CHEMBL624582,,6277.0,,1,1,,F,,,BAO_0000218,10986
50535,,N,,,6711,Acanthocheilonema viteae,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,,Intermediate,,CHEMBL624583,,6277.0,,1,1,,F,,,BAO_0000218,10986
80018,,N,,,6712,Homo sapiens,Inhibitory activity against human tumor cell line A0375 melanoma.,,Intermediate,,CHEMBL624584,,9606.0,455.0,1,1,A-375,F,,,BAO_0000219,13227
12512,,D,,,6713,Rattus norvegicus,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,,Expert,,CHEMBL624585,,10116.0,,9,1,,B,,Brain membranes,BAO_0000249,4481
114,,D,,,6714,Homo sapiens,Forskolin-induced cAMP production at human A1 adenosine receptor,,Expert,,CHEMBL875165,,9606.0,,9,1,,F,,,BAO_0000019,16931
114,,H,,,6715,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,,Autocuration,,CHEMBL619490,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6716,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,Autocuration,,CHEMBL619491,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6717,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,,Expert,,CHEMBL619492,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6718,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,,Expert,,CHEMBL619493,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6719,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,,Autocuration,,CHEMBL619494,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6720,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,,Autocuration,,CHEMBL619495,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6721,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,,Autocuration,,CHEMBL619496,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,D,,,6722,Homo sapiens,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,,Expert,,CHEMBL619497,,9606.0,449.0,9,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6723,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,,Autocuration,,CHEMBL619498,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6724,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,,Autocuration,,CHEMBL619499,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6725,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,,Expert,,CHEMBL619500,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6726,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,,Autocuration,,CHEMBL619501,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6727,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,,Expert,,CHEMBL619502,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6728,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,,Autocuration,,CHEMBL619503,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6729,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,Autocuration,,CHEMBL619504,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6730,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,,Autocuration,,CHEMBL621298,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6731,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,,Expert,,CHEMBL621299,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6732,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,,Autocuration,,CHEMBL621300,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6733,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,,Autocuration,,CHEMBL621301,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
114,,H,,,6734,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,,Expert,,CHEMBL621302,,,449.0,8,1,CHO,F,,,BAO_0000219,3850
80013,,N,,,6735,Oryctolagus cuniculus,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,,Intermediate,,CHEMBL621303,,9986.0,164.0,1,1,A10,F,,,BAO_0000219,12680
22226,,U,,,6736,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells,,Autocuration,,CHEMBL621304,,10116.0,164.0,0,1,A10,F,,,BAO_0000219,1313
22226,,U,,,6737,Rattus norvegicus,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,,Autocuration,,CHEMBL621305,,10116.0,164.0,0,1,A10,F,,,BAO_0000219,1313
80013,,N,,,6738,Rattus norvegicus,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,,Intermediate,,CHEMBL621306,,10116.0,164.0,1,1,A10,F,,,BAO_0000219,17567
80013,,N,,,6739,Rattus norvegicus,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,,Intermediate,,CHEMBL618444,,10116.0,164.0,1,1,A10,F,,,BAO_0000219,17567
80013,,N,,,6740,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,,Intermediate,,CHEMBL618445,,10116.0,164.0,1,1,A10,F,,,BAO_0000219,11819
80089,,N,,,6741,Cricetulus griseus,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,,Intermediate,,CHEMBL618446,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,13436
80089,,N,,,6742,Cricetulus griseus,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,,Intermediate,,CHEMBL618447,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12687
80089,,N,,,6743,Cricetulus griseus,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,,Intermediate,,CHEMBL618448,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12651
80089,,N,,,6744,Cricetulus griseus,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,,Intermediate,,CHEMBL618449,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,13300
80089,,N,,,6745,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,Intermediate,,CHEMBL618637,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,15296
80089,,N,,,6746,Cricetulus griseus,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",,Intermediate,,CHEMBL618638,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,15328
80089,,N,,,6747,Cricetulus griseus,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),,Intermediate,,CHEMBL618639,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,13302
80089,,N,,,6748,Cricetulus griseus,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",,Expert,,CHEMBL618640,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,14367
80089,,N,,,6749,Cricetulus griseus,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,,Expert,,CHEMBL618641,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,17002
80089,,N,,,6750,Cricetulus griseus,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,,Intermediate,,CHEMBL618642,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,13436
80089,,N,,,6751,Cricetulus griseus,Inhibitory activity against aerobic growth of AA8 cells.,,Intermediate,,CHEMBL618643,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,13435
80089,,N,,,6752,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Intermediate,,CHEMBL884013,,10029.0,185.0,1,1,CHO-AA8,A,,,BAO_0000219,10503
80089,,N,,,6753,Cricetulus griseus,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Expert,,CHEMBL622723,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,10503
80089,,N,,,6754,Cricetulus griseus,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,,Intermediate,,CHEMBL622724,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,10503
80089,,N,,,6755,Cricetulus griseus,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,,Expert,,CHEMBL622725,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,15090
80089,,N,,,6756,Cricetulus griseus,Cytotoxicity against AA8 cell line,,Expert,,CHEMBL622726,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,10368
80089,,N,,,6757,Cricetulus griseus,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),,Intermediate,,CHEMBL622727,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12651
80089,,N,,,6758,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Intermediate,,CHEMBL622728,,10029.0,185.0,1,1,CHO-AA8,A,,,BAO_0000219,12687
80089,,N,,,6759,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Intermediate,,CHEMBL622729,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,12687
80089,,N,,,6760,Cricetulus griseus,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),,Intermediate,,CHEMBL622730,,10029.0,185.0,1,1,CHO-AA8,A,,,BAO_0000219,12687
80089,,N,,,6761,Cricetulus griseus,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,,Intermediate,,CHEMBL622731,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,1890
80089,,N,,,6762,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,Intermediate,,CHEMBL622732,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,10747
80089,,N,,,6763,Cricetulus griseus,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,,Intermediate,,CHEMBL622733,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,10747
22224,,U,,,6764,Cricetulus griseus,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),,Autocuration,,CHEMBL622734,,10029.0,,0,1,,F,,,BAO_0000218,11616
80089,,N,,,6765,Cricetulus griseus,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,,Expert,,CHEMBL622735,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,11616
22224,,U,,,6766,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,,Autocuration,,CHEMBL618746,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,3471
22224,,U,,,6767,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,,Autocuration,,CHEMBL618747,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,3471
22224,,U,,,6768,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,,Autocuration,,CHEMBL620540,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,3471
22224,,U,,,6769,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,,Autocuration,,CHEMBL620541,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,3471
22224,,U,,,6770,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,,Autocuration,,CHEMBL620542,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,3471
22224,,U,,,6771,Cricetulus griseus,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,,Autocuration,,CHEMBL620543,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,3471
22224,,U,,,6772,Cricetulus griseus,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,,Autocuration,,CHEMBL618832,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,3471
80089,,N,,,6773,Cricetulus griseus,Concentration required to reduce AA8 cell survival by 10%,,Expert,,CHEMBL618833,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,11616
22224,,U,,,6774,Cricetulus griseus,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",,Autocuration,,CHEMBL618834,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,2656
22224,,U,,,6775,Cricetulus griseus,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,Autocuration,,CHEMBL618835,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,10518
22224,,U,,,6776,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,,Autocuration,,CHEMBL618836,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,10518
22224,,U,,,6777,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,,Autocuration,,CHEMBL618837,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,10518
22224,,U,,,6778,Cricetulus griseus,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,,Autocuration,,CHEMBL618838,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,10518
22224,,U,,,6779,Cricetulus griseus,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,,Autocuration,,CHEMBL618839,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,16156
22224,,U,,,6780,Cricetulus griseus,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,,Autocuration,,CHEMBL618840,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,2656
22224,,U,,,6781,Cricetulus griseus,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",,Autocuration,,CHEMBL618841,,10029.0,,0,1,,F,,,BAO_0000019,11005
22224,,U,,,6782,Cricetulus griseus,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,,Autocuration,,CHEMBL618842,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,11942
22224,,U,,,6783,Cricetulus griseus,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,,Autocuration,,CHEMBL618843,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,2128
50588,,N,,,6784,Canis lupus familiaris,Half life period after 15 mg/kg iv dose in Dogs,,Intermediate,,CHEMBL618844,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,6785,Canis lupus familiaris,Half life period after 30 mg/kg po dose in Dogs,,Intermediate,,CHEMBL618845,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,6786,Canis lupus familiaris,Half life was measured after oral 2b administration (tested in 6 dogs),,Intermediate,,CHEMBL618846,In vivo,9615.0,,1,1,,A,,,BAO_0000218,9579
50588,,N,,,6787,Canis lupus familiaris,Half life was measured in dog after oral 17b administration,,Intermediate,,CHEMBL618847,In vivo,9615.0,,1,1,,A,,,BAO_0000218,9579
50588,,N,,,6788,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,,Intermediate,,CHEMBL618848,In vivo,9615.0,,1,1,,A,,,BAO_0000218,9579
50588,,N,,,6789,Canis lupus familiaris,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,,Intermediate,,CHEMBL618849,In vivo,9615.0,,1,1,,A,,,BAO_0000218,9579
50588,,N,,,6790,Canis lupus familiaris,Tmax value after 15 mg/kg iv dose in Dogs,,Intermediate,,CHEMBL618850,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,6791,Canis lupus familiaris,Tmax value after 30 mg/kg po dose in Dogs,,Intermediate,,CHEMBL618851,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,6792,Canis lupus familiaris,Compound was evaluated for its half life when administered intravenously in dog,,Intermediate,,CHEMBL873815,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3184
50588,,N,1969.0,,6793,Canis lupus familiaris,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),Plasma,Intermediate,,CHEMBL618852,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5017
50588,,N,,,6794,Canis lupus familiaris,Elimination Half-life of compound was determined in dog,,Intermediate,,CHEMBL618853,,9615.0,,1,1,,A,,,BAO_0000218,6821
50588,,N,,,6795,Canis lupus familiaris,Half life of compound in dog following oral administration,,Intermediate,,CHEMBL618854,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,,,6796,Canis lupus familiaris,Half life of compound was determined in dog,,Intermediate,,CHEMBL618855,,9615.0,,1,1,,A,,,BAO_0000218,17267
50588,,N,178.0,,6797,Canis lupus familiaris,Half life of compound was determined in dog blood,Blood,Intermediate,,CHEMBL618856,,9615.0,,1,1,,A,,,BAO_0000218,4727
50588,,N,,,6798,Canis lupus familiaris,Half life after oral and iv dosing in dogs,,Intermediate,,CHEMBL875827,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5238
50588,,N,,,6799,Canis lupus familiaris,Half life in dogs in hours,,Intermediate,,CHEMBL618857,,9615.0,,1,1,,A,,,BAO_0000218,4942
50588,,N,,,6800,Canis lupus familiaris,Half life on i.v. administration of 2 mg/kg was measured in dog,,Intermediate,,CHEMBL618858,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6505
50588,,N,,,6801,Canis lupus familiaris,t1/2 in dog after oral dose (1 mg/kg),,Intermediate,,CHEMBL618859,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5130
50588,,N,,,6802,Canis lupus familiaris,Half life was evaluated in dog,,Intermediate,,CHEMBL618860,,9615.0,,1,1,,A,,,BAO_0000218,1475
50588,,N,,,6803,Canis lupus familiaris,Half life period of compound was determined after intravenous administration at 2 mg/kg,,Intermediate,,CHEMBL618861,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17804
50588,,N,,,6804,Canis lupus familiaris,Half life period of compound was determined after peroral administration at 2 mg/kg,,Intermediate,,CHEMBL622539,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17804
50588,,N,,,6805,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,,Intermediate,,CHEMBL622540,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6084
50588,,N,,,6806,Canis lupus familiaris,Half life period (10 mg/kg) was determined in dog,,Intermediate,,CHEMBL873803,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6084
50588,,N,,,6807,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 0.3 mg/kg,,Intermediate,,CHEMBL873804,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5542
50588,,N,,,6808,Canis lupus familiaris,Half life period by po administration in dog at a dose of 0.3 mg/kg,,Intermediate,,CHEMBL624311,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5542
50588,,N,,,6809,Canis lupus familiaris,Half life period in dog,,Intermediate,,CHEMBL624312,,9615.0,,1,1,,A,,,BAO_0000218,6084
50588,,N,,,6810,Canis lupus familiaris,Half life period in dogs after oral administration at 1 mg/kg,,Intermediate,,CHEMBL624313,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6241
50588,,N,,,6811,Canis lupus familiaris,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Intermediate,,CHEMBL624314,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1916
50588,,N,,,6812,Canis lupus familiaris,Half-life of compound was determined in dogs,,Intermediate,,CHEMBL624315,,9615.0,,1,1,,A,,,BAO_0000218,6621
50588,,N,1969.0,,6813,Canis lupus familiaris,Half-life in dog plasma,Plasma,Intermediate,,CHEMBL624316,,9615.0,,1,1,,A,,,BAO_0000218,1696
50588,,N,,,6814,Canis lupus familiaris,Half-life in mongrel dogs was determined,,Intermediate,,CHEMBL624317,,9615.0,,1,1,,A,,,BAO_0000218,17800
50588,,N,,,6815,Canis lupus familiaris,Half-life in dog upon oral administration,,Intermediate,,CHEMBL624318,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17657
50588,,N,,,6816,Canis lupus familiaris,Half-life in dog upon oral administration; Unable to calculate,,Intermediate,,CHEMBL624319,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17657
50588,,N,,,6817,Canis lupus familiaris,Half-life was measured in dog,,Intermediate,,CHEMBL624496,,9615.0,,1,1,,A,,,BAO_0000218,4239
50588,,N,,,6818,Canis lupus familiaris,Half-life was measured in dog,,Intermediate,,CHEMBL624497,,9615.0,,1,1,,A,,,BAO_0000218,5985
50588,,N,,,6819,Canis lupus familiaris,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,,Intermediate,,CHEMBL624498,,9615.0,,1,1,,A,,,BAO_0000218,9932
50588,,N,,,6820,Canis lupus familiaris,Oral half life was determined,,Intermediate,,CHEMBL624499,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5199
50588,,N,1969.0,,6821,Canis lupus familiaris,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,Plasma,Intermediate,,CHEMBL624500,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5199
50588,,N,1969.0,,6822,Canis lupus familiaris,Plasma half life was evaluated,Plasma,Intermediate,,CHEMBL624501,,9615.0,,1,1,,A,,,BAO_0000218,1475
50588,,N,1969.0,,6823,Canis lupus familiaris,Plasma half life was evaluated in Dog,Plasma,Intermediate,,CHEMBL623666,,9615.0,,1,1,,A,,,BAO_0000218,1475
50588,,N,1969.0,,6824,Canis lupus familiaris,Plasma half life was evaluated in dog,Plasma,Intermediate,,CHEMBL623667,,9615.0,,1,1,,A,,,BAO_0000218,1475
50588,,N,,,6825,Canis lupus familiaris,T1/2 (Half-life) was after oral administration at 5 mg/kg,,Intermediate,,CHEMBL623668,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6316
50588,,N,,,6826,Canis lupus familiaris,Tested for the half life value in dog,,Intermediate,,CHEMBL623669,,9615.0,,1,1,,A,,,BAO_0000218,4883
50588,,N,,,6827,Canis lupus familiaris,Maximum time at the dose of 2 mg/kg in dog,,Intermediate,,CHEMBL623670,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4727
50588,,N,,,6828,Canis lupus familiaris,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,,Intermediate,,CHEMBL623671,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1916
50588,,N,178.0,,6829,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Blood,Intermediate,,CHEMBL875945,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1337
50588,,N,178.0,,6830,Canis lupus familiaris,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Blood,Intermediate,,CHEMBL623672,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1337
50588,,N,,,6831,Canis lupus familiaris,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,,Intermediate,,CHEMBL623673,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6265
50588,,N,,,6832,Canis lupus familiaris,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),,Intermediate,,CHEMBL623674,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4809
50588,,N,,,6833,Canis lupus familiaris,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,,Intermediate,,CHEMBL623675,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5983
50588,,N,,,6834,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",,Intermediate,,CHEMBL872526,,9615.0,,1,1,,A,,,BAO_0000218,5313
50588,,N,,,6835,Canis lupus familiaris,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",,Intermediate,,CHEMBL623676,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5313
50588,,N,1969.0,,6836,Canis lupus familiaris,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,Plasma,Intermediate,,CHEMBL623677,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17650
50588,,N,1969.0,,6837,Canis lupus familiaris,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,Plasma,Intermediate,,CHEMBL623678,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5199
50588,,N,1969.0,,6838,Canis lupus familiaris,Time taken for maximum plasma concentration in dog,Plasma,Intermediate,,CHEMBL623679,,9615.0,,1,1,,A,,,BAO_0000218,933
50588,,N,,,6839,Canis lupus familiaris,Time to reach Cmax after oral administration to dogs,,Intermediate,,CHEMBL623680,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16367
50588,,N,1969.0,,6840,Canis lupus familiaris,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,Plasma,Intermediate,,CHEMBL623681,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6348
50588,,N,,,6841,Canis lupus familiaris,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,,Intermediate,,CHEMBL623682,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6316
50588,,N,,,6842,Canis lupus familiaris,Tmax after peroral administration (1 mg/kg) was determined in dog,,Intermediate,,CHEMBL623683,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6215
50588,,N,,,6843,Canis lupus familiaris,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,,Expert,,CHEMBL623684,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3598
50588,,N,,,6844,Canis lupus familiaris,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,,Intermediate,,CHEMBL622745,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4527
50588,,N,,,6845,Canis lupus familiaris,Tmax after peroral administration in dogs at 2.4 uM/kg,,Intermediate,,CHEMBL622746,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17764
50594,,N,,,6846,Mus musculus,In vivo Cmax in mice at dose of 100 mg/kg,,Intermediate,,CHEMBL622747,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,6847,Mus musculus,In vivo Cmax in mice at dose of 50 mg/kg,,Intermediate,,CHEMBL622748,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5969
50594,,N,,,6848,Mus musculus,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,,Intermediate,,CHEMBL622749,In vivo,10090.0,,1,1,,A,,,BAO_0000218,4573
50594,,N,1969.0,,6849,Mus musculus,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),Plasma,Intermediate,,CHEMBL622750,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3277
50594,,N,1969.0,,6850,Mus musculus,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,Plasma,Intermediate,,CHEMBL623411,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17734
50594,,N,1969.0,,6851,Mus musculus,Maximum concentration obtained in mouse plasma was determined,Plasma,Intermediate,,CHEMBL875946,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3132
50594,,N,1969.0,,6852,Mus musculus,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,Plasma,Intermediate,,CHEMBL623412,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3132
50594,,N,1969.0,,6853,Mus musculus,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,Plasma,Intermediate,,CHEMBL623413,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6348
50594,,N,1969.0,,6854,Mus musculus,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,Plasma,Intermediate,,CHEMBL623414,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17729
50594,,N,1969.0,,6855,Mus musculus,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,Plasma,Intermediate,,CHEMBL623415,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17729
50594,,N,1969.0,,6856,Mus musculus,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,Plasma,Intermediate,,CHEMBL623416,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17729
50594,,N,1969.0,,6857,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,Plasma,Intermediate,,CHEMBL623417,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17728
50594,,N,1969.0,,6858,Mus musculus,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,Plasma,Intermediate,,CHEMBL623418,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17728
50594,,N,1969.0,,6859,Mus musculus,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,Plasma,Intermediate,,CHEMBL623419,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17728
50594,,N,,,6860,Mus musculus,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,,Intermediate,,CHEMBL622816,In vivo,10090.0,,1,1,,A,,,BAO_0000218,4066
50594,,N,,,6861,Mus musculus,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,,Intermediate,,CHEMBL623313,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6178
50594,,N,,,6862,Mus musculus,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,,Intermediate,,CHEMBL623314,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6178
50594,,N,,,6863,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,,Intermediate,,CHEMBL876788,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3760
50594,,N,,,6864,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,,Intermediate,,CHEMBL623315,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3760
50594,,N,,,6865,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,,Intermediate,,CHEMBL623316,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3760
50594,,N,,,6866,Mus musculus,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,,Intermediate,,CHEMBL623317,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3760
50594,,N,,,6868,Mus musculus,Cmax in male mice after 2 mg/kg oral dose,,Intermediate,,CHEMBL623319,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5961
50594,,N,,,6869,Mus musculus,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,,Intermediate,,CHEMBL623320,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6137
50594,,N,,,6870,Mus musculus,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,,Intermediate,,CHEMBL623321,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3802
50594,,N,,,6871,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,,Intermediate,,CHEMBL623322,,10090.0,,1,1,,A,,,BAO_0000218,3535
50594,,N,,,6872,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,,Intermediate,,CHEMBL623323,,10090.0,,1,1,,A,,,BAO_0000218,3535
50594,,N,,,6873,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,,Intermediate,,CHEMBL623324,,10090.0,,1,1,,A,,,BAO_0000218,3535
50594,,N,,,6874,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,,Intermediate,,CHEMBL623325,,10090.0,,1,1,,A,,,BAO_0000218,3535
50594,,N,,,6875,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,,Intermediate,,CHEMBL623326,,10090.0,,1,1,,A,,,BAO_0000218,3535
50594,,N,,,6876,Mus musculus,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,,Intermediate,,CHEMBL623327,,10090.0,,1,1,,A,,,BAO_0000218,3535
50594,,N,1969.0,,6877,Mus musculus,Maximum concentration in plasma upon oral administration in mouse,Plasma,Intermediate,,CHEMBL623328,,10090.0,,1,1,,A,,,BAO_0000218,2862
50594,,N,1969.0,,6878,Mus musculus,Maximum plasma concentration was evaluated in mice after oral administration,Plasma,Intermediate,,CHEMBL623329,,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,1969.0,,6879,Mus musculus,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,Plasma,Intermediate,,CHEMBL623330,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2675
50594,,N,,,6880,Mus musculus,Dose at which the compound induced fecal excretion in mice,,Intermediate,,CHEMBL876789,,10090.0,,1,1,,A,,,BAO_0000218,5399
80013,,N,,,6893,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,,Expert,,CHEMBL623333,,10116.0,164.0,1,1,A10,F,,,BAO_0000219,11819
80013,,N,,,6894,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,,Expert,,CHEMBL623334,,10116.0,164.0,1,1,A10,F,,,BAO_0000219,11819
80013,,N,,,6895,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,,Expert,,CHEMBL627536,,10116.0,164.0,1,1,A10,F,,,BAO_0000219,11819
80013,,N,,,6896,Rattus norvegicus,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,,Expert,,CHEMBL627537,,10116.0,164.0,1,1,A10,F,,,BAO_0000219,11819
80013,,N,,,6897,Rattus norvegicus,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),,Intermediate,,CHEMBL627538,,10116.0,164.0,1,1,A10,F,,,BAO_0000219,16361
80655,,N,,,6898,Homo sapiens,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,,Intermediate,,CHEMBL884106,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,2288
80655,,N,,,6899,Homo sapiens,Anticancer activity against human ovarian carcinoma A121 cells,,Intermediate,,CHEMBL625294,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,10404
80655,,N,,,6900,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,,Intermediate,,CHEMBL625295,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,14790
80655,,N,,,6901,Homo sapiens,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,,Intermediate,,CHEMBL625296,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,14790
80655,,N,,,6902,Homo sapiens,Growth inhibition of human ovarian carcinoma (A121) cell line,,Expert,,CHEMBL625297,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,14253
80655,,N,,,6903,Homo sapiens,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,,Expert,,CHEMBL625298,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,13617
80655,,N,,,6904,Homo sapiens,Cytotoxicity against human A121 ovarian cells,,Intermediate,,CHEMBL625960,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,1003
80655,,N,,,6905,Homo sapiens,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,,Intermediate,,CHEMBL625961,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,830
80655,,N,,,6906,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma A21,,Intermediate,,CHEMBL625962,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,12307
80655,,N,,,6907,Homo sapiens,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,,Intermediate,,CHEMBL624717,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,14254
80655,,N,,,6908,Homo sapiens,Inhibitory activity of compound against human A121 ovarian cell line.,,Intermediate,,CHEMBL624718,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,13370
80655,,N,,,6909,Homo sapiens,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,,Intermediate,,CHEMBL624719,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,14790
80655,,N,,,6910,Homo sapiens,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,,Intermediate,,CHEMBL624720,,9606.0,393.0,1,1,A121,F,,,BAO_0000219,3614
80012,,N,,,6911,Homo sapiens,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,,Intermediate,,CHEMBL624721,,9606.0,622.0,1,1,A 172,F,,,BAO_0000219,2664
80012,,N,,,6912,Homo sapiens,In vitro cytotoxicity against A172 human tumor cell lines.,,Expert,,CHEMBL624722,,9606.0,622.0,1,1,A 172,F,,,BAO_0000219,2037
80012,,N,,,6913,Homo sapiens,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,,Intermediate,,CHEMBL877597,,9606.0,622.0,1,1,A 172,F,,,BAO_0000219,14539
80012,,N,,,6914,Homo sapiens,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,,Intermediate,,CHEMBL624723,,9606.0,622.0,1,1,A 172,F,,,BAO_0000219,2836
80012,,N,,,6915,Homo sapiens,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,,Intermediate,,CHEMBL624724,,9606.0,622.0,1,1,A 172,F,,,BAO_0000219,10708
104729,,H,,,6916,Canis lupus familiaris,Association constant against A2 adenosine receptor,,Autocuration,,CHEMBL624725,,9615.0,,4,1,,B,,,BAO_0000224,8975
80656,,N,,,6917,fish,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,,Intermediate,,CHEMBL624726,,,1085.0,1,1,A2,F,,,BAO_0000219,7645
104713,,D,,,6918,Rattus norvegicus,Ratio of Ki for adenosine A2 and A1 receptor binding,,Autocuration,,CHEMBL857535,,10116.0,,5,1,,B,,,BAO_0000224,11377
80014,,N,,,6919,Homo sapiens,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,,Expert,,CHEMBL624727,,9606.0,623.0,1,1,A204,F,,,BAO_0000219,13528
80014,,N,,,6920,Homo sapiens,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,,Expert,,CHEMBL624728,,9606.0,623.0,1,1,A204,F,,,BAO_0000219,10160
80015,,N,,,6921,Homo sapiens,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,,Intermediate,,CHEMBL624729,,9606.0,404.0,1,1,A2058,F,,,BAO_0000219,15144
80657,,N,,,6922,Homo sapiens,Growth inhibition against Human squamous cell line(A 253),,Intermediate,,CHEMBL624730,,9606.0,973.0,1,1,A253 cell line,F,,,BAO_0000219,13160
80657,,N,,,6923,Homo sapiens,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,,Intermediate,,CHEMBL624731,,9606.0,973.0,1,1,A253 cell line,F,,,BAO_0000219,12898
80657,,N,,,6924,Homo sapiens,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,,Intermediate,,CHEMBL624732,,9606.0,973.0,1,1,A253 cell line,F,,,BAO_0000219,13069
80657,,N,,,6925,Homo sapiens,Growth inhibition of A253 cell lines.,,Intermediate,,CHEMBL883245,,9606.0,973.0,1,1,A253 cell line,F,,,BAO_0000219,15984
80657,,N,,,6926,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),,Intermediate,,CHEMBL624733,,9606.0,973.0,1,1,A253 cell line,F,,,BAO_0000219,15564
80657,,N,,,6927,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,Intermediate,,CHEMBL624734,,9606.0,973.0,1,1,A253 cell line,F,,,BAO_0000219,15564
80657,,N,,,6928,Homo sapiens,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,,Intermediate,,CHEMBL624735,,9606.0,973.0,1,1,A253 cell line,F,,,BAO_0000219,15564
81034,,N,,,6929,Homo sapiens,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,,Intermediate,,CHEMBL621780,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,4720
81034,,N,,,6930,Homo sapiens,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,,Intermediate,,CHEMBL877598,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16112
81034,,N,,,6931,Homo sapiens,Cytotoxic activity against A2780 human ovarian carcinoma cell line,,Expert,,CHEMBL621781,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16597
81034,,N,,,6932,Homo sapiens,Cytotoxicity against human cancer cell lines A2780 (ovarian),,Intermediate,,CHEMBL621782,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16378
81034,,N,,,6933,Homo sapiens,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,,Expert,,CHEMBL621783,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16085
81034,,N,,,6934,Homo sapiens,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,,Intermediate,,CHEMBL621784,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16317
81034,,N,,,6935,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,Intermediate,,CHEMBL621785,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15748
81034,,N,,,6936,Homo sapiens,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,,Expert,,CHEMBL621968,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16597
81034,,N,,,6937,Homo sapiens,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,,Expert,,CHEMBL621969,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16597
81034,,N,,,6938,Homo sapiens,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,,Expert,,CHEMBL621970,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16597
81034,,N,,,6939,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,,Intermediate,,CHEMBL621971,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15608
81034,,N,,,6940,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,,Intermediate,,CHEMBL621972,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15608
81034,,N,,,6941,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,,Intermediate,,CHEMBL884108,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15608
22224,,U,,,6942,Cricetulus griseus,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,,Autocuration,,CHEMBL623826,,10029.0,,0,1,,F,,,BAO_0000019,15296
22224,,U,,,6943,Cricetulus griseus,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,,Autocuration,,CHEMBL623827,,10029.0,185.0,0,1,CHO-AA8,A,,,BAO_0000219,10251
22224,,U,,,6944,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic conditions,,Autocuration,,CHEMBL623828,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,10251
22224,,U,,,6945,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,,Autocuration,,CHEMBL623829,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,10251
22224,,U,,,6946,Cricetulus griseus,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),,Autocuration,,CHEMBL623830,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,10251
22224,,U,,,6947,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8,,Autocuration,,CHEMBL623831,,10029.0,,0,1,,F,,,BAO_0000019,11858
22224,,U,,,6948,Cricetulus griseus,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],,Autocuration,,CHEMBL623832,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,11858
80089,,N,,,6949,hampster,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,,Expert,,CHEMBL623833,,36483.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,11616
80089,,N,,,6950,Cricetulus griseus,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,,Expert,,CHEMBL623834,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,11616
22224,,U,,,6951,Cricetulus griseus,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,,Autocuration,,CHEMBL623835,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,10518
22224,,U,,,6952,Cricetulus griseus,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,,Autocuration,,CHEMBL623836,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,11396
22224,,U,,,6953,Cricetulus griseus,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,,Autocuration,,CHEMBL623837,,10029.0,185.0,0,1,CHO-AA8,F,,,BAO_0000219,10518
80089,,N,,,6954,Cricetulus griseus,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,,Expert,,CHEMBL623838,,10029.0,185.0,1,1,CHO-AA8,F,,,BAO_0000219,11616
12675,,H,,,6955,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,,Autocuration,,CHEMBL623839,,,,8,1,,F,,,BAO_0000019,14837
12675,,H,,,6956,,Number of binding sites (n) of isolated serum protein AAG,,Autocuration,,CHEMBL623840,,,,8,1,,F,,,BAO_0000019,14837
22222,,M,,,6957,,Association constant for binding to AATT duplex,,Intermediate,,CHEMBL623841,,,,3,1,,B,,,BAO_0000225,16037
100090,,N,,,6958,Homo sapiens,Inhibition of ABAE human fibroblast cell proliferation,,Expert,,CHEMBL623842,,9606.0,416.0,1,1,ABAE,F,,,BAO_0000219,16597
80668,,N,,,6959,Mus musculus,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",,Intermediate,,CHEMBL623843,,10090.0,1064.0,1,1,AC755,F,,,BAO_0000218,8831
102444,,D,,,6960,Oryctolagus cuniculus,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,,Expert,,CHEMBL618669,,9986.0,,9,1,,F,,,BAO_0000218,13419
102444,,D,,,6961,Oryctolagus cuniculus,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,,Expert,,CHEMBL618670,In vivo,9986.0,,9,1,,F,,,BAO_0000218,13419
69,,H,,,6962,,Inhibitory activity against angiotensin-converting enzyme (ACE).,,Autocuration,,CHEMBL618671,,,,8,1,,B,,,BAO_0000357,15778
69,,H,,,6963,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,,Autocuration,,CHEMBL618672,,,,8,1,,B,,,BAO_0000357,15778
80669,,N,,,6964,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,,Intermediate,,CHEMBL618673,,9606.0,978.0,1,1,ACH-2 cell line,F,,,BAO_0000219,12988
80669,,N,,,6965,Homo sapiens,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),,Intermediate,,CHEMBL618674,,9606.0,978.0,1,1,ACH-2 cell line,F,,,BAO_0000219,12988
22224,,U,,,6966,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,,Autocuration,,CHEMBL618675,,11676.0,998.0,0,1,T cell line,F,,,BAO_0000219,12988
22224,,U,,,6967,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),,Autocuration,,CHEMBL618676,,11676.0,998.0,0,1,T cell line,F,,,BAO_0000219,12988
22224,,U,,,6968,Human immunodeficiency virus 1,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),,Autocuration,,CHEMBL618677,,11676.0,998.0,0,1,T cell line,F,,,BAO_0000219,12988
80025,,N,,,6969,Homo sapiens,Inhibition of growth of renal cancer ACHN cell line,,Intermediate,,CHEMBL618678,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,11843
80025,,N,,,6970,Homo sapiens,Inhibition of growth of ACHN renal cancer cell line,,Intermediate,,CHEMBL618679,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,16939
80025,,N,,,6971,Homo sapiens,Inhibitory concentration required against ACHN renal cancer cell line,,Intermediate,,CHEMBL618680,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,4782
80025,,N,,,6972,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line,,Expert,,CHEMBL618681,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,6310
80025,,N,,,6973,Homo sapiens,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,,Intermediate,,CHEMBL618682,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,6310
80025,,N,,,6974,Homo sapiens,Cytotoxic activity against ACHN Renal cancer cell line,,Intermediate,,CHEMBL618683,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,12858
80025,,N,,,6975,Homo sapiens,Cytotoxicity evaluation against ACHN renal cancer cells,,Intermediate,,CHEMBL618684,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,17380
80025,,N,,,6976,Homo sapiens,In vitro antitumor activity against human renal ACHN cell line,,Intermediate,,CHEMBL618685,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,5858
80025,,N,,,6977,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,Intermediate,,CHEMBL876499,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,3838
80025,,N,,,6978,Homo sapiens,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,,Intermediate,,CHEMBL618686,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,3838
80025,,N,,,6979,Homo sapiens,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",,Intermediate,,CHEMBL618687,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,5406
80025,,N,,,6980,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,Intermediate,,CHEMBL618688,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,4071
80025,,N,,,6981,Homo sapiens,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,,Expert,,CHEMBL618689,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,4071
80025,,N,,,6982,Homo sapiens,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,,Intermediate,,CHEMBL618690,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,4071
80025,,N,,,6983,Homo sapiens,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,,Intermediate,,CHEMBL618691,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,15002
80025,,N,,,6984,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,Intermediate,,CHEMBL619373,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,14769
80025,,N,,,6985,Homo sapiens,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",,Intermediate,,CHEMBL884008,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,13958
80025,,N,,,6986,Homo sapiens,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,,Intermediate,,CHEMBL619374,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,1665
80025,,N,,,6987,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line,,Intermediate,,CHEMBL619375,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,15354
80025,,N,,,6988,Homo sapiens,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,,Intermediate,,CHEMBL619376,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,15354
80025,,N,,,6989,Homo sapiens,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,,Intermediate,,CHEMBL619377,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,13978
80025,,N,,,6990,Homo sapiens,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,,Intermediate,,CHEMBL619378,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,6798
50588,,N,,,6991,Canis lupus familiaris,Tmax value after administration of 4 mg/Kg oral dose in dog,,Intermediate,,CHEMBL872527,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2959
50588,,N,,,6992,Canis lupus familiaris,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",,Intermediate,,CHEMBL876500,,9615.0,,1,1,,A,,,BAO_0000218,9932
50588,,N,,,6993,Canis lupus familiaris,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,Intermediate,,CHEMBL619379,,9615.0,,1,1,,A,,,BAO_0000218,5546
50588,,N,,,6994,Canis lupus familiaris,Volume distribution after 15 mg/kg iv dose in Dogs,,Intermediate,,CHEMBL619538,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,6995,Canis lupus familiaris,Volume distribution after 30 mg/kg po dose in Dogs,,Intermediate,,CHEMBL619539,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,6996,Canis lupus familiaris,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,,Intermediate,,CHEMBL619540,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4257
50588,,N,,,6997,Canis lupus familiaris,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,,Intermediate,,CHEMBL619541,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4305
50588,,N,,,6998,Canis lupus familiaris,Volume of distribution was evaluated in dog,,Intermediate,,CHEMBL619542,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5472
50588,,N,,,6999,Canis lupus familiaris,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,,Intermediate,,CHEMBL619543,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6062
50588,,N,,,7000,Canis lupus familiaris,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,,Expert,,CHEMBL619544,,9615.0,,1,1,,A,,,BAO_0000218,3598
50588,,N,,,7001,Canis lupus familiaris,The compound was tested for volume of distribution in dog,,Intermediate,,CHEMBL619545,In vivo,9615.0,,1,1,,A,,,BAO_0000218,12500
50588,,N,,,7002,Canis lupus familiaris,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,,Intermediate,,CHEMBL619546,In vivo,9615.0,,1,1,,A,,,BAO_0000218,12500
50588,,N,,,7003,Canis lupus familiaris,Vd (1 mg/kg) was determined in dog (in vivo),,Intermediate,,CHEMBL619547,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,7004,Canis lupus familiaris,Vd in dog,,Intermediate,,CHEMBL619548,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,7005,Canis lupus familiaris,Volume distribution was determined,,Intermediate,,CHEMBL619549,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4219
50588,,N,,,7006,Canis lupus familiaris,Volume of distribution in dog,,Intermediate,,CHEMBL619550,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1696
50588,,N,,,7007,Canis lupus familiaris,Volume of distribution by as 4 fold increase by iv administration in dogs,,Intermediate,,CHEMBL876501,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5542
50588,,N,,,7008,Canis lupus familiaris,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,,Intermediate,,CHEMBL619551,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5199
50588,,N,,,7009,Canis lupus familiaris,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Intermediate,,CHEMBL619552,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6348
50588,,N,,,7010,Canis lupus familiaris,Volume distribution at the dose of 2 mg/kg in dog,,Intermediate,,CHEMBL619553,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4727
50588,,N,,,7011,Canis lupus familiaris,Steady state volume of distribution was determined,,Intermediate,,CHEMBL618722,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16367
50588,,N,,,7012,Canis lupus familiaris,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,,Intermediate,,CHEMBL618723,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2652
50588,,N,,,7013,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Intermediate,,CHEMBL618724,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,7014,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,Intermediate,,CHEMBL618725,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,7015,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),,Intermediate,,CHEMBL618726,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,7016,Canis lupus familiaris,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),,Intermediate,,CHEMBL618727,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5334
50588,,N,,,7017,Canis lupus familiaris,Pharmacokinetic property (vdss) was measured in dog,,Intermediate,,CHEMBL624233,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4239
50588,,N,,,7018,Canis lupus familiaris,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,,Intermediate,,CHEMBL624234,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4709
50588,,N,,,7019,Canis lupus familiaris,Vdss was determined after iv 0.1 mg/kg administration in dog,,Intermediate,,CHEMBL624235,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5600
50588,,N,,,7020,Canis lupus familiaris,Volume displacement was calculated in dog,,Intermediate,,CHEMBL624236,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6057
50588,,N,,,7021,Canis lupus familiaris,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,Intermediate,,CHEMBL624237,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5654
50588,,N,,,7022,Canis lupus familiaris,Volume distribution constant was determined,,Intermediate,,CHEMBL624238,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5505
50588,,N,,,7023,Canis lupus familiaris,Volume distribution at a dose of 1 uM/kg in dog was determined,,Intermediate,,CHEMBL624239,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4527
50588,,N,,,7024,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,Intermediate,,CHEMBL875829,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4521
50588,,N,,,7025,Canis lupus familiaris,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Intermediate,,CHEMBL624240,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4521
50588,,N,,,7026,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,,Intermediate,,CHEMBL624241,In vivo,9615.0,,1,1,,A,,,BAO_0000218,15660
50588,,N,,,7027,Canis lupus familiaris,Volume distribution (Vdss) was measured in dog,,Intermediate,,CHEMBL624242,In vivo,9615.0,,1,1,,A,,,BAO_0000218,15660
50588,,N,,,7028,Canis lupus familiaris,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Intermediate,,CHEMBL624243,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6679
50588,,N,,,7029,Canis lupus familiaris,Volume of distribution in steady state was determined in dog,,Intermediate,,CHEMBL624244,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5145
50588,,N,,,7030,Canis lupus familiaris,Volume of distribution of compound was determined in dog,,Intermediate,,CHEMBL624245,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6821
50588,,N,,,7031,Canis lupus familiaris,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,,Intermediate,,CHEMBL624246,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4137
50588,,N,,,7032,Canis lupus familiaris,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),,Intermediate,,CHEMBL624247,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5334
50588,,N,,,7033,Canis lupus familiaris,Volume of distribution (Vdss) was measured in dog,,Intermediate,,CHEMBL624248,In vivo,9615.0,,1,1,,A,,,BAO_0000218,15660
50588,,N,,,7034,Canis lupus familiaris,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Intermediate,,CHEMBL624249,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6642
50588,,N,,,7035,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate,,CHEMBL624250,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6641
50588,,N,,,7036,Canis lupus familiaris,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate,,CHEMBL624251,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6642
50588,,N,,,7037,Canis lupus familiaris,Maximum rate of depolarization of the upstroke of the action potential,,Intermediate,,CHEMBL624252,,9615.0,,1,1,,A,,,BAO_0000218,11659
50588,,N,,,7038,Canis lupus familiaris,Steady state volume distribution in dog,,Intermediate,,CHEMBL624253,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6448
50588,,N,,,7039,Canis lupus familiaris,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,,Intermediate,,CHEMBL624950,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5474
50588,,N,,,7040,Canis lupus familiaris,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,,Intermediate,,CHEMBL624951,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1466
50588,,N,,,7041,Canis lupus familiaris,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,,Intermediate,,CHEMBL875830,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,,,7042,Canis lupus familiaris,Volume distribution in dog after administration of 1 mg/kg iv,,Intermediate,,CHEMBL624952,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,,,7043,Canis lupus familiaris,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,,Intermediate,,CHEMBL624953,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17764
50588,,N,,,7044,Canis lupus familiaris,Vss after intravenous administration (0.5 mg/kg) was determined in dog,,Intermediate,,CHEMBL624954,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6215
50588,,N,,,7045,Canis lupus familiaris,Vss on i.v. administration of 2 mg/kg was measured in dog,,Intermediate,,CHEMBL624955,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6505
50588,,N,,,7046,Canis lupus familiaris,Vss was determined,,Intermediate,,CHEMBL624956,,9615.0,,1,1,,A,,,BAO_0000218,3639
50588,,N,,,7047,Canis lupus familiaris,Vss in dog,,Intermediate,,CHEMBL625129,,9615.0,,1,1,,A,,,BAO_0000218,3639
50588,,N,,,7048,Canis lupus familiaris,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,,Intermediate,,CHEMBL625130,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6062
50588,,N,,,7049,Canis lupus familiaris,Volume distribution in dogs,,Intermediate,,CHEMBL625131,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4942
50588,,N,,,7050,Canis lupus familiaris,Volume of distribution in dog,,Intermediate,,CHEMBL625132,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17796
50588,,N,,,7051,Canis lupus familiaris,Tested for the oral bioavailability in dog,,Intermediate,,CHEMBL872263,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4883
50594,,N,,,7060,Mus musculus,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,,Intermediate,,CHEMBL624336,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17837
50594,,N,,,7061,Mus musculus,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,,Intermediate,,CHEMBL624337,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17729
50594,,N,,,7062,Mus musculus,Bioavailability after peroral administration of 50 mg/kg of dose in mice,,Intermediate,,CHEMBL624338,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17729
50594,,N,,,7063,Mus musculus,Bioavailability was measured in mouse,,Intermediate,,CHEMBL624339,In vivo,10090.0,,1,1,,A,,,BAO_0000218,4239
50594,,N,,,7064,Mus musculus,Bioavailability in mouse,,Intermediate,,CHEMBL624340,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17592
50594,,N,,,7065,Mus musculus,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,,Intermediate,,CHEMBL624341,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6348
50594,,N,,,7066,Mus musculus,Bioavailability in mouse,,Intermediate,,CHEMBL624342,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2801
50594,,N,,,7067,Mus musculus,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,,Intermediate,,CHEMBL624343,In vivo,10090.0,,1,1,,A,,,BAO_0000218,2801
50594,,N,,,7068,Mus musculus,Oral bioavailability in mouse,,Intermediate,,CHEMBL624344,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17718
50594,,N,,,7069,Mus musculus,Oral availability at 50 mg/kg po in male mice,,Intermediate,,CHEMBL624345,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5727
50594,,N,,,7070,Mus musculus,Oral bioavailability in mouse (dose 10 mg/kg),,Intermediate,,CHEMBL624346,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5302
50594,,N,,,7071,Mus musculus,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,,Expert,,CHEMBL624347,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3598
50594,,N,,,7072,Mus musculus,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",,Intermediate,,CHEMBL624348,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5961
50594,,N,,,7074,Mus musculus,Oral bioavailability in mouse,,Intermediate,,CHEMBL622754,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6091
50594,,N,,,7075,Mus musculus,Oral bioavailability in vivo in mice;ND=Not determined,,Intermediate,,CHEMBL622755,In vivo,10090.0,,1,1,,A,,,BAO_0000218,6091
50594,,N,,,7076,Mus musculus,Oral bioavailability in mouse at 10 mg/kg of the compound,,Intermediate,,CHEMBL622756,In vivo,10090.0,,1,1,,A,,,BAO_0000218,5711
50594,,N,,,7077,Mus musculus,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),,Intermediate,,CHEMBL622757,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17728
50594,,N,,,7078,Mus musculus,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),,Intermediate,,CHEMBL622758,In vivo,10090.0,,1,1,,A,,,BAO_0000218,17728
50594,,N,,,7079,Mus musculus,Tested for bioavailability of the compound,,Intermediate,,CHEMBL622759,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3802
50594,,N,,,7080,Mus musculus,Tested for half life at the dose of 10 mg/kg when administered intravenously,,Intermediate,,CHEMBL622760,In vivo,10090.0,,1,1,,A,,,BAO_0000218,3802
50594,,N,1969.0,,7081,Mus musculus,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,Plasma,Intermediate,,CHEMBL622761,,10090.0,,1,1,,A,,,BAO_0000218,14029
50594,,N,1969.0,,7082,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma. ,Plasma,Intermediate,,CHEMBL622762,,10090.0,,1,1,,A,,,BAO_0000218,14029
50594,,N,1969.0,,7083,Mus musculus,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,Plasma,Intermediate,,CHEMBL622763,,10090.0,,1,1,,A,,,BAO_0000218,14029
50594,,N,1969.0,,7084,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,Plasma,Intermediate,,CHEMBL622764,,10090.0,,1,1,,A,,,BAO_0000218,14029
50594,,N,1969.0,,7085,Mus musculus,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,Plasma,Intermediate,,CHEMBL622765,,10090.0,,1,1,,A,,,BAO_0000218,14029
50594,,N,,,7086,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,,Intermediate,,CHEMBL622766,,10090.0,,1,1,,F,,,BAO_0000218,17753
50594,,N,,,7087,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,,Intermediate,,CHEMBL622767,,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,,,7088,Mus musculus,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,,Intermediate,,CHEMBL622768,,10090.0,,1,1,,A,,,BAO_0000218,17753
50594,,N,178.0,,7089,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Blood,Intermediate,,CHEMBL875948,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,178.0,,7090,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Blood,Intermediate,,CHEMBL622769,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,178.0,,7091,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Blood,Intermediate,,CHEMBL622770,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,178.0,,7092,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Blood,Intermediate,,CHEMBL622771,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,178.0,,7093,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Blood,Intermediate,,CHEMBL622772,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,178.0,,7094,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Blood,Intermediate,,CHEMBL622773,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,178.0,,7095,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Blood,Intermediate,,CHEMBL622774,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000001.0,,7096,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Bone,Intermediate,,CHEMBL621725,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000001.0,,7097,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Bone,Intermediate,,CHEMBL621726,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
81034,,N,,,7098,Homo sapiens,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,,Intermediate,,CHEMBL621727,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15608
81034,,N,,,7099,Homo sapiens,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,,Expert,,CHEMBL622413,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,3290
81034,,N,,,7100,Homo sapiens,Compound was evaluated for cytotoxicity against A2780 cell line,,Intermediate,,CHEMBL622414,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,2859
81034,,N,,,7101,Homo sapiens,Inhibition of A2780 cell clonogenic assay,,Expert,,CHEMBL622415,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15688
81034,,N,,,7102,Homo sapiens,Cytotoxic effect on ovarian cancer cell line (A2780),,Expert,,CHEMBL884001,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,5642
81034,,N,,,7103,Homo sapiens,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,,Intermediate,,CHEMBL622416,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,6633
81034,,N,,,7104,Homo sapiens,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",,Intermediate,,CHEMBL622417,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,3906
81034,,N,,,7105,Homo sapiens,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,,Expert,,CHEMBL622590,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,6788
81034,,N,,,7106,Homo sapiens,Antiproliferative activity against human A2780 cells,,Expert,,CHEMBL622591,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17582
81034,,N,,,7107,Homo sapiens,Inhibition of human A2780 cell proliferation,,Expert,,CHEMBL622592,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17764
81034,,N,,,7108,Homo sapiens,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,,Expert,,CHEMBL622593,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17764
81034,,N,,,7109,Homo sapiens,Inhibition of human A2780 cell proliferation (No data),,Expert,,CHEMBL622594,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17764
81034,,N,,,7110,Homo sapiens,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,,Intermediate,,CHEMBL622595,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,2815
81034,,N,,,7111,Homo sapiens,Compound was evaluated against human Ovarian carcinoma cell line A2780,,Intermediate,,CHEMBL622596,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16930
81034,,N,,,7112,Homo sapiens,Growth inhibition against A2780 wild-type ovarian cell lines,,Expert,,CHEMBL622597,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17777
81034,,N,,,7113,Homo sapiens,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,,Intermediate,,CHEMBL622598,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17777
104766,,D,,,7114,Homo sapiens,Inhibition of tubulin polymerization in human ovarian cancer cell lines,,Autocuration,,CHEMBL622599,,9606.0,,5,1,,F,,,BAO_0000019,16936
81034,,N,,,7115,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,Intermediate,,CHEMBL622600,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13759
81034,,N,,,7116,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,Intermediate,,CHEMBL622601,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13759
81034,,N,,,7117,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,,Intermediate,,CHEMBL622602,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13759
81034,,N,,,7118,Homo sapiens,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,,Intermediate,,CHEMBL622603,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13759
81034,,N,,,7119,Homo sapiens,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,Intermediate,,CHEMBL622604,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15292
81034,,N,,,7120,Homo sapiens,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,,Intermediate,,CHEMBL622605,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15292
81034,,N,,,7121,Homo sapiens,In vitro inhibition of human ovarian cell line A2780,,Expert,,CHEMBL622606,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15069
81034,,N,,,7122,Homo sapiens,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",,Expert,,CHEMBL619463,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15069
81034,,N,,,7123,Homo sapiens,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),,Intermediate,,CHEMBL619464,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,14073
81034,,N,,,7124,Homo sapiens,Concentration required to inhibit A2780-cell growth by 50%,,Expert,,CHEMBL619465,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,14553
81034,,N,,,7125,Homo sapiens,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,,Expert,,CHEMBL619466,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13040
81034,,N,,,7126,Homo sapiens,Cytotoxic effect on human ovarian (A2780) cancer cell line,,Expert,,CHEMBL619467,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,6891
81034,,N,,,7127,Homo sapiens,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,,Intermediate,,CHEMBL619468,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15569
81034,,N,,,7128,Homo sapiens,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,,Expert,,CHEMBL619469,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,14190
81034,,N,,,7129,Homo sapiens,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,Expert,,CHEMBL619470,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15014
81034,,N,,,7130,Homo sapiens,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,,Intermediate,,CHEMBL619471,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15014
81034,,N,,,7131,Homo sapiens,Cytotoxicity against human ovarian carcinoma A2780 cell line,,Intermediate,,CHEMBL619472,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17496
81034,,N,,,7132,Homo sapiens,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",,Intermediate,,CHEMBL619473,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13617
81034,,N,,,7133,Homo sapiens,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",,Intermediate,,CHEMBL874368,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13617
81034,,N,,,7134,Homo sapiens,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",,Intermediate,,CHEMBL884003,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13617
81034,,N,,,7135,Homo sapiens,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",,Intermediate,,CHEMBL622690,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13617
81034,,N,,,7136,Homo sapiens,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,,Intermediate,,CHEMBL622691,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17672
81034,,N,,,7137,Homo sapiens,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,Intermediate,,CHEMBL622692,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,4544
81034,,N,,,7138,Homo sapiens,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,,Intermediate,,CHEMBL623406,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,4544
81034,,N,,,7139,Homo sapiens,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",,Intermediate,,CHEMBL884004,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16317
81034,,N,,,7140,Homo sapiens,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,,Intermediate,,CHEMBL623407,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15099
81034,,N,,,7141,Homo sapiens,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,,Intermediate,,CHEMBL623408,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13978
81034,,N,,,7142,Homo sapiens,In vitro antitumor activity against A2780 cell line.,,Expert,,CHEMBL623409,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,12989
81034,,N,,,7143,Homo sapiens,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,,Intermediate,,CHEMBL623410,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,5574
81034,,N,,,7144,Homo sapiens,In vitro cytotoxicity against A2780 human ovarian cancer cell line,,Expert,,CHEMBL623576,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,13528
80025,,N,,,7145,Homo sapiens,Inhibitory activity against kidney A-CHN tumor cell growth in culture,,Intermediate,,CHEMBL623577,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,12782
80025,,N,,,7146,Homo sapiens,The IC50 value was measured on ACHN cell line in renal tumor type.,,Intermediate,,CHEMBL623578,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,14255
80025,,N,,,7147,Homo sapiens,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,,Intermediate,,CHEMBL623579,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,16364
80025,,N,,,7148,Homo sapiens,In vitro lethal concentration against most sensitive ACHN cell line,,Expert,,CHEMBL623580,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,17376
80025,,N,,,7149,Homo sapiens,Tested for cytotoxic activity against renal cancer ACHN cell line,,Intermediate,,CHEMBL623581,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,12016
80025,,N,,,7150,Homo sapiens,Compound tested for growth inhibition of renal cancer cell line ACHN,,Intermediate,,CHEMBL857456,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,6058
80025,,N,,,7151,Homo sapiens,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,,Intermediate,,CHEMBL623582,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,17708
80025,,N,,,7152,Homo sapiens,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,,Intermediate,,CHEMBL623583,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,15176
80025,,N,,,7153,Homo sapiens,In vitro anticancer activity against ACHN renal cancer cell line,,Intermediate,,CHEMBL623584,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,2806
80025,,N,,,7154,Homo sapiens,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,,Intermediate,,CHEMBL623585,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,15300
80025,,N,,,7155,Homo sapiens,Percent selectivity was evaluated in renal ACHN cell lines,,Intermediate,,CHEMBL623586,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,16364
80025,,N,,,7156,Homo sapiens,In vitro inhibitory activity against renal ACHN cancer cell line,,Intermediate,,CHEMBL623587,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,13859
80025,,N,,,7157,Homo sapiens,Tested for cytotoxicity against ACHN cell lines in renal cancer,,Intermediate,,CHEMBL875279,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,11970
80025,,N,,,7158,Homo sapiens,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,,Intermediate,,CHEMBL623588,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,2450
80025,,N,,,7159,Homo sapiens,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,,Intermediate,,CHEMBL623589,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,12696
80025,,N,,,7160,Homo sapiens,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,,Intermediate,,CHEMBL623590,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,12400
80025,,N,,,7161,Homo sapiens,Cytotoxic effect on renal cancer line ACHN,,Expert,,CHEMBL623591,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,12888
80025,,N,,,7162,Homo sapiens,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,,Intermediate,,CHEMBL623592,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,3156
80025,,N,,,7163,Homo sapiens,In vitro inhibition of Renal Cancer ACHN cell lines,,Intermediate,,CHEMBL623593,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,3381
80025,,N,,,7164,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells,,Intermediate,,CHEMBL623594,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,16747
80025,,N,,,7165,Homo sapiens,Antitumor activity against human renal adenocarcinoma ACHN cells.,,Expert,,CHEMBL621833,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,16748
80025,,N,,,7166,Homo sapiens,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,,Intermediate,,CHEMBL621834,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,12062
80025,,N,,,7167,Homo sapiens,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),,Intermediate,,CHEMBL621835,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,14769
80025,,N,,,7168,Homo sapiens,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",,Intermediate,,CHEMBL621836,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,15895
80025,,N,,,7169,Homo sapiens,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,,Intermediate,,CHEMBL621837,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,17376
80025,,N,,,7170,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,,Intermediate,,CHEMBL875280,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,14882
80025,,N,,,7171,Homo sapiens,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,,Intermediate,,CHEMBL621838,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,14882
80025,,N,,,7172,Homo sapiens,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,,Intermediate,,CHEMBL621839,,9606.0,626.0,1,1,ACHN,F,,,BAO_0000219,15661
22224,,U,,,7173,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,,Autocuration,,CHEMBL621840,,,,0,1,,A,,,BAO_0000019,9680
10647,,H,,,7174,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,,Autocuration,,CHEMBL621841,,,,8,1,,F,,,BAO_0000019,14579
50529,,N,,,7175,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,,Expert,,CHEMBL622979,,10358.0,468.0,1,1,HEL,F,,,BAO_0000218,17290
50529,,N,,,7176,Cytomegalovirus,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,,Intermediate,,CHEMBL876595,,10358.0,,1,1,,F,,,BAO_0000218,17290
12159,,H,,,7177,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),,Autocuration,,CHEMBL620221,,,,8,1,,B,,,BAO_0000357,15891
12159,,H,,,7178,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),,Autocuration,,CHEMBL620222,,,,8,1,,B,,,BAO_0000357,15890
80670,,N,,,7179,Bos taurus,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,,Intermediate,,CHEMBL620506,,9913.0,979.0,1,1,ADDP cell line,F,,,BAO_0000219,3801
80671,,N,,,7180,Mus musculus,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,,Intermediate,,CHEMBL620507,,10090.0,980.0,1,1,ADJ/PC6,F,,,BAO_0000219,9222
80671,,N,,,7181,Mus musculus,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,,Intermediate,,CHEMBL620508,,10090.0,980.0,1,1,ADJ/PC6,F,,,BAO_0000219,9222
80671,,N,,,7182,Mus musculus,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",,Intermediate,,CHEMBL620509,,10090.0,980.0,1,1,ADJ/PC6,F,,,BAO_0000219,7257
80671,,N,,,7183,Mus musculus,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,,Intermediate,,CHEMBL620510,,10090.0,980.0,1,1,ADJ/PC6,F,,,BAO_0000219,7257
80671,,N,,,7184,Mus musculus,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,,Intermediate,,CHEMBL620511,,10090.0,980.0,1,1,ADJ/PC6,A,,,BAO_0000219,7257
80671,,N,,,7185,Mus musculus,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,,Intermediate,,CHEMBL620512,,10090.0,980.0,1,1,ADJ/PC6,F,,,BAO_0000219,8084
22224,,U,,,7186,Mus musculus,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,,Autocuration,,CHEMBL620513,,10090.0,,0,1,,F,,,BAO_0000019,14943
22224,,U,,,7187,Mus musculus,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,,Autocuration,,CHEMBL620514,,10090.0,,0,1,,F,,,BAO_0000019,14943
22224,,U,,,7188,Mus musculus,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,,Autocuration,,CHEMBL620515,,10090.0,,0,1,,F,,,BAO_0000019,14943
22224,,U,,,7189,Bacillus subtilis,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),,Autocuration,,CHEMBL620516,In vivo,1423.0,,0,1,,A,,,BAO_0000218,10524
50588,,N,1969.0,,7190,Canis lupus familiaris,AUC value in dog after IV administration at a dose of 5 mg/kg,Plasma,Intermediate,,CHEMBL620517,,9615.0,,1,1,,A,,,BAO_0000218,3546
50588,,N,1969.0,,7191,Canis lupus familiaris,AUC value in dog after oral administration at a dose of 5 mg/kg,Plasma,Intermediate,,CHEMBL620518,,9615.0,,1,1,,A,,,BAO_0000218,3546
50588,,N,,,7192,Canis lupus familiaris,Cmax value in dog after oral administration at a dose of 5 mg/kg,,Intermediate,,CHEMBL620519,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3546
50588,,N,,,7193,Canis lupus familiaris,Bioavailability in dog after oral administration at a dose of 5 mg/kg,,Intermediate,,CHEMBL621386,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3546
50588,,N,,,7194,Canis lupus familiaris,Tmax value in dog after oral administration at a dose of 5 mg/kg,,Intermediate,,CHEMBL621387,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3546
50588,,N,,,7195,Canis lupus familiaris,Compound was evaluated for its clearance when administered intravenously in dog,,Intermediate,,CHEMBL621388,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3184
50588,,N,,,7196,Canis lupus familiaris,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Intermediate,,CHEMBL621389,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16456
50588,,N,,,7197,Canis lupus familiaris,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,Intermediate,,CHEMBL621390,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4809
22229,,U,,,7198,,Calculated partition coefficient (clogP),,Intermediate,,CHEMBL621391,,,,0,1,,P,,,BAO_0000100,4219
50588,,N,,,7199,Canis lupus familiaris,Half life in dog,,Intermediate,,CHEMBL621392,,9615.0,,1,1,,A,,,BAO_0000218,3748
50588,,N,,,7200,Canis lupus familiaris,Time taken for EC90 was determined when tested in dog,,Intermediate,,CHEMBL621393,,9615.0,,1,1,,A,,,BAO_0000218,3132
50588,,N,,,7201,Canis lupus familiaris,Half life (iv) was determined,,Intermediate,,CHEMBL621394,,9615.0,,1,1,,A,,,BAO_0000218,4219
50588,,N,2107.0,,7202,Canis lupus familiaris,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,Liver,Intermediate,,CHEMBL621395,,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,7203,Canis lupus familiaris,Area under the curve was calculated in dog after iv administration,,Intermediate,,CHEMBL621396,,9615.0,,1,1,,A,,,BAO_0000218,6057
50588,,N,,,7204,Canis lupus familiaris,Area under the curve was calculated in dog after peroral administration,,Intermediate,,CHEMBL621397,,9615.0,,1,1,,A,,,BAO_0000218,6057
50588,,N,,,7205,Canis lupus familiaris,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,,Intermediate,,CHEMBL621398,,9615.0,,1,1,,A,,,BAO_0000218,17853
50588,,N,,,7206,Canis lupus familiaris,pKa was evaluated in dog,,Intermediate,,CHEMBL618818,,9615.0,,1,1,,A,,,BAO_0000218,3639
50588,,N,,,7207,Canis lupus familiaris,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,,Intermediate,,CHEMBL618819,,9615.0,,1,1,,A,,,BAO_0000218,14541
50588,,N,,,7208,Canis lupus familiaris,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Intermediate,,CHEMBL618820,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16456
50588,,N,,,7209,Canis lupus familiaris,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,,Intermediate,,CHEMBL873810,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16456
50588,,N,,,7210,Canis lupus familiaris,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,,Intermediate,,CHEMBL876606,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2652
50588,,N,,,7211,Canis lupus familiaris,Compound was evaluated for the half-life (t 1/2) in hours,,Intermediate,,CHEMBL618821,,9615.0,,1,1,,A,,,BAO_0000218,3624
50588,,N,178.0,,7212,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,Blood,Intermediate,,CHEMBL618822,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1337
50588,,N,178.0,,7213,Canis lupus familiaris,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,Blood,Intermediate,,CHEMBL618823,In vivo,9615.0,,1,1,,A,,,BAO_0000218,1337
50588,,N,,,7214,Canis lupus familiaris,Half life after intravenous administration of 1 mg/kg in dog,,Intermediate,,CHEMBL618824,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4709
50588,,N,,,7215,Canis lupus familiaris,Half life was measured in dog,,Intermediate,,CHEMBL618825,,9615.0,,1,1,,A,,,BAO_0000218,15660
50588,,N,,,7216,Canis lupus familiaris,Half life period in dog after 5 mg/kg dose,,Intermediate,,CHEMBL618826,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5302
50588,,N,,,7217,Canis lupus familiaris,Half life period was evaluated in dog; 4-4.8,,Intermediate,,CHEMBL618827,,9615.0,,1,1,,A,,,BAO_0000218,17791
50588,,N,,,7218,Canis lupus familiaris,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,,Intermediate,,CHEMBL618828,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6348
50588,,N,,,7219,Canis lupus familiaris,Half-life was determined in dog after a3 mg/kg of iv dose,,Intermediate,,CHEMBL618829,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4257
50588,,N,,,7220,Canis lupus familiaris,Half-life was determined,,Intermediate,,CHEMBL618830,,9615.0,,1,1,,A,,,BAO_0000218,3771
50588,,N,,,7221,Canis lupus familiaris,Half life in dogs,,Intermediate,,CHEMBL618831,,9615.0,,1,1,,A,,,BAO_0000218,6305
50588,,N,1969.0,,7222,Canis lupus familiaris,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,Plasma,Intermediate,,CHEMBL619489,In vivo,9615.0,,1,1,,A,,,BAO_0000218,13501
50588,,N,,,7223,Canis lupus familiaris,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,,Intermediate,,CHEMBL619649,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17594
50588,,N,,,7224,Canis lupus familiaris,Compound was evaluated for the half life period after iv administration in Beagle dog.,,Intermediate,,CHEMBL876607,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3045
50588,,N,,,7225,Canis lupus familiaris,Compound was evaluated for the half life period after oral administration in conscious dog.,,Intermediate,,CHEMBL619650,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3043
50588,,N,,,7226,Canis lupus familiaris,Compound was tested for half life in dog,,Intermediate,,CHEMBL619651,,9615.0,,1,1,,A,,,BAO_0000218,4839
50588,,N,,,7227,Canis lupus familiaris,Compound was tested for its half life in dog,,Intermediate,,CHEMBL619652,,9615.0,,1,1,,A,,,BAO_0000218,4839
50588,,N,,,7228,Canis lupus familiaris,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,,Intermediate,,CHEMBL619653,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5802
50588,,N,,,7229,Canis lupus familiaris,Half life of compound in dog was determined,,Intermediate,,CHEMBL619654,,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,,,7230,Canis lupus familiaris,Half life (iv) was determined,,Intermediate,,CHEMBL619655,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4219
50588,,N,178.0,,7231,Canis lupus familiaris,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),Blood,Intermediate,,CHEMBL619656,,9615.0,,1,1,,A,,,BAO_0000218,13966
50588,,N,1969.0,,7232,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Plasma,Intermediate,,CHEMBL873812,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3994
50588,,N,1969.0,,7233,Canis lupus familiaris,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,Plasma,Intermediate,,CHEMBL621365,In vivo,9615.0,,1,1,,F,,,BAO_0000218,3994
50588,,N,,,7234,Canis lupus familiaris,Half life in dog,,Intermediate,,CHEMBL621366,,9615.0,,1,1,,A,,,BAO_0000218,4453
50588,,N,1969.0,,7235,Canis lupus familiaris,Half life in dog plasma,Plasma,Intermediate,,CHEMBL621367,,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,1969.0,,7236,Canis lupus familiaris,Half life in dog plasma after administration of 0.25 mg/kg iv,Plasma,Intermediate,,CHEMBL621368,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,1969.0,,7237,Canis lupus familiaris,Half life in dog plasma after administration of 1 mg/kg iv,Plasma,Intermediate,,CHEMBL621369,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6535
50588,,N,1969.0,,7238,Canis lupus familiaris,Half life in dog plasma was determined at dose 10 mg/kg,Plasma,Intermediate,,CHEMBL621370,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3132
50588,,N,,,7239,Canis lupus familiaris,Half life in dog was determined,,Intermediate,,CHEMBL621371,,9615.0,,1,1,,A,,,BAO_0000218,5374
50588,,N,,,7240,Canis lupus familiaris,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),,Intermediate,,CHEMBL621372,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5007
50588,,N,1969.0,,7241,Canis lupus familiaris,Half life upon exposure to human plasma,Plasma,Intermediate,,CHEMBL621373,,9615.0,,1,1,,A,,,BAO_0000218,16907
50588,,N,,,7242,Canis lupus familiaris,Half life was calculated in dog,,Intermediate,,CHEMBL621374,,9615.0,,1,1,,A,,,BAO_0000218,6057
50588,,N,,,7243,Canis lupus familiaris,Half life was determined,,Intermediate,,CHEMBL621375,,9615.0,,1,1,,A,,,BAO_0000218,5006
50588,,N,,,7244,Canis lupus familiaris,Half life was determined,,Intermediate,,CHEMBL621376,,9615.0,,1,1,,A,,,BAO_0000218,5473
50588,,N,,,7245,Canis lupus familiaris,Half life by intravenous administration of 1.2 mg/kg in dog,,Intermediate,,CHEMBL619624,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4368
50588,,N,,,7246,Canis lupus familiaris,Half life in dog,,Intermediate,,CHEMBL875840,,9615.0,,1,1,,A,,,BAO_0000218,6448
50588,,N,,,7247,Canis lupus familiaris,Half life in dog after intra venous administration of the compound,,Intermediate,,CHEMBL619625,,9615.0,,1,1,,A,,,BAO_0000218,4353
50588,,N,,,7248,Canis lupus familiaris,Half life in dog after intra venous administration of the compound; ND means Not determined,,Intermediate,,CHEMBL619626,,9615.0,,1,1,,A,,,BAO_0000218,4353
50588,,N,,,7249,Canis lupus familiaris,Half life in dog after po administration of the compound,,Intermediate,,CHEMBL619627,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4353
50588,,N,,,7250,Canis lupus familiaris,Half life in dog after po administration of the compound; ND means Not determined,,Intermediate,,CHEMBL873817,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4353
50588,,N,,,7251,Canis lupus familiaris,Half life in dog at the single oral dose of 1 mg/kg,,Intermediate,,CHEMBL619628,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6265
50588,,N,,,7252,Canis lupus familiaris,Half life in dogs,,Intermediate,,CHEMBL619629,,9615.0,,1,1,,A,,,BAO_0000218,5006
50588,,N,,,7253,Canis lupus familiaris,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,,Intermediate,,CHEMBL619630,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5356
50588,,N,,,7254,Canis lupus familiaris,Half life in rat,,Intermediate,,CHEMBL619631,,9615.0,,1,1,,A,,,BAO_0000218,405
50588,,N,,,7255,Canis lupus familiaris,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),,Intermediate,,CHEMBL619632,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6642
50594,,N,10000001.0,,7256,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Bone,Intermediate,,CHEMBL619633,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000001.0,,7257,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Bone,Intermediate,,CHEMBL875841,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000001.0,,7258,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Bone,Intermediate,,CHEMBL619634,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000001.0,,7259,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Bone,Intermediate,,CHEMBL619635,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000001.0,,7260,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Bone,Intermediate,,CHEMBL619636,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000004.0,,7261,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Gut,Intermediate,,CHEMBL619637,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000004.0,,7262,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Gut,Intermediate,,CHEMBL619638,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000004.0,,7263,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Gut,Intermediate,,CHEMBL619639,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000004.0,,7264,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Gut,Intermediate,,CHEMBL619640,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000004.0,,7265,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Gut,Intermediate,,CHEMBL619641,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000004.0,,7266,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Gut,Intermediate,,CHEMBL619642,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,10000004.0,,7267,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Gut,Intermediate,,CHEMBL619643,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,948.0,,7268,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Heart,Intermediate,,CHEMBL619644,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,948.0,,7269,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Heart,Intermediate,,CHEMBL621112,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,948.0,,7270,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Heart,Intermediate,,CHEMBL621113,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,948.0,,7271,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Heart,Intermediate,,CHEMBL621114,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,948.0,,7272,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Heart,Intermediate,,CHEMBL621115,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,948.0,,7273,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Heart,Intermediate,,CHEMBL621116,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,948.0,,7274,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Heart,Intermediate,,CHEMBL621117,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2113.0,,7275,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Kidney,Intermediate,,CHEMBL621118,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2113.0,,7276,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Kidney,Intermediate,,CHEMBL621119,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2113.0,,7277,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Kidney,Intermediate,,CHEMBL621120,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2113.0,,7278,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Kidney,Intermediate,,CHEMBL621757,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2113.0,,7279,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Kidney,Intermediate,,CHEMBL621758,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2113.0,,7280,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Kidney,Intermediate,,CHEMBL621759,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2113.0,,7281,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Kidney,Intermediate,,CHEMBL621760,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2107.0,,7282,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Liver,Intermediate,,CHEMBL621761,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2107.0,,7283,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Liver,Intermediate,,CHEMBL621762,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2107.0,,7284,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Liver,Intermediate,,CHEMBL621763,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2107.0,,7285,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Liver,Intermediate,,CHEMBL624502,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2107.0,,7286,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Liver,Intermediate,,CHEMBL624503,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2107.0,,7287,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Liver,Intermediate,,CHEMBL624504,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2107.0,,7288,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Liver,Intermediate,,CHEMBL624505,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2048.0,,7289,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Lung,Intermediate,,CHEMBL624506,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
81034,,N,,,7290,Homo sapiens,In vitro cytotoxicity against A2780 (human ovarian cancer),,Intermediate,,CHEMBL624507,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,5895
81034,,N,,,7291,Homo sapiens,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,,Intermediate,,CHEMBL624508,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,6338
81034,,N,,,7292,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,,Intermediate,,CHEMBL624509,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15163
81034,,N,,,7293,Homo sapiens,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,,Intermediate,,CHEMBL624510,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15163
81034,,N,,,7294,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,,Expert,,CHEMBL875956,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15000
81034,,N,,,7295,Homo sapiens,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,,Expert,,CHEMBL839885,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15000
81034,,N,,,7296,Homo sapiens,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,,Expert,,CHEMBL624511,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,14729
81034,,N,,,7297,Homo sapiens,In vitro cytotoxicity against A2780 cell line,,Intermediate,,CHEMBL624512,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17270
81034,,N,,,7298,Homo sapiens,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,,Intermediate,,CHEMBL624513,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,5685
81034,,N,,,7299,Homo sapiens,In vitro inhibitory activity against human ovarian cancer A2780 cell line,,Intermediate,,CHEMBL624514,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,3563
81034,,N,,,7300,Homo sapiens,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,,Intermediate,,CHEMBL618547,,9606.0,478.0,1,1,A2780,F,,,BAO_0000218,17753
81034,,N,,,7301,Homo sapiens,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",,Intermediate,,CHEMBL618548,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16317
81034,,N,,,7302,Homo sapiens,Inhibition of tubulin polymerization in analogy of ca.,,Intermediate,,CHEMBL618549,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7303,Homo sapiens,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,,Intermediate,,CHEMBL618550,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,3801
81034,,N,,,7304,Homo sapiens,Cytotoxic effect in ovarian cancer cell line (A2780),,Expert,,CHEMBL618551,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,6181
81034,,N,,,7305,Homo sapiens,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,,Intermediate,,CHEMBL618552,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,5318
81034,,N,,,7306,Homo sapiens,Tested for the cytotoxicity in A2780 ovarian cell line,,Intermediate,,CHEMBL618553,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,4840
81034,,N,,,7307,Homo sapiens,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),,Intermediate,,CHEMBL618554,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15748
81034,,N,,,7308,Homo sapiens,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,,Intermediate,,CHEMBL618555,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15748
80017,,N,,,7309,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,,Intermediate,,CHEMBL618556,,,481.0,1,1,A2780cisR,F,,,BAO_0000219,15748
80017,,N,,,7310,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),,Intermediate,,CHEMBL618557,,,481.0,1,1,A2780cisR,F,,,BAO_0000219,15748
80017,,N,,,7311,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,,Intermediate,,CHEMBL618558,,,481.0,1,1,A2780cisR,F,,,BAO_0000219,15748
80017,,N,,,7312,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),,Intermediate,,CHEMBL618559,,,481.0,1,1,A2780cisR,F,,,BAO_0000219,15748
81034,,N,,,7313,Homo sapiens,In vivo log of cells killed after administration of compound in A2780 cell line,,Intermediate,,CHEMBL618560,,9606.0,478.0,1,1,A2780,F,,,BAO_0000218,17753
81034,,N,,,7314,Homo sapiens,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,,Intermediate,,CHEMBL618561,In vivo,9606.0,478.0,1,1,A2780,F,,,BAO_0000218,17753
81034,,N,,,7315,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,,Intermediate,,CHEMBL618562,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7316,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,,Intermediate,,CHEMBL618563,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7317,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,,Intermediate,,CHEMBL618564,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7318,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,,Intermediate,,CHEMBL618565,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7319,Homo sapiens,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),,Intermediate,,CHEMBL618566,,9606.0,478.0,1,1,A2780,F,,,BAO_0000218,17528
81034,,N,,,7320,Homo sapiens,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,,Intermediate,,CHEMBL618567,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,6633
81034,,N,,,7321,Homo sapiens,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,,Expert,,CHEMBL618568,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,15000
81034,,N,,,7322,Homo sapiens,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,,Expert,,CHEMBL618569,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,17528
81034,,N,,,7323,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,,Intermediate,,CHEMBL621857,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7324,Homo sapiens,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,,Intermediate,,CHEMBL621858,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7325,Homo sapiens,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,,Intermediate,,CHEMBL621859,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7326,Homo sapiens,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",,Intermediate,,CHEMBL621860,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7327,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),,Intermediate,,CHEMBL621861,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7328,Homo sapiens,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",,Expert,,CHEMBL621862,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7329,Homo sapiens,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Intermediate,,CHEMBL621863,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7330,Homo sapiens,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Intermediate,,CHEMBL621864,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7331,Homo sapiens,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),,Intermediate,,CHEMBL621865,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,16936
81034,,N,,,7332,Mus musculus,In vitro antiproliferative activity against A2780 cell line,,Intermediate,,CHEMBL621866,,10090.0,478.0,1,1,A2780,F,,,BAO_0000219,17737
81034,,N,,,7333,Mus musculus,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,,Expert,,CHEMBL621867,,10090.0,478.0,1,1,A2780,F,,,BAO_0000219,17764
81034,,N,,,7334,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,,Intermediate,,CHEMBL621868,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,3830
81034,,N,,,7335,Homo sapiens,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,,Intermediate,,CHEMBL875282,,9606.0,478.0,1,1,A2780,F,,,BAO_0000219,3829
50588,,N,,,7336,Canis lupus familiaris,Vc value in dog after IV administration at a dose of 5 mg/kg,,Intermediate,,CHEMBL621869,,9615.0,,1,1,,A,,,BAO_0000218,3546
50588,,N,,,7337,Canis lupus familiaris,Half life period in dog after IV administration at a dose of 5 mg/kg,,Intermediate,,CHEMBL621870,In vivo,9615.0,,1,1,,A,,,BAO_0000218,3546
22224,,U,,,7338,Cercopithecidae,Area under curve was determine after peroral administration at 10 mpk in Rhesus,,Autocuration,,CHEMBL621871,,9527.0,,0,1,,A,,,BAO_0000019,5668
22224,,U,1969.0,,7339,Cercopithecidae,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Plasma,Autocuration,,CHEMBL621243,,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,1969.0,,7340,Cercopithecidae,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,Plasma,Autocuration,,CHEMBL621244,,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,7341,Macaca fascicularis,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,,Autocuration,,CHEMBL621245,In vivo,9541.0,,0,1,,A,,,BAO_0000218,4256
22224,,U,,,7342,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,,Autocuration,,CHEMBL621246,In vivo,9541.0,,0,1,,A,,,BAO_0000218,4256
22224,,U,,,7343,Macaca fascicularis,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,,Autocuration,,CHEMBL621247,In vivo,9541.0,,0,1,,A,,,BAO_0000218,4256
22224,,U,,,7344,Rattus norvegicus,Oral Bioavailability in rat,,Autocuration,,CHEMBL618386,In vivo,10116.0,,0,1,,A,,,BAO_0000218,4256
22224,,U,,,7345,Cercopithecidae,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,,Autocuration,,CHEMBL618387,,9527.0,,0,1,,A,,,BAO_0000218,1916
22224,,U,,,7346,Cercopithecidae,Area under curve value in monkey at a dose of 5 mg/kg,,Autocuration,,CHEMBL618388,,9527.0,,0,1,,A,,,BAO_0000218,5302
22224,,U,,,7347,Cercopithecidae,Area under curve was determined in monkey after a 3 mg/kg of oral dose,,Autocuration,,CHEMBL618389,,9527.0,,0,1,,A,,,BAO_0000218,4257
22224,,U,,,7348,Cercopithecidae,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,,Autocuration,,CHEMBL618574,,9527.0,,0,1,,A,,,BAO_0000019,5355
22224,,U,,,7349,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,,Autocuration,,CHEMBL618575,,9527.0,,0,1,,A,,,BAO_0000019,5355
22224,,U,,,7350,Cercopithecidae,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,,Autocuration,,CHEMBL618576,,9527.0,,0,1,,A,,,BAO_0000019,5355
22224,,U,,,7351,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,,Autocuration,,CHEMBL618577,,9527.0,,0,1,,A,,,BAO_0000218,6078
22224,,U,,,7352,Cercopithecidae,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,,Autocuration,,CHEMBL876487,,9527.0,,0,1,,A,,,BAO_0000218,6078
22224,,U,,,7353,Cercopithecidae,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,,Autocuration,,CHEMBL618578,,9527.0,,0,1,,A,,,BAO_0000218,6062
22224,,U,,,7354,Cercopithecidae,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Autocuration,,CHEMBL618579,,9527.0,,0,1,,A,,,BAO_0000218,2661
22224,,U,,,7355,Cercopithecidae,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Autocuration,,CHEMBL618580,,9527.0,,0,1,,A,,,BAO_0000019,2661
22224,,U,,,7356,Cercopithecidae,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,,Autocuration,,CHEMBL618581,,9527.0,,0,1,,A,,,BAO_0000218,5394
22224,,U,,,7357,Cercopithecidae,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,,Autocuration,,CHEMBL618582,,9527.0,,0,1,,A,,,BAO_0000218,4397
22224,,U,,,7358,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,,Autocuration,,CHEMBL618583,,9527.0,,0,1,,A,,,BAO_0000218,17509
22224,,U,,,7359,Cercopithecidae,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,,Autocuration,,CHEMBL618584,,9527.0,,0,1,,A,,,BAO_0000218,17509
22224,,U,,,7360,Cercopithecidae,Oral AUCN in monkey (dosed at 0.5 mpk iv ),,Autocuration,,CHEMBL618585,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6641
22224,,U,,,7361,Cercopithecidae,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),,Autocuration,,CHEMBL618586,,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,7362,Cercopithecidae,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration,,CHEMBL618587,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,7363,Cercopithecidae,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,,Autocuration,,CHEMBL618588,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3443
22224,,U,,,7364,Cercopithecidae,Binding towards monkey plasma protein at 10 uM,,Autocuration,,CHEMBL618589,,9527.0,,0,1,,A,,,BAO_0000019,17409
22224,,U,,,7365,Cercopithecidae,Binding towards monkey plasma protein at 100 uM,,Autocuration,,CHEMBL618590,,9527.0,,0,1,,A,,,BAO_0000019,17409
22224,,U,,,7366,Cercopithecidae,Apparent bioavailability in squirrel monkey was determined,,Autocuration,,CHEMBL872262,In vivo,9527.0,,0,1,,A,,,BAO_0000218,1052
22224,,U,,,7367,Cercopithecidae,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,,Autocuration,,CHEMBL618591,In vivo,9527.0,,0,1,,A,,,BAO_0000218,13501
22224,,U,,,7368,monkey,Bioavailability in monkey (dose 2 mg/kg),,Autocuration,,CHEMBL618592,In vivo,9443.0,,0,1,,A,,,BAO_0000218,17509
22224,,U,,,7369,Cercopithecidae,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,,Autocuration,,CHEMBL876488,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5394
22224,,U,,,7370,Cercopithecidae,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,,Autocuration,,CHEMBL618593,In vivo,9527.0,,0,1,,A,,,BAO_0000218,2661
22224,,U,,,7371,monkey,Bioavailability in monkey (i.d. dosing),,Autocuration,,CHEMBL618594,In vivo,9443.0,,0,1,,A,,,BAO_0000218,11219
22224,,U,,,7372,Cercopithecidae,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,,Autocuration,,CHEMBL618595,In vivo,9527.0,,0,1,,A,,,BAO_0000218,3045
22224,,U,,,7373,Cercopithecidae,Clearance of the drug was measured in cynomolgus,,Autocuration,,CHEMBL621469,,9527.0,,0,1,,A,,,BAO_0000019,17796
22224,,U,,,7374,Cercopithecidae,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,,Autocuration,,CHEMBL621470,In vivo,9527.0,,0,1,,A,,,BAO_0000218,1399
22224,,U,,,7375,Cercopithecidae,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,,Autocuration,,CHEMBL621471,In vivo,9527.0,,0,1,,A,,,BAO_0000218,2661
22224,,U,1969.0,,7376,Macaca mulatta,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,Plasma,Autocuration,,CHEMBL621472,In vivo,9544.0,,0,1,,A,,,BAO_0000218,5005
22224,,U,,,7377,Cercopithecidae,Plasma clearance in rhesus monkey was determined,,Autocuration,,CHEMBL621473,In vivo,9527.0,,0,1,,A,,,BAO_0000218,17267
22224,,U,,,7378,Cercopithecidae,Plasma clearance in monkey after administration of 1 mg/kg iv,,Autocuration,,CHEMBL621474,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6535
22224,,U,,,7379,Cercopithecidae,Plasma clearance in cynomolgus monkey,,Autocuration,,CHEMBL621475,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5922
22224,,U,,,7380,Cercopithecidae,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,,Autocuration,,CHEMBL621476,In vivo,9527.0,,0,1,,A,,,BAO_0000218,6221
22224,,U,,,7381,Cercopithecidae,Plasma clearance after peroral administration at 10 mpk in Rhesus,,Autocuration,,CHEMBL624290,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5668
22224,,U,,,7382,Cercopithecidae,The total clearance was determined after intravenous administration in cynomolgus monkeys,,Autocuration,,CHEMBL624291,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,7383,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,,Autocuration,,CHEMBL624292,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,7384,Cercopithecidae,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,,Autocuration,,CHEMBL624293,In vivo,9527.0,,0,1,,A,,,BAO_0000218,5355
22224,,U,,,7385,Cercopithecidae,Tested for Clearance upon iv administration to african green monkey,,Autocuration,,CHEMBL624294,In vivo,9527.0,,0,1,,A,,,BAO_0000218,4578
22224,,U,,,7386,Cercopithecidae,Clearance in monkey,,Autocuration,,CHEMBL624295,In vivo,9527.0,,0,1,,A,,,BAO_0000218,17592
50588,,N,,,7387,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate,,CHEMBL624296,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6641
50588,,N,,,7388,Canis lupus familiaris,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),,Intermediate,,CHEMBL624297,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6642
50588,,N,,,7389,Canis lupus familiaris,Half life was evaluated after intravenous administration to dogs,,Intermediate,,CHEMBL624298,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16367
50588,,N,,,7390,Canis lupus familiaris,Half life was evaluated in dog,,Intermediate,,CHEMBL624299,,9615.0,,1,1,,A,,,BAO_0000218,5472
50588,,N,,,7391,Canis lupus familiaris,Half life was evaluated in dog,,Intermediate,,CHEMBL624300,,9615.0,,1,1,,A,,,BAO_0000218,5474
50588,,N,,,7392,Canis lupus familiaris,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,,Intermediate,,CHEMBL624301,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5654
50588,,N,,,7393,Canis lupus familiaris,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),,Intermediate,,CHEMBL624302,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,7394,Canis lupus familiaris,Half life period after intravenous administration in dog,,Intermediate,,CHEMBL876026,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,7395,Canis lupus familiaris,Half life period after oral administration (2.5 mg/kg) in dog was determined,,Intermediate,,CHEMBL624303,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6221
50588,,N,,,7396,Canis lupus familiaris,Half life period at a dose of 1 uM/kg in dog was determined,,Intermediate,,CHEMBL624304,,9615.0,,1,1,,A,,,BAO_0000218,4527
50588,,N,,,7397,Canis lupus familiaris,Half life period was determine after peroral administration at 10 mpk in dog,,Intermediate,,CHEMBL624305,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,7398,Canis lupus familiaris,Half life period was determine after peroral administration at 5 mpk in dog,,Intermediate,,CHEMBL624306,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5668
50588,,N,,,7399,Canis lupus familiaris,Half life period was determined,,Intermediate,,CHEMBL624307,,9615.0,,1,1,,A,,,BAO_0000218,3854
50588,,N,,,7400,Canis lupus familiaris,Half life period was determined,,Intermediate,,CHEMBL624308,,9615.0,,1,1,,A,,,BAO_0000218,5505
50588,,N,,,7401,Canis lupus familiaris,Half life period by iv administration in dog at a dose of 6 mg/kg,,Intermediate,,CHEMBL624309,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6251
50588,,N,,,7402,Canis lupus familiaris,Half life period was evaluated in dog,,Intermediate,,CHEMBL624310,,9615.0,,1,1,,A,,,BAO_0000218,1918
50588,,N,,,7403,Canis lupus familiaris,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,,Intermediate,,CHEMBL625003,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5546
50588,,N,,,7404,Canis lupus familiaris,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),,Intermediate,,CHEMBL625004,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4809
50588,,N,,,7405,Canis lupus familiaris,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,,Intermediate,,CHEMBL625005,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6215
50588,,N,,,7406,Canis lupus familiaris,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,,Intermediate,,CHEMBL873813,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4527
50588,,N,,,7407,Canis lupus familiaris,Half-life after oral dose of compound at 3 mg/kg in dogs,,Intermediate,,CHEMBL625006,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17594
50588,,N,,,7408,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,,Intermediate,,CHEMBL625007,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,,,7409,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,,Intermediate,,CHEMBL876027,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,,,7410,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,,Intermediate,,CHEMBL625008,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,,,7411,Canis lupus familiaris,Half-life of compound in dog following p.o. administration of 1 mg/kg,,Intermediate,,CHEMBL625009,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17839
50588,,N,1969.0,,7412,Canis lupus familiaris,Half-life of compound in plasma of dog was determined,Plasma,Intermediate,,CHEMBL625010,,9615.0,,1,1,,A,,,BAO_0000218,5210
50588,,N,,,7413,Canis lupus familiaris,Half-life of compound was determined in dogs,,Intermediate,,CHEMBL625011,,9615.0,,1,1,,A,,,BAO_0000218,5210
50588,,N,,,7414,Canis lupus familiaris,Half-life after administration of 4 mg/Kg oral dose in dog,,Intermediate,,CHEMBL621553,In vivo,9615.0,,1,1,,A,,,BAO_0000218,2959
50588,,N,,,7415,Canis lupus familiaris,Half-life after intravenous administration of 1 mg/kg/h in dog,,Intermediate,,CHEMBL621554,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4137
50588,,N,,,7416,Canis lupus familiaris,Half-life in Dog,,Intermediate,,CHEMBL621555,,9615.0,,1,1,,A,,,BAO_0000218,5064
50588,,N,,,7417,Canis lupus familiaris,Half-life in Dog,,Intermediate,,CHEMBL621556,,9615.0,,1,1,,A,,,BAO_0000218,5147
50588,,N,,,7418,Canis lupus familiaris,Half-life in dog,,Intermediate,,CHEMBL621557,,9615.0,,1,1,,A,,,BAO_0000218,5145
50588,,N,,,7419,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg,,Intermediate,,CHEMBL621558,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6123
50588,,N,,,7420,Canis lupus familiaris,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,,Intermediate,,CHEMBL621559,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6123
50588,,N,,,7421,Canis lupus familiaris,Half-life in dogs,,Intermediate,,CHEMBL621560,,9615.0,,1,1,,A,,,BAO_0000218,4333
50588,,N,,,7422,Canis lupus familiaris,Half-life in dogs; ND indicates not determined,,Intermediate,,CHEMBL876028,,9615.0,,1,1,,A,,,BAO_0000218,4333
50588,,N,1969.0,,7423,Canis lupus familiaris,Half-life in plasma of dog,Plasma,Intermediate,,CHEMBL621561,,9615.0,,1,1,,A,,,BAO_0000218,12500
50588,,N,1969.0,,7424,Canis lupus familiaris,Half-life in plasma of dog at dose of 3-10 mgkg,Plasma,Intermediate,,CHEMBL621562,,9615.0,,1,1,,A,,,BAO_0000218,12500
50588,,N,,,7425,Canis lupus familiaris,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,,Intermediate,,CHEMBL621563,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6005
50588,,N,,,7426,Canis lupus familiaris,Half-life was measured in dog after an iv dose of 1 mg/kg,,Intermediate,,CHEMBL621564,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6062
50588,,N,,,7427,Canis lupus familiaris,Half-life was measured in dogs after an oral dose of 10 uM/kg,,Intermediate,,CHEMBL621565,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17650
50588,,N,,,7428,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,,Intermediate,,CHEMBL621566,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5530
50588,,N,,,7429,Canis lupus familiaris,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,,Intermediate,,CHEMBL621567,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5530
50588,,N,,,7430,Canis lupus familiaris,Half-life of the compound after 0.3 mg/kg po administration in dog,,Intermediate,,CHEMBL622978,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5600
50588,,N,,,7431,Canis lupus familiaris,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,,Intermediate,,CHEMBL873814,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6039
50588,,N,,,7432,Canis lupus familiaris,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,,Intermediate,,CHEMBL623219,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6039
50588,,N,,,7433,Canis lupus familiaris,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,,Intermediate,,CHEMBL624477,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6039
50588,,N,,,7434,Canis lupus familiaris,t1/2 in dog,,Intermediate,,CHEMBL624478,,9615.0,,1,1,,A,,,BAO_0000218,6227
50588,,N,,,7435,Canis lupus familiaris,Half-life period measured in dogs,,Intermediate,,CHEMBL624479,,9615.0,,1,1,,A,,,BAO_0000218,14541
50588,,N,,,7436,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,,Intermediate,,CHEMBL624480,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4521
50588,,N,,,7437,Canis lupus familiaris,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,,Intermediate,,CHEMBL623595,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4521
50588,,N,,,7438,Canis lupus familiaris,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,,Intermediate,,CHEMBL623596,In vivo,9615.0,,1,1,,A,,,BAO_0000218,6679
50588,,N,1969.0,,7439,Canis lupus familiaris,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",Plasma,Intermediate,,CHEMBL623597,In vitro,9615.0,,1,1,,A,,,BAO_0000218,1116
50588,,N,,,7440,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog,,Intermediate,,CHEMBL623598,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5444
50588,,N,,,7441,Canis lupus familiaris,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,,Intermediate,,CHEMBL623599,In vivo,9615.0,,1,1,,A,,,BAO_0000218,5444
50588,,N,,,7442,Canis lupus familiaris,Longer half-life in dog (i.v.) at 0.5 mpk,,Intermediate,,CHEMBL623600,In vivo,9615.0,,1,1,,A,,,BAO_0000218,17853
50588,,N,,,7443,Canis lupus familiaris,Oral bioavailability in dog (dose 5 uM/kg),,Intermediate,,CHEMBL623601,In vivo,9615.0,,1,1,,A,,,BAO_0000218,4353
50588,,N,,,7444,Canis lupus familiaris,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,,Intermediate,,CHEMBL623602,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,7445,Canis lupus familiaris,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,,Intermediate,,CHEMBL623603,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50588,,N,,,7446,Canis lupus familiaris,Bioavailability in dog (dose 1 mg/kg i.v.),,Intermediate,,CHEMBL623604,In vivo,9615.0,,1,1,,A,,,BAO_0000218,16452
50594,,N,2048.0,,7447,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Lung,Intermediate,,CHEMBL623605,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2048.0,,7448,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Lung,Intermediate,,CHEMBL623606,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2048.0,,7449,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Lung,Intermediate,,CHEMBL623607,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2048.0,,7450,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Lung,Intermediate,,CHEMBL623608,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2048.0,,7451,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Lung,Intermediate,,CHEMBL623609,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2048.0,,7452,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Lung,Intermediate,,CHEMBL623610,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2385.0,,7453,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Muscle tissue,Intermediate,,CHEMBL623611,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2385.0,,7454,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,Muscle tissue,Intermediate,,CHEMBL623612,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2385.0,,7455,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Muscle tissue,Intermediate,,CHEMBL623613,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2385.0,,7456,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Muscle tissue,Intermediate,,CHEMBL623614,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2385.0,,7457,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Muscle tissue,Intermediate,,CHEMBL623615,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2385.0,,7458,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Muscle tissue,Intermediate,,CHEMBL623616,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2385.0,,7459,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Muscle tissue,Intermediate,,CHEMBL623617,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,14.0,,7460,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Zone of skin,Intermediate,,CHEMBL875944,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,14.0,,7461,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Zone of skin,Intermediate,,CHEMBL623618,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,14.0,,7462,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Zone of skin,Intermediate,,CHEMBL623619,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,14.0,,7463,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Zone of skin,Intermediate,,CHEMBL623620,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,14.0,,7464,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Zone of skin,Intermediate,,CHEMBL623621,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,14.0,,7465,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Zone of skin,Intermediate,,CHEMBL623622,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,14.0,,7466,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Zone of skin,Intermediate,,CHEMBL623623,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2106.0,,7467,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Spleen,Intermediate,,CHEMBL623624,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2106.0,,7468,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Spleen,Intermediate,,CHEMBL618521,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2106.0,,7469,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Spleen,Intermediate,,CHEMBL618522,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2106.0,,7470,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Spleen,Intermediate,,CHEMBL618523,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2106.0,,7471,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Spleen,Intermediate,,CHEMBL618524,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2106.0,,7472,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Spleen,Intermediate,,CHEMBL618525,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,2106.0,,7473,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Spleen,Intermediate,,CHEMBL624586,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,945.0,,7474,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,Stomach,Intermediate,,CHEMBL624587,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,945.0,,7475,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,Stomach,Intermediate,,CHEMBL624588,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,945.0,,7476,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,Stomach,Intermediate,,CHEMBL624589,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,945.0,,7477,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,Stomach,Intermediate,,CHEMBL624590,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,945.0,,7478,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,Stomach,Intermediate,,CHEMBL624591,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,945.0,,7479,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,Stomach,Intermediate,,CHEMBL624592,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50594,,N,945.0,,7480,Mus musculus,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,Stomach,Intermediate,,CHEMBL624593,In vivo,10090.0,,1,1,,A,,,BAO_0000218,10107
50597,,N,,,7481,Rattus norvegicus,Oral bioavailability in rat,,Intermediate,,CHEMBL624594,In vivo,10116.0,,1,1,,A,,,BAO_0000218,4689
50597,,N,,,7482,Rattus norvegicus,Tested for the bioavailability in rat,,Intermediate,,CHEMBL624595,In vivo,10116.0,,1,1,,A,,,BAO_0000218,4950
50597,,N,,,7483,Rattus norvegicus,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),,Intermediate,,CHEMBL624596,In vivo,10116.0,,1,1,,A,,,BAO_0000218,5328
50597,,N,,,7484,Rattus norvegicus,Bioavailability in rat,,Intermediate,,CHEMBL624597,In vivo,10116.0,,1,1,,A,,,BAO_0000218,406
50597,,N,,,7485,Rattus norvegicus,Bioavailability in rat,,Intermediate,,CHEMBL624598,In vivo,10116.0,,1,1,,A,,,BAO_0000218,12500
50597,,N,,,7486,Rattus norvegicus,Bioavailability in rat (dose 3-10 mg/kg),,Intermediate,,CHEMBL624599,In vivo,10116.0,,1,1,,A,,,BAO_0000218,12500
50597,,N,,,7487,Rattus norvegicus,Bioavailability in rat,,Intermediate,,CHEMBL875166,In vivo,10116.0,,1,1,,A,,,BAO_0000218,5247
50597,,N,1969.0,,7488,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,Plasma,Intermediate,,CHEMBL624600,In vivo,10116.0,,1,1,,A,,,BAO_0000218,4186
50597,,N,1969.0,,7489,Rattus norvegicus,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,Plasma,Intermediate,,CHEMBL624601,In vivo,10116.0,,1,1,,A,,,BAO_0000218,4186
50597,,N,,,7490,Rattus norvegicus,Half life after oral administration was determined in rats at 6 mg/kg,,Intermediate,,CHEMBL624602,In vivo,10116.0,,1,1,,A,,,BAO_0000218,6647
50597,,N,,,7491,Rattus norvegicus,Half life was determined,,Intermediate,,CHEMBL624603,,10116.0,,1,1,,A,,,BAO_0000218,6484
50597,,N,,,7492,Rattus norvegicus,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,,Intermediate,,CHEMBL624604,In vivo,10116.0,,1,1,,A,,,BAO_0000218,3249
50597,,N,1969.0,,7493,Rattus norvegicus,Plasma half life in rat at oral dose 2.8 mg/mk body weight,Plasma,Intermediate,,CHEMBL624605,In vivo,10116.0,,1,1,,A,,,BAO_0000218,6281
50597,,N,,,7494,Rattus norvegicus,Half life in rats,,Intermediate,,CHEMBL624606,,10116.0,,1,1,,A,,,BAO_0000218,3307
50597,,N,178.0,,7495,Rattus norvegicus,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,Blood,Intermediate,,CHEMBL624607,In vivo,10116.0,,1,1,,A,,,BAO_0000218,12058
50597,,N,,,7496,Rattus norvegicus,Hill coefficient of the compound,,Intermediate,,CHEMBL624608,,10116.0,,1,1,,A,,,BAO_0000218,8833
50597,,N,178.0,,7497,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,Blood,Intermediate,,CHEMBL624609,,10116.0,,1,1,,A,,,BAO_0000218,3193
50597,,N,178.0,,7498,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,Blood,Intermediate,,CHEMBL624610,,10116.0,,1,1,,A,,,BAO_0000218,3193
50597,,N,178.0,,7499,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,Blood,Intermediate,,CHEMBL624611,,10116.0,,1,1,,A,,,BAO_0000218,3193
50597,,N,178.0,,7500,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,Blood,Intermediate,,CHEMBL624612,,10116.0,,1,1,,A,,,BAO_0000218,3193
50597,,N,178.0,,7501,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,Blood,Intermediate,,CHEMBL875167,,10116.0,,1,1,,A,,,BAO_0000218,3193
50597,,N,178.0,,7502,Rattus norvegicus,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,Blood,Intermediate,,CHEMBL624613,,10116.0,,1,1,,A,,,BAO_0000218,3193
50597,,N,178.0,,7503,Rattus norvegicus,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",Blood,Intermediate,,CHEMBL624614,,10116.0,,1,1,,A,,,BAO_0000218,3193
50597,,N,,,7504,Rattus norvegicus,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,,Intermediate,,CHEMBL624392,,10116.0,,1,1,,A,,,BAO_0000218,5960
50597,,N,955.0,,7505,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,Brain,Intermediate,,CHEMBL624393,In vivo,10116.0,,1,1,,A,,,BAO_0000218,13950
50597,,N,955.0,,7506,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,Brain,Intermediate,,CHEMBL624394,In vivo,10116.0,,1,1,,A,,,BAO_0000218,13950
50597,,N,955.0,,7507,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,Brain,Intermediate,,CHEMBL624395,In vivo,10116.0,,1,1,,A,,,BAO_0000218,13950
50597,,N,955.0,,7508,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,Brain,Intermediate,,CHEMBL624396,In vivo,10116.0,,1,1,,A,,,BAO_0000218,13950
50597,,N,955.0,,7509,Rattus norvegicus,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,Brain,Intermediate,,CHEMBL624397,In vivo,10116.0,,1,1,,A,,,BAO_0000218,13950
50597,,N,2046.0,,7510,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,Thyroid gland,Intermediate,,CHEMBL624398,In vivo,10116.0,,1,1,,A,,,BAO_0000218,13950
50597,,N,2046.0,,7511,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,Thyroid gland,Intermediate,,CHEMBL624399,In vivo,10116.0,,1,1,,A,,,BAO_0000218,13950
50597,,N,2046.0,,7512,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,Thyroid gland,Intermediate,,CHEMBL624400,In vivo,10116.0,,1,1,,A,,,BAO_0000218,13950
50597,,N,2046.0,,7513,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,Thyroid gland,Intermediate,,CHEMBL624401,In vivo,10116.0,,1,1,,A,,,BAO_0000218,13950
50597,,N,2046.0,,7514,Rattus norvegicus,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,Thyroid gland,Intermediate,,CHEMBL624402,In vivo,10116.0,,1,1,,A,,,BAO_0000218,13950
50597,,N,178.0,,7515,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Blood,Intermediate,,CHEMBL624403,In vivo,10116.0,,1,1,,A,,,BAO_0000218,9866
50597,,N,178.0,,7516,Rattus norvegicus,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,Blood,Intermediate,,CHEMBL624404,In vivo,10116.0,,1,1,,A,,,BAO_0000218,9866
50597,,N,178.0,,7517,Rattus norvegicus,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,Blood,Intermediate,,CHEMBL624405,In vivo,10116.0,,1,1,,A,,,BAO_0000218,9866
50597,,N,10000001.0,,7518,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Bone,Intermediate,,CHEMBL624406,In vivo,10116.0,,1,1,,A,,,BAO_0000218,9866
50597,,N,10000001.0,,7519,Rattus norvegicus,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,Bone,Intermediate,,CHEMBL624407,In vivo,10116.0,,1,1,,A,,,BAO_0000218,9866
50597,,N,10000001.0,,7520,Rattus norvegicus,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,Bone,Intermediate,,CHEMBL624408,In vivo,10116.0,,1,1,,A,,,BAO_0000218,9866
50597,,N,948.0,,7521,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,Heart,Intermediate,,CHEMBL618644,In vivo,10116.0,,1,1,,A,,,BAO_0000218,9866
50597,,N,948.0,,7522,Rattus norvegicus,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,Heart,Intermediate,,CHEMBL618645,In vivo,10116.0,,1,1,,A,,,BAO_0000218,9866
50597,,N,948.0,,7523,Rattus norvegicus,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,Heart,Intermediate,,CHEMBL618646,In vivo,10116.0,,1,1,,A,,,BAO_0000218,9866
